<SEC-DOCUMENT>0001055726-21-000055.txt : 20210809
<SEC-HEADER>0001055726-21-000055.hdr.sgml : 20210809
<ACCEPTANCE-DATETIME>20210809160042
ACCESSION NUMBER:		0001055726-21-000055
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210809
DATE AS OF CHANGE:		20210809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		211156337

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:685d0eaa-cf71-473e-b825-35e9cdd023e3,g:d59d2343-5bf4-47b2-b6cf-d3f10d74095a,d:ca0a70fe2a8047f7bda7a3d9dbe49bde--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ino="http://www.inovio.com/20210630" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV8xLTEtMS0xLTA_c229cdaa-6c8e-4653-b44b-761158b216d5">Jun 30, 2021</ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV80LTEtMS0xLTA_9b6349bf-7b12-4f5c-a39a-90b872187bc1">false</ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV82LTEtMS0xLTA_ef2a07b0-c4a3-4f52-bb19-277f48dae386">2021</ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV83LTEtMS0xLTA_da88fecc-10d7-4578-96c6-63d7ceee369c">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV85LTEtMS0xLTA_5e3c89aa-9bae-4fa9-9e14-b6a280376842">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV8xMC0xLTEtMS0w_0aa83c02-67ef-4307-83c2-cdc29bbf4c88">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i11839e6989af49a292b4e10ab48b712a_D20210101-20210630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1Mg_7c2a02d6-d7ff-4cb3-9069-106f0e2331f1">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfMi0xLTEtMS0w_a96a096d-fa83-4ae6-b9b8-49d42b190057">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iab4e7c41161447e1a1a8d07237954cb4_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfNS0yLTEtMS0w_fd2066bb-c8dc-43f2-880e-61c1cd8cb772">0.0002110595</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4387c26933424d9096e5a67cc6e310e0_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfNi0yLTEtMS0w_a3dd577c-a8de-4fae-8029-8143d6d4db49">0.0002756873</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i93769b4e1cd94005890eb64e29ddbcd8_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfNy0yLTEtMS0w_f10fc8b6-a3e6-4e37-ad92-c7975335b7ff">0.0002147766</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i83ed6177c4804f6aa764dfbd829ecaa8_I20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iad1208ba98074d448260b48944e05ebe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc098f58f8a041b08a33357d6648fbc0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32b8bf36ec4d469591d90e39f3ec8e81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ee9a992e9d4aecbed299eb5413def8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e1e9bb6dd649dfa52090802d4a0072_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecf790ef87d429c90f4ebc744136636_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d79f4dc5474687846e3b39dfca505c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4761e01b5c81478a816114b036289275_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf3b64ae03f46cfbeb3fc8dc8a97ca8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0126e377d2444cbed98c98dca66844_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id697003739b14dbabbe3d698b5c6670a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb6dd3bc70a471ab465c71da214cea2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b398cfbf4a4650b18fe5d6ea487fb8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbfb78a03fb44fdfb83c5a956c89ea69_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i493fb6cfff2d460993ffab8a845aaa8d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if232bf82d12541779d14e8a336ace449_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda3de1762204459935f37915d69c1b6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i12aac99aaaf741349f86a989fa764482_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799a2702ab5a4bd4a435e11c1046de46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44709f40e8a943049398893f00a24be2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e84c6e219d4b4ab6f799165f3ff3f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5bb1d8705d24b5cb342ad0d76c412f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id506e21662664607abb5ada53bef4c71_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i293a954b904244158be4beb19eadc1eb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6be5b29e6e640aeb3b3c6f8c8b4b46a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia305805348c642e181a5a220764cd0cb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie410c23f3d734e22a654add21f7dd4be_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd07f46a44cf47b29f251e9f8b53b448_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3c65da07554ec0a475b65aec785e3e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8b502204b444ec8fc08ad865e94b35_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9fc53bfe459451e93c099b12e3d7d7d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib97826d72ea649e4b70791285961ac6c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69edae5e51e45c6a95fcd35749a9236_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3da144150804a6fbb5a9f2eb556643e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108e0d957d844157b477393aead9cc52_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1439ad58b8a4b8d80f168ebe9e96082_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fd181698642459c9825e12bed9aa37d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3abe12b5c3451b84594cfcc6853c43_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i254bd042051242849bc85dee66371184_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42516c7d860c496fa39ae9ebb52897c6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ebf817b5d604254a7317c1108eb9e22_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if20cd84b26984f8f9e8f6f29f783d43c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica81cf786c5d4fff8fd605675e3eac0a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f44eaa8aa2459ca2f8c8563adf249b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c97a020ced432dba7dfa7f21e090af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7027e5aeb5e64cd7ad992e12c7a0fb56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7c265546d74b3c8712996af91049b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1879c69872f8418ab00a9d6a48983451_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0493a38b630a49bc902812a2465a3617_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8eecef92b9240d5bfdf9e6810786a6e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ff215ce28014289ac0323b81097347d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005c775b4401470a90ee91adfbb417b8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a0656da9344a8a8b854e2ca77a6732_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa58a8fc43214b7bbd63cc831b027ff0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee8db81f57e4c278a66fdfcba5073cc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4fb0140f8414f75b8e619c79cf2a649_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0caffc4cfd24e629b7a9fa306e19b99_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb00ed027cf4a6bb677b4122123ec1a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc901c89fb3492ea30e005f1f9c9e8b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icabb95078cd04d3b859cdd387e239ad7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i886aa86a8ef3444899784ec9f609e6e7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0963ef6fa894e47b9e2458dad5bd538_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbfee2e1b2af4f098563291bfb7a6e6d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4152dc4545d04bab8fe2acc7fb1b3424_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1eb417f6f754a2ea880089bb2a38945_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92715916320442a9ca37398433d7c01_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5677a5c642824f42ad93623935b5b5bf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6030a2333ec842288f8ea1f6eea367a2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae8485bffe44645bcc2d2d69167e061_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b7911f846a04e46825317fba23a0d2e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11839e6989af49a292b4e10ab48b712a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c3eb7929d54a7db36dd6d7dbc2b7dd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f2d9f6575543589f663ac5ade5d146_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4430b09f8f4a3d9c5b6e2ef7fa048f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf6343817df4d51b56069690f181906_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8419a4c84d46487aa9709be5474b797c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:context id="i5bc7989f3223430dbcc2ce0a18701c95_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83d3a2efc6e49fa9fd97fa96d8adcec_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42c406f875024b2bb0c68f572a31cd9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i510a549b3ec34defbede167e3f43db38_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f229a241b946588368e702a0bfb111_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2706bc18dc264d7f80c2c3df55033508_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6816a859d85847e482e3a9f0779b70fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e7cf41bc39a400f8c65d4ac89cb740f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4379956285af4a64828e8aed46e6fc8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59b2f82a49c24e32adbb66d496dda53e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cfaf8d38f5648c19f2ea139b9b26baf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51d461609384e719322b34eb0028974_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f3ac792a0624a46adde92d9a011757a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dc69a851d9e4e609cc585a27766de44_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7015122ae2124cc496b05b2e9f7e4d96_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a6f1f19ef548cca073dbd3bb6f4e78_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia791cbcc956646499769e8fd73d3f0da_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if19edaa6e2cc4d4bac4bd7a20b22e0ab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a1e910e01534d50ada88b9157528ea0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa3846d736e946a395c5e4a35be5dda3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195cff6b53c543e79e1b7a11b9e1e066_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1713bb34c3046b5b8c3fb55489e9da9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae0695b197b427cb51e9553cf7567c3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8730b43b27914e7aad78d1a3e3c967ea_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ca670336a984af492bfea37611a6fc6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc709f4b94bc48ed922b211843a64806_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bfff0eba5124813b5d1d472946eca2b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2063a61ba08e4166b1cddf9ccca281e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie423d6a2d8714a8f9455c1d4c07b71ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b0fd8f591c349f3a5e3a09df3fda89c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d1fecace3114e4e8dc9bbf39dbc9e69_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5efcc9635b543f288d5ac148668e8be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b14d9a9f0a04ed881500352253a7910_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee92b5ff60e34bdc86aeec302d9c2bf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79c69a9ae1284a36bb632aed6602a513_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb94388dbd194288ba834bcc4e711204_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72086878455242579c997bb7d0dbafca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d2855764184d899799d1f6e766ef05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd724b7e4b434a0299f128f23b08a6f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie555d9e8436b4b7c816532c5dba1b774_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41fa24018fea4d7789e40b137a122c1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e632e4521a403eabd9a0d1cd065f58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dae7058a7c24aad9e604be62fc80f77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i885b976e592548cab96e1ad94a5f5ca6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98ee59d71b964e1b903875f0effd8913_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd6370c584d45d1980fe5eae38e0f14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15f13a0132e4e6a88992dc32184349a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cdd7b8ef815473385e371284b1691bb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658f1d80d9ae443e8ed687c6a2037b8e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b5d1ccf26e443ea857b84e229ce359_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f8942f622e48a99283907789ffa607_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f14f4877fcc414dbb3be5f50ae03388_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449fddef645f4a30a1891aa40c4f6f0d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f168c1581a04f49b0e144ce91a5b415_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90cb8338f9474cb7b4f4e085bba18709_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9694c3b5185b4167946bc4ade85f653b_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="idb65bbc9382a4813ad514235377b41b5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbf958eded24955b7f7345d5fff5691_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife6839a934ca45f6a9f657888e33b403_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7b13bbac7745c18bcb6916ba590376_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied29f23ff8a24d14ba72e1520dbcbe12_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb6494a5734438caccf162208d9c9e9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i586e28029d9349b8990dda0e65156664_D20190801-20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4387c26933424d9096e5a67cc6e310e0_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e32422bc844eba90a640f03b45dce5_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaad05c89c7a4003898310c3fcc4bef8_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb48eed1dd1d450f97688eeb9d9b1075_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48cbe06ea9db47109f2c6aa21e985ed6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3325f0757ae043c6b5ac88744b9c348b_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8ee829033246dd9adf6d9303496b62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaaf8fc6a6c144978817e6793fd2365a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f211979e784e9bbb20076cc52f7e54_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a26ab4a585a46dca8422a60ddfe24b4_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2908c92d06bf4769bdd733e5d00c8200_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d34dff54d0e4a038bfa48e0e67a8e99_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442ae70cad5c4076acaead0487e51e18_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f6c67ea61a42c8a33b20a0edfa3e86_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab4e7c41161447e1a1a8d07237954cb4_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93769b4e1cd94005890eb64e29ddbcd8_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689dc147815948f0886fb748641b715b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77178543290247baada87cc58713a47e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5014003f2f6f483b8391af1fa2db26e8_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c22ff37c374753ade05595b7204ddb_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a378f1adfd4003a890450ab84a2bd9_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f31aeb778524005bde1396b19356f60_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0d7c5a50ca41b28dad429b0cb851a4_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ee577f7a7e4579bb39bba035abaee4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33badcdaab9f4b948718c8bce4d00c22_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bbbdeacd5fc468588e3dc03b0a7861e_D20200403-20200512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-03</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44318d1ef4e4fd298cb0d5f9506f23a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2005c7bb31a94776aff831320305c606_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbea9bf1e25743b78635a4f7dced6bd6_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia838f5b6a3354692a049e285a3f8c1ab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ce38f7c67443e49e518a149cc81961_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da088e105ad4f18ad8b9d31ec870555_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd59942851345caa9bfa5f0f8f2c395_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7720390ee14d46e0af301a676fc1e147_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcbd43fff7ff49d2b5186181ccc1ee3e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0df4c9eb1a604d84a5994034871feeb9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c9b4d010164a689b6d9c3c41f23c03_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d2d9234b5a431cbf09724c62882b4e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ae4261b99c4a6e810082721dff0e62_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c583306369d41e29983388433b751ce_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9fb06d2b7b14b53aa4aa3861c628292_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97026c92ba624f5eb88dedb4f4fd222a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b6b2ddbdd8e403393dd968eb554812d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i409887a8fa6a4346a1975b51ea0e7e16_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b2caeab20c408da8ce4dbb3e47ca39_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f3835a374c242d7a7e25920391ff721_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6843efcb854eb59c1d1c8cfa5945bb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6840ef28448241779743cf158cd253ec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9220dabb97347baaad3b955c7ca131c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice27ffbaffd34874afe23deb45a41f1d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75baa0c985dc4a80846a6c09d447a541_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01f6e99b41046cea288d454a397131b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c4a44eb23a64f2a8177b06eccfd5462_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf811d4883d349a090d95c8c69bfc003_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e764caa439a41a78c114122d5dd11fb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i516d344bdae6478b9cbb0eb47830b5bf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a074845daa435895695e2ec5b8a0a9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7fe878a23244e578b1d0fe5755cc0fa_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6adba9b5cfe8432498fb5b3d434a4541_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c44a7a4bb0e423fbd2ec314824724ad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084bec39b5ca4a51a9902a9ff9ad928f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb3f0be101b47a18fcc503057ad42f1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7334687cb4a947de92ae0eb9f74ab59d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5e991cb67b41b5987aee77b9140631_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f8e4b6b88849388af7af4775429f82_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfb07957bc8448e898eec6cc1d4f178_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab9cee1a62047fb8051e1d941df796b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3baa7582b441aab8b2cad5aea5a16d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5ffc18c04b4a18bc872e736b8e3274_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff71523015949a3a75328d8f76bc7c6_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5758f42e8641cca8f706945d684248_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bfa0efcd5e94977acef14e343d8c32f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9758e3169bf42408ff0026a43dd6c32_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39000bc0ed2f4334bb3f0d81cbac8fef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b00238ffc3b48c5a7ddb81b78793302_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee4bc461464046a39879834a877ac90d_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aaebaef4a484e99a1f72fd27c49260c_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db0b6c7420847968706776cec806a32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fbd471a37474f43870e9353685a3362_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647dbd99928840369aa848a876ffaef7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc72a58c0cfa4fec9b889e44cf304615_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9cf11cba38341b4909eff0dd1632ec2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id242696b659b49afadf87dff3bed0cc3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79aa827c9e8f4b358c9a1724e62d1c61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i66a148722afa41b185cd4eef30e25fdb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b665a2cbce54f4a94dd8ecf309380fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae75de8f5854856a0f90d658ba0bcd8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i110b3be318af4daab8582df0596dd792_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ino:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i0dc2a7ba5e24419aa07ad87b72b18c9c_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db89a2c66514d7498b690857971a626_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c8ad24eca624a71a7fb21cdcced5abe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica98223bf1ed447193c67fa870204517_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ccd78a11244d749d8dd9859e9ce310_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44786c100124c789efc53e8f92bfde9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95c7a96f00054646b6f751e13b02c56e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72b40649a6a84f138cb3a6dcb7498815_D20171229-20171229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-29</xbrli:startDate><xbrli:endDate>2017-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537aa32e3c5f4baf82bacfc6e7b0d869_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i564bbcf0dabf424f86f296be903e20b0_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if69d1eee3fca4367a054a928d24cff8d_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia92556534d574bbc94e10cc84341c759_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ad39f285414f30b79535cfaba7daa2_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba45b8937a894f6b9a5129658feedbc3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie861c939ef624bffbd0b88dbfdf9c693_D20171231-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-31</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafce45fcd5d548d596dd6d619e8eacd5_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c98d6b5b8a4c33898800f47a20e3ff_D20190302-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-02</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ff72c6a8dc403c95f8ee874839211b_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df90724be6143258a8fdee15d4e93e6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6407575bd8b340a1a2a8f8810560320a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaeaf41dd77446d3927ea1c114867dba_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i192e249f20ad47fd87c6efd63533083b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaca810872ff8493db0d62372edb6bd01_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8220fcd140d74557b083a926e4253873_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b88e02327942f9ae78274a728a6c7a_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i761da9fe1ff8435f937cde9607056cae_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78961ef0362494d9ca8a3a24f0402d9_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63751304353e47dfa5578ae4af319b3b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae69df542d9c4fbab5f22042b834a657_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5944f9592ca4638842dcafe5504d740_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f7c6a9e4960494e8081fc7f145ad847_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa54cd5e2c5b4aee983f8f582c668686_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieda7c74c79e1485082bb7462bb0aec90_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02069efe34d14945a75f312034c48d56_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a4ecfa456040578debe0c705bb0cb0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i904f52b9d85542868818618a457d155a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e44b859e87640b9887e249f509f22b2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia079900790b44ee39d2535ab8a76f7c7_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f7a9d3dc10499f8b65f4f3b1c7d04b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8772e190853b4c34b869b43e00154114_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f531494334b4657bad6357a54553f03_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1282eb1a458f4357a1ac8a3d8b4fa3ea_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba1c591d1f53449fb9a0ca78b60e0636_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b6bab09ed848df86ba826cc4961c16_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b4d555b69d4dca91e2e11a14be2165_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1efaad3a5848b9b2664bb608171aa6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id32424115c5249fdab21269b2a97590e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b465568e394137b0167411e7b5c097_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf3e49c10cc4f94a383960947e82228_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e127c1524564bae89ca80e255ad2678_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e185f6790bc47528495934e156680eb_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df2a303132e4f7f96ff6997a31a1212_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccb9c884d87d48218ffe7d83101d494f_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c02b65034ce49e890afd34400d720ae_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667c2fdb4d5345df8d39328da874e2ad_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb35c7b8b7e4a2a8b77665cb4247493_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb812a090bdf454a8d614a22e3087514_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7c36741569485ca8d859069b46f092_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02456b81a37f4ae6a5c063b014c525f2_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i196f4528a0a9490b9a924875a4215545_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac9bc58c8414810ae3dff09c8e549af_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if173908cc8354a3187bf1e82e65a5550_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9ba1ec7a1a485a8b2bda6032474f24_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230f14716d1a4c2e895e45f0ed84c399_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dcc915ba16e470c810717cdca71bc8a_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i751954486ff04a2585b50cca7a7a1f66_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id548d70b807a41cdbafa0a873651db92_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603b348bf030425286b8663a7233f3b2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7eefa6dfb474f59a56c5498e9af5934_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ddd5fa80e1f4d619dac2b863cd3a051_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b994018688462294e9fc2216b8b645_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eed2f09111e4adc973bc8d68b9050b1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565b71404f58429384bf7e01598dd420_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec0c50e342949c6b66d38190dde51e1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc6d252ee23a41b88a2b37888e87aff6_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEz_c226ff12-2ce2-4670-b4fa-30decfd01c0c">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6MTJlMTU2ODg0ZDNjNDg3NmIwMDIzYzExMDU1ZjBmMmIvdGFibGVyYW5nZToxMmUxNTY4ODRkM2M0ODc2YjAwMjNjMTEwNTVmMGYyYl8wLTAtMS0xLTA_ff19112d-4900-49a9-abf3-2535bf82616c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6ZGMyZTI5NDZiYTAzNDc0ZDkzOWY3ZGEwMmVmNzA2MmQvdGFibGVyYW5nZTpkYzJlMjk0NmJhMDM0NzRkOTM5ZjdkYTAyZWY3MDYyZF8wLTAtMS0xLTA_aa2e9b97-be79-4b48-b127-e8504bdc7da8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE0_9638b7ba-9b0d-4451-9a6c-ac61d5e8928f">001-14888</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20210630_g1.jpg" alt="ino-20210630_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE1_81350c95-5492-4ddc-bda9-b0a86b9ac967">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NGYyYzA5MDBlNmFhNGRhMTkwZDIzMTcyMDc2MmRkODgvdGFibGVyYW5nZTo0ZjJjMDkwMGU2YWE0ZGExOTBkMjMxNzIwNzYyZGQ4OF8wLTAtMS0xLTA_e7f98c2e-0147-46ee-accf-95d2ad17749d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NGYyYzA5MDBlNmFhNGRhMTkwZDIzMTcyMDc2MmRkODgvdGFibGVyYW5nZTo0ZjJjMDkwMGU2YWE0ZGExOTBkMjMxNzIwNzYyZGQ4OF8wLTItMS0xLTA_66d8c4fb-7ca4-4fb7-b2b0-4c5917f34429">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA4_fbf7203c-6397-4a76-a929-9725d6c9a3f4">660 W. GERMANTOWN PIKE, SUITE 110</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA5_2db64d1e-f163-40a2-a730-f580ded4d9dd">PLYMOUTH MEETING</ix:nonNumeric>, <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEw_32cdbf57-b27b-4f72-93f4-b67f699d751a">PA</ix:nonNumeric>  <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE2_2ac7be9c-663b-418b-a11a-b967a0d95e24">19462</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEx_23a5fea3-f419-4d98-8cc6-35ae41a096d2">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE3_7de4135d-30b7-4b95-b784-061e0c340d69">440-4200</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.069%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6YWVlNzg3MjBkMTVhNDdmYTk2ZDgyYzM3NWIwZTBiMzcvdGFibGVyYW5nZTphZWU3ODcyMGQxNWE0N2ZhOTZkODJjMzc1YjBlMGIzN18xLTAtMS0xLTA_724ff894-325a-4aac-923b-ae423447536d">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6YWVlNzg3MjBkMTVhNDdmYTk2ZDgyYzM3NWIwZTBiMzcvdGFibGVyYW5nZTphZWU3ODcyMGQxNWE0N2ZhOTZkODJjMzc1YjBlMGIzN18xLTEtMS0xLTA_4021fe4f-bdbc-4b17-a318-b8324cb9a22f">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6YWVlNzg3MjBkMTVhNDdmYTk2ZDgyYzM3NWIwZTBiMzcvdGFibGVyYW5nZTphZWU3ODcyMGQxNWE0N2ZhOTZkODJjMzc1YjBlMGIzN18xLTItMS0xLTA_a68ecf26-faa5-46b5-88fb-90ce916be2b1">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEy_75fdc898-41a6-4c5a-b41b-fa48accd588d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA2_02614417-cfd3-4cc9-8f97-50a28cee67b3">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NTk3ZjI0YmI0NjZmNGZmZTg1ODM3NmVkNDkxMWQzZTAvdGFibGVyYW5nZTo1OTdmMjRiYjQ2NmY0ZmZlODU4Mzc2ZWQ0OTExZDNlMF8wLTAtMS0xLTA_ee23d0fe-7060-4404-9bbc-89f3b535ca17">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NTk3ZjI0YmI0NjZmNGZmZTg1ODM3NmVkNDkxMWQzZTAvdGFibGVyYW5nZTo1OTdmMjRiYjQ2NmY0ZmZlODU4Mzc2ZWQ0OTExZDNlMF8yLTQtMS0xLTA_e8e498df-c97c-470d-9fa3-92c948cf3863">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NTk3ZjI0YmI0NjZmNGZmZTg1ODM3NmVkNDkxMWQzZTAvdGFibGVyYW5nZTo1OTdmMjRiYjQ2NmY0ZmZlODU4Mzc2ZWQ0OTExZDNlMF80LTQtMS0xLTA_a6b8695f-493e-4cf8-8ec0-e1e8835ca3bb">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA3_3b9c04fd-8bd1-45a0-93c3-a6cb34cd8fef">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i83ed6177c4804f6aa764dfbd829ecaa8_I20210806" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMDky_e0d298ab-e9bf-4e5a-b636-4aa20fb00f96">210,356,896</ix:nonFraction> as of August&#160;6, 2021.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended June&#160;30, 2021</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_13">Part I.  Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_16">a) Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_19">b) Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_22">c) Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_25">d) Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_28">e) Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_31">f) Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_103">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_103">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_121">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_121">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_124">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_124">36</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_127">Part II.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_127">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_130">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_130">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_133">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_133">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_136">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_136">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_139">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_139">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_142">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_145">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_145">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_145">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_148">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_148">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_151">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_151">61</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risks include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">Our planned Phase 3 clinical trial of INO-4800 in the United States as a potential COVID-19 vaccine has been placed on partial clinical hold by the U.S. FDA, which may cause delays in our ability to conduct a Phase 3 clinical trial in the United States.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. The option of seeking an Emergency Use Authorization may no longer exist if the public health emergency has expired or if a sufficient supply of COVID-19 vaccines have obtained full Biologics License Approval, or foreign equivalent, by the time we are ready to submit an application. If we do not timely apply for such an emergency use authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or monoclonal antibody products.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">A small number of licensing partners and government contracts account for a substantial portion of our revenue.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have agreements with government agencies, which are subject to termination and uncertain future funding.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We face intense and increasing competition and many of our competitors have significantly greater resources and experience.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_13"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.  Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_16"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:74.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNC0xLTEtMS0w_739ade15-9953-46ec-a6e1-baf6722874eb">58,925,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNC0zLTEtMS0w_39cac9a8-6090-495d-80f3-6442003a80a5">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNS0xLTEtMS0w_f3cf9f3c-be2d-4ca7-bb60-402d3846b095">384,752,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNS0zLTEtMS0w_fa82d8df-5419-423c-9244-f84684722c54">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNi0xLTEtMS0w_5eb933b3-fcc3-4afd-b623-a00772fea51e">13,128,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNi0zLTEtMS0w_0cd99ff3-6cb8-4d67-be24-19fa395db4b1">18,559,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNy0xLTEtMS0w_a9077a44-599e-4afd-b6d1-83f9fbce222d">722,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNy0zLTEtMS0w_665c2499-6f3d-40c3-b82d-71b4a1e2440a">503,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOC0xLTEtMS0w_7994b227-4c36-4aed-9a6b-d1c33020e5a4">84,592,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOC0zLTEtMS0w_6d66c195-7302-4f6d-b55c-f305702ac91d">40,357,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOS0xLTEtMS0w_a5e76e10-d176-43eb-97d5-7173457e0ad6">303,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOS0zLTEtMS0w_54cbbe83-454d-4323-a3b5-60c141d8f608">106,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTEtMS0xLTEtMA_d5604903-4ef5-4ce6-a511-e956dfbfda93">542,424,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTEtMy0xLTEtMA_3f0578db-ae1a-4067-ba1e-3e3c5e1037aa">471,170,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTItMS0xLTEtMA_4d63c6be-f20f-42da-bdd5-2ad40c703172">18,111,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTItMy0xLTEtMA_4173ac08-b358-41ca-8f13-0ada177e1b88">11,348,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTMtMS0xLTEtMA_26f1f788-dfb3-4a19-830c-b9534ca08126">3,908,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTMtMy0xLTEtMA_f85a384c-c08a-49ac-80e3-6606b7f5fc18">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTQtMS0xLTEtMA_858db244-4a37-4521-ae91-f30b509caad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTQtMy0xLTEtMA_f24393c0-d047-4f29-874b-ffe7e48425cb">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTUtMS0xLTEtMA_5caffdf1-79b5-4f33-88d3-f9e5db281220">2,879,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTUtMy0xLTEtMA_0155ef40-0a6a-441c-8167-6647d2fa739b">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTYtMS0xLTEtMA_66c095d2-93b1-473a-9316-a0df1f30a143">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTYtMy0xLTEtMA_3f737805-2f91-4e78-8f69-9985f56909ec">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTctMS0xLTEtMA_9f0043c0-494c-47f6-a3cf-9bc0ec11ba1b">12,173,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTctMy0xLTEtMA_32debae0-ee9a-422b-9ac1-5139463e0896">12,741,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTgtMS0xLTEtMA_6f3ba18c-4d6f-46a1-8cff-24763ea1a8a2">1,830,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTgtMy0xLTEtMA_3802bbc1-8147-4bab-960d-016ed5e535b1">25,957,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTktMS0xLTEtMA_8f67a75b-dbd7-47ce-8a1d-8d65ed954d66">591,842,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTktMy0xLTEtMA_b0c0c67d-0124-4f4f-974a-50f170819c0b">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjItMS0xLTEtMA_5ae47cf6-404b-43e4-83e7-a686d9b9bd7b">30,095,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjItMy0xLTEtMA_bf2ca63d-0446-4a29-871d-63b388f2efd7">21,203,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjMtMS0xLTEtMA_a09068bb-6cbc-4825-a37a-acfd14be1120">1,773,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjMtMy0xLTEtMA_e9698a3b-9bbf-45d8-afa4-892fece2eb47">642,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjQtMS0xLTEtMA_e53bcbda-f2b5-411a-aa43-b5869cf8baba">10,416,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjQtMy0xLTEtMA_68cf4647-5fb3-42e4-be8b-d3f4740ef98b">9,950,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjYtMS0xLTEtMA_b132271f-bfec-4603-9c41-48a43bba9795">109,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjYtMy0xLTEtMA_44a90d11-7789-4386-ae91-e27ce3a16ac3">46,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjktMS0xLTEtMA_e7e3a8bd-b209-4fba-a6f6-3a050873d991">2,463,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjktMy0xLTEtMA_eb5b3ff7-704c-4f12-aebf-a92f03b12384">2,329,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzAtMS0xLTEtMA_98cf5dfc-c2bc-4558-bc4e-253856e1ba4d">6,859,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzAtMy0xLTEtMA_137b56e0-b6ac-4be9-8250-986b495f0dc3">7,474,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzEtMS0xLTEtMA_171b9508-b62d-4efd-a9eb-69a6ceb2a987">31,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzEtMy0xLTEtMA_04e00484-6738-4e1f-85c6-cea88c37f456">58,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzMtMS0xLTEtMA_c5f656db-8c53-439d-86ea-a8ea29b1bae0">51,748,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzMtMy0xLTEtMA_006c9d23-f0b8-46fa-b6e9-26a64b9b3b28">41,705,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzQtMS0xLTEtMA_a8ec0e01-606b-4292-960c-6512ce0f4bb0">71,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzQtMy0xLTEtMA_d6f89ea1-29c6-424d-8882-472efa104194">79,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzYtMS0xLTEtMA_3ddaf106-b069-4b00-bb5b-55bd392540d9">14,536,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b8bf36ec4d469591d90e39f3ec8e81_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzYtMy0xLTEtMA_55298f13-de44-4a8f-b47c-90076f9a1cef">14,139,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ee9a992e9d4aecbed299eb5413def8_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzctMS0xLTEtMA_5541887b-0892-4abc-965e-5224e790f893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e1e9bb6dd649dfa52090802d4a0072_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzctMy0xLTEtMA_789aea76-3b9e-43fc-ae79-77fa208946ce">4,515,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDAtMS0xLTEtMA_6700502b-203e-4910-8191-ed5f5d13e429">16,797,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDAtMy0xLTEtMA_c6767dbc-e3f1-4782-acfb-d56bc3a89239">18,063,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDEtMS0xLTEtMA_ba851d9c-f779-4189-bfbd-e677a114a90f">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDEtMy0xLTEtMA_16ebc96b-7731-4dc4-806c-83d307bbc327">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDItMS0xLTEtMA_9fcc0ea4-f2a0-4f7b-9e59-22f36c5deb4c">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDItMy0xLTEtMA_3fe16c63-b1d2-4d3b-a1ae-1e4bce68fedf">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDMtMS0xLTEtMA_334a2750-9345-46eb-967a-dbd19713b704">64,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDMtMy0xLTEtMA_200626f9-08aa-4303-9df3-993e8c1700a6">57,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDQtMS0xLTEtMA_f7e27ac9-3fb1-4361-8139-186d8a3c74ae">83,288,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDQtMy0xLTEtMA_b2c78578-59d1-4c17-9332-a768119448f7">78,631,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDYtMS0xLTEtMA_d9f14bb3-76cd-4e27-bb4b-3c1119f28935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDYtMy0xLTEtMA_f9a77bb5-3392-40b4-8a28-e9f90dcb9161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDctMS0xLTEtMA_023506bc-c1bd-4721-8f9a-4bb19c9a2a84">210,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDctMy0xLTEtMA_25543f70-f5ba-458a-a5d8-d3a04976284e">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDgtMS0xLTEtMA_b2e9396e-7350-4656-98d9-8906a3adb333">1,551,348,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDgtMy0xLTEtMA_8a5bf5b8-e52d-43df-9e37-19808f1dac3c">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDktMS0xLTEtMA_fb095f10-b74f-47cb-8783-f618e3bec085">1,042,738,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDktMy0xLTEtMA_c11cb022-3d22-407e-bcf9-90c969e5757f">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTAtMS0xLTEtMA_942ab5b5-dbb3-4a18-9684-359135c7b51a">265,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTAtMy0xLTEtMA_be0675ec-2f2f-4817-a0c1-284ed4cc3694">256,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTEtMS0xLTEtMA_d63d5b6d-9016-4a50-9495-24ef69970f65">508,553,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTEtMy0xLTEtMA_8d412271-a8ea-4ee1-899f-773cf7767317">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTQtMS0xLTEtMA_ca2e8d16-3235-40b5-8a6c-bdf503a50272">591,842,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTQtMy0xLTEtMA_ef271da6-4938-4f9e-90f6-083243b9fed0">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ecf790ef87d429c90f4ebc744136636_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy0xLTEtMS0w_6189240d-553c-46a2-bc22-25b9b245f754">82,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d79f4dc5474687846e3b39dfca505c_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy0zLTEtMS0w_defe504a-a32b-4984-800e-50697613138f">74,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4761e01b5c81478a816114b036289275_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy01LTEtMS0w_40503389-8c4a-4e04-963b-d6f961821eb5">122,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bf3b64ae03f46cfbeb3fc8dc8a97ca8_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy03LTEtMS0w_71d798ce-1a08-4695-aad5-4e2615e68c36">145,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements with affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb0126e377d2444cbed98c98dca66844_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC0xLTEtMS0w_5fad1dc2-8287-48f8-b1c9-b1f668fdb6a9">74,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id697003739b14dbabbe3d698b5c6670a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC0zLTEtMS0w_8c4abe77-6f61-443c-8dcc-9ca41c371862">95,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb6dd3bc70a471ab465c71da214cea2_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC01LTEtMS0w_035052ba-de77-416e-93e6-7e49974e83fd">124,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b398cfbf4a4650b18fe5d6ea487fb8_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC03LTEtMS0w_2bf044df-9580-4d01-9458-437e1f6de508">1,267,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbfb78a03fb44fdfb83c5a956c89ea69_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS0xLTEtMS0w_c5c54da1-baa1-4ee6-b6f4-ce5358902636">115,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493fb6cfff2d460993ffab8a845aaa8d_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS0zLTEtMS0w_ba838034-5482-4da0-93dc-8c5cad874e97">97,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if232bf82d12541779d14e8a336ace449_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS01LTEtMS0w_959c6580-dfdf-43ef-b561-21c7c01fd558">396,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda3de1762204459935f37915d69c1b6_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS03LTEtMS0w_96d7b971-0c24-4bd5-87e8-0d6f69869813">181,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC0xLTEtMS0w_1a89a032-3fff-4d64-8f7f-d8954f2edd50">272,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC0zLTEtMS0w_238fa39e-95d8-4ac6-b893-fcd1dd018944">267,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC01LTEtMS0w_757cd839-478a-4037-830f-479c1932f81e">643,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC03LTEtMS0w_4ea2bb2e-1779-42ad-81df-07bd32cfc845">1,594,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtMS0xLTEtMA_7a63c17f-951d-4ff2-8f6a-9fca7829e3cb">70,808,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtMy0xLTEtMA_edd13d93-fcee-481e-9ca9-09ead0dbc29a">22,376,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtNS0xLTEtMA_4f5fce7f-fb30-48f3-a281-a744ad625654">109,852,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtNy0xLTEtMA_38e2fcc0-cd35-416a-be8a-eb2fac79ed60">41,487,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtMS0xLTEtMA_b9c16f5e-1bbd-4e97-b5d8-9a2868010161">12,666,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtMy0xLTEtMA_14533849-b208-4fdf-a8ab-b8f111918379">11,071,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtNS0xLTEtMA_b93ba9cf-69d0-4a59-9010-af4f72f3e0f5">26,547,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtNy0xLTEtMA_db3b4bf6-8558-4537-a49b-2f02696a8b20">18,519,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtMS0xLTEtMA_6eaee500-a375-41b3-ac0a-c29ca51104e2">83,474,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtMy0xLTEtMA_342c470d-0d19-474e-9d8d-a2d31ce02083">33,448,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtNS0xLTEtMA_31c553a6-f30f-43e4-97d7-e5ac7ba4c371">136,400,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtNy0xLTEtMA_e1758c4b-15a8-41bb-baf0-4d884c7cc965">60,007,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtMS0xLTEtMA_ae1d1190-09ab-4b79-984c-a53176253a1a">83,201,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtMy0xLTEtMA_f5976086-e1c0-4de5-a852-ba73dee95710">33,180,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtNS0xLTEtMA_b0422dcc-dbb0-4e2a-a2d4-f640629f9b92">135,756,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtNy0xLTEtMA_27ad989c-8f32-435c-92ec-4cfac330c251">58,413,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtMS0xLTEtMA_2901343f-5734-46ad-bf10-1c28e647b774">928,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtMy0xLTEtMA_abb816c5-5ab6-4fcd-b587-78b04ae0cae2">1,067,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtNS0xLTEtMA_42cbed2e-afb5-4664-ad29-05ff42a66018">1,697,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtNy0xLTEtMA_b1c766a9-d035-4c72-8e6a-48fcc31f9770">1,483,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctMS0xLTEtMA_5629ae22-7823-4d51-946b-d0149c535dec">466,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctMy0xLTEtMA_17257e68-cec0-4d50-9d48-e7d9226870be">2,846,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctNS0xLTEtMA_c9134a7c-2b38-4b5d-a9ec-77fb67f1e592">979,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctNy0xLTEtMA_7df67515-8245-4a0a-8389-9a9ecaaa34f3">5,650,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktMS0xLTEtMA_8ee15d70-25e8-4405-a89f-0f327796d9a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktMy0xLTEtMA_e3e928a3-ee7d-47f9-8850-caa7f2dfd07a">97,755,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktNS0xLTEtMA_c90bc00f-2825-4f6a-a598-bc73ca2a8a9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktNy0xLTEtMA_6323998e-4e68-42ad-ac9b-9b8253dc2f46">110,976,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtMS0xLTEtMA_2bfbbba6-8749-4168-9433-806ce0db6b30">278,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtMy0xLTEtMA_22e93bda-f6dd-4760-ba99-caaf7ccccea4">3,883,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtNS0xLTEtMA_c02001e1-6566-4655-a22c-4a14984f3e87">551,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtNy0xLTEtMA_15e05d90-0d4f-4adb-8650-fdfa96029a95">9,298,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtMS0xLTEtMA_db99196d-4404-48cf-817b-5f3cccc47b3c">136,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtMy0xLTEtMA_16abd1b0-0118-4ad8-87be-75f64b36a586">4,358,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtNS0xLTEtMA_f7984269-e8e2-4efc-acdd-f1b6da3595fc">711,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtNy0xLTEtMA_eaa700ba-3b8a-46a8-9e96-44fb2402dfe8">691,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItMS0xLTEtMA_f91ccd75-daa1-4eb8-849e-d7e5e9a2c31c">185,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItMy0xLTEtMA_f7055b4f-04d4-46ad-a9b4-c9cf2bbedeb6">152,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItNS0xLTEtMA_db560e10-caf0-4bbd-b145-eaa5f8ae50e3">194,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItNy0xLTEtMA_f8a01a0d-db12-45f3-a3d5-b9398ea84ad4">577,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtMS0xLTEtMA_d62c4d23-54a8-48c6-a37e-a891618e6934">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtMy0xLTEtMA_63f77d19-311f-4f55-b69f-d39cbfdf22d1">4,121,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtNS0xLTEtMA_4bb414be-06ac-4300-a0a6-87f7a0d18e6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtNy0xLTEtMA_8a74fad4-bd65-4140-85b4-215a59a23538">4,121,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctMS0xLTEtMA_df2980e7-122e-4f51-965f-1fc24e454944">82,139,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctMy0xLTEtMA_de61e8b4-c363-4755-8ca4-dbdc895ad758">128,270,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctNS0xLTEtMA_484ffaf8-5c22-44e5-9438-b97bf891159f">136,107,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctNy0xLTEtMA_cf0c00bf-f3bc-4b99-9ca5-23c73043916f">161,406,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktMS0xLTEtMA_17525e78-7d6f-44a1-8254-36eb5c1ffaf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktMy0xLTEtMA_f69afdf8-74a3-40b5-ad46-921af8bf1c41">901,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktNS0xLTEtMA_995a7c92-51b5-4d44-bef0-237622024a9c">434,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktNy0xLTEtMA_086e5ac5-6f02-426d-b30d-32db05b9ab10">901,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtMS0xLTEtMA_232c12fe-242e-49a6-bc53-8611e38703e4">82,139,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtMy0xLTEtMA_4f959147-5968-431c-8274-a8ba0b952516">129,172,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtNS0xLTEtMA_0ee59537-318c-4299-ac15-9b2c71bba07e">136,542,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtNy0xLTEtMA_475581e3-5451-464e-bc14-3aed32884fcd">162,307,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtMS0xLTEtMA_fe4d69a0-1d42-4f97-a15b-b135bb301011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtMy0xLTEtMA_57ac0018-60e5-4c38-80d3-b84543020f70">469,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtNS0xLTEtMA_9f465252-2c7a-440d-bde2-fbb061a22ddd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtNy0xLTEtMA_1ef5e119-a8fb-48c2-8a8d-157b3b931237">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItMS0xLTEtMA_cd41d7de-cb97-4376-a3ce-4c048932f4b3">82,139,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItMy0xLTEtMA_496224fa-0e02-448d-be58-8e614a1ccdff">128,703,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItNS0xLTEtMA_6de12d0d-8693-4a3c-9004-2313864eb8ca">136,542,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItNy0xLTEtMA_862ae637-7fdd-42bd-a552-9991370baadd">161,244,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMS0xLTEtMA_77a3f73e-fbd6-4334-85e4-cd667d5bb5a3"><ix:nonFraction unitRef="usdPerShare" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMS0xLTEtMA_a5efaadd-db5f-4afe-b2a8-307b6e6c5f1f">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMy0xLTEtMA_6da92e00-fe90-4e50-8f36-0687cf5bab12"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMy0xLTEtMA_c3af9eeb-49e4-4873-b2d6-a003963024bb">0.83</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNS0xLTEtMA_22949fe9-eeba-4bf4-aa63-3fcbafb46c27"><ix:nonFraction unitRef="usdPerShare" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNS0xLTEtMA_bf9e1c2c-c285-4783-a05c-1ec3cb805c6c">0.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNy0xLTEtMA_173de90c-1f29-4cba-893f-a445a363ea77"><ix:nonFraction unitRef="usdPerShare" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNy0xLTEtMA_c5c95ae0-8f82-44a3-9c44-136079f4babf">1.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMS0xLTEtMA_6926f7c8-718c-4fa6-ac14-cc577c310a8e"><ix:nonFraction unitRef="shares" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMS0xLTEtMA_a9bb2cdb-03cd-46c4-a4a7-154f3dbf6990">209,561,064</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMy0xLTEtMA_625882e8-57f8-4856-ba29-f35dbadfb006"><ix:nonFraction unitRef="shares" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMy0xLTEtMA_643e9d9e-eadd-4ce5-9f5f-741ac9730254">155,807,054</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNS0xLTEtMA_eeeeddb7-bbd2-4e09-abfc-18f65e1a7f8a"><ix:nonFraction unitRef="shares" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNS0xLTEtMA_fe8371e3-975c-44a6-a599-f4fe8ed07167">206,007,497</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNy0xLTEtMA_8e6a0024-a56d-4525-ac4d-882ec0a2f26d"><ix:nonFraction unitRef="shares" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNy0xLTEtMA_a011ba71-f9e8-4fde-917d-3517b78fd9f0">140,215,158</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi0xLTEtMS0w_32644c79-dc26-4350-8957-4464a9a11b81">82,139,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi0zLTEtMS0w_f3f910fd-c1b5-4a17-9a76-ecc0b95e08fb">129,172,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi01LTEtMS0w_44f4ab9d-f602-4e13-81de-278e57e4587f">136,542,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi03LTEtMS0w_73302694-a67b-4134-a326-631b805632aa">162,307,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS0xLTEtMS0w_130cf7b6-51b9-4bc7-858e-2137ff4e4354">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS0zLTEtMS0w_6cc04836-63da-4bf6-81a6-b78e35243673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS01LTEtMS0w_04921324-2036-42f5-abc6-93f5a25683cc">11,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS03LTEtMS0w_87f04d03-b6f5-4f8c-80a9-3d09bdc8a797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi0xLTEtMS0w_65293462-ea13-4e27-9b0d-e60c44f61321">2,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi0zLTEtMS0w_2966902d-a103-47fb-83ee-151de94a2564">846,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi01LTEtMS0w_d78ad60c-b9a0-4109-9d3a-515ca3e60e50">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi03LTEtMS0w_4632ea03-7557-4081-8809-cf753713ba9e">1,082,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS0xLTEtMS0w_a28dadab-9a2d-4da6-ae49-8ec3f2918400">82,140,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS0zLTEtMS0w_a643d1c2-4b9a-4bf5-b1b1-982f92281d26">128,325,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS01LTEtMS0w_0420ab5a-2f5c-497d-a97d-65894933337e">136,551,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS03LTEtMS0w_83a6e019-7d58-4749-91ab-8fd8604a6a88">163,390,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtMS0xLTEtMA_c2fb362f-dc24-46c3-a2e1-3b69ede3a517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtMy0xLTEtMA_a77b7193-9efb-4cec-a1c4-efae9c5364c8">469,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtNS0xLTEtMA_c020e626-794a-4626-b35e-b4c54137739b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtNy0xLTEtMA_e92fec6d-9f9e-4c80-9746-9316be7e99c4">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtMS0xLTEtMA_37218585-b3ca-494a-8db1-6a719d8aed9a">82,140,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtMy0xLTEtMA_98c4ac6d-6f0c-45f0-82e0-c5e1dfc1241c">127,856,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtNS0xLTEtMA_c42f354d-8dd5-4c83-b69c-22b107b3dff0">136,551,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtNy0xLTEtMA_29e87e4f-3072-4023-b5fa-32e3f4d6ccb8">162,326,751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12aac99aaaf741349f86a989fa764482_I20201231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xLTEtMS0w_f8ef5a73-e5bf-4697-a412-8e81febd9d36">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12aac99aaaf741349f86a989fa764482_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0zLTEtMS0w_29f6d84f-c7a8-461c-bb11-8d29cb320c45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i799a2702ab5a4bd4a435e11c1046de46_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy01LTEtMS0w_02adf9ab-e9a7-4472-a525-77478ec5d69d">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799a2702ab5a4bd4a435e11c1046de46_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy03LTEtMS0w_5b39612b-10a0-4648-936b-2bd7df308eb2">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44709f40e8a943049398893f00a24be2_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy05LTEtMS0w_7570aaa7-0c13-43f7-b2f9-538f39f0becc">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85e84c6e219d4b4ab6f799165f3ff3f6_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xMS0xLTEtMA_84a4c4ea-c547-41e9-9ed3-736c6a502636">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5bb1d8705d24b5cb342ad0d76c412f9_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xMy0xLTEtMA_b5af81f5-a84f-463c-b41f-08a1911dbc6d">256,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xNy0xLTEtMA_f834c594-fc27-4b42-addf-331101148d2e">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs of $<ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC0wLTEtMS0wL3RleHRyZWdpb246MWQ2MDk0ZGFjNTBmNDkzZWI1ZDA4YWU0OWYyYTUxNDlfNjU_e002f314-6ae6-402f-8ff2-7ac0f2ca2849">531,000</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC01LTEtMS0w_86cf3d1e-b23d-4f74-b591-8ebd77ec31f4">20,355,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC03LTEtMS0w_d7812302-1f78-41dd-a24b-f5afc98df449">20,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC05LTEtMS0w_1c1664d0-82d5-4569-a329-99e6d8208cc9">162,084,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC0xNy0xLTEtMA_c3ae4974-a2dc-45a2-9165-40afd308c6f6">162,105,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of December 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS01LTEtMS0w_72374c60-819b-4fbc-a19d-dd0dd2dd9461">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS03LTEtMS0w_1eab4dde-a4f8-46b6-b921-31b238157852">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS05LTEtMS0w_5cb8236a-5efb-479f-8ebb-4fbd4099153b">4,376,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS0xNy0xLTEtMA_3664dbd6-641b-4d5c-a45f-f37614824a7b">4,377,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi01LTEtMS0w_cfcb1b4f-6b06-4662-bd6e-dd65f59ddc45">1,118,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi03LTEtMS0w_062dd984-32d7-437e-b252-31e093df0f0f">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi05LTEtMS0w_9b3576aa-d0e3-43eb-a02c-81ffa6c85e7d">1,202,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi0xNy0xLTEtMA_655aea9f-7624-4599-9829-179c7027219a">1,201,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNy05LTEtMS0w_c60e4d05-753c-44f8-8bfd-bc4ae9a5bc3e">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNy0xNy0xLTEtMA_7a29274b-302f-4b02-9291-32c76b7888b3">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6be5b29e6e640aeb3b3c6f8c8b4b46a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOC0xMS0xLTEtMA_0acb83c4-34ae-41aa-b4c8-0f3abee4996a">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOC0xNy0xLTEtMA_da191c2e-9871-4eca-9035-006f95dd49a3">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia305805348c642e181a5a220764cd0cb_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOS0xMy0xLTEtMA_3c4e636a-c558-448e-87fa-8a2d52f93991">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOS0xNy0xLTEtMA_5b9ced1f-450a-456b-aefe-b527e23b3401">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia305805348c642e181a5a220764cd0cb_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTAtMTMtMS0xLTA_d631841c-d5b1-434e-b8c1-ac75d1b2ddd1">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTAtMTctMS0xLTA_6050d94d-0811-4688-ad00-8cc5d684a44f">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie410c23f3d734e22a654add21f7dd4be_I20210331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMS0xLTEtMA_d0acd26d-b349-4cab-a7d7-f7d5826833cb">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie410c23f3d734e22a654add21f7dd4be_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMy0xLTEtMA_c8489efd-e120-4c1b-a15b-be504d8542b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd07f46a44cf47b29f251e9f8b53b448_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtNS0xLTEtMA_28b968eb-a010-452e-bff9-a86d91155bbe">209,334,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd07f46a44cf47b29f251e9f8b53b448_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtNy0xLTEtMA_89fb5034-0507-4e56-a391-01706c303925">209,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb3c65da07554ec0a475b65aec785e3e_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtOS0xLTEtMA_76cd07d0-9068-44d2-8855-e6c9cfac6752">1,542,261,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd8b502204b444ec8fc08ad865e94b35_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMTEtMS0xLTA_1e8bd1dc-2a95-4b7b-800d-d1ef3d96c9a7">960,598,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9fc53bfe459451e93c099b12e3d7d7d_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMTMtMS0xLTA_4778d6d7-1ccc-446f-a695-0314b7054f73">265,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97826d72ea649e4b70791285961ac6c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMTctMS0xLTA_f32c18f2-d8bd-465a-91f4-5b9109e944b7">581,606,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib69edae5e51e45c6a95fcd35749a9236_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtNS0xLTEtNDI_28a20c65-324e-4031-a586-092ad5e6ea96">812,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib69edae5e51e45c6a95fcd35749a9236_D20210401-20210630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtNy0xLTEtNDI_c8537d6f-0930-4448-9e93-56fd8f915569">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3da144150804a6fbb5a9f2eb556643e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtOS0xLTEtNDI_5e560803-8226-47dc-8e30-a1c40e039646">3,440,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtMTctMS0xLTQy_e2a2c474-12c9-4e07-acdd-ead077765d3e">3,441,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3da144150804a6fbb5a9f2eb556643e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTQtOS0xLTEtNDI_42aea164-4283-46d3-962d-fe55c429a84b">5,646,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTQtMTctMS0xLTQy_4db49f3a-9e4d-46a4-9fbb-8d929dd030d4">5,646,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i108e0d957d844157b477393aead9cc52_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTUtMTEtMS0xLTQy_63644812-bb55-4c07-bb03-96eebf62c68b">82,139,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTUtMTctMS0xLTQy_e3011708-00fc-4cf4-9978-a27b0d6b5dc4">82,139,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1439ad58b8a4b8d80f168ebe9e96082_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTYtMTMtMS0xLTQy_78253903-fbce-4f18-8b7e-21d4f884bcd9">2,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTYtMTctMS0xLTQy_8c27ba3c-5e56-4e61-9150-85c0baf5a6d7">2,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1439ad58b8a4b8d80f168ebe9e96082_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTctMTMtMS0xLTQy_b3df5628-c46e-461e-aefa-5e91b12d7d33">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTctMTctMS0xLTQy_e0eee643-8c9b-489b-8685-3778a9097334">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fd181698642459c9825e12bed9aa37d_I20210630" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMS0xLTEtNjA_ba20d384-0e91-4614-a344-0e4a1e990db4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd181698642459c9825e12bed9aa37d_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMy0xLTEtNjA_a94e5bac-ac97-44ce-9470-de631ad186d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3abe12b5c3451b84594cfcc6853c43_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtNS0xLTEtNjA_2e56ce5e-737c-4e87-886f-d488db7ef63b">210,146,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3abe12b5c3451b84594cfcc6853c43_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtNy0xLTEtNjA_684635b7-6de8-403a-ad97-8815048e256d">210,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i254bd042051242849bc85dee66371184_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtOS0xLTEtNjA_7f2cc302-70cd-41f5-8607-0d7505cd4be0">1,551,348,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42516c7d860c496fa39ae9ebb52897c6_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMTEtMS0xLTYw_475bb6ce-de9d-42de-938c-21492038f600">1,042,738,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ebf817b5d604254a7317c1108eb9e22_I20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMTMtMS0xLTYw_de3777a1-d0d4-4d6c-aacf-187f708011d2">265,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMTctMS0xLTYw_cd2c7c5b-3df7-489d-8494-e20c4a6eff82">508,553,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.567%"><tr><td style="width:1.0%"></td><td style="width:27.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Six Months Ended June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if20cd84b26984f8f9e8f6f29f783d43c_I20191231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMS0xLTEtMA_f944f81b-4824-4958-8400-d015218b7ecc">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20cd84b26984f8f9e8f6f29f783d43c_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMy0xLTEtMA_41db982f-b66e-4fe3-ab8b-a4dbea5b9cb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica81cf786c5d4fff8fd605675e3eac0a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtNS0xLTEtMA_fba9e008-37f7-4bbd-a6f5-2f1b27a7b127">101,361,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica81cf786c5d4fff8fd605675e3eac0a_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtNy0xLTEtMA_6520d879-c038-4550-82bc-ea8d7637065a">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f44eaa8aa2459ca2f8c8563adf249b_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtOS0xLTEtMA_6bb8796f-dc27-4b7e-9ca8-408c5397fab6">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2c97a020ced432dba7dfa7f21e090af_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTEtMS0xLTA_0774c207-4484-4fb4-b0df-524994426db7">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7027e5aeb5e64cd7ad992e12c7a0fb56_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTMtMS0xLTA_7617e612-146f-4d07-b04e-9df201ca2a38">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7c265546d74b3c8712996af91049b6_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTUtMS0xLTA_4c5e5168-2700-47a7-ad8d-5931dc33ecb8">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1879c69872f8418ab00a9d6a48983451_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTctMS0xLTA_47e5b70d-1d10-43cb-8a2d-19dadb1d7412">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtNS0xLTEtMA_11da7a0c-29a2-4838-ab5a-e8b9e8fedb7d">43,148,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtNy0xLTEtMA_5374f53b-287b-4913-8c18-ec01b0e59197">43,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtOS0xLTEtMA_59c36025-afbc-4144-a879-66fea2409dd6">208,198,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtMTctMS0xLTA_61e26667-2e11-471d-b7be-ac97e1d451e8">208,241,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtNS0xLTEtMA_bbfeb133-592e-4b7a-a70b-2df88fa05d3f">1,405,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtNy0xLTEtMA_e39877a9-0d74-4c04-aff4-e346805d8d84">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtOS0xLTEtMA_2e7d2c83-8f98-4b7d-abaa-ee8ae8284f72">3,099,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtMTctMS0xLTA_b90f9f4b-50bb-4066-b7d3-e33171ed6ab3">3,100,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzYtOS0xLTEtMA_fe715955-dc0e-45cb-b297-b6f7e898ca5a">4,017,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzYtMTUtMS0xLTA_b3f29857-010d-43f1-aa52-8c0ee8a3e8a8">16,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzYtMTctMS0xLTA_bde235d0-71cf-4fcf-9bed-658db7842926">4,001,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzctMTUtMS0xLTA_a1fbc84c-2e59-40ef-a937-f0ff53f764cc">2,169,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzctMTctMS0xLTA_0c8a43da-669f-4d97-9592-6f7c0d930145">2,169,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8eecef92b9240d5bfdf9e6810786a6e_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzgtMTEtMS0xLTA_0cb7acfc-5174-407f-a9c5-92fcc6073fef">32,541,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzgtMTUtMS0xLTA_dd3f702e-9d6c-4bf3-802a-93dd473ffbd2">594,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzgtMTctMS0xLTA_fe8c015e-04eb-42c5-9590-f695080dfb2c">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff215ce28014289ac0323b81097347d_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzktMTMtMS0xLTA_9a081950-0180-4fd0-8092-d28bc0431e55">1,929,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzktMTctMS0xLTA_d58a7d7f-ff1e-41d0-901b-447227154fe3">1,929,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i005c775b4401470a90ee91adfbb417b8_I20200331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMS0xLTEtMA_d93dacb3-804f-45d1-9a53-2b7f38cf1e4c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005c775b4401470a90ee91adfbb417b8_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMy0xLTEtMA_ae88d82b-17fb-4090-9ddf-9a18512fae0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1a0656da9344a8a8b854e2ca77a6732_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtNS0xLTEtMA_6f54c6a4-78fd-466d-a26c-461c01d0a2d1">145,915,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a0656da9344a8a8b854e2ca77a6732_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtNy0xLTEtMA_9a84fdbd-cf36-4d99-97e1-26df2b2220b6">145,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa58a8fc43214b7bbd63cc831b027ff0_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtOS0xLTEtMA_e6836fac-01ec-4f82-89c7-d607730ea43c">957,962,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ee8db81f57e4c278a66fdfcba5073cc_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTEtMS0xLTA_74185c72-488a-4864-a989-5a420fa1ebbf">772,326,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4fb0140f8414f75b8e619c79cf2a649_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTMtMS0xLTA_69f6890f-8487-4079-8043-e894cb891a89">1,456,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0caffc4cfd24e629b7a9fa306e19b99_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTUtMS0xLTA_7288ec6d-ec33-45d8-9b90-281d19d5e300">3,529,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb00ed027cf4a6bb677b4122123ec1a_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTctMS0xLTA_dc757703-30f3-4e62-a599-0608ecc96f97">187,854,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtNS0xLTEtMA_dd819dd7-bdf8-42de-98e5-1d262fc7e1d2">12,041,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtNy0xLTEtMA_21552ab2-e30e-4b83-8f9e-72c63deea162">12,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtOS0xLTEtMA_719edc34-23cc-42e1-8866-3a61c1b713ee">121,706,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtMTctMS0xLTA_9c338b38-07d9-4f76-8a7e-d29db595ba58">121,718,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibfc901c89fb3492ea30e005f1f9c9e8b_D20200401-20200630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItMS0xLTEtMA_e7d6a38b-2624-4082-a87f-fbeb8b6ea063">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItNS0xLTEtMA_2725b7d8-4453-482e-adad-515eb3433298">5,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItNy0xLTEtMA_bbb12a9d-cc49-4451-94a8-9ca481c38d57">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItOS0xLTEtMA_c5839a75-42ec-422a-a06c-4794d3fd9c7e">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItMTctMS0xLTA_fabe4158-3e9a-4bb6-8019-2126b024eae7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtNS0xLTEtMA_64dd57d2-ee96-4d94-83b9-f3d20b9cf8fb">794,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtNy0xLTEtMA_e49bba61-483a-4690-82cc-534e36a7c1f8">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtOS0xLTEtMA_5747fb49-8373-4019-af65-3ca0816d9398">4,421,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtMTctMS0xLTA_e2906e38-05cb-4c07-bb5b-822d79b1f052">4,422,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDQtOS0xLTEtMA_aef5b2d6-5573-41f5-a869-917071e48f24">3,654,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDQtMTUtMS0xLTA_ae423cd3-05d4-445c-82c2-70769a03abbe">8,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDQtMTctMS0xLTA_198406db-4a1c-43ef-a896-5a4256a23c08">3,662,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDUtMTUtMS0xLTA_0a854081-2ee5-4f68-b0b7-a3c0ee8dbad0">209,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDUtMTctMS0xLTA_261fcc96-28ae-4959-a8df-3c61014700e4">209,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDYtMTUtMS0xLTA_fbb47562-9bd7-455c-bf4b-c4d62270bb92">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDYtMTctMS0xLTA_a62529a1-d0fb-45e5-98a8-eb1eadfe1833">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icabb95078cd04d3b859cdd387e239ad7_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDctMTEtMS0xLTA_7b3bd959-e493-45d5-83f8-8f21de98379a">128,703,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDctMTUtMS0xLTA_202a8aca-2239-46e7-a482-ef7b2daaf18d">469,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDctMTctMS0xLTA_54b4cfb0-9cf4-4332-ba61-033a5284dba5">129,172,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886aa86a8ef3444899784ec9f609e6e7_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDgtMTMtMS0xLTA_25c6e951-223d-41fe-9665-63248d0766c3">846,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDgtMTctMS0xLTA_ddd18b04-246d-4d1d-ae44-ae72a0e86897">846,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0963ef6fa894e47b9e2458dad5bd538_I20200630" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMS0xLTEtMA_0233d166-1108-4424-8866-a0a951e3ff2c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0963ef6fa894e47b9e2458dad5bd538_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMy0xLTEtMA_1e56e713-c1b2-4374-8886-8ca76327cc4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbfee2e1b2af4f098563291bfb7a6e6d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktNS0xLTEtMA_bbd811ce-b047-46d5-8871-56bc54d4da65">158,756,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfee2e1b2af4f098563291bfb7a6e6d_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktNy0xLTEtMA_de652c75-9309-44fe-a0f4-445ec89c52a6">158,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4152dc4545d04bab8fe2acc7fb1b3424_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktOS0xLTEtMA_695a124a-2180-4997-b765-2306073e1b37">1,087,745,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1eb417f6f754a2ea880089bb2a38945_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTEtMS0xLTA_f9993ef5-c5c9-4f3c-8f09-0c6fc70281f3">901,029,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id92715916320442a9ca37398433d7c01_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTMtMS0xLTA_ca7c3982-94e3-4d5c-a124-2f6a3ea850fb">610,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5677a5c642824f42ad93623935b5b5bf_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTUtMS0xLTA_fb39c22d-f127-4a4f-ac3b-9d5cd2f6cd71">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6030a2333ec842288f8ea1f6eea367a2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTctMS0xLTA_986cc988-053d-4291-bf31-0b3990a12119">186,360,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_28"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMy0xLTEtMS0w_2530b86f-ebfe-4389-91c1-1cbda2442225">136,542,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMy0zLTEtMS0w_e900904a-5cb7-48d9-95b2-ac4fafb0b604">162,307,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNS0xLTEtMS0w_4d2ad9d4-b6b3-428c-b422-46bfffa7e54b">1,361,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNS0zLTEtMS0w_b4e57f8a-f628-4e44-a560-eb59f20fd2dc">1,608,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNi0xLTEtMS0w_e566ab15-9767-4375-9e76-273900177140">266,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNi0zLTEtMS0w_5c132b92-5a99-4aa0-a2f0-43161584b9b4">273,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOC0xLTEtMS0w_0b75be13-8811-4660-acb9-ffb5e009eb8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOC0zLTEtMS0w_9e0442e8-c2aa-4549-a38c-1dc7c2d87cc7">110,976,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOS0xLTEtMS0w_17d83ae7-2fd8-4e53-9455-3d383517af25">15,242,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOS0zLTEtMS0w_f5468521-924b-459d-bc22-3e7f04880f00">7,663,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:NonCashInterestIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTItMS0xLTEtMA_41e092a4-bbef-4099-8c00-dba548a7f8ae">435,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:NonCashInterestIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTItMy0xLTEtMA_144599ba-0b36-46ab-8d02-c6e7602fdef1">3,013,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTQtMS0xLTEtMA_84e2fc1b-a09a-4688-9503-f77ee4c09e8c">153,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTQtMy0xLTEtMA_157128ae-80d7-4c8d-b050-0ded0752209c">576,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of receivable with shares of common stock from affiliated entity (PLS)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTYtMS0xLTEtMA_a403e5c8-3a46-405b-9d75-694e5fc62a7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTYtMy0xLTEtMA_05aaa537-f348-4f86-a691-44f368f63aff">1,713,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTctMS0xLTEtMA_1f07a7f0-ebba-4c15-bae4-28c5e5f0f331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTctMy0xLTEtMA_fd8f61bb-9eb1-435c-9b1c-92f5c694b750">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on equity investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTgtMS0xLTEtMA_b002f112-67e3-46ce-bb8c-d6e2b50211bf">551,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTgtMy0xLTEtMA_ddf9fc1f-3bc4-44ef-ae13-8611745c4fed">9,298,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTktMS0xLTEtMA_47300142-e9ac-49f7-ac0c-720cc17c95d9">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTktMy0xLTEtMA_4037282c-a164-4271-a149-64b314e66dc7">901,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjItMS0xLTEtMA_34eaf906-4755-4aa4-bebb-71909bd63d76">711,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjItMy0xLTEtMA_e7a6f707-0b0f-456f-a844-623775687181">691,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="ino:OperatingLeaseNonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjMtMS0xLTEtMA_05a77eaa-fdf9-4d00-bf68-069a34217496">567,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:OperatingLeaseNonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjMtMy0xLTEtMA_8a0fbab7-7b55-45f3-91ee-e501d7a1c41f">517,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized transaction gain on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjYtMS0xLTEtMA_f359fcc5-fd57-4674-9834-fd9c22dc4a49">176,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjYtMy0xLTEtMA_b7f8eb79-f332-458d-ad78-643702da4b95">474,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjgtMS0xLTEtMA_9474c4ee-b1f8-4083-ac0f-b8feb449cf68">5,431,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjgtMy0xLTEtMA_c4383805-be05-4bb5-9e3e-266ccd457c80">2,813,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjktMS0xLTEtMA_29322e02-3917-4f7c-a749-60f376a69c14">219,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjktMy0xLTEtMA_ac147e1b-e34e-47d0-9ef4-7ff87c75cc0c">865,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzAtMS0xLTEtMA_141b69a6-f117-48b5-81cb-59c9abaa709f">51,944,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzAtMy0xLTEtMA_0cc7828e-db1b-472e-aa96-387c29a3695c">3,084,082</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzEtMS0xLTEtMA_bef7d456-a96b-4f64-9d90-8cbd5219da09">197,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzEtMy0xLTEtMA_060067fc-9368-4b3f-baed-882e8c7b9198">1,330,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzMtMS0xLTEtMA_98f8a6d1-4514-4a21-a083-41a75ea530b3">24,126,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzMtMy0xLTEtMA_b1f6c323-726a-4290-a56a-14d4c6931449">116,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzQtMS0xLTEtMA_e8d1a817-fee6-450e-a823-826fedb2b3bf">8,891,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzQtMy0xLTEtMA_a6965a1f-4561-47a8-9a97-d3ba18579267">732,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzUtMS0xLTEtMA_a8849c4d-af5a-4c17-b8d9-ab71af4277be">465,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzUtMy0xLTEtMA_38fae5f9-8287-4e42-982a-01d8fada12f0">2,882,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzYtMS0xLTEtMA_cae0798a-19e1-477a-ab0e-57113cd4e4b3">1,130,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzYtMy0xLTEtMA_4190c41b-4bdc-484e-a1f8-68a994c452b3">4,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzctMS0xLTEtMA_3c3d107b-c35c-4b05-a061-b7e949ed2a1b">55,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzctMy0xLTEtMA_320a95b6-1b50-451b-a45c-c2b5214a6b21">92,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzgtMS0xLTEtMA_ac31812a-0381-4650-9c44-15677f2bdcd3">6,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzgtMy0xLTEtMA_12144346-229f-4aed-be77-a96aa6dca628">62,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDAtMS0xLTEtMA_51a68a40-5507-4c8d-992a-373f5629c57d">1,131,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDAtMy0xLTEtMA_c0b0e494-9867-4cf5-9a67-4d8846789668">1,022,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDEtMS0xLTEtMA_9ced9efc-63d3-4bea-a3f5-15da03638011">615,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDEtMy0xLTEtMA_3504737f-f96e-43ec-bdbb-c7160d069704">4,265,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDItMS0xLTEtMA_ffbcf316-8274-45e7-8b73-fe2c3ab3aaf3">21,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDItMy0xLTEtMA_b6a754ab-c6cc-4549-b37b-2124806df63f">63,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDQtMS0xLTEtMA_37b0fe6e-f888-4317-a3c2-f0838baa48d8">6,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDQtMy0xLTEtMA_a87228c1-0005-4514-8961-73910ff50745">29,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDUtMS0xLTEtMA_001b92b4-5739-4f17-a12a-770b7fd88077">131,326,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDUtMy0xLTEtMA_c88c3132-980d-45af-9361-02beb23a2868">52,604,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDctMS0xLTEtMA_54c5c4e3-fddb-457a-9f0d-99efe2701868">307,857,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDctMy0xLTEtMA_923113b5-918f-40fb-aef1-d78f7c512c07">138,698,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDgtMS0xLTEtMA_6619282d-8de6-4e29-b341-4b13852efd63">83,466,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDgtMy0xLTEtMA_b95d9919-df84-4da6-9d66-19d68c6c3b98">47,455,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDktMS0xLTEtMA_bf82032d-7d75-49e7-a4ab-a53999a1f2c1">418,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDktMy0xLTEtMA_e0b375f3-83dc-4fd8-93cc-de6917617112">176,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTQtMS0xLTEtMA_6588a940-075b-496f-b813-3c76e9c38c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTQtMy0xLTEtMA_9fb785bf-a498-4334-be76-81166561390c">2,774,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTUtMS0xLTEtMA_8876393e-d74a-4a84-9686-597ae524fd21">224,808,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTUtMy0xLTEtMA_9a704fd9-de52-4bb1-b060-655a68da07e6">94,194,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTktMS0xLTEtMA_e564535f-ce20-499e-8fde-6c8d7a58d960">162,105,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTktMy0xLTEtMA_6707d2cc-9b06-42da-beca-2075d7742442">329,960,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjAtMS0xLTEtMA_a3d3fdcf-8d0d-4d62-ae69-87bf71beb8fc">6,154,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjAtMy0xLTEtMA_ac516b4a-5f09-4712-baac-ebaa99ea851f">9,599,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjEtMS0xLTEtMA_6d7cbf2c-7fd8-478b-9579-fb47e819b990">3,915,160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjEtMy0xLTEtMA_142ab2ac-fc79-49d7-b670-e50ba5a3d289">2,076,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjItMS0xLTEtMA_fbe057e5-193e-451b-b7e9-43ddecc21132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjItMy0xLTEtMA_36cc8309-108b-41f1-8e01-a91d4596fd68">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from Geneos issuance of note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjMtMS0xLTEtMA_10a2617b-1bf1-49d9-a11b-98da25b9350e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjMtMy0xLTEtMA_46de8424-fe82-4926-a480-ae3215faca52">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjQtMS0xLTEtMA_02bf7a61-7c39-4f82-9486-3e9ae4068080">164,344,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjQtMy0xLTEtMA_b3968129-9bfd-475d-925b-67cc8cfdea94">340,035,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjUtMS0xLTEtMA_517eaa27-3775-4ca9-bf0f-7a2e3dce537b">11,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjUtMy0xLTEtMA_91e0318f-d600-430d-beae-69d6d3219dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) Increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjYtMS0xLTEtMA_caf1cad0-cd1f-4f9d-8b33-14e12317fccf">191,802,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjYtMy0xLTEtMA_c3c6d69d-2067-4e14-ab6e-1c716f1c0380">193,236,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjctMS0xLTEtMA_7c9f748f-a529-44c9-acea-deb46dc87982">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1879c69872f8418ab00a9d6a48983451_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjctMy0xLTEtMA_2d014439-f241-4ff0-b1d5-a167f7ee3dbe">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjgtMS0xLTEtMA_a55b3725-b3c2-4d06-9072-3e08594de3f8">58,925,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6030a2333ec842288f8ea1f6eea367a2_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjgtMy0xLTEtMA_3c3373df-6eac-498e-903e-428f446b07cd">215,432,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzEtMS0xLTEtMA_6b2e894f-5edc-4f07-97e3-adf1156bcb80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzEtMy0xLTEtMA_0ad8f1e6-7b91-4e9d-8667-26e3a905f686">1,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzItMS0xLTEtMA_c23f00aa-4b27-4063-afef-c5cd84f4a8fd">544,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzItMy0xLTEtMA_6ee1aea5-9317-4e8e-aa3c-4b3464135a0b">2,636,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_34"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">1. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNC9mcmFnOjVmYjM1ZGM4YTVkNDRhYmVhZjk4MDFkZmMzODM0YTRmL3RleHRyZWdpb246NWZiMzVkYzhhNWQ0NGFiZWFmOTgwMWRmYzM4MzRhNGZfMzUwOQ_72a72b86-98c0-4c99-a5f2-ed42081e60d8" continuedAt="i43c076743c4947b595fac1debd99e6c6" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="i43c076743c4947b595fac1debd99e6c6"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicine candidates are made using its proprietary SynCon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date have shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corporation.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for COVID-19; Middle East Respiratory Syndrome, or MERS; Lassa fever; HIV; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_37"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNzQ0Mw_ca409aa4-25ae-4a7b-8e2f-b69b98d0a221" continuedAt="i5121a93946bf4c12a0483d9847b19712" escape="true">Basis of Presentation, Liquidity and Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="i5121a93946bf4c12a0483d9847b19712" continuedAt="i9fe44cd33c494785b627b69b4ecaf5ae"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNzQ0Nw_46d21628-8ce4-4ce7-996f-01a579726d41" continuedAt="ia7651dc1880f44b3ad3bef8404a52e05" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2021 and 2020 and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and six months ended June 30, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><ix:continuation id="i9fe44cd33c494785b627b69b4ecaf5ae" continuedAt="id1345ed3cc4b4c098c16a98e98fe2dac"><ix:continuation id="ia7651dc1880f44b3ad3bef8404a52e05" continuedAt="i1d5e644ce9fa4e528f4586ad6a57f278"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. As of June&#160;30, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority-owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMjk1Ng_249a995d-0101-4d0d-8317-6be379c0b809">82.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMjE5OTAyMzI2MzAzNA_65258f44-d316-4487-a295-0b632f8c25cc">136.5</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Capital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMzAwNg_612f7ea3-b77f-4fc9-ab91-c22fb4328a52">490.7</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMzA0MA_49cb3c24-3f83-430c-8d31-9f9717b88ff4">1.0</ix:nonFraction> billion as of June&#160;30, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMzM4Nw_99a7c669-a60d-45b5-ad25-16e3808be8f8">443.7</ix:nonFraction> million as of June&#160;30, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0ae8485bffe44645bcc2d2d69167e061_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNDAyMw_8bb6c204-b9b0-4490-8f4e-8b5593bf05ad">162.1</ix:nonFraction>&#160;million from a January 2021 underwritten public offering and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6b7911f846a04e46825317fba23a0d2e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNDA5NQ_ad1807ea-0805-4688-a87e-8f546dbf85fc">454.5</ix:nonFraction> million under past Sales Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id1345ed3cc4b4c098c16a98e98fe2dac"><ix:continuation id="i1d5e644ce9fa4e528f4586ad6a57f278">effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_40"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0Mzc_109fb3a1-7860-4b5c-bbcd-bcae89494e98" continuedAt="iea52b4ba96e84a35a92b204ec6fc1313" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="iea52b4ba96e84a35a92b204ec6fc1313" continuedAt="i35f3c8e6a5a54247a1f87023cb201f20"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDc_f4583133-0180-4cfa-b1af-d7ebf73bfd8d" continuedAt="ic8c1f36dc3334100a5ce9e5e7e9475a9" escape="true">Collaboration Agreements </ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="ic8c1f36dc3334100a5ce9e5e7e9475a9" continuedAt="i321872ed65f843dd852679050927ab80"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i321872ed65f843dd852679050927ab80"> (&#8220;Topic 606&#8221;).</ix:continuation> </span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NTE_3ac3bfa7-e3fa-4766-a194-49892469c46c" continuedAt="i56aed30b6b70421f82372099972caf45" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><ix:continuation id="i35f3c8e6a5a54247a1f87023cb201f20" continuedAt="ie67e74d5454c4b11a19d3bf0cc016210"><ix:continuation id="i56aed30b6b70421f82372099972caf45"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="ino:GrantPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0Mjg_6af3b9df-05bb-48f1-8caf-0433c6d5ce1f" continuedAt="i4e6cd7a2139f4bdcb467614ff836bb9c" escape="true">Grants</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i4e6cd7a2139f4bdcb467614ff836bb9c" continuedAt="iaa2cf6898bc2441d82afab19ffb5ed92"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa2cf6898bc2441d82afab19ffb5ed92">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDg_a6568855-6e51-4544-af5b-b427ad4c566d" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0MzA_26f35ab7-aeae-447d-ad56-70c75a2cf578" continuedAt="i63949bf7fe4b4978b7582fe977774007" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i63949bf7fe4b4978b7582fe977774007">Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0MzE_986490b9-ea58-4aec-8608-7788ee3e72d9" continuedAt="i21bdd1819d5140ea902f94b1b76ae5d7" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1Mg_7c2a02d6-d7ff-4cb3-9069-106f0e2331f1">two</span> to <ix:nonNumeric contextRef="ic6c3eb7929d54a7db36dd6d7dbc2b7dd_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1OA_658068bc-f2b2-497a-91fc-5945e4b48643">18</ix:nonNumeric>&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><ix:continuation id="ie67e74d5454c4b11a19d3bf0cc016210" continuedAt="i88582d3a73cc40e48109e826c31e1a45"><ix:continuation id="i21bdd1819d5140ea902f94b1b76ae5d7" continuedAt="i19eeaff6a4694dc6a71c990dea5628f7"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTA0MzI_afc7a56a-f17d-44f1-836c-ffeee42d8816">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTA0NDA_f2568e49-aa82-4858-bfbf-e365c3be91eb">3.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through June&#160;30, 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i19eeaff6a4694dc6a71c990dea5628f7">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</ix:continuation> See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDY_a1fd3202-3456-403d-ad17-1432532185d7" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDk_c1881e2a-6dc2-473f-8edb-30b9f53355c3" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDE_ca468ae0-5ae9-4f42-87a6-18382f33d634" continuedAt="i7cc56d7df3924b148f36a70716da1393" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i88582d3a73cc40e48109e826c31e1a45"><ix:continuation id="i7cc56d7df3924b148f36a70716da1393">equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation></ix:continuation>&#160;</span></div><div style="margin-top:5pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80My9mcmFnOmU0N2QzM2FiY2E4NjQ4Y2M5ZDJhYTY4NDkyZWVjZGFmL3RleHRyZWdpb246ZTQ3ZDMzYWJjYTg2NDhjYzlkMmFhNjg0OTJlZWNkYWZfMTEzNQ_58ed8bf9-15cb-4026-b86e-8f899f2e9b40" continuedAt="i0094a4c96dbc4261abb3731008ba58cc" escape="true">Impact of Recently Issued Accounting Standards </ix:nonNumeric></span></div><ix:continuation id="i0094a4c96dbc4261abb3731008ba58cc"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80My9mcmFnOmU0N2QzM2FiY2E4NjQ4Y2M5ZDJhYTY4NDkyZWVjZGFmL3RleHRyZWdpb246ZTQ3ZDMzYWJjYTg2NDhjYzlkMmFhNjg0OTJlZWNkYWZfMTE0NA_5d03c529-4c5d-4807-b23a-c2e826c55c52" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_46"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfNDE1_30367cbc-82d8-41d4-927e-be67494e8226" continuedAt="i01adbd26a7e94e5fa88791261798521a" escape="true">Revenue Recognition  </ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01adbd26a7e94e5fa88791261798521a">During the three and six months ended June 30, 2021, the Company recognized total revenue under collaborative research and development arrangements of $<ix:nonFraction unitRef="usd" contextRef="i58f2d9f6575543589f663ac5ade5d146_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMTUx_f1b62da8-231b-4adc-985f-9a5c96492744">75,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ice4430b09f8f4a3d9c5b6e2ef7fa048f_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjE5OTAyMzI1NjA2MA_7c0a06b2-8f5a-4311-a717-33116539ae94">125,000</ix:nonFraction>, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $<ix:nonFraction unitRef="usd" contextRef="i4cf6343817df4d51b56069690f181906_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjIz_c348a26c-693c-49cd-9a29-c12c896d554e">198,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8419a4c84d46487aa9709be5474b797c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjE5OTAyMzI1NjAzMg_2dd9d695-db9d-4990-99c3-cd3ee4244372">519,000</ix:nonFraction>, respectively, from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three and six months ended June 30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMzU4_deac66a7-dbb5-40af-9ece-d3c5dc941bf9">35,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjE5OTAyMzI1NjAyMA_d181b928-7503-47b0-bb28-7a2949a2f0bb">39,000</ix:nonFraction>, respectively, were in deferred revenue as of December 31, 2020.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMzA0Nw_2c9016df-4f3c-46c4-94b9-a61f711042e1" continuedAt="i26a364eff45d4f03b3e63b8f576975c2" escape="true">Short-term Investments</ix:nonNumeric></span></div><ix:continuation id="i26a364eff45d4f03b3e63b8f576975c2" continuedAt="i5efad5fa893a4f6dae1a49ed0c20c4be"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Short-term investments at June&#160;30, 2021 consisted of mutual funds, U.S. treasury securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2021, the Company recorded gross realized gain on investments of $<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfOTY2_21cf23b2-e30b-49d1-a246-19b682bcdc01">358,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfOTcz_a7b2e739-c35a-4811-b3f8-96763edac64f">358,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTAzMw_36f03359-bfec-479d-8df2-80bbaabf2ff6">194,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTA0MA_97df5c47-9269-435c-825a-935df56634ef">204,000</ix:nonFraction>, respectively. During the three and six months ended June 30, 2020, the Company recorded gross realized gain on investments of $<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE0Nw_7ed70585-45f7-4173-b5bd-dea67a5d924f">585,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE1Nw_2874f97f-4033-4f74-a885-fd2172ff6777">635,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE2Nw_199aad22-7735-48c3-8c9c-02248e807e07">686,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE3Nw_3682f0cd-ee01-4ce8-9539-6f1ad6e257c2">1.2</ix:nonFraction>&#160;million, respectively. During the three and six months ended June 30, 2021, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTE2NA_57338cbe-dd1d-4bfc-8b44-dd887a8c3506">136,000</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTE3MQ_d24b3c8f-c46d-483a-b1ba-cc738697a045">711,000</ix:nonFraction>), respectively. During the three and six months ended June 30, 2020, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE5MQ_beca3b21-44ac-44a1-8d8a-58fa1da5b932">4.4</ix:nonFraction>&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTIwNQ_01b384ed-23ca-48a4-b924-b0964cf3e009">691,000</ix:nonFraction>), respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2021, the Company had <ix:nonFraction unitRef="position" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTY3MA_5f87c3ce-a303-4cf7-b1b7-b1b830f503a1">22</ix:nonFraction> available-for-sale securities in an unrealized loss position, of which <ix:nonFraction unitRef="position" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTY3NA_47653eab-27d4-4d33-9c41-2f6ed74cdb0f">four</ix:nonFraction> with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTY3Nw_da2748c0-5393-435b-b7aa-5ad0de1b7475">211,000</ix:nonFraction> were in such position for longer than 12 months.</span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMzA0Mg_9b187495-2dae-4814-a796-e94e544bd54c" continuedAt="icc2e226c7c6147d09dc4ee951be94d32" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of June&#160;30, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi0zLTEtMS0w_c110f4d2-b90b-4956-9f0c-3e9d1f322e0f">207,475,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi01LTEtMS0w_0442b626-8495-46f6-b774-bc664baf91a0">1,563,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi03LTEtMS0w_37efd383-c7bc-4141-bd99-6864328f2eb9">579,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi05LTEtMS0w_1ad0bb05-e51a-4b04-aed3-d1dd187517ac">208,459,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="if83d3a2efc6e49fa9fd97fa96d8adcec_D20210101-20210630" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy0xLTEtMS0wL3RleHRyZWdpb246ZDZmOTdmNjZiMGJlNGNiYmE0ODc5MTVhMzIwMDY5NmFfMTQ_361d3728-850f-4a72-a8b3-bc437d76339f">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy0zLTEtMS0w_0925efbf-c3ea-4edc-95bd-29dfdd015096">170,203,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy01LTEtMS0w_e1cdd990-5fb5-4af6-b44a-dc69ae0b1114">10,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy03LTEtMS0w_93771b03-d6aa-4243-a5d1-95ba9b2f2be8">4,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy05LTEtMS0w_cba269ed-5bd0-42d5-8fe3-7bc466b1f306">170,210,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i510a549b3ec34defbede167e3f43db38_D20210101-20210630" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS0xLTEtMS0wL3RleHRyZWdpb246OWZhZWY3NzYxNGM1NDZlNDgzZWQyMTU2Yjk0YzNlMTNfMTQ_16921289-4409-478b-8234-728ab9c5b771">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f229a241b946588368e702a0bfb111_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS0zLTEtMS0w_abe60b91-a35f-4eaa-ae74-72042417261a">2,972,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f229a241b946588368e702a0bfb111_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS01LTEtMS0w_4b60c34c-d0e8-4e08-9c2a-4a411454281b">25,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f229a241b946588368e702a0bfb111_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS03LTEtMS0w_dba3e86e-408f-4a12-ab39-7b387e28e668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f229a241b946588368e702a0bfb111_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS05LTEtMS0w_e5066e8f-0749-4d77-ae93-b14bf74bb5f4">2,998,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi0zLTEtMS0w_eb89ed76-32d6-48fa-9cc1-27c4a29d8239">3,130,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi01LTEtMS0w_c2d8545e-a866-4f7a-99d2-226f1ad8c94f">2,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi03LTEtMS0w_00b8b632-b7e7-4ca3-b3b9-15e06d9fc0b7">49,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi05LTEtMS0w_ee8b04cc-ce7d-4fd1-91a9-d6d180dddb97">3,084,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC0zLTEtMS0w_920f65af-e949-407a-b221-f062bafe4a0e">383,783,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC01LTEtMS0w_a974e371-bdc5-493d-8c7d-9ff845a7c233">1,602,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC03LTEtMS0w_3674dc7c-20b9-490f-a566-303672f48db4">633,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC05LTEtMS0w_189cc30a-07f3-479f-b288-3766b6162058">384,752,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><ix:continuation id="i5efad5fa893a4f6dae1a49ed0c20c4be"><ix:continuation id="icc2e226c7c6147d09dc4ee951be94d32"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi0zLTEtMS0w_80259d76-66d4-4a8e-9054-199d02100241">153,177,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi01LTEtMS0w_d775f297-6b8c-43f1-98c3-f29016339b9d">2,339,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi03LTEtMS0w_9910cbaf-d05c-442d-b167-7d0b33791db1">644,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi05LTEtMS0w_ec2786fe-54a9-4038-88a1-15588c32338d">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;<ix:nonNumeric contextRef="i9e7cf41bc39a400f8c65d4ac89cb740f_D20200101-20200630" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy0xLTEtMS0wL3RleHRyZWdpb246MTA4YWI3MjNlYzBhNDE0YmEyZDhhYWZlYzRmY2YxMzRfMTQ_3c87a2cd-af87-4ed4-8fbd-010e193608d6">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy0zLTEtMS0w_8c8fb323-f79a-4132-bc1e-6e3b0675884d">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy01LTEtMS0w_33bf58a2-855c-40ab-b1ac-a58d6fbd77ce">26,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy03LTEtMS0w_f8581691-4719-431b-8f64-d13312a5ea8c">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy05LTEtMS0w_4dba59a7-e20b-480b-b4d7-9f9986a7b72f">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC0zLTEtMS0w_6fa2d356-eecf-4d4a-a565-6fa0b23de834">3,062,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC01LTEtMS0w_d1588c6a-0c52-44cc-a942-1d72d2097fd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC03LTEtMS0w_8f28f10c-f0ce-4bf0-a8f3-e857d880719e">36,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC05LTEtMS0w_30000b64-6b99-4916-a36e-7ce5394c2491">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy0zLTEtMS0w_55c107b0-0499-4596-9508-1b2c82ea0b3b">159,239,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy01LTEtMS0w_ecf7b215-43eb-4ec8-b4bf-c4971101c0d7">2,365,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy03LTEtMS0w_5088a972-6697-4581-a996-af3887b1033d">690,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy05LTEtMS0w_ffe98573-1e1d-4ef0-a292-b80c9dfa92fc">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2021&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div></ix:continuation><div><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_55"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RleHRyZWdpb246OTRkMzgyMzdhZTAyNDdiM2IxNTk0YWEwMzY5Y2I3NDhfMzQ2MA_185d6aeb-c9ec-4efc-a214-cb50f5332d5c" continuedAt="i019506afa8894a7bb415f195b15350b8" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i019506afa8894a7bb415f195b15350b8" continuedAt="i7f5487ac9ab94c29913ea9a9c6ab923c"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company does not have any liabilities measured at fair value on a recurring basis and did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the six months ended June 30, 2021 or 2020. </span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RleHRyZWdpb246OTRkMzgyMzdhZTAyNDdiM2IxNTk0YWEwMzY5Y2I3NDhfMzQ2Mw_29411f56-dd59-4eff-abbc-9fc5e36597d8" continuedAt="i769ae0cfaf8a48a2964c1f1e0e48be70" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59b2f82a49c24e32adbb66d496dda53e_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS0xLTEtMS0w_8ac55195-a412-4f10-899a-8380787737b1">208,459,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfaf8d38f5648c19f2ea139b9b26baf_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS0zLTEtMS0w_bdf88fdd-879d-4994-9700-4646d30710d9">208,459,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51d461609384e719322b34eb0028974_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS01LTEtMS0w_ab8d50d0-da8e-46b1-bbe9-973fe1f24930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f3ac792a0624a46adde92d9a011757a_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS03LTEtMS0w_62b66b6e-f76d-4535-b9bd-a627671974e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc69a851d9e4e609cc585a27766de44_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtMS0xLTEtMA_4291e7b5-b753-47e6-a4b5-483e68c64878">170,210,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7015122ae2124cc496b05b2e9f7e4d96_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtMy0xLTEtMA_e5b8058c-e070-4829-857c-b005a4d83867">170,210,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a6f1f19ef548cca073dbd3bb6f4e78_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtNS0xLTEtMA_0ef7abf8-d5eb-4224-a3ea-d7a608b3a2ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia791cbcc956646499769e8fd73d3f0da_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtNy0xLTEtMA_58fa0a3f-4192-4af2-b7da-8d134cc6912d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if19edaa6e2cc4d4bac4bd7a20b22e0ab_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItMS0xLTEtMA_8dcc1fba-fc3d-4a66-bf43-b5b29290ad63">2,998,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1e910e01534d50ada88b9157528ea0_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItMy0xLTEtMA_c52f0804-1a93-47ee-b33a-338eff19bbf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa3846d736e946a395c5e4a35be5dda3_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItNS0xLTEtMA_f47f6123-de7d-48ee-9948-9a93f0feac4f">2,998,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195cff6b53c543e79e1b7a11b9e1e066_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItNy0xLTEtMA_f9aa83a5-761a-4342-9c70-90c26a3ff7e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1713bb34c3046b5b8c3fb55489e9da9_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtMS0xLTEtMA_2fc068fc-fc29-4825-9e5d-670116a250a3">3,084,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae0695b197b427cb51e9553cf7567c3_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtMy0xLTEtMA_f0fecc6e-1156-4b6c-a506-7a7c2a05313e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8730b43b27914e7aad78d1a3e3c967ea_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtNS0xLTEtMA_9a07c65c-ad4f-4c8f-980b-344efed2a40f">3,084,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ca670336a984af492bfea37611a6fc6_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtNy0xLTEtMA_0ca0d1e4-b679-4f80-be6e-40284a249bf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc709f4b94bc48ed922b211843a64806_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtMS0xLTEtMA_83c950ac-7bdc-4fe6-9307-8dfc76c6a505">384,752,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfff0eba5124813b5d1d472946eca2b_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtMy0xLTEtMA_4c1b5736-c62b-4ea1-85de-105689f0d4ef">378,669,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtNS0xLTEtMA_16ee30cf-9966-4445-a529-185fc312bb13">6,082,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtNy0xLTEtMA_ddeb2ec5-9ed1-49b3-a763-afb59d794527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc709f4b94bc48ed922b211843a64806_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtMS0xLTEtMA_77da727c-89c5-4141-bcfe-05d5b156ad6c">3,908,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfff0eba5124813b5d1d472946eca2b_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtMy0xLTEtMA_6c7dbff0-0b7a-40d7-8174-6b17c0117d70">3,908,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtNS0xLTEtMA_d9d03dd0-987e-4d09-8f06-2f7f75299c57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtNy0xLTEtMA_f2bd1402-78f2-4ccb-ac3e-81bd240f3709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc709f4b94bc48ed922b211843a64806_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtMS0xLTEtMA_a2274792-d935-41b7-a7ad-9d5c87dcf176">388,661,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfff0eba5124813b5d1d472946eca2b_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtMy0xLTEtMA_583292c1-9f8a-418b-99e7-395e20f86a39">382,578,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtNS0xLTEtMA_30f29378-d3d5-4a0d-b300-93d7f8096924">6,082,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtNy0xLTEtMA_dd2f8340-a6a4-4623-ad04-b5a5ca2476ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7f5487ac9ab94c29913ea9a9c6ab923c"><ix:continuation id="i769ae0cfaf8a48a2964c1f1e0e48be70"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2063a61ba08e4166b1cddf9ccca281e7_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS0xLTEtMS0w_97465ec0-bcea-4500-b07a-92f944daf98b">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie423d6a2d8714a8f9455c1d4c07b71ce_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS0zLTEtMS0w_fec2e6a6-dda4-4480-9ba2-d0eb4b40f26b">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0fd8f591c349f3a5e3a09df3fda89c_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS01LTEtMS0w_0876f23e-db9d-42d8-8c43-134b29e73c6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d1fecace3114e4e8dc9bbf39dbc9e69_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS03LTEtMS0w_7e0b9605-eade-489c-996c-06fd6468c154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5efcc9635b543f288d5ac148668e8be_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC0xLTEtMS0w_00851267-dcad-4efa-a69c-40574109d561">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b14d9a9f0a04ed881500352253a7910_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC0zLTEtMS0w_4de84fc5-8c4b-42ca-bb9c-d220b5fed0b4">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee92b5ff60e34bdc86aeec302d9c2bf7_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC01LTEtMS0w_4e261db3-e917-438e-9f0a-5296ff4ec282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c69a9ae1284a36bb632aed6602a513_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC03LTEtMS0w_1fb997f2-86ba-4254-84a4-7733925a9453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb94388dbd194288ba834bcc4e711204_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS0xLTEtMS0w_82dce1d3-f1f6-4308-aa33-66987f24e247">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i72086878455242579c997bb7d0dbafca_I20201231" xsi:nil="true" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS0zLTEtMS0w_2059f989-ab6e-4f39-9769-f431fd73333e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d2855764184d899799d1f6e766ef05_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS01LTEtMS0w_ecd4f714-9313-4302-a418-9907c1c3a0ce">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd724b7e4b434a0299f128f23b08a6f7_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS03LTEtMS0w_830cd871-b3f5-49f6-97c8-90abbc2409fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie555d9e8436b4b7c816532c5dba1b774_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtMS0xLTEtMA_a49ba1fe-7517-4e91-8eb7-98b5e589d925">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fa24018fea4d7789e40b137a122c1f_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtMy0xLTEtMA_e758c274-859f-465e-8379-86bce8052309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e632e4521a403eabd9a0d1cd065f58_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtNS0xLTEtMA_d4c1dc77-f604-4783-9f81-25b5e41c2146">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dae7058a7c24aad9e604be62fc80f77_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtNy0xLTEtMA_2c1227d7-eada-4654-b624-7cfdca1546d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i885b976e592548cab96e1ad94a5f5ca6_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItMS0xLTEtMA_2d6e77e2-0845-4b41-bd96-905832988557">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ee59d71b964e1b903875f0effd8913_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItMy0xLTEtMA_f327ca27-657c-415c-910c-4305aa03ce9f">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd6370c584d45d1980fe5eae38e0f14_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItNS0xLTEtMA_fd52d72b-0f1c-4bda-9999-59ebf5d7f3fb">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15f13a0132e4e6a88992dc32184349a_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItNy0xLTEtMA_c9324c03-2c24-4581-b4a3-85a8f3f825ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i885b976e592548cab96e1ad94a5f5ca6_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtMS0xLTEtMA_814d9ef6-e338-48d9-b796-e5b536478af9">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ee59d71b964e1b903875f0effd8913_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtMy0xLTEtMA_e687e39c-4a96-4ba0-95c8-2e6512fca725">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd6370c584d45d1980fe5eae38e0f14_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtNS0xLTEtMA_4d7e1692-4c0b-4f70-b6f9-c8f740a64dd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15f13a0132e4e6a88992dc32184349a_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtNy0xLTEtMA_621a1832-1ae3-44a4-a7f0-0c1cf19ffc36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i885b976e592548cab96e1ad94a5f5ca6_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtMS0xLTEtMA_8cf58e4c-a6fe-4b57-a070-755e4916204a">225,372,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ee59d71b964e1b903875f0effd8913_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtMy0xLTEtMA_461f2016-cfb3-445c-be98-b7af61cf2bbb">219,330,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd6370c584d45d1980fe5eae38e0f14_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtNS0xLTEtMA_bd8fb158-ac32-437c-8fd6-788122d90ff0">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15f13a0132e4e6a88992dc32184349a_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtNy0xLTEtMA_3cfc9be5-2f90-4b1e-bcff-8686e2313393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at June&#160;30, 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="i9cdd7b8ef815473385e371284b1691bb_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RleHRyZWdpb246OTRkMzgyMzdhZTAyNDdiM2IxNTk0YWEwMzY5Y2I3NDhfMTc0NQ_8cf8d23f-f15d-4d14-ab8f-300c4bd451a0">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain (loss) on investment in affiliated entities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at June&#160;30, 2021 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of June&#160;30, 2021.</span></div></ix:continuation><div style="margin-top:5pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_58"></div><div style="margin-bottom:3pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNzEz_10ccf709-c31b-4db7-af75-c994aa5109e1" continuedAt="idc64dbd37ff24ebeb2c69bbc0a7a7fef" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idc64dbd37ff24ebeb2c69bbc0a7a7fef" continuedAt="icf699c5e432e401682478d172e396960"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNzE2_a154e830-1b78-4080-9a05-89103835134b" continuedAt="i9655c053d2a94eba90c1a968ee5024ca" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.918%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy0zLTEtMS0w_dd1ae8b5-9907-4202-8e83-608c6ebfb15b">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy03LTEtMS0w_ec285973-bd27-48e2-938b-13d3fea87f6f">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy05LTEtMS0w_eb27fa78-56c4-4647-8c3c-3277f0d7f0e6">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy0xMy0xLTEtMA_4cc2bf43-6e1e-4972-9cd9-8ec525261e6a">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i658f1d80d9ae443e8ed687c6a2037b8e_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0xLTEtMS0w_a3b3a1d4-9c8f-43eb-b84a-5be4133c861f">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0zLTEtMS0w_aa6736ed-2e88-4738-9760-3e02fc6fcfec">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi01LTEtMS0w_6f0c0e94-dc5e-4598-8fc3-fb63c02ea13e">1,291,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi03LTEtMS0w_7580e26e-8773-4e98-b763-d6545974e1bf">32,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi05LTEtMS0w_6b1713f6-777e-4ff6-9eb6-3bd6028a54c9">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0xMS0xLTEtMA_11de684c-991e-4d75-b4de-a6e295df75ff">1,276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0xMy0xLTEtMA_5eb53892-69ba-411b-b223-51e0c13d73c6">46,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25b5d1ccf26e443ea857b84e229ce359_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0xLTEtMS0w_6b9cd460-78b4-40e0-9c6d-85d0d3854dc0">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f8942f622e48a99283907789ffa607_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0zLTEtMS0w_41d1d3f3-c4fa-4503-88a2-c74a18221b51">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0f8942f622e48a99283907789ffa607_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS01LTEtMS0w_f503d8c2-6b09-4fb2-8dde-3fa0f35d2240">2,608,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f8942f622e48a99283907789ffa607_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS03LTEtMS0w_9cfd8a8b-4306-4537-8926-81391563e3b0">2,491,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS05LTEtMS0w_c5ff6380-054d-4ce6-82c3-35ca012c065d">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0xMS0xLTEtMA_1c80693d-8e9a-4308-a031-eba7ced1b685">2,468,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0xMy0xLTEtMA_09e98556-ffab-486b-a06e-560a6b3e0603">2,631,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f14f4877fcc414dbb3be5f50ae03388_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMS0xLTEtMA_20d4667b-6d1a-41d2-bf2a-98048926772d">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449fddef645f4a30a1891aa40c4f6f0d_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMy0xLTEtMA_6c5772d8-30cb-456b-8194-54bf1bc0e3ed">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i449fddef645f4a30a1891aa40c4f6f0d_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtNS0xLTEtMA_7114567b-cd54-4b79-891f-822088febca3">3,693,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449fddef645f4a30a1891aa40c4f6f0d_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtNy0xLTEtMA_b85f1b75-0286-4a99-91c6-0ef5070310ed">356,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f168c1581a04f49b0e144ce91a5b415_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtOS0xLTEtMA_034460ae-c811-4a4f-a6f8-6788ac438ae9">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f168c1581a04f49b0e144ce91a5b415_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMTEtMS0xLTA_b703ad25-228e-4015-8245-2ef0e0d8c90c">3,581,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f168c1581a04f49b0e144ce91a5b415_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMTMtMS0xLTA_1c4d6851-64f0-431a-ab1e-795d14850556">468,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90cb8338f9474cb7b4f4e085bba18709_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMS0xLTEtMA_3f4e4927-a364-46fe-8ffc-070d4131c57a">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMy0xLTEtMA_4eb50091-c149-4292-9e22-5fc93e185663">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtNS0xLTEtMA_0fa6f392-142d-4cae-ad6d-87bc8d9bf3b0">7,593,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtNy0xLTEtMA_3ba9481d-8a97-4cf8-b90a-2d549a992397">2,879,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtOS0xLTEtMA_ffd2c01a-9211-45d7-9f69-aafec08be6a1">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMTEtMS0xLTA_54f50d6e-6be8-4e52-983e-96eae75f06b9">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMTMtMS0xLTA_9e40c54d-8525-4288-acc9-59f4035ace55">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItMy0xLTEtMA_ed4190ea-27e8-44b1-8309-f83629894110">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItNS0xLTEtMA_098e9fb0-fedf-4ba8-9063-028dc9b6f0ea">7,593,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItNy0xLTEtMA_73d24fed-19df-496d-a74f-7209838250ca">13,393,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItOS0xLTEtMA_00cdb437-0b32-4417-9651-6600649ba660">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItMTEtMS0xLTA_a8de83f3-4bb0-45dc-867f-ec1b6ee44cd6">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItMTMtMS0xLTA_8bb271cc-db78-49f8-8a9a-8b147d77e466">13,660,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9655c053d2a94eba90c1a968ee5024ca" continuedAt="i95711c86291249e1a2abb8299f896959">(b)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"><ix:continuation id="i95711c86291249e1a2abb8299f896959">Other intangible assets represent the estimated fair value of acquired intellectual property.</ix:continuation> </span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf699c5e432e401682478d172e396960">Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNTI3_8ccc05d2-3f27-469b-ad23-d419bb905587">130,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfMjE5OTAyMzI1NjI5MA_11e90268-bd76-447e-a81f-0e741174a275">267,000</ix:nonFraction>, respectively. Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfMjE5OTAyMzI1NjM3Ng_80aee7eb-9e58-4e37-bf74-6d530a5264d9">137,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfMjE5OTAyMzI1NjM4NA_3ab63536-77e2-4933-91ab-e7816cabdbd2">274,000</ix:nonFraction>, respectively. Estimated aggregate amortization expense is $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNTc2_96119333-f517-43f1-b4e8-0790af8eee2d">254,000</ix:nonFraction> for the remainder of fiscal year 2021, $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjE2_6ac940c6-93fe-451b-b4c1-ba32f63051d3">493,000</ix:nonFraction> for 2022, $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjI4_38e0fab0-8824-48ad-9637-76d7785eee7e">276,000</ix:nonFraction> for 2023, $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjQw_1efbad8b-0972-4ba0-8115-7f08a6feb432">253,000</ix:nonFraction> for 2024, $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjUy_372eda80-096f-4f2f-bbd6-bf84c9a8d398">253,000</ix:nonFraction> for 2025 and $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjY3_bfc562ff-ff1f-4d65-a3a7-b2695d432ac8">1.4</ix:nonFraction> million for 2026 and subsequent years combined.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_61"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI4ODk_61cfa3ed-d338-4abe-bdb3-d7786385eaed" continuedAt="ib2c45ea4e5e444a2988414867b5d8439" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="ib2c45ea4e5e444a2988414867b5d8439" continuedAt="ibaf555037b79441c9f68cfc370568389"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTM2_98ea9104-0578-4629-9dc1-b8e0358be535">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTcz_35900a79-15aa-42a3-bf33-35947335f19c">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDE5_ad4136af-019f-459e-8c0f-4b5ae68acedc">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of <ix:nonFraction unitRef="number" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNjI4_5d33f1d2-63f8-4b80-b496-ded3ec261dac">6.50</ix:nonFraction>% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTQ0MA_1c7d3397-0a19-4720-8761-523397c7ea2f">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTc1NA_03ba8f88-4ef7-42d5-82f3-90e85371c1b8">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTgwNQ_21a477e0-769d-419e-9818-2725aa4aca38">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="day" contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTg2MQ_1cffd579-f9cc-48b9-98cf-1977157f39e6">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjEzMg_20dc92c1-cffe-416d-b450-f054bbfd9815">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjY3MQ_2d212408-2cb4-4046-a128-d0af9eba3669">78.5</ix:nonFraction> million are allocated first to the liability component based on the fair </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibaf555037b79441c9f68cfc370568389" continuedAt="i45a8501c48e54ea0a8d242922ff492fd"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $<ix:nonFraction unitRef="usd" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjk4Nw_df5d1069-aad0-4257-86cd-cfcc5cefc58e">62.2</ix:nonFraction> million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $<ix:nonFraction unitRef="usd" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMzE5OQ_4b8f7de7-82a4-46ae-b3ef-a84e173689d6">2.8</ix:nonFraction> million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMzg2Mw_3d81b35a-b761-474d-a5a8-92f513bd59ac">18.6</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is <ix:nonFraction unitRef="number" contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDA5Mw_11eb2ff9-f393-4cd6-a56c-3dde3f86264e">13.1</ix:nonFraction>%. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $<ix:nonFraction unitRef="usd" contextRef="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDE5MA_91badd2d-2d58-46b9-b9dd-3bc839500d66">62.1</ix:nonFraction>&#160;million of principal amount of the Notes, which were settled for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> an aggregate of <ix:nonFraction unitRef="shares" contextRef="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDI2Ng_ab93946c-6b0b-49e9-af05-da5d06752761">11,535,660</ix:nonFraction> shares of the Company's common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The fair value of the Notes at the date of conversion was $<ix:nonFraction unitRef="usd" contextRef="i7cbf958eded24955b7f7345d5fff5691_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDM2NQ_d31f83d9-8141-4e27-a9b6-cfdc579b67ed">43.7</ix:nonFraction>&#160;million compared to the carrying value of $<ix:nonFraction unitRef="usd" contextRef="i7cbf958eded24955b7f7345d5fff5691_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDQwMg_43ec5d8f-a8e7-4944-b39b-97b6a4aa0d3b">52.5</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDQyMQ_9086bbbf-ad06-4fba-9f33-2fd9f7e08389">8.8</ix:nonFraction> million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI4ODI_1c41fa46-2301-4b19-8f26-51c24741008f" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at June&#160;30, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMC0xLTEtMS0w_abce213a-1d39-4e2a-a527-33712a934671">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMS0xLTEtMS0w_6cbc79e2-d836-4ff6-811f-cf427de631d6">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMi0xLTEtMS0w_75fd3f3a-2046-49f5-9ac1-9510dddd502d">1,963,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMy0xLTEtMS0w_efe19bb0-d54d-4e61-9975-c490725e0ef9">270,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentAccruedInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfNC0xLTEtMS0w_c1cb5c64-ce32-445f-9d5c-4310be69a84a">355,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfNS0xLTEtMS0w_3e068df2-9f77-4a13-8a20-0f8ca93ceebe">14,536,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ife6839a934ca45f6a9f657888e33b403_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDc5Mw_7bd3765c-4b20-4d27-bf38-a46247c42b39">467,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4d7b13bbac7745c18bcb6916ba590376_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDgwMA_69b6ba69-453d-48c7-9323-e67e567b61b8">930,000</ix:nonFraction>, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="ife6839a934ca45f6a9f657888e33b403_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDg2OQ_5d2c7ad4-9804-46be-9827-e5577a5a7d50">267,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4d7b13bbac7745c18bcb6916ba590376_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDg3Ng_52c3fbe1-76b8-4676-ada7-2e40045f9f35">533,000</ix:nonFraction>, respectively, related to the contractual interest coupon. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ied29f23ff8a24d14ba72e1520dbcbe12_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc2Nw_97d8bf66-d019-4079-9507-d84ecdc772a0">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0cb6494a5734438caccf162208d9c9e9_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc2OQ_3b683f3a-69a0-4563-899d-de3add2badff">4.2</ix:nonFraction>&#160;million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="ied29f23ff8a24d14ba72e1520dbcbe12_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc4NQ_ff80652c-0745-4d28-a5e9-277c6b2f9639">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0cb6494a5734438caccf162208d9c9e9_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc5OQ_610931f6-e4fa-4dc0-89e0-41ef352ee904">2.6</ix:nonFraction>&#160;million, respectively, related to the contractual interest coupon.</span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI4ODQ_48031256-a936-43a9-a8be-5ca2bbeaee28" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTA3Nw_2f1551bc-4595-49ce-9ca8-72f021cfca6c">6.5</ix:nonFraction>% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfMS0yLTEtMS0w_b6e26b36-e9e6-4fe2-bfb0-d2821451fab2">534,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfMi0yLTEtMS0w_4506fec0-314f-4ae6-9906-6fc9db787216">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfMy0yLTEtMS0w_f124cee1-57a6-43be-8f5c-7bd03690b954">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfNC0yLTEtMS0w_ae8f58a6-0c17-49a7-b9a5-9bfc86ddc7a4">16,948,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfNi0yLTEtMS0w_6cb8945a-7342-4849-8011-06a4cefa5981">19,616,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="padding-left:22.5pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent of the August 2019 Bonds with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTI2Mw_88105dc3-6e59-4b11-bcac-cebc35a7db99">18</ix:nonFraction> billion Korean Won (KRW) (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTMwMg_4f55d945-e407-4aa2-9c2e-f98b0a3604cf">15.0</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i586e28029d9349b8990dda0e65156664_D20190801-20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTU1Mw_236906cc-75f9-49b9-9d2c-e94e852c383a">14.5</ix:nonFraction> million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTcwMQ_e11fa5fa-dadd-407d-83d5-2754be3b884d">1.00</ix:nonFraction>% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4387c26933424d9096e5a67cc6e310e0_D20200803-20200803" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTkyNA_aef7c1fb-28a8-40f7-ad27-2e93bc7c94eb">4,962,364</ix:nonFraction> shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i45a8501c48e54ea0a8d242922ff492fd" continuedAt="i3494b59458d94864a25e427a882aa0c8"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i17e32422bc844eba90a640f03b45dce5_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNjE1MQ_ead78133-366b-481e-aa47-341307364e84">4.00</ix:nonFraction> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.69 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="idaad05c89c7a4003898310c3fcc4bef8_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNjYzMQ_165ca422-8abd-4306-b8da-e700dd5abbb3">3.14</ix:nonFraction> per share).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNzA2Mg_54594d88-3092-4f0c-addc-3c68f80331a1">7.1</ix:nonFraction> million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODExOQ_3cefdc55-76fc-4ffe-9186-ea33f92ce83b">7.3</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibb48eed1dd1d450f97688eeb9d9b1075_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODMzMw_85619367-6032-4a41-9eef-0198c0c3ab2a">672,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i48cbe06ea9db47109f2c6aa21e985ed6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODg4MA_40f05e79-0c7c-44ac-b8f5-db76a1bb2c28">1.3</ix:nonFraction>&#160;million, respectively, of interest expense related to the August 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="ibb48eed1dd1d450f97688eeb9d9b1075_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODM5OQ_7ee6255e-b296-438d-93d2-80a23b41b350">37,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i48cbe06ea9db47109f2c6aa21e985ed6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODg5NA_0e72d527-45b6-40b2-bf94-4da5f5b43626">75,000</ix:nonFraction>, respectively, related to the contractual interest coupon.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the August 2020 conversion in full of the August 2019 Bonds, the derivative liability associated with the August 2019 Bonds was revalued at $<ix:nonFraction unitRef="usd" contextRef="i3325f0757ae043c6b5ac88744b9c348b_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODU3NA_73aeb65c-c572-42a3-a86e-0f95ae849bc7">84.5</ix:nonFraction> million. The change in fair value of the derivative liability was an increase of $<ix:nonFraction unitRef="usd" contextRef="i0d8ee829033246dd9adf6d9303496b62_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODY1MA_cf2f73b9-9265-413b-a07a-a1af1967526f">75.7</ix:nonFraction> million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i0d8ee829033246dd9adf6d9303496b62_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODkzMw_6312300a-ece9-40c1-85d7-06d55b88e854">8.2</ix:nonFraction>&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the <ix:nonFraction unitRef="shares" contextRef="icaaf8fc6a6c144978817e6793fd2365a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTMwOA_80de2a81-78f0-452f-81d0-6b7710c91d5b">4,692,364</ix:nonFraction> shares of the Company's common stock issued upon conversion.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i28f211979e784e9bbb20076cc52f7e54_I20191226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTU2NA_00808b6d-bcd7-46ba-a786-4fd75b870eda">4.7</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i28f211979e784e9bbb20076cc52f7e54_I20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTU5MA_7c10f7c8-c051-408c-9455-2cf5d27de10a">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i8a26ab4a585a46dca8422a60ddfe24b4_D20191226-20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTc0Mw_2f1d8f5c-98f8-456c-b2d8-8273322c38be">4.0</ix:nonFraction> million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i28f211979e784e9bbb20076cc52f7e54_I20191226" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTg5Nw_45646053-5ede-490a-b984-93c82c98c458">1.00</ix:nonFraction>% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8a26ab4a585a46dca8422a60ddfe24b4_D20191226-20191226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTAxMjk_38ff3c53-ebf1-4b98-936b-e086d11608d3">1,009,450</ix:nonFraction> shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i2908c92d06bf4769bdd733e5d00c8200_I20191226" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTAzNjQ_7d962354-fe81-4bb8-9be1-7948f31c0af4">4.00</ix:nonFraction> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3494b59458d94864a25e427a882aa0c8" continuedAt="i412fc202c2cd4a838834fba8988cfe81"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds was <ix:nonFraction unitRef="number" contextRef="i6d34dff54d0e4a038bfa48e0e67a8e99_I20210630" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI0NjI_7ad5d2b5-b72b-4f33-af24-b0b25965fa2d">6.2</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the six months ended June 30, 2021,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI1MDg_8f464e2b-77d3-4bfe-8d55-bd936970522b">50,000</ix:nonFraction> of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI1OTg_d2fb60e7-4ad0-4ffc-8555-27b7be8a4b2b">9,000</ix:nonFraction> related to the contractual interest coupon. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i442ae70cad5c4076acaead0487e51e18_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTMyNw_4adffb51-881b-4db7-91cd-78a4de1b635c">60,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia0f6c67ea61a42c8a33b20a0edfa3e86_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTMzNg_06dc1ead-a5e3-4f1d-95e5-74319773462f">122,000</ix:nonFraction>, respectively, of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i442ae70cad5c4076acaead0487e51e18_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTM0Ng_bd703c90-0128-45f7-b2fa-144344d083c8">10,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia0f6c67ea61a42c8a33b20a0edfa3e86_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTM1NQ_d2987351-07b0-4b61-97c2-da971e427690">20,000</ix:nonFraction>, respectively, related to the contractual interest coupon.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i412fc202c2cd4a838834fba8988cfe81"> As of June 30, 2021, all outstanding December 2019 Bonds were converted into <ix:nonFraction unitRef="shares" contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI3MzQ_b028737b-bdbe-46a2-82aa-8f522227a60f">1,009,450</ix:nonFraction> shares of the Company's common stock. Upon conversion, the $<ix:nonFraction unitRef="usd" contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI3OTY_21d9bbde-7aa5-405a-bfe0-05b652092486">4.4</ix:nonFraction>&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.</ix:continuation>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_67"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDM5NQ_acbb9274-cdc5-4242-9e54-b67250784223" continuedAt="i31ce82c2be164af49b81ec883ed5374e" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i31ce82c2be164af49b81ec883ed5374e" continuedAt="id80e1eebcd7d41bb91eb7e8f2fb83954"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDM4OA_ec06accf-81ee-4953-b6e9-b5ce0376a9c1" escape="true"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2021 and December&#160;31, 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0wLTEtMS0wL3RleHRyZWdpb246ZjVhNTljMTk2MWZkNGVhYjg4OGE0OWQxMWJlYThlYTRfMjg_22c9f2db-2b46-4146-9774-08d7a39090ca"><ix:nonFraction unitRef="usdPerShare" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0wLTEtMS0wL3RleHRyZWdpb246ZjVhNTljMTk2MWZkNGVhYjg4OGE0OWQxMWJlYThlYTRfMjg_edb68bea-e788-45f9-8744-c4df0028dcb5">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0xLTEtMS0w_e0b1f838-7b50-4e93-b762-0b70fc194276">600,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0zLTEtMS0w_b3d27168-6254-4fb9-9811-13c36cce4fb7">210,146,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi01LTEtMS0w_d69db047-ed15-4755-9f9b-4f2bdd813276">210,146,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi03LTEtMS0w_f76e69d7-a5ce-4b1b-860b-45efcf06e92e">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i689dc147815948f0886fb748641b715b_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0wLTEtMS0wL3RleHRyZWdpb246MmNjNjA3YjRjOWNmNDdhYTk5NDNlMTJjNzM0ZGZiNjJfNDA_030da638-6412-483a-a2d9-580a8e0d28cf"><ix:nonFraction unitRef="usdPerShare" contextRef="i77178543290247baada87cc58713a47e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0wLTEtMS0wL3RleHRyZWdpb246MmNjNjA3YjRjOWNmNDdhYTk5NDNlMTJjNzM0ZGZiNjJfNDA_b5a276fd-82e3-4a62-940d-088eb26a7fef">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i689dc147815948f0886fb748641b715b_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0xLTEtMS0w_c4846a73-f661-4bdf-bf5e-aea44f513c29">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i689dc147815948f0886fb748641b715b_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0zLTEtMS0w_4e06e22f-42f6-4dbf-9f08-7b0ed77dd155">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i689dc147815948f0886fb748641b715b_I20210630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS01LTEtMS0w_ab2e9147-dbfb-4b5e-89a2-e5ff6289deaf">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77178543290247baada87cc58713a47e_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS03LTEtMS0w_84ed23db-287d-4bc0-b458-50088d37a4c1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, <ix:nonFraction unitRef="shares" contextRef="i5014003f2f6f483b8391af1fa2db26e8_D20200601-20200630" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTc0_5e7f6bd3-e203-4433-9b6f-64e9a22b5d88">14</ix:nonFraction> shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i59c22ff37c374753ade05595b7204ddb_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjYy_05e93dfc-677e-477c-b0db-8d613dbd9a49">5,147</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i35a378f1adfd4003a890450ab84a2bd9_D20210125-20210125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzkx_75f0aa84-f1ec-4b31-b8ad-083885e55c82">20,355,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9f31aeb778524005bde1396b19356f60_I20210125" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDQ3_8e320a03-b8a5-4d69-bdf9-795fe22893c0">8.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i9f31aeb778524005bde1396b19356f60_I20210125" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNTk4_4a54a282-7ce1-4bb2-bffb-b0749438f70d">162.1</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="i6a0d7c5a50ca41b28dad429b0cb851a4_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNzg5_6aa83111-ad4d-4131-b57e-9575f0773569">100.0</ix:nonFraction> million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent acted as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $<ix:nonFraction unitRef="usd" contextRef="i6a0d7c5a50ca41b28dad429b0cb851a4_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTE2OQ_be607ec1-2626-485c-a8a2-7b3cb6f8b8bd">100.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i78ee577f7a7e4579bb39bba035abaee4_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTE3NQ_3a937e0f-76ae-4755-b7eb-0b874b431771">250.0</ix:nonFraction> million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i33badcdaab9f4b948718c8bce4d00c22_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTIxMQ_0b7db0c1-fafb-45a7-afff-32405e0c9d93">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i8bbbdeacd5fc468588e3dc03b0a7861e_D20200403-20200512" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTYyOA_e4ee986a-f461-41d2-b26c-c282b1457083">250.0</ix:nonFraction> million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTY5Ng_3f7da662-a95a-44ad-bade-c531277777ac">43,148,952</ix:nonFraction> shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTgxMA_3031815e-1f69-4e85-b367-0e18d642ff32">4.92</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTg2Mw_bc196bd4-af74-4923-8a11-457de60a955b">208.2</ix:nonFraction> million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i33badcdaab9f4b948718c8bce4d00c22_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTg5OQ_1f819cdd-06b9-4857-9833-7b88103947a4">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company sold a total of <ix:nonFraction unitRef="shares" contextRef="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjAyMw_0349ea0c-d12d-40f9-9e5c-6b07283c3f27">22,919,934</ix:nonFraction> shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjEzNQ_85977f99-1a9f-4b6a-ae14-4d2a13d2a4a2">10.91</ix:nonFraction> per share resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjE4Nw_acd27732-3514-4607-a100-8f9db675146e">246.2</ix:nonFraction> million. As of December 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="if44318d1ef4e4fd298cb0d5f9506f23a_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjMwNA_5f6dd58e-f1c0-461e-913c-6d3bef29d0d9">no</ix:nonFraction> remaining capacity under the New Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id80e1eebcd7d41bb91eb7e8f2fb83954" continuedAt="if7730886fe1143e8bfa4592c7aa0c35e">2016 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i2005c7bb31a94776aff831320305c606_I20160513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzExNA_69ddd0aa-0203-47bb-adb7-6499bb4fa54c">20,000,000</ix:nonFraction> shares. On the first business day of each calendar year, such maximum number of shares is further increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i2005c7bb31a94776aff831320305c606_I20160513" decimals="INF" format="ixt:numdotdecimal" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzIyOA_17e75c49-76c5-4668-ac82-272e32b2077e">2,000,000</ix:nonFraction> shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares increased by <ix:nonFraction unitRef="shares" contextRef="ifbea9bf1e25743b78635a4f7dced6bd6_I20210101" decimals="INF" format="ixt:numdotdecimal" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzUxMg_4c2ed322-21b7-4ecf-ab36-0e5e2a46af5f">2,000,000</ix:nonFraction>. At June&#160;30, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="ia838f5b6a3354692a049e285a3f8c1ab_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzUzOQ_61c881e1-2bbc-4208-9057-d476f9acde10">4,998,253</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="ia838f5b6a3354692a049e285a3f8c1ab_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzYyMw_3bcdb1e1-77a4-46cf-ae57-ada43fb376ed">2,516,102</ix:nonFraction> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="ia838f5b6a3354692a049e285a3f8c1ab_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzcyOA_da2d94dc-6979-4486-878e-615d8aae6d1b">7,814,677</ix:nonFraction> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over <ix:nonNumeric contextRef="i23ce38f7c67443e49e518a149cc81961_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzg4NQ_53c796da-e5b8-40ce-8f57-97b463dc755d">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i23ce38f7c67443e49e518a149cc81961_D20210101-20210630" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzkyNw_47bd4304-d758-4ab4-8620-57cde8b3f6d5">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if7730886fe1143e8bfa4592c7aa0c35e">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At June&#160;30, 2021, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i0da088e105ad4f18ad8b9d31ec870555_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDIxMA_a98ebb2c-3bc5-42d3-ba8e-b41c3cb8d1f1">2,516,141</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="iacd59942851345caa9bfa5f0f8f2c395_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDMzNg_ca086abd-b82f-49a0-bbaa-8b04948cd8ab">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="iacd59942851345caa9bfa5f0f8f2c395_D20210101-20210630" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDM3OA_933320bd-4ad3-4e04-9eb2-8319657afb85">ten years</ix:nonNumeric>.</ix:continuation> </span></div><div><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_70"></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RleHRyZWdpb246ZmY5OTJhNmFmN2JlNDZiNjk3YTdmNTkxYzJjNzYzNDZfMTY4OA_9a87be53-b378-49d6-a6e1-c3b685faf93e" continuedAt="i88c567e3b74245eb875ef4d3528856ab" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="i88c567e3b74245eb875ef4d3528856ab"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2021 and 2020, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds would have been anti-dilutive.</span></div><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RleHRyZWdpb246ZmY5OTJhNmFmN2JlNDZiNjk3YTdmNTkxYzJjNzYzNDZfMTcwNA_1edcd22d-dbd0-4221-ba5c-1d6a7bb40d10" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three and six months ended June 30, 2021 and 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7720390ee14d46e0af301a676fc1e147_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMi0xLTEtMS0w_f3d99dbb-1856-46d7-b279-dfe33f1e935b">10,330,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcbd43fff7ff49d2b5186181ccc1ee3e_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMi0zLTEtMS0w_92f99fb6-b484-41cb-87ae-081bdd9dc7c6">9,193,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0df4c9eb1a604d84a5994034871feeb9_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMy0xLTEtMS0w_0344ba47-4bf0-48f9-b818-c481c806cde0">2,516,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45c9b4d010164a689b6d9c3c41f23c03_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMy0zLTEtMS0w_eeec3db2-6198-4a79-ad22-0fcb8e8c0322">2,868,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36d2d9234b5a431cbf09724c62882b4e_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNC0xLTEtMS0w_576fd6c9-51fc-4241-9e39-d1e09102fcbf">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59ae4261b99c4a6e810082721dff0e62_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNC0zLTEtMS0w_7ae202b5-8881-4ed7-b67b-aaa0d67a6a0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c583306369d41e29983388433b751ce_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNS0xLTEtMS0w_0385d3f0-ab63-45be-923c-e85042a96630">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9fb06d2b7b14b53aa4aa3861c628292_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNS0zLTEtMS0w_ed33e299-f63e-456e-9302-8f1e3adc3c80">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97026c92ba624f5eb88dedb4f4fd222a_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNi0xLTEtMS0w_0c510df4-7a20-423c-85c5-a2040e446204">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b6b2ddbdd8e403393dd968eb554812d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNi0zLTEtMS0w_845bf092-ab43-4527-982b-32d3a0aabcc1">14,585,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i409887a8fa6a4346a1975b51ea0e7e16_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNy0xLTEtMS0w_3a39d1a3-ba69-437d-af38-9bae657b34e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1b2caeab20c408da8ce4dbb3e47ca39_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNy0zLTEtMS0w_81a187d2-9ea2-4a32-b8bd-9c51fa200c2c">4,962,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f3835a374c242d7a7e25920391ff721_D20210101-20210630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOC0xLTEtMS0w_d43beb5b-ed3a-4494-b68d-c97d407401d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc6843efcb854eb59c1d1c8cfa5945bb_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOC0zLTEtMS0w_c81f33e2-a572-4737-b31f-1b807d2aaeb5">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOS0xLTEtMS0w_1274b78f-3c26-4f8c-932f-c20b96c4f2df">16,563,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOS0zLTEtMS0w_3613fc8b-cfd5-4359-b282-acfe948c4de0">32,622,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_76"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzQ2OA_ba86273c-94ee-4596-a359-f927a1bb3347" continuedAt="ie5a5bef59af9439bb2772e5b53ae4b8d" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie5a5bef59af9439bb2772e5b53ae4b8d" continuedAt="i1f2d5194dd074c3c9ccc4fdf649c4636">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1f2d5194dd074c3c9ccc4fdf649c4636"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzQ2MQ_47f9f521-238a-4c8d-8aee-3a2af73efbe7" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0xLTEtMS0w_6ca20cac-c17a-4bd9-b885-702639153b7b">0.99</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0zLTEtMS0w_f1e290c9-e71d-493e-8700-fed03ae91475">0.40</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0xMC0xLTEtMA_861b542e-fb42-4792-ae9b-a8c7911cbd3b">0.90</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0xMi0xLTEtMA_58031023-9612-40e9-abc9-1d6db94b4298">0.67</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0xLTEtMS0w_366f8b5f-adf0-4aea-830d-7f3697c72ed4">93</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0zLTEtMS0w_9276f002-b897-44b2-96cc-fc054379a05e">80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0xMC0xLTEtMA_3f6033da-f35b-48e9-b15a-0cd99d0a47f3">92</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0xMi0xLTEtMA_e64742f4-26ac-4653-a238-75e7abcf26ac">77</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0xLTEtMS0w_13ca4ba4-18b1-4ed8-a696-0399cf426b70">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0zLTEtMS0w_dcde58bf-2c2b-4d80-bfbf-ab84058264d2">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0xMC0xLTEtMA_92265260-98c2-4925-a4a2-8e083d9f2c10">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0xMi0xLTEtMA_927d5446-7b00-4735-8cdd-5e6b73f38dd8">5.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0xLTEtMS0w_b014b87d-4c66-42df-97a7-a2630de1110a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0zLTEtMS0w_043c035c-7bf9-4076-9e42-812d293856ec">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0xMC0xLTEtMA_91ce95b7-b2c7-4b9e-a544-7faa789b13de">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0xMi0xLTEtMA_b46cbb72-9fbb-4847-ba99-802b4b12e5f1">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i6840ef28448241779743cf158cd253ec_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTU5Mw_e23da35d-6a10-4c67-95d2-13105b8e5d8e">5.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia9220dabb97347baaad3b955c7ca131c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTA0Mw_ee630796-2058-4bb2-86b7-69b108fc1d11">14.5</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ice27ffbaffd34874afe23deb45a41f1d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTYyOA_748daee0-5f9d-4561-a7af-85ce944ba868">2.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i75baa0c985dc4a80846a6c09d447a541_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTA1MQ_b622ed32-1613-436c-a094-055ecf455296">7.9</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="ib01f6e99b41046cea288d454a397131b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTcwOQ_95efca10-9ce7-4f65-9081-3c02ecedf689">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8c4a44eb23a64f2a8177b06eccfd5462_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTA1OQ_4ea39423-08ca-4ac9-a03c-ecb57ef0e909">6.6</ix:nonFraction> million, respectively, was included in general and administrative expenses.</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="idf811d4883d349a090d95c8c69bfc003_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTU2MQ_e9104dd1-1fcc-48dd-9bde-9c366af025a2">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9e764caa439a41a78c114122d5dd11fb_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTU3Ng_6331f805-f344-4071-bacd-3c104832fa1d">7.1</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i516d344bdae6478b9cbb0eb47830b5bf_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTU5MQ_f87b1275-f920-4e97-a2a4-55cfc278c8c4">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56a074845daa435895695e2ec5b8a0a9_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTYwNg_1423cfed-ad04-452d-b0d6-b774e5b16cd3">4.1</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="if7fe878a23244e578b1d0fe5755cc0fa_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTYyMQ_36557eab-2f3a-4e85-9d32-9d0a1825a12f">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6adba9b5cfe8432498fb5b3d434a4541_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTYzNg_d3c03e12-87e5-4f9f-a152-5b104a4e5bca">3.0</ix:nonFraction> million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTgwNA_b274ed58-e0b5-42ce-af66-37a4e6a27bfa">19.8</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTk1NA_a7b1be83-797b-4042-a569-ca967dd6bd46">2.3</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjA3Mw_1ec68efb-a513-4d67-a91e-9085a2eab919">5.25</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTY3Mg_dd69aae0-c431-42c7-9c3c-6aa060dc4fe7">7.91</ix:nonFraction> for employee and director stock options granted during the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTY4MQ_f0758b85-6649-4814-9d0d-da516f0337fa">9.52</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTY4OQ_e93758c9-9e61-420d-8ee9-1e12f2629087">6.19</ix:nonFraction> for the three and six months ended June 30, 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i4c44a7a4bb0e423fbd2ec314824724ad_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE4NQ_54c60ec4-5c33-4f19-9ab8-2dc7520b8f4f">16.8</ix:nonFraction> million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i084bec39b5ca4a51a9902a9ff9ad928f_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjM0MA_d2890122-7f97-4732-8734-83fe582354c8">2.1</ix:nonNumeric> years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i2eb3f0be101b47a18fcc503057ad42f1_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjQwOQ_1a46fc2c-74ee-4c37-a1a8-e34622208b3d">6.81</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i084bec39b5ca4a51a9902a9ff9ad928f_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTcyMw_18c82345-cb94-4968-958a-0723586f1d79">10.64</ix:nonFraction> for service-based RSUs granted during the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7334687cb4a947de92ae0eb9f74ab59d_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTczOA_8b2e6859-cc5f-446a-905e-e6c1c05cd803">14.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="icc5e991cb67b41b5987aee77b9140631_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTc0Ng_c2b9ee2f-d780-4afa-aed9-a2261cb794a3">9.12</ix:nonFraction> for the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i73f8e4b6b88849388af7af4775429f82_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjcwOQ_845c8a17-1577-4818-8cec-81b7d9584caf">308,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8cfb07957bc8448e898eec6cc1d4f178_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTc5MA_f356b316-e003-4a04-ac2c-7b89edf846c6">737,000</ix:nonFraction>, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="idab9cee1a62047fb8051e1d941df796b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTkwMQ_5bdddf2f-0e25-43e8-9707-b8dcd1109f04">224,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0e3baa7582b441aab8b2cad5aea5a16d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTkwOQ_b17baf67-fa76-48b0-9b0f-dda34fc86d3c">607,000</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjc3NQ_da6d55b2-c6f2-4c32-b674-19c9eccf24fc">663,353</ix:nonFraction> performance-based RSUs to executives under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: <ix:nonFraction unitRef="number" contextRef="i3e5ffc18c04b4a18bc872e736b8e3274_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjg5Mw_467cf288-e0a1-4fbb-8874-ed7846a6622d">50</ix:nonFraction>% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining <ix:nonFraction unitRef="number" contextRef="i2ff71523015949a3a75328d8f76bc7c6_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzAxNQ_0f2bd72e-4f4c-47cf-be2e-42d4fd3290de">50</ix:nonFraction>% of the shares in each tranche will vest upon subsequent completion of a <ix:nonNumeric contextRef="i2ff71523015949a3a75328d8f76bc7c6_D20200828-20200828" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzQ2Nw_aeb7db25-0eda-4587-ac1f-fa75a5e8d281">one-year</ix:nonNumeric> service period. The total grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828" decimals="-5" format="ixt:numdotdecimal" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzE4MA_c42d9ef5-a9ff-44c0-b550-86a775d2d840">8.0</ix:nonFraction>&#160;million based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzIzNA_5ca6d13d-842d-49d0-9426-abb0bfe2ef07">12.06</ix:nonFraction>. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June&#160;30, 2021</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the six months then ended.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzAwMQ_20a3a806-a59b-4e1e-a5d7-5813d2a7e3e7" continuedAt="i32e1aa35a55142ff9d90f566c968f5ec" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i32e1aa35a55142ff9d90f566c968f5ec" continuedAt="i38d24d22d0784256a9aa79eeee85690e"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned <ix:nonFraction unitRef="shares" contextRef="iec5758f42e8641cca8f706945d684248_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfODQ_05b3d833-9369-465e-a58c-50df5a65a8cb">597,808</ix:nonFraction> shares of common stock in PLS as of June&#160;30, 2021, representing a <ix:nonFraction unitRef="number" contextRef="iec5758f42e8641cca8f706945d684248_I20210630" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTQy_d78f8991-1283-4b39-a71b-6366538e01b5">19.7</ix:nonFraction>% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three and six months ended June 30, 2021, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="i58f2d9f6575543589f663ac5ade5d146_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzg5_f1b62da8-231b-4adc-985f-9a5c96492744">75,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ice4430b09f8f4a3d9c5b6e2ef7fa048f_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODU2OQ_7c0a06b2-8f5a-4311-a717-33116539ae94">125,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7bfa0efcd5e94977acef14e343d8c32f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzk2_d875a8f7-c9c3-4b33-ae33-4d64d70d4be0">64,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic9758e3169bf42408ff0026a43dd6c32_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODYwMg_bff310a8-2454-4221-a06e-9ccf4d614542">1.2</ix:nonFraction> million, for the three and six months ended June 30, 2020, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i39000bc0ed2f4334bb3f0d81cbac8fef_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfNDc4_50506fca-c2df-42f1-b37f-c6834ab6871e">99,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6b00238ffc3b48c5a7ddb81b78793302_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfNDg1_d022ca21-9715-48c0-9492-206da951546f">67,000</ix:nonFraction>, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i38d24d22d0784256a9aa79eeee85690e"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="iee4bc461464046a39879834a877ac90d_D20160301-20160331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementExpensesToReimburse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTEzNw_a6af9b91-8dc9-4b2c-a8c1-443bd8b03f75">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="iee4bc461464046a39879834a877ac90d_D20160301-20160331" format="ixt-sec:durwordsen" name="ino:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzAwMA_d3dbf049-904e-45ea-9fdf-84619d4011b0">five-year</ix:nonNumeric> term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under the agreements.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company received a&#160;$<ix:nonFraction unitRef="usd" contextRef="i9aaebaef4a484e99a1f72fd27c49260c_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTQ5MQ_0c24aac8-0266-4124-b9b2-1b86144f631a">6.1</ix:nonFraction> million&#160;sub-grant through Wistar to develop a dMAb against the Zika infection, with funding extended through December 2021. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i0db0b6c7420847968706776cec806a32_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTc5OA_9efb4de4-1e54-4e97-b92e-e0a32ca9329c">10.7</ix:nonFraction>&#160;million sub-grant through Wistar for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="i0db0b6c7420847968706776cec806a32_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedOptionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjAxOQ_ed8f1e69-da19-419e-b943-9be3901736e7">6.0</ix:nonFraction>&#160;million in funding through September 2024.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and six months ended June 30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i8fbd471a37474f43870e9353685a3362_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjI4NA_6f5a95b7-4759-4c31-ae28-0a9d3bcb63a2">381,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i647dbd99928840369aa848a876ffaef7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODYzMg_b3292c1f-280b-40f7-870f-3fa4efeeec09">610,000</ix:nonFraction>, respectively, and for the three and six months ended June 30, 2020 the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ifc72a58c0cfa4fec9b889e44cf304615_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjI5MQ_fad80534-6ba6-4e02-80e1-fcb2062c4930">73,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id9cf11cba38341b4909eff0dd1632ec2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODY1Nw_c1950bc0-20cf-4ba6-b7c2-37a0e66ac506">691,000</ix:nonFraction>, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill &amp; Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three and six months ended June 30, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i8fbd471a37474f43870e9353685a3362_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjY1Ng_b42af1f0-dbcd-4893-ad75-e1b5bfaca092">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i647dbd99928840369aa848a876ffaef7_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODcxNw_a27078bb-2a7e-43e4-a55b-4f0bf94b5d99">1.6</ix:nonFraction> million, respectively. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="ifc72a58c0cfa4fec9b889e44cf304615_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODc5NA_67f335bf-322a-4fde-867b-b13cb5ffad39">408,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id9cf11cba38341b4909eff0dd1632ec2_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODgwMg_c0daf182-45b7-4464-bb41-16cf974744db">770,000</ix:nonFraction>, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjc0NQ_e311e02a-05b5-46f4-8d28-998fbea5d82d">617,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i79aa827c9e8f4b358c9a1724e62d1c61_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjc1Mg_a74eada0-adc4-49bb-aa24-8d284d68b692">425,000</ix:nonFraction>, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjgyNw_91a49798-f729-4a4c-b6ad-e4f7a9b76922">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i79aa827c9e8f4b358c9a1724e62d1c61_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjgzNA_5044466e-e3b1-4b36-9360-87e31bd3fc5a">643,000</ix:nonFraction>, respectively, related to Wistar. As of June&#160;30, 2021, the Company had a prepaid expense balance of $<ix:nonFraction unitRef="usd" contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODkxNQ_e5998e4c-51da-4729-b305-03ee9cd1372f">303,000</ix:nonFraction> and recorded $<ix:nonFraction unitRef="usd" contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjg5Nw_5340306e-2b3c-4338-a81f-e0ae7e9b1abf">69,000</ix:nonFraction> as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_82"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.  <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzA4MA_835f5093-bae0-439a-9a69-f18d6083b729" continuedAt="icbdecdd33f5a4891b6bb81fd37a626e1" escape="true">Leases                                                  </ix:nonNumeric></span></div><ix:continuation id="icbdecdd33f5a4891b6bb81fd37a626e1" continuedAt="i1855e9c673ad4ae6be0c218c9df50b27"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i66a148722afa41b185cd4eef30e25fdb_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMTAw_3024b95b-271d-4334-9723-21af44c75094">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="i1b665a2cbce54f4a94dd8ecf309380fd_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMTkx_0fa56284-d401-45ef-8768-2873069e2e00">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of <ix:nonNumeric contextRef="i3ae75de8f5854856a0f90d658ba0bcd8_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzUy_a9c01808-9aaf-442a-9d34-45bfede6b5ea">2.4</ix:nonNumeric> to <ix:nonNumeric contextRef="i110b3be318af4daab8582df0596dd792_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzU4_35ea9eef-4f8d-40b2-827e-cbc29e39e553">8.5</ix:nonNumeric> ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzA3NQ_a39ea3f2-841d-4ce5-9b86-a1b722dee5d0" continuedAt="idbfe0b9946f14a29a1b14a4d86f37e35" escape="true">As of June&#160;30, 2021, the maturities of the Company's operating lease liabilities were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1855e9c673ad4ae6be0c218c9df50b27"><div><ix:continuation id="idbfe0b9946f14a29a1b14a4d86f37e35"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMC0xLTEtMS0w_340339c0-f566-4087-b430-1cb1111919ce">1,994,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMS0xLTEtMS0w_0c52723a-bd0d-42ae-b40d-423e82c29ffc">4,045,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMi0xLTEtMS0w_cedb9b5b-6a19-4e97-a83b-6e788a574425">4,023,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMy0xLTEtMS0w_e3cdfe75-b735-4fda-adf3-b2c496de7dd9">3,001,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNC0xLTEtMS0w_d0daaddc-27e3-4b66-a830-a3cda5b7fb3e">3,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNS0xLTEtMS0w_6a685fe2-6027-4485-80ac-677c22f6a5ac">9,888,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNi0xLTEtMS0w_b0fa9b61-dd8b-4ac1-8478-21521da1e3d2">26,014,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNy0xLTEtMS0w_faf1f1c6-2dcd-4e18-9681-0b7c6d389bb4">6,753,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfOC0xLTEtMS0w_8ebdb49d-3795-4ef9-a0e7-82fdd3fdac22">19,261,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfOS0xLTEtMS0w_39d8b7db-8e4c-4b57-a557-b529bc36c9b4">2,464,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMTAtMS0xLTEtMA_e0bb14df-f6d5-4742-8ada-af8e59385a35">16,797,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMTItMS0xLTEtMA_689479df-31b9-4fa6-ba55-fb20459309c2">7.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad1208ba98074d448260b48944e05ebe_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMTMtMS0xLTEtMA_f18e896c-b86a-4d00-b711-b72d27f8d65d">8.5</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjAzMw_6e299373-fe4d-445a-b4b1-ddbde5d93ce3">827,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjA0MA_d61b0063-eea7-4e9e-ad2b-7203b43cec37">1.7</ix:nonFraction> million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjE5OTAyMzI1ODgwNg_75cc8e3b-a8eb-475c-9ea7-c54e10ebc6a6">814,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjE5OTAyMzI1ODgxNg_9d0e2881-04e7-46fc-acf3-b6705b53fac3">1.7</ix:nonFraction>&#160;million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="agreement" contextRef="i0dc2a7ba5e24419aa07ad87b72b18c9c_D20191001-20191231" decimals="INF" format="ixt-sec:numwordsen" name="ino:LesseeOperatingLeaseNumberOfAgreementsToSublease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMTA0NDUzNjA0NjcxNzU_e5efa4cc-f2c9-4724-b78b-9adab6c88f8d">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="i8db89a2c66514d7498b690857971a626_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjM3NA_1022eb1b-8898-4ad8-8244-9a7ac2046bc0">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg5NjQ_4566662c-fb2d-4c3b-b4f2-84f5c8bb7fb0" continuedAt="i8b48705d7a8f4b85811dbe66733c3509" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="i8b48705d7a8f4b85811dbe66733c3509" continuedAt="ia252b3a37d1c4a03936d159397f41821"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#8217;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred in conducting the trial in Greater China. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia252b3a37d1c4a03936d159397f41821" continuedAt="i1be25053ec4843ffb74ab4792b4afac0"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfODgw_63a704dc-cd19-4f2e-b558-b41508f4edde">3.0</ix:nonFraction>&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfOTc3_967c41fc-421d-4374-b753-52bfc8bbef63">206.0</ix:nonFraction>&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. As of December 31, 2020 the Company had earned a $<ix:nonFraction unitRef="usd" contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementPaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI2MQ_623f4004-90a8-4559-a60c-076194754f2b">2.0</ix:nonFraction>&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for <ix:nonNumeric contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" format="ixt-sec:durwordsen" name="ino:CollaborationAgreementRoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTgyMw_c800ef08-bb39-4faa-9aab-bd20340612b3">ten years</ix:nonNumeric> after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostMaintenance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY3MzA0Ng_48836268-f8a3-4ce2-97b1-23d0ca8915e8">1.5</ix:nonFraction>&#160;million for a period of <ix:nonNumeric contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" format="ixt-sec:durwordsen" name="ino:AnnualMaintenancePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY3MzA1OQ_0c8f691e-7165-4d9d-a91c-b301d25a822b">five years</ix:nonNumeric>, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNTE0Mw_24cc1e0a-1ffd-48a7-9a52-7d1fd742360a">3.0</ix:nonFraction>&#160;million upfront payment plus the initial $<ix:nonFraction unitRef="usd" contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementPaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNTE3OQ_be403dff-14ca-440a-934f-19c28cd287ed">2.0</ix:nonFraction>&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i6c8ad24eca624a71a7fb21cdcced5abe_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjA1MQ_fb490a6d-dd71-4f5c-8425-aacc92717aa8">5.0</ix:nonFraction>&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $<ix:nonFraction unitRef="usd" contextRef="ica98223bf1ed447193c67fa870204517_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjMzOQ_8745c875-700f-4927-8702-6d9a8a69a920">5.0</ix:nonFraction>&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. For the six months ended June 30, 2021, <ix:nonFraction unitRef="usd" contextRef="i71ccd78a11244d749d8dd9859e9ce310_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjU0Mg_76385e7f-f090-49e9-b99e-fde92b9e3de8">no</ix:nonFraction> revenue was recognized from Advaccine. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="ic44786c100124c789efc53e8f92bfde9_I20210630" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjY2NQ_5efd3ac0-ec27-4e8e-8e54-9d9401db7dc8">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i95c7a96f00054646b6f751e13b02c56e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjY3Mg_df278630-131d-49cb-a977-e2af841dd536">7.1</ix:nonFraction>&#160;million, respectively, from Advaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reevaluated the Advaccine Agreement under ASC Topics 606 and 808 as of the date of the June 2021 amendments and determined that the Global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore should be accounted for under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, no contra-research and development expense has been recorded from Advaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1be25053ec4843ffb74ab4792b4afac0" continuedAt="i2b67fa9393cd47a18aad9f6b24eeb519"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the <ix:nonNumeric contextRef="i72b40649a6a84f138cb3a6dcb7498815_D20171229-20171229" format="ixt-sec:durwordsen" name="ino:CollaborationAgreementTerritoryExpansionOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzMzMQ_3a93bcdd-4150-4872-b599-c14fa245fe57">three years</ix:nonNumeric> following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="i537aa32e3c5f4baf82bacfc6e7b0d869_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:ProceedsFromCollaborativeAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzQ1NQ_fb3c0a17-602f-4ed5-b915-07687a10cb7f">19.4</ix:nonFraction> million in March 2018 which comprised the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i537aa32e3c5f4baf82bacfc6e7b0d869_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzUxMQ_64139942-1595-4585-b055-6123a3f27d08">23.0</ix:nonFraction> million less $<ix:nonFraction unitRef="usd" contextRef="i564bbcf0dabf424f86f296be903e20b0_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementCorporateIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzUxOQ_c3e5173c-473c-45f7-ab79-2d7f30179fd4">2.2</ix:nonFraction> million in foreign income taxes and $<ix:nonFraction unitRef="usd" contextRef="i564bbcf0dabf424f86f296be903e20b0_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementForeignNonIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzU1MA_2f93122c-12cb-4779-a80d-4947dd00247f">1.4</ix:nonFraction> million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $<ix:nonFraction unitRef="usd" contextRef="if69d1eee3fca4367a054a928d24cff8d_I20180331" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAdvisoryFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzg0Nw_d98c6654-459b-45ec-a45e-01e04cdbb718">960,000</ix:nonFraction> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfODQzNQ_a3c1a741-3221-41dd-9de7-c6ecd7eb7272">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630" format="ixt-sec:duryear" name="ino:CollaborationAgreementRoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfODk3Ng_34251167-ef36-4b1d-8db1-575f9c39bf82">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfOTU5OA_a1b55f01-7353-453e-ae96-f801fdd538e7">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630" format="ixt-sec:durday" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfOTY0Ng_6f2d5c56-feaf-4f96-b01c-7617a32ee41e">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTAxMzk_be318aaa-a6ee-4599-bc4d-f8ff7509ac8d">23.0</ix:nonFraction> million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price. As of June&#160;30, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="ia92556534d574bbc94e10cc84341c759_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTEwODE_da817e58-999a-4510-a74c-7e65c5efdb20">23.0</ix:nonFraction> million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if9ad39f285414f30b79535cfaba7daa2_D20150901-20150930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTE3ODk_d67b0ea2-6274-4a75-99b5-4c877e309873">27.5</ix:nonFraction> million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $<ix:nonFraction unitRef="usd" contextRef="iba45b8937a894f6b9a5129658feedbc3_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTE5NTg_2e1131f2-5108-4063-853e-39ba8e5f7dcf">125</ix:nonFraction> million and potential future commercial event-based payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="iba45b8937a894f6b9a5129658feedbc3_D20210101-20210630" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTIwMjk_fc2dc210-a5eb-41fe-a9a5-79a131cfbee0">115</ix:nonFraction> million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.   </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $<ix:nonFraction unitRef="usd" contextRef="ie861c939ef624bffbd0b88dbfdf9c693_D20171231-20171231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI2NjI_27d510e1-f034-49b9-b51c-c765fe84644f">27.5</ix:nonFraction> million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payme</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt. In both December 2018 and March </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2b67fa9393cd47a18aad9f6b24eeb519" continuedAt="i96166533a5c6498daf70d08318f95403"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019, the Company recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="iafce45fcd5d548d596dd6d619e8eacd5_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI4NTk_4e722d95-06a0-423b-a52d-da644be9072a"><ix:nonFraction unitRef="usd" contextRef="i46c98d6b5b8a4c33898800f47a20e3ff_D20190302-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI4NTk_f4e18242-c6ba-49aa-97b7-f7f20ca3f684">2.0</ix:nonFraction></ix:nonFraction>&#160;million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i42ff72c6a8dc403c95f8ee874839211b_D20180401-20180430" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTM3MjU_3addfadb-0c08-494b-b5de-9a06be1d4bec">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="i42ff72c6a8dc403c95f8ee874839211b_D20180401-20180430" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg5NzA_f47e5e61-70d4-44f4-88de-00d47fc6778b">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three and six months ended June 30, 2021, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i3df90724be6143258a8fdee15d4e93e6_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQwMjA_f5214ea3-babb-4453-8529-bdd388db59e0">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6407575bd8b340a1a2a8f8810560320a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NDU2Ng_1580d5e1-00c9-4c5e-bfbc-ac0c17fa5a60">4.4</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. During the three and six months ended June 30, 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="icaeaf41dd77446d3927ea1c114867dba_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQwMjg_faa85148-ec4e-42ac-9015-cc2bdbec3a78">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i192e249f20ad47fd87c6efd63533083b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NDc0MA_82208bf6-c674-4fec-bf9d-8f3dce751f82">2.9</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of June&#160;30, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="iaca810872ff8493db0d62372edb6bd01_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQxNjg_36b8dd01-573f-404c-aa77-00b3cacc0957">316,000</ix:nonFraction> recorded as grant funding liability on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="i8220fcd140d74557b083a926e4253873_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQzMzg_01e96986-9362-460b-8de8-71181b76c55d">9.0</ix:nonFraction> million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i03b88e02327942f9ae78274a728a6c7a_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ1MDQ_d25e38fa-9dbe-445e-ad16-d4db2bf5aa03">6.9</ix:nonFraction> million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $<ix:nonFraction unitRef="usd" contextRef="i761da9fe1ff8435f937cde9607056cae_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ2ODI_e4474587-6dcd-4f04-b934-d4ffb4aff966">5.0</ix:nonFraction> million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="id78961ef0362494d9ca8a3a24f0402d9_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ4NjQ_fe9d8ec9-1737-4f04-9bcc-3301ef426e36">1.3</ix:nonFraction> million to support large-scale manufacturing of INO-4800. During the three and six months ended June 30, 2021, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i63751304353e47dfa5578ae4af319b3b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ5ODE_6f6eeff9-e327-4ff9-a2fd-c3f03163a87d">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae69df542d9c4fbab5f22042b834a657_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NDc2NQ_a4afe879-c2cd-416e-b482-5a7e138a8324">3.5</ix:nonFraction> million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. During the three and six months ended June 30, 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="ic5944f9592ca4638842dcafe5504d740_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTY4MA_7344b8be-da18-4a2b-a235-ab534c51281e">5.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7f7c6a9e4960494e8081fc7f145ad847_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTY5NQ_b9f3e579-2846-4e27-a09a-d08d33280488">8.1</ix:nonFraction> million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of June&#160;30, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ifa54cd5e2c5b4aee983f8f582c668686_I20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTUxMjc_ca849f53-1dcc-48de-a747-f1dfdbe25890">2.9</ix:nonFraction> million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="ieda7c74c79e1485082bb7462bb0aec90_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTUzOTQ_1c08ffc1-9e52-4b9f-af16-d7b198088c6a">2.2</ix:nonFraction> million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="i02069efe34d14945a75f312034c48d56_D20190801-20190830" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTU3NTc_41150b0c-a5f8-4275-bc48-f0e1dcbaaa54">1.1</ix:nonFraction> million for the project. During the three and six months ended June 30, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i97a4ecfa456040578debe0c705bb0cb0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTgyOA_ed2f903f-5192-4ddd-87db-374cbb7e82ee">36,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i904f52b9d85542868818618a457d155a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTgzNw_b552e022-e5a2-4587-b9f0-d49767e716f5">170,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. During the three and six months ended June 30, 2021, the amounts recorded were minimal. As of June&#160;30, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i7e44b859e87640b9887e249f509f22b2_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTU5NDk_4133064a-a5b6-42c2-a084-711a74559ff4">575,000</ix:nonFraction> recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="ia079900790b44ee39d2535ab8a76f7c7_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTYxMTY_fc1453ae-92e2-47ed-94a5-02beb9df5d44">5.0</ix:nonFraction> million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three and six months ended June 30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i01f7a9d3dc10499f8b65f4f3b1c7d04b_D20210401-20210630" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTYyNjY_3c44e4ab-8839-4c3d-80fe-d53feff0cee2">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8772e190853b4c34b869b43e00154114_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTYyNzM_471a0ce2-4ea4-4a2d-9488-d1fc7fe20908">893,000</ix:nonFraction>, respectively, and during the three and six months ended June 30, 2020 recorded $<ix:nonFraction unitRef="usd" contextRef="i7f531494334b4657bad6357a54553f03_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTkyNg_140ca0cd-63ed-4337-9c63-8ae66fe08195">850,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1282eb1a458f4357a1ac8a3d8b4fa3ea_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTkzNg_e5f596b3-95e2-4d94-b922-f71e0b776971">913,000</ix:nonFraction>, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $<ix:nonFraction unitRef="usd" contextRef="iba1c591d1f53449fb9a0ca78b60e0636_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTcyOTM_131b5ee0-fc32-4c56-bb86-0089524b125a">54.5</ix:nonFraction> million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i96166533a5c6498daf70d08318f95403"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $<ix:nonFraction unitRef="usd" contextRef="i40b6bab09ed848df86ba826cc4961c16_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTgxNTc_afe4a9bb-ab02-40b7-ac25-6227b1359735">16.6</ix:nonFraction> million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i56b4d555b69d4dca91e2e11a14be2165_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg0NDI_4e8905e3-c4de-41be-aea9-9c1339e7e796">13.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4b1efaad3a5848b9b2664bb608171aa6_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTk3OQ_60de2c7e-d9a1-4cb4-af87-53ab77c025a6">21.2</ix:nonFraction>&#160;million, respectively, as contra-research and development expense related to the OTA Agreement. During the three and six months ended June 30, 2020, there was <ix:nonFraction unitRef="usd" contextRef="id32424115c5249fdab21269b2a97590e_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY1OTEwOA_2acfd21e-e90b-48d6-bcc7-e2f70965ceec"><ix:nonFraction unitRef="usd" contextRef="i44b465568e394137b0167411e7b5c097_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY1OTEwOA_65a154a9-e252-411a-8db1-96130f79ab7e">no</ix:nonFraction></ix:nonFraction> contra-research and development expense recorded related to the OTA Agreement. As of June&#160;30, 2021 and December 31, 2020, the Company had an accounts r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eceivable balance of $<ix:nonFraction unitRef="usd" contextRef="ifdf3e49c10cc4f94a383960947e82228_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg2MTA_236c0795-749c-4e41-881c-d10e5e466168">12.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7e127c1524564bae89ca80e255ad2678_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg2MTc_587afa05-4bf4-4fa1-b618-e91fa2a8806b">11.4</ix:nonFraction>&#160;million, respectively, on the condensed consolidated balance sheet from the DoD. As of June&#160;30, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ifdf3e49c10cc4f94a383960947e82228_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrantsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI5MzEyNg_24d3efb4-38ea-4ca9-9ebc-409a545ced82">3.0</ix:nonFraction>&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to the Procurement Contract.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_88"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84OC9mcmFnOjU3M2IzNmMyNmE5ZDQwZTZhMWVkZTZmNTJiN2QzM2FkL3RleHRyZWdpb246NTczYjM2YzI2YTlkNDBlNmExZWRlNmY1MmI3ZDMzYWRfMTcwMg_ddb29823-ddc1-44c3-a9ad-7b9647717e49" continuedAt="i3903d68a567e465788b22ae013bf7f49" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3903d68a567e465788b22ae013bf7f49" continuedAt="iae3f9e61c3aa4d6180674dff1d9e67f6">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</ix:continuation></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iae3f9e61c3aa4d6180674dff1d9e67f6">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;For the three and six months ended June&#160;30, 2021, the Company has not recorded any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_91"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTkxNw_bf157bc4-d8f2-4761-a735-2405265299d6" continuedAt="iba50524bfc12481aa9e442ceea748c40" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="iba50524bfc12481aa9e442ceea748c40" continuedAt="id7e5e61bbeb44e60bcbacca0744df4d2"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$<ix:nonFraction unitRef="usd" contextRef="i0e185f6790bc47528495934e156680eb_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMzc4_98688c49-3a98-4970-97a3-76bff4461a14">1.2</ix:nonFraction> million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i4df2a303132e4f7f96ff6997a31a1212_I20190228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfNTA3_1d0814b1-dfb0-4bbf-aebc-03aff23723be">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="iccb9c884d87d48218ffe7d83101d494f_I20200131" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODAw_5f88b623-e9d3-42e5-9513-77bb7e6fb7c9">800,000</ix:nonFraction>. Following this transaction, as of March 31, 2020, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i5c02b65034ce49e890afd34400d720ae_I20200331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODcx_5ece1031-6daf-4b24-85ca-5f8ce4cd06ba">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i667c2fdb4d5345df8d39328da874e2ad_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTEyMg_9223dcd7-70c1-412d-9898-091d3f192c9c">800,000</ix:nonFraction>.  Following this transaction, the Company owned <ix:nonFraction unitRef="number" contextRef="i2fb35c7b8b7e4a2a8b77665cb4247493_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTE3Mw_4057eedc-f69f-42ef-8043-d2d0d69e1802">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTg0Mw_c2193de1-938a-47eb-a9a9-5926bf939370">4.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTg1Ng_33e89b9c-1286-4196-9eb4-09f013101df8">2.4</ix:nonFraction> million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTkxNg_a4a6e329-2d3b-4b51-9389-9a5df0e0ab5b" continuedAt="i513cf5504aea49729f3f610e910bd87e" escape="true">The following table shows the amounts related to the deconsolidation accounting: </ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id7e5e61bbeb44e60bcbacca0744df4d2" continuedAt="i5159175d9c1b4a49912acd4f1336293c"><ix:continuation id="i513cf5504aea49729f3f610e910bd87e" continuedAt="ic547674dbd2e41ae836cd0316cf6ead9"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="ino:WorkingCapitalExcludingCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMC0xLTEtMS0w_e7784b51-3be5-4a21-b60a-45278deb4519">59,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMS0xLTEtMS0w_1eb2796d-802f-4003-b0b3-3d38f2862174">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMi0xLTEtMS0w_9478d92c-a063-4c13-952a-5a9c900419a0">16,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMy0xLTEtMS0w_2b3aae85-4467-4a0e-8403-92f7dbc49f25">3,181,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedInterestFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfNC0xLTEtMS0w_2503c74d-7db7-4466-b5a9-1bd0746143f9">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfNS0xLTEtMS0w_0ffa9403-8789-43d6-b2ee-2d7a60e17571">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfNi0xLTEtMS0w_f0ea8a5a-d42f-4ec9-abfd-3128dc7024d5">2,774,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="iea7c36741569485ca8d859069b46f092_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMjE3NA_f993d316-c0dc-4ae1-a473-f3cb09b85fd4">47</ix:nonFraction>% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02456b81a37f4ae6a5c063b014c525f2_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMS0xLTEtMS0w_32d7e5c6-be53-4efb-964f-e759722f8eb4">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02456b81a37f4ae6a5c063b014c525f2_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMS0zLTEtMS0w_1f09932d-92cb-4c16-8f2f-37e2ce347449">0.273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02456b81a37f4ae6a5c063b014c525f2_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMS01LTEtMS0w_e8c8ad68-72fd-431a-8191-d1ad8c9e070b">819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i196f4528a0a9490b9a924875a4215545_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMi0xLTEtMS0w_b7b317b1-f7dd-47c8-988d-6b72f68b032a">2,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i196f4528a0a9490b9a924875a4215545_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMi0zLTEtMS0w_8a57d988-1d46-4ba5-9130-9b3134e05ab8">1.325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i196f4528a0a9490b9a924875a4215545_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMi01LTEtMS0w_81fdb2e9-58de-4c37-96e8-14368008d753">2,799,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMy0xLTEtMS0w_1d2360c1-cb8c-4395-9b05-50afc222919f">5,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMy01LTEtMS0w_0c66099c-a89a-486c-b6e0-472ec61b119c">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption. The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. <ix:nonNumeric contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTkxNQ_01cfd171-ebcf-477e-af47-1ce9ccc920eb" continuedAt="i5c2554f941df47e5937dc540e7c74c69" escape="true">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><ix:continuation id="i5c2554f941df47e5937dc540e7c74c69"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ac9bc58c8414810ae3dff09c8e549af_D20200601-20200601" format="ixt-sec:duryear" name="ino:AlternativeInvestmentMeasurementInputTerm" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMC0xLTEtMS0w_a0df14b9-2cb0-464a-991b-f8644c8dbc84">2.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if173908cc8354a3187bf1e82e65a5550_I20200601" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMS0xLTEtMS0w_0cdea95f-46ee-4fc7-a7b6-8f608bdedce9">70</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife9ba1ec7a1a485a8b2bda6032474f24_I20200601" decimals="4" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMi0xLTEtMS0w_1212bc4f-b404-485a-87e8-d5bff2d6cb25">2.46</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="ino:EquityMethodInvestmentEnterpriseValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMy0xLTEtMS0w_a82ab5df-b644-480e-a3b5-e2d40dc9937e">4,966,531</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5159175d9c1b4a49912acd4f1336293c" continuedAt="i5cd27472ceea4338872adb9e17bdc93b"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i230f14716d1a4c2e895e45f0ed84c399_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfNjg4OA_960b9b05-ff8f-47fc-bf36-fb8294db97ce">1.4</ix:nonFraction>&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i9dcc915ba16e470c810717cdca71bc8a_I20201130" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfNzUyMw_d5425773-ab7c-4833-955f-2997907cbae7">36</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i751954486ff04a2585b50cca7a7a1f66_D20200601-20201231" decimals="-5" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODUwNA_65511e8d-5966-4e6d-acc9-8ab61e4e7d0a">4.6</ix:nonFraction> million and for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="id548d70b807a41cdbafa0a873651db92_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODU2NQ_b34276a4-e034-4dfb-8060-ae815124da4b">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="id548d70b807a41cdbafa0a873651db92_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODU4Mw_606216bd-3e9e-4354-9e1f-765ec4be7da6">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="i603b348bf030425286b8663a7233f3b2_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODY1Mw_b6761ba2-cd1b-46af-87a1-bacbd6b9f139">0</ix:nonFraction>. Of the total amount, $<ix:nonFraction unitRef="usd" contextRef="ie7eefa6dfb474f59a56c5498e9af5934_D20200601-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODY3OA_727fbd2e-ef9c-4015-9365-534eebe3b5af">819,000</ix:nonFraction> has been allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i3ddd5fa80e1f4d619dac2b863cd3a051_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODc2NQ_5a40828a-ecb0-4500-9a9a-5492adc3c0ab">0</ix:nonFraction> as of March 31, 2021. <ix:continuation id="ic547674dbd2e41ae836cd0316cf6ead9" continuedAt="ic880bb8aedc34d73a67bf954bb56f0ae">The remaining $<ix:nonFraction unitRef="usd" contextRef="id0b994018688462294e9fc2216b8b645_D20200601-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODgwNA_559472bc-897d-4c36-912b-4e36e3e60d6a">4.2</ix:nonFraction> million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i7eed2f09111e4adc973bc8d68b9050b1_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODk3MA_9bd730e3-68e4-4261-bf86-4269793d2a80">0</ix:nonFraction> as of March 31, 2021 as shown in the table below:</ix:continuation></span></div><div style="margin-top:5pt"><ix:continuation id="ic880bb8aedc34d73a67bf954bb56f0ae"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb812a090bdf454a8d614a22e3087514_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfMS0yLTEtMS0w_e6ddccb8-daf4-4993-984f-97ce24badcdc">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565b71404f58429384bf7e01598dd420_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfMi0yLTEtMS0w_205f797b-8dbe-40ae-bce5-44d9eade9819">1,399,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 1, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i751954486ff04a2585b50cca7a7a1f66_D20200601-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfMy0yLTEtMS0w_36e1ee23-6e85-4c85-b6fc-68f856c3d83a">4,584,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id548d70b807a41cdbafa0a873651db92_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfNC0yLTEtMS0w_2af7a53d-8a37-4d39-a4ba-89a7652900d7">434,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i603b348bf030425286b8663a7233f3b2_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfNS0yLTEtMS0w_c316c179-294b-427a-a8ec-f06a5b1ece87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="i1ec0c50e342949c6b66d38190dde51e1_I20210630" decimals="INF" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTA3Nw_f524c872-6f14-4387-a012-db9d2b850cd9">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="ibc6d252ee23a41b88a2b37888e87aff6_I20210228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTM4OQ_3d11bc91-d899-42f3-a65c-7025aba635f1">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i5cd27472ceea4338872adb9e17bdc93b" continuedAt="ie65f7196266f4fa8aa6cacdc96ef6ba4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie65f7196266f4fa8aa6cacdc96ef6ba4">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or SEC, on March 1, 2021 (our 2020 Annual Report). Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2020 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and product candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our product candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare laws and proposals; and the impact of COVID-19 on us and our third-party contractors and suppliers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_106"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). Our DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, we have demonstrated that DNA medicines can be delivered directly into cells in the body through our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel DNA medicine candidates are made using our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches, namely cellular uptake. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date have shown a favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to advance, protect and, once approved, commercialize our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Advaccine, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), Defense Advanced Research Projects Agency ("DARPA"), The U.S. Department of Defense ("DoD"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for COVID-19; Middle East Respiratory Syndrome, or MERS; Lassa fever; HIV; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had an accumulated deficit of $1.0 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 On Our Business</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operationally, we have experienced some disruptions as a result of the COVID-19 pandemic. Our clinical trial operations have been adversely affected, including our ability to initiate and conduct our planned trials on our expected timelines and our ability to recruit and retain patients in our trials. Our data collection timelines have also been impacted, as an increasing number of trial participants are either not able or do not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples. As a result, it is taking longer than anticipated to complete the data collection process.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the outbreak, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. We have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. We have also implemented a mask-wearing mandate for all on-site activities. Non-essential business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity has not been negatively impacted to date by the pandemic. During the year ended December 31, 2020, we raised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$454.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net proceeds from the sale of shares of our common stock through our "at-the-market" equity offering program and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in January 2021 we closed an underwritten public offering with net proceeds to us of $162.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which further enhanced our liquidity and capital resources. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our cash and cash equivalents and short-term investments were $443.7 million.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to closely monitor the impact of the COVID-19 pandemic on our employees, collaborators and service providers. The extent to which the pandemic will impact our business and operations will depend on future developments, including travel restrictions in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain. For additional information on the potential effects of the COVID-19 pandemic on our business, financial condition and results of operations, see the &#8220;Risk Factors&#8221; section below in Part II, Item 1A of this Form 10-Q.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_109"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting policies since December 31, 2020. For a description of our critical accounting policies that affect our significant judgments and estimates used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2020 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2020 Annual Report. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_112"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;4 to the Condensed Consolidated Financial Statements, included in this Quarterly Report.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_115"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $273,000 and $644,000, respectively, for the three and six months ended June 30, 2021, as compared to $267,000 and $1.6 million, respectively, for the three and six months ended June 30, 2020. Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities, for the three and six months ended June 30, 2021 and 2020. The decrease in revenue for the six-month period year over year was primarily due to less milestone revenue earned from our affiliated entity PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses for the three and six months ended June 30, 2021 were $70.8 million and $109.9 million, respectively, as compared to $22.4 million and $41.5 million, respectively, for the three and six months ended June 30, 2020. In each case, the significant increase was primarily attributable to manufacturing scale-up activities for INO-4800 in 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These INO-4800 activities included:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses related to the acquisition and installation of manufacturing equipment, which increased by $21.9 million for each of the three-month and six-month periods; and </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">drug manufacturing, outside services and clinical study expenses, which increased by $16.2 million and $27.9 million for the three-month and six-month periods, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other increases for the three-month and six-month periods year over year included:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$7.9 million and $10.5 million, respectively, in engineering services and expensed equipment related to our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device array automation project;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$3.5 million and $8.3 million, respectively in employee and contractor compensation; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$3.0 million and $3.7 million, respectively, in drug manufacturing expenses related to our RRP study; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$894,000 and $3.8 million, respectively, in employee stock-based compensation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These increases were offset by increases in contra-research and development expense recorded from grant agreements of $</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.1 million and $16.9 million for the three-month and six-month periods, respectively, among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $17.2 million and $31.0 million, respectively, for the three and six months ended June 30, 2021 as compared to $9.1 million and $14.1 million, respectively, for the three and six months ended June 30, 2020. The increase for the three-month period year over year was primarily due to an increase of $13.4 million earned under the DoD grant, offset by decreases of $4.6 million and $850,000 earned under the grants from CEPI and Gates, respectively, related to INO-4800 and device development activities, among other variances. The increase for the six-month period year over year was primarily due to increases of $21.2 million and $1.5 million earned under the DoD grant and CEPI grants related to our Lassa fever and MERS vaccine candidates, respectively. These increases were offset by decreases of $4.6 million and $1.1 million from our CEPI grants related to INO-4800 and device development and the MCDC grant, respectively, among other variances.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $12.7 million and $26.5 million, respectively, for the three and six months ended June 30, 2021, as compared to $11.1 million and $18.5 million, respectively, for the three and six months ended June 30, 2020. Increases for the three-month and six-month periods year over year included:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.1 million and $3.8 million, respectively, in employee and consultant stock-based compensation;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.0 million and $1.4 million, respectively, in employee compensation;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$84,000 and $2.0 million, respectively, in legal and accounting expenses; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$588,000 and $1.0 million, respectively, in insurance expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by lower expenses for work performed related to corporate marketing and communications of $640,000 and $1.3 million, respectively, among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the three and six months ended June 30, 2021 was $5.3 million and $14.5 million, respectively. Of these amounts, $2.7 million and $7.9 million, respectively, was included in research and development expenses, and $2.6 million and $6.6 million, respectively, was included in general and administrative expenses. Total employee and director stock-based compensation expense for the three and six months ended June 30, 2020 was $3.4 million and $7.1 million, respectively. Of these amounts, $1.8 million and $4.1 million, respectively, was included in research and development expenses, and $1.6 million and $3.0 million, respectively, was included in general and administrative expenses. The year over year increase was primarily related to a higher weighted average grant date fair value for the awards granted in the first quarter 2021 and grants vesting during the period. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three and six months ended June 30, 2021 was $928,000 and $1.7 million, respectively, as compared to $1.1 million and $1.5 million, respectively, for the three and six months ended June 30, 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three and six months ended June 30, 2021 was $467,000 and $980,000,   respectively, as compared to $2.8 million and $5.7 million, respectively, for the three and six months ended June 30, 2020. The decrease for the three and six-month periods year over year was due to less interest expense recorded for our convertible senior notes, or the Notes, due to the partial conversions of the Notes into shares of our common stock in the third and fourth quarters of 2020 and full conversion of December 2021 Bonds in March 2021, as well as no interest expense recorded on our August 2019 Bonds due to their full conversion into shares of our common stock in August 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of derivative liability.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The change in fair value of derivative liability for the three and six months ended June 30, 2020 was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$97.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$111.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. We determined that our August 2019 Bonds included an embedded conversion feature that was considered to be a derivative liability requiring bifurcation from the debt instrument and separate recognition in our financial statements. The conversion feature was revalued at the end of each reporting period and immediately prior to the conversion of the August 2019 Bonds in August 2020, with&#160;the resulting changes in fair value reflected in the condensed consolidated&#160;statements of operations. There was no change in fair value for the three and six months ended June 30, 2021, as the derivative liability was derecognized upon the conversion in full of the August 2019 Bonds in August 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (loss) on investment in affiliated entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) results from the change in the fair market value of our investment in PLS for a gain of $279,000 and a loss of $552,000, respectively, for the three and six months ended June 30, 2021 as compared to the change in the fair market value of the investments in PLS and GeneOne for a loss of $3.9 million and gain of $9.3 million, respectively, for the three and six months ended June 30, 2020. During the third quarter of 2020, we sold our full equity interest in GeneOne. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net unrealized gain (loss) on available-for-sale equity securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain (loss) on available-for-sale equity securities for the three and six months ended June 30, 2021 of $136,000 and $(711,000), respectively, as compared to $4.4 million and $(691,000), respectively, for the three and six months ended June 30, 2020, resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on deconsolidation of Geneos.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The gain recorded represents the excess of the fair value of our retained noncontrolling investment in Geneos and the carrying amount of the noncontrolling interest over the carrying amount of Geneos' assets and liabilities as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in net loss of Geneos.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation in June 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_118"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had cash, cash equivalents and short-term investments of $443.7 million and working capital of $490.7 million, as compared to $411.6 million and $429.5 million, respectively, as of December&#160;31, 2020. The increase in cash and short-term investments during the six months ended June&#160;30, 2021 was primarily due to the net proceeds from the sale of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our common stock in an underwritten public offering in January 2021, offset by expenditures related to our research and development activities, clinical trials and various general and administrative expenses related to legal, consultants, accounting and audit, and corporate development.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $131.3 million and $52.6 million for the six months ended June 30, 2021 and 2020, respectively. Net cash used in operating activities for the six months ended June 30, 2021 consisted of net loss of&#160;$136.5 million, less use of net cash in operating assets and liabilities of&#160;$14.0 million partially offset by net non-cash adjustments of&#160;$19.2 million. The net cash used in operating activities included a $27.8 million increase in prepaid expenses and other assets, primarily made up of prepayments for facilities, equipment and manufacturing related to INO-4800. The primary non-cash adjustments to net loss included stock-based compensation of&#160;$15.2 million, depreciation and amortization of $1.6 million, and net unrealized loss on available-for-sale equity securities of $711,000, among other items. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June 30, 2020 consisted of net loss of&#160;$162.3 million,&#160;less use of net cash in operating assets and liabilities of&#160;$913,000, partially offset by net non-cash adjustments of&#160;$110.6 million. The primary non-cash expenses added back to net loss included the increase in fair value of derivative liability of $111.0 million, stock-based compensation of&#160;$7.7 million, interest expense of $3.0 million and depreciation and amortization of&#160;$1.9 million. These non-cash expenses were offset by non-cash gain on investment in affiliated entities of $9.3 million, gain on deconsolidation of Geneos of $4.1 million and the acquisition of investment in our affiliated entity PLS of $1.7 million through the settlement of accounts receivable with additional shares of PLS common stock.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $224.8 million and $94.2 million for the six months ended June 30, 2021 and 2020, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $164.3 million and $340.0 million for the six months ended June 30, 2021 and 2020, respectively. The variance was primarily due to the proceeds from the sale of common stock under the ATM sales agreement in 2020, offset by the net proceeds from the January 2021 underwritten public offering.  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Issuances of Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we closed an underwritten public offering of 20,355,000 shares of our common stock at a public offering price of $8.50 per share. The net proceeds, after deducting the underwriters' discounts and commissions and other estimated offering expenses payable by us, were $162.1&#160;million. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with an outside placement agent, or the Placement Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. In the first quarter of 2020, we entered into amendments to the&#160;Sales Agreement to increase the amount of our common stock that could be sold through the Placement Agent under the Sales Agreement to an aggregate offering price of up to $250.0 million. During the three months ended March 31, 2020, we sold 43,148,952 shares of common stock under the Sales Agreement for aggregate net proceeds of $208.2 million. Following these sales, there was no remaining capacity under this Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, we entered into a new sales agreement, or the New Sales Agreement, with the same Placement Agent to sell shares of our common stock. On that same day, we filed a prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for aggregate gross proceeds of up to $150.0 million. On May 12, 2020 we filed an additional prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for an additional $100.0 million of gross proceeds, bringing the maximum gross proceeds of sales under the New Sales Agreement to $250.0 million. Through December 31, 2020, we sold 22,915,934 shares of common stock under the New Sales Agreement for aggregate net proceeds of $246.2 million. As of December 31, 2020, there was no remaining capacity under the New Sales Agreement.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, stock options to purchase 1,194,696 shares of common stock were exercised for aggregate net proceeds to us of $6.2 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $3.9 million. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, stock options to purchase 1,649,874 shares of common stock were exercised for aggregate net proceeds to us of $9.6 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $2.1 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had an accumulated deficit of $1.0 billion and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. These activities will require additional financing. If these activities are successful and if we receive approval from the FDA to market our product candidates, then we will need to raise additional funding to market and sell the approved products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Contractual Obligations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all outstanding December 2019 Bonds were converted into 1,009,450 shares of our common stock. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_121"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in the area of changes in United States interest rates and conditions in the credit markets, and the recent fluctuations in interest rates and availability of funding in the credit markets primarily impact the performance of our investments. We do not have any material foreign currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities.  Due to the short-term maturities of our cash equivalents and the low risk profile of our investments at June&#160;30, 2021, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness, consisting of the Notes, is fixed and not subject to fluctuations in interest rates.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment in affiliated entity at June&#160;30, 2021 represents our ownership interest in the Korean-based company PLS. We report this investment at fair value on the condensed consolidated balance sheet using the closing price of PLS shares of common stock as reported on the date of determination on the Korea New Exchange Market.</span></div><div style="margin-top:14pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the three and six months ended June 30, 2021 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. We do not have any foreign currency hedging instruments in place. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_124"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of June&#160;30, 2021 at the reasonable assurance level. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff. On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants. On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants&#8217; motion to dismiss. The court granted Defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements. The court denied Defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, Defendants filed their answer to the complaint. On July 29, 2021, Plaintiffs moved to certify the class action. The case is now in discovery.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name our current directors as defendants. The Devarakonda complaint also names one of our former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to defend these actions vigorously.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. We intend to vigorously defend ourselves against GeneOne&#8217;s claims. On January 29, 2021, we filed preliminary objections to the complaint.  </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_133"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, the risk factors discussed in our 2020 Annual Report, which we filed with the SEC on March 1, 2021, in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock could decline. You should also consider the more detailed description of our business contained in our 2020 Annual Report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses to date; as of June&#160;30, 2021, our accumulated deficit was approximately $1.0 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine, DNA immunotherapy and dMAB product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAbs and electroporation equipment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing our electroporation-based DNA delivery technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products and product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">debt service obligations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility and turmoil, particularly in light of the COVID-19 pandemic, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our electroporation equipment and product candidates in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. To the extent that our product candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment or product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidates' clinical and other benefits outweigh its safety risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications or, with respect to our clinical trials for INO-4800, mass vaccination efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or DNA encoded monoclonal antibody products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human vaccine programs, which includes our COVID-19 vaccine candidate INO-4800, our immunotherapy programs and our DNA encoded monoclonal antibodies program are in various stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine candidates and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our vaccine product candidates, including INO-4800. The success of our efforts to develop and commercialize our product candidates, including INO-4800, could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. The ability to manufacture sufficient quantities of INO-4800 on a large scale is particularly challenging and will require substantial resources and the engagement of third parties, which we may not be able to obtain on a timely basis, or at all.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our planned Phase 3 clinical trial of INO-4800 in the United States as a potential COVID-19 vaccine has been placed on partial clinical hold by the U.S. FDA, which may cause delays in our ability to conduct clinical trials in the United States.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our planned clinical development of INO-4800 in the United States as a potential COVID-19 vaccine has been placed on partial clinical hold by the U.S. FDA, which means that we cannot commence a Phase 3 clinical trial in the United States. Although the partial clinical hold does not necessarily prevent us from starting our planned Phase 3 clinical trials outside of the United States, foreign regulatory authorities may require that we satisfactorily resolve the FDA&#8217;s remaining questions relating to the CELLECTRA 2000 device, or such foreign regulatory authorities may impose similar requirements, before we can commence or complete the portion of our Phase 3 clinical trial to be conducted in foreign countries. We are actively working to address the FDA&#8217;s questions. There can be no assurance, however, regarding the timing of the FDA&#8217;s agreement to lift the partial clinical hold or whether we will ultimately be successful in obtaining any such determination from the FDA to do so.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delays in the commencement of our Phase 3 clinical trial or completion of ongoing clinical testing for INO-4800 could significantly affect our product development costs. We do not know whether our planned Phase 3 clinical trial will begin on time or be completed on schedule, if at all. In addition, our ongoing clinical trials for INO-4800 may not be completed on schedule, or at all, and could be placed on additional holds by regulators either in the United States or in foreign jurisdictions for reasons unrelated to our current hold. If we experience delays in completion of, or if we terminate, any of our clinical trials relating to INO-4800, the commercial prospects for our product candidate may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Newly emerging SARS-CoV-2 variants could reduce the immunogenicity and effectiveness of INO-4800 as a potential COVID-19 vaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Multiple variants of the virus that causes COVID-19 have been documented in the United States and globally during this pandemic. The new SARS-CoV-2 variants could be less affected by the immune responses generated by INO-4800 in the vaccine recipients and therefore could reduce the overall efficacy of the vaccine in controlling severe COVID-19 disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. The option of seeking an Emergency Use Authorization may no longer exist if the public health emergency has expired or if a sufficient supply of COVID-19 vaccines have obtained full Biologics License Approval, or foreign equivalent, by the time we are ready to submit an application. If we do not timely apply for such an emergency use authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek an Emergency Use Authorization, or EUA, from the FDA or similar authorization from regulatory authorities outside of the United States, such as conditional marketing authorization from the EMA. If we apply for an EUA and it is granted, an EUA will authorize us to market and sell our COVID-19 vaccine under certain conditions of authorization as long as the public health emergency exists. The FDA expects that companies which receive an EUA for COVID-19 vaccines will proceed to licensure of their vaccine products under a full Biologics License Application. The FDA may issue an EUA during a Public Health Emergency if the agency determines that the potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. There is no guarantee that we will apply for an EUA or other similar authorization or, if we do apply, that we will be able to obtain such authorization. If an EUA or other authorization is granted, we will rely on the FDA or other applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. An EUA authorizing the marketing and sale of our product will terminate upon expiration of the Public Health Emergency, which is a determination made by the Secretary of Health and Human Services. The FDA may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of authorization. If our competitors obtain full biologics licensure, the FDA or foreign regulatory authorities may no longer grant EUAs for COVID-19 vaccines if the medical need has been met, thereby forcing us to seek full biologics licensure. If we apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our COVID-19 vaccine, which could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our electroporation devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our product candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our product candidates requires significant expertise and capital </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and to supply product candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our product candidates, including INO-4800. In 2020, VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we have engaged several additional third-party contract manufacturers to support the planned large-scale manufacturing of INO-4800. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity on commercially reasonable terms. Our inability to secured sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for INO-4800 or any of our other product candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. For example, in connection with our planned Phase 3 clinical trials of INO-4800 to be conducted outside of the United States, some regulatory authorities have indicated concerns with placebo-controlled efficacy trials of a COVID-19 vaccine, which means that we would not be able to open clinical trial sites in those countries. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our product candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional product candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of for the treatment of recurrent respiratory papillomatosis. We have sought and may continue to seek Orphan Drug Designation for one or more of our other product candidates, including but not limited to VGX-3100 for the treatment of HPV-16-/18-associated anal dysplasia, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of for the treatment of recurrent respiratory papillomatosis, and even if we obtain Orphan Drug Designation for our other product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our product candidates, we may never receive such designations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax reform legislation enacted in 2017 reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. This reduction could further limit the advantage of, and may impact our future business strategy with respect to, seeking the Orphan Drug Designation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to enter into agreements with other highly-regarded organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts account for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the NIAID, DARPA and the DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in April 2021 we were notified by the DoD that they will discontinue funding for the Phase 3 segment of our INNOVATE trial.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.   </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement, including with respect to COVID-19 vaccines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Growth and Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, during 2020, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of our INO-4800 vaccine candidate against COVID-19 in violation of certain federal securities laws. We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigation matters, described in this report, are ongoing, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even though we intend to vigorously defend ourselves in these actions, there can be no assurance that we will ultimately prevail. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, since named SARS-CoV-2, causing the disease known as COVID-19, was reported in China. Since then, COVID-19 has spread globally, resulting in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &#8220;pandemic&#8221; in March 2020 and United States also declaring a national emergency. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines could be negatively affected by COVID-19, which could then materially and adversely affect our business, financial condition and results of operations. Further, we have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. We have also implemented a mask-wearing mandate for all on-site activities. Non-essential business travel has been suspended and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact our productivity, or could disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as local jurisdictions continue to put restrictions in place or reinstitute restrictions they had previously lifted, our ability to continue to conduct and enroll patients in our clinical trials, manufacture our product candidates and pursue collaborations may also be limited. Such events may result in business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, could also affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital. Although we have raised significant funds from the sale of our common stock in the public markets during the pandemic, there can be no guarantee that we will be able to continue to so, which could negative affect our future liquidity. In addition, if a global economic recession results following the spread of COVID-19, including newly emerging SARS-CoV-2 variants, its impact could materially affect our business and the value of our common stock.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19, including newly emerging SARS-CoV-2 variants, globally has and could continue to adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, COVID-19 has adversely impacted the timeline for data collection for our VGX-3100 program. An increasing number of trial participants are either not able or do not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for this trial. As a result, it is taking longer than anticipated to complete the data collection process. Further, the COVID-19 outbreak could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of patients to enroll in trials, patients withdrawing from trials following enrollment as a result of contracting COVID-19 or other health conditions, or the inability of patients to comply with clinical trial protocols as quarantines and travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. These restrictions may delay the conduct of multiple clinical trials including our Phase 1 through 3 clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including travel restrictions in the United States and other countries, the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 is highly uncertain.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and many of our competitors have significantly greater resources and experience. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing COVID-19 vaccines, cancer vaccines and immunotherapies, and several products such as the CAR-Ts developed by our competitors have been approved for human use. Some of our competitors have already received regulatory approval for their COVID-19 vaccines and have mass vaccination efforts underway in our target markets. The earlier market entry of these other vaccines, and their actual or perceived efficacious or success relative to our own, has led to and may continue to lead to diversion of funding away from us, decreased demand for INO-4800, if approved, and difficulty in finding participants for our clinical trials. All of these factors could substantially impact our ability to complete the development of, commercialize and generate revenues from INO-4800. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days from December 2018 to January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our electroporation equipment and DNA vaccine, DNA immunotherapy and dMAb candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA.   Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage, and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through December 31, 2021 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and implemented others under its existing authority. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021.  On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation (MFN) executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction against implementation of the interim final rule. On January 13, 2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not appeal the preliminary injunction granted in the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN Model interim final rule shall not commence earlier than sixty (60) days after publication of that regulation in the Federal Register. Based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and which, beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct research and development activities in China through our collaboration with Advaccine, which is conducting and funding the Phase 2 trial of INO-4800 in China. In addition, we are party to a license and collaboration agreement with China-based company ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to increased costs for clinical materials that are manufactured in China. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">given the nature of the COVID-19 pandemic, governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations, particularly developments concerning the prospects of INO-4800 as a potential vaccine candidate against COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other product candidates to address COVID-19 or other diseases; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative perception of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global unrest, terrorist activities, and economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics, including COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the COVID-19 outbreak. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations on the Notes;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our products receives regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption in or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Jobs Act of 2017 was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The new federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the federal tax law.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_136"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_139"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_142"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_145"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_148"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ica0a70fe2a8047f7bda7a3d9dbe49bde_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit 3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August 10, 2011 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Form 8-K current report filed on August 12, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10xqex101.htm">10.1&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10xqex101.htm">Amended and Restated Collaboration and License Agreement dated June 7, 2021, by and between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10qex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10qex311.htm">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10qex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10qex312.htm">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10qex321.htm">32.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-63021x10qex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain confidential portions of this exhibit (indicated by asterisks) were omitted pursuant to applicable regulations.</span></div></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="margin-top:7.5pt;padding-left:11.25pt;text-indent:-11.25pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ica0a70fe2a8047f7bda7a3d9dbe49bde_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ino-63021x10xqex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3f61f46011724635ba611c38554656c5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit&#160;10.1 </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amended and Restated Collaboration and License Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of June 7, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a corporation organized and existing under the laws of Delaware and having a place of business at 60 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a corporation having a place of business at B1-308, No. 218 Xinghu Street, Suzhou 214002, Jiangsu Province, China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Inovio and Advaccine are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Inovio is currently conducting research and development of the Vaccine (as defined below) and the Product (as defined below)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Advaccine is a pharmaceutical company with experience in developing pharmaceutical products in, among other regions, the Advaccine Territory (as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have been collaborating in co-development of Vaccine since January 2020, including conducting preclinical studies, early stage clinical trials and other development activities in connection with the Product, and desire to continue the collaboration for the Development, Manufacturing and Commercialization of the Product (with each capitalized term as respectively defined below)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in furtherance of such collaboration, the Parties wish to co-develop the Product under a Global Phase 3 Study (as defined below) in accordance with the terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Inovio and Advaccine previously entered into that certain Collaboration and License Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) dated as of December 31, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to which Inovio granted Advaccine the exclusive right to Develop, Manufacture and Commercialize the Product in Greater China (with each capitalized term as respectively defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in furtherance of such collaboration, the Parties wish to expand the scope of territories exclusively licensed to Advaccine&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Advaccine and Inovio have entered into that certain Non-exclusive License Agreement, dated as of December 31, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Exclusive License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Advaccine granted Inovio a non-exclusive license to certain DNA vaccine manufacturing processes.</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%">1</font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) for Inovio, the U.S. generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (ii) for Advaccine, the International Financial Reporting Standards (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or any other accounting standards it is required to adopt under the applicable Laws, in either case consistently applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167;301 et seq., and&#47;or the Public Health Service Act, 42 U.S.C. &#167;&#167;262 et seq., as such may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patents that claim Advaccine Inventions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, (a)&#160;mainland China, Taiwan, Hong Kong and Macau (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Greater China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (b) the countries listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto (each of mainland China, Taiwan, Hong Kong, Macau and the countries listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Region</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverse Risk</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any risk of an adverse effect on the Development, procurement or maintenance of Regulatory Approval, Manufacture or Commercialization of the Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Party, a Person that controls, is controlled by or is under common control with such Party.  For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise.  For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease to have any rights, including license and sublicense rights, under this Agreement by reason of being an Affiliate of such Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means laws, regulations, or orders prohibiting the provision of a financial or other advantage for a corrupt purpose or otherwise in connection with the improper performance of a relevant function, including without limitation, to the extent applicable, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Corruption of Foreign Public Officials Act (CFPOA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">US Foreign Corrupt Practices Act (FCPA)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">UK Bribery Act 2010</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and similar laws governing corruption and bribery, whether public, commercial or both, to the extent applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Array</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means device arrays used in combination with the Inovio Device.</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular Product that has received Regulatory Approval for a particular indication in a particular Region and is being marketed and sold by Advaccine or any of its Affiliates or Sublicensees in the applicable Region, a biologic product that (a) is sold in such region by a Third Party that is not a sublicensee of Advaccine or its Affiliate, and where such Third Party did not purchase or acquire such product in a chain of distribution that included any of Advaccine or its Affiliates or sublicensees, and (b) has received Regulatory Approval (with all references in the definitions for Biosimilar Product and Regulatory Approval to the &#8220;Product&#8221; to be deemed references to such biologic product) in such Region for the same indication as the applicable Product as a &#8220;bioequivalent,&#8221; &#8220;biosimilar&#8221; or similar designation of interchangeability by the applicable Regulatory Authority in such Region pursuant to an expedited or abbreviated approval process, where (i) such Product is the reference product in such Region, and (ii) such Regulatory Approval referred to or relied on the approved Marketing Authorization Application for such Product held by Advaccine or its Affiliate or Sublicensee in such Region or the data contained or incorporated by reference in such approved Marketing Authorization Application for such Product in such Region. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day other than Saturday, Sunday or any day that banks in Suzhou, China&#59; Plymouth Meeting, PA&#59; or New York City, New York, are required or permitted to be closed. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30, or December 31. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for the first Calendar Year, the period beginning on the Effective Date and ending on December 31, 2021, and for each Calendar Year thereafter each 12-month period commencing on January 1, and ending on December 31, except that the last Calendar Year will commence on January 1 of the year in which this Agreement expires or terminates and end on the effective date of such expiration or termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to either Party&#58; (a) the sale of all or substantially all of such Party&#8217;s assets or business relating to this Agreement (other than to an Affiliate of such Party)&#59; (b) a merger, reorganization or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation&#59; or (c) a Person, or group of Persons, acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control of such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Supply Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Inovio&#8217;s Manufacturing Expenses for the clinical supply of Product in connection with the Global Phase 3 Study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any clinical testing of a pharmaceutical or biologic product in human subjects.  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CMC Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Information related to the chemistry, manufacturing and controls of the Product, as specified by the FDA, NMPA and other applicable Regulatory Authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison activities, marketing, pricing, reimbursement, sale, and distribution of the Products, including strategic marketing, sales force detailing, advertising, market the Product support, all customer support, the Product distribution and invoicing and sales activities&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall exclude any activities relating to the Manufacture of the Product.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to either Party&#8217;s obligations under this Agreement, the carrying out of such obligations with a level of efforts and resources consistent with the commercially reasonable practices of a similarly situated company in the pharmaceutical industry for the active and diligent commercialization of a similarly situated branded pharmaceutical product as the Product at a similar stage of commercialization, taking into account efficacy, safety, patent and regulatory exclusivity, anticipated or approved labeling, present and future market potential, competitive market conditions, the profitability of the product in light of pricing and reimbursement issues, and all other relevant factors.  It is understood that in fulfilling any obligation to use Commercially Reasonable Efforts in this Agreement, a Party shall not take into account (i) any other pharmaceutical product such Party is then researching, developing, manufacturing or commercializing outside the scope of this Agreement, (ii) the payments required to be made by such Party to the other Party under this Agreement, (iii) such Party&#8217;s access to sufficient personnel, capital or resources to conduct its responsibilities hereunder in accordance with the foregoing standards or (iv) political considerations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Technical Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CTD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a set of specifications for application dossier adopted by the ICH for organizing applications of pharmaceuticals for human use to regulatory authorities. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any biological or pharmaceutical product, other than the Vaccine or the Product, that is intended for the prevention of the disease caused by SARS-CoV-2. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Party means any and all Information of such Party or its Affiliates that is disclosed to the other Party or its Affiliates under this Agreement, whether in oral, written, graphic, or electronic form.  In addition, all Information disclosed by a Party or its Affiliates pursuant to the mutual non-disclosure agreement between Beijing Advaccine Biotechnology Co., Ltd. and Inovio dated January 27, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be deemed to be Confidential Information of such Party disclosed hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any use or disclosure of any such Information that is authorized under </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Article 12 shall not be restricted by, or be deemed a violation of, the Confidentiality Agreement.  For clarity, Inovio Licensed Know-How shall be deemed Confidential Information of Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any material, Information, Patent or other intellectual property right, possession of the right, whether directly or indirectly, and whether by ownership, license, or otherwise, to grant a license, sublicense, or other right to or under, such material, Information, Patent, or intellectual property right without violating the terms of any existing agreement or other arrangement with any Third Party&#59; provided that, with respect to any material, Information, Patent or other intellectual property right obtained by Inovio after the Prior Effective Date from a Third Party, Inovio shall be deemed to Control such material, Information, Patent or other intellectual property right only if it possesses the right to grant such license, sublicense, or other right thereto without being obligated to pay any royalties or other consideration therefor, unless Advaccine agrees in advance of any grant of rights thereto to pay such royalties or other consideration. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Patent and a Product, that the Manufacture, use, offer for sale, sale or import of such Product by an unlicensed Third Party would infringe a Valid Claim in such Patent&#59; provided, however, that in determining whether a claim of a pending Patent application would be infringed, it shall be treated as if issued in the form then currently being prosecuted.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial Application which provides comprehensive information about the investigational medicinal product(s) and planned trial, enabling Regulatory Authorities to assess the acceptability of conducting the applicable study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all data, including CMC Information, non-clinical data, preclinical data and clinical data, generated by or on behalf of a Party or its Affiliates or their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio), pursuant to activities conducted under this Agreement.  For clarity, Data does not include any patentable Inventions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all activities conducted relating to preclinical and clinical trials, toxicology testing, statistical analysis, publication and presentation of study results with respect to the Products, and the reporting, preparation and submission of regulatory applications (including any CMC Information) for obtaining, registering and maintaining Regulatory Approval of the Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall exclude any activities relating to the Manufacture of the Product.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means R&#38;D Out-Of-Pocket Costs, R&#38;D Internal Costs, and Clinical Supply Costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Drug Substance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means bulk drug substance that is represented for use in a drug that, when used in the Manufacturing of a drug, becomes an active pharmaceutical ingredient.   </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the European Medicines Agency or any successor entity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration or any successor entity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all prophylactic and therapeutic use in humans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means with respect to a Region, the first sale of a Product in such Region to a Third Party by or on behalf of Advaccine, its Affiliates or Sublicensees after Regulatory Approval has been obtained in such Region. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Advaccine&#8217;s fiscal year that starts on January 1 and ends on December 31.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means employees of Inovio or its Affiliates, excluding personnel performing administrative and corporate functions (including human resources, finance, legal and investor relations). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTE Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any period, the FTE Rate multiplied by the number of hours of FTEs expended by Inovio during such period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a rate of &#91;***&#93; per hour.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the then-current requirements, standards, practices and procedures promulgated or endorsed by the FDA as set forth in 21 Code of Federal Regulations Parts 50, 54, 56, and 312 and the guidelines entitled &#8220;Guidance for Industry E6 Good Clinical Practice&#58; Consolidated Guidance,&#8221; including related regulatory requirements imposed by the FDA, and comparable regulatory standards, practices and procedures promulgated by the NMPA or other Regulatory Authority applicable in the Advaccine Territory, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means those certain Development Costs incurred on or after &#91;***&#93; in connection with either Party&#8217;s conduct of the Global Phase 3 Study in accordance with the Global Phase 3 Study Plan.  For clarity, Global Development Costs excludes (i) any costs or expenses incurred by Advaccine in connection with its activities under the Global Phase 3 Study in Greater China, and (ii) any costs or expenses incurred by Inovio, its Affiliates, Sublicensees or Third Parties that are solely related to its activities in connection with the performance of the Clinical Trial in the US under the Global Phase 3 Study. For clarity, Global Development Costs shall include costs incurred by Inovio in the US in connection with the conduct of Global Phase 3 Study that are not specific to the dosing of patients in the Clinical Trial in the US, such as trial management and operations costs, pharmacovigilance costs, on-going stability costs, regulatory costs, and analytical testing costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Phase 3 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain Phase 3 Clinical Trial described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, attached hereto, to be conducted by Inovio and Advaccine (other than in Greater China, where such Phase 3 Clinical Trial will be conducted by Advaccine).  For clarity, Global </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase 3 Study does not include any Clinical Trials not specifically described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Global Phase 3 Study Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> and does not include any Clinical Trial that will be conducted by Each Party independently</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For additional clarity, Global Phase 3 Study does include any Clinical Trial conducted by a Global Purchasing Entity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Phase 3 Study Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that certain development plan for the Global Phase 3 Study set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, attached hereto, , as such development plan may be updated or amended from time to time in accordance with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Laboratory Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards promulgated by NMPA or other Regulatory Authority applicable to the Advaccine Territory, as may be updated from time to time, including applicable quality guidelines promulgated under the ICH.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) the good manufacturing practices required by the FDA and set forth in the FDCA or FDA regulations (including without limitation 21 U.S.C. 351 and 21 CFR Parts 210 and 211), policies, guidances or guidelines, or any applicable equivalent within a regulatory jurisdiction, including, without limitation, any applicable current good manufacturing practices requirements and pharmaceutical industry standards for the manufacture and testing of investigational pharmaceutical materials in force from time-to-time in the European Union (including, without limitation, Directive 2003&#47;94&#47;EC laying down the principles and guidelines of good manufacturing practice), the relevant national implementations of these rules and any relevant national and European Commission and EMA guidance and, in particular, Annex 13 of the Guide to Good Manufacturing Practice entitled &#8220;Manufacture of investigational medicinal products&#8221;, as updated and amended from time-to-time, in each case in effect at any time during the term of this Agreement, for the manufacture, handling and testing of investigational pharmaceutical products&#59; (b) the corresponding requirements of each applicable Regulatory Agency or other governmental authority, and (c) any other guidances, procedures, practices, arrangements, additions or clarifications, as the Parties may agree in writing from time-to-time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) any official or employee of any Governmental Authority, or any department, agency, or instrumentality thereof (including without limitation commercial entities owned or controlled, directly or indirectly, by a Governmental Authority), (b) any political party or official thereof, or any candidate for political office, or (c) any official or employee of any public international organization. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any multi-national, national, federal, state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible form, including know-how, copyrights, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulae, software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, clinical test data and data resulting from non-clinical studies), CMC Information, stability data and other study data and procedures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Clinical Trial, enrollment of the first patient in such Clinical Trial.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Inovio&#8217;s proprietary electroporation device CELLECTRA&#174; 2000 and CELLECTRA&#174; 3PSP, including any improvements and variants thereof Controlled by Inovio, and the associated Arrays, applicators and components. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Information (including Data and Regulatory Materials) that (a)(i) is Controlled by Inovio or its Affiliates as of the Prior Effective Date with respect to Greater China and as of the Effective Date outside of Greater China or (ii) becomes Controlled by Inovio or its Affiliates during the Term, and (b) is necessary for the Development, Manufacture, or Commercialization of the Vaccine and&#47; or the Product in the Field in the Advaccine Territory.  For clarity, Inovio Licensed Know-How shall include Inovio&#8217;s interest in any Information included in Inovio Inventions and Joint Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all Patents that (a)(i) are Controlled by Inovio or its Affiliates as of the Prior Effective Date with respect to Greater China and as of the Effective Date outside of Greater China or (ii) become Controlled by Inovio or its Affiliates during the Term, and (b) Cover the Vaccine and&#47;or the Product in the Field in the Advaccine Territory.  Inovio Licensed Patents include the Patents listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and Inovio&#8217;s interest in any Joint Patents that may be filed during the Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Product-Specific Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Inovio Licensed Patents specifically claiming the composition of matter of, or the method of making or using, the Vaccine and&#47;the Product in the Field in the Advaccine Territory.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties acknowledge and agree that the Patents listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are Inovio Product-Specific Licensed Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Inovio Licensed Know-How and Inovio Licensed Patents. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the world except for the Advaccine Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio US Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Phase 3 Clinical Trial or any other trials that are equivalent or similar to a Pivotal Clinical Trial, as requested by the FDA or at its own initiative, designed or intended to ascertain efficacy of the Product in a larger population, to be conducted by Inovio, itself or by its Affiliate or a Third Party in the U.S. or any other jurisdictions in the Inovio Territory. </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any inventions and&#47;or discoveries, including processes, manufacture, composition of matter, Information, methods, assays, designs, protocols, and formulas, and improvements or modifications thereof, patentable or otherwise, that are generated, developed, conceived or reduced to practice (constructively or actually) by or on behalf of a Party or its Affiliates or their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) (a) pursuant to activities conducted under this Agreement, or (b) in connection with the Development, Manufacture, and Commercialization of the Product, in each case of (a) and (b), including all rights, title and interest in and to the intellectual property rights therein and thereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Inventions shall exclude Data.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Patents that claim Joint Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, municipal, city or other political subdivision, domestic or foreign.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality control, quality assurance testing and release, post-marketing validation testing, inventory control and management, storing and transporting the Vaccine or the Product (as well as the Array), including oversight and management of vendors therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular drug product supplied by Inovio pursuant to Section 7.1&#58; (a) if Inovio or its Affiliate Manufactures the applicable drug product, the actual manufacturing cost of such drug product (as determined in accordance with U.S. GAAP consistently applied with its other products)&#59; or (b) if a Third Party Manufactures such drug product, the actual transfer price paid by Inovio or its Affiliate to such Third Party for the Manufacture of such drug product without any additional mark-up&#59; in each case of (a) and (b), excluding the external costs of insurance and transportation, import and export taxes and fees, and similar charges, for such drug product. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a particular unit of Product or Inovio Device used in connection with the Global Phase 3 Study&#58; (a) if Inovio or its Affiliate Manufactures the applicable Product or Inovio Device, the actual manufacturing cost of such Product or Inovio Device (as determined in accordance with U.S. GAAP consistently applied with its other products)&#59; or (b) if a Third Party Manufactures such Product or Inovio Device, the actual transfer price paid by Inovio or its Affiliate to such Third Party for the Manufacture of such Product or Inovio Device without any additional mark-up&#59; in each case of (a) and (b), excluding the external costs of insurance and transportation, import and export taxes and fees, and similar charges, for such Product or Inovio Device.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing Authorization Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means new drug application, biologics license application, or other marketing authorization application to the </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">appropriate Regulatory Authority for approval to market a Product, but excluding pricing approvals.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the gross amounts billed or invoiced by Advaccine, its Affiliates and their respective Sublicensees for sales of the Products to Third Parties, less the following deductions to the extent reasonable, customary, and actually allowed and taken with respect to such sales&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">trade, cash or quantity discounts not already reflected in the amount invoiced, to the extent related to the gross amount billed or invoiced&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">price reductions, rebates and administrative fees (including those paid or credited to pharmacy benefit managers, governmental authorities or otherwise) (provided that, such administrative fees shall not be in excess, in the aggregate of &#91;***&#93; of Net Sales with respect to any given Calendar Quarter)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">shipping costs, including freight, insurance and other transportation charges or costs incurred in shipping of the Products to Third Parties (provided that, such shipping costs shall not be in excess of &#91;***&#93; of Net Sales with respect to any given Calendar Quarter)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">sales, use, excise, value-added or similar taxes, customs duties and other governmental fees, charges and surcharges imposed on the sale of the Products&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">amounts repaid or credited by reason of rejections, defects, recalls or returns&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">amounts paid or credited for wholesaler chargebacks&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">any receivables that have been included in gross sales and are deemed to be uncollectible according to Accounting Standards (any such bad debt deductions shall be applied to Net Sales in the period in which such receivables are written off) (provided that, the amount of such receivables shall not be in excess of &#91;***&#93; of Net Sales with respect to any given Calendar Quarter).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, amounts received or invoiced by Advaccine, its Affiliates, or their respective Sublicensees for the sale of the Product among Advaccine, its Affiliates or their respective Sublicensees shall not be included in the computation of Net Sales hereunder unless the purchasing entity is the end-user.  For purposes of determining Net Sales, the Product shall be deemed to be sold when billed or invoiced.  Net Sales shall be accounted for in accordance with standard Advaccine practices for operation by Advaccine, its Affiliates or their respective Sublicensees, as practiced in the Advaccine Territory, but in any event in accordance with Accounting Standards consistently applied in the Advaccine Territory.  For clarity, a particular item may only be deducted once in the calculation of Net Sales.  Notwithstanding anything to the contrary in the foregoing, to the extent any amounts deducted pursuant to subsections (d) or (g) above are subsequently recovered by Advaccine, its Affiliates, </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or their respective Sublicensees during the Term, such recovered amounts shall be deemed &#8220;Net Sales&#8221; for the subsequent Calendar Quarter&#59; provided that, if no royalties are owed by Advaccine for such subsequent Calendar Quarter pursuant to Section 8.4, Advaccine shall promptly refund such recovered amounts to Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The transfer of any Product to an Affiliate, Sublicensee, or other Third Party (x) in connection with the research, development or testing of a Product (including, without limitation, the conduct of Clinical Trials), (y) for purposes of distribution as promotional samples, or (z) at nominal cost for indigent or similar public support or compassionate use programs, will not, in any case, be considered a Net Sale of a Product under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to any transfer of any Product in the Advaccine Territory for any substantive consideration other than monetary consideration on arm&#8217;s length terms, for the purposes of calculating the Net Sales under this Agreement, such Product shall be deemed to be sold exclusively for money at the average Net Sales price charged to Third Parties for cash sales in the Advaccine Territory during the applicable reporting period (or if there were only de minimus cash sales in the Advaccine Territory, at the fair market value as determined by comparable markets).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine, its Affiliates, and their respective Sublicensees shall sell the Product as a standalone product and will not sell the Product as a part of a bundle with other products or offer packaged arrangements to customers that include the Product, except with Inovio&#8217;s prior written consent.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that a Product is sold by Advaccine, its Affiliates or their respective Sublicensees in a relevant Region as part of a Combination Product, where &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any unified dose (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">., not a kit of two separate and distinct drug dosage forms that are priced and sold separately) of pharmaceutical product which is comprised of (x) a Product and (y) other therapeutically active compound(s) not licensed by Inovio to Advaccine hereunder (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Net Sales of such Product, for the purposes of determining royalty payments, shall be determined by the subsections below&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NMPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the National Medical Products Administration of the People&#8217;s Republic of China, formerly known as the China Food and Drug Administration, or any successor agency or authority thereto. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) pending patent applications, issued patents, utility models and designs&#59; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing&#59; and (c) extensions, renewals or restorations of any of the foregoing by existing or future extension, renewal or restoration mechanisms, including supplementary protection certificate, patent term additions, patent term extensions or the equivalent thereof. </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means an individual, corporation, partnership, limited liability company, limited partnership, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase&#8239;2 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any human clinical trial of a Vaccine conducted mainly to test the effectiveness of chemical or biologic agents or other types of interventions for purposes of identifying the appropriate dose for a Phase 3 Clinical Trial for a particular indication or indications that would satisfy the requirements of 21&#8239;CFR &#167;&#8239;312.21(b) or its non-United States equivalents. A &#8220;Phase 2&#47;3 Clinical Trial&#8221; shall be deemed to be a Phase 2 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 2 component, in accordance with the applicable protocol. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Phase&#8239;3 Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any human clinical trial of a Vaccine designed to&#58; (i) establish that such Product is safe and efficacious for its intended use&#59; (ii) define warnings, precautions and adverse reactions that are associated with the Product in the dosage range to be prescribed&#59; and (iii) support regulatory approval of such Product, that would satisfy the requirements of 21&#8239;CFR &#167;&#8239;312.21(c) or its non-United States equivalents.&#160; A &#8220;Phase 2&#47;3 Clinical Trial&#8221; shall be deemed to be a Phase 3 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 3 component, in accordance with the applicable protocol. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pivotal Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a pivotal study in human patients with a defined dose or a set of defined doses of the Product designed or intended to ascertain efficacy and safety of the Product for the purpose of enabling the preparation and forming the primary basis for submission of a Marketing Authorization Application for the Product to the competent Regulatory Authority in a Region of the Advaccine Territory, which may be a Phase 2 Clinical Trial or a Phase 3 Clinical Trial. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any pharmaceutical&#47;biological product in any form comprising the Vaccine, with or without an Inovio Device.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proper Conduct Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means, Advaccine, its Affiliates and Sublicensees, and each of their Representatives not, directly or indirectly, (a) making, offering, authorizing, providing or paying anything of value in any form, whether in money, property, services or otherwise to any Government Official, or other Person charged with similar public or quasi-public duties, or to any customer, supplier, or any other Person, or to any employee thereof, or failing to disclose fully any such payments in violation of the laws of any relevant jurisdiction to (i) obtain favorable treatment in obtaining or retaining business for it or any of its Affiliates, (ii) pay for favorable treatment for business secured, (iii) obtain special concessions or for special concessions already obtained, for or in respect of it or any of its Affiliates, in each case which would have been in violation of any applicable Laws, (iv) influence an act or decision of the recipient (including a decision not to act) in connection with the Person&#8217;s or its Affiliate&#8217;s business, (v) induce the recipient to use his or her influence to affect any government act or decision in connection with the Person&#8217;s or its Affiliate&#8217;s business or (vi) induce the recipient to violate his or her duty of loyalty to his or her organization, or as a reward for having done so&#59; </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) engaging in any transactions, establishing or maintaining any fund or assets in which it or any of its Affiliates shall have proprietary rights that have not been recorded in the books and records of it or any of its Affiliates&#59; (c) making any unlawful payment to any agent, employee, officer or director of any Person with which it or any of its Affiliates does business for the purpose of influencing such agent, employee, officer or director to do business with it or any of its Affiliates&#59; (d) violating any provision of applicable Anti-Corruption Laws&#59; (e) making any payment in the nature of bribery, fraud, or any other unlawful payment under the applicable Laws of any jurisdiction where it or any of its Affiliates conducts business or is registered&#59; or, (f) if such Person or any of its Representatives is a Government Official, improperly using his or her position as a Government Official to influence the award of business or regulatory approvals to or for the benefit of such Person, its Representatives or any of their business operations, or failing to recuse himself or herself from any participation as a Government Official in decisions relating to such Person, its Representatives or any of their business operations. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">R&#38;D Out-Of-Pocket Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means amounts actually paid by Inovio or Affiliates of Inovio to Third Parties for goods and services required in order for Inovio to conduct the Global Phase 3 Study. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">R&#38;D Internal Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all FTE Costs of Inovio and Affiliates of Inovio incurred directly in connection with the conduct of the Global Phase 3 Study, but for clarity R&#38;D Internal Costs shall not include FTEs associated with the Manufacture of the Product, which shall be calculated and shared, if applicable, based on the Manufacturing Expenses and not separately charged as FTEs.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all approvals (including marketing authorization approvals, supplements, amendments, pre- and post-approvals, and pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the Manufacture, distribution, marketing, importation, exportation, use or commercial sale of a Product in a given country or regulatory jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, in a particular country or jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval in such country or jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means regulatory applications (including CTA and MAA), submissions, notifications, communications, correspondence, registrations, Regulatory Approvals and&#47;or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise Commercialize the Products in a particular country or jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, as to any Person, such Person&#8217;s Affiliates and its and their successors, controlling Persons, directors, officers and employees.</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Third Party that has received a license or other right under the Inovio Technology in accordance with Section 2.1(c), but shall not include (i) any Third Party wholesaler or distributor engaged for the sale of the Product (even if such wholesaler or distributor is granted a right or license to sell Product) provided that such wholesaler or distributor does not make any royalty, milestone, profit share or other payment to Advaccine or its Affiliate based on such wholesaler&#8217;s or distributor&#8217;s sale of the Product&#59; or (ii) any Third Party contract research organization or manufacturer providing services to Advaccine or its Affiliate (even if such contract research organization or manufacturer is granted a right or license to make the Vaccine or the Product). For clarity, the gross invoiced price for sale of the Product to any wholesaler, distributor, contract research organization or manufacturer described above shall be included in Net Sales.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Person other than a Party or an Affiliate of a Party.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S. Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a U.S. dollar, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">US$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be interpreted accordingly. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">USA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the United States of America, including all possessions and territories thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means INO-4800, which includes the DNA plasmid identified as pGX9501, encoding the Spike protein of SARS-CoV-2. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means a claim (including a process, use, or composition of matter claim) of (a) an issued and unexpired patent that has not (i) irretrievably lapsed or been revoked, dedicated to the public or disclaimed or (ii) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal, or (b) a pending patent application that has been prosecuted in good faith pending for no more than seven (7) years since its priority date and has not been abandoned or finally disallowed without the possibility of appeal. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.45pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any period of twelve (12) consecutive months.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:8.45pt">Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; The following table identifies the location of definitions set forth in various Sections of the Agreement&#58;  </font></div><div style="margin-bottom:6pt;padding-left:5.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Defined Terms</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accused Party</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Housemarks</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Indemnitees</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Inventions</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1(d)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Product Mark</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6(a)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Sublicense Agreement</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1(c)</font></div></td></tr></table></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:5.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agreement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Alliance Manager</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bankruptcy Laws</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.13</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Claims</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Clinical Manufacturing Technology Transfer Agreement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Clinical Supply Agreement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Combination Product</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commercialization Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Confidentiality Agreement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.21</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Development Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Divestiture</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective Date</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enforcing Party</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive Officer</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First Supplemental Development Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">GAAP</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Greater China</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IFRS</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnified Party</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnifying Party</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Infringement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Infringement Action</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Initial Development Plan</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Device Commercial Supply Agreement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Indemnitees</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Inventions</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1(d)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Partner</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insolvency Event</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insolvent Party</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.13</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Inventions</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1(d)(iii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joint Steering Committee</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Losses</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Exclusive License Agreement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recitals</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Insolvent Party</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.13</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other Products</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.62</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PDF</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.12</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pharmacovigilance Agreement</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.8</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prior Agreement</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recitals</font></td></tr></table></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:5.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prior Effective Date</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Recitals</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Materials</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.8</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Region</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Remedial Action</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.9</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty Term</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SEC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities Regulators</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SIAC</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SIAC Rules</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Step-In Rights</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tax Withholding</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VAT</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.9(c)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Working Group</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LICENSE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;License to Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, Inovio hereby grants Advaccine an exclusive (even as to Inovio except as provided in Section 2.1(b) below) license, with the right to sublicense (solely as provided in Section 2.1(c)), under the Inovio Technology, to Develop, Manufacture and have Manufactured (solely in accordance with Section 7.2), distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise Commercialize the Products in the Field in the Advaccine Territory.  For clarity, no rights shall be granted to Advaccine under this Section 2.1(a), with respect to the Development, Manufacture or Commercialization of any product containing or using for administration an Inovio Device without the Vaccine.  For further clarity and unless otherwise agreed in Section 2.1(d), no rights shall be granted to Advaccine under this Section 2.1(a) with respect to the Manufacture of the Inovio Device other than the right to Manufacture the Arrays in the Advaccine Territory.  As consideration for the foregoing license and access to and transfers of know-how under this Agreement, Advaccine will make certain payments to Inovio as set out in, and subject to the terms and conditions of, Article 8.  Notwithstanding the foregoing to the contrary, in the event that Advaccine &#91;***&#93; and the &#91;***&#93;Payment Cap has been reached, Inovio will have the right to convert the foregoing license to a non-exclusive license for all countries in the Advaccine Territory (outside of Greater China), unless Advaccine agrees to pay to Inovio its fifty percent (50%) share of Development Costs pursuant to Section 8.1(b) that are in excess of the &#91;***&#93;Payment Cap, subject to Section 8.1(b)(ii).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Inovio Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the exclusive rights granted to Advaccine in Section 2.1(a), Inovio and its Affiliates shall retain the following&#58;  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the right to practice the Inovio Technology within the scope of the license granted to Advaccine under Section 2.1(a) in order to perform, or have performed by a Third Party contractor, Inovio&#8217;s obligations under this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the right to Manufacture or have Manufactured the Products anywhere in the world for sale and use in the Inovio Territory, provided that Inovio shall obtain prior written consent, not to be unreasonably withheld, from Advaccine before Manufacturing or having Manufactured the Products in the Advaccine Territory using any rights granted to Inovio under the Non-Exclusive License Agreement for sale and use in the Inovio Territory&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">the right to practice and license the Inovio Technology outside the scope of the license granted to Advaccine under Section 2.1(a)&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">the right to conduct activities under the Global Phase 3 Study Plan in the Advaccine Territory (excluding in Greater China) in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Sublicense Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall not have the right to grant sublicenses of the license granted in Section 2.1(a) without Inovio&#8217;s express prior written consent, except that Advaccine may grant such sublicense without Inovio&#8217;s consent to its Affiliates.  Upon receiving approval from Inovio for the grant of a sublicense to a Third Party, Advaccine shall, within thirty (30) days after granting any such sublicense, notify Inovio of the grant of such sublicense and provide Inovio with a true and complete copy of the sublicense agreement (which may have financial information and other confidential information redacted, provided that such redacted information is not reasonably necessary for Inovio to assess compliance of the sublicense agreement with this Section 2.1(c)) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Advaccine Sublicense Agreement shall be consistent with the terms and conditions of this Agreement, and Advaccine shall be solely responsible for all of its Sublicensees&#8217; activities and any and all failures by its Sublicensees to comply with the applicable terms of this Agreement.  Without limiting the foregoing, each Advaccine Sublicense Agreement shall include the following additional terms and conditions&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the Sublicensee shall be bound by non-use and non-disclosure obligations no less stringent than those set forth in this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">the Sublicensee shall not have any right to grant further sublicenses to the Inovio Technology (excluding sublicenses to Third Party contractors, including distributors and wholesalers)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">the Sublicensee shall not have any right to prosecute or maintain or enforce any Inovio Licensed Patents&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">the Sublicensee shall assign or license to Advaccine all Data and Inventions generated by such Sublicensee, and shall grant Advaccine all of the rights necessary for Advaccine to fulfill its obligations under Sections 9.1(a) and 9.1(d).</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Additional License. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio hereby agrees to expand the license granted to Advaccine under Section 2.1 for Advaccine, by itself or through any of its Affiliates or a Third Party, to conduct the Phase 3 Clinical Trial in the Inovio Territory at Advaccine&#8217;s own cost and expense for the purpose of obtaining the Regulatory Approval of the Product in the Advaccine Territory, in the event of (i) unless a Phase 3 Clinical Trial in the Inovio Territory has already been completed, a Change of Control of Inovio, where the acquirer of Inovio, by itself or through any of its Affiliates or a Third Party, is developing, manufacturing or commercializing any Competing Product for the Advaccine Territory&#59; (ii) an official request by any Regulatory Authority in the Advaccine Territory&#59; (iii) the occurrence of such circumstances as described in Section 4.2&#59; or (iv) otherwise upon mutual agreement of the Parties&#59; provided, however, that Inovio shall have the right to review and approve the protocols and design of such Phase 3 Clinical Trial.  Inovio hereby agrees to expand the license granted to Advaccine under Section 2.1 for Advaccine to have the Inovio Device Manufactured in the U.S. or any other mutually agreed upon country by a Third Party contract manufacturer for use with the Product in the Advaccine Territory in the event of the occurrence of an Insolvency Event of Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Inovio Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio has the right, in its sole discretion, to enter into one or more agreements with Third Parties and grant such Third Parties the right to Develop, Manufacture and&#47;or Commercialize the Products in one or more countries in the Inovio Territory (each such Third Party, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that (a) Inovio shall remain solely responsible for any Inovio Partner&#8217;s activities, and (b) the grant of such rights to such Inovio Partner shall not affect Inovio&#8217;s obligations under the Agreement.  So long as such Inovio Partner(s) is not actively developing or commercializing any Competing Product in the Advaccine Territory, (i) Inovio shall have the right (but not the obligation) to fulfill any of its obligations under this Agreement through Inovio Partner(s), including Inovio&#8217;s obligations under Article 3, and (ii) Inovio shall have the right to disclose to Inovio Partner(s) all Information solely regarding the Products, including all Regulatory Materials relating thereto, disclosed by Advaccine to Inovio under this Agreement, for use by Inovio Partner(s) in their Development, Manufacture and Commercialization of the Product in the Inovio Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that (A) all such Information disclosed to Inovio Partner(s) by Inovio shall be deemed the Confidential Information of Advaccine, and (B) any Inovio Partner(s) that receive such information shall be obligated to abide by restrictions on disclosure and use substantially similar to the provisions set forth in Section 12.1 and Inovio shall remain responsible for the Inovio Partner(s)&#8217; performance of such obligations and compliance with such restrictions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Negative Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine covenants that, except as explicitly set forth in this Agreement, it will not, and will not permit any of its Affiliates or Sublicensees to, use or practice any Inovio Technology outside the scope of the license granted to it under Section 2.1(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.4&#160;&#160;&#160;&#160;No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as explicitly set forth in this Agreement, neither Party shall be deemed by estoppel or implication to have granted the other Party any license or other right to any intellectual property of such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.5&#160;&#160;&#160;&#160;Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Exclusivity Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Advaccine hereby covenants not to, itself or through any Affiliate or Third Party, Develop, Manufacture or Commercialize any Competing Product in the Field in the Advaccine Territory.  For clarity, the foregoing restrictions shall not apply to (i) internal research and internal non good laboratory practices preclinical work by either Party&#59; and (ii) any Development, Manufacture and Commercialization of any Combination Product by Advaccine in the Advaccine Territory upon mutual agreement of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Advaccine Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that, in connection with an Advaccine Change of Control, Advaccine or any of its Affiliates obtains or holds the rights to a Competing Product that would cause Advaccine to be in breach of Section 2.5(a), then upon written notice to Inovio within thirty (30) days after such rights are first obtained, Advaccine shall elect one of the following&#58; (A) to terminate this Agreement pursuant to Section 13.2, in which case such notice will serve as notice of termination under Section 13.2&#59; or (B) to (or have its Affiliate) sell, exclusively license or transfer rights to the Competing Product to a Third Party without Advaccine or any of its Affiliates receiving a continuing share of profit, royalty payments, or other economic interest in the success of such Competing Product in the Advaccine Territory (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in which case Advaccine or any of its Affiliates shall, or shall cause the applicable entity to, complete the Divestiture of such Competing Product within twelve (12) months from the date of such Advaccine Change of Control, in which case the conduct of activities with respect to such Competing Product by Advaccine or any of its Affiliates during such 12-month period shall not be deemed a breach of Advaccine&#8217;s exclusivity obligations under Section 2.5, provided that such activities with respect to such Competing Product during such 12-month period are conducted independently of the activities conducted under this Agreement and no Inovio Technology or Advaccine Inventions is used in the conduct of such activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:60.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.6&#160;&#160;&#160;&#160;Transfer of Inovio Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio shall provide Advaccine with complete and accurate copies of the Inovio Licensed Know-How directly applicable to the Vaccine, the Product and the Arrays to the extent expressly provided for in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and in accordance with the timeline specified therein.  The JSC shall establish a reasonable process and schedule for the transfer of additional Inovio Licensed Know-How related to the Vaccine, the Product and the Array as required for the filing of an MAA in the Advaccine Territory and any other necessary Inovio Licensed Know-How that subsequently comes into existence and becomes Controlled by Inovio or its Affiliates during the Term.  Inovio shall reasonably cooperate with Advaccine in providing Advaccine only with copies of such Inovio Licensed Know-How directly applicable to the Vaccine, the Product and the Array (but not the Inovio Device) in accordance with the process and schedule agreed upon through the JSC.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GOVERNANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party has prior to the Effective Date appointed a representative having the appropriate qualifications, including a general understanding of pharmaceutical development, manufacturing, and commercialization issues, to act as its alliance </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">manager under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Alliance Managers shall serve as the primary contact points between the Parties for the purpose of providing each Party with information on the progress and results of Advaccine&#8217;s Development, Manufacturing, and Commercialization of the Products.  The Alliance Managers shall also be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties with respect to the Products.  Each Party may replace its Alliance Manager at any time upon written notice to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Joint Steering Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Formation&#59; Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties have established a joint steering committee under the Prior Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) which JSC shall be responsible for the overall coordination and oversight of the Parties&#8217; activities under this Agreement.  The role of the JSC shall be&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">to review, discuss and coordinate the overall strategy for the Development, Manufacturing, and Commercialization of the Products in the Field in the Advaccine Territory, including related regulatory activities&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">to review, discuss and approve the Initial Development Plan and any proposed amendments or revisions to the Development Plan, including the First Supplemental Development Plan and those with respect to clinical Development activities set forth in Section 4.4(b)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">to review and discuss (but not approve) the Commercialization Plan and any proposed amendments or revisions to such plan, and review and discuss (but not approve) the Commercialization of the Products in the Field in the Advaccine Territory (including any pricing strategy with respect to the Products)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">to coordinate the Commercialization of the Products in the Advaccine Territory and Inovio Territory to ensure consistent global marketing of the Products in the Field&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">to review, discuss and approve the Global Phase 3 Study Plan and any proposed amendments or revisions thereto&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">to perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as determined by the Parties in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Members</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The JSC shall be comprised of an equal number of representatives from each Party.  Each Party&#8217;s representatives shall be an officer or employee of such Party or its Affiliate having sufficient seniority within the applicable Party to make decisions arising within the scope of the JSC&#8217;s responsibilities.  In addition, at least one of Advaccine&#8217;s JSC representatives must be someone whose job responsibilities within Advaccine include active involvement in the development and implementation of Advaccine&#8217;s Development </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(including regulatory) strategy with respect to the Products in the Field in the Advaccine Territory (at all times that Advaccine or its Affiliate or sublicensee is conducting such Development) or Advaccine&#8217;s Commercialization strategy with respect to the Products in the Field in the Advaccine Territory (at all times that Advaccine or its Affiliate or sublicensee is conducting such Commercialization), and each of Advaccine&#8217;s JSC representatives must have up-to-date knowledge of Advaccine&#8217;s ongoing and planned Development (including regulatory) and Commercialization activities with respect to the Products in the Field in the Advaccine Territory (at all times that Advaccine is conducting such activities).  Each Party shall initially appoint two (2) representatives to the JSC.  The JSC may change its size from time to time by unanimous consent of its representatives, and each Party may replace its representatives at any time upon written notice to the other Party.  Each Party shall appoint one (1) of its representatives on the JSC to act as the co-chairperson.  The role of the co-chairpersons shall be to convene and preside at the JSC meetings and to ensure the circulation of meeting agendas at least five (5) Business Days in advance of JSC meetings and the preparation of meeting minutes and any pre-read materials in accordance with Section 3.2(c), but the co-chairpersons shall have no additional powers or rights beyond those held by other JSC representatives.  Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend meetings of the JSC, provided that such attendees shall not vote or otherwise participate in the decision-making process of the JSC and are subject to obligations of confidentiality substantially similar to the provisions set forth in Section&#160;12.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC shall meet at least once per Calendar Quarter during the Term, unless the Parties mutually agree in writing to a different frequency for such meetings.  Either Party may also call a special JSC meeting (by videoconference or teleconference) by at least ten (10) Business Days prior written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the JSC no later than ten (10) Business Days prior to the special meeting with materials reasonably adequate to enable an informed decision.  The JSC may meet in person, by videoconference or by teleconference.  All JSC meetings shall be conducted in English, and all communications, reports and records by and between the Parties under this Agreement shall be in English.  The co-chairpersons shall alternate responsibility for preparing reasonably detailed written minutes of the JSC meetings that reflect, without limitation, all material decisions made at such meetings.  The co-chairpersons (or their designees) shall send draft meeting minutes to each representative of the JSC for review and approval within ten (10) Business Days after the JSC meeting.  Such minutes shall be deemed approved unless one or more JSC representatives object to the accuracy of such minutes within ten (10) Business Days of receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Decision Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC shall strive to seek consensus in its actions and decision making process and all decisions by the JSC shall be made by consensus, with each Party having collectively one (1) vote in all decisions.  If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement as to such matter (to the extent that such matter requires the agreement of the Parties hereunder) within ten (10) Business Days after such matter was brought to the JSC for resolution or after such matter has been referred to the JSC, then, </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine&#8217;s Executive Officer shall have the final decision making authority with respect to such matter within the JSC&#8217;s authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Inovio&#8217;s Executive Officer shall have the final decision making authority with respect to such matter within the JSC&#8217;s authority that relates to the Global Phase 3 Study (including any amendment to the Global Phase 3 Study Plan) and Inovio&#8217;s Executive Officer shall have the right in their sole discretion to veto any decision by Advaccine reasonably likely to result in Adverse Risk on the Inovio Technology, or the safety or efficacy of the Product, or the Development or Commercialization of the Product in the Inovio Territory, including any other global Clinical Trial of Product or Regulatory Approval of any Product in the Inovio Territory, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that (i) any decision to Develop, Manufacture or Commercialize the Product as a Combination Product in the Advaccine Territory will require the mutual agreement of the Parties, and (ii) Advaccine shall not have the right, by virtue of its decision-making authority, to cause Inovio to violate the terms of any agreement with a Third Party, or cause Inovio to violate any applicable Laws, ethical requirement, or intellectual property right of any Third Party, and Advaccine&#8217;s exercise of its decision-making authority shall be subject to the limitations set forth in Section 3.3&#59; provided, that Inovio shall provide Advaccine with an explanation as to why any such decision of Advaccine would cause Inovio to violate the terms of any agreement with a Third Party, or cause Inovio to violate any applicable Laws, ethical requirement, or intellectual property right of any Third Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, the JSC shall be a forum for discussing, but shall not have any decision-making authority with respect to, Inovio&#8217;s Development of the Product in the Inovio Territory, and Inovio shall have full control and authority over the Development, Commercialization of the Product in the Inovio Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;Limitation of JSC Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC shall only have the powers expressly assigned to it in this Article 3 and elsewhere in this Agreement and shall not have the authority to&#58; (a) modify or amend the terms and conditions of this Agreement&#59; (b) waive or determine either Party&#8217;s compliance with the terms and conditions of under this Agreement&#59; or (c) decide any issue in a manner that would conflict with the express terms and conditions of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;Discontinuation of the JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The activities to be performed by the JSC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services.  The JSC shall continue to exist until the first to occur of&#58; (a) the Parties mutually agree to disband the JSC&#59; or (b) Inovio provides written notice to Advaccine of its intention to disband and no longer participate in the JSC.  Thereafter, the JSC shall have no further obligations under this Agreement and each Party shall designate a contact person for the exchange of information relevant to activities that would have been performed by the JSC under this Agreement and decisions of the JSC shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;Working Groups</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  From time to time, the JSC may establish and delegate duties of the JSC to sub-committees or directed teams (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Working Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) on an &#8220;as-needed&#8221; basis to oversee particular projects or activities&#59; provided that in any case neither Party shall be required by the Working Group to assume any responsibility, financial or otherwise, beyond those agreed to in writing by such Party, in particular pursuant to each Party&#8217;s respective obligations under this Agreement.  Each such Working Group shall be constituted and shall operate as the JSC </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determines.  Working Groups may be established on an ad hoc basis for purposes of a specific project or on such other basis as the JSC may determine.  Each Working Group and its activities shall be subject to the oversight, review and approval of, and shall report to, the JSC.  In no event shall the authority of the Working Group exceed that of the JSC.  All decisions of a Working Group shall be by consensus.  Any disagreement between the members of a Working Group shall be referred to the JSC for resolution.  </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DEVELOPMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Overview&#59; Diligence of Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Advaccine shall be solely responsible for the Development of the Products in the Field in the Advaccine Territory, at its own cost and expense (except as otherwise expressly set forth herein), including (except as set forth in Section 4.8) all non-clinical and clinical studies and collection of CMC Information, as necessary to obtain the Regulatory Approval for the Products in any Region in the Advaccine Territory.  Advaccine shall maintain adequate funding and use Commercially Reasonable Efforts to Develop and obtain the Regulatory Approval for the Products in the Field in each Region in the Advaccine Territory.  Without limiting the generality of the foregoing, Advaccine shall use Commercially Reasonable Efforts to conduct its Development activities under and in accordance with the Development Plan, as well as Manufacturing activities related to such Development, as set forth in the Initial Development Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Diligence of Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Inovio shall (i) use Commercially Reasonable Efforts to Develop and obtain the Regulatory Approval for the Products in the Field in the United States, and shall provide all reasonable assistance and cooperation to assist and support Advaccine, at Advaccine&#8217;s sole cost and expense, as specified in this Agreement, the Development Plan or as reasonably requested by Advaccine from time to time, in obtaining the Regulatory Approval for the Products (as well as the Inovio Device and the Array for use in connection with the Products) in the Advaccine Territory&#59; (ii) use Commercially Reasonable Efforts, together with Advaccine, to design the Global Phase 3 Study Plan and conduct the activities associated with the Global Phase 3 Study in accordance with the Global Phase 3 Study Plan and applicable Laws&#59; and (iii) use Commercially Reasonable Efforts to achieve the first dosing of the Global Phase 3 Study &#91;***&#93;.  Except for circumstances provided in Section 2.1(d) (i), (ii) and (iv), in the event that, within twelve (12) months from the Prior Effective Date, the Inovio US Trial is not Initiated or Inovio decides not to conduct or is not required to conduct the Inovio US Trial, Inovio shall inform Advaccine thereof in writing.  In such an event, Advaccine may elect to conduct a Phase 3 Clinical Trial in the Inovio Territory at its own cost and expense for the purpose of obtaining Regulatory Approval of the Product in the Advaccine Territory, subject to Section 2.1(d)&#59; provided, however, that Inovio shall have the right to review and approve the protocols and design of such Phase 3 Clinical Trial.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine has  prepared and submitted to the JSC an initial, summary plan and budget for research and Development of the Vaccine and the Products in the Field in Greater China  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within thirty (30) days after the Prior Effective Date, and the Initial Development Plan has been reviewed and approved by the JSC.  Within ninety (90) days after the Prior Effective Date, Advaccine has  prepared and submitted to the JSC a detailed plan containing the strategy, activities, study designs, timeline, study material needs (including </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio Devices and the Vaccine) and budget for research and Development of the Vaccine and the Products in the Field in Greater China  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Supplemental</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and together with the Initial Development Plan and any subsequent updates pursuant to this Section 4.3, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The First Supplemental Development Plan included among other things, all material non-clinical and clinical studies, CMC Information collection activities and regulatory activities with respect to the Vaccine and the Products to be conducted by or on behalf of Advaccine or its Affiliates or their respective Sublicensees in Greater China. From time to time during the Term (but at least once per Fiscal Year), Advaccine shall prepare amendments and updates, as appropriate, to the then-current Development Plan (including for Development activities (other than with respect to the Global Phase 3 Study) in the Advaccine Territory (both in and outside of Greater China)), and shall submit such amendments and updates to the JSC in accordance with Section 4.4. For further clarity, if there are no amendments or updates to the then-current Development Plan that are applicable in a Fiscal Year, Advaccine&#8217;s sole responsibility under this Section 4.3 during such Fiscal Year shall be to inform Inovio that the then-current Development Plan is up to date.  Advaccine shall be solely responsible for the day-to-day conduct of Development within the Advaccine Territory and all decisions associated therewith, except for the Global Phase 3 Study as otherwise provided in this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Other Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Pre-Clinical Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Advaccine may conduct pre-clinical studies to generate and obtain Data that is reasonably useful for the Development of any Product in the Field in the Advaccine Territory, provided that Advaccine shall promptly amend the Development Plan to include such pre-clinical studies and submit such amendment to the JSC for review and approval. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Clinical Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   If Advaccine wishes to conduct any Clinical Trials for the Development of any Product in the Field other than as set forth in the First Supplemental Development Plan in the Advaccine Territory, Advaccine may propose an amendment to the Development Plan to include such Clinical Trials and submit such amendment to the JSC for review and approval.  If and upon receipt of such proposal, the JSC shall promptly (but in any event within thirty (30) days) review and decide on whether to approve such proposal.  Upon the JSC&#8217;s approval of such amendment, such Clinical Trials shall be included in the amended Development Plan and Advaccine may conduct such Clinical Trials at its own cost.  Advaccine shall ensure that any Clinical Trials conducted in the Advaccine Territory, whether by itself or through a subcontractor pursuant to Section&#160;4.10, are conducted only at medical facilities that are qualified and registered with the NMPA or any other applicable Regulatory Authority. For clarity, Advaccine shall not conduct any Clinical Trials of any Product outside of the Field.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Global Phase 3 Study Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to oversight by the Parties through the JSC, Inovio will use Commercially Reasonable Efforts to conduct the Global Phase 3 Study jointly with Advaccine in both the Inovio Territory and the Advaccine Territory (other than Greater China) in accordance with the Global Phase 3 Study Plan, and, to the extent expressly set forth in the Global Phase 3 Study Plan, Advaccine will jointly participate in the Global Phase 3 Study with Inovio (except for the Clinical Trial in the US) to the extent the activities to be conducted by Advaccine in support of such Global Phase 3 Study are included in </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Global Phase 3 Study Plan. Advaccine and Inovio will equally share the Global Development Costs in accordance with Section 8.1(b). For clarity, Inovio will be solely responsible for conducting the Clinical Trial in the US. For clarity, the current Global Phase 3 Study Plan does not include Clinical Trial sites in Greater China, where Advaccine will be solely responsible for conducting Development activities in Greater China. To the extent permissible by the applicable Laws or the Regulatory Authorities, Advaccine shall be identified and acknowledged as Inovio&#8217;s collaboration partner or co-developer with respect to Vaccine. In the event that Inovio enters into an agreement with a Global Purchasing Entity that authorizes such Global Purchasing Entity to conduct a portion of the Global Phase 3 Study in the Advaccine Territory (other than Greater China) in accordance with Section 6.6, then Inovio will work directly with such Global Purchasing Entity regarding such portion of the Global Phase 3 Study and will update the JSC with respect to such Development activities. For clarity, the Development activities conducted by such Global Purchasing Entity will not be subject to the approval of the JSC.  The foregoing provisions shall apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the event that Advaccine enters into an agreement with a Global Purchasing Entity that authorizes such Global Purchasing Entity to conduct a portion of the Global Phase 3 Study in the Inovio Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As agreed to between the Parties, Inovio may provide such technical assistance and cooperation to Advaccine as Advaccine may reasonably request, at Advaccine&#8217;s sole cost and expense, as necessary or reasonably useful for Advaccine to Develop or Commercialize the Products in the Field in the Advaccine Territory. The foregoing provisions shall apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the event that Inovio reasonably requests technical assistance and cooperation from Advaccine, which will be at Inovio&#8217;s sole cost and expense, as necessary or reasonably useful for Inovio to Develop or Commercialize the Products in the Field in the Inovio Territory. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Development Records.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Advaccine shall maintain complete, current and accurate records of all activities (and all Data and other Information resulting from such activities) conducted with respect to Products by Advaccine, its Affiliates and their respective Sublicensees in the Advaccine Territory.  Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.  Advaccine shall document all non-clinical studies and Clinical Trials for the Products in formal written study records according to applicable Laws, including applicable national and international guidelines such as ICH, GCP and GLP, and shall, at Inovio&#8217;s reasonable request, provide Inovio English translations thereof (to the extent prepared and originated in a language other than English) at Inovio&#8217;s sole cost and expense.  Subject to provisions in Section 4.9, Inovio shall have the right to review and copy such records at reasonable times and to obtain access to the original to the extent necessary or useful for regulatory or patent purposes and for legal proceedings in accordance with this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Inovio shall maintain, and shall cause its Affiliate, licensees or contractors to maintain complete, current and accurate records of all activities (and all Data and other Information resulting from such activities) in connection with the Global Phase 3 Study </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">according to the Global Phase 3 Study Plan and applicable Laws, including applicable national and international guidelines such as ICH, GCP and GLP.  Advaccine shall have the right to, upon reasonable prior written notice and by itself or through its designees, examine such records, review and copy such records and to obtain access to the original to the extent necessary, and audit the conduct of the Global Phase 3 Study conducted by Inovio, its Affiliates, licensee or Third Party Contractors, solely for the purpose of verifying the compliance of the Global Phase 3 Study with the Global Phase 3 Study Plan and the applicable Laws.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.6&#160;&#160;&#160;&#160;Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall keep Inovio reasonably informed as to the progress and results of Advaccine&#8217;s, its Affiliates&#8217; and their respective Sublicensees&#8217; Development activities (including prompt reporting of available clinical Data).  Without limiting the foregoing, at each regularly scheduled JSC meeting, Advaccine shall provide Inovio with a reasonably detailed written report summarizing its Development activities performed since the last JSC meeting and the results thereof, as reasonably sufficient to enable Inovio to determine Advaccine&#8217;s compliance with its diligence obligations under Section 4.1&#59; provided that, even if the JSC does not hold a meeting in one or more Calendar Quarters, Advaccine shall provide such written report to Inovio at least once every Calendar Quarter.  At such JSC meeting, the Parties shall discuss the status, progress and results of Advaccine&#8217;s, its Affiliates&#8217; and their respective Sublicensees&#8217; Development activities.  Advaccine shall promptly respond to Inovio&#8217;s reasonable questions or requests for additional information relating to such Development activities.  In addition, within thirty (30) days after the end of each Fiscal Year, Advaccine shall provide Inovio with a detailed written annual report regarding the progress of its Development activities and any results therefrom.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.7&#160;&#160;&#160;&#160;Development Reports for Global Phase 3 Study.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio shall keep Advaccine reasonably informed as to the progress and results of Inovio&#8217;s Development activities under the Global Phase 3 Study (including prompt reporting of available clinical Data). Without limiting the foregoing, at each JSC meeting during the conduct of the Global Phase 3 Study, Inovio shall provide Advaccine with a reasonably detailed written report summarizing its activities performed since the last JSC meeting and the results thereof, as reasonably sufficient to enable Advaccine to determine Inovio&#8217;s compliance with its diligence obligations under Section 4.2&#59; provided that, even if the JSC does not hold any regularly scheduled meeting during the course of the Global Phase 3 Study, Inovio shall provide such written report to Advaccine at least once every Calendar Quarter.  At such JSC meeting, the Parties shall discuss the status, progress and results of the Global Phase 3 Study, and Inovio shall promptly respond to Advaccine&#8217;s reasonable questions or requests for additional information relating to such activities.  In addition and to the extent applicable, within thirty (30) days after the end of each Fiscal Year, Inovio shall provide Advaccine with a detailed written report regarding the progress of the Global Phase 3 Study and any results therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.8&#160;&#160;&#160;&#160;Data Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to Inovio&#8217;s obligation with respect to the transfer of Inovio Licensed Know-How set forth under Section 2.6 and each Party&#8217;s adverse event and safety Data reporting obligations pursuant to Section 5.8, but subject to the remainder of this Section 4.8 and Section 4.9, each Party shall, at its sole cost and expense, promptly provide the other Party with copies of any Data and Regulatory Materials related to the Vaccine or the Products generated by or on behalf of such Party or its Affiliates or Sublicensees in the performance of Development activities hereunder that would be reasonably necessary for the Development, Manufacture and Commercialization of the </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vaccine or the Products in the Field in the other Party&#8217;s respective territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The JSC may establish reasonable policies to effectuate the exchange of additional Product Materials between the Parties.  Advaccine shall have the right to use the data provided by Inovio hereunder for the purpose of obtaining and maintaining Regulatory Approval for and Commercializing the Product in the Field in the Advaccine Territory.  Inovio shall have the right to use the data provided by Advaccine hereunder for the purpose of obtaining and maintaining Regulatory Approval for and Commercializing the Product in the Inovio Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.9&#160;&#160;&#160;&#160;Clinical Trial Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge and agree that certain government approval or filing may be required in the Advaccine Territory before certain Data generated from the Clinical Trials in the Advaccine Territory may be provided to or otherwise made available to Inovio or its designee.  The Parties agree to use their Commercially Reasonable Efforts to collaborate with each other and with Third Parties in obtaining such approval or filing in the most efficient manner as permitted by the applicable Laws.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.10&#160;&#160;&#160;&#160;Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Advaccine, upon prior express written consent from Inovio, shall have the right to engage subcontractors to conduct any activities necessary for Development or Manufacturing (subject to the terms of Article 7) of the Products, including but not limited to non-clinical studies, Clinical Trials, CMC activities, and regulatory services for the Products, under this Agreement, provided that such subcontractors (a) are bound by written obligations of confidentiality, non-use and compliance with applicable Laws, including Proper Conduct Practices, consistent with this Agreement and have agreed in writing to assign to Advaccine all Data, Information, inventions or other intellectual property generated by such subcontractor in the course of performing such subcontracted work, (b) are capable of producing Data (including non-clinical Data, clinical Data and CMC Information, as applicable) acceptable to the NMPA, the FDA and the EMA (and other applicable Regulatory Authorities in the Advaccine Territory, the United States or the European Union) and (c) as applicable, with respect to matters covered by Article 7, meet the specifications and requirements thereunder. Advaccine shall remain responsible for any obligations that have been delegated or subcontracted to any subcontractor, and shall be responsible for the performance of its subcontractors.  </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REGULATORY MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Regulatory Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Subject to the terms and conditions of this Agreement, Advaccine will be responsible, at its sole cost and expense, for the conduct of all regulatory activities required to obtain and maintain Regulatory Approval of the Products (including the Inovio Device and the Arrays for use in connection with the Products) in the Field in the Advaccine Territory, including the preparation and submission of all Regulatory Materials and all communications and interactions with Regulatory Authorities, as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">necessary to obtain Regulatory Approval for the Products in any Region in the Field in the Advaccine Territory.  Advaccine shall be responsible for filing each CTA in the Field in the Advaccine Territory for each Product.  Advaccine shall be responsible for filing each MAA in the Field in the Advaccine Territory for each Product in Advaccine&#8217;s name.  The Development Plan shall include the regulatory strategy for obtaining </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Approval of the Products in the Field in the Advaccine Territory.  Advaccine shall use Commercially Reasonable Efforts to carry out its regulatory obligations for the Products pursuant to such strategy. Notwithstanding the foregoing to the contrary, Inovio and Advaccine will be jointly responsible for, through the JSC, with Inovio taking the lead in the conduct of all regulatory activities required to obtain and maintain, in connection with Global Phase 3 Study, Regulatory Approval of the Products (including the Inovio Device and the Arrays for use in connection with the Products) in the Field in the Advaccine Territory outside of Greater China until completion of the Global Phase 3 Study.   Upon completion of the Global Phase 3 Study, Inovio will promptly transfer to Advaccine (including its Affiliate or Sublicensee) all Regulatory Materials related to the Global Phase 3 Study that are specific to the Advaccine Territory.  In the event that any of such Regulatory Materials cannot be transferred to Advaccine (including its Affiliate or their respective Sublicensee), or Advaccine (including its Affiliate or Sublicensee) is not permitted to apply for the MAA of the Product (including the Inovio Device and the Arrays for use in connection with the Products) in reliance on such Regulatory Materials in any Region outside Greater China, due to the requirements of the applicable Laws or the Regulatory Authorities in such Region, Inovio shall continue to hold such Regulatory Materials and to conduct all the necessary regulatory activities to obtain the MAA of the Product (including the Inovio Device and the Arrays for use in connection with the Products) in such Region in the name of itself, its Affiliate or Sublicensee but for the benefit of Advaccine (and subject to reimbursement by Advaccine of Inovio&#8217;s costs and expenses with respect thereto)&#59; and Inovio shall, subject to reimbursement by Advaccine of Inovio&#8217;s costs and expenses, continue working with Advaccine to provide all necessary support to facilitate and achieve the transfer of the Regulatory Materials or the MAA of the Product (including the Inovio Device and the Arrays for use in connection with the Products) to Advaccine (including its Affiliates or their respective Sublicensees) as contemplated in this paragraph.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Inovio shall provide all reasonable assistance and cooperation to Advaccine as Advaccine may reasonably request, at Advaccine&#8217;s sole cost and expense, during the Term of this Agreement, with respect to the satisfaction of Advaccine&#8217;s obligations under Section 5.1(a), including (i) in connection with the preparation of Regulatory Materials, (ii) (A) making available competent personnel to attend regulatory meetings or join such meetings by teleconference and (B) providing documentation within Inovio&#8217;s possession and control, in each case as requested by Regulatory Authorities at Advaccine&#8217;s cost, and (iii) providing Advaccine with additional Product Materials in the Inovio Territory as requested by Regulatory Authorities in the Advaccine Territory within a reasonable timeframe commensurate with the volume of Advaccine&#8217;s reasonable request.  In the event that Inovio believes that such requests are not reasonable or are otherwise burdensome to Inovio, then such matter shall be promptly submitted to the JSC for review and discussion. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Regulatory Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall (a) provide Inovio with copies of the original documents (in the electronic format in which it has been prepared by Advaccine) of draft package inserts, CTA and CTD, and, at Inovio&#8217;s request, together with English translations (to the extent originated by Advaccine in Chinese), for Inovio&#8217;s review and comment, in connection with obtaining or maintaining any MAA approval for the Products in the Field in the Advaccine Territory, prior to the submission of such documents to the Regulatory Authority in the Advaccine Territory&#59; and </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) shall keep Inovio informed of any material verbal or written communication or question relating to the Products received by Advaccine from the Regulatory Authority in the Advaccine Territory.  Except as required by applicable Law or with Inovio&#8217;s express written permission, Advaccine, its Affiliates and Sublicensees shall not submit any Regulatory Materials to, or communicate with, any Regulatory Authority in the Inovio Territory regarding any Products&#59; provided, that if such submission or communication is required by applicable Law, Advaccine shall, if legally permitted, promptly notify Inovio in writing of such requirement and the content of such submission or communication. Except to the extent in connection with the exercise of its retained rights under Section 2.1(b), Inovio, its Affiliate and Sublicensees shall not submit any Regulatory Materials to, or communicate with, any Regulatory Authority in the Advaccine Territory regarding any Products.  If such submission or communication is required by applicable Law, Inovio shall, if legally permitted, promptly notify Advaccine in writing of such requirements and the content of such submission or communication. Notwithstanding the foregoing to the contrary, the Parties shall jointly prepare the Regulatory Materials and Inovio shall have the right to lead the submission of such Regulatory Materials with Regulatory Authorities in the Advaccine Territory (other than in Greater China) with respect to the Global Phase 3 Study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;Meetings with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall lead all interactions with Regulatory Authorities in the Advaccine Territory with respect to the Products for use in the Field.  Advaccine shall keep Inovio reasonably informed of any material regulatory developments related to the Products in the Field in the Advaccine Territory.  At each regularly scheduled JSC meeting, Advaccine shall provide Inovio with a list and schedule of any in-person meeting or teleconference with the applicable Regulatory Authorities (or related advisory committees) in the Advaccine Territory planned for the next Calendar Quarter that relates to any Product in the Field.  In addition, Advaccine shall notify Inovio as soon as reasonably possible (but in no event later than two (2) Business Days if possible) after Advaccine becomes aware of any additional such meetings or teleconferences that become scheduled for such Calendar Quarter.  Inovio shall provide all assistance and documentation reasonably requested by Advaccine to prepare for any such meeting or teleconference, including making available competent personnel to attend any such meeting or teleconference at Advaccine&#8217;s reasonable request (subject to reimbursement by Advaccine of Inovio&#8217;s costs and expenses with respect thereto).  To the extent permitted by applicable Laws and by the Regulatory Authorities (as reasonably determined by Advaccine), Inovio shall have the right to participate (whether directly or through a representative) in all such meetings and teleconferences, at Inovio&#8217;s cost.  Notwithstanding the foregoing to the contrary, Inovio shall have the right to lead all interactions with Regulatory Authorities in the Advaccine Territory (other than in Greater China) with respect to the Global Phase 3 Study, and Inovio shall keep Advaccine reasonably informed of such regulatory activities in a manner similar to Advaccine&#8217;s obligations to Inovio under this Section 5.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.4&#160;&#160;&#160;&#160;Regulatory Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise provided in this Agreement, Advaccine shall be responsible for the costs and expenses incurred in connection with the preparation and filing of any and all Regulatory Materials and the maintenance of any and all Regulatory Approvals (including MAA approvals) for the Products in the Field in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.5&#160;&#160;&#160;&#160;Right of Reference to Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby grants to the other Party the right of reference to all Regulatory Materials pertaining to the Products submitted by or on behalf of such Party, subject to provisions in Section 4.9.  The receiving Party may use such right of </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reference solely for the purpose of seeking, obtaining and maintaining Regulatory Approval of the Products in its respective territory.  Each Party shall support the other Party, as reasonably requested by such other Party and at such other Party&#8217;s expense, in obtaining Regulatory Approvals in such other Party&#8217;s territory, including providing necessary documents or other materials required by applicable Laws to obtain Regulatory Approval in such territory, all in accordance with the terms and conditions of this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.6&#160;&#160;&#160;&#160;No Harmful Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party believes that the other Party is taking or intends to take any action with respect to any Product that could reasonably be expected to have an Adverse Risk, whether in the Inovio Territory or in the Advaccine Territory, such Party may bring the matter to the attention of the JSC and the Parties shall discuss in good faith to promptly resolve such concern.  Without limiting the foregoing, unless the Parties otherwise agree&#58; (a) (i) Advaccine shall not communicate with any Regulatory Authority having jurisdiction outside the Advaccine Territory, unless so ordered by such Regulatory Authority, in which case Advaccine shall immediately notify Inovio of such order&#59; and (ii) Advaccine shall not submit any Regulatory Materials or seek Regulatory Approvals for the Vaccine or the Product in the Inovio Territory&#59; and (b) (i) except to the extent in connection with the exercise of its retained rights under Section 2.1(b), Inovio shall not communicate with any Regulatory Authority having jurisdiction outside the Inovio Territory, unless in connection with the Global Phase 3 Study or so ordered by such Regulatory Authority, in which case Inovio shall immediately notify Advaccine of such order&#59; (ii) except to the extent in connection with the Global Phase 3 Study or with the exercise of its retained rights under Section 2.1(b), Inovio shall not submit any Regulatory Materials or seek Regulatory Approvals for the Vaccine or the Product in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.7&#160;&#160;&#160;&#160;Notification of Threatened Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall immediately notify the other Party (including by providing notice to the other Party&#8217;s Alliance Manager) of any information it receives regarding any threatened or pending action, inspection or communication by or from any Third Party, including without limitation a Regulatory Authority, which may affect the Development, Manufacture, Commercialization or regulatory status of any Product.  Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.8&#160;&#160;&#160;&#160;Adverse Event Reporting and Safety Data Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Before the Initiation of a Clinical Trial with respect to the Development of any Product in the Advaccine Territory by or on behalf of Advaccine, the Parties shall enter into or amend the then current pharmacovigilance agreement to define and finalize the actions that the Parties shall employ with respect to such Product to protect patients and promote their well-being in a written pharmacovigilance agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the Development of the Product globally.  Further, unless otherwise agreed by the JSC, no later than sixty (60) days before the anticipated launch date of any Product in the Advaccine Territory, the Parties shall enter into a separate Pharmacovigilance Agreement for the Commercialization of the Product.  Each of the Pharmacovigilance Agreements shall include mutually acceptable guidelines and procedures for the receipt, investigation, recording, communication, and exchange (as between the Parties) of adverse event reports, pregnancy reports, and any other information concerning the safety of the Product, and other routine pharmacovigilance reporting requirements.  Such guidelines and procedures shall be in accordance with, and enable the Parties to </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">fulfill, local and national regulatory reporting obligations under applicable Laws.  Furthermore, such agreed procedure shall be consistent with relevant ICH guidelines, except where said guidelines may conflict with existing local regulatory reporting safety reporting requirement, in which case local reporting requirement shall prevail.  The Pharmacovigilance Agreement shall provide for an adverse event database for the Products in the Field in the Advaccine Territory to be maintained by Advaccine at Advaccine&#8217;s expense, and a global safety database for the Products to be maintained by Inovio at Inovio&#8217;s expense.  As between the Parties, Advaccine shall be responsible for preparing all adverse event reports and responses to safety issues and requests of Regulatory Authorities relating to the Products in the Field in the Advaccine Territory, and Advaccine shall be responsible for filing such reports and responses with Regulatory Authorities in the Advaccine Territory.  As between the Parties, Advaccine shall also be responsible for reporting any quality complaints, adverse events and safety data related to the Products in the Field in the Advaccine Territory to Inovio for inclusion in the global safety database.  Each Party hereby agrees to comply with its respective obligations under such Pharmacovigilance Agreement and to cause its Affiliates and permitted Sublicensees to comply with such obligations.  Notwithstanding the foregoing to the contrary, Inovio shall be responsible for the pharmacovigilance activities in the Advaccine Territory (other than Greater China) in connection with the Global Phase 3 Study, provided  however that, a copy of any pharmacovigilance-related filings or reporting for the Global Phase 3 Study shall be provided to Advaccine for review and comment pursuant to the Pharmacovigilance Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.9&#160;&#160;&#160;&#160;Remedial Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party will notify the other Party immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Product may be subject to any recall, corrective action or other regulatory action taken by virtue of applicable Laws (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action.  Advaccine shall, and shall ensure that its Affiliates and Sublicensees will, maintain adequate records to permit the Parties to trace the packaging, labeling, distribution, sale and use (to the extent possible) of the Product in the Advaccine Territory.  Advaccine shall have sole discretion with respect to any matters relating to any Remedial Action in the Advaccine Territory, including the decision to commence such Remedial Action and the control over such Remedial Action in its territory, at its cost and expense. Notwithstanding the foregoing to the contrary, any Remedial Action in connection with the Global Phase 3 Study in the Advaccine Territory (other than Greater China) shall be jointly decided by the Parties. </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMMERCIALIZATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Advaccine shall have the sole right and responsibility for and have operational control over all aspects of the Commercialization of the Products in the Field in the Advaccine Territory, including&#58;  (a) developing and executing a commercial launch and pre-launch plan, (b)&#160;negotiating with applicable Governmental Authorities regarding the price and reimbursement status of the Products&#59; (c) marketing, advertising and promotion&#59; (d) booking sales and distribution and performance of related services&#59; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables&#59; (f) providing customer support, including handling medical queries, and performing other related functions&#59; and (g) conforming its practices and procedures to </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">applicable Laws relating to the marketing, detailing and promotion of the Products in the Field in the Advaccine Territory.  Advaccine shall bear all of the costs and expenses incurred in connection with such Commercialization activities.  Advaccine shall use Commercially Reasonable Efforts to Commercialize the Products in the Advaccine Territory and to actively market and sell the Products in the Advaccine Territory and to expand annual Net Sales of the Products in the Advaccine Territory.  Without limiting the generality of the foregoing, Advaccine shall use Commercially Reasonable Efforts to conduct its Commercialization activities under and in accordance with the Commercialization Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.2&#160;&#160;&#160;&#160;Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall Commercialize the Products in the Field in the Advaccine Territory pursuant to a commercialization plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Commercialization Plan shall include (i) a detailed description of all key strategic decisions (including messaging, branding, marketing, advertising, sales force positioning, number of representatives and details, pricing strategy, etc.), implementation tactics and pre-launch and post-launch activities&#59; (ii) a reasonably detailed description and timeline of Advaccine&#8217;s, its Affiliates&#8217; and their respective Sublicensees&#8217; Commercialization activities for the Products in the Advaccine Territory for the next Fiscal Year, including medical marketing activities, sales forecasts and projections, pricing, reimbursement, market research, sales training, distribution channels, customer service and sales force matters related to the launch and sale of the Products in the Advaccine Territory, and (iii) a strategic plan for Commercialization of the Products in the Advaccine Territory for the following two (2) Fiscal Years.  In the event that Advaccine&#8217;s Commercialization Plan requires the use of Inovio internal resources to conduct additional activities, the extent of such need shall be clearly specified in the Commercialization Plan and will require the prior written approval of Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Initial Plan and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within a reasonable time (but no less than six (6) months) prior to the anticipated Regulatory Approval of each Product in the Advaccine Territory, Advaccine shall prepare and present to the JSC an initial Commercialization Plan for review and discussion (but not approval) by the JSC.  From time to time (but at least on an annual basis) during the Term, Advaccine shall prepare updates and amendments, as appropriate, to the then-current Commercialization Plan (including to take into account changed circumstances that are material to the Commercialization of Product, including changes in the marketplace, relative success of the Product, and other relevant factors influencing such plan and activities), and shall submit all updates and amendments to the Commercialization Plan to the JSC for review and discussion (but not approval).  Notwithstanding anything to the contrary contained in this Agreement, the Commercialization Plan, and any updates and amendments thereto, shall not require the approval of the JSC or Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.3&#160;&#160;&#160;&#160;Data Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall keep Inovio reasonably informed of Advaccine&#8217;s, its Affiliates&#8217; and their respective Sublicensees&#8217; Commercialization activities with respect to the Products in the Field in the Advaccine Territory.  Inovio shall provide to Advaccine, upon Advaccine&#8217;s request, and no more than once every six (6) months, at Inovio&#8217;s cost, copies of any materials prepared by or on behalf of Inovio that are necessary or reasonably useful in connection with Advaccine&#8217;s Commercialization of the Products in the Field in the Advaccine Territory (including </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relevant training materials, global brand and global market research, in each case, with respect to the Products), and, to the extent elected by Advaccine, Advaccine shall have the right to use such materials in connection with the Commercialization of the Products in the Field in the Advaccine Territory in accordance with the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.4&#160;&#160;&#160;&#160;No Diversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby covenants and agrees that it shall not, and shall ensure that its Affiliates and Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) will not, directly or indirectly, promote, market, distribute, import, sell or have sold the Products, including via internet or mail order, in the other Party&#8217;s territory.  With respect to any country in the other Party&#8217;s territory, a Party shall not, and shall ensure that its Affiliates and their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) will not&#58; (a) establish or maintain any branch, warehouse or distribution facility for the Products in such countries, (b) knowingly engage in any advertising or promotional activities relating to the  Products that are directed primarily to customers or other purchaser or users of the  Products located in such countries, (c) actively solicit orders for the  Products from any prospective purchaser located in such countries, or (d) knowingly sell or distribute the Products to any person in such Party&#8217;s territory who intends to sell or has in the past sold the Products in such countries.  If either Party receives any order for any Product from a prospective purchaser reasonably believed to be located in a country in the other Party&#8217;s territory, such Party shall immediately refer that order to the other Party and such Party shall not accept any such orders.  Each Party shall not deliver or tender (or cause to be delivered or tendered) the Products into a country in the other Party&#8217;s territory.  Each Party shall not, and shall ensure that its Affiliates and their respective Sublicensees (in the case of Advaccine) or licensees, including Inovio Partners (in the case of Inovio) will not, knowingly restrict or impede in any manner the other Party&#8217;s exercise of its retained exclusive rights in the other Party&#8217;s territory. For the avoidance of doubt, nothing in this Section 6.4 shall limit Inovio&#8217;s retained rights under Section 2.1(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.5&#160;&#160;&#160;&#160;Field Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine hereby covenants that it shall not, and shall cause its Affiliates and Sublicensees not to, promote or encourage the use of the Products in the Advaccine Territory for any use outside the Field.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.6&#160;&#160;&#160;&#160;Global Purchasing Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that a global purchasing entity such as &#91;***&#93; (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Purchasing Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) desires to enter into a purchase agreement for the Product in both the Inovio Territory and the Advaccine Territory (outside Greater China), the Parties shall enter into good faith negotiations for an arrangement to supply Product in the Advaccine Territory (excluding Greater China) to such organizations for such commercialization in the Advaccine Territory(outside Greater China).  Each Party shall provide reasonable notice to the other Party in advance of submission of any proposal to a Global Purchasing Entity to allow the non-submitting Party to review the proposal.  In the event that Inovio enters into any such agreement with such Global Purchasing Entity, Advaccine will use Commercially Reasonable Efforts to provide the Product for use in the Advaccine Territory (outside Greater China) at a reasonable and affordable price which shall be designed to maximize access and shall be negotiated and agreed by the Parties in good faith.  In the event Advaccine cannot supply to such sufficient quantities of Product, Inovio (or its designee) will have the right to manufacture and&#47;or supply such quantities of Product to meet the agreed needs of such Global Purchasing Entity in the Advaccine Territory (outside Greater China).  Notwithstanding the foregoing, Advaccine shall not </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">submit a proposal to any Global Purchasing Entity for the Product that includes countries in the Inovio Territory without the prior written approval of Inovio.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MANUFACTURE AND SUPPLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1&#160;&#160;&#160;&#160;Clinical Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Clinical Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Inovio will supply Advaccine&#8217;s clinical requirements of the applicable Inovio Device for clinical use in the Advaccine Territory, at Inovio&#8217;s fully burdened manufacturing cost plus an agreed-to profit margin to support preclinical development and clinical studies in the Field in the Advaccine Territory.  Upon Advaccine&#8217;s reasonable request, the Parties agree to negotiate in good faith the terms and conditions of a supply of Inovio Device manufactured by or on behalf of Inovio under a separate agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Clinical Supply Agreement shall contain commercially reasonable terms as may be agreed upon in good faith by the Parties.  Notwithstanding the foregoing, Advaccine shall have the right to Manufacture in the Advaccine Territory any Arrays used with the Inovio Device for use in the Field in the Advaccine Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Vaccine Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Inovio will supply Advaccine&#8217;s clinical requirements of the Vaccine for clinical use in the Advaccine Territory, at Inovio&#8217;s fully burdened manufacturing cost plus an agreed-to profit margin to support preclinical development and clinical studies in the Field in the Advaccine Territory.  Upon Advaccine&#8217;s reasonable request, the Parties agree to negotiate in good faith the terms and conditions of a supply of the Vaccine manufactured by or on behalf of Inovio under a separate agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Vaccine Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall have the right to appoint additional or alternative suppliers (or conduct its own Manufacturing) of the applicable Vaccine for clinical use in the Advaccine Territory.  Additionally, Inovio may elect to transfer Manufacturing responsibility for the Vaccine to Advaccine.  Upon either Party&#8217;s request, the Parties shall enter into a manufacturing technology transfer agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Manufacturing Technology Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as more fully detailed below.  Under such Clinical Manufacturing Technology Transfer Agreement, Inovio shall transfer to Advaccine (or its designee) such documents and information, and provide such technical assistance and support, necessary or reasonably useful for Advaccine to Manufacture or have Manufactured the Vaccine or the Products, to the extent Controlled by Inovio as of such date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that (i) Advaccine shall notify Inovio of any such Third Party contractor and shall not engage with such Third Party contractor if Inovio believes in good faith that such Third Party contractor is not capable of manufacturing the applicable Vaccine with sufficient quality to satisfy GMP requirements, and (ii) any such Third Party contractor shall (A) be bound by written obligations of confidentiality, non-use and compliance with applicable Laws (including Proper Conduct Practices, GMP and any regulations required by the NMPA, the FDA and the EMA), consistent with this Agreement and have agreed in writing to assign to Advaccine all Data, Information, inventions or other </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">intellectual property generated by such subcontractor in the course of performing such subcontracted work, and (B) upon reasonable prior written notice given by Inovio to Advaccine, shall permit Inovio or its representatives to audit, during such subcontractor&#8217;s normal business hours and without additional charge, the performance of Manufacturing activities hereunder, the facilities used and relevant processes, systems, books, documents and records, in order to determine Advaccine&#8217;s compliance with this Agreement. Advaccine shall pay Inovio&#8217;s reasonable external costs (including FTEs) incurred in connection with providing such information or assistance pursuant to this Section 7.1(c).   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2&#160;&#160;&#160;&#160;Commercial Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Commercial Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the Term, Inovio will supply Advaccine&#8217;s commercial requirements of the applicable Inovio Device for commercial use in the Field in the Advaccine Territory, at Inovio&#8217;s fully burdened manufacturing cost plus an agreed-to profit margin.  Upon Advaccine&#8217;s reasonable request, the Parties agree to negotiate in good faith the terms and conditions of a supply of Inovio Device manufactured by or on behalf of Inovio under a separate agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Device</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Inovio Device Commercial Supply Agreement shall contain commercially reasonable terms as may be agreed upon in good faith by the Parties.  Notwithstanding the foregoing, Advaccine shall have the right to Manufacture Arrays used with the Inovio Device for use in the Field in the Advaccine Territory.  Notwithstanding the foregoing, in the event that Inovio is unable to supply sufficient quantity of the Inovio Device pursuant to the Inovio Device Commercial Supply Agreement to meet at least eighty-five percent (85%) of Advaccine forecasted requirements of the Products in the Advaccine Territory for a period of six (6) consecutive months, then Inovio shall establish a second source supplier for the Inovio Device in order to Manufacture the Inovio Device for use in the Advaccine Territory for use with the Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Manufacture and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine assumes responsibility for the manufacture and supply of the Vaccine itself or through a contract manufacturer, for commercial use in the Field in the Advaccine Territory.  Advaccine assumes responsibility for the manufacture and supply of any Arrays itself or through a contract manufacturer for use in the Field in the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that neither Party has already initiated a technology transfer in accordance with Section 7.1(c), then, upon either Party&#8217;s request, the Parties shall enter into a manufacturing technology transfer agreement for the applicable Vaccine in the manner set forth in Section 7.1(c).  Advaccine shall pay Inovio&#8217;s reasonable external costs incurred in connection with providing such information or assistance pursuant to this Section 7.2(c).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3&#160;&#160;&#160;&#160;Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine will be solely responsible for the distribution of the Products in the Field in the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;Brand Security and Anti-Counterfeiting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties will establish contacts for communication regarding brand security issues, and each Party shall reasonably cooperate with the </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other Party with respect thereto.  Practices around these incidents will comply with Inovio&#8217;s then-current standards, where such standards define product security features, warehouse&#47;cargo protection requirements, and response and communication process for such incidents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPENSATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.1&#160;&#160;&#160;&#160;Upfront Payment&#59; Global Development Cost Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Upfront Payment&#59; Annual Maintenance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio hereby acknowledges receipt of the upfront payment paid by Advaccine under the Prior Agreement. Beginning in the first Calendar Year after First Commercial Sale of the Product in the Advaccine Territory (outside of Greater China), Advaccine shall pay to Inovio a non-refundable, non-creditable annual maintenance fee of One Million Five Hundred Thousand U.S. Dollars (US$1,500,000), payable on each anniversary of the date of First Commercial Sale of the Product in the Advaccine Territory (outside of Greater China), for the first five anniversaries thereof the Effective Date&#59; provided, that such annual maintenance fee shall be creditable against royalties payable under Section 8.4 with respect to Net Sales in the Advaccine Territory (outside of Greater China) in such Calendar Year.   Notwithstanding the foregoing, Advaccine shall not be subject to such annual maintenance fee if Inovio fails to supply sufficient quantity of the Inovio Device in breach of the Inovio Device Commercial Supply Agreement.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Global Development Cost Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">The Parties shall share on an equal basis all Global Development Costs incurred on or after &#91;***&#93;.  Promptly following the end of each Calendar Quarter during which Global Development Costs are incurred by or on behalf of Inovio (but in no event later than thirty (30) days following the end of such Calendar Quarter), Inovio will provide to Advaccine an expense report (in a form which shall be agreed by the Parties through the JSC) disclosing such incurred shared Global Development Costs. Within thirty (30) Business Days following receipt of such expense report by Advaccine, Advaccine will make a payment of its fifty percent (50%) share of such Global Development Costs. For clarity, the Parties desire Advaccine to make payments directly to Third Party service providers of the Global Phase 3 Study, however, in the event that such direct payments are not feasible or permitted by such Third Party service provider, Advaccine shall pay its share of the Global Development Costs directly to Inovio.  The provisions of Sections 8.6, 8.7, 8.8(a), and 8.9 shall apply to such payments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, the total amount of payments by Advaccine for the Global Development Costs and the payments of Milestone Event #2 defined in Section 8.2 shall be capped at US$&#91;***&#93;prior to &#91;***&#93; (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Payment Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Upon &#91;***&#93;, Advaccine and Inovio shall agree upon a payment timeline by which Advaccine will pay to Inovio any amounts that would have been payable by Advaccine to Inovio under this Section 8.1(b) and Section 8.2 but for the &#91;***&#93;Payment Cap (such timeline not to exceed &#91;***&#93;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">In the event that Advaccine reasonably believes, by exercising its audit rights pursuant to Section 4.5(b) in connection with the records and conduct of the Global </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Phase 3 Study, that there are significant deviations from the Global Phase 3 Study Plan or significant non-compliance with applicable Laws in the conduct of the Global Phase 3 Study, it shall have the discretion to discontinue its payments for subsequent Global Development Costs and request Inovio to take corrective and preventive actions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.2&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall pay to Inovio the one-time, non-refundable, non-creditable payments set forth in the table below. Advaccine shall notify Inovio in writing within ten (10) days of achievement by a Product of a regulatory milestone event (except for milestone No. 3, which Inovio shall notify Advaccine upon achievement) and Advaccine shall pay to Inovio the required milestone payment within thirty (30) Business Days of the achievement by a Product of the applicable milestone event.  </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bdd6ee;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:15.3pt;padding-right:6.5pt;text-indent:-16.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No.</font></div></td><td colspan="3" style="background-color:#bdd6ee;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27.05pt;padding-right:27.05pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Event</font></div></td><td colspan="3" style="background-color:#bdd6ee;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enrollment of first subject in first Phase 2 Clinical Trial or Pivotal Clinical Trial for the Product in the Advaccine Territory</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enrollment of first subject in first Phase 3 Clinical Trial or Pivotal Clinical Trial for the Product in the Advaccine Territory</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Marketing Authorization for a Product in the Field by the First Regulatory Authority in the Advaccine Territory</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Marketing Authorization for a Product in the Field in the U.S. by the FDA</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First Commercial Sale of a Product in the Advaccine Territory</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Inovio acknowledges receipt of Milestone Payment #1 from Advaccine pursuant to the terms of the Prior Agreement and no further payment is required under this Agreement for Milestone Event #1.  Additionally, notwithstanding the earlier achievement of Milestone Event #2, Milestone Payment #2 may be deferred by Advaccine &#91;***&#93; and shall be subject to the &#91;***&#93;Payment Cap.  If any development milestone event set forth above is achieved before any prior development milestone event, then such prior development milestone event(s) shall then also be due and payable together with the achieved development milestone event. For the avoidance of doubt, two or more development milestones may be achieved concurrently. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.3&#160;&#160;&#160;&#160;Commercial Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Advaccine shall pay to Inovio the additional one-time, non-refundable, non-creditable payments set forth in the table below within forty-five (45) Business Days after the Calendar Quarter in which the aggregate Net Sales of the Products sold in the Advaccine Territory in a Calendar Year of the corresponding threshold value indicated below is first achieved.  For clarity, each of the following milestone payments shall be payable only once regardless of the number of times such milestone is achieved.</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:9.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:65.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commercial Milestone Event</font></td><td colspan="3" style="background-color:#c6d9f1;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate Net Sales of the Products in the Advaccine Territory in a given Calendar Year first reaches &#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.4&#160;&#160;&#160;&#160;Royalties on Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Royalty Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Section 8.4, Advaccine shall pay to Inovio non-creditable, non-refundable royalties equal to &#91;***&#93; Net Sales of all Products in the Advaccine Territory on a Product-by- Product and Region-by-Region basis during the applicable Royalty Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Royalties payable under Section 8.4(a) shall be paid by Advaccine (on a Product-by-Product and Region-by-Region basis) from the period beginning on the date of the First Commercial Sale of each Product in a Region in the Advaccine Territory and continuing until the later of&#58; (i) ten (10) years from the date of First Commercial Sale of such Product in such Region, and (ii) expiration of the last Valid Claim of an Inovio Licensed Patent Covering such Product in such Region (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  For clarity, if a Valid Claim of an Inovio Licensed Patent Covers the Manufacture of such Product in such Region, then regardless of whether such Product is actually Manufactured in such Region, such Product shall be deemed to be Covered by a Valid Claim of an Inovio Licensed Patent in such Region.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Royalty Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Biosimilar Entry</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Product is generating Net Sales in a Region during the applicable Royalty Term at a time when a Biosimilar Product with respect to such Product is being sold in such Region, and such Biosimilar Product(s) obtain (x) a market share of at least &#91;***&#93; in such Region on a volume basis, then, subject to Section 8.4(c)(iv), the royalty rates applicable to Net Sales of such Product in such Region shall be reduced to &#91;***&#93; of the royalty rate set forth in Section 8.4(a), or (y) a market share of at least &#91;***&#93;in such Region on a volume basis, then, subject to Section 8.4(c)(iv), the royalty rates applicable to Net Sales of such Product in such Region shall be reduced to &#91;***&#93; of the royalty rate set forth in Section 8.4(a), but in each case of (x) and (y) only for so long as the Biosimilar Product with respect to such Product is being sold in such Region with such market share.  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.36pt">Third Party Royalty Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Advaccine determines (based on advice of outside Patent counsel) that it is necessary to obtain a license to any Patent owned by a Third Party that contains claims that cover the Vaccine in a Region in the Advaccine Territory (i.e., but for such license, the making, having made, using, selling, offering for sale, or importing of the Vaccine, as contained in or comprising a Product, would infringe such Patent owned by such Third Party in such Region) and Advaccine obtains such a license, then, subject to Section 8.4(c)(iv), Advaccine shall have the right to deduct, from the royalty payment that would otherwise be payable to Inovio pursuant to Section 8.4(a) with respect to Net Sales of such Product in such Region in a particular Calendar Quarter, an amount equal to &#91;***&#93; of the payments by Advaccine to such Third Party pursuant to such license on account of the sale of such Product in such Region during such Calendar Quarter&#59; provided that (i) in no event will the royalty payment that would otherwise be payable to Inovio pursuant to this Section 8.4 with respect to Net Sales of such Product in such Region in such particular Calendar Quarter (without regard to any other reductions) be reduced by more than &#91;***&#93; in any given Calendar Quarter as a result of any deduction under this Section 8.4(c)(ii) and (ii) Advaccine will be entitled to carry forward to subsequent Calendar Quarters any amounts with respect to which Advaccine would have been entitled to take a deduction pursuant to this Section 8.4(c)(ii) but is unable to take such deduction pursuant to the foregoing sub-clause (i).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.03pt">No Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For each Product and for any period during the Royalty Term in which the sale of such Product in a given country is neither&#58; (i) Covered by any Valid Claim of an Inovio Licensed Patent or Joint Patent nor (ii) protected by any data exclusivity right applicable to such Product in such country, then the Royalty rate applicable to Net Sales of such Product in such country during such period shall be equal to &#91;***&#93; of the applicable Royalty rate set forth in this Section 8.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Notwithstanding the foregoing, in no event shall the operation of Section 8.4(c)(i), Section 8.4(c)(ii) or Section 8.4(c)(iii)), individually or in combination, reduce the royalties paid to Inovio with respect to the Net Sales of any Product in any Region in the Advaccine Territory in any Calendar Quarter to less than &#91;***&#93; of the amount that would otherwise have been payable to Inovio pursuant to Section 8.4(a) with respect to such Net Sales.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.5&#160;&#160;&#160;&#160;Royalty Payments&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Royalties under Section 8.4 shall be calculated and reported for each Calendar Quarter during the Royalty Term and shall be paid within thirty&#160;(30) Business Day after the end of the applicable Calendar Quarter, commencing with the Calendar Quarter in which the First Commercial Sale of a Product occurs.  Each payment of royalties shall be accompanied by a report of Net Sales of the Products by Advaccine, its Affiliates and their respective Sublicensees in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including&#58; (a) the amount of gross sales and Net Sales of the Products in the Advaccine Territory on a Product-by-Product and Region-by-Region basis, (b) an itemized calculation showing the deductions from gross sales (by major category as set forth in the definition of Net Sales) to determine Net Sales, and (c) a calculation of the amount of royalties due to Inovio in U.S. Dollars, including the application of any exchange rate used. </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.6&#160;&#160;&#160;&#160;Payment Method&#59; Foreign Exchange&#59; Blocked Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments owed by Advaccine under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Inovio.  For clarity, all payments by Advaccine to Inovio pursuant to Sections 8.1, 8.2, 8.3 and 8.4 shall be in U.S. Dollars.  The rate of exchange to be used in computing the amount of currency equivalent in U.S. Dollars of any amounts payable in U.S. Dollars by Advaccine to Inovio under this Agreement shall be determined and calculated (i) with respect to the Chinese Yuan, using the middle rate published by the Bank of China for exchange of US dollars with the Chinese Yuan on the date of transfer of the payment, and (ii) with respect to any other currency, the average rate of exchange based on OANDA rates for the Calendar Quarter in which the applicable payment is due.  In the event that, by reason of applicable Laws in the Advaccine Territory, it becomes impossible or illegal for Advaccine or its Affiliate to transfer, or have transferred on its behalf, payments to Inovio, Advaccine shall promptly notify Inovio of the conditions preventing such transfer and such payments shall be deposited in local currency in the relevant country to the credit of Inovio in a recognized banking institution designated by Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.7&#160;&#160;&#160;&#160;Interest on Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Inovio does not receive payment of any sum due to it on or before the due date, interest shall thereafter accrue on the sum due to Inovio until the date of payment at the per annum rate of &#91;***&#93; over the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable by applicable Laws, whichever is lower, with such interest compounded quarterly. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.8&#160;&#160;&#160;&#160;Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Advaccine shall, and shall cause its Affiliates and their respective Sublicensees to, maintain in accordance with Accounting Standards, reasonably complete and accurate records in sufficient detail to permit Inovio to confirm the accuracy of the calculation of royalty payments and the achievement of the milestone events.  All payments and other relevant amounts under this Agreement shall be accounted for in accordance with Accounting Standards.  Upon reasonable prior written notice, in any event no less than thirty (30) days prior written notice, such records shall be available for examination during regular business hours and in a manner that does not interfere with Advaccine&#8217;s business activities for a period of three (3) years from the end of the Fiscal Year to which they pertain, and not more often than once each Fiscal Year, by an independent certified public accountant selected by Inovio and reasonably acceptable to Advaccine, for the sole purpose of verifying the accuracy of the financial reports furnished by Advaccine pursuant to this Agreement and any payments with respect thereto.  Any such auditor shall not disclose Advaccine&#8217;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by Advaccine or the amount of payments due under this Agreement.  Any amounts shown to be owed but unpaid shall be paid within thirty (30) days from the accountant&#8217;s report, plus interest (as set forth in Section 8.7) from the original due date.  Inovio shall bear the full cost of such audit unless such audit discloses an underpayment by Advaccine of more than &#91;***&#93; of the amount due for the audited period, in which case Advaccine shall bear the full cost of such audit</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Inovio shall, and shall ensure that its Affiliates and its and their respective employees, agents and contractors, maintain complete and accurate records with respect to  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inovio&#8217;s pharmacovigilance-related obligations set forth in Section 5.8.  Upon reasonable prior written notice, such records shall be available for examination during regular business hours for a period of three (3) years from the end of the Fiscal Year to which they pertain, and not more often than once each Fiscal Year by Advaccine or its designee that is reasonably acceptable to Inovio, for the sole purpose of ensuring compliance with NMPA and other Regulatory Authority regulations.  Any such records shall be deemed Confidential Information of Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.9&#160;&#160;&#160;&#160;Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Taxes on Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in this Section 8.9, each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 8.9(d), if Advaccine is required by applicable Laws to make any tax deduction, tax withholding or similar payment (other than value-added tax, any goods and services tax, harmonized sales tax and any similar provincial sales tax) from any amount paid or payable by Advaccine to Inovio (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under this Agreement, then in the case of any payments to be made by Advaccine to Inovio under this Agreement (including pursuant to Sections 8.1, 8.2, 8.3, and 8.4), Advaccine will (A) deduct and withhold the amount of such Tax Withholding for the account of Inovio to the extent required by applicable Laws (such amounts payable to Inovio shall be reduced by the amount of Tax Withholding deducted and withheld) and (B) pay any such Tax Withholding (including any additional Tax Withholding required with respect to Advaccine&#8217;s additional payments under this Section 8.9) directly to the proper Governmental Authority. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments due to Inovio from Advaccine pursuant to this Agreement shall be paid exclusive of, and without reduction for, any value-added tax (including, for greater certainty, any goods and services tax, harmonized sales tax and any similar taxes) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (which, if applicable, shall be payable by Advaccine). Advaccine shall be responsible for the payment of all VAT applicable to the payments made by Advaccine to Inovio under this Agreement in the Advaccine Territory and shall file all applicable VAT tax returns or seek any exemption or reduction of such VAT pursuant to any applicable Laws.  Inovio shall cooperate, to the extent reasonably required, with the filing of any such VAT tax returns or any application of reduction or exemption of such VAT with the proper Government Authority in the Advaccine Territory. Advaccine shall indemnify Inovio for any VAT imposed on Inovio in the Advaccine Territory with respect to the payments made to it by Advaccine under this Agreement and if Inovio directly pays any such VAT, Advaccine shall promptly reimburse Inovio for such VAT including all reasonable related costs.  If Inovio determines that it is required to report any such tax, Advaccine shall promptly provide Inovio with applicable receipts and other documentation necessary or appropriate for such report.  For clarity, this Section 8.9(c) is not intended to limit Advaccine&#8217;s right to deduct VAT in determining Net Sales.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Tax Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Without limiting Section 8.9(b) and 8.9(c), the Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate Tax Withholding or similar obligations in respect of payments made by Advaccine to Inovio under </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">this Agreement (including pursuant to Sections 8.1, 8.2, 8.3 and 8.4).  To the extent Advaccine is required to make any Tax Withholdings for any payment to Inovio, Advaccine shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Inovio an official tax certificate or other evidence of such withholding sufficient to enable Inovio to claim such payment of taxes from any applicable Government Authority.  Inovio shall provide Advaccine any tax forms or other similar documentation that may be reasonably necessary in order for Advaccine not to make any Tax Withholdings or to make Tax Withholdings at a reduced rate under an applicable bilateral income tax treaty, and shall update such forms and documentation from time to time as necessary to reflect changes in facts.  Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Laws, of Tax Withholdings, VAT or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT.  Specifically, in the event that any tax has been withheld upon a payment made under this Agreement or has otherwise been remitted to a Governmental Authority, if requested by either Party, and if, and for so long as, the Parties acting in good faith mutually agree that there is a reasonable prospect of successfully obtaining a refund of such tax, then the other Party shall, at the requesting Party&#8217;s sole cost and expense, seek a refund of such tax from the proper Governmental Authority. In the event that any taxes withheld or reimbursed by Advaccine under Section 8.9(a) are subsequently refunded to Advaccine by the appropriate Governmental Authority, Advaccine shall pay over the amount of such refund, less any cash Taxes attributable to the receipt thereof and any reasonable expenses incurred by Advaccine in obtaining such refund. Advaccine agrees to reasonably cooperate with Inovio and its Affiliates in the pursuit of such tax refund (including, if required by applicable Laws or by the applicable Governmental Authority, permitting Inovio to seek such tax refund in Advaccine&#8217;s name and participating in any application or appeal that requires that Advaccine be the party applying for such tax refund, solely with Advaccine&#8217;s prior written consent)&#59; provided that, Inovio agrees to assume responsibility for direct payment of lawyers&#8217; and other advisors&#8217; fees and any other costs associated with seeking such refund.  Notwithstanding anything contained in the Agreement to the contrary, in the event that Inovio is unable to utilize any portion of a Tax Withholding as tax credit to effectively lower its income tax for the applicable tax year during which the applicable payment is received, Advaccine shall reimburse Inovio for any such portion thereof within forty-five (45) days after receipt of an invoice from Inovio (and shall gross-up Inovio for any Tax Withholding on such payment). </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.1&#160;&#160;&#160;&#160;Ownership&#59; License Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Data Generated by Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio shall solely own all Data generated by Inovio.  For clarity, all Data solely directed to the Vaccine and the Array Controlled by Inovio are included in the Inovio Licensed Know-How and licensed to Advaccine under Section 2.1(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Data Generated by Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Advaccine shall solely own all Data generated by Advaccine in the Development of the Vaccine and the Products in the Field in the </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advaccine Territory.  Advaccine hereby grants to Inovio (i) an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, to use such Data generated and owned by Advaccine for the purpose of seeking and maintaining any Regulatory Approval for the Vaccine or the Product in the Inovio Territory, and (ii) upon expiration or termination of the Agreement (other than termination of the Agreement by Advaccine pursuant to Sections 13.4 or 13.5), an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses, to use such Data generated and owned by Advaccine for the Development, Manufacture and Commercialization of the Vaccine or the Product in the Field in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Product Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this Agreement, each Party hereby grants to the other Party a fully-paid up, royalty-free exclusive license, with the right to grant sublicenses under multiple tiers, to use Product Materials generated and owned by such Party, solely to the extent reasonably necessary for the Development, Manufacture (with respect to Advaccine, solely to the extent applicable under Section 7.2) and Commercialization of the Vaccine and the Product in the Field in the other Party&#8217;s respective territory during the Term of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inventorship of any Invention will be determined in accordance with the standards of inventorship and conception under U.S. patent laws.  </font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Inovio Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Invention generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Inovio, its Affiliates and their respective licensees (including Inovio Partners), including their employees, agents and contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be solely and exclusively owned by Inovio. For clarity, any and all Inovio Inventions that are Controlled by Inovio and reasonably necessary for the Development, Manufacture and Commercialization of the Vaccine and the Product in the Field in the Advaccine Territory shall be included in the Inovio Technology licensed to Advaccine under Section 2.1(a), including any Patent rights therein. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.36pt">Advaccine Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Inventions generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Advaccine, its Affiliates and their respective Sublicensees, including their employees, agents and contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be solely and exclusively owned by Advaccine.  Advaccine shall disclose in writing to Inovio all Advaccine Inventions promptly following the generation, development, conception or reduction to practice thereof.  Advaccine hereby grants Inovio (A) an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under the Advaccine Inventions in the Inovio Territory, and (B) upon expiration or termination of this Agreement (other than termination of this Agreement by Advaccine pursuant to Sections 13.4 or 13.5) an irrevocable, perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses, under the Advaccine Inventions in the Advaccine Territory, in each case of (A) and (B), solely for the Development, Manufacture and Commercialization of the Vaccine or the Products in the Field.   </font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.03pt">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Invention generated, developed, conceived or reduced to practice (constructively or actually) jointly by or on behalf of Advaccine and Inovio, their Affiliates and respective Sublicensees, including their employees, agents and contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall be jointly owned by the Parties, and, subject to the licenses set forth in this Agreement, each Party may freely exploit such Joint Inventions without any duty to account to the other Party.  Each Party shall disclose in writing to the other Party all Joint Inventions promptly following the generation, development, conception or reduction to practice thereof.  Advaccine hereby grants Inovio an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under its rights in such Joint Inventions (i) in the Inovio Territory, and (ii) upon termination of the Agreement (other than termination of the Agreement by Advaccine pursuant to Sections 13.4 or 13.5), in the Advaccine Territory, in each case of (i) and (ii), solely for the Development, Manufacture and Commercialization of the Vaccine or the Product in the Field.  Inovio hereby grants Advaccine an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses, under its rights in such Joint Inventions in the Advaccine Territory solely for the Development, Manufacture and Commercialization of the Vaccine or the Product in the Field. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Affiliates, Sublicensees and Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party  shall ensure that each of its Affiliates, Sublicensees and subcontractors under this Agreement has a contractual obligation to disclose to it all Data, Product Materials and Inventions generated, invented, discovered, developed, made or otherwise created by them or their employees, agents or independent contractors, and to provide sufficient rights with respect thereto, so that each Party  can comply with its obligations to the other Party under this Section 9.1.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.2&#160;&#160;&#160;&#160;Patent Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the purpose of this Article 9, &#8220;prosecution&#8221; of Patents shall include, without limitation, all communication and other interaction with any patent office or patent authority having jurisdiction over a Patent application throughout the world in connection with any pre-grant proceedings and post-grant proceeding, including opposition proceedings. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Inovio Licensed Patents&#59; Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in Section 9.2(d), as between the Parties, Inovio shall have the sole right to prepare, file, prosecute and maintain or abandon the Inovio Licensed Patents on a worldwide basis.  Except as set forth in Section 9.2(d), as between the Parties, Inovio shall have the sole right to prepare, file, prosecute and maintain or abandon the Joint Patents on a worldwide basis.  Inovio shall provide Advaccine with a copy of the draft prepared for the filing of a Joint Patent, before the filing of such Joint Patent and will consider in good faith comments thereto provided by Advaccine in connection with the filing thereof.  Inovio shall, at the request of Advaccine, provide Advaccine with regular updates on the prosecution of the Inovio Product-Specific Licensed Patents and Joint Patents in the Field in the Advaccine Territory.  For clarity, Advaccine shall not have any rights pursuant to this Agreement with respect to any Inovio Licensed Patents in the Inovio Territory (including any Step-In Rights relating thereto).</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Advaccine Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in Section 0(d), as between the Parties, Advaccine shall have the sole right to prepare, file, prosecute and maintain or abandon the Advaccine Patents.  Advaccine shall provide Inovio with a copy of the draft prepared for the filing of a Advaccine Patent, before the filing of such Advaccine Patent and will consider in good faith comments thereto provided by Inovio in connection with the filing thereof.  Advaccine shall provide Inovio with regular updates on the prosecution of the Advaccine Patents in the Field in the Advaccine Territory.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Step-In Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either Party may cease prosecution and&#47;or maintenance of any Patent that such Party is responsible for prosecuting and maintain pursuant to this Section 0 on a country-by-country basis by providing the other Party written notice reasonably in advance of such due date.  If the responsible Party elects to cease prosecution or maintenance of the relevant Patent in a country, the other Party, shall have the right, but not the obligation, at its sole discretion and cost, to continue prosecution or maintenance of such Patent and in such country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Step-In Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), provided that Advaccine may only exercise its Step-In Rights with respect to Joint Patents and Inovio Product-Specific Licensed Patents in the Advaccine Territory.  If the other Party elects to continue prosecution or maintenance or elects to file additional applications following the responsible Party&#8217;s election to cease prosecution or maintenance pursuant to this Section 0(d), the responsible Party shall transfer the applicable patent files to such other Party or its designee and execute such documents and perform such acts at the responsible Party&#8217;s expense as may be reasonably necessary to allow the other Party to initiate or continue such filing, prosecution or maintenance at the other Party&#8217;s sole expense.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall provide the other Party with all reasonable assistance and cooperation in the patent prosecution efforts set forth in this Section 0, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.3&#160;&#160;&#160;&#160;Patent Term Extensions in the Advaccine Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC will discuss and recommend for which, if any, of the Patents within the Inovio Licensed Patents, Advaccine Patents and Joint Patents in the Advaccine Territory the Parties should seek patent term extensions.   If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before the JSC, the representatives of the Parties cannot reach an agreement as which Patents such extensions should be sought for, (a) Inovio, in the case of Inovio Licensed Patents and Joint Patents, and (b) Advaccine, in the case of Advaccine Patents, shall have the final decision-making authority with respect to applying for any such patent term extension in the Advaccine Territory, and will act with reasonable promptness in light of the development stage of the Products to apply for any such patent term extension, where it so elects&#59; provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that if only one such Patent can obtain a patent term extension, the Parties will consult in good faith to determine which such Patent should be the subject of efforts to obtain a patent term extension, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">further provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that, if an Inovio Licensed Patent is the only Patent that is eligible for a patent term extension with respect to a Product in the Advaccine Territory, then (i) Advaccine shall have the right, but not the obligation, to request Inovio to apply for such patent term extension at Advaccine&#8217;s sole discretion and cost, and (ii) upon Inovio&#8217;s receipt of such request, Inovio shall use Commercially Reasonable Efforts to apply for such patent term extension.  Each Party will cooperate fully with the other Party in making such filings or actions, for example and </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">without limitation, making available all required regulatory Data and Information and executing any required authorizations to apply for such patent term extension.  All expenses incurred in connection with activities of each Party with respect to the Patent(s) for which such Party seeks patent term extensions pursuant to this Section 9.3 shall be borne by such Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.4&#160;&#160;&#160;&#160;Patent Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Notification&#59; Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party becomes aware of any existing or threatened infringement of any Inovio Licensed Patent, Advaccine Patent or Joint Patent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), it shall promptly notify the other Party in writing to that effect and the Parties will consult with each other regarding any actions to be taken with respect to such Infringement.  Each Party shall share with the other Party all Information available to it regarding such alleged Infringement, pursuant to a mutually agreeable &#8220;common interest agreement&#8221; executed by the Parties under which the Parties agree to their shared, mutual interest in the outcome of any suit or other action to enforce the Inovio Licensed Patents, Advaccine Patent and Joint Patent against such Infringement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Enforcement Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">Inovio Product-Specific Licensed Patents&#59; Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Inovio shall have the first right, but not the obligation, to bring an appropriate suit or other action against any Person engaged in the Infringement of any Inovio Product-Specific Licensed Patent or Joint Patent in the Advaccine Territory, at Inovio&#8217;s cost and expense.  If Inovio elects to commence a suit or other action to enforce the applicable Inovio Product-Specific Licensed Patent or Joint Patent against such Infringement in the Advaccine Territory, then Advaccine shall have the right to join such enforcement action upon written notice to Inovio, and the Parties shall share the cost and expense of such enforcement action equally.  If Inovio notifies Advaccine in writing that it does not intend to commence a suit or other action to enforce the applicable Inovio Product-Specific Licensed Patent or Joint Patent against such Infringement or to take other action to secure the abatement of such Infringement, or fails to take any such action after a period of forty-five (45) Business Days following either Party&#8217;s receipt of the notice of Infringement pursuant to Section 9.4(a), then, to the extent that such Infringement is resulting from a Third Party&#8217;s use or sale of a product that competes with a Product in the Field in the Advaccine Territory, Advaccine shall have the right, but not the obligation, to commence such a suit or take such action, at Advaccine&#8217;s sole cost and expense&#59; provided that, in the event the Person engaged in the Infringement of any Inovio Product-Specific Licensed Patent or Joint Patent in the Advaccine Territory is also engaged in such Infringement in the Inovio Territory, and Inovio has commenced a suit to secure the abatement of such Infringement in the Inovio Territory, then Inovio shall promptly notify Advaccine thereof and Advaccine shall not have the right to commence such suit or action without the prior written consent of Inovio, not to be unreasonably withheld. In such case, Inovio shall take appropriate actions in order to enable Advaccine to commence a suit or take the actions set forth in the preceding sentence.  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Neither Party shall settle any such suit or action under Section 9.4(b)(i)(1) in any manner that would negatively impact the Inovio Product-Specific Licensed Patents or Joint Patents or that would limit or restrict the ability of Advaccine to sell the Products in the Advaccine Territory, without the prior written consent of the other Party.  For clarity, Advaccine shall not have the right to commence any such suit or action against any existing or threatened infringement of the Inovio Product-Specific Licensed Patents or Joint Patents outside the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.36pt">Advaccine Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall have the first right, but not the obligation, to bring an appropriate suit or other action against any Person engaged in the Infringement of any Advaccine Patent, at Advaccine&#8217;s cost and expense.  If Advaccine elects to commence a suit to enforce the applicable Advaccine Patent against such Infringement, where such Infringement relates to the Commercialization in the Advaccine Territory of unauthorized products containing the Vaccine, then Inovio shall have the right to join such enforcement action upon notice to Advaccine, and in this case the Parties shall share the cost and expense of such enforcement action equally.  If Advaccine notifies Inovio that it does not intend to commence a suit to enforce the applicable Advaccine Patent against such Infringement or to take other action to secure the abatement of such Infringement, or fails to take any such action after a period of ninety (90) days, then Inovio shall have the right, but not the obligation, to commence such a suit or take such action, at Inovio&#8217;s cost and expense.  In such case, Advaccine shall take appropriate actions in order to enable Inovio to commence a suit or take the actions set forth in the preceding sentence.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Collaboration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall provide to the Party bringing a claim, suit or action under Section 9.4(b) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Enforcing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) with reasonable assistance in such enforcement, including joining such action as a party plaintiff if required by applicable Laws to pursue such action.  The Enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, and shall reasonably consider the other Party&#8217;s comments on any such efforts.  The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the Enforcing Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Expenses and Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Enforcing Party shall be solely responsible for any expenses it incurs as a result of such enforcement action, except that the Parties shall share equally the cost and expense of the enforcement action when Inovio is the Enforcing Party and Advaccine elects to join the enforcement action.  If the Enforcing Party recovers monetary damages in such claim, suit or action brought under Section 9.4(b), such recovery shall be allocated first to the reimbursement of any documented expenses incurred by the Parties in such enforcement action, and any remaining amounts shall be shared by the Parties as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if (A) Inovio is the Enforcing Party under Section 9.4(b)(i)(1) and Advaccine elects to join the enforcement action and share the cost and expenses related thereto, or (B) Advaccine is the Enforcing Party under Section 9.4(b)(ii) and Inovio elects to join the enforcement action and share the cost and expenses related thereto&#58; &#91;***&#93; of the remaining </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">amounts shall be retained by Inovio, and &#91;***&#93; of the remaining amounts shall be paid to Advaccine&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">if Inovio is the Enforcing Party (A) under Section 9.4(b)(i)(1) and Advaccine does not elect to join the enforcement action and share the cost and expenses related thereto, or (B) under Section 9.4(b)(ii)&#58; &#91;***&#93; of the remaining amounts shall be retained by Inovio, and &#91;***&#93; of the remaining amounts shall be paid to Advaccine&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">if Advaccine is the Enforcing Party (A) under Section 9.4(b)(ii) and Inovio does not elect to join the enforcement action and share the cost and expenses related thereto, or (B) under Section 9.4(b)(i)(1)&#58; &#91;***&#93; of the remaining amounts shall be retained by Advaccine, and &#91;***&#93; of the remaining amounts shall be paid to Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Sections 9.4(c) and 9.4(d) shall survive the termination of this Agreement solely with respect to any pending enforcement action initiated during the Term under this Section 9.4.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.5&#160;&#160;&#160;&#160;Third Party Infringement Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Manufacture, use or sale of the Products in the Field in the Advaccine Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent infringement against Inovio or Advaccine (or their respective Affiliates, licensees or Sublicensees) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Infringement Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such Party shall promptly notify the other Party hereto in writing.  Subject to Article 11, the Party for which the Infringement Action is brought against (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accused Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall have the right to direct and control the defense of such Infringement Action, at its own expense with counsel of its choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the other Party may participate in the defense and&#47;or settlement thereof, at its own expense with counsel of its choice.  In any event, the Accused Party agrees to keep the other Party reasonably informed of all material developments in connection with any such Infringement Action for which the Accused Party exercises its right to direct and control the defense.  The Accused Party agrees not to settle such Infringement Action, or make any admissions or assert any position in such Infringement Action, in a manner that would adversely affect the rights or interests of the other Party, without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed.  Subject to Article 11, if the Accused Party does not exercise its right to direct and control the defense of an Infringement Action that is brought against the other Party, then the other Party shall have such right and it shall agree to keep  the Accused Party reasonably informed of all material developments in connection with such Infringement Action and it shall not settle such Infringement Action, or make any admissions or assert any position in such Infringement Action, in a manner that would materially adversely affect the rights or interests of the Accused Party, without the prior written consent of the Accused Party, which shall not be unreasonably withheld or delayed. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.6&#160;&#160;&#160;&#160;Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Subject to Section 9.6(c) below, Advaccine shall Commercialize the Products in the Field in the Advaccine Territory under any trademark owned or Controlled by Advaccine (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Product Mark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that, prior to finalizing any Advaccine Product Mark, Advaccine shall provide Inovio with such proposed trademark and related trade </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">dress and shall reasonably consider in good faith Inovio&#8217;s comments with respect thereto.  Advaccine shall, and shall cause its Affiliates and Sublicensees to, use the Advaccine Product Mark solely in connection with the Development, Manufacturing, and Commercialization of the Products in the Field in the Advaccine Territory.  Advaccine shall own all rights in the Advaccine Product Mark, and all goodwill in the Advaccine Product Mark shall accrue to Advaccine.  Advaccine shall register and maintain, at Advaccine&#8217;s cost and expense, the Advaccine Product Marks in the Advaccine Territory.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Subject to Section 9.6(c) below, Advaccine shall have the right to brand the Products in the Field in the Advaccine Territory with those trademarks of Advaccine that are associated with Advaccine&#8217;s name or identity (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Housemarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Advaccine shall own all rights in the Advaccine Housemarks, and all goodwill in the Advaccine Housemarks shall accrue to Advaccine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In connection with Advaccine&#8217;s use of any Advaccine Product Mark or Advaccine Housemark, subject to Section 9.6(d), Advaccine shall not, and shall cause its Affiliates and their respective Sublicensees to not make any use of trademarks that are confusingly similar to any trademarks or housemarks of Inovio or its Affiliates (including the corporate name of Inovio or any of its Affiliates), without the prior written consent of Inovio. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Notwithstanding anything to the contrary, to the extent required by applicable Laws, (i) Advaccine may include Inovio&#8217;s name and corporate logo on the Product label, packaging, promotional&#47;marketing materials to indicate that the Product is in-licensed from Inovio, and shall display Inovio&#8217;s name and corporate logo with equal prominence and comparable size, resolution, print quality, and location, as instructed by Inovio from time to time, as Advaccine&#8217;s name and corporate logo is displayed, and (ii) Inovio hereby grants to Advaccine a non-exclusive, fully paid-up, royalty free, sublicensable license to use Inovio&#8217;s name and corporate logo solely for the Commercialization of the Product in the Field in the Advaccine Territory, to the extent consistent with the foregoing.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPRESENTATIONS AND WARRANTIES&#59; COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.1&#160;&#160;&#160;&#160;Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby represents and warrants to the other Party, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Corporate Existence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, it is a company or corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Corporate Power, Authority and Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder&#59; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder&#59; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party that is enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar Laws affecting creditors&#8217; rights and remedies generally&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution and delivery of this Agreement, the performance of such Party&#8217;s obligations in the conduct of the Development Plan and the license to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of applicable Laws existing as of the Effective Date&#59; (ii) do not and will not conflict with or violate the certificate of incorporation or by-laws (or other constating documents) of such Party&#59; and (iii) do not and will not conflict with, violate, breach or constitute a material default under any contractual obligations of such Party or any of its Affiliates existing as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">No Violation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither such Party nor any of its Affiliates is under any obligation to any Person, contractual or otherwise, that is in violation of the terms of this Agreement or that would impede the fulfillment of such Party&#8217;s obligations hereunder&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither such Party nor any of its Affiliates is debarred or disqualified under the Act or comparable applicable Laws outside the U.S.&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">No Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No authorization, consent, approval of a Third Party, nor to such Party&#8217;s knowledge, any license, permit, exemption of or filing or registration with or notification to any court or Governmental Authority is or will be necessary for the (i) valid execution and delivery of this Agreement by such Party&#59; or (ii) the consummation by such Party of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.2&#160;&#160;&#160;&#160;Additional Representations and Warranties of Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio represents and warrants to Advaccine, as of the Effective Date, as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio (i) has the right to grant the license that it grants in Section 2.1(a)&#59; and (ii) has not granted, and will not grant during the Term,  any right to any Third Party that would conflict with the License that it grants in Section 2.1(a) or rights granted to Advaccine hereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Notice of Infringement or Misappropriation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It has not received any written notice from any Third Party asserting or alleging that (i) any research, development, manufacture, or commercialization of a Product by Inovio prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third Party, or (ii) the Development, Manufacture, or Commercialization of the Vaccine and the Products in the Advaccine Territory would infringe or misappropriate the intellectual property rights of such Third Party&#59; to Inovio&#8217;s actual knowledge, except as otherwise disclosed to Advaccine prior to the Effective Date, the Development, Manufacture or Commercialization of the Vaccine and theProducts does not infringe or misappropriate any intellectual property rights of any Third Party&#59; </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Non-Infringement of Rights by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To Inovio&#8217;s actual knowledge, no Third Party is infringing or has infringed the Inovio Product-Specific Licensed Patents as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Non-Assertion by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To Inovio&#8217;s actual knowledge, no Third Party has asserted in writing that the issued patents within the Inovio Licensed Patents set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are invalid or unenforceable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">No Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  There is no pending, and to Inovio&#8217;s actual knowledge, no threatened, adverse action, suit or proceeding against Inovio involving any Inovio Technology or the safety (including any product liability claim) of a Product&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Prosecution of Inovio Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except with respect to any Inovio Product-Specific Licensed Patents for which Inovio has ceased prosecution and&#47;or maintenance and granted Advaccine Step-In Rights therewith pursuant to Section 9.2(d), all maintenance fees, annuity payments, and similar payments relating to the Inovio Product-Specific Licensed Patents in the Advaccine Territory have been made, and during the Term will be made, in a timely manner.  To Inovio&#8217;s actual knowledge, prior to the Effective Date, Inovio has not taken action or failed to undertake an action, in connection with filing, prosecuting and maintaining the Inovio Product-Specific Licensed Patents set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in the Advaccine Territory in violation of any applicable Laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To Inovio&#8217;s actual knowledge, Inovio has complied with all applicable Laws in connection with the prosecution of the Inovio Product-Specific Licensed Patents, including the duty of candor owed to any patent office pursuant to such Laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Inovio Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio does not have actual knowledge of any Information which leads it to believe that any issued patents included in the Inovio Licensed Patents set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are invalid or unenforceable&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.69pt">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio has not entered, and shall not enter, into any agreement with any Third Party that is in conflict with the rights granted to Advaccine under this Agreement, and has not taken and shall not take any action that would in any way prevent it from granting the rights granted to Advaccine under this Agreement, or that would otherwise materially conflict with or adversely affect Advaccine&#8217;s rights under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.3&#160;&#160;&#160;&#160;Additional Representations and Warranties of Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine represents and warrants to Inovio that, to Advaccine&#8217;s knowledge as of the Effective Date Advaccine does not Control any Patent that is necessary to make, use, import, offer for sale or sell the Products in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.4&#160;&#160;&#160;&#160;Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Each Party shall, and shall ensure that its Affiliates and their respective Sublicensees will, comply in all respects with Proper Conduct Practices, and all applicable Laws </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(including all applicable Laws regarding data privacy) in the Development, Manufacturing, and Commercialization of the Products and performance of its obligations under this Agreement, including the ICH, GCP, GLP and any Regulatory Authority and Governmental Authority health care programs having jurisdiction in such Party&#8217;s respective territory, each as may be amended from time to time.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Each Party shall immediately notify the other Party if it has any information or suspicion that there may be a violation of any applicable Laws (including Anti-Corruption Laws) in connection with its performance under this Agreement or the Development or Commercialization of any Product hereunder.  In the event that either Party has violated or been suspected of violating any of its obligations, representations, warranties or covenants in Section 10.4(a), such Party will take reasonable actions to remedy such breach and to prevent further such breaches from occurring.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Notwithstanding the foregoing, each Party will have the right, upon reasonable prior written notice and during the other Party&#8217;s regular business hours, to audit the other Party&#8217;s books and records in the event that a suspected violation of any Anti-Corruption Law needs to be investigated (in such Party&#8217;s reasonable, good-faith discretion).  Such audit shall be conducted by such Party&#8217;s audit team comprised of qualified auditors who have received anticorruption training. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For clarity, a credible finding, after a reasonable investigation, of any breach of Section 10.4(a) or 10.4(b) with respect to any Anti-Corruption Law, shall be deemed a material breach of this Agreement and allow the non-breaching Party to terminate this Agreement in accordance with Section 13.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.5&#160;&#160;&#160;&#160;Additional Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to any covenants made by Advaccine elsewhere in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Advaccine hereby covenants to Inovio that neither Advaccine nor any of its Affiliates or Sublicensees, will employ or use the services of any Person who is debarred or disqualified under the Act, or comparable applicable Laws outside the U.S., in connection with activities relating to any Product&#59; and in the event that Advaccine becomes aware of the debarment or disqualification or threatened debarment or disqualification of any Person providing services to Advaccine or any of its Affiliates with respect to any activities relating to any Product, Advaccine will immediately notify Inovio in writing and Advaccine will cease, or cause its Affiliate to cease (as applicable), employing, contracting with, or retaining any such Person to perform any services relating to any Product&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Each Party hereby covenants to the other Party that neither such Party nor any of its Affiliates, nor any of their respective employees shall use any confidential information obtained from any Third Party (including any prior employer) to which such Party or any of its Affiliates, or any of their respective employees has a duty to keep in confidence such information, directly or indirectly, whether obtained prior to the Effective Date or during the Term, in connection with activities performed under this Agreement, unless consented to in writing by such Third party, and such Party shall be solely responsible and liable for, and shall </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">52</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">indemnify the other Party pursuant to Article 11 in connection with, any breach of this covenant by such Party, any of its Affiliates, or their respective employees.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.6&#160;&#160;&#160;&#160;No Other Representations or Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY OR ITS AFFILIATES, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.  FOR CLARITY AND WITHOUT LIMITING THE FOREGOING, INOVIO MAKES NO REPRESENTATION OR WARRANTY CONCERNING THE PRODUCTS OR INOVIO TECHNOLOGY EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 10. </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.1&#160;&#160;&#160;&#160;Indemnification by Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Inovio shall defend, indemnify, and hold Advaccine and its Affiliates and their respective officers, directors, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from and against any and all losses, damages, liabilities, actually incurred expenses and costs, including reasonable legal expense and attorneys&#8217; fees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to which any Advaccine Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">arising out of, based on, or resulting from (a) the Development, Manufacture, or Commercialization of the Products in the Field in the Advaccine Territory by or on behalf of Inovio or its Affiliates prior to the Prior Effective Date with respect to Greater China and prior to the Effective Date outside of Greater China, (b) the conduct of the Global Phase 3 Study under this Agreement, (c) the Development, Manufacture, or Commercialization of the Products in the Inovio Territory, (d) the breach of any of Inovio&#8217;s obligations under this Agreement, including Inovio&#8217;s representations, warranties or covenants set forth herein, (e) the conduct of any pharmacovigilance-related activities set forth in Section 5.8 by or on behalf of Inovio (except to the extent that such Claim arises from Advaccine&#8217;s provision of false, misleading, inaccurate or incomplete information to Inovio under Section 5.8 or Advaccine&#8217;s breach of its obligations under the Pharmacovigilance Agreement) or (f) the willful misconduct or negligent acts of any Inovio Indemnitee.  The foregoing indemnity obligation shall not apply to the extent that (i) the Advaccine Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Inovio&#8217;s defense of the relevant Claim is materially prejudiced by such failure, or (ii) any Claim arises from, is based on, or results from any activity or occurrence for which Advaccine is obligated to indemnify the Inovio Indemnitees under Section 11.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.2&#160;&#160;&#160;&#160;Indemnification by Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine shall defend, indemnify, and hold Inovio and its Affiliates and their respective officers, directors, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from and against any and all Losses to which any Inovio Indemnitee may become subject as a result of any Claims arising out of, based on, or resulting from (a) the Development, Manufacture, or Commercialization of the Products by or on behalf of Advaccine or its Affiliates or </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicensees on or after the Prior Effective Date with respect to Greater China and on or after the Effective Date outside of Greater China (except to the extent that any such activities are conducted by or on behalf of Inovio or its Affiliates) (including any Infringement Actions), (b) the breach of any of Advaccine&#8217;s obligations under this Agreement, including Advaccine&#8217;s representations, warranties, or covenants set forth herein, or (c) the willful misconduct or negligent acts of any Advaccine Indemnitee.  The foregoing indemnity obligation shall not apply to the extent that (i) the Inovio Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Advaccine&#8217;s defense of the relevant Claim is materially prejudiced by such failure, or (ii) any Claim arises from, is based on, or results from any activity or occurrence for which Inovio is obligated to indemnify the Advaccine Indemnitees under Section 11.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.3&#160;&#160;&#160;&#160;Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Party claiming indemnity under this Article 11 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) promptly after learning of such Claim and shall offer control of the defense of such Claim to the Indemnifying Party.  The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense of the Claim for which indemnity is being sought.  The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice.  The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money.  So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle or compromise any such Claim without the prior written consent of the Indemnifying Party.  If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Article 11.  Notwithstanding anything contained in this Section 11.3, the provisions of Section 9.5 shall govern the defense of any Infringement Actions.  Additionally, in the event that Inovio has elected to defend any such Infringement Action, then Advaccine shall not be obligated to indemnify Inovio for any Claims related to such Infringement Action&#59; rather, the Parties shall share equal responsibility for any Losses resulting therefrom. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.4&#160;&#160;&#160;&#160;Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 OR 11.2, OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF ITS EXCLUSIVITY OBLIGATIONS IN SECTION 2.5 OR ITS CONFIDENTIALITY OBLIGATIONS IN ARTICLE 12.  </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.5&#160;&#160;&#160;&#160;Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated.  It is understood that such insurance shall not be construed to create a limit of either Party&#8217;s liability with respect to its indemnification obligations under this Article 11.  Each Party shall provide the other Party with written evidence of such insurance upon request.  Each Party shall provide the other Party with written notice at least thirty (30) days prior to the cancellation, nonrenewal or material change in such insurance.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.1&#160;&#160;&#160;&#160;Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees that, during the Term and for a period of ten (10) years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder or thereunder) any Confidential Information of the other Party, except to the extent expressly agreed in writing by the Parties.  The foregoing confidentiality and non-use obligations shall not apply to any portion of the other Party&#8217;s Confidential Information that the receiving Party can demonstrate by competent written proof&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliate in breach of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">was disclosed to the receiving Party or its Affiliate without any confidentiality obligations by a Third Party who, to the Party&#8217;s knowledge, had a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">was independently discovered or developed by the receiving Party or its Affiliate without use of or reference to the other Party&#8217;s Confidential Information, as evidenced by a contemporaneous writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.2&#160;&#160;&#160;&#160;Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the obligations set forth in Section 12.1, a Party may disclose the other Party&#8217;s Confidential Information and the terms of this Agreement to the extent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">such disclosure is reasonably necessary (i) for the filing or prosecuting of Patent rights as contemplated herein&#59; (ii) to comply with the requirements of Regulatory Authorities with respect to obtaining and maintaining Regulatory Approval of the Product&#59; or (iii) for the prosecuting or defending litigation as contemplated herein&#59;</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">such disclosure is reasonably necessary to its or its Affiliate&#8217;s employees, agents, consultants, contractors, licensees or Sublicensees, (including Inovio Partners) on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights hereunder&#59; provided that in each case, the disclosees are bound by written obligations of confidentiality consistent with those contained in this Agreement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">such disclosure is (i) reasonably necessary to comply with applicable Laws, including regulations or rules promulgated by applicable securities commissions (or other securities regulatory authorities), security exchanges (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Regulators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, including without limitation to, the Securities and Futures Commission of Hong Kong, The Stock Exchange of Hong Kong Limited, the China Securities Regulatory Commission, the Shanghai Stock Exchange or the U.S. Securities and Exchange Commission), court order, administrative subpoena or order&#59; or (ii) at the request of applicable Securities Regulators, or reasonably anticipated by one Party that such disclosure will be required by applicable Laws or applicable Securities Regulators&#59;  and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">solely with respect to the terms of this Agreement and excluding disclosure of any other Confidential Information, such disclosure is reasonably necessary to any bona fide potential or actual investor, acquiror, merger partner, or other financial or commercial partner for the sole purpose of evaluating or carrying out an actual or potential investment, acquisition or other business relationship&#59; provided that in connection with such disclosure, such Party shall inform each disclosee of the confidential nature of such Confidential Information and require each disclosee to treat such Confidential Information as confidential.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section 12.2(a), 12.2(c) or 12.2(d), such Party shall promptly notify the other Party of such required disclosure, to the extent that it is legally authorized or permitted to so, and shall use reasonable efforts to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the required disclosure.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.3&#160;&#160;&#160;&#160;Publicity&#59; Terms of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Parties agree that the existence or terms of this Agreement are the Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth in this Section 12.3.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">If either Party desires to make a public disclosure concerning the existence or terms of this Agreement, such Party shall give the proposed text of such disclosure to the other Party reasonably in advance (but in any case no less than three (3) Business Days prior to the disclosure) for its prior review and approval (except as otherwise provided herein), which approval shall not be unreasonably withheld or delayed.  A Party commenting on such a proposed disclosure shall provide its comments, if any, within three (3) Business Days after receiving the proposed disclosure for review (or such shorter period of time as necessitated by regulatory requirements).  In addition, where required by applicable Laws, including regulations promulgated by applicable security exchanges, either Party shall have the right to make a press </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">56</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">release or other public disclosure regarding the achievement of each milestone under this Agreement as it is achieved, the achievements of Regulatory Approval in the Advaccine Territory as they occur, or the occurrence of other events that affect either Party&#8217;s rights or obligations under this Agreement, including the results of any Clinical Trial of the Products, whether in the Advaccine Territory or the Inovio Territory&#59; provided that such Party shall provide the proposed text of such disclosure to the other Party at least one (1) Business Day in advance, and the other Party shall provide its comments thereto within such one (1) Business Day.  In relation to the other Party&#8217;s review of such an announcement, such other Party may make specific, reasonable comments on such proposed press release within the prescribed time for commentary.  Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement that has already been publicly disclosed by such Party, or by the other Party, in accordance with this Section 12.3.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The Parties acknowledge that either or both Parties or their Affiliates may be obligated to file under applicable Laws a copy of this Agreement with Governmental Authorities, including, without limitation, the U.S. Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Each Party and its Affiliates shall be entitled to make such a required filing, provided that it requests confidential treatment of the commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available.  In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show provisions for which such Party or its Affiliate intends to seek confidential treatment and shall reasonably consider and incorporate the other Party&#8217;s timely comments thereon to the extent consistent with the legal requirements, with respect to the filing Party or Affiliate, governing disclosure of material agreements and material information that must be publicly filed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.4&#160;&#160;&#160;&#160;Technical Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party may publish peer reviewed manuscripts, or give other forms of public disclosure such as abstracts and presentations, of results of studies carried out under this Agreement or otherwise pertaining to the Development of the Vaccine or the Products in the Advaccine Territory, without the opportunity for prior review and comment by the other Party in accordance with this Section 12.4, except to the extent required by applicable Laws.  A Party seeking publication shall provide the other Party the opportunity to review and comment on any such proposed publication at least five (5) calendar days for abstracts ten (10) calendar days for manuscripts prior to its intended submission for publication.  The other Party shall provide the Party seeking publication with its comments in writing, if any, within three (3) calendar days for abstracts and seven (7) calendar days for manuscripts after receipt of such proposed publication.  The Party seeking publication shall consider in good faith any comments thereto provided by the other Party and shall comply with the other Party&#8217;s request to remove any and all of such other Party&#8217;s Confidential Information from the proposed publication. Further, if Inovio reasonably determines and notifies Advaccine that a proposed publication is reasonably likely to result in Adverse Risk in the Inovio Territory, Advaccine shall not submit such publication unless and until the Parties agree to a proposal to mitigate such Adverse Risk. In addition, the Party seeking publication shall delay the submission for a period up to thirty (30) calendar days in the event that the other Party can demonstrate reasonable need for such delay for the preparation and filing of a patent application.  If the other Party fails to provide its comments to the Party seeking publication within the specified time frame, such other Party shall be deemed to not have any comments, and the Party seeking publication shall be free to publish in accordance with this Section 12.4.  The </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party seeking publication shall provide the other Party a copy of the manuscript at the time of the submission.  Each Party agrees to acknowledge the contributions of the other Party and its employees in all publications in accordance with scientific practices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.5&#160;&#160;&#160;&#160;Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party acknowledges that its breach of this Article 12 will cause irreparable harm to the other Party, which cannot be reasonably or adequately compensated in damages in an action at law.  By reasons thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any actual or threatened breach of the obligations relating to Confidential Information set forth in this Article 12 by the other Party.  </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.1&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall commence upon the Prior  Effective Date and, unless earlier terminated pursuant to this Article 13, shall remain in effect until the expiration of the Royalty Term on a Region-by-Region basis.  Upon the expiration (but not early termination) of this Agreement, on a Region-by-Region basis, the licenses granted hereunder by Inovio to Advaccine shall become fully paid-up and royalty free&#59; provided that such licenses shall thereafter be granted on a non-exclusive basis.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.2&#160;&#160;&#160;&#160;Termination by Advaccine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine may terminate this Agreement in its entirety for convenience upon (i) nine (9) months prior written notice to Inovio (if such notice is provided before the First Commercial Sale in any Region) or (ii) eighteen (18) months prior written notice to Inovio (if such notice is provided following the First Commercial Sale in any Region)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in each case under (i) and (ii) Inovio may, in its discretion, upon prior written notice to Advaccine accelerate the effectiveness of such termination to the extent permitted by Law in the Advaccine Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.3&#160;&#160;&#160;&#160;Termination by Inovio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Inovio may terminate this Agreement upon written notice to Advaccine, if Advaccine ceases all Development (including all regulatory activities) or all Commercialization of the Products (including through Sublicensees and contractors) in the Advaccine Territory for a period of nine (9) or more consecutive months, unless Development or Commercialization of the Products was prevented throughout such period by a force majeure for which Advaccine provided notice pursuant to Section 15.2 prior to or at the start of such period and that persisted throughout such period despite Advaccine&#8217;s Commercially Reasonable Efforts to remove or mitigate it. Such termination shall go into effect on the date specified in the applicable termination notice. For clarity, a delay by Regulatory Authorities and&#47;or a decision by Regulatory Authorities to suspend a Clinical Trial (e.g., a &#8220;regulatory hold&#8221;) shall not give Inovio the right to terminate this Agreement under this Section 13.3(a), so long as Advaccine continues to use Commercially Reasonable Efforts to remove such regulatory hold.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Inovio may terminate this Agreement in its entirety upon thirty (30) days&#8217; prior written notice to Advaccine, if Advaccine or its Affiliates or their respective Sublicensees </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(directly or indirectly, individually or in association with any other Person) challenges the validity, enforceability or scope of any Inovio Licensed Patent, unless during such thirty (30)-day period the subject challenge is permanently dismissed or withdrawn and is not thereafter reinstituted or continued&#59; provided that in the event a Sublicensee of Advaccine initiates such challenge, Inovio may not terminate this Agreement if (i) Advaccine successfully causes such Sublicensee to abort such challenge within such thirty (30)-day period, or (ii) Advaccine (A) provides Inovio a written notice of its intent to terminate its sublicense with such Sublicensee within such thirty (30)-day period, and (B) successfully terminates such sublicense within such thirty (30)-day period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.4&#160;&#160;&#160;&#160;Termination for Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall have the right to terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party materially breaches its obligations under this Agreement (including, with respect to Advaccine, any failure to make a payment under Section 8.1(b) (whether to Inovio or directly to any Third Party service provider) when due) and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material breach within ninety (90) (or thirty (30) days in case of failure to make a payment due under this Agreement for reasons other than that set forth in Section 8.6) days from the date of such notice&#59; provided that, if either Party disputes (a) whether such material breach has occurred, or (b) whether the defaulting Party has cured such material breach, the Parties agree to resolve the dispute as expeditiously as possible under Article 14.  It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. Each Party hereby acknowledges that as of the Effective Date such Party is not aware of any material breach by the other Party or any other events of termination under Section 13.3 and 13.5 of the Prior Agreement.  Notwithstanding the foregoing, in the event of any failure by Advaccine to make a payment under Section 8.1(b) (whether to Inovio or directly to any Third Party service provider) when due), Inovio&#8217;s right to terminate this Agreement shall not include the territory of Greater China, rather such termination right shall be limited to the Advaccine Territory (other than Greater China).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.5&#160;&#160;&#160;&#160;Termination Due to Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either Party may terminate this Agreement if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof, or if the other Party proposes or becomes a Party to any dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insolvency Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.6&#160;&#160;&#160;&#160;Effect of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon any termination of this Agreement, the following shall apply (in addition to any other rights and obligations under this Agreement with respect to such termination)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All licenses and other rights granted by Inovio to Advaccine under this Agreement shall terminate.  Inovio shall have a reversion of all rights previously </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">59</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">licensed to Advaccine hereunder for which the relevant licenses have terminated on a fully paid-up and royalty-free basis, itself or with or through an Affiliate or Third Party, to Develop and Commercialize the Products in the Field in the Advaccine Territory at Inovio&#8217;s discretion. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advaccine will (i) responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices, any on-going Clinical Trials for which it has responsibility hereunder in which patient dosing has commenced or, (ii) unless if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, at Inovio&#8217;s reasonable request, (A) transfer to Inovio of its designee such Clinical Trial to the extent permitted under applicable Laws and accepted pharmaceutical industry norms and ethical practices, or (B) if reasonably practicable and not adverse to patient safety, complete such Clinical Trials and Inovio shall reimburse Advaccine its reasonable, out-of-pocket costs associated therewith.  For clarity, except as provided for above, Advaccine may transfer to Inovio or its designee or wind-down any ongoing Clinical Trials prior to the date of termination in accordance with accepted pharmaceutical industry norms and ethical practices and Advaccine will be responsible for any costs associated with such transfer or wind-down.  Notwithstanding the foregoing, if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, then Inovio will be responsible for any costs associated with such wind-down.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Regulatory Materials&#59; Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Except if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, Advaccine shall (i) provide and assign to Inovio or its designee all Regulatory Materials, including Regulatory Approvals, for the Products to the extent possible under applicable Laws in the Advaccine Territory, (ii) promptly provide to Inovio all Data (to the extent not already provided to Inovio), including pharmacovigilance data, generated by or on behalf of Advaccine, and (iii) promptly return or destroy, at Inovio&#8217;s election, all Confidential Information of Inovio.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, upon Inovio&#8217;s written request, Advaccine shall grant to Inovio, effective as of the date of such request, an exclusive, transferable, fully paid-up, royalty free, sublicensable license to use Advaccine Product Marks in connection with the Commercialization of the Products in the Advaccine Territory (and excluding, for clarity, any Advaccine Housemarks). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Transition Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon Inovio&#8217;s reasonable request, (i) Advaccine shall provide such assistance as may be reasonably necessary or useful for Inovio to continue the Development and Commercialization of the Products in the Advaccine Territory, to the extent Advaccine or its Affiliate is then performing or having performed such activities, including upon the reasonable request of Inovio, assigning (to the extent Advaccine has rights to assign) or using Commercially Reasonable Efforts to amend as appropriate any agreements or arrangements Advaccine or its Affiliate have with any Third Party for the Development, distribution, sale or otherwise Commercialization of the Products&#59; and (ii) Advaccine shall provide Inovio with copies of any promotional and marketing materials generated by or on behalf of Advaccine with respect to the Products prior to the effective date of termination. If this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, Inovio shall bear all costs arising out of any of </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">60</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the transition assistance activities set forth in clause (i) or (ii) performed by Advaccine. If this Agreement is terminated by Advaccine pursuant to Section 13.2 or by Inovio pursuant to Sections 13.3, 13.4, or 13.5, Advaccine shall bear all costs arising out of any of the transition assistance activities set forth in clause (i) or (ii) performed by Advaccine. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that this Agreement is terminated in its entirety, Inovio shall have the right, but not the obligation, to purchase any and all of the inventory of the Products held by Advaccine or its Affiliates as of the date of termination, at a price equal to the transfer price paid by Advaccine to Inovio for such inventory.  Notwithstanding the foregoing, if this Agreement is terminated by Advaccine pursuant to Sections 13.4 or 13.5, upon Advaccine&#8217;s request, at its sole discretion, Inovio shall re-purchase any and&#47;or all of its inventory of the Products, at a price equal to the transfer price paid by Advaccine to Inovio (if supplied by Inovio) or Advaccine&#8217;s manufacturing cost (if manufactured by Advaccine or its subcontractor) therefor.  Advaccine shall also have the right to continue to be permitted to sell such inventory for up to at least twelve (12) months after the effective date of termination of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.7&#160;&#160;&#160;&#160;Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any expiration or termination of this Agreement shall not affect rights or obligations of the Parties under this Agreement that have accrued prior to the date of expiration or termination (including with respect to any payments that have accrued prior to the effective date of expiration or termination of this Agreement).  Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination of this Agreement&#58; Sections 2.4, 4.5, 8.5 through 8.9 (inclusive), 9.1(a), 9.1(b), 9.1(d), 10.6, 13.6, 13.7 and 13.8 and Articles 1, 11, 12, 14 and 15.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.8&#160;&#160;&#160;&#160;Termination Not Sole Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.1&#160;&#160;&#160;&#160;Disputes&#59; Internal Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties recognize that disputes as to certain matters may from time to time arise that relate to either Party&#8217;s rights and&#47;or obligations hereunder.  It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation.  To accomplish this objective, the Parties agree that, except as otherwise provided in Section 3.2(d), if a dispute arises under or relates to this Agreement, including, without limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, and the Parties are unable to resolve such dispute within thirty (30) days after such dispute is first identified by either Party in writing to the other, the Parties shall refer such dispute to a senior executive of each of Inovio (or one of its Affiliates) and Advaccine (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for attempted resolution by good faith negotiations within thirty (30) days after notice referring to the dispute is received.  If the dispute is not resolved within such thirty (30) days, then the dispute shall be resolved by arbitration in accordance with Section 14.2 and </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">61</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">thereafter neither Party shall have any further obligation under this Section 14.1.  Notwithstanding the foregoing, and without waiting for the expiration of any such thirty (30)-day periods, each Party shall each have the right to apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect the rights or property of such Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.2&#160;&#160;&#160;&#160;Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All disputes arising out of or in connection with this Agreement, including any questions regarding its formation, existence, validity or termination, or the scope or applicability of this agreement to arbitrate, shall be referred to and finally resolved by arbitration administered by the Singapore International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under the Arbitration Rules of the Singapore International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIAC Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) for the time being in force and as may be amended by the rest of this clause. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The seat, or legal place, of arbitration shall be the Republic of Singapore.  There shall be three (3) arbitrators, with two (2) arbitrators to be respectively nominated by each Party and the third (presiding) arbitrator to be appointed by SIAC.  The language of the arbitration shall be English.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Any decision or arbitral award of SIAC shall be final and binding on each Party.  If any Party fails to implement the final arbitral award, the other Party may file an application for the enforcement of the arbitral award to a court with competent jurisdiction.  The costs of arbitration shall be borne by the losing Party or as otherwise determined by the arbitral tribunal.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In the course of arbitration, the Parties shall make Commercially Reasonable Efforts to continue to implement the Agreement except for those matters subject to arbitration.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Each Party retains the right to apply to any court of competent jurisdiction for interim and&#47;or conservatory measures, including pre-arbitral attachments or preliminary injunctions, and any such request shall not be deemed incompatible with, or a waiver of, this agreement to arbitrate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties and members of the arbitral tribunal except (i) to the extent that disclosure may be required of a Party to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, (ii) with the consent of all Parties, (iii) where needed for the preparation or presentation of a claim or defense in this arbitration, (iv) where such information is already in the public domain other than as a result of a breach of this clause, or (v) by order of the arbitral tribunal upon application of a Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">For avoidance of doubt, nothing contained in this Section 14.2 shall operate as a restriction on a Party's rights to terminate this Agreement pursuant to Article 13. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.3&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be governed by and construed under, and all disputes arising under or in connection with this Agreement shall be resolved in accordance with, </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">62</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the laws of the State of New York, U.S., without regard to the conflicts of law provisions thereof.  The United Nations Convention on International Contracts on the Sale of Goods does not apply to this Agreement and is expressly and entirely excluded.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.1&#160;&#160;&#160;&#160;Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, including the Schedules and Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof (other than the Non-Exclusive License Agreement, and that certain Research Service Contract dated December 30, 2020), including the Prior Agreement.  The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Confidentiality Agreement or the Prior Agreement.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.2&#160;&#160;&#160;&#160;Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.  Such excuse shall be continued only for so long as (a) the condition constituting force majeure continues and (b) the nonperforming Party takes all reasonable efforts to remove the condition.  For purposes of this Agreement, force majeure shall include conditions beyond the reasonable control of the applicable Party, which may include an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, pandemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, action or inaction of any Governmental Authority, and failure of plant or machinery.  Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party.  If a force majeure persists for more than ninety (90) days, then the Parties will discuss in good faith the modification of the Parties&#8217; obligations under this Agreement in order to mitigate the delays caused by such force majeure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.3&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.3, and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable courier service, (b) five (5) Business Days after mailing, if mailed by first class certified or registered airmail, postage prepaid, return receipt requested, or (c) if sent by electronic mail, upon electronic confirmation of receipt.</font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Inovio&#58;  &#160;&#160;&#160;&#160;Inovio Pharmaceuticals, Inc. </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">600 W. Germantown Pike, Suite 110</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plymouth Meeting, PA 19462</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; &#91;***&#93;</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; &#91;***&#93;</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;with copies to (which shall not constitute notice)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Inovio Pharmaceuticals, Inc. </font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">600 W. Germantown Pike, Suite 110</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plymouth Meeting, PA 19462</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; &#91;***&#93;</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; &#91;***&#93;</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font><br></font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font><br></font></div><div style="padding-left:171.35pt;text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cooley LLP<br>500 Boylston Street<br>Boston, MA 02116-3737<br>USA</font></div><div style="padding-left:171.35pt;text-indent:-171.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Attn&#58; &#91;***&#93;</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; &#91;***&#93;</font></div><div style="padding-left:171.35pt;text-align:justify;text-indent:-171.35pt"><font><br></font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to Advaccine&#58;  &#160;&#160;&#160;&#160;Advaccine Biopharmaceuticals Suzhou Co., Ltd.</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;18 Qingqiu Road</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Suzhou, China</font></div><div style="padding-left:171pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58;  &#91;***&#93;</font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-1.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#160;&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with copies to (which shall not constitute notice)&#58;</font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font><br></font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Partner </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sidley Austin LLP </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Suite 608, Tower C2   </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Oriental Plaza, Beijing </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1000738 China </font></div><div style="padding-left:172.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58; &#91;***&#93;</font></div><div style="padding-left:172.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:172.1pt;text-indent:-136.1pt"><font><br></font></div><div style="padding-left:172.1pt;text-align:justify;text-indent:-136.1pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.4&#160;&#160;&#160;&#160;No Strict Construction&#59; Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party.  Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.  The headings of each Article and Section in this Agreement have </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">64</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section.  Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#8220;or&#8221; is used in the inclusive sense (and&#47;or).  The term &#8220;including&#8221; as used herein means including, without limiting the generality of any description preceding such term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Assignment&#59; Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as provided in Section 15.5(b), this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party.  Any attempted assignment not in accordance with the foregoing shall be null and void and of no legal effect.  Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.  The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Notwithstanding the foregoing, Inovio may, without the consent of Advaccine, (i) assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of Inovio, or in whole to its successor-in-interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction&#59; (ii)&#160;sell or otherwise assign to any Third Party Inovio&#8217;s right to receive any payment (or portion thereof) from Advaccine under this Agreement, and&#47;or (iii) grant a security interest in its rights, title and interest in, to and under this Agreement.  If Inovio sells or assigns to any Third Party a right to receive a portion or all of its payments under this Agreement, such Third Party shall also have the right to receive the information received by Inovio pursuant to this Agreement and to conduct audits in accordance with Section 8.8 and Advaccine shall, at Inovio&#8217;s request, cooperate to facilitate the provision of any such information and the payment of any such amounts directly to such Third Party.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Notwithstanding the foregoing, Advaccine may without consent of Inovio, assign this Agreement or delegate its rights and obligations hereunder in whole or in part to an Affiliate of Advaccine (provided that in such case, Advaccine shall inform Inovio of such assignment or delegation and remain responsible for the performance of its Affiliate under this Agreement), or in whole to its successor-in-interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.6&#160;&#160;&#160;&#160;Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates.  Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.  Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">65</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.7&#160;&#160;&#160;&#160;Further Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.8&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by an arbitral tribunal constituted in accordance with Section 14.2, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof.  The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.9&#160;&#160;&#160;&#160;No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any delay in enforcing a Party&#8217;s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party&#8217;s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.10&#160;&#160;&#160;&#160;Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way.  Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.11&#160;&#160;&#160;&#160;English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.12&#160;&#160;&#160;&#160;Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed via electronic signature or via the exchange of signed portable document format (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PDF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) versions of this Agreement.  Such electronic signatures, and signatures on PDF versions of this Agreement, will be considered the legally binding equivalent of wet-ink, original, hand-written signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.13&#160;&#160;&#160;&#160;Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the U.S. Code and other similar laws in any jurisdiction outside the U.S. (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bankruptcy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under the Bankruptcy Laws.  Upon the occurrence of any Insolvency Event with respect to a Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insolvent Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Insolvent Party agrees that the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Insolvent Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Laws.  Each Party shall, during the Term, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property.  Each Party agrees and acknowledges that &#8220;embodiments&#8221; of intellectual property within the meaning of Section 365(n) include, without limitation, laboratory notebooks, cell lines, product samples and inventory, research studies and data, Regulatory Approvals and Regulatory Materials, in each case to the extent related to the Products.  If (i) a case is commenced during the Term by or against a Party </font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">66</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under the Bankruptcy Laws, (ii) this Agreement is rejected as provided for under the Bankruptcy Laws, and (iii) the Non-Insolvent Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Insolvent Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall (x) provide to the Non-Insolvent Party immediately upon the Non-Insolvent Party&#8217;s written request copies of all such intellectual property (including embodiments thereof) held by the Insolvent Party and such successors and assigns, or otherwise available to them, and (y) not interfere with the Non-Insolvent Party&#8217;s rights under this Agreement, or any related agreements between the Parties, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in the Bankruptcy Laws.  Whenever the Insolvent Party or any of its successors or assigns provides to the Non-Insolvent Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 15.13, the Non-Insolvent Party shall have the right to perform the Insolvent Party&#8217;s obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by the Non-Insolvent Party shall release the Insolvent Party from liability resulting from rejection of the license or the failure to perform such obligations.  All rights, powers and remedies of the Non-Insolvent Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws.  In particular, it is the intention and understanding of the Parties  that the rights granted to the Parties under this Section 15.13 are essential to the Parties&#8217; respective businesses and the Parties acknowledge that damages are not an adequate remedy.  The Parties agree that they intend the following rights to extend to the maximum extent permitted by applicable Laws, and to be enforceable under Section 365(n) of Title 11 of the U.S. Code&#58; (A) the right of access to any intellectual property (including embodiments thereof) of the Insolvent Party, or any Third Party with whom the Insolvent Party contracts to perform an obligation of the Insolvent Party under this Agreement, and, in the case of the Third Party, which is necessary for the Development, Manufacture and Commercialization of Products&#59; and (B) the right to contract directly with any Third Party to complete the contracted work upon failure of the Insolvent Party to comply with its applicable obligations.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#123;Signature Page Follows&#125;</font></div><div><font><br></font></div><div id="i3f61f46011724635ba611c38554656c5_4"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">67</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">In Witness Whereof, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Parties have executed this Collaboration and License Agreement in duplicate originals by their duly authorized officers as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> &#47;s&#47; J. Joseph Kim</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; J. Joseph Kim, PhD</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President &#38; CEO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#47;s&#47; Jane Yu </font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Jane Yu</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  President</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:77.9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">68</font></div><div><font><br></font></div></div></div><div id="i3f61f46011724635ba611c38554656c5_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIST OF EXHIBITS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule 1.4&#58;&#160;&#160;&#160;&#160;Advaccine Territory</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule 1.39&#58;&#160;&#160;&#160;&#160;Global Phase 3 Study </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule 1.40&#58;&#160;&#160;&#160;&#160;Global Phase 3 Study Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A&#58;&#160;&#160;&#160;&#160;Inovio Licensed Patents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B&#58;&#160;&#160;&#160;&#160;Inovio Licensed Know-How </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule 1.4</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Advaccine Territory </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.923%"><tr><td style="width:1.0%"></td><td style="width:32.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #9cc2e5;border-left:0.25pt solid #bdd6ee;border-top:0.25pt solid #bdd6ee;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Kazakhstan</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Uzbekistan</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Turkmenistan</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Tajikistan</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Kyrgyz Republic</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Afghanistan</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Mongolia</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Bangladesh</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.5pt">Sri Lanka</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.95pt">Nepal</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.95pt">Maldives</font></div><div style="margin-bottom:0.12pt;padding-left:15.55pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.95pt">Bhutan</font></div></td><td colspan="3" style="border-bottom:1pt solid #9cc2e5;border-left:0.25pt solid #bdd6ee;border-top:0.25pt solid #bdd6ee;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.36pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;13.  Indonesia</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14. Thailand</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15. Philippines</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16. Vietnam</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17. Singapore</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18. Malaysia</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19. Myanmar</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20. Cambodia</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21. Laos</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22. Brunei</font></div><div style="padding-left:20.07pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23. Timor-Leste</font></div></td><td colspan="3" style="border-bottom:1pt solid #9cc2e5;border-left:0.25pt solid #bdd6ee;border-right:0.25pt solid #bdd6ee;border-top:0.25pt solid #bdd6ee;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;24. Iraq</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25. Jordan</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26. Azerbaijan</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27. Cyprus</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28. Yemen</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29. Lebanon</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">30. Georgia</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">31. Armenia</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">32. Pakistan</font></div><div style="padding-left:22.32pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">33. Turkey</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule 1.39</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Phase 3 Study</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Schedule 1.40</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Phase 3 Study Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Patents</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr style="height:13pt"><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="15" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="15" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-left:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td></tr><tr><td colspan="21" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;border-left:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inovio Licensed Know-How</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ino-63021x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iea46eb59f70e4860b53a661f85fdd999_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, J. Joseph Kim, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:5pt;margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ino-63021x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4ea0c093ea964092a91352c1aad98501_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:9pt;padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ino-63021x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i151971b998b0430bb99bec20f3b75f05_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending June&#160;30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ino-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:685d0eaa-cf71-473e-b825-35e9cdd023e3,g:d59d2343-5bf4-47b2-b6cf-d3f10d74095a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.inovio.com/role/OrganizationandOperations">
        <link:definition>2101101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertainties" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties">
        <link:definition>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies">
        <link:definition>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesDetails" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>2105103 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPoliciesDetails" roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Critical Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactofRecentlyIssuedAccountingStandards" roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards">
        <link:definition>2107104 - Disclosure - Impact of Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>2108105 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionDetails">
        <link:definition>2409403 - Disclosure - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestments" roleURI="http://www.inovio.com/role/ShorttermInvestments">
        <link:definition>2110106 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables">
        <link:definition>2311301 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails">
        <link:definition>2412404 - Disclosure - Short-term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.inovio.com/role/FairValueMeasurements">
        <link:definition>2114107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.inovio.com/role/FairValueMeasurementsTables">
        <link:definition>2315302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2417407 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>2118108 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2319303 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
        <link:definition>2420408 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2421409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>2122109 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2323304 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2424410 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
        <link:definition>2425411 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>2426412 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2127110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2328305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
        <link:definition>2429413 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2430414 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.inovio.com/role/NetLossPerShare">
        <link:definition>2131111 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>2332306 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
        <link:definition>2433415 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>2134112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>2335307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationDetails">
        <link:definition>2436416 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2137113 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2438417 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.inovio.com/role/Leases">
        <link:definition>2139114 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.inovio.com/role/LeasesTables">
        <link:definition>2340308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.inovio.com/role/LeasesNarrativeDetails">
        <link:definition>2441418 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails">
        <link:definition>2442419 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2143115 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2444420 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2145116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>2146117 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>2347309 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>2448421 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDeconsolidationAccountingDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails">
        <link:definition>2449422 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncInvestmentInGeneosDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails">
        <link:definition>2450423 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncFairValueAssumptionsDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails">
        <link:definition>2451424 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredstockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails">
        <link:definition>2452425 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_AnnualMaintenancePeriod" abstract="false" name="AnnualMaintenancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RelatedPartyTransactionsTextualAbstract" abstract="true" name="RelatedPartyTransactionsTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" abstract="true" name="MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GrantPolicyPolicyTextBlock" abstract="false" name="GrantPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementForeignNonIncomeTaxes" abstract="false" name="CollaborativeAgreementForeignNonIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OtherCounterpartyMember" abstract="true" name="OtherCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementPaymentEarned" abstract="false" name="CollaborationAgreementPaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_December2019ConvertibleBondsMember" abstract="true" name="December2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CELLECTRA2000DeviceMember" abstract="true" name="CELLECTRA2000DeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAdvisoryFees" abstract="false" name="CollaborativeAgreementAdvisoryFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ConvertibleBondsMember" abstract="true" name="ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_AlternativeInvestmentMeasurementInputTerm" abstract="false" name="AlternativeInvestmentMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_WorkingCapitalExcludingCash" abstract="false" name="WorkingCapitalExcludingCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateNoncurrent" abstract="false" name="DeferredGrantFundingFromAffiliateNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OperatingLeaseNonCashLeaseExpense" abstract="false" name="OperatingLeaseNonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" abstract="false" name="LesseeOperatingLeaseNumberOfAgreementsToSublease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" abstract="false" name="SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NewSalesAgreementMember" abstract="true" name="NewSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromCollaborativeAgreement" abstract="false" name="ProceedsFromCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PriorSalesAgreementMember" abstract="true" name="PriorSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementTerritoryExpansionOptionPeriod" abstract="false" name="CollaborationAgreementTerritoryExpansionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LicensewithAffiliatedEntitiesMember" abstract="true" name="LicensewithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" abstract="false" name="IncreaseDecreaseInDeferredRevenueFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SalesAgreementsMember" abstract="true" name="SalesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_August2019ConvertibleBondsMember" abstract="true" name="August2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentAccruedInterest" abstract="false" name="DebtInstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_InitialConversionPriceMember" abstract="true" name="InitialConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementCorporateIncomeTax" abstract="false" name="CollaborativeAgreementCorporateIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EquityMethodInvestmentEnterpriseValue" abstract="false" name="EquityMethodInvestmentEnterpriseValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ino-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:685d0eaa-cf71-473e-b825-35e9cdd023e3,g:d59d2343-5bf4-47b2-b6cf-d3f10d74095a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e1b3499-f289-4b23-911d-6d3766452035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eb590e6f-9459-443c-b9b7-56b3ececacc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e1b3499-f289-4b23-911d-6d3766452035" xlink:to="loc_us-gaap_PreferredStockValue_eb590e6f-9459-443c-b9b7-56b3ececacc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_09128be0-c8f7-4a4c-bfbf-6431c721dcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e1b3499-f289-4b23-911d-6d3766452035" xlink:to="loc_us-gaap_CommonStockValue_09128be0-c8f7-4a4c-bfbf-6431c721dcb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c7c92ae3-9f38-4d75-9e05-ba6fbcfed944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e1b3499-f289-4b23-911d-6d3766452035" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c7c92ae3-9f38-4d75-9e05-ba6fbcfed944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1cd32252-5ff3-465f-9f89-f96705a93aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e1b3499-f289-4b23-911d-6d3766452035" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1cd32252-5ff3-465f-9f89-f96705a93aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_12732ba7-c238-4dcb-b722-6729bb814ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9e1b3499-f289-4b23-911d-6d3766452035" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_12732ba7-c238-4dcb-b722-6729bb814ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_01560ee2-326e-4dd6-9a27-acba20a4adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_AssetsCurrent_01560ee2-326e-4dd6-9a27-acba20a4adc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff783bad-1780-4356-9666-d2db4c01d3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff783bad-1780-4356-9666-d2db4c01d3df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8df3b020-a3d3-45d4-b268-46e0ba5a6e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_EquityMethodInvestments_8df3b020-a3d3-45d4-b268-46e0ba5a6e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e4ebb124-8ee8-43e0-a148-4377b73f1ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e4ebb124-8ee8-43e0-a148-4377b73f1ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e1fdea08-3b13-4ca2-b5d8-6a496f5fa8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_e1fdea08-3b13-4ca2-b5d8-6a496f5fa8dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_465c50c5-040c-49c3-a5ae-61aa3c5115fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_465c50c5-040c-49c3-a5ae-61aa3c5115fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ba90944f-bdd4-45fb-bc05-16dcb6f1e2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_Goodwill_ba90944f-bdd4-45fb-bc05-16dcb6f1e2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_711d8b87-53d9-4808-84c4-560ea7cfac63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_482bbfc3-5740-454d-9eed-0b4ba43df2f1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_711d8b87-53d9-4808-84c4-560ea7cfac63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4ab3db7-fd83-41be-ac11-f404230fbfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b3f4de78-7480-4a97-8c4a-57ecb2b08bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4ab3db7-fd83-41be-ac11-f404230fbfb1" xlink:to="loc_us-gaap_Liabilities_b3f4de78-7480-4a97-8c4a-57ecb2b08bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_841045f8-f754-4cd8-b191-807edc28a24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4ab3db7-fd83-41be-ac11-f404230fbfb1" xlink:to="loc_us-gaap_StockholdersEquity_841045f8-f754-4cd8-b191-807edc28a24b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d7d174bf-ab0d-41c3-a219-d96db23550d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfa5e51d-1d70-4785-bbbd-b96487dc5e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7d174bf-ab0d-41c3-a219-d96db23550d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cfa5e51d-1d70-4785-bbbd-b96487dc5e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f36ea3ac-19b3-4449-bcdb-c9f1f40373e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7d174bf-ab0d-41c3-a219-d96db23550d4" xlink:to="loc_us-gaap_ShortTermInvestments_f36ea3ac-19b3-4449-bcdb-c9f1f40373e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_816f01e1-943e-4703-9b22-44f1899f1944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7d174bf-ab0d-41c3-a219-d96db23550d4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_816f01e1-943e-4703-9b22-44f1899f1944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_c1f7f673-8e68-49e2-9392-98d6c882ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7d174bf-ab0d-41c3-a219-d96db23550d4" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_c1f7f673-8e68-49e2-9392-98d6c882ed63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a460708-0a68-47d7-86c9-3152eb3deb76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7d174bf-ab0d-41c3-a219-d96db23550d4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a460708-0a68-47d7-86c9-3152eb3deb76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_c607b351-7105-480b-916f-c6669b0a5a65" xlink:href="ino-20210630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7d174bf-ab0d-41c3-a219-d96db23550d4" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_c607b351-7105-480b-916f-c6669b0a5a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b7132d2a-39b9-4bf8-86b7-ca8da6c0ccdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b7132d2a-39b9-4bf8-86b7-ca8da6c0ccdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_d3853334-c9e6-4304-92d4-1b8f1664dced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_d3853334-c9e6-4304-92d4-1b8f1664dced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_04b2a4d9-5c28-41c9-8077-c4f3ee526eae" xlink:href="ino-20210630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_04b2a4d9-5c28-41c9-8077-c4f3ee526eae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e013a3b7-0c49-47db-b40a-f0044043bedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e013a3b7-0c49-47db-b40a-f0044043bedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a25b0536-c085-4b64-97e8-704808635bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a25b0536-c085-4b64-97e8-704808635bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_4b3438e4-9751-4889-9d1b-c1ef075f3bbd" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:to="loc_ino_DeferredGrantFundingCurrent_4b3438e4-9751-4889-9d1b-c1ef075f3bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_ab39139b-0a4e-4cc2-b1e1-70b666bb9016" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_70c88e91-5012-44a4-87b3-477147a726fd" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_ab39139b-0a4e-4cc2-b1e1-70b666bb9016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cff59fcb-57a8-4304-96ec-812b705345e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:to="loc_us-gaap_LiabilitiesCurrent_cff59fcb-57a8-4304-96ec-812b705345e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_dbcc9c98-1f06-425d-b2a0-dfe2b94f4a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_dbcc9c98-1f06-425d-b2a0-dfe2b94f4a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_e33f234e-8d94-4a70-a9ad-2154b2ef2ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:to="loc_us-gaap_ConvertibleDebt_e33f234e-8d94-4a70-a9ad-2154b2ef2ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7cc1c20f-8098-4d3b-b7b2-fece2eaa0a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7cc1c20f-8098-4d3b-b7b2-fece2eaa0a2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_99cd8b37-e643-4222-bf50-b1c6d8e2a0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_99cd8b37-e643-4222-bf50-b1c6d8e2a0df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_83c6ff88-c810-4587-ab5b-1163fe3a995c" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_83c6ff88-c810-4587-ab5b-1163fe3a995c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0290d964-e142-48fa-b572-5caf8f4293b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c96693e7-289b-4fa3-84e0-ecc1dc20536b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0290d964-e142-48fa-b572-5caf8f4293b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d85fe996-1b93-48da-892a-8861a30cef82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2614588-b659-4a90-b44a-cb3de2c5a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d85fe996-1b93-48da-892a-8861a30cef82" xlink:to="loc_us-gaap_ProfitLoss_f2614588-b659-4a90-b44a-cb3de2c5a5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c9e222a-869a-421f-a513-65c4ff2c7633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d85fe996-1b93-48da-892a-8861a30cef82" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c9e222a-869a-421f-a513-65c4ff2c7633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_875a8b1d-8413-4265-bd02-4b479e45db18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1cfe6d6a-975f-4d2b-b1e1-846047184127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_875a8b1d-8413-4265-bd02-4b479e45db18" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1cfe6d6a-975f-4d2b-b1e1-846047184127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14a4505d-4236-4651-97bc-e86593885325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_875a8b1d-8413-4265-bd02-4b479e45db18" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_14a4505d-4236-4651-97bc-e86593885325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d6c05533-5862-428e-849a-a8ac7c15a503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_us-gaap_OperatingIncomeLoss_d6c05533-5862-428e-849a-a8ac7c15a503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_7a6aa031-3edf-4cd9-b959-08ee369a8238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_us-gaap_InterestIncomeOperating_7a6aa031-3edf-4cd9-b959-08ee369a8238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_30e836a0-29ec-4b73-a217-beeca667ba31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_us-gaap_InterestExpense_30e836a0-29ec-4b73-a217-beeca667ba31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_f741d74d-d5a7-494e-91d5-9ccc7b7d7e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_f741d74d-d5a7-494e-91d5-9ccc7b7d7e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_f344735a-4222-4484-bcde-fd55a190c48e" xlink:href="ino-20210630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_f344735a-4222-4484-bcde-fd55a190c48e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fcfcb932-d934-48d1-99cb-42f20fdb164b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fcfcb932-d934-48d1-99cb-42f20fdb164b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2511ba31-83d7-48c9-b11c-9c7d4d9b9ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2511ba31-83d7-48c9-b11c-9c7d4d9b9ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_24216a1c-2c53-4d91-b794-b4a8bcb0fd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb4e3908-c0d6-43b1-9c24-66db890c8da4" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_24216a1c-2c53-4d91-b794-b4a8bcb0fd85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bc078c97-13ad-4e88-addf-80f478666d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0ad953e3-236e-4776-b638-fe848910cb67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bc078c97-13ad-4e88-addf-80f478666d41" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0ad953e3-236e-4776-b638-fe848910cb67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7b1e3edf-f4f0-4044-90d8-052b6d848408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_bc078c97-13ad-4e88-addf-80f478666d41" xlink:to="loc_us-gaap_OperatingExpenses_7b1e3edf-f4f0-4044-90d8-052b6d848408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_28d7aacf-95ee-4b3d-95a4-13b81c840b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_265147c4-c1d4-437c-9cfb-469f4f5aba5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_28d7aacf-95ee-4b3d-95a4-13b81c840b60" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_265147c4-c1d4-437c-9cfb-469f4f5aba5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2de95582-c15d-4f8d-92b0-34b5a275c6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_28d7aacf-95ee-4b3d-95a4-13b81c840b60" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2de95582-c15d-4f8d-92b0-34b5a275c6c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f8b23cfc-ca9d-409f-9925-65f46bf421d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a075002e-2d88-4f99-873c-df22aff5f17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f8b23cfc-ca9d-409f-9925-65f46bf421d1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a075002e-2d88-4f99-873c-df22aff5f17f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8688f2a0-1493-4c25-b599-a2c697a543ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f8b23cfc-ca9d-409f-9925-65f46bf421d1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8688f2a0-1493-4c25-b599-a2c697a543ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_01bd8373-8b1d-4592-b31e-44467f36e439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_17603b4d-c01d-479f-962f-54d1353ca6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_01bd8373-8b1d-4592-b31e-44467f36e439" xlink:to="loc_us-gaap_ProfitLoss_17603b4d-c01d-479f-962f-54d1353ca6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8073672f-7519-456a-9940-dad983f864db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_01bd8373-8b1d-4592-b31e-44467f36e439" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8073672f-7519-456a-9940-dad983f864db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_47d280e0-f43f-4287-bc62-97839ea4a2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_01bd8373-8b1d-4592-b31e-44467f36e439" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_47d280e0-f43f-4287-bc62-97839ea4a2d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_faecb0f6-d554-4d67-a6e3-11728d750ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48d7bc75-ed7f-4f88-9679-52bb6438b4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_faecb0f6-d554-4d67-a6e3-11728d750ffe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48d7bc75-ed7f-4f88-9679-52bb6438b4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bcee9898-30c7-4f88-97b4-95e38be8a38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_faecb0f6-d554-4d67-a6e3-11728d750ffe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bcee9898-30c7-4f88-97b4-95e38be8a38a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d87fe111-f7e5-4147-a867-2eaf9edf0b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_faecb0f6-d554-4d67-a6e3-11728d750ffe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d87fe111-f7e5-4147-a867-2eaf9edf0b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28d6da36-b74d-43db-9455-8466807c4866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_faecb0f6-d554-4d67-a6e3-11728d750ffe" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_28d6da36-b74d-43db-9455-8466807c4866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a54c8d53-a026-453e-aec3-ab14d5ebe795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_be53c149-a6f1-4b94-b6ef-a55a1b3dceca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a54c8d53-a026-453e-aec3-ab14d5ebe795" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_be53c149-a6f1-4b94-b6ef-a55a1b3dceca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_1133c73d-b795-45ca-aeb9-3fa037841631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a54c8d53-a026-453e-aec3-ab14d5ebe795" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_1133c73d-b795-45ca-aeb9-3fa037841631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_daec42a0-bdad-4392-9a7b-35573bac051d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a54c8d53-a026-453e-aec3-ab14d5ebe795" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_daec42a0-bdad-4392-9a7b-35573bac051d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c0770f48-04f6-4fea-bd93-5250647f80d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a54c8d53-a026-453e-aec3-ab14d5ebe795" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c0770f48-04f6-4fea-bd93-5250647f80d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_22794dcd-eeae-49d8-b98d-45bd7d09234a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a54c8d53-a026-453e-aec3-ab14d5ebe795" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_22794dcd-eeae-49d8-b98d-45bd7d09234a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_27eaadbc-5803-4b20-803a-661556f9bba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_27eaadbc-5803-4b20-803a-661556f9bba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_0991be32-8781-4a47-893a-beab829f8a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_0991be32-8781-4a47-893a-beab829f8a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_e33f7df2-221c-4cf9-8482-1103aeddb922" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_e33f7df2-221c-4cf9-8482-1103aeddb922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_994ca3b8-178f-4f6d-af67-101d7bc3aa82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_ShareBasedCompensation_994ca3b8-178f-4f6d-af67-101d7bc3aa82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ac043055-d82b-45c3-a47a-e43a421d3e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ac043055-d82b-45c3-a47a-e43a421d3e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_5332441e-4a19-4ecd-8e36-6a2dfededaa2" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_5332441e-4a19-4ecd-8e36-6a2dfededaa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_fc766b6d-2cc8-4fca-a311-392bf9e4e449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_fc766b6d-2cc8-4fca-a311-392bf9e4e449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_eb7836f8-2586-40be-a71e-a3faeeef3d66" xlink:href="ino-20210630.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_eb7836f8-2586-40be-a71e-a3faeeef3d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_2cd24d18-e3a2-4cf7-b514-01557a6bfa00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_2cd24d18-e3a2-4cf7-b514-01557a6bfa00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_90c0161e-dcd0-419e-93d5-3fa9ae37444a" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_90c0161e-dcd0-419e-93d5-3fa9ae37444a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_d9e7a030-a11e-487d-a342-22d92d33bd1f" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_d9e7a030-a11e-487d-a342-22d92d33bd1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_42f51f63-e33e-40a2-94d2-3d9b91503b42" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_42f51f63-e33e-40a2-94d2-3d9b91503b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a709f29-b058-4f17-8e43-42583d64a3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9a709f29-b058-4f17-8e43-42583d64a3f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_fc840d84-c829-4dee-9775-1ddfd93ebb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_fc840d84-c829-4dee-9775-1ddfd93ebb87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_44ca6ba2-9ebc-4908-8c0f-f41318327566" xlink:href="ino-20210630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_44ca6ba2-9ebc-4908-8c0f-f41318327566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34a481a6-483c-4cff-9552-d6370de9b906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_34a481a6-483c-4cff-9552-d6370de9b906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_5b86be65-e4e3-44b9-80ce-cd813c1e4f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_GainLossOnInvestments_5b86be65-e4e3-44b9-80ce-cd813c1e4f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1a369eaf-c43d-4d9c-80fe-802aa4248249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1a369eaf-c43d-4d9c-80fe-802aa4248249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_006a45d7-9abd-4288-9946-e6e5b59f2930" xlink:href="ino-20210630.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_NonCashInterestIncomeExpense_006a45d7-9abd-4288-9946-e6e5b59f2930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_461af797-f027-444d-a8cb-5eadaf9ae16a" xlink:href="ino-20210630.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_461af797-f027-444d-a8cb-5eadaf9ae16a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c6c3025f-aa0c-4e57-9036-8ec4dd726093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_ProfitLoss_c6c3025f-aa0c-4e57-9036-8ec4dd726093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c990601a-1592-4670-a187-d29f1445a89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_c990601a-1592-4670-a187-d29f1445a89e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_389f6262-1f21-4c48-b850-5043bf5464c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_Depreciation_389f6262-1f21-4c48-b850-5043bf5464c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_fd41f6ad-9186-4b61-bdf6-ac9ea4d7b320" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_fd41f6ad-9186-4b61-bdf6-ac9ea4d7b320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a05d82d-ebd5-410d-a6ea-1b8ba17c916f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="25" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a05d82d-ebd5-410d-a6ea-1b8ba17c916f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_97667d28-3c1b-4335-b33c-3664b7b68164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="26" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_97667d28-3c1b-4335-b33c-3664b7b68164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_bcc71356-d3e3-4500-88c9-cc6bdb1bb0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="27" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_bcc71356-d3e3-4500-88c9-cc6bdb1bb0b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aded55d1-7dc2-4ac3-847f-9b64eec49705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="28" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bdb750e0-7a8b-4523-8395-b4fa5a472119" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_aded55d1-7dc2-4ac3-847f-9b64eec49705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a62499-a91a-403a-aeca-8eacb99a036d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_48c0afa2-aa32-4e73-a9b7-24e598691c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a62499-a91a-403a-aeca-8eacb99a036d" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_48c0afa2-aa32-4e73-a9b7-24e598691c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_135eff66-ab3a-45ab-9fde-cd8b9c4d1467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a62499-a91a-403a-aeca-8eacb99a036d" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_135eff66-ab3a-45ab-9fde-cd8b9c4d1467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_5cbc9f38-70d7-481b-95d5-471c6c3c0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a62499-a91a-403a-aeca-8eacb99a036d" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_5cbc9f38-70d7-481b-95d5-471c6c3c0a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8952094c-5a84-45de-a561-7631d198df4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_85a62499-a91a-403a-aeca-8eacb99a036d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8952094c-5a84-45de-a561-7631d198df4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2c08ea4-4076-467c-9119-e5646431c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_03ce13d7-1002-450f-a234-55817384239a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2c08ea4-4076-467c-9119-e5646431c7ba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_03ce13d7-1002-450f-a234-55817384239a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62a8dc89-4f0b-4136-b6ca-b003b8676de8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2c08ea4-4076-467c-9119-e5646431c7ba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62a8dc89-4f0b-4136-b6ca-b003b8676de8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b02362d7-a1ff-42ed-b060-ce110fd0c823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f2c08ea4-4076-467c-9119-e5646431c7ba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b02362d7-a1ff-42ed-b060-ce110fd0c823" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ad1bdc28-a82d-4468-8706-bbd91d141478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_69954ca1-2d27-41b9-b7ae-8447608e8b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ad1bdc28-a82d-4468-8706-bbd91d141478" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_69954ca1-2d27-41b9-b7ae-8447608e8b83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a91a82cd-194a-4974-91c9-a3cc79168245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ad1bdc28-a82d-4468-8706-bbd91d141478" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a91a82cd-194a-4974-91c9-a3cc79168245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_0e01bdc6-9875-4f37-a1c7-cf6f50ec8676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ad1bdc28-a82d-4468-8706-bbd91d141478" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_0e01bdc6-9875-4f37-a1c7-cf6f50ec8676" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bf03535a-0732-4fd6-9309-f4aa579dd0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_a8a35e5e-c024-4638-9c16-373574d41240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_bf03535a-0732-4fd6-9309-f4aa579dd0ff" xlink:to="loc_us-gaap_GoodwillGross_a8a35e5e-c024-4638-9c16-373574d41240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_154eebba-3bba-4f83-a1dc-26f69b666bc9" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_af0540dd-96f0-4175-9039-f844e931f83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_154eebba-3bba-4f83-a1dc-26f69b666bc9" xlink:to="loc_us-gaap_GoodwillGross_af0540dd-96f0-4175-9039-f844e931f83e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_86365e23-d444-4f34-9de4-9cfc63774e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_154eebba-3bba-4f83-a1dc-26f69b666bc9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_86365e23-d444-4f34-9de4-9cfc63774e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6bf3edc7-dee4-4ece-a5fa-4df45b05fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4e405591-7368-4f24-a1a0-efd3adb4f18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6bf3edc7-dee4-4ece-a5fa-4df45b05fa62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4e405591-7368-4f24-a1a0-efd3adb4f18a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_432f29fe-063e-4464-874e-8db79ba8510d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6bf3edc7-dee4-4ece-a5fa-4df45b05fa62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_432f29fe-063e-4464-874e-8db79ba8510d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_207d9eb9-83b7-4848-9b06-5dbb896da1df" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aef9d8d9-fece-4dd1-921c-0b3bf08eaeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_207d9eb9-83b7-4848-9b06-5dbb896da1df" xlink:to="loc_us-gaap_Goodwill_aef9d8d9-fece-4dd1-921c-0b3bf08eaeaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cddd9bd-6dc5-471f-a277-0ce825549751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_207d9eb9-83b7-4848-9b06-5dbb896da1df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7cddd9bd-6dc5-471f-a277-0ce825549751" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a06d74c6-0ec6-408d-978d-ced5687772e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d967a020-f5b4-4701-af6b-c93d2967b5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a06d74c6-0ec6-408d-978d-ced5687772e7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d967a020-f5b4-4701-af6b-c93d2967b5d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a962fcd7-70f8-4aa6-af59-1aa9c30ad96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a06d74c6-0ec6-408d-978d-ced5687772e7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a962fcd7-70f8-4aa6-af59-1aa9c30ad96b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_858a54a6-634d-4990-b8a1-a1d864f1ce0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a06d74c6-0ec6-408d-978d-ced5687772e7" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_858a54a6-634d-4990-b8a1-a1d864f1ce0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_69e96ee3-76bc-4658-b5e1-2a7319e5b7d5" xlink:href="ino-20210630.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a06d74c6-0ec6-408d-978d-ced5687772e7" xlink:to="loc_ino_DebtInstrumentAccruedInterest_69e96ee3-76bc-4658-b5e1-2a7319e5b7d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_76ba2caa-5511-4b69-b7be-ab78edfc4f8f" xlink:href="ino-20210630.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a06d74c6-0ec6-408d-978d-ced5687772e7" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_76ba2caa-5511-4b69-b7be-ab78edfc4f8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_09c8a965-c98d-4dd4-9d64-49a8e2c897bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a05f0f61-1ab4-4086-a939-a16289ce067a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_09c8a965-c98d-4dd4-9d64-49a8e2c897bf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a05f0f61-1ab4-4086-a939-a16289ce067a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_99844990-cb23-4273-8226-2e3171ae1ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_09c8a965-c98d-4dd4-9d64-49a8e2c897bf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_99844990-cb23-4273-8226-2e3171ae1ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bc03de9a-e662-4de2-86cd-f43740bc8092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_09c8a965-c98d-4dd4-9d64-49a8e2c897bf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_bc03de9a-e662-4de2-86cd-f43740bc8092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a83ae585-7aae-4f06-9f3c-3d4cd292235a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_09c8a965-c98d-4dd4-9d64-49a8e2c897bf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a83ae585-7aae-4f06-9f3c-3d4cd292235a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4025c395-2ff4-4d41-8c7b-59043a4f72f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8a4a0108-3e39-4a67-bd8f-276e4fc1fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4025c395-2ff4-4d41-8c7b-59043a4f72f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8a4a0108-3e39-4a67-bd8f-276e4fc1fbd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_553349f6-7189-4172-b0eb-7e03e39341a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4025c395-2ff4-4d41-8c7b-59043a4f72f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_553349f6-7189-4172-b0eb-7e03e39341a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e946fc3a-a586-4972-ba53-9572d5298c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4025c395-2ff4-4d41-8c7b-59043a4f72f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e946fc3a-a586-4972-ba53-9572d5298c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a94aa578-8c7d-4661-8db9-a2d956f40c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4025c395-2ff4-4d41-8c7b-59043a4f72f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a94aa578-8c7d-4661-8db9-a2d956f40c11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3612cbf3-9315-45d6-b3b2-d47896ab35f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4025c395-2ff4-4d41-8c7b-59043a4f72f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3612cbf3-9315-45d6-b3b2-d47896ab35f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_736c7038-68da-441c-8789-3fb1921a4ece" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4025c395-2ff4-4d41-8c7b-59043a4f72f7" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_736c7038-68da-441c-8789-3fb1921a4ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0da664b1-8163-4185-be72-49ff2ebf5955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6397913a-4952-454e-ae06-6b138eb5d1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0da664b1-8163-4185-be72-49ff2ebf5955" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6397913a-4952-454e-ae06-6b138eb5d1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a612064-1cfe-4a71-996d-ca33d5c306cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0da664b1-8163-4185-be72-49ff2ebf5955" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a612064-1cfe-4a71-996d-ca33d5c306cd" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ino-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:685d0eaa-cf71-473e-b825-35e9cdd023e3,g:d59d2343-5bf4-47b2-b6cf-d3f10d74095a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i08460811205c43618dd87a6076365e54_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:to="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d7d4be45-9e16-4ac4-a483-4e21f868a6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d7d4be45-9e16-4ac4-a483-4e21f868a6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_04219f29-06f0-4963-8118-5cf6d154761f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_ShortTermInvestments_04219f29-06f0-4963-8118-5cf6d154761f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6559b7fd-da45-42cb-aae3-79a54e097e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6559b7fd-da45-42cb-aae3-79a54e097e84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_12e3f8b6-d371-4336-9475-a69e2bd3fe6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_12e3f8b6-d371-4336-9475-a69e2bd3fe6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_580c37fc-5427-42eb-ae02-2e1f7048fb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_580c37fc-5427-42eb-ae02-2e1f7048fb4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_9e510500-de01-4ba8-91ae-da525674b549" xlink:href="ino-20210630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_9e510500-de01-4ba8-91ae-da525674b549" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4471965a-7da4-4934-b778-9a566953e595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_AssetsCurrent_4471965a-7da4-4934-b778-9a566953e595" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_23813849-9303-4b80-b4ef-8c1d4b7a5b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_23813849-9303-4b80-b4ef-8c1d4b7a5b3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_130fe1b4-5c9c-4ef0-9a76-17921d51ad48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_130fe1b4-5c9c-4ef0-9a76-17921d51ad48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0de0c707-3d35-4513-afbb-55be78a0ccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_EquityMethodInvestments_0de0c707-3d35-4513-afbb-55be78a0ccb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9fab2c42-c720-42f9-a882-1c6c770848de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9fab2c42-c720-42f9-a882-1c6c770848de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73ea3b96-bc7e-44a0-8884-a1043251332b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_Goodwill_73ea3b96-bc7e-44a0-8884-a1043251332b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff730d23-4239-4087-8601-f1d7be9e5136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff730d23-4239-4087-8601-f1d7be9e5136" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d0f7454f-ccb4-44f2-a3b9-fc58acb3f55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d0f7454f-ccb4-44f2-a3b9-fc58acb3f55f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_85532af5-e482-46ee-9b12-18dbba6550e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_Assets_85532af5-e482-46ee-9b12-18dbba6550e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_59e59e88-279a-4641-8095-7ee2e420c936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_59e59e88-279a-4641-8095-7ee2e420c936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_8d693189-3af0-4114-9bfc-4342ee52c3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_8d693189-3af0-4114-9bfc-4342ee52c3dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_50c53a7c-fdd6-4981-9b95-c054780cb56e" xlink:href="ino-20210630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_50c53a7c-fdd6-4981-9b95-c054780cb56e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f0c2342d-5c54-4245-9c70-462b384c656b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f0c2342d-5c54-4245-9c70-462b384c656b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bec9206b-8db2-4ca5-b18e-ee157b8d983a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bec9206b-8db2-4ca5-b18e-ee157b8d983a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_8f0b013c-ac03-4ebd-9363-b4c66a6cd907" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_ino_DeferredGrantFundingCurrent_8f0b013c-ac03-4ebd-9363-b4c66a6cd907" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b19b9f2-c7ae-46f3-ac13-1f549a85d4c7" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b19b9f2-c7ae-46f3-ac13-1f549a85d4c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4fe9eaad-3790-4853-abab-6d49b5512b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_LiabilitiesCurrent_4fe9eaad-3790-4853-abab-6d49b5512b61" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19ba1058-63b8-4b94-a440-105c9434f314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19ba1058-63b8-4b94-a440-105c9434f314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_12d5039c-2c9b-4f7c-92df-44e001c76b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_ConvertibleDebt_12d5039c-2c9b-4f7c-92df-44e001c76b88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95c83e40-1aec-41e6-bd8b-60abe9f9c3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95c83e40-1aec-41e6-bd8b-60abe9f9c3fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_19e8b065-2da9-4249-8fd7-ee4ccbb337b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_19e8b065-2da9-4249-8fd7-ee4ccbb337b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_0dd5a156-e8cf-4f67-9be5-3aa26479b3ec" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_0dd5a156-e8cf-4f67-9be5-3aa26479b3ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_22d8b13f-d35b-4e94-bb3e-c63d96d3fab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_22d8b13f-d35b-4e94-bb3e-c63d96d3fab6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6a6acb06-3df7-4754-a177-b5fe2ab28d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_Liabilities_6a6acb06-3df7-4754-a177-b5fe2ab28d00" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_43b23d5c-47da-40fb-b3ea-2f04635bd7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_PreferredStockValue_43b23d5c-47da-40fb-b3ea-2f04635bd7d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bbf4505b-c1c2-4cb1-9ce3-fcdf55e40c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_CommonStockValue_bbf4505b-c1c2-4cb1-9ce3-fcdf55e40c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ccf6f0ee-9f46-46b7-83b6-d7b473f5c934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ccf6f0ee-9f46-46b7-83b6-d7b473f5c934" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aff2d78b-5b0b-4255-8fbc-5df7e51428f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aff2d78b-5b0b-4255-8fbc-5df7e51428f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3bff190b-fbca-4857-92cb-3a1087b35182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3bff190b-fbca-4857-92cb-3a1087b35182" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7f17304-723e-4b58-90c9-87e7e7af0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_StockholdersEquity_a7f17304-723e-4b58-90c9-87e7e7af0a03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ccd7b337-8040-48d7-b08d-2689b09c1d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ccd7b337-8040-48d7-b08d-2689b09c1d3c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_116f7723-c1dc-4423-a74d-0fae997a870c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:to="loc_us-gaap_StatementTable_116f7723-c1dc-4423-a74d-0fae997a870c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60c58aff-f008-4a32-9c30-540a33fd5e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_116f7723-c1dc-4423-a74d-0fae997a870c" xlink:to="loc_us-gaap_DebtInstrumentAxis_60c58aff-f008-4a32-9c30-540a33fd5e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60c58aff-f008-4a32-9c30-540a33fd5e8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_60c58aff-f008-4a32-9c30-540a33fd5e8f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60c58aff-f008-4a32-9c30-540a33fd5e8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_60c58aff-f008-4a32-9c30-540a33fd5e8f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b0f668ad-6932-46be-a5bb-2f1eebe29f09" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b0f668ad-6932-46be-a5bb-2f1eebe29f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_4566b2d8-97c6-4e32-a192-4cb94d29e808" xlink:href="ino-20210630.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:to="loc_ino_ConvertibleBondsMember_4566b2d8-97c6-4e32-a192-4cb94d29e808" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i4a22388526bd408184a687abf60cd883_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_60ab4f32-1e2d-43e3-8563-3d213f6260d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_RevenuesAbstract_60ab4f32-1e2d-43e3-8563-3d213f6260d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_175574bf-735c-4299-a2bd-3ea136d5836f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_60ab4f32-1e2d-43e3-8563-3d213f6260d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_175574bf-735c-4299-a2bd-3ea136d5836f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d17ac5e6-4bfd-499f-86e7-13a0d998ffdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d17ac5e6-4bfd-499f-86e7-13a0d998ffdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eba5e24f-421e-4966-b6ac-288fbfa9bfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eba5e24f-421e-4966-b6ac-288fbfa9bfc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cdcd0394-813b-4130-afa3-646971053cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:to="loc_us-gaap_OperatingExpenses_cdcd0394-813b-4130-afa3-646971053cdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13e1b546-ae5b-4dfe-aae8-942b732f8b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_OperatingIncomeLoss_13e1b546-ae5b-4dfe-aae8-942b732f8b0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_1eada72f-73c7-4f2c-ab35-f5d5b61da204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_InterestIncomeOperating_1eada72f-73c7-4f2c-ab35-f5d5b61da204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b534d2d4-4350-4c50-b730-4a411b597f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_InterestExpense_b534d2d4-4350-4c50-b730-4a411b597f57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3e60e4ff-4bfd-45e8-93e0-832cc2a97c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3e60e4ff-4bfd-45e8-93e0-832cc2a97c5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0c59a079-7f2b-45cc-8694-dee5d4bdcb4f" xlink:href="ino-20210630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0c59a079-7f2b-45cc-8694-dee5d4bdcb4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e5e8b8e0-dd21-42b2-895b-6bc9fb46339b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e5e8b8e0-dd21-42b2-895b-6bc9fb46339b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_654fbb11-aaff-4fe1-97e0-0ed16a135d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_654fbb11-aaff-4fe1-97e0-0ed16a135d78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_4e2e160a-809b-4617-80df-f7601b157028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_4e2e160a-809b-4617-80df-f7601b157028" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_726be9cc-1ef7-4fe9-85d5-cbc76d4f3403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_726be9cc-1ef7-4fe9-85d5-cbc76d4f3403" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5486e652-c504-4e99-9cfe-e11dbf575691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5486e652-c504-4e99-9cfe-e11dbf575691" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6fa83cac-e637-4888-9aec-d733ce359d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_ProfitLoss_6fa83cac-e637-4888-9aec-d733ce359d3b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d588818c-d296-4112-9b59-37d032261214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d588818c-d296-4112-9b59-37d032261214" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1408bce-c516-44f0-b7a7-c3056b0c0a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_NetIncomeLoss_f1408bce-c516-44f0-b7a7-c3056b0c0a4c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6fd9be41-b921-4fbf-81a0-c4187f28d2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:to="loc_us-gaap_EarningsPerShareBasic_6fd9be41-b921-4fbf-81a0-c4187f28d2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b6ae5ea4-4787-418c-8128-a63e6baaee97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b6ae5ea4-4787-418c-8128-a63e6baaee97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e7cdc0cd-5118-4b5b-8764-d3973afa8206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e7cdc0cd-5118-4b5b-8764-d3973afa8206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab53487a-53ff-496a-9f4b-fdca095d610f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab53487a-53ff-496a-9f4b-fdca095d610f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_83ad7aa9-748e-4497-8f78-f28cd2644503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_StatementTable_83ad7aa9-748e-4497-8f78-f28cd2644503" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_934c86e1-9c0a-476c-a5a2-9c76ddd96c32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_83ad7aa9-748e-4497-8f78-f28cd2644503" xlink:to="loc_srt_ProductOrServiceAxis_934c86e1-9c0a-476c-a5a2-9c76ddd96c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_934c86e1-9c0a-476c-a5a2-9c76ddd96c32_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_934c86e1-9c0a-476c-a5a2-9c76ddd96c32" xlink:to="loc_srt_ProductsAndServicesDomain_934c86e1-9c0a-476c-a5a2-9c76ddd96c32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_934c86e1-9c0a-476c-a5a2-9c76ddd96c32" xlink:to="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c500ec6c-163f-499f-a263-b176ef8cbc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:to="loc_us-gaap_LicenseMember_c500ec6c-163f-499f-a263-b176ef8cbc0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_df5def49-fc9d-4997-b792-ef758bb88188" xlink:href="ino-20210630.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_df5def49-fc9d-4997-b792-ef758bb88188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_07f203fd-55d0-4126-98b4-f32568bc688f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_07f203fd-55d0-4126-98b4-f32568bc688f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i0df140f552be4fc08cd690107e6f50af_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ae3dcfa-21e9-4ece-a09f-9e42b505e95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ae3dcfa-21e9-4ece-a09f-9e42b505e95b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6405ead6-82ba-4524-8ef6-a2818c499abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_SharesIssued_6405ead6-82ba-4524-8ef6-a2818c499abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ee8bb6a-ae7e-4f06-8884-3b9c0898e492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ee8bb6a-ae7e-4f06-8884-3b9c0898e492" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_30cd06ec-c58e-440c-bfd6-1e1fad0fc81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_30cd06ec-c58e-440c-bfd6-1e1fad0fc81d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6bbc6387-5cab-432f-8e0b-13aa836e5333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6bbc6387-5cab-432f-8e0b-13aa836e5333" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410541c3-5d20-46da-8ac1-1d46e0afd076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410541c3-5d20-46da-8ac1-1d46e0afd076" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_82c859ed-6a0b-4743-b2bd-3ddf07388c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_82c859ed-6a0b-4743-b2bd-3ddf07388c6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bc429cd6-e7ef-4ead-87cb-b9a1071c7c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bc429cd6-e7ef-4ead-87cb-b9a1071c7c86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2b47230-ceed-456e-baa9-a8cf28af2227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2b47230-ceed-456e-baa9-a8cf28af2227" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ff7949-9ca9-4441-8739-340c93304918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ff7949-9ca9-4441-8739-340c93304918" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_6e4c32db-dc37-4efe-ba1d-c5fd158055ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_6e4c32db-dc37-4efe-ba1d-c5fd158055ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_7dcf4e73-83ec-41fc-932d-8d10c222513d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_7dcf4e73-83ec-41fc-932d-8d10c222513d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0011bc10-9f99-4b2f-a78b-5cb21803d3da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_ProfitLoss_0011bc10-9f99-4b2f-a78b-5cb21803d3da" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_75f562b2-61f9-4173-b2dc-e5efc739e723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_75f562b2-61f9-4173-b2dc-e5efc739e723" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c5f45d93-f11c-4710-b6bf-2782585585ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c5f45d93-f11c-4710-b6bf-2782585585ec" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5d2b270f-18c3-4302-91ad-9b577677709a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ceb251b-23b9-4148-91f1-4283e5431d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_95a34ef4-6340-40eb-aa33-612d1a24a79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2ae3dcfa-21e9-4ece-a09f-9e42b505e95b" xlink:to="loc_us-gaap_StatementTable_95a34ef4-6340-40eb-aa33-612d1a24a79b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14256e15-c75d-4586-a653-5a5b2d62e86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_95a34ef4-6340-40eb-aa33-612d1a24a79b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14256e15-c75d-4586-a653-5a5b2d62e86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14256e15-c75d-4586-a653-5a5b2d62e86c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14256e15-c75d-4586-a653-5a5b2d62e86c" xlink:to="loc_us-gaap_EquityComponentDomain_14256e15-c75d-4586-a653-5a5b2d62e86c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14256e15-c75d-4586-a653-5a5b2d62e86c" xlink:to="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_bb044665-264a-4e68-86f3-c2b615fb3cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_PreferredStockMember_bb044665-264a-4e68-86f3-c2b615fb3cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_071aeb6e-d70d-4f72-83b5-5566397b6925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_CommonStockMember_071aeb6e-d70d-4f72-83b5-5566397b6925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a0dfbef9-1a3e-4a9b-8e0e-d6f8b3698484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a0dfbef9-1a3e-4a9b-8e0e-d6f8b3698484" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_99555159-461c-4a8f-8d40-6bc687320a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_RetainedEarningsMember_99555159-461c-4a8f-8d40-6bc687320a22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5644a031-7927-45eb-be79-37d9e49a44c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5644a031-7927-45eb-be79-37d9e49a44c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_232869d3-f145-4043-b978-661c65623da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_232869d3-f145-4043-b978-661c65623da5" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended" id="i9620ffe013ce46519001384497146845_BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_968d8baf-8670-4c0f-b9b6-6f81414cc707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_NetIncomeLoss_968d8baf-8670-4c0f-b9b6-6f81414cc707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_b6a9cc47-9a3c-4fa4-a118-a9e8ab8c14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_Capital_b6a9cc47-9a3c-4fa4-a118-a9e8ab8c14bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cd50cd5e-fca2-419a-9838-1edaa4d4f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cd50cd5e-fca2-419a-9838-1edaa4d4f8ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2f9d7ec-a082-4f5c-a8ea-bf897e45a591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2f9d7ec-a082-4f5c-a8ea-bf897e45a591" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bb625267-1346-45cc-a922-be1a835957d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bb625267-1346-45cc-a922-be1a835957d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8b23673d-5ccf-4d02-a1de-2e9d1948792e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8b23673d-5ccf-4d02-a1de-2e9d1948792e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8b23673d-5ccf-4d02-a1de-2e9d1948792e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8b23673d-5ccf-4d02-a1de-2e9d1948792e" xlink:to="loc_us-gaap_ClassOfStockDomain_8b23673d-5ccf-4d02-a1de-2e9d1948792e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2d50c3f7-2d8c-4b43-a000-a1831f06d362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8b23673d-5ccf-4d02-a1de-2e9d1948792e" xlink:to="loc_us-gaap_ClassOfStockDomain_2d50c3f7-2d8c-4b43-a000-a1831f06d362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_928f625c-2775-4dc7-9e0e-2cc781d04c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2d50c3f7-2d8c-4b43-a000-a1831f06d362" xlink:to="loc_us-gaap_CommonStockMember_928f625c-2775-4dc7-9e0e-2cc781d04c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_6f06ad49-fe78-48fb-b359-6c0f208cf5cb" xlink:href="ino-20210630.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_6f06ad49-fe78-48fb-b359-6c0f208cf5cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_21d5da0d-5b9f-437b-8f08-7e62267c98c3" xlink:href="ino-20210630.xsd#ino_SalesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:to="loc_ino_SalesAgreementsMember_21d5da0d-5b9f-437b-8f08-7e62267c98c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#CriticalAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended" id="ie4f3fbd8c76f4965a9206b2ac33642b6_CriticalAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ad7ee67a-91eb-48e3-ac8d-fc1612111ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ad7ee67a-91eb-48e3-ac8d-fc1612111ac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_49eb7bf5-7654-4e81-b435-61e0bbb377ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_49eb7bf5-7654-4e81-b435-61e0bbb377ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11217b88-dc3a-464a-ac21-30acf8940ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11217b88-dc3a-464a-ac21-30acf8940ecd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a2c3d16-b6b5-4208-a2b5-0983fc447e18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11217b88-dc3a-464a-ac21-30acf8940ecd" xlink:to="loc_srt_RangeAxis_9a2c3d16-b6b5-4208-a2b5-0983fc447e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a2c3d16-b6b5-4208-a2b5-0983fc447e18_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9a2c3d16-b6b5-4208-a2b5-0983fc447e18" xlink:to="loc_srt_RangeMember_9a2c3d16-b6b5-4208-a2b5-0983fc447e18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9a2c3d16-b6b5-4208-a2b5-0983fc447e18" xlink:to="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed0983ff-1c0c-4731-b49b-5658c90d6268" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:to="loc_srt_MinimumMember_ed0983ff-1c0c-4731-b49b-5658c90d6268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_17f11015-b0cd-40ba-9205-8726a444cb1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:to="loc_srt_MaximumMember_17f11015-b0cd-40ba-9205-8726a444cb1b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#RevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended" id="i58f83f846a2644bcbaa92500f587a2ef_RevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bc62b38a-75da-454c-b1be-416e595687d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bc62b38a-75da-454c-b1be-416e595687d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f4c5c66-c057-484a-bcad-2f7765c5dfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f4c5c66-c057-484a-bcad-2f7765c5dfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ae3c6fc7-79cc-4ad7-a0a6-8155876b73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ae3c6fc7-79cc-4ad7-a0a6-8155876b73a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_148020b8-520a-4176-a62c-f776dac9119e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ae3c6fc7-79cc-4ad7-a0a6-8155876b73a3" xlink:to="loc_srt_CounterpartyNameAxis_148020b8-520a-4176-a62c-f776dac9119e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_148020b8-520a-4176-a62c-f776dac9119e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_148020b8-520a-4176-a62c-f776dac9119e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_148020b8-520a-4176-a62c-f776dac9119e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_148020b8-520a-4176-a62c-f776dac9119e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_74493d44-7008-43cb-8cdf-4806886ef3dc" xlink:href="ino-20210630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:to="loc_ino_PlumblineLifeSciencesMember_74493d44-7008-43cb-8cdf-4806886ef3dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_cefd4b19-c690-4363-baeb-4694f502254d" xlink:href="ino-20210630.xsd#ino_OtherCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:to="loc_ino_OtherCounterpartyMember_cefd4b19-c690-4363-baeb-4694f502254d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="ib4e94e5b5a114994934e950ee7b7b8f3_ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_75c900d0-ae21-474c-9bee-0354a30919e9" xlink:href="ino-20210630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_75c900d0-ae21-474c-9bee-0354a30919e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e770f919-4a08-43ee-b1f2-d6a4168c1d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e770f919-4a08-43ee-b1f2-d6a4168c1d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_772cf4b8-9146-4c75-89c9-f59263fb59ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_772cf4b8-9146-4c75-89c9-f59263fb59ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12e7ffd9-470c-4b58-85fd-07d643dc91d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12e7ffd9-470c-4b58-85fd-07d643dc91d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b9ad5b9-005e-409b-b921-3fdb793bf0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b9ad5b9-005e-409b-b921-3fdb793bf0c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d7a6e338-be5d-43e0-b27e-675feedd803f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d7a6e338-be5d-43e0-b27e-675feedd803f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3bf77d01-a202-4314-86d4-ac57864f23ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d7a6e338-be5d-43e0-b27e-675feedd803f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3bf77d01-a202-4314-86d4-ac57864f23ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3bf77d01-a202-4314-86d4-ac57864f23ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3bf77d01-a202-4314-86d4-ac57864f23ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3bf77d01-a202-4314-86d4-ac57864f23ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3bf77d01-a202-4314-86d4-ac57864f23ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_97252e20-2c0b-43ef-aad6-1c3adeb40d36" xlink:href="ino-20210630.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_ino_MutualFundsMember_97252e20-2c0b-43ef-aad6-1c3adeb40d36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_36f19def-7859-493b-ad29-ca81bd4656cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_36f19def-7859-493b-ad29-ca81bd4656cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4b0822e8-59a3-4507-a244-18c3a2079465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4b0822e8-59a3-4507-a244-18c3a2079465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_97bf7303-0245-4122-80ef-1807cc95c91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_97bf7303-0245-4122-80ef-1807cc95c91f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i9a70b0ef854b44e391d1385db1145535_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca6083c6-0943-4234-931c-2e2d177f6bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca6083c6-0943-4234-931c-2e2d177f6bff" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d941e680-8726-4922-8f5f-55ac57ab3b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d941e680-8726-4922-8f5f-55ac57ab3b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ec95de69-0ebe-4c23-b239-09caee13d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ec95de69-0ebe-4c23-b239-09caee13d46e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_da70bb9c-9f3f-49ef-a22a-572988941244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_da70bb9c-9f3f-49ef-a22a-572988941244" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e13dd803-8053-40dc-97d1-44a3518f7f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e13dd803-8053-40dc-97d1-44a3518f7f7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca6083c6-0943-4234-931c-2e2d177f6bff" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9d4be168-3707-42fc-8f3d-67c9e91ae8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9d4be168-3707-42fc-8f3d-67c9e91ae8d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d4be168-3707-42fc-8f3d-67c9e91ae8d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9d4be168-3707-42fc-8f3d-67c9e91ae8d4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d4be168-3707-42fc-8f3d-67c9e91ae8d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3785e8fb-183a-4881-8c48-011bac051e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9d4be168-3707-42fc-8f3d-67c9e91ae8d4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3785e8fb-183a-4881-8c48-011bac051e4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_020e5333-3757-4806-97ae-ac292851b27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3785e8fb-183a-4881-8c48-011bac051e4f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_020e5333-3757-4806-97ae-ac292851b27e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ae2ad3de-769f-46ab-8470-cfe713d092aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ae2ad3de-769f-46ab-8470-cfe713d092aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae2ad3de-769f-46ab-8470-cfe713d092aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ae2ad3de-769f-46ab-8470-cfe713d092aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae2ad3de-769f-46ab-8470-cfe713d092aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ae2ad3de-769f-46ab-8470-cfe713d092aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_8cb64d47-9e41-422c-bba9-d107f7ddba5e" xlink:href="ino-20210630.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_ino_MutualFundsMember_8cb64d47-9e41-422c-bba9-d107f7ddba5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_8cf2315b-3b38-439a-9783-3e916ed0fe4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_8cf2315b-3b38-439a-9783-3e916ed0fe4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e787388c-d8c1-459c-8e7c-6aa5956481b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e787388c-d8c1-459c-8e7c-6aa5956481b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_8136f735-c1e0-4aad-a5ce-077a95ea24ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_8136f735-c1e0-4aad-a5ce-077a95ea24ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_421471e8-bfdb-4dd1-a70a-71ebd9eeb0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_421471e8-bfdb-4dd1-a70a-71ebd9eeb0ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94d12c19-9474-48ef-8380-ec145729b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94d12c19-9474-48ef-8380-ec145729b40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1f95145b-2a4b-4d76-95ea-717c89d7c700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1f95145b-2a4b-4d76-95ea-717c89d7c700" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i92e60d6e665d40b684f55e1ecac44a7e_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e4dc1e73-e5bb-483a-90e8-28b11a428e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_d5f5bbf9-512b-43d6-9936-2b1f445895dc" xlink:href="ino-20210630.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e4dc1e73-e5bb-483a-90e8-28b11a428e18" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_d5f5bbf9-512b-43d6-9936-2b1f445895dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_46bd1eff-78fb-4d60-9491-10b2849ae0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_d5f5bbf9-512b-43d6-9936-2b1f445895dc" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_46bd1eff-78fb-4d60-9491-10b2849ae0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e4dc1e73-e5bb-483a-90e8-28b11a428e18" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e570ff87-180b-4b6a-b08c-7666ef95194e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e570ff87-180b-4b6a-b08c-7666ef95194e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e570ff87-180b-4b6a-b08c-7666ef95194e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e570ff87-180b-4b6a-b08c-7666ef95194e" xlink:to="loc_us-gaap_ClassOfStockDomain_e570ff87-180b-4b6a-b08c-7666ef95194e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_28b11c4a-cc20-4481-8d39-32919da85b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e570ff87-180b-4b6a-b08c-7666ef95194e" xlink:to="loc_us-gaap_ClassOfStockDomain_28b11c4a-cc20-4481-8d39-32919da85b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f30afde3-b901-42b2-bb5e-66731e0b3b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_28b11c4a-cc20-4481-8d39-32919da85b99" xlink:to="loc_us-gaap_CommonStockMember_f30afde3-b901-42b2-bb5e-66731e0b3b23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ade405a6-c0ae-4af3-9a43-82ea0a517bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ade405a6-c0ae-4af3-9a43-82ea0a517bb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ade405a6-c0ae-4af3-9a43-82ea0a517bb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ade405a6-c0ae-4af3-9a43-82ea0a517bb9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ade405a6-c0ae-4af3-9a43-82ea0a517bb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db9d123-bc21-4011-bd59-a002a451a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ade405a6-c0ae-4af3-9a43-82ea0a517bb9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db9d123-bc21-4011-bd59-a002a451a03c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4e5fbeda-640b-419c-a3f7-42c99ac47998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db9d123-bc21-4011-bd59-a002a451a03c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4e5fbeda-640b-419c-a3f7-42c99ac47998" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="i99183fade016471b9f03216ef57b050f_GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ea24c830-b961-4f97-b1e4-4a55d32bb60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ea24c830-b961-4f97-b1e4-4a55d32bb60d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_9eeec5a4-2ad0-4b30-a9af-397d995fb8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:to="loc_us-gaap_GoodwillGross_9eeec5a4-2ad0-4b30-a9af-397d995fb8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bd17e4f3-545c-464f-806d-4c87a4b9ae6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:to="loc_us-gaap_Goodwill_bd17e4f3-545c-464f-806d-4c87a4b9ae6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_307bb6ed-985e-486a-b1cf-9bf557b9382a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_307bb6ed-985e-486a-b1cf-9bf557b9382a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d914649-3af0-41ef-9d36-af1d0945fab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d914649-3af0-41ef-9d36-af1d0945fab7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_501eb59c-2336-408f-9bde-ba010828c689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_501eb59c-2336-408f-9bde-ba010828c689" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e85e4c6-60ab-4fa4-b5c8-282b7375faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e85e4c6-60ab-4fa4-b5c8-282b7375faf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_91b6775d-740e-47fa-8c11-5b03c22b9694" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_91b6775d-740e-47fa-8c11-5b03c22b9694" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_cac05e11-c2a9-4eb1-9de7-c7c9f44b017f" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_cac05e11-c2a9-4eb1-9de7-c7c9f44b017f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ea24c830-b961-4f97-b1e4-4a55d32bb60d" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13e0041c-e4f9-459e-997c-08df8e20f711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:to="loc_srt_RangeAxis_13e0041c-e4f9-459e-997c-08df8e20f711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13e0041c-e4f9-459e-997c-08df8e20f711_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13e0041c-e4f9-459e-997c-08df8e20f711" xlink:to="loc_srt_RangeMember_13e0041c-e4f9-459e-997c-08df8e20f711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47754f0d-6caa-4733-a772-0fabe3ea3e1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13e0041c-e4f9-459e-997c-08df8e20f711" xlink:to="loc_srt_RangeMember_47754f0d-6caa-4733-a772-0fabe3ea3e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_5b306c0d-3251-43fe-bfef-212f3d02ff1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_47754f0d-6caa-4733-a772-0fabe3ea3e1b" xlink:to="loc_srt_WeightedAverageMember_5b306c0d-3251-43fe-bfef-212f3d02ff1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2c576e8-62f6-4d51-b5be-aeda72f28d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2c576e8-62f6-4d51-b5be-aeda72f28d15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2c576e8-62f6-4d51-b5be-aeda72f28d15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2c576e8-62f6-4d51-b5be-aeda72f28d15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b2c576e8-62f6-4d51-b5be-aeda72f28d15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2c576e8-62f6-4d51-b5be-aeda72f28d15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_1bce2223-1917-4afe-934a-21cb3c979dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:to="loc_us-gaap_LicensingAgreementsMember_1bce2223-1917-4afe-934a-21cb3c979dea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_106e9220-5390-473e-8871-fd6739b5238f" xlink:href="ino-20210630.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:to="loc_ino_BiojectMember_106e9220-5390-473e-8871-fd6739b5238f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e0109645-5b2b-49f0-b5f4-e2473c627ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e0109645-5b2b-49f0-b5f4-e2473c627ec3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="i950076533c5e414f8c9df50e216646cc_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_56521b83-d889-44a2-852f-25c034c624d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_56521b83-d889-44a2-852f-25c034c624d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c57e28-3019-4e91-95de-942a9132f16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c57e28-3019-4e91-95de-942a9132f16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9065aee5-fa1f-40ff-be61-910a9e61df58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9065aee5-fa1f-40ff-be61-910a9e61df58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_aa4c629d-cfe4-413c-88e7-93c919bcf18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_aa4c629d-cfe4-413c-88e7-93c919bcf18d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5f9cf1b8-4f97-4e28-b1e9-47ab39f6b0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5f9cf1b8-4f97-4e28-b1e9-47ab39f6b0af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eafeae2a-8f57-4a91-82db-404774986a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eafeae2a-8f57-4a91-82db-404774986a3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_adda57d8-0a87-4c02-9e5c-a2a7b66cf3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_adda57d8-0a87-4c02-9e5c-a2a7b66cf3ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_e55a575a-8a8b-4c73-abfb-9fd9b4c11bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_e55a575a-8a8b-4c73-abfb-9fd9b4c11bc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d325d09e-d6f4-4516-9c67-3d909e2dbddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d325d09e-d6f4-4516-9c67-3d909e2dbddc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9ca2ac5f-7daf-40a0-ac85-1556f00f2672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9ca2ac5f-7daf-40a0-ac85-1556f00f2672" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_7654111a-91d4-4917-809f-b08ddbc1931f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_7654111a-91d4-4917-809f-b08ddbc1931f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_69a4abec-ee77-4346-a1ce-d231fe0f70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_69a4abec-ee77-4346-a1ce-d231fe0f70f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6ad34350-c018-478b-8cac-7f06f22fba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6ad34350-c018-478b-8cac-7f06f22fba4b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2d923de9-0fd3-48b0-8590-c6128e5164ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2d923de9-0fd3-48b0-8590-c6128e5164ec" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dac39901-723e-45d1-a56e-b8d2afa86995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dac39901-723e-45d1-a56e-b8d2afa86995" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6cdc9a59-881e-4dcd-a888-0d914b8d53b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6cdc9a59-881e-4dcd-a888-0d914b8d53b8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_679246d9-f8b3-4442-8f39-cd5e35058ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_679246d9-f8b3-4442-8f39-cd5e35058ac5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0f422179-0de7-4e62-a39f-70441dd98a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_InterestExpense_0f422179-0de7-4e62-a39f-70441dd98a73" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7d1c3801-d71e-4bd4-a0ab-64f4f0207198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_InterestExpenseDebt_7d1c3801-d71e-4bd4-a0ab-64f4f0207198" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_350347ab-eb54-44ac-8df9-033dfac52b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_350347ab-eb54-44ac-8df9-033dfac52b8a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7b3474cd-d669-4886-95d3-468da6fe24a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7b3474cd-d669-4886-95d3-468da6fe24a9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2492b82e-52d3-435b-bb1b-0be67e9c20a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2492b82e-52d3-435b-bb1b-0be67e9c20a3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_411eafce-8750-4a97-b7ce-85aef05c6a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_411eafce-8750-4a97-b7ce-85aef05c6a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_411eafce-8750-4a97-b7ce-85aef05c6a40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_411eafce-8750-4a97-b7ce-85aef05c6a40" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_411eafce-8750-4a97-b7ce-85aef05c6a40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9a08a8cc-7ea7-44b6-8def-c70d5b11a5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_411eafce-8750-4a97-b7ce-85aef05c6a40" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9a08a8cc-7ea7-44b6-8def-c70d5b11a5a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_01bdc572-51a2-4145-ad8f-4f891a0e7fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9a08a8cc-7ea7-44b6-8def-c70d5b11a5a3" xlink:to="loc_us-gaap_ConvertibleDebtMember_01bdc572-51a2-4145-ad8f-4f891a0e7fbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_372fdcc3-cbe7-44df-8cf3-512320eca230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_DebtInstrumentAxis_372fdcc3-cbe7-44df-8cf3-512320eca230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_372fdcc3-cbe7-44df-8cf3-512320eca230_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_372fdcc3-cbe7-44df-8cf3-512320eca230" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_372fdcc3-cbe7-44df-8cf3-512320eca230_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_372fdcc3-cbe7-44df-8cf3-512320eca230" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ddc8f475-b3e9-4cb2-840e-3495f9fb8650" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ddc8f475-b3e9-4cb2-840e-3495f9fb8650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_1aac783d-dc52-4192-a483-ebe788b74bd2" xlink:href="ino-20210630.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:to="loc_ino_August2019ConvertibleBondsMember_1aac783d-dc52-4192-a483-ebe788b74bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_ef816839-f007-4847-a08d-db8facd36779" xlink:href="ino-20210630.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:to="loc_ino_December2019ConvertibleBondsMember_ef816839-f007-4847-a08d-db8facd36779" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_c8f4ad81-95b9-435a-8774-f87901d2007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_c8f4ad81-95b9-435a-8774-f87901d2007d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_c8f4ad81-95b9-435a-8774-f87901d2007d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_c8f4ad81-95b9-435a-8774-f87901d2007d" xlink:to="loc_us-gaap_DebtConversionNameDomain_c8f4ad81-95b9-435a-8774-f87901d2007d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_f834e4ba-43ea-41b4-b58f-b56103a66441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_c8f4ad81-95b9-435a-8774-f87901d2007d" xlink:to="loc_us-gaap_DebtConversionNameDomain_f834e4ba-43ea-41b4-b58f-b56103a66441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_d41b1ed6-e752-4025-8fe5-b9332c04dbeb" xlink:href="ino-20210630.xsd#ino_InitialConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_f834e4ba-43ea-41b4-b58f-b56103a66441" xlink:to="loc_ino_InitialConversionPriceMember_d41b1ed6-e752-4025-8fe5-b9332c04dbeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f1dff7dc-69c0-43f6-965a-63b791f59d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f1dff7dc-69c0-43f6-965a-63b791f59d4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f1dff7dc-69c0-43f6-965a-63b791f59d4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1dff7dc-69c0-43f6-965a-63b791f59d4f" xlink:to="loc_us-gaap_ClassOfStockDomain_f1dff7dc-69c0-43f6-965a-63b791f59d4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69f5ea6a-b008-4066-9120-825449aa0513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1dff7dc-69c0-43f6-965a-63b791f59d4f" xlink:to="loc_us-gaap_ClassOfStockDomain_69f5ea6a-b008-4066-9120-825449aa0513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d4cd4ac9-8e8b-4681-99a7-fe351d2fce4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_69f5ea6a-b008-4066-9120-825449aa0513" xlink:to="loc_us-gaap_CommonStockMember_d4cd4ac9-8e8b-4681-99a7-fe351d2fce4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended" id="if3f25ffbc2204b28b27312f8749efe8a_ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_44ed22ad-6dcf-48ee-bdd1-333a6ee29747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_44ed22ad-6dcf-48ee-bdd1-333a6ee29747" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_dc772134-3703-4e52-931f-88ebf275b056" xlink:href="ino-20210630.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_dc772134-3703-4e52-931f-88ebf275b056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_069ed325-11fe-4114-a0a4-711e123a614d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_069ed325-11fe-4114-a0a4-711e123a614d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9536c3bb-59a5-4c47-918f-4c910c9d1fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9536c3bb-59a5-4c47-918f-4c910c9d1fad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_834191ae-e554-43e3-85bb-3e35acbac5f5" xlink:href="ino-20210630.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_ino_DebtInstrumentAccruedInterest_834191ae-e554-43e3-85bb-3e35acbac5f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a6b6ba76-7716-4b09-8bdc-4c8c3af97afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_LongTermDebt_a6b6ba76-7716-4b09-8bdc-4c8c3af97afb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_98163654-41c1-487f-ab0b-18c7850233f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_DebtInstrumentTable_98163654-41c1-487f-ab0b-18c7850233f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_98163654-41c1-487f-ab0b-18c7850233f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8c149ed-2789-4708-b02c-f522bcd3410a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8c149ed-2789-4708-b02c-f522bcd3410a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c2c66298-535b-4f96-9f49-4c43b8e90b70" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8c149ed-2789-4708-b02c-f522bcd3410a" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c2c66298-535b-4f96-9f49-4c43b8e90b70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="i2b1dcfe834024331844574c4d6ff5708_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d398cca2-cd2e-4ce7-8782-0590a116aa41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d398cca2-cd2e-4ce7-8782-0590a116aa41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0074ab76-c1b6-4c8f-b80b-b4840682ca72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0074ab76-c1b6-4c8f-b80b-b4840682ca72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_014f84bf-e3c4-4292-831e-98676b8530ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_014f84bf-e3c4-4292-831e-98676b8530ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1d38ec8f-a11a-4fc4-be57-e823912a6154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1d38ec8f-a11a-4fc4-be57-e823912a6154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2533f1c4-90a4-43c0-b665-9c6ea1ad3719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebt_2533f1c4-90a4-43c0-b665-9c6ea1ad3719" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_91d2b817-32ab-4844-80f1-1a90e3663cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_91d2b817-32ab-4844-80f1-1a90e3663cae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe879c7b-c472-4e83-96be-90f35ebb5111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe879c7b-c472-4e83-96be-90f35ebb5111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe879c7b-c472-4e83-96be-90f35ebb5111_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe879c7b-c472-4e83-96be-90f35ebb5111" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe879c7b-c472-4e83-96be-90f35ebb5111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5cb0cf46-c775-4aaa-a1bd-f5c7e7e9c0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe879c7b-c472-4e83-96be-90f35ebb5111" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5cb0cf46-c775-4aaa-a1bd-f5c7e7e9c0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_79200d2d-c16b-4778-98d0-0406fb9381d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5cb0cf46-c775-4aaa-a1bd-f5c7e7e9c0d6" xlink:to="loc_us-gaap_ConvertibleDebtMember_79200d2d-c16b-4778-98d0-0406fb9381d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cac6233e-45ee-4d82-8490-143336974f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:to="loc_us-gaap_DebtInstrumentAxis_cac6233e-45ee-4d82-8490-143336974f77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cac6233e-45ee-4d82-8490-143336974f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cac6233e-45ee-4d82-8490-143336974f77" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cac6233e-45ee-4d82-8490-143336974f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_85d9d422-98ff-4220-9ab1-90203a505611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cac6233e-45ee-4d82-8490-143336974f77" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_85d9d422-98ff-4220-9ab1-90203a505611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_24a38e5c-cf8e-4fe4-9aed-ed6d53675deb" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_85d9d422-98ff-4220-9ab1-90203a505611" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_24a38e5c-cf8e-4fe4-9aed-ed6d53675deb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended" id="ie87b43072dc746ca838fb9a75bf74610_StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2ac0faab-f621-4a23-82a2-22d4faa5d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ac0faab-f621-4a23-82a2-22d4faa5d3c6" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a975dcac-6d3c-49e7-8fa1-1e0dc087a2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a975dcac-6d3c-49e7-8fa1-1e0dc087a2d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cfd55239-1572-4fb1-acfe-a9fa150ad450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cfd55239-1572-4fb1-acfe-a9fa150ad450" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_58e87038-2b7a-41eb-9424-1562471404ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockSharesIssued_58e87038-2b7a-41eb-9424-1562471404ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8df3ba21-c78e-4739-bcdc-eddabda3907e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8df3ba21-c78e-4739-bcdc-eddabda3907e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c79b7b04-666d-4528-bcd1-d5042d7c0746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c79b7b04-666d-4528-bcd1-d5042d7c0746" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f442cac6-5659-4727-b3bd-b17cd865e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f442cac6-5659-4727-b3bd-b17cd865e73b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dcd73dbe-8899-4c2d-8a8c-c51d471c3166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dcd73dbe-8899-4c2d-8a8c-c51d471c3166" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5c9757f9-8b91-4836-a1cd-ec808b5569be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5c9757f9-8b91-4836-a1cd-ec808b5569be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c74c28bc-feb2-4496-900b-feffa52b110c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ac0faab-f621-4a23-82a2-22d4faa5d3c6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c74c28bc-feb2-4496-900b-feffa52b110c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aea7f2f2-25a5-405e-82a4-d14b63df7231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c74c28bc-feb2-4496-900b-feffa52b110c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aea7f2f2-25a5-405e-82a4-d14b63df7231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aea7f2f2-25a5-405e-82a4-d14b63df7231_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aea7f2f2-25a5-405e-82a4-d14b63df7231" xlink:to="loc_us-gaap_ClassOfStockDomain_aea7f2f2-25a5-405e-82a4-d14b63df7231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1190ecd-ef69-40ad-b710-0126e3440825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aea7f2f2-25a5-405e-82a4-d14b63df7231" xlink:to="loc_us-gaap_ClassOfStockDomain_e1190ecd-ef69-40ad-b710-0126e3440825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1a14a762-3410-4c2b-96d2-2f45b8c26e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e1190ecd-ef69-40ad-b710-0126e3440825" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1a14a762-3410-4c2b-96d2-2f45b8c26e35" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i1ab978faaf1d4feb9e31db4a1abddaef_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ea9cec9b-de04-4c95-82ed-e755da998b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ea9cec9b-de04-4c95-82ed-e755da998b0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_f3ff04d0-4dff-49a5-84d9-85d714caa86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_f3ff04d0-4dff-49a5-84d9-85d714caa86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38387343-0def-4d23-b100-8c4ffa634130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38387343-0def-4d23-b100-8c4ffa634130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b7fc5d95-5aa4-4233-a108-1f0617020e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b7fc5d95-5aa4-4233-a108-1f0617020e8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_7b7585ae-759e-42b3-add0-cde32c6486af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_7b7585ae-759e-42b3-add0-cde32c6486af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_e0e81b53-22f3-40ec-8081-e4b5d5e30e6a" xlink:href="ino-20210630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_e0e81b53-22f3-40ec-8081-e4b5d5e30e6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_4218f4b7-11a0-4bc7-918a-f84b8bec2d9f" xlink:href="ino-20210630.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_4218f4b7-11a0-4bc7-918a-f84b8bec2d9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_14c33103-2dbd-43b7-9779-e617f53d0e69" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_14c33103-2dbd-43b7-9779-e617f53d0e69" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_a54b53ae-b34e-429a-9010-be151ffb5897" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_a54b53ae-b34e-429a-9010-be151ffb5897" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e1c300a4-5d58-4719-bd12-9144478be92e" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e1c300a4-5d58-4719-bd12-9144478be92e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_02d73759-e72e-4b96-ac1a-60573011d8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_02d73759-e72e-4b96-ac1a-60573011d8ea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_817372c2-d702-4cfc-8a11-a61278fb9e99" xlink:href="ino-20210630.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_817372c2-d702-4cfc-8a11-a61278fb9e99" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_9938c378-14c1-4656-a1ef-a359b08fb28b" xlink:href="ino-20210630.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_9938c378-14c1-4656-a1ef-a359b08fb28b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e93e7e80-baba-4892-a95e-75c01cdb6e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e93e7e80-baba-4892-a95e-75c01cdb6e8f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ccf088a-9b54-4bef-8db5-1f357c710e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ccf088a-9b54-4bef-8db5-1f357c710e2d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_f91d3b32-c67f-4951-a2a5-105c7f2dd3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_f91d3b32-c67f-4951-a2a5-105c7f2dd3db" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcb96798-4017-4f77-a049-04d62220d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcb96798-4017-4f77-a049-04d62220d31f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ac8ca4e3-532c-4e51-bc76-bed0e521f523" xlink:href="ino-20210630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ac8ca4e3-532c-4e51-bc76-bed0e521f523" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_85a52bae-5a8b-4252-82a3-d84065e7c469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_85a52bae-5a8b-4252-82a3-d84065e7c469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_85a52bae-5a8b-4252-82a3-d84065e7c469_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_85a52bae-5a8b-4252-82a3-d84065e7c469" xlink:to="loc_us-gaap_ClassOfStockDomain_85a52bae-5a8b-4252-82a3-d84065e7c469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_85a52bae-5a8b-4252-82a3-d84065e7c469" xlink:to="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1910761e-2c1c-4de1-a7f7-ff0c1fae4fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1910761e-2c1c-4de1-a7f7-ff0c1fae4fb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_af6add71-3446-472b-b1c1-8116b6f44724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:to="loc_us-gaap_CommonStockMember_af6add71-3446-472b-b1c1-8116b6f44724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_44fea718-9975-470a-a1ea-f49ff2b35273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_44fea718-9975-470a-a1ea-f49ff2b35273" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44fea718-9975-470a-a1ea-f49ff2b35273_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44fea718-9975-470a-a1ea-f49ff2b35273" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_44fea718-9975-470a-a1ea-f49ff2b35273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44fea718-9975-470a-a1ea-f49ff2b35273" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_684290a2-6c32-4122-9f2a-60ebfb7bb124" xlink:href="ino-20210630.xsd#ino_PriorSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:to="loc_ino_PriorSalesAgreementMember_684290a2-6c32-4122-9f2a-60ebfb7bb124" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_8a71f2d1-40de-4813-b7ad-cf17fc017506" xlink:href="ino-20210630.xsd#ino_NewSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:to="loc_ino_NewSalesAgreementMember_8a71f2d1-40de-4813-b7ad-cf17fc017506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:to="loc_us-gaap_PlanNameAxis_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf" xlink:to="loc_us-gaap_PlanNameDomain_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf" xlink:to="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_31659b8b-debe-496d-bc79-5b89633a84bc" xlink:href="ino-20210630.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:to="loc_ino_A2016IncentivePlanMember_31659b8b-debe-496d-bc79-5b89633a84bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_ce4ed9b3-fde8-4245-8bb5-d060a9d269db" xlink:href="ino-20210630.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:to="loc_ino_A2007IncentivePlanMember_ce4ed9b3-fde8-4245-8bb5-d060a9d269db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended" id="i041fccfb96d848d382c05880a86b1067_NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38a08494-ee8c-4fe3-8667-1fd08c959546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f3abdf10-98a9-4d44-a895-c3495bd5d207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38a08494-ee8c-4fe3-8667-1fd08c959546" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f3abdf10-98a9-4d44-a895-c3495bd5d207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38a08494-ee8c-4fe3-8667-1fd08c959546" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0cc4934a-cc7d-411e-9f9a-1146cfd46466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:to="loc_us-gaap_DebtInstrumentAxis_0cc4934a-cc7d-411e-9f9a-1146cfd46466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cc4934a-cc7d-411e-9f9a-1146cfd46466_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0cc4934a-cc7d-411e-9f9a-1146cfd46466" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cc4934a-cc7d-411e-9f9a-1146cfd46466_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0cc4934a-cc7d-411e-9f9a-1146cfd46466" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7b27cf9e-58c9-4208-ae3c-f5149b7badbc" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7b27cf9e-58c9-4208-ae3c-f5149b7badbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_9bf605b6-661f-463e-b990-c2f0d2c238e1" xlink:href="ino-20210630.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:to="loc_ino_August2019ConvertibleBondsMember_9bf605b6-661f-463e-b990-c2f0d2c238e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_c9c2b7f5-46e1-4d5e-8a1f-8accdcc50f60" xlink:href="ino-20210630.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:to="loc_ino_December2019ConvertibleBondsMember_c9c2b7f5-46e1-4d5e-8a1f-8accdcc50f60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b96fac23-65c8-47aa-8440-717a14f87b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b96fac23-65c8-47aa-8440-717a14f87b1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b96fac23-65c8-47aa-8440-717a14f87b1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b96fac23-65c8-47aa-8440-717a14f87b1b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b96fac23-65c8-47aa-8440-717a14f87b1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b96fac23-65c8-47aa-8440-717a14f87b1b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db564693-f27b-44c6-9220-29de3d0e30a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db564693-f27b-44c6-9220-29de3d0e30a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_2c4e661f-0ff1-459f-9d45-d0f13d764848" xlink:href="ino-20210630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_2c4e661f-0ff1-459f-9d45-d0f13d764848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_097ba226-7f50-4090-834b-6268ed150e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_097ba226-7f50-4090-834b-6268ed150e4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b43b3e70-d526-4bfc-830f-45b39be10b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b43b3e70-d526-4bfc-830f-45b39be10b03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_53d3e4ba-76e0-47fd-bcb8-e6fa7fc6afd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_53d3e4ba-76e0-47fd-bcb8-e6fa7fc6afd9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i86ff85e7f3de45a4919402f174547cbd_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645bc0f9-50c2-4b06-9f43-37b4222f352d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645bc0f9-50c2-4b06-9f43-37b4222f352d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6784ad10-eaba-460a-920b-92484aae0753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6784ad10-eaba-460a-920b-92484aae0753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_192e6987-6a2d-43bb-bab6-5326e30cc934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_192e6987-6a2d-43bb-bab6-5326e30cc934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_78e7c7ee-59c2-4a74-b4e0-150b366b3e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_78e7c7ee-59c2-4a74-b4e0-150b366b3e14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_03ce192e-95ff-4da0-8c9a-984b5cbad274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensation_03ce192e-95ff-4da0-8c9a-984b5cbad274" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e65e02-9006-4a08-8041-f50d4ae5d399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e65e02-9006-4a08-8041-f50d4ae5d399" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f61d78aa-2f70-4d65-9b35-ef5451f76e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f61d78aa-2f70-4d65-9b35-ef5451f76e23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7266523-1dc4-4394-b295-2d6ef821e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7266523-1dc4-4394-b295-2d6ef821e8e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96812ddd-66be-4668-9de8-e7322548f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96812ddd-66be-4668-9de8-e7322548f4d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c3d9ad2-2723-4f17-a770-56af3499b6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c3d9ad2-2723-4f17-a770-56af3499b6dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77581068-0abd-4ba4-9c14-226f85aa32b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77581068-0abd-4ba4-9c14-226f85aa32b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7bdbeb13-a31f-4019-ba08-81657fe6de91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7bdbeb13-a31f-4019-ba08-81657fe6de91" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a4472dc-5d10-473e-9477-0f0644e707f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a4472dc-5d10-473e-9477-0f0644e707f7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_d164cf6d-447f-4e59-be8e-3816e487f971" xlink:href="ino-20210630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_d164cf6d-447f-4e59-be8e-3816e487f971" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_AwardTypeAxis_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e28186b2-9b23-41a9-a1b0-f17fe9630b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e28186b2-9b23-41a9-a1b0-f17fe9630b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2675a128-36e5-4f68-acd7-71918ea2e51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2675a128-36e5-4f68-acd7-71918ea2e51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b0b09a55-19d8-415a-b7c1-00abecacffd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_srt_TitleOfIndividualAxis_b0b09a55-19d8-415a-b7c1-00abecacffd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b0b09a55-19d8-415a-b7c1-00abecacffd4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b0b09a55-19d8-415a-b7c1-00abecacffd4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b0b09a55-19d8-415a-b7c1-00abecacffd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b0b09a55-19d8-415a-b7c1-00abecacffd4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_fd273ff8-51c9-4f33-b175-251fc5dac630" xlink:href="ino-20210630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:to="loc_ino_EmployeesAndDirectorsMember_fd273ff8-51c9-4f33-b175-251fc5dac630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_30cfcf37-f53e-4165-8f68-ca692e7015c9" xlink:href="ino-20210630.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:to="loc_ino_NonEmployeeMember_30cfcf37-f53e-4165-8f68-ca692e7015c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e389dbef-7a94-4db2-b7af-f268ae6acdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e389dbef-7a94-4db2-b7af-f268ae6acdfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e389dbef-7a94-4db2-b7af-f268ae6acdfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e389dbef-7a94-4db2-b7af-f268ae6acdfe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e389dbef-7a94-4db2-b7af-f268ae6acdfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e389dbef-7a94-4db2-b7af-f268ae6acdfe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_79d33d60-c155-45a4-931b-f818714c314a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_79d33d60-c155-45a4-931b-f818714c314a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ec96649d-374b-4274-9394-529ba304ed5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ec96649d-374b-4274-9394-529ba304ed5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_45c5129f-d62d-49c9-ad68-a3567ab2dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_PlanNameAxis_45c5129f-d62d-49c9-ad68-a3567ab2dec9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_45c5129f-d62d-49c9-ad68-a3567ab2dec9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_45c5129f-d62d-49c9-ad68-a3567ab2dec9" xlink:to="loc_us-gaap_PlanNameDomain_45c5129f-d62d-49c9-ad68-a3567ab2dec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a30b8391-f9ae-424c-827e-af5afcdc8137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_45c5129f-d62d-49c9-ad68-a3567ab2dec9" xlink:to="loc_us-gaap_PlanNameDomain_a30b8391-f9ae-424c-827e-af5afcdc8137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_38484c3e-42d4-4262-b44c-1c6adb04379e" xlink:href="ino-20210630.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a30b8391-f9ae-424c-827e-af5afcdc8137" xlink:to="loc_ino_A2016IncentivePlanMember_38484c3e-42d4-4262-b44c-1c6adb04379e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_beaba38a-0101-4d7f-9060-14fefebdf2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_VestingAxis_beaba38a-0101-4d7f-9060-14fefebdf2ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_beaba38a-0101-4d7f-9060-14fefebdf2ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_beaba38a-0101-4d7f-9060-14fefebdf2ea" xlink:to="loc_us-gaap_VestingDomain_beaba38a-0101-4d7f-9060-14fefebdf2ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_beaba38a-0101-4d7f-9060-14fefebdf2ea" xlink:to="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_47755caf-ae44-4d38-b379-900bbfb2487c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_47755caf-ae44-4d38-b379-900bbfb2487c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d1a3d8-8264-4670-9b34-4964bd451805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d1a3d8-8264-4670-9b34-4964bd451805" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="if4f27a1471524066911ed727ad743c5a_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_dc73301e-660b-46da-95aa-8fd042790af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:href="ino-20210630.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dc73301e-660b-46da-95aa-8fd042790af5" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_70ccd0b7-b7b0-4afd-8d70-ef8218308f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_70ccd0b7-b7b0-4afd-8d70-ef8218308f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d58b2c80-de84-4fc8-a788-0138c3828771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d58b2c80-de84-4fc8-a788-0138c3828771" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a0f414a-439a-443c-88e0-51c684894368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a0f414a-439a-443c-88e0-51c684894368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_dabac162-2a91-47a7-aca5-bdf123b23d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_dabac162-2a91-47a7-aca5-bdf123b23d25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_4ebac7f7-edc7-4411-acf2-cbc1d06353b5" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_4ebac7f7-edc7-4411-acf2-cbc1d06353b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_3424fdcf-9447-48bc-b733-5476dd081c6b" xlink:href="ino-20210630.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeArrangementTerm_3424fdcf-9447-48bc-b733-5476dd081c6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_301c47a1-3a1c-473b-bc92-77ae53d28d00" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_301c47a1-3a1c-473b-bc92-77ae53d28d00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_9ca225ce-c523-45a9-87b0-fc644cc98b86" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_9ca225ce-c523-45a9-87b0-fc644cc98b86" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_6298547d-a6ea-408d-8dab-84400d53169b" xlink:href="ino-20210630.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_GrantProceedsReceived_6298547d-a6ea-408d-8dab-84400d53169b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_17dfb8a1-2b88-41e2-b1f2-a54b892ed2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_17dfb8a1-2b88-41e2-b1f2-a54b892ed2dc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cd7e18b4-5ca9-4263-936d-3eb581cecf39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cd7e18b4-5ca9-4263-936d-3eb581cecf39" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_37a8b85b-d513-4c6a-b65c-69042db39747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_37a8b85b-d513-4c6a-b65c-69042db39747" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_adaa951a-7444-4ecb-aa33-17880d245b98" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_adaa951a-7444-4ecb-aa33-17880d245b98" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dc73301e-660b-46da-95aa-8fd042790af5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_07494dac-a35e-4044-aa20-8f6eb235e59b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_srt_CounterpartyNameAxis_07494dac-a35e-4044-aa20-8f6eb235e59b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07494dac-a35e-4044-aa20-8f6eb235e59b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_07494dac-a35e-4044-aa20-8f6eb235e59b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07494dac-a35e-4044-aa20-8f6eb235e59b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c817af6c-a5b3-4963-b7db-5d4a4cbfdf61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_07494dac-a35e-4044-aa20-8f6eb235e59b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c817af6c-a5b3-4963-b7db-5d4a4cbfdf61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_1e215744-97c9-432d-9cea-0ebeb9183c4b" xlink:href="ino-20210630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c817af6c-a5b3-4963-b7db-5d4a4cbfdf61" xlink:to="loc_ino_PlumblineLifeSciencesMember_1e215744-97c9-432d-9cea-0ebeb9183c4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_90a066f8-56a5-4caa-a750-6505f1ea015b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_90a066f8-56a5-4caa-a750-6505f1ea015b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_90a066f8-56a5-4caa-a750-6505f1ea015b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_90a066f8-56a5-4caa-a750-6505f1ea015b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_90a066f8-56a5-4caa-a750-6505f1ea015b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f94d0ede-4d69-4f7a-87d8-eae7057698ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_90a066f8-56a5-4caa-a750-6505f1ea015b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f94d0ede-4d69-4f7a-87d8-eae7057698ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_fdf37a5e-5246-431b-8013-c09221c7cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f94d0ede-4d69-4f7a-87d8-eae7057698ca" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_fdf37a5e-5246-431b-8013-c09221c7cf8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b70b29b1-6d56-4ed7-bc64-c2e728b216fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b70b29b1-6d56-4ed7-bc64-c2e728b216fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b70b29b1-6d56-4ed7-bc64-c2e728b216fe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b70b29b1-6d56-4ed7-bc64-c2e728b216fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b70b29b1-6d56-4ed7-bc64-c2e728b216fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_513cda8c-4c41-49e4-9159-30d082a5a838" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b70b29b1-6d56-4ed7-bc64-c2e728b216fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_513cda8c-4c41-49e4-9159-30d082a5a838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_7337a399-4615-484c-b273-4203499ec20f" xlink:href="ino-20210630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_513cda8c-4c41-49e4-9159-30d082a5a838" xlink:to="loc_ino_PlumblineLifeSciencesMember_7337a399-4615-484c-b273-4203499ec20f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0" xlink:to="loc_us-gaap_RelatedPartyDomain_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0" xlink:to="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2c245883-3a44-4bd0-b28b-c45ab5be9f71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:to="loc_srt_DirectorMember_2c245883-3a44-4bd0-b28b-c45ab5be9f71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_7c67b5fd-efad-4487-97db-c2ebf84ed0e1" xlink:href="ino-20210630.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:to="loc_ino_TheWistarInstituteMember_7c67b5fd-efad-4487-97db-c2ebf84ed0e1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="idf272ab028fd4364a064967beef7b037_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_6803f615-3044-4128-84da-86d6ae417a72" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_6803f615-3044-4128-84da-86d6ae417a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8897d800-dbd2-4058-85f5-ab8c2b3ed755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8897d800-dbd2-4058-85f5-ab8c2b3ed755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ca2f1f95-8878-4fb1-b524-10bf2d895ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_us-gaap_LeaseCost_ca2f1f95-8878-4fb1-b524-10bf2d895ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_a2c55d78-e115-40d2-9fc7-a17eaa560f35" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_a2c55d78-e115-40d2-9fc7-a17eaa560f35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c697519d-2432-441c-af43-3757d3048d97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c697519d-2432-441c-af43-3757d3048d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c697519d-2432-441c-af43-3757d3048d97_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c697519d-2432-441c-af43-3757d3048d97" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c697519d-2432-441c-af43-3757d3048d97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c697519d-2432-441c-af43-3757d3048d97" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_2ea05f44-f977-4f8f-8269-4b68cd6fecfe" xlink:href="ino-20210630.xsd#ino_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:to="loc_ino_SanDiegoOfficeMember_2ea05f44-f977-4f8f-8269-4b68cd6fecfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_02d61241-9667-4f81-af08-54ac242d93f5" xlink:href="ino-20210630.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_02d61241-9667-4f81-af08-54ac242d93f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c548445b-6960-4628-9797-b5362020445c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:to="loc_srt_RangeAxis_c548445b-6960-4628-9797-b5362020445c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c548445b-6960-4628-9797-b5362020445c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c548445b-6960-4628-9797-b5362020445c" xlink:to="loc_srt_RangeMember_c548445b-6960-4628-9797-b5362020445c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c548445b-6960-4628-9797-b5362020445c" xlink:to="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d649f7a-21af-48e3-9773-a16dfa0bc8ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:to="loc_srt_MinimumMember_6d649f7a-21af-48e3-9773-a16dfa0bc8ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f3c879d3-7f81-4212-ac66-3f7deb5ddd21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:to="loc_srt_MaximumMember_f3c879d3-7f81-4212-ac66-3f7deb5ddd21" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="ic22d823f61bb4689843f81f8df701cf7_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_04431ae2-2641-4335-9e85-e78df6d8ffcd" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_04431ae2-2641-4335-9e85-e78df6d8ffcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bfaadb35-cfc8-47e2-a027-e97ea47e4d5c" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bfaadb35-cfc8-47e2-a027-e97ea47e4d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_bb0b7f5a-fd9a-4cb2-8aad-6e8a4f200372" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_bb0b7f5a-fd9a-4cb2-8aad-6e8a4f200372" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_a9098e2e-fb3a-4f59-87e9-26568af9eedb" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_a9098e2e-fb3a-4f59-87e9-26568af9eedb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_aac94cab-62a0-4b7b-926f-a47d227edb60" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_aac94cab-62a0-4b7b-926f-a47d227edb60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_683c29cc-8f18-4b94-b26d-cbf27e13bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_683c29cc-8f18-4b94-b26d-cbf27e13bd6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_a9f641f6-4b2e-4787-b0af-dbbea4bf16d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_AccountsReceivableNet_a9f641f6-4b2e-4787-b0af-dbbea4bf16d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_0901113f-6c44-4e0c-b085-e0bd4695f1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_CostMaintenance_0901113f-6c44-4e0c-b085-e0bd4695f1ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_2c17f406-7ba8-4d0d-83cc-9b2de56f3dc1" xlink:href="ino-20210630.xsd#ino_AnnualMaintenancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_AnnualMaintenancePeriod_2c17f406-7ba8-4d0d-83cc-9b2de56f3dc1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_d13296a1-166f-42b2-81b1-be7f76ca1a6e" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_d13296a1-166f-42b2-81b1-be7f76ca1a6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_63e40f19-1a56-4c88-8463-e4cf9bcbe555" xlink:href="ino-20210630.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_63e40f19-1a56-4c88-8463-e4cf9bcbe555" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_fe181e9e-892c-48bb-a79f-cca005c41e9e" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_fe181e9e-892c-48bb-a79f-cca005c41e9e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_713ab735-f3aa-4fa3-b573-8fcc1e57ee10" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_713ab735-f3aa-4fa3-b573-8fcc1e57ee10" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_896db0ef-28d1-4c32-87f7-578d06675e71" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_896db0ef-28d1-4c32-87f7-578d06675e71" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_de8fc034-c5ca-44f6-a75e-007c839b8bd5" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_de8fc034-c5ca-44f6-a75e-007c839b8bd5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_29624645-da9b-4d2d-ac15-f028caf98a23" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_29624645-da9b-4d2d-ac15-f028caf98a23" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_4bcd3d2c-f3dc-4713-9341-b50be8d4092f" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_4bcd3d2c-f3dc-4713-9341-b50be8d4092f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_41104cb7-8497-442a-9796-5ebb0e86b84e" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_41104cb7-8497-442a-9796-5ebb0e86b84e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3243b756-e158-4c2a-bec3-d47fe18512fa" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3243b756-e158-4c2a-bec3-d47fe18512fa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_6aea22d3-76d2-48dc-9602-042bab63a406" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_6aea22d3-76d2-48dc-9602-042bab63a406" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_773a841e-6bf0-4a81-9438-57372aba483b" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_DeferredGrantFundingCurrent_773a841e-6bf0-4a81-9438-57372aba483b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_1d470900-e15f-421e-978b-450e9bac1ff8" xlink:href="ino-20210630.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_1d470900-e15f-421e-978b-450e9bac1ff8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_1d501f46-cd43-46e1-92de-d337cae0f88c" xlink:href="ino-20210630.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_GrantProceedsReceived_1d501f46-cd43-46e1-92de-d337cae0f88c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_c7b458b1-79a4-4031-aecd-3c07d9f26553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_c7b458b1-79a4-4031-aecd-3c07d9f26553" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_2434d5f3-3d08-4eb3-82a3-724893a69988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_GrantsReceivable_2434d5f3-3d08-4eb3-82a3-724893a69988" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_srt_CounterpartyNameAxis_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_6c78007d-2794-418e-803c-3234ffeea5d4" xlink:href="ino-20210630.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_AdvaccineMember_6c78007d-2794-418e-803c-3234ffeea5d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_7cf5f432-c8b5-4fcf-9890-3a144100a15a" xlink:href="ino-20210630.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_ApolloBioMember_7cf5f432-c8b5-4fcf-9890-3a144100a15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_cde7c2a4-6e9b-4c85-97fc-2ba4317aac4d" xlink:href="ino-20210630.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_AstraZenecaMember_cde7c2a4-6e9b-4c85-97fc-2ba4317aac4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_492c194d-1a2f-409c-a640-3ee376048967" xlink:href="ino-20210630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_492c194d-1a2f-409c-a640-3ee376048967" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_28537954-bb62-4914-ac8b-104325eb434e" xlink:href="ino-20210630.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_28537954-bb62-4914-ac8b-104325eb434e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_b9cb3c0f-7305-4172-993b-a7034b39810d" xlink:href="ino-20210630.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_DepartmentOfDefenceMember_b9cb3c0f-7305-4172-993b-a7034b39810d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52a6ed14-79f3-426b-a443-f6f5c81f047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52a6ed14-79f3-426b-a443-f6f5c81f047b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52a6ed14-79f3-426b-a443-f6f5c81f047b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52a6ed14-79f3-426b-a443-f6f5c81f047b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_52a6ed14-79f3-426b-a443-f6f5c81f047b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffbfddea-f83c-49c1-86f0-1f58d0a05cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52a6ed14-79f3-426b-a443-f6f5c81f047b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffbfddea-f83c-49c1-86f0-1f58d0a05cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1a3499a2-5525-4070-9ab7-591399c54a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffbfddea-f83c-49c1-86f0-1f58d0a05cd0" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1a3499a2-5525-4070-9ab7-591399c54a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_77d6f14d-4bd5-4aae-8f86-b0024db55729" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_srt_ProductOrServiceAxis_77d6f14d-4bd5-4aae-8f86-b0024db55729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_77d6f14d-4bd5-4aae-8f86-b0024db55729_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_77d6f14d-4bd5-4aae-8f86-b0024db55729" xlink:to="loc_srt_ProductsAndServicesDomain_77d6f14d-4bd5-4aae-8f86-b0024db55729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_77d6f14d-4bd5-4aae-8f86-b0024db55729" xlink:to="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b9d8bc94-dc8f-43f3-8ab3-a1cc3792f128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_us-gaap_LicenseMember_b9d8bc94-dc8f-43f3-8ab3-a1cc3792f128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_b5c6d2b6-dfed-4fdd-9d06-f11ffd1022c4" xlink:href="ino-20210630.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_b5c6d2b6-dfed-4fdd-9d06-f11ffd1022c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_980ace13-c545-4936-8964-ff5810d6a8cc" xlink:href="ino-20210630.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_980ace13-c545-4936-8964-ff5810d6a8cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_a9cac55c-f116-42c3-b759-b4acb75dd446" xlink:href="ino-20210630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_a9cac55c-f116-42c3-b759-b4acb75dd446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_c8ac043a-73b7-4c3b-8268-1ac0815b2f73" xlink:href="ino-20210630.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_INO4800Member_c8ac043a-73b7-4c3b-8268-1ac0815b2f73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_3b2cb333-a5fe-4922-ac35-8688dae9aab8" xlink:href="ino-20210630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_3b2cb333-a5fe-4922-ac35-8688dae9aab8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_9ba44b33-243f-41f5-abdc-5663b4b840f2" xlink:href="ino-20210630.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_CELLECTRA2000DeviceMember_9ba44b33-243f-41f5-abdc-5663b4b840f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f00a9ab7-74cb-44ad-a035-77383efae3e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_srt_MajorCustomersAxis_f00a9ab7-74cb-44ad-a035-77383efae3e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f00a9ab7-74cb-44ad-a035-77383efae3e7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f00a9ab7-74cb-44ad-a035-77383efae3e7" xlink:to="loc_srt_NameOfMajorCustomerDomain_f00a9ab7-74cb-44ad-a035-77383efae3e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4f6e641d-fdfd-4af3-b02e-133348ff9a5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f00a9ab7-74cb-44ad-a035-77383efae3e7" xlink:to="loc_srt_NameOfMajorCustomerDomain_4f6e641d-fdfd-4af3-b02e-133348ff9a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_b18ce1df-c625-4df6-bc14-b700bb3b0982" xlink:href="ino-20210630.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f6e641d-fdfd-4af3-b02e-133348ff9a5d" xlink:to="loc_ino_AdvaccineMember_b18ce1df-c625-4df6-bc14-b700bb3b0982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a794045e-4e98-43f8-9ec7-122d4156ba23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a794045e-4e98-43f8-9ec7-122d4156ba23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a794045e-4e98-43f8-9ec7-122d4156ba23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a794045e-4e98-43f8-9ec7-122d4156ba23" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a794045e-4e98-43f8-9ec7-122d4156ba23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_918a2d34-cc5e-4732-b3bb-47446766250c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a794045e-4e98-43f8-9ec7-122d4156ba23" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_918a2d34-cc5e-4732-b3bb-47446766250c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2e644741-d7be-4807-9364-1fe715782b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_918a2d34-cc5e-4732-b3bb-47446766250c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2e644741-d7be-4807-9364-1fe715782b5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_fdf59fcf-8b28-4236-884e-58d8db78df69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_fdf59fcf-8b28-4236-884e-58d8db78df69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_fdf59fcf-8b28-4236-884e-58d8db78df69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fdf59fcf-8b28-4236-884e-58d8db78df69" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_fdf59fcf-8b28-4236-884e-58d8db78df69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a855e8dd-bed4-4dcb-9eea-72627a79ffdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fdf59fcf-8b28-4236-884e-58d8db78df69" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a855e8dd-bed4-4dcb-9eea-72627a79ffdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_17e01ca4-0b9c-4b1b-9ace-973ae566bebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a855e8dd-bed4-4dcb-9eea-72627a79ffdf" xlink:to="loc_us-gaap_ForeignCountryMember_17e01ca4-0b9c-4b1b-9ace-973ae566bebc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="i423ee60f0a7e4f4d942c197617439426_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6d0c585c-89ed-4738-bb8f-aacecef92f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6d0c585c-89ed-4738-bb8f-aacecef92f41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_46b0e823-6d86-4fc9-a8a6-38a8cdf09fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_46b0e823-6d86-4fc9-a8a6-38a8cdf09fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_53ae3666-5ba7-4d32-9256-ccfba684556a" xlink:href="ino-20210630.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_53ae3666-5ba7-4d32-9256-ccfba684556a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24227628-6037-4923-8bb5-4e7032f62579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24227628-6037-4923-8bb5-4e7032f62579" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_ea76177f-d029-43ce-81cd-13fc2c470d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_ea76177f-d029-43ce-81cd-13fc2c470d33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_51f02a28-d703-4e3f-84c0-32d33edea37c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_51f02a28-d703-4e3f-84c0-32d33edea37c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_4397af84-3241-4c54-a1cc-1a7c5a2c21aa" xlink:href="ino-20210630.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_4397af84-3241-4c54-a1cc-1a7c5a2c21aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fef3a3e2-59c8-4416-a6d6-081e887aad66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fef3a3e2-59c8-4416-a6d6-081e887aad66" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8646f532-0407-49fd-aa99-f9b543bbfe9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_EquityMethodInvestments_8646f532-0407-49fd-aa99-f9b543bbfe9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_37518877-a4ca-4480-8e31-faa675b25afb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:to="loc_srt_CounterpartyNameAxis_37518877-a4ca-4480-8e31-faa675b25afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37518877-a4ca-4480-8e31-faa675b25afb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_37518877-a4ca-4480-8e31-faa675b25afb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37518877-a4ca-4480-8e31-faa675b25afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_430afebc-d076-44f1-bd6e-e0a386cf79e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_37518877-a4ca-4480-8e31-faa675b25afb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_430afebc-d076-44f1-bd6e-e0a386cf79e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_b23f7794-b6f7-497d-8c4b-254424c75879" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_430afebc-d076-44f1-bd6e-e0a386cf79e9" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_b23f7794-b6f7-497d-8c4b-254424c75879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0ff2baac-1b85-4bcb-8fc5-a098aad9e786" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:to="loc_srt_OwnershipAxis_0ff2baac-1b85-4bcb-8fc5-a098aad9e786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0ff2baac-1b85-4bcb-8fc5-a098aad9e786_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0ff2baac-1b85-4bcb-8fc5-a098aad9e786" xlink:to="loc_srt_OwnershipDomain_0ff2baac-1b85-4bcb-8fc5-a098aad9e786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_84b5eae2-a7f5-4e58-a7da-a0d2d98097f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0ff2baac-1b85-4bcb-8fc5-a098aad9e786" xlink:to="loc_srt_OwnershipDomain_84b5eae2-a7f5-4e58-a7da-a0d2d98097f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_68814f2e-1e8c-4286-9a38-d587eed753f0" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_84b5eae2-a7f5-4e58-a7da-a0d2d98097f2" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_68814f2e-1e8c-4286-9a38-d587eed753f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_69de3b02-d567-4036-8d0a-b510269febb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:to="loc_us-gaap_StatementClassOfStockAxis_69de3b02-d567-4036-8d0a-b510269febb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69de3b02-d567-4036-8d0a-b510269febb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_69de3b02-d567-4036-8d0a-b510269febb7" xlink:to="loc_us-gaap_ClassOfStockDomain_69de3b02-d567-4036-8d0a-b510269febb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_69de3b02-d567-4036-8d0a-b510269febb7" xlink:to="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f72620b0-740f-42aa-a496-d165a35df53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:to="loc_us-gaap_CommonStockMember_f72620b0-740f-42aa-a496-d165a35df53f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b1015538-f77d-4f2c-85fa-567900ed4306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:to="loc_us-gaap_PreferredStockMember_b1015538-f77d-4f2c-85fa-567900ed4306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_f2b5a998-4976-4b1d-9da3-0676a8915007" xlink:href="ino-20210630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:to="loc_ino_SeriesAOnePreferredStockMember_f2b5a998-4976-4b1d-9da3-0676a8915007" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended" id="i8e930209e34f457b854555d7442ec8b9_GeneosTherapeuticsIncDeconsolidationAccountingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_d75f982d-734c-4199-a8de-8ae20be8d464" xlink:href="ino-20210630.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_ino_WorkingCapitalExcludingCash_d75f982d-734c-4199-a8de-8ae20be8d464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_b1259be0-d0b8-4a53-b034-81883cc13834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_NotesPayable_b1259be0-d0b8-4a53-b034-81883cc13834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f033486a-c119-4317-9000-2c1cb3165ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f033486a-c119-4317-9000-2c1cb3165ff0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9ad90a0f-16dc-4a8e-a657-37d88885e503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_MinorityInterest_9ad90a0f-16dc-4a8e-a657-37d88885e503" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_b8a694be-eec5-47f4-a1ba-720d47dc9826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_b8a694be-eec5-47f4-a1ba-720d47dc9826" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_26db39fd-9296-420e-ae81-1e8379473444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_26db39fd-9296-420e-ae81-1e8379473444" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_3d0dd0fb-5313-431f-ade5-fe74dbb1bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_3d0dd0fb-5313-431f-ade5-fe74dbb1bd7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_2c7e8c7e-e45b-4a5f-9ede-e77d5e58bdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_MinorityInterestTable_2c7e8c7e-e45b-4a5f-9ede-e77d5e58bdbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f0f77ec9-5667-42d4-b626-00e7b6e0859d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_2c7e8c7e-e45b-4a5f-9ede-e77d5e58bdbc" xlink:to="loc_srt_CounterpartyNameAxis_f0f77ec9-5667-42d4-b626-00e7b6e0859d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0f77ec9-5667-42d4-b626-00e7b6e0859d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f0f77ec9-5667-42d4-b626-00e7b6e0859d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f0f77ec9-5667-42d4-b626-00e7b6e0859d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_585e87de-30b3-4088-afe0-5c9ac3681922" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f0f77ec9-5667-42d4-b626-00e7b6e0859d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_585e87de-30b3-4088-afe0-5c9ac3681922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_4942a564-ebe0-44e5-a494-a4d26f960ded" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_585e87de-30b3-4088-afe0-5c9ac3681922" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_4942a564-ebe0-44e5-a494-a4d26f960ded" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended" id="ib11415a5c5924c9cba4a6cb926cc02af_GeneosTherapeuticsIncInvestmentInGeneosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_43c9f76e-c49c-4d70-b747-f3503621e977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_43c9f76e-c49c-4d70-b747-f3503621e977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0541f359-1560-45de-be4e-ac810af0828b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:to="loc_us-gaap_SharePrice_0541f359-1560-45de-be4e-ac810af0828b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b0aeefcf-b427-443c-b7b3-47b46f80b9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:to="loc_us-gaap_EquityMethodInvestments_b0aeefcf-b427-443c-b7b3-47b46f80b9d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:to="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fa96f3a6-f72c-4190-bd28-f7389b1dda86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fa96f3a6-f72c-4190-bd28-f7389b1dda86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fa96f3a6-f72c-4190-bd28-f7389b1dda86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fa96f3a6-f72c-4190-bd28-f7389b1dda86" xlink:to="loc_us-gaap_ClassOfStockDomain_fa96f3a6-f72c-4190-bd28-f7389b1dda86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fa96f3a6-f72c-4190-bd28-f7389b1dda86" xlink:to="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18e8eb27-263d-439c-a3f0-7e59bd54da69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:to="loc_us-gaap_CommonStockMember_18e8eb27-263d-439c-a3f0-7e59bd54da69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b44c8189-aef3-4065-a1ee-d3ed2e63cf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:to="loc_us-gaap_PreferredStockMember_b44c8189-aef3-4065-a1ee-d3ed2e63cf8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:to="loc_srt_CounterpartyNameAxis_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd8f560f-d54b-4f7f-8608-1321666ae6dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd8f560f-d54b-4f7f-8608-1321666ae6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_e017cc95-01e4-4c73-8b0f-0f0602dc31a5" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd8f560f-d54b-4f7f-8608-1321666ae6dc" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_e017cc95-01e4-4c73-8b0f-0f0602dc31a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended" id="i161e917d9072431dbddf8f4a4fc77064_GeneosTherapeuticsIncFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_57c3bb46-42dd-4792-b676-3d356cc3b946" xlink:href="ino-20210630.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_57c3bb46-42dd-4792-b676-3d356cc3b946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_505a19bb-0917-4abd-badd-ef223839aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_505a19bb-0917-4abd-badd-ef223839aa12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_45cf8cf8-87e1-4647-aaaa-15aa65e6e3a3" xlink:href="ino-20210630.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_45cf8cf8-87e1-4647-aaaa-15aa65e6e3a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:to="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9237f045-2846-4376-a68b-eafca763620c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:to="loc_srt_CounterpartyNameAxis_9237f045-2846-4376-a68b-eafca763620c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9237f045-2846-4376-a68b-eafca763620c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9237f045-2846-4376-a68b-eafca763620c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9237f045-2846-4376-a68b-eafca763620c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f44fb0-5743-41d4-b479-0e9f5da82a05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9237f045-2846-4376-a68b-eafca763620c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f44fb0-5743-41d4-b479-0e9f5da82a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_f1c25ee0-271f-4c4a-8cb0-bd88fb55a5f3" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f44fb0-5743-41d4-b479-0e9f5da82a05" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_f1c25ee0-271f-4c4a-8cb0-bd88fb55a5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_749af9cf-be3d-41b8-94e2-134d74f81cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_749af9cf-be3d-41b8-94e2-134d74f81cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_749af9cf-be3d-41b8-94e2-134d74f81cc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_749af9cf-be3d-41b8-94e2-134d74f81cc5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_749af9cf-be3d-41b8-94e2-134d74f81cc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_749af9cf-be3d-41b8-94e2-134d74f81cc5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_5e3545be-5713-45cd-b25a-5cfdc39f9ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_5e3545be-5713-45cd-b25a-5cfdc39f9ec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_3630493e-177c-402a-b0a1-f4c5a6f887c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_3630493e-177c-402a-b0a1-f4c5a6f887c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7846729b-7e5c-47bf-9323-6d2428b44afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7846729b-7e5c-47bf-9323-6d2428b44afc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended" id="idfec69724a814c819fca27526a9c8cd3_GeneosTherapeuticsIncPreferredstockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_4b668468-981b-4ea0-9a0b-c8e24ba20e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_4b668468-981b-4ea0-9a0b-c8e24ba20e64" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_46ed3295-7075-48e9-9412-2f7eef0b29ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:to="loc_us-gaap_EquityMethodInvestments_46ed3295-7075-48e9-9412-2f7eef0b29ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1622179d-f788-4b48-a397-7774375d2984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1622179d-f788-4b48-a397-7774375d2984" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_865a480e-26e2-4a76-a9ef-486dcdd3a596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_4b668468-981b-4ea0-9a0b-c8e24ba20e64" xlink:to="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19fd5535-d2f2-44c5-83a2-2f6e47721724" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:to="loc_srt_CounterpartyNameAxis_19fd5535-d2f2-44c5-83a2-2f6e47721724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fd5535-d2f2-44c5-83a2-2f6e47721724_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_19fd5535-d2f2-44c5-83a2-2f6e47721724" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fd5535-d2f2-44c5-83a2-2f6e47721724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b91a636-b936-4285-ad32-e6466ba06eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_19fd5535-d2f2-44c5-83a2-2f6e47721724" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b91a636-b936-4285-ad32-e6466ba06eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_80ac3aef-ec20-4b28-ad0b-f460fc16a8e5" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b91a636-b936-4285-ad32-e6466ba06eec" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_80ac3aef-ec20-4b28-ad0b-f460fc16a8e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11dac6bb-87d0-4c5d-82f4-d5e112eba83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11dac6bb-87d0-4c5d-82f4-d5e112eba83f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_11dac6bb-87d0-4c5d-82f4-d5e112eba83f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11dac6bb-87d0-4c5d-82f4-d5e112eba83f" xlink:to="loc_us-gaap_ClassOfStockDomain_11dac6bb-87d0-4c5d-82f4-d5e112eba83f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9344a07-7bc6-4a7b-b464-7062c55dfd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11dac6bb-87d0-4c5d-82f4-d5e112eba83f" xlink:to="loc_us-gaap_ClassOfStockDomain_a9344a07-7bc6-4a7b-b464-7062c55dfd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_350fd207-282f-471f-bd92-d0b817d93954" xlink:href="ino-20210630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a9344a07-7bc6-4a7b-b464-7062c55dfd00" xlink:to="loc_ino_SeriesAOnePreferredStockMember_350fd207-282f-471f-bd92-d0b817d93954" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ino-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:685d0eaa-cf71-473e-b825-35e9cdd023e3,g:d59d2343-5bf4-47b2-b6cf-d3f10d74095a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_004565ad-d313-4e13-8d43-65c221bdabe4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_794d5ef8-a00e-40a6-9f6f-df1e44c27103_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_06f78c1a-bb2f-4a38-a324-3bfef4e180e8_negatedLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_072ceb9b-14bd-43ec-bcc7-f3beb27d7851_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_2538ec49-0c24-4734-83aa-4ade2277e83e_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20210630.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c66b7149-2f4b-408a-9618-e335ad342ee3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_acb15a84-796c-49ef-8cd9-3bd649426528_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_79d60596-e89d-4dc5-a247-2ab7b383ac38_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_909ac8ab-53d2-4df5-9753-1d8283f08ebe_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f6ddab40-08b3-4a03-8065-a3df7221ccd4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_25459439-8f6c-4f82-9083-1b356d644489_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_03ceff4b-dc77-4d8f-8faa-71e6bb500516_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember" xlink:href="ino-20210630.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenPublicOfferingMember" xlink:to="lab_ino_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_323137ed-0d51-4885-9826-0db6c705fa13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f742263e-17cd-4e16-9a86-b2effa50e9f2_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3cf1a63e-c8f5-489a-b3b6-b7a7b1342b5e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b095b372-5b93-4f28-b7e6-99d6840e46db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_2087e413-80bf-44d5-9f26-64b91da6d796_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostMaintenance_38aeaf3d-e645-4872-b7b4-c846100062a9_terseLabel_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_us-gaap_CostMaintenance_label_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMaintenance" xlink:to="lab_us-gaap_CostMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ba95aea6-c0f9-452b-95e7-cbd1ea5aa154_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_8d15d128-7ca1-4be9-a19d-d34212375a09_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entity, net of current portion</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_5ac0b13d-a088-456c-b1f8-722d92f82bd0_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2fedb837-84c8-4de9-b990-204178c1ed6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_71d45224-35ac-4dcf-a97b-e5b759bb6fa8_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_a3e56b2f-dbe4-4cd3-9604-1f0dc1810e64_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dcbb9551-d42b-4929-92f8-418508f9dd2b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a91961cc-882f-4af2-a546-8e1b36911a8b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_090e2c66-1557-4a23-a9a2-52459f7b4fee_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_32e29bd3-e89d-4965-9d1b-41a899c35bb6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a8cd43bc-7e2c-40a6-82cc-7c8fea0a75ff_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e19ba620-fcab-4c2f-9db3-b85b6b6c0363_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_a1c6663b-7568-40c7-bb50-f53e03474dbe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_696d4bdf-2d02-43be-ae10-b800bd8ccb0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1977031b-46d6-473d-80c0-51ab4e2ae642_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_b734fe57-1eae-49db-afe3-1587c65b7785_terseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under share based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20210630.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_4e80962a-e7d1-45eb-a134-8d50af87b43b_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20210630.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bd9f0158-9bc6-4ab7-918e-aafde1c5500b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_f1e69818-ed40-4613-a161-427a1a0048a7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_9d28dae4-031f-44e9-8863-b4d9f023b9e6_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_d0e75c23-6b1a-439c-ad2a-474c0c0848a1_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_label_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementPaymentEarned" xlink:to="lab_ino_CollaborationAgreementPaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_420f4150-e4ad-411c-b509-d572c1eb6b9d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_a7c0cca6-dca8-4ab7-96b9-73ed00b706ba_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_label_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:to="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f9d3307a-7b9a-4b5a-9465-c5cc009e0c23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f321a2a5-da0a-4771-8850-e91f0d3b6eda_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2617cf57-2e16-4108-b182-ff83dbad5c80_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2fefb7e1-7967-4d47-8e85-e906573316cb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_cb4c7bb9-0de5-406c-8972-744b18be3ecd_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_ed547c08-1d00-427b-8560-28756cf80955_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20210630.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_0f780fb4-f3e6-4efe-b9ff-25a6097d9b4d_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6f32d31d-a2c3-40a0-bce0-d0b220f07094_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5bb6bea8-70bd-4278-a658-05d0416c6877_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_c78de9ad-dfec-413a-a79d-532d2d7fe02d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_5a9b360f-cb78-49de-a629-483c9e48eedd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_544ff497-a4eb-4c49-b249-b7a4b981fb51_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, net book value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dbed3a9a-f53d-44d0-91fe-f51948dcc62d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_16527f86-831a-4e3a-85a2-80f6af172116_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_98e369fd-d094-4e72-a94d-3e379ad840de_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense on intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_a15944d6-f8b3-4d62-b1d4-e5e9bc0c355f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions and other estimated offering expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities for Commissions, Expense and Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:to="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1a9eb793-b2e0-44f0-9344-a5c852d5e49b_terseLabel_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2026</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ino-20210630.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cfded5bf-9139-4d10-ba35-0521e6482984_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cf9e11f0-8a7b-4d79-9de5-b9dc60499f91_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_94fb8ded-43d8-434b-afa3-e6069fb35967_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_66e51745-9e02-44d3-8ff9-c038ae0e10b8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_de550ac9-d90b-4775-9d0a-67121a9f575c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_ad87334f-b0e1-4dcd-8e32-f537d0f24ab5_terseLabel_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input, expected term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_label_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_documentation_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:href="ino-20210630.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:to="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_0ec70b88-1f39-4739-90fe-2b0b864d4d0f_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Territory expansion option period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:to="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_630031aa-3d80-4d20-9525-e6c465d2d850_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f1aaf838-f80a-4d66-8ec4-d2333c5c6148_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_c6c33643-87d6-4e3c-a340-98e0ed9501b6_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6bd0142f-40a7-419c-9f9c-e940392f8a78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_846c703a-f1ed-424e-90f0-66ee21f3f87f_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20210630.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_baa7c454-846c-4df0-9486-e68b04e26079_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3adf11af-aa10-416a-9166-6203840d6906_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_767e2b9b-d621-48a8-b9cc-f305ac9429be_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember" xlink:href="ino-20210630.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember" xlink:to="lab_ino_December2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_68211b9b-b579-4f9e-8bb5-34d51a55c52b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_776e97e0-1acd-47fa-913c-a90ba256bbbb_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2590391e-d62b-4e11-a86d-9ce6ac99f272_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4be242f3-0306-40fc-874a-9cc632d6cd9b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_902955f2-08ea-43ef-95bc-9ee9e70c101e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_aa239b9e-3469-49d4-ad9a-746b6a6350e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddadd863-eb7f-4e9e-b4bb-2ec9b8a0a47f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_dc483d99-183d-4d48-a3c0-3f9f41b49e2b_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d4328abb-259e-4800-b23d-bb1b11cbe64d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_9555ad6c-9f54-4183-8f64-ddb20261573c_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_a15b9a7c-bd77-44d8-ba71-4270ad6216f7_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20210630.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_92dcaf08-9a88-4e98-9c44-56720554bcaa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_30074285-3421-4fcc-a361-2439f2ebd08d_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20210630.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ab3377ff-7eec-413d-9f04-aafe09e6533d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_b41000c7-4146-4039-8e70-201017dcd6bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_392e4119-f86d-4204-bbe7-548455a3432e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f11f61ab-7111-4d8e-9004-b318d33be500_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a1b0f600-bd50-4827-b3da-f2ee528ac22e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_202eb744-db4c-4374-a7ca-10d37fcccfe8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of date conversion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_07d796ec-09a8-4e75-898b-bb31429442ff_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_26c48547-4457-4655-80fe-b9492d32d1c5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a3f763ee-7ccb-4c23-9187-28bf17a8049e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a0188d6d-22bf-4e4d-8146-556ac0288138_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_e8f0274e-eaf1-4a21-8005-70fe21cea65e_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20210630.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d7a83436-d042-435b-bee3-eef8cab502b8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b0c7cb22-61f7-409c-ac98-e1d6bc4ac564_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_8cabe439-4e29-4bb4-9b3f-6c3d4f20851c_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_7ddaa35b-71ae-4f89-b029-79b070fc5c4b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of investment</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_319343d5-a52b-4ce5-bcf9-b918baadcd1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_b656e327-b4c1-4811-aebe-d9fd477735e7_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_d5d2a0cf-aef1-41ad-9775-d2dd84220a72_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_b2cca504-fcaf-4f80-80bc-cfe5bd34086b_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received in upfront payment</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_label_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_documentation_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement" xlink:href="ino-20210630.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromCollaborativeAgreement" xlink:to="lab_ino_ProceedsFromCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1aab0f38-c795-41cf-933d-125207d2916c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6269edb2-643d-434e-9f49-7ac34828be70_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3e1a0979-f6e4-4a40-a441-f31f5397043a_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1b24e95a-18c8-42b8-bba7-c534c79ea989_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable/accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3464552b-0938-435e-b749-396a947832ef_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_ca61417c-ef8a-4458-a0d2-0fab4e602c43_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0610ccb9-463c-4ee7-8968-4d592e344fcc_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20210630.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_95356b22-368d-4a8b-86bd-306aa9e832ab_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20210630.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_82ad4815-ca1e-428b-9b2f-1200d4d0e7a3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_8f3304fc-ab4c-4a2c-a14d-01c15b7530a7_verboseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20210630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4f5d0f2-2da8-4400-af35-241b16b9878d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_a8b156ee-c477-41c4-aa0e-9e7f959e5683_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_9afdc3de-75cb-4ca3-add1-a20b59924900_negatedTerseLabel_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital (excluding cash)</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_label_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_documentation_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash" xlink:href="ino-20210630.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapitalExcludingCash" xlink:to="lab_ino_WorkingCapitalExcludingCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a4b7d352-cea5-4f7c-bfd8-2ce9387c7274_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_dc4c0106-a429-4288-9dbb-f00f4e64fad7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c1341ce3-cf6d-4eb4-bbee-aa1266ba6154_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_76d5ef47-2c84-4ae8-a28a-8fb391595e71_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill and Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20210630.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_cc26353c-24a9-4b40-a170-d4f54d23b046_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_b5a652e9-972a-4609-a9fd-fceb47db3151_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2d880624-f047-45b7-ac68-41de984b663f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_33fd51bb-bfd0-4b89-99ef-4452036ecad7_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:to="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_789994c4-0010-4834-a3b9-b2db2e45e1c5_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20210630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_679766fa-bb8c-4fb9-bc91-565c4b876278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1a390201-0e30-4a1e-b3b5-f34496d7d054_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_d944c8fb-a495-442f-bbc4-637e4d4de0ba_negatedLabel_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of receivable with shares of common stock from affiliated entity (PLS)</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_label_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_documentation_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:href="ino-20210630.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:to="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ebc09cf8-6dda-4f3b-be9c-f535e8a8d539_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_be032d68-1ad7-429e-8829-b1f2d946b4bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_91bf17b9-e578-433c-87be-ced09a0b5533_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_044cff66-52ea-4a36-8b54-0e17a6e33fc3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid balance</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9719e83e-6df0-4427-b7df-0ca689aad3e8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c769ee29-3eed-4c60-8329-229c9d66a3d9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3aa63726-8dfd-4aa2-9e58-d223a6a60d1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c4fc1bf1-2f99-474d-93c2-2d0b667403f7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f64799e7-37ed-459c-94b8-aa63a5defd5c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7842e576-2cad-4321-ba87-0e537d78d6da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_56883eb9-f2ad-4ae9-a8dd-b90b56b339ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementsMember_0bb437e4-9adf-4d8d-9767-100075e83f0f_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_label_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember" xlink:href="ino-20210630.xsd#ino_SalesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementsMember" xlink:to="lab_ino_SalesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_697c97ff-4bdf-4133-ae6c-ebcc5a637270_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a863c5fa-ad1b-4f23-905a-04126ee9297c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_de90f19b-a1e3-4604-a3d5-9bdd9ae39607_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_be428455-143b-4cf0-a496-6cc79a8c7669_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2a2f6438-e62a-4998-aaf0-9742bbbbe156_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d52fcb9c-3b18-4cc3-b0d9-f7d90ef162d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_24a05375-cba4-45c8-93a5-00ee3ee8bd93_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9912a37b-31a3-45b8-9339-822e108f6427_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c5e38030-d991-4bba-ba73-633d82a62c9a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7dd89266-1c52-493e-937c-a21981aa3656_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_8ebe7ca6-2312-4715-bd83-9a0b94d13d1a_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20210630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7334c30b-fe35-4043-a8ce-f944b497198f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Liquidity and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f91770a4-f93d-4d28-ac91-fca52fa6f02d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_90345a58-b1e7-4bbe-96e6-0c624aec4371_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3d85f34d-3d19-4c93-8af1-7b3208c22ee1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_11a8d90e-8c08-4c0e-8df5-11d36fbed65f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1ced7e44-3f20-4c0b-b8dd-a8077c03acec_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_43a749fa-81eb-4120-9805-5f1a9035166e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6faa71bd-c784-427d-b586-f105a122b157_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_d7eb289e-a9c9-491a-88a4-2630b36c69ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9bb81200-d19e-47f0-af03-343a940b40d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_d84b19e2-95c0-4c0e-985a-50ac0ff5b8d7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b569dafc-df87-4770-8a1d-b9ef718c1003_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2eedc17-7aa0-474e-a76b-d6077d08aeb7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_2d9f3729-2d7f-44d0-97ee-5cd98cfd0fff_verboseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos enterprise value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:href="ino-20210630.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:to="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_2429365b-c85f-445e-a2b4-48095c266e39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a33e3fc1-35ec-474a-a8f9-0b217a42c6dc_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_8fd94f0e-4d88-4525-929a-a78017907e73_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5dd9b69f-d819-4715-8425-354a08e2748f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_9cdc21b3-2f52-47b3-af3e-c1fd802873fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_506649e4-c671-4ca3-937c-75f24ae6fca7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_fdc8c377-a606-433a-ad8b-aab73d9319fa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Geneos issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_de15622b-26e2-4d77-9c78-c5db9e0cc1a6_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_440d8c89-cadf-4786-9daa-c872fb025820_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20210630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ffeae343-c762-49cc-9e78-da5fadd4b7ef_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_613f46c7-ca90-40e5-a1d9-862b34938ed8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_62dfe722-d460-4397-a017-318154be0346_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_c2097f6d-ca24-4e3d-a007-5e44689d5e7c_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cd3a3749-3d26-4579-af5b-8b0b28ee5531_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_40210802-cd1e-468e-b8b2-a089db1791b2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_c52d217f-a77c-4b2e-a6b0-aeeb2b2cbae3_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20210630.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_25727ba2-615e-4feb-b912-260f7c203f80_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_09c661e8-eb32-4ed2-970e-f7f44abf34be_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_8b4c60f5-fddd-4c0f-a6e1-f67bda220a6b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_27338eff-d00e-4535-b2c3-58ffa69438da_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d2708955-f308-4f05-879e-0641f9f9087f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e5b7cdd7-d910-45d6-9276-02dc2d753310_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c984aab1-e1d4-4da2-b7fc-671d52fb0fb6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_ed6b4fb4-23e1-4df5-bd70-05ba08d81f1a_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_6de263c1-6cb0-4f3c-9ad6-a6a5a63930b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4f375145-4d69-47cb-b1f7-2fbbfa0ea20a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_c3e7896f-4ea7-4afc-9829-b73fd16aedc2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ea4f76ba-e43b-4318-b7c5-39fdf8d561e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_06abe65e-dccb-4b5f-8d5a-13fa44a2a341_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten public offering, common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_5f0e1565-acbd-4c44-8dfe-34432cf7e8d8_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20210630.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d649bcc6-a7ef-483d-a79c-b9cdd8a56da6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4ef545a6-06bc-4aa1-9581-5b37fcbbd042_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized transaction gain on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_26495899-3ee0-4978-88f0-c86c829a0720_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b921a9e4-0d1e-43dc-89e9-21abab46b1ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_139491ee-1bd8-477b-ad28-3dd4b23c627e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_201ae306-e7d4-4177-af45-b1ddcbcf9898_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_19c32e58-0df8-42eb-b006-060852d19043_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3d29fcb7-e13c-4c69-aa88-dc71666014a2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_7436b1ad-ce50-44e6-94b3-91885121e31e_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1940ca9c-fac1-4c64-9315-cba541d95ae5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_475a928d-870c-4ff9-ba28-61c1c1406c72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d8919a4e-7f72-49dd-87cf-fa410fe935d1_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_58b55d2b-a7cd-4b34-9a7e-30b39340289e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_28506a9a-a908-47d6-bcdf-399767aea894_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest in Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_9983e570-3957-4e63-a404-ceac0a545331_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_e67561f5-38fb-43ae-9af4-1a30f8307518_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_93189c3d-e7e8-4fb6-b482-150842a68f39_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_62e0ad06-6cd8-4301-b586-507b9246ef07_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d22a0ba9-1eb9-4ed8-b318-24fd417f4806_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertibleBondsMember_278e0689-7edf-49fa-bc8b-ea021f1ce48d_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember" xlink:href="ino-20210630.xsd#ino_ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember" xlink:to="lab_ino_ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_83e2090f-7a88-4119-b84a-e4bce3006852_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9c7f8e37-eedf-496f-9d92-967397acdaf6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_edcdab3e-b1e0-42c1-977e-c50d10a424b3_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20210630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3101249d-0aa5-40f1-b91d-73018fe2588f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_060416d0-2dca-460e-9bb4-4e764766ac51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_41d8b285-ecf6-41c9-941b-6ffa8cf8cf0b_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_757b119c-d476-4d5e-8a05-86645ef6fdd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_f963bdad-0050-4328-adb1-e8447cdeb935_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20210630.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_e9cb777a-1881-4702-9537-01ef62172809_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c4855fd2-9421-4155-b667-85f222e16204_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of carrying value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_345d9842-87d4-49b1-8f47-c9002adfd234_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_28350adb-770b-4f45-a45f-9833e588b807_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_796e7cd3-9ff5-42b9-8c15-747dbf6eee21_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest" xlink:href="ino-20210630.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccruedInterest" xlink:to="lab_ino_DebtInstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_939329c8-789f-4dc5-9f2f-89da9b0572f3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9bae2f8e-4b1b-4fc4-a44d-100a3fa343c7_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38f55828-6ba0-499b-8a74-ea5319fa12da_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb01354f-95e0-4903-b9fc-7a46ea5b0f4e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84997b17-4183-4f93-bca6-1774fb946635_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_936da772-8db9-4899-a2fc-b43a310c2d75_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_f1c39c2c-bbc1-47f4-9016-a23cbb0df1cc_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20210630.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_369b4de3-0696-4087-8dbf-440d84402261_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_88dcdc70-8a2b-4a8e-b9fd-86260a18ca16_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7550aacf-2159-434c-a5b8-4934ccf02aae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_b5d28e34-14a0-4546-adfd-7ebb7b06fcce_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual maturity (less than)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20210630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c92e1b39-2107-4d2a-ab95-b38dedee0385_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_b86948e5-d514-4010-a3dd-8cf8cacfd344_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_786635fa-d157-478d-ad3c-9bbf68f95010_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_beb8205a-06bf-43eb-913a-862fdaaf1588_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_230d9274-db95-4843-880d-e3b6bea22db0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_97564ed0-7037-49be-894c-6d3b10817884_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_28305f9b-62cf-481d-b066-9ddee441a469_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f56bccd1-235e-458d-9304-86fe2dd6fe85_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c4ea7067-b89b-4109-b02a-0f74a4cfdbcd_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4bab2c70-fea7-4432-8544-50f6dddeb4d0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0107cf05-6b96-4f10-a317-5e927bbe4f69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e11cec34-bd97-40d1-8c73-9b39ec48ff39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_40bb1c12-7124-4cc7-b584-9635ea232343_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2fcb366a-c223-4771-8e99-22e3f2875260_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_88cf2ff6-954a-430e-a7b7-b076e7b6c759_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_0117b359-f92c-420c-bb2b-53de650b542f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_01271b29-0cc5-4c0b-8fba-ae4dc79737c7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d774bd1f-b9ff-4a16-bf7a-fed133bc4856_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_898ebf35-9611-46b1-9ba5-c6fb1a1e787a_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_78b004a5-b827-48e6-883a-3163923caecb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2e0a3c59-dc32-4e71-b0bc-a44c803bb0ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3e15f14f-6195-4a23-ab1d-179a581d4886_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_dcbbca98-b49c-42b7-acb4-753752f8cf07_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_243c6b4c-0780-4977-8eee-8bbfabd8378a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_9aaf9bdc-70c8-4a0b-b930-7349b0560e0e_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2656da5e-b06c-4d11-8ad9-5dbe8d991518_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_06e94c80-6dda-4fdb-ad7a-87f7e53d8b4f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_55418991-2666-4851-84f3-c4e00ba2c207_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_7ca6f1f1-f2b5-4750-91b8-a4fb1296c8bb_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_8ae3345c-f1fa-4f67-a296-2ba1011d94c7_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3e04717f-98ae-477c-bd4f-9a3c90df68bd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1a2df427-aaa1-4642-b61d-941fb142e5ef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b82e42ef-cc1a-4be0-af22-de79e0d7869e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_374d6944-9ae6-4773-9acd-428a3bbe7e17_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_2f74a161-242e-414c-a5d7-66b6dde0614b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3c239ed9-d50f-4b2b-9aac-bcaf2e011510_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0b6ff3a3-4e97-4e19-afa3-f39f5860852e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7c532018-e247-436e-85d7-c219a1672b54_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_94952fbf-174b-4a08-86bc-c6dfb4119d79_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20210630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_1f577849-02f3-4e5e-9d62-61c49ee01526_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3ab6156d-cf6b-4501-94ea-5407aafc750e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_0f306e00-bd52-4101-a34a-e0f89b60dde6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e698ae71-813c-45d3-ad3a-4904b142decc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_a347ab45-4ceb-4479-8ca7-8538d4bfa37a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument principal amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d3750f3d-21be-46b5-9c13-721b8036b4a4_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_c9aab834-6949-4e37-b84a-c887e3ddcf8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_3b607d99-7630-4d6b-8479-4aa2f24222f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_a150fe45-d0a2-479c-921c-926e1b86d297_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_75b68af5-c6a8-4387-860a-ee00ecac4bed_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20210630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1e8b2d4d-3aae-4001-a601-1ad9f186d6db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2d97b9f0-86cb-4e11-943d-a3cf2aed41fe_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6bfb71ec-5cc9-4b2f-aa96-30bf9362a22f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d96f2e85-7880-49b7-adc5-4ad5242e8948_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_4e73f100-7eb3-4572-b94d-ced4f4bb9b52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_7ce93b37-46db-4b86-b24a-5a7d58ddef37_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7a0c2493-76ac-4833-b3dd-71b5f29c340e_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_66b8751d-1bc6-4b27-984f-bf714dff71d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9bc3e2b8-57db-403b-af8e-1351e7d67691_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_74a9bda3-3b80-4b48-a8f7-0bd39b1f114e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_57737035-7691-4e00-81bd-a4b8b257803b_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_66b34037-8185-4551-8f22-7ac0f937215c_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c2e8c83b-5a0a-4c67-89fc-004b3a018041_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_8c459ae6-37b6-4880-bdee-3615e8694a64_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_82bca8a4-9aa2-4cb5-bce8-7cc37bb16251_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_3d3c1ada-9770-463e-924b-6d2d756130bc_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_14714c1c-9f7a-4e90-9705-798923afcbea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_25b26f71-6465-4136-9eac-ed0a61fb209e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_97f7f419-cdf5-4c37-b9bc-de168b926092_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_f8ea44c9-0940-4d1a-9282-3de961b575ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1c322ec3-c2ef-42b4-ba42-30749bcbe4cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5d5157ed-6ca0-42e6-86e7-372284ef8bac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_981ba8ed-93f5-49cf-80c7-ff4974a7e163_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated development and regulatory event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_a333bde3-b822-4683-a51f-da2526d9548d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b825f37d-f795-46ec-8aed-826cab29a0b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_c8864061-4a69-4e71-8b2e-d70fd514e47e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_9c23dfd3-d314-4d0c-8c84-1396268636db_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_eaf4df45-16a4-4a15-a7a5-2ca639f0e2cd_netLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_e34db653-2cc7-463c-9d04-6d340cd67fd1_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos upon deconsolidation</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_9a5b7266-7bf4-4dc5-94a2-3fadcc3552ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos as of March 31, 2021</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_41bdd1eb-c9d4-45e7-be0c-25c2cef05b25_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_bea5da95-9b47-4418-b0ad-0b2d1408e1ab_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoOfficeMember_892a4d65-8633-46a3-8779-87c1849ac6fa_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember" xlink:href="ino-20210630.xsd#ino_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember" xlink:to="lab_ino_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3aa2d156-6546-43c1-9391-4e9995984199_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_d40ee3b1-ec13-4d65-8415-e341694ae5c1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_8ce481ec-94da-41a0-93bb-182ab77f5ea5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c4c07e80-5f58-4133-90a3-b3828666bd7e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e9c1729-4970-4445-a8e0-f1afb1500ece_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41e9f098-0e64-4d31-8931-9796ac42e4ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_49bf6fb3-65ae-42fe-a134-7b0f34498b8e_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PriorSalesAgreementMember_41ad88ce-3c8c-4bdd-9340-e312c7d604dc_verboseLabel_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_label_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember" xlink:href="ino-20210630.xsd#ino_PriorSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PriorSalesAgreementMember" xlink:to="lab_ino_PriorSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f9a7f5af-4bdb-4d21-bd77-0f200d6862be_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_1d2423a5-c65a-4985-bd1a-3a33a861672b_verboseLabel_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_label_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_documentation_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:href="ino-20210630.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a37f3953-84b4-46aa-a3c8-cd944520fdfa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2c307e8b-6ddf-4a28-b5e8-21b1f7bba8eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5f39b653-4fb6-482d-a30a-526e6eb55c1c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c4539d16-e2f3-4837-94af-5fb40eb750a7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_e62dbfbf-32ae-424f-92f9-b04e2bb3e55a_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_195aee35-3e3c-41f8-9d0b-b08e32bd0d9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AstraZenecaMember_87f11999-c0be-47cc-90eb-35235efb4a6c_terseLabel_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ino_AstraZenecaMember_label_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ino_AstraZenecaMember_documentation_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember" xlink:href="ino-20210630.xsd#ino_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AstraZenecaMember" xlink:to="lab_ino_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1e2987ee-b7d8-4de9-aabe-ae3a7810071c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_bd9821e9-93b3-42d4-9dc9-34510d48ce8e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e97cef55-31d0-4f09-923c-6542a5750e46_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b36c6276-536a-4d41-824f-6c1229f2ad98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_09507dd0-08e6-4c56-91ad-9d6ab9fd2260_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:href="ino-20210630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e6a54f83-b68a-41f9-8957-f37adc62777f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ed2a826e-f539-4aac-8a45-a4c4e296939d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9c9ebb2a-5ca0-45fa-860e-2b16e0ce8098_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_0c8eb36d-e3d5-4d21-a335-b65194306691_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherCounterpartyMember_4af8fd15-9b1a-4b79-8c98-454295f177bc_terseLabel_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_label_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_documentation_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember" xlink:href="ino-20210630.xsd#ino_OtherCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherCounterpartyMember" xlink:to="lab_ino_OtherCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0152141b-bad5-4e38-bcc6-954f99ad5e7e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ec872556-e46e-4ad5-ba4f-b3150c08238b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f3d788b3-2c82-4c4f-a330-6954c797da59_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_38e31191-44dd-4ffd-ad9e-1668af9347b5_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember" xlink:href="ino-20210630.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember" xlink:to="lab_ino_August2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_092cdccf-b9f0-42f8-b68f-329d8d20cdb9_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_5429a182-5219-492a-848f-186baf478fef_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20210630.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3002b643-04f2-4cfc-87f3-c3ba41ab5e31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7f902a31-daac-480b-bb99-c05a32fba6f5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ff464c80-f7c4-4392-9a65-f8b0dfab9720_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5946c04c-ab97-4e76-bab1-e9e6ecc0882b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0aa4ec2d-7397-42cb-8eb6-e8aef88e6fca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_e385baff-1693-4a4f-b337-0f8e3580c814_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_61e7ac95-a62b-462c-8e50-810e19eccf4d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_efc237b5-5241-43a7-8e0e-716ce51b7061_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_71aa9642-c7f5-4cb4-bd04-4eb4807439b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_08930498-ec44-4437-ace3-f6d501c5b086_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_132ddcea-279d-4a77-82ff-ae6303675617_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d0160f3f-e2fa-4e02-ad82-a870b9eac837_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_070af119-dbf9-4d1e-9e68-34df657f87b1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_a3ca6e35-fd34-46ec-8938-a712ade016d5_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ac4c83ef-b8a4-4a13-93b9-fd7a6ffe4999_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c1e9691d-cd15-49d6-9b47-d18d7a8cf3a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_999fc37b-9b1b-4d2b-9d4f-7856e0deaef0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_380a042f-dbe4-4079-9d39-7d79830e9519_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_5cb7114f-376b-4e95-a128-de1328d7678c_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20210630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_37b4df74-36be-4050-b17f-547507a07d13_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2d7ea19e-699b-46ff-8796-16b611d1c7a5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b8c569b7-b588-4c1e-96c5-370704dd1d98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Intangible Assets by Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_c3c9e8b7-d099-4583-b400-00782da8844d_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4e68c917-49a6-4595-8848-488e53ecbaac_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f8ef9907-7c9b-443c-82f8-b8d129536d58_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_aa742e5f-fff3-4b2d-a995-3eec625c0c9a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_fb4b6668-8191-42a7-9fad-da5f013076b2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d973c2e2-c4c5-4382-a8b0-2d768e9f9977_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_a3895e87-1342-4298-a58e-6f9d8bf13cf2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_35048838-220a-4592-95e4-40dbd37f5621_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_b715c02a-b8ab-4fd6-9fbb-4fc71fb54c82_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5f53547d-cbdd-45f4-af61-a75585f375cf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_18f7a898-08ce-45a8-b9b4-01571bf1fd6a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a8d46b73-08b4-4b83-a2b2-fa206226849a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_fa09d9f9-4108-4ae3-8893-6811186f730e_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_1f189903-2217-4ac6-90b8-06331bbc5e08_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a624fb09-a75e-4a61-8cfc-a6643b47aa73_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3088212a-f79c-451c-bfb1-1e50eca3703a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_53e970d0-1417-44fe-a881-761f38ed78fc_verboseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Deferred Revenue From Related Parties</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:to="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_fb1c95c7-c49f-4dac-a3da-5ee463c838e6_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20210630.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b4b8f049-50ed-4230-9a9a-70bdf1d1f77f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_fb6d4973-1fc8-4c58-8218-78133354cec3_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_30148eb0-8e0a-459e-8d07-dc598fe4ac64_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c1a2ce77-b931-4f76-8567-4c3453f3e7e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b42d3139-1a73-4771-b708-8e031e39fb82_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7e335265-4fb9-4966-ade7-5208dcf2b27b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0ae07dcf-9483-487c-93b5-c6a8eafd6463_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfb34ac6-82d5-496a-98ec-20e10a5d31aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3d28d112-1200-4fa8-a1ca-e16085cccd9a_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_22a552ca-c769-4a4d-a9c8-7424388c6b62_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e0e5b357-d2d2-4bc8-9827-8fd09ee8fc1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9eecdb11-3a5e-49c2-b1e3-dc1cc69a7c96_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ae54d28a-6113-451c-92fd-f4ef5950da6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c5c95062-af56-4597-a501-0de11ff2109b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_a2429b07-2afe-4b6b-9218-89d1b1615765_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99c61eb9-fada-460e-a143-d4bc6f09bc0a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d2d2cf9c-556e-4edd-a4a4-5f864afb3129_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_48966b3b-8339-41d5-b0f7-b6d8756f1929_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_422fbf81-25a1-4ec7-bf92-af2b9ce81fc5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ab2c8120-507c-4d34-8ebb-f9123be724ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_19bf47e6-e73b-4cdd-b6e8-051556d0cb84_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_ac88485d-7e41-4d97-a235-5763ce3973fc_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20210630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NewSalesAgreementMember_db834a82-b025-4539-956c-6e6ec99b7861_terseLabel_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_label_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember" xlink:href="ino-20210630.xsd#ino_NewSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NewSalesAgreementMember" xlink:to="lab_ino_NewSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4364e1c6-6bce-4333-b60e-ae1e9d648a9d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d82b337a-beba-412a-8429-df6b410e84bc_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_0e0ca4cc-d0d2-4d76-9a5b-12830e4b5242_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_a88bfd16-db3e-4d23-8a92-a1600f225807_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_b7e17999-5c06-43f8-8d1c-52bc19755f56_terseLabel_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantPolicyPolicyTextBlock" xlink:href="ino-20210630.xsd#ino_GrantPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantPolicyPolicyTextBlock" xlink:to="lab_ino_GrantPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_82a33147-b904-43a3-a02d-78ea5bb8ae3e_terseLabel_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_label_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_documentation_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense" xlink:href="ino-20210630.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLeaseNonCashLeaseExpense" xlink:to="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_93a66248-8484-4a57-a6d6-e422bc84eb9b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_695faca9-96a8-4ef7-b979-ecf3b55c092b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_a6350f80-6f2e-4d24-a6ac-a37ebe443c0f_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5fe8bf3-c06f-46c9-bfc8-063778b822c8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_36c756ba-e6ff-491c-b3a1-ce792f8bb984_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_65ee0640-199f-4c62-b161-cd3a4d411d88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_65608545-3038-4908-9773-b981ecd1a5ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_9d79d0b1-f1b5-43df-a109-4e2cdaddc2c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b5eab8c8-b0de-40d6-b399-092cf2de0bb3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_40513716-5f53-41e8-aed4-341ed64b7909_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_1a6a9c90-e619-4073-b40e-34c89f5edb5c_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign non-corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_label_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Foreign Non-Income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Non-Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:to="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_faf59cf6-675a-42df-b4c0-7c750d21bc1f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d949b768-2508-4267-909e-465f910675f3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d0044ddc-a210-4e6f-a170-23357a3e6db6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0e92a444-8ba3-4409-9edc-f5d06291f04e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_897fd2b3-b474-47b9-8b65-6807edccb3fd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_8da44a44-5538-41d0-a8d9-2a3c2e3220dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e82fe4d0-ec02-4db9-8fe5-eafe15dbec91_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_86893a04-77c7-46ab-b7a1-46737cf0f0f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for remainder of 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_78baee47-cf5f-4f1f-a689-ab94102a05b0_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_985ed965-622b-4c68-8b0a-3ae5bc649a2d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e694507-1d98-4908-b9d3-7eaf566fc06b_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ca0b4c56-43cb-46df-ac1e-5ef8a12eb8d8_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_09652ebe-93c6-4a2f-94ae-005f8ebdd300_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1be2f925-58d0-4a45-90de-ed2ca36705e1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_de90d875-85e6-4611-8e6a-93e63a873e07_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated commercial event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_53b14009-96de-4dbd-8a2a-b998d513256c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_19edf6ee-fae5-4d7f-990a-14638b0aafe7_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20210630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_0d0c172b-8a03-48db-b870-159b0025ca0b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Capital_435e023f-15f8-4cd6-bcc6-ad8a6fbcdec9_terseLabel_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_us-gaap_Capital_label_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banking Regulation, Total Capital, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Capital" xlink:to="lab_us-gaap_Capital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_3965a04a-884e-4b96-8e87-41bbeba93f6c_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_8bb00cc9-0bbc-4676-9d14-dcc012bef6b7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_3c1a485c-1634-48f1-8aca-ceb3081cd25c_verboseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_24081b9f-85ed-45d5-aaab-b8792556b808_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_44c6528f-58d4-4b83-a383-18bddda6f944_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_9fe78021-678d-4db2-b082-e2dc12094227_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_24cb1a99-8400-445e-8e25-a2af3f81f554_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20210630.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_94b3a353-96d0-49d0-8d7d-83f8a118248e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investment in Geneos retained</link:label>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Interest, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:to="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_ea7ac4f2-599a-48e2-8e7d-ed9f29ce807f_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7bf6d706-d49a-4556-b733-61bca6c19209_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_761bc6cd-f496-4f24-bec5-0ba8b42ae161_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b553befc-5140-4d78-96d9-c94bc9291478_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4111cf3a-a0ba-4f7d-a6bb-ce60fa19f349_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_2899d8d8-b830-4866-b9f8-2d059bc66143_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_ad6585e8-af47-4e6b-81df-6b3291d397ea_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20210630.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_102a99f7-c164-4f24-8dd9-76dd7b4ffa5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e9755c5a-d752-4906-bc9d-257348152699_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_af1145e3-97c2-46e1-aabd-77c5ef0c1559_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_776515b3-8c85-4713-8994-449ced6d8ea0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_d5396aa9-645d-42e4-b891-d9bb9d507bf6_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fe1bbeb5-bc39-4e5b-97d0-5cf008e66f12_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_3f444d54-e736-41fd-bca3-e065ae0098b4_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d81dfa82-cf40-4d87-94f7-1a9e74b22272_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c659d50c-8576-4bde-944e-80567934a2f5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_0a26177b-909c-4b9d-8d74-98fb7fbd35bb_negatedLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20210630.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_d9b9caab-84b5-4549-aaf7-2a9714ac0fd5_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dfe86cd7-ae62-4d1c-b14c-9a17df2c6abf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_16bdc97f-d67b-41f5-b6ad-8f0ba6256831_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_30de53a1-7f89-4582-98c9-a6d7e0b7593e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_d343ac32-e2c2-4b0e-99e9-1ff9976a6f48_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember" xlink:href="ino-20210630.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA2000DeviceMember" xlink:to="lab_ino_CELLECTRA2000DeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_65cf2fa5-2b19-49ba-9b50-8cf163d01207_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5017293c-3ca3-44fb-b87c-f1d474ef1717_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_03e69e37-8b35-4190-9998-f8aa47b09575_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_f02276f2-0ea8-4435-88c6-c7f1164c5f2d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f695b38e-03bc-4724-90f8-e91c05b95fc7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_139f3de6-1ba9-48ed-98ea-82e9edd0d394_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_83b6f36b-9b48-4745-b930-e0b6de09ba5c_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20210630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_89d0cf14-111e-4486-bb93-f22a4da3b283_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0c7748cd-fe35-4b61-aa5a-f7e568d583a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0f9ba5b9-8e34-4a10-a83b-5ef3bf911563_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_430b2078-8b74-48ac-a8f6-8abe01b7f0d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_938d64f3-67e7-4625-8028-e7beec67c052_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b6b9a504-8147-4702-a6bf-61f197c090f3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_733c2d97-6b4b-414e-8d7c-c9340f7c7f3c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a57a039e-3b0c-4931-8a18-d3db28a475a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_62877683-a44c-4e76-b408-d2d9e223f17b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_f60ae27c-82b2-4563-9f06-8ef39fd652a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_fd43c06f-79a3-4ad1-b62c-9fb34f843a27_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20210630.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_51e8d58e-8e9b-4e5b-a93c-7113203f6f6d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_7be6705d-638b-4fd2-ba71-f11d3f77dc64_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_ecce358e-0fcd-4250-8f6f-8811f58576a8_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_09c7d176-5b48-4d1a-853d-f47aa2169207_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bdd6ed4f-6183-426c-bd34-e15daaa51553_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e10a556c-0cbd-411e-a198-3f31a2e6693a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_4cb1cc26-f6ca-43b3-9336-60892d2b835a_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d23e5b3f-e1f8-4f1b-9bc0-481ea28cef02_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2fbe6d2f-6fd4-48ec-ae39-236583a76ee6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_663b55a2-de0d-4e43-a9df-84768fbeddc1_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements with affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:href="ino-20210630.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5deb41bb-c06c-46d0-a17c-89ba5953653d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_250c80a8-c74e-40eb-ac18-e3a5131b55f1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e9c4369e-2a14-4e2e-9de0-284277e33b24_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AnnualMaintenancePeriod_983144a5-6800-4b25-b8f7-215b2dbbf70d_terseLabel_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_label_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_documentation_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod" xlink:href="ino-20210630.xsd#ino_AnnualMaintenancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AnnualMaintenancePeriod" xlink:to="lab_ino_AnnualMaintenancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_80130fff-7963-4ce7-a7b8-2adf1dacebef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6435f7a9-24bb-4d7f-ad06-3ba4ae548110_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_28a6c0d9-a313-4014-832e-da5f01331235_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_efc2c742-8fb8-484a-989c-fed5200b34ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8948fcb1-2017-4c02-a817-62974f5a426a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_af98766f-7041-4a14-b998-95439ef4691b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_517fbd64-640a-4db2-9216-45ac73436dde_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_14a98072-f7bc-4b27-b251-592bc54da44f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ded3a353-453f-473f-8c68-d5e3bea62de4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_57d3913a-1134-4904-9278-c308d585e791_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f342ee49-6f0a-4800-9c95-9e0f080b36b4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_eb3039c8-2bfa-4787-8a88-3fc0d60fadb8_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_7e03d675-3a1f-452c-a508-218ed4cdf010_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_653b5fea-407d-400d-b79e-6f24b3725cf9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_890b9247-c292-4f00-bcde-ee748b09dbfb_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_70e238d4-2853-427d-b760-543da62b2fcf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8dad6120-0f6c-4891-92b3-672019849357_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_572038de-89c2-4d8a-8ae4-9a7322056318_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d8149665-edaf-478f-a941-f45e1e957e70_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_f9fcafab-ec7f-42e9-934f-29d8bb455719_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_61fb6019-c5e9-417a-8f65-c69d752e1f7e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_72fa04d2-047c-4640-b23a-c55cca5dbd3b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f62b32e5-905b-4dff-8d82-b35da1c34533_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_652b5c51-7dca-4e5f-9532-26cbb117c49e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_84d7e8cb-07eb-4cc4-81db-cd71ee344d88_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06be8ad6-e13d-4a94-9a74-2e4f44587fee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_34443113-c216-4a7f-9fd5-8ccaedc3d0ae_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_3e437442-a6db-4a5c-b138-4c9ed48d82a7_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20210630.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9d666a92-b197-4374-ac85-344e3ca94f0d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1ff2c19c-d3d5-4334-8c3f-30f23800b0a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_ad87c256-afdc-4986-9460-79f1ab797b0e_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_b653ff9d-cc28-441c-8df1-265b2aaf9440_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20210630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_ec8cad26-3ac6-4a34-ade1-2231ba216762_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_24fd6703-ba53-443f-8641-89d70a07301b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_010faeef-d8b9-4d3f-be36-b8bdd6b79250_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement weighted average price per share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_385053ce-5f4a-457e-b746-1d53a0457136_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20210630.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_d295e3a1-9c3b-4af4-89e6-361700598cda_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InitialConversionPriceMember_111543b9-51d9-4c72-9680-08990585680b_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember" xlink:href="ino-20210630.xsd#ino_InitialConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember" xlink:to="lab_ino_InitialConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_02f26c0c-583e-445c-aec2-3416b34b37b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1d8e1224-a5a2-4087-ada0-588e3bff3888_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b1ca846d-ab83-429d-b988-bb156624bc35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_412520ef-651d-4605-baed-b1287f39bff4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bc5a2e82-5229-44e7-84c5-ececab8df6e7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_4cc0e6dc-026d-4b24-886d-4766bca8ad5d_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_bb23071d-b6c2-415e-afa0-20d1516a3eba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8c979b23-225f-4555-9732-ec0f71b1d630_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_dc4978bb-28aa-4a61-8e37-f4f60950a705_verboseLabel_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_label_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_documentation_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities and fair value measurements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:href="ino-20210630.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:to="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_8d019d23-ab1d-4d5b-8c2c-1ae86fb286b4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a07149f1-597c-43e3-ab75-3bb9382bc0b6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_643af97b-663f-41ef-ad53-535ce04dcd48_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_4773ffb3-64cd-472a-a1d4-86c6930bbb4e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4c1fd140-c532-4baa-9939-c3c660632f93_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net book value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8af909a3-26b4-432d-8a8e-649410e934bf_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_f42f6230-e6e3-48c9-b85e-f14a43f31310_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, net book value</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_245a70f6-5030-4329-936d-02639e220f89_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0e144348-f2dd-40dd-ab34-b1f5ebace687_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_b88146ee-7751-4ffd-81e5-d0422dc3cccd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_495c5cd4-739e-4b9e-9bf5-8de7c87b433c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_3a980793-0d98-4a6d-b39d-7c828eb20624_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f5ccf35a-d1bf-4b27-9e1b-e627e43ce872_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_27a355ff-a2f1-449b-ab3e-e366b86b19a6_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e8b576dd-0ea9-41fe-af23-7aeb4edf6fe6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_e5a09fa1-e068-42f0-b814-1528767fe8c7_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:to="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_05fe376b-5447-4cc7-b61b-c59d331b715d_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_19973251-0acb-45bf-8b35-310af4858496_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever and MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20210630.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0bab93d7-5735-48e7-a1e6-a25a3c081cb5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_0026a67a-4cce-4fd2-b6f1-f13bd069befb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount on the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4202caf6-b32a-48df-a3aa-3e317889bdc2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d3b014-6144-43a9-85ce-0ce6a1a2d156_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ino-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:685d0eaa-cf71-473e-b825-35e9cdd023e3,g:d59d2343-5bf4-47b2-b6cf-d3f10d74095a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cb390ee8-a7c6-4e82-97c9-18b90e9e68ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_DocumentType_cb390ee8-a7c6-4e82-97c9-18b90e9e68ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_87f0e7fb-32f5-40ca-aa5e-ff404c1ca30a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_DocumentQuarterlyReport_87f0e7fb-32f5-40ca-aa5e-ff404c1ca30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_73c74c89-7588-4400-8e22-7e6b09903bf5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_DocumentPeriodEndDate_73c74c89-7588-4400-8e22-7e6b09903bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_38944386-30d6-4e21-afaa-74d9d31dcc23" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_DocumentTransitionReport_38944386-30d6-4e21-afaa-74d9d31dcc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1d08d971-94c9-4d9e-8b8e-735866fd61bd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityFileNumber_1d08d971-94c9-4d9e-8b8e-735866fd61bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ac8b0d18-c749-45a8-9f74-c44234dcf3ca" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityRegistrantName_ac8b0d18-c749-45a8-9f74-c44234dcf3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d7d6f564-0d6e-49b1-afe2-baa9925201cc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d7d6f564-0d6e-49b1-afe2-baa9925201cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_00206a3a-3465-4a35-8a5b-4c1788faeb6a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityTaxIdentificationNumber_00206a3a-3465-4a35-8a5b-4c1788faeb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1c3d0a01-5a2d-4c39-aba9-960b08feb430" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityAddressAddressLine1_1c3d0a01-5a2d-4c39-aba9-960b08feb430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_70edebfc-54c9-4a0d-aa1e-571ad0937b7c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityAddressCityOrTown_70edebfc-54c9-4a0d-aa1e-571ad0937b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c4db0d30-790a-4286-adff-09d4b878b107" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityAddressStateOrProvince_c4db0d30-790a-4286-adff-09d4b878b107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_100eac48-c560-44be-9674-1e991940b227" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityAddressPostalZipCode_100eac48-c560-44be-9674-1e991940b227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1aca5b18-5fdf-4c9a-9303-2ec8a4697b18" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_CityAreaCode_1aca5b18-5fdf-4c9a-9303-2ec8a4697b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_31385ea4-7f5e-45d6-9f3d-dc5905a6ac88" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_LocalPhoneNumber_31385ea4-7f5e-45d6-9f3d-dc5905a6ac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_97978bc8-f317-4809-b9c5-a8d58e077e4c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_Security12bTitle_97978bc8-f317-4809-b9c5-a8d58e077e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_579d9964-e008-4542-964d-ecb0e3c18e3d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_TradingSymbol_579d9964-e008-4542-964d-ecb0e3c18e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_72536086-a2f4-47b2-897f-a76918c8ef8b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_SecurityExchangeName_72536086-a2f4-47b2-897f-a76918c8ef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1721b1ac-1118-4644-bf6d-bf37e6143488" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityCurrentReportingStatus_1721b1ac-1118-4644-bf6d-bf37e6143488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f0c50b69-2574-4ece-afce-779cabefe0ed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityInteractiveDataCurrent_f0c50b69-2574-4ece-afce-779cabefe0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dd256a03-27f6-4ce3-883a-db2e41bb98e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityFilerCategory_dd256a03-27f6-4ce3-883a-db2e41bb98e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_53dc9761-60c1-4cc4-85d2-fdd144173492" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntitySmallBusiness_53dc9761-60c1-4cc4-85d2-fdd144173492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d101cae8-51d8-4f86-9db6-e885b1c8f697" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityEmergingGrowthCompany_d101cae8-51d8-4f86-9db6-e885b1c8f697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2c48c25e-8869-4b67-bf98-b5c9a662e9e8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityShellCompany_2c48c25e-8869-4b67-bf98-b5c9a662e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_01bfbb58-c75e-4b1e-a9a9-63d882bed944" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_01bfbb58-c75e-4b1e-a9a9-63d882bed944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_54d69be6-d0a6-48cb-99d6-ddf6f39472a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_AmendmentFlag_54d69be6-d0a6-48cb-99d6-ddf6f39472a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e1ab0871-d660-47dd-8bee-8ef5fa591d6a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_DocumentFiscalYearFocus_e1ab0871-d660-47dd-8bee-8ef5fa591d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bded6aec-43e2-44d5-a1a1-67f352014b81" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bded6aec-43e2-44d5-a1a1-67f352014b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7b246121-c464-4668-a7a7-ddfcfa5aa01a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_EntityCentralIndexKey_7b246121-c464-4668-a7a7-ddfcfa5aa01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0dbde779-89b9-4790-9897-b15e1331187c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ad6846b1-381d-405e-88e3-ddd54aaebbc8" xlink:to="loc_dei_CurrentFiscalYearEndDate_0dbde779-89b9-4790-9897-b15e1331187c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4a346791-06e8-407d-8094-522ec0da7386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_116f7723-c1dc-4423-a74d-0fae997a870c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a346791-06e8-407d-8094-522ec0da7386" xlink:to="loc_us-gaap_StatementTable_116f7723-c1dc-4423-a74d-0fae997a870c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_60c58aff-f008-4a32-9c30-540a33fd5e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_116f7723-c1dc-4423-a74d-0fae997a870c" xlink:to="loc_us-gaap_DebtInstrumentAxis_60c58aff-f008-4a32-9c30-540a33fd5e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_60c58aff-f008-4a32-9c30-540a33fd5e8f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b0f668ad-6932-46be-a5bb-2f1eebe29f09" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b0f668ad-6932-46be-a5bb-2f1eebe29f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_4566b2d8-97c6-4e32-a192-4cb94d29e808" xlink:href="ino-20210630.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8d46af4a-df23-4f74-b44c-ec7e6669cbd0" xlink:to="loc_ino_ConvertibleBondsMember_4566b2d8-97c6-4e32-a192-4cb94d29e808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_116f7723-c1dc-4423-a74d-0fae997a870c" xlink:to="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:to="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d7d4be45-9e16-4ac4-a483-4e21f868a6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d7d4be45-9e16-4ac4-a483-4e21f868a6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_04219f29-06f0-4963-8118-5cf6d154761f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_ShortTermInvestments_04219f29-06f0-4963-8118-5cf6d154761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6559b7fd-da45-42cb-aae3-79a54e097e84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6559b7fd-da45-42cb-aae3-79a54e097e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_12e3f8b6-d371-4336-9475-a69e2bd3fe6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_12e3f8b6-d371-4336-9475-a69e2bd3fe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_580c37fc-5427-42eb-ae02-2e1f7048fb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_580c37fc-5427-42eb-ae02-2e1f7048fb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_9e510500-de01-4ba8-91ae-da525674b549" xlink:href="ino-20210630.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_9e510500-de01-4ba8-91ae-da525674b549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4471965a-7da4-4934-b778-9a566953e595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11fe0776-7a59-42f6-8b30-7bf21352a360" xlink:to="loc_us-gaap_AssetsCurrent_4471965a-7da4-4934-b778-9a566953e595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_23813849-9303-4b80-b4ef-8c1d4b7a5b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_23813849-9303-4b80-b4ef-8c1d4b7a5b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_130fe1b4-5c9c-4ef0-9a76-17921d51ad48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_130fe1b4-5c9c-4ef0-9a76-17921d51ad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0de0c707-3d35-4513-afbb-55be78a0ccb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_EquityMethodInvestments_0de0c707-3d35-4513-afbb-55be78a0ccb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9fab2c42-c720-42f9-a882-1c6c770848de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9fab2c42-c720-42f9-a882-1c6c770848de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73ea3b96-bc7e-44a0-8884-a1043251332b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_Goodwill_73ea3b96-bc7e-44a0-8884-a1043251332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff730d23-4239-4087-8601-f1d7be9e5136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff730d23-4239-4087-8601-f1d7be9e5136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d0f7454f-ccb4-44f2-a3b9-fc58acb3f55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d0f7454f-ccb4-44f2-a3b9-fc58acb3f55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_85532af5-e482-46ee-9b12-18dbba6550e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_59e4d112-ae78-43ca-b6b7-e3d57c9a4fc1" xlink:to="loc_us-gaap_Assets_85532af5-e482-46ee-9b12-18dbba6550e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8a8f6a36-e0dc-4ef5-9866-488396b66265" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_59e59e88-279a-4641-8095-7ee2e420c936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_59e59e88-279a-4641-8095-7ee2e420c936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_8d693189-3af0-4114-9bfc-4342ee52c3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_8d693189-3af0-4114-9bfc-4342ee52c3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_50c53a7c-fdd6-4981-9b95-c054780cb56e" xlink:href="ino-20210630.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_50c53a7c-fdd6-4981-9b95-c054780cb56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f0c2342d-5c54-4245-9c70-462b384c656b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f0c2342d-5c54-4245-9c70-462b384c656b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bec9206b-8db2-4ca5-b18e-ee157b8d983a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bec9206b-8db2-4ca5-b18e-ee157b8d983a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_8f0b013c-ac03-4ebd-9363-b4c66a6cd907" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_ino_DeferredGrantFundingCurrent_8f0b013c-ac03-4ebd-9363-b4c66a6cd907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b19b9f2-c7ae-46f3-ac13-1f549a85d4c7" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b19b9f2-c7ae-46f3-ac13-1f549a85d4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4fe9eaad-3790-4853-abab-6d49b5512b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fbda37b3-bcc7-4136-8011-9a80de50fc3c" xlink:to="loc_us-gaap_LiabilitiesCurrent_4fe9eaad-3790-4853-abab-6d49b5512b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19ba1058-63b8-4b94-a440-105c9434f314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_19ba1058-63b8-4b94-a440-105c9434f314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_12d5039c-2c9b-4f7c-92df-44e001c76b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_ConvertibleDebt_12d5039c-2c9b-4f7c-92df-44e001c76b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95c83e40-1aec-41e6-bd8b-60abe9f9c3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_95c83e40-1aec-41e6-bd8b-60abe9f9c3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_19e8b065-2da9-4249-8fd7-ee4ccbb337b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_19e8b065-2da9-4249-8fd7-ee4ccbb337b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_0dd5a156-e8cf-4f67-9be5-3aa26479b3ec" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_0dd5a156-e8cf-4f67-9be5-3aa26479b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_22d8b13f-d35b-4e94-bb3e-c63d96d3fab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_22d8b13f-d35b-4e94-bb3e-c63d96d3fab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6a6acb06-3df7-4754-a177-b5fe2ab28d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_Liabilities_6a6acb06-3df7-4754-a177-b5fe2ab28d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_43b23d5c-47da-40fb-b3ea-2f04635bd7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_PreferredStockValue_43b23d5c-47da-40fb-b3ea-2f04635bd7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bbf4505b-c1c2-4cb1-9ce3-fcdf55e40c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_CommonStockValue_bbf4505b-c1c2-4cb1-9ce3-fcdf55e40c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ccf6f0ee-9f46-46b7-83b6-d7b473f5c934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ccf6f0ee-9f46-46b7-83b6-d7b473f5c934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aff2d78b-5b0b-4255-8fbc-5df7e51428f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aff2d78b-5b0b-4255-8fbc-5df7e51428f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3bff190b-fbca-4857-92cb-3a1087b35182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3bff190b-fbca-4857-92cb-3a1087b35182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a7f17304-723e-4b58-90c9-87e7e7af0a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8dac891e-e1d6-4c49-8258-a853a294d035" xlink:to="loc_us-gaap_StockholdersEquity_a7f17304-723e-4b58-90c9-87e7e7af0a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ccd7b337-8040-48d7-b08d-2689b09c1d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_40318f93-821d-4094-88c3-049e79b62bb1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ccd7b337-8040-48d7-b08d-2689b09c1d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3ca3cc61-57f1-4f0d-906e-37cf77f03d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_83ad7aa9-748e-4497-8f78-f28cd2644503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ca3cc61-57f1-4f0d-906e-37cf77f03d4f" xlink:to="loc_us-gaap_StatementTable_83ad7aa9-748e-4497-8f78-f28cd2644503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_934c86e1-9c0a-476c-a5a2-9c76ddd96c32" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_83ad7aa9-748e-4497-8f78-f28cd2644503" xlink:to="loc_srt_ProductOrServiceAxis_934c86e1-9c0a-476c-a5a2-9c76ddd96c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_934c86e1-9c0a-476c-a5a2-9c76ddd96c32" xlink:to="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c500ec6c-163f-499f-a263-b176ef8cbc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:to="loc_us-gaap_LicenseMember_c500ec6c-163f-499f-a263-b176ef8cbc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_df5def49-fc9d-4997-b792-ef758bb88188" xlink:href="ino-20210630.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_df5def49-fc9d-4997-b792-ef758bb88188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_07f203fd-55d0-4126-98b4-f32568bc688f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_db377068-a076-472a-a40d-f1cbe89ca454" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_07f203fd-55d0-4126-98b4-f32568bc688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_83ad7aa9-748e-4497-8f78-f28cd2644503" xlink:to="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_60ab4f32-1e2d-43e3-8563-3d213f6260d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_RevenuesAbstract_60ab4f32-1e2d-43e3-8563-3d213f6260d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_175574bf-735c-4299-a2bd-3ea136d5836f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_60ab4f32-1e2d-43e3-8563-3d213f6260d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_175574bf-735c-4299-a2bd-3ea136d5836f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d17ac5e6-4bfd-499f-86e7-13a0d998ffdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d17ac5e6-4bfd-499f-86e7-13a0d998ffdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eba5e24f-421e-4966-b6ac-288fbfa9bfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eba5e24f-421e-4966-b6ac-288fbfa9bfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cdcd0394-813b-4130-afa3-646971053cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2ee31757-82fc-433f-9686-ebf9a682d414" xlink:to="loc_us-gaap_OperatingExpenses_cdcd0394-813b-4130-afa3-646971053cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13e1b546-ae5b-4dfe-aae8-942b732f8b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_OperatingIncomeLoss_13e1b546-ae5b-4dfe-aae8-942b732f8b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_1eada72f-73c7-4f2c-ab35-f5d5b61da204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_InterestIncomeOperating_1eada72f-73c7-4f2c-ab35-f5d5b61da204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b534d2d4-4350-4c50-b730-4a411b597f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_InterestExpense_b534d2d4-4350-4c50-b730-4a411b597f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3e60e4ff-4bfd-45e8-93e0-832cc2a97c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3e60e4ff-4bfd-45e8-93e0-832cc2a97c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0c59a079-7f2b-45cc-8694-dee5d4bdcb4f" xlink:href="ino-20210630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0c59a079-7f2b-45cc-8694-dee5d4bdcb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e5e8b8e0-dd21-42b2-895b-6bc9fb46339b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e5e8b8e0-dd21-42b2-895b-6bc9fb46339b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_654fbb11-aaff-4fe1-97e0-0ed16a135d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_654fbb11-aaff-4fe1-97e0-0ed16a135d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_4e2e160a-809b-4617-80df-f7601b157028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_4e2e160a-809b-4617-80df-f7601b157028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_726be9cc-1ef7-4fe9-85d5-cbc76d4f3403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_726be9cc-1ef7-4fe9-85d5-cbc76d4f3403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5486e652-c504-4e99-9cfe-e11dbf575691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5486e652-c504-4e99-9cfe-e11dbf575691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6fa83cac-e637-4888-9aec-d733ce359d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_ProfitLoss_6fa83cac-e637-4888-9aec-d733ce359d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d588818c-d296-4112-9b59-37d032261214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d588818c-d296-4112-9b59-37d032261214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1408bce-c516-44f0-b7a7-c3056b0c0a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3d432213-e856-4fde-a08f-5276312853a8" xlink:to="loc_us-gaap_NetIncomeLoss_f1408bce-c516-44f0-b7a7-c3056b0c0a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6fd9be41-b921-4fbf-81a0-c4187f28d2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:to="loc_us-gaap_EarningsPerShareBasic_6fd9be41-b921-4fbf-81a0-c4187f28d2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b6ae5ea4-4787-418c-8128-a63e6baaee97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5001eda7-d903-4424-9b2b-afe7eb757b02" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b6ae5ea4-4787-418c-8128-a63e6baaee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_065288ce-acb7-4899-b33a-1a4de1c33497" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e7cdc0cd-5118-4b5b-8764-d3973afa8206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e7cdc0cd-5118-4b5b-8764-d3973afa8206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab53487a-53ff-496a-9f4b-fdca095d610f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bd748423-9c89-42b7-a544-ac2d02f2c47b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab53487a-53ff-496a-9f4b-fdca095d610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_887d88e3-a77c-4a61-9bd7-5be3b766f5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b94fb99e-ee16-4e52-976b-46ef44be2c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_887d88e3-a77c-4a61-9bd7-5be3b766f5b1" xlink:to="loc_us-gaap_ProfitLoss_b94fb99e-ee16-4e52-976b-46ef44be2c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_95b9921d-1c9e-492f-8faf-137181bd5baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_887d88e3-a77c-4a61-9bd7-5be3b766f5b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_95b9921d-1c9e-492f-8faf-137181bd5baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_700dbd63-2e40-4af2-b455-7a20ccec31ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_95b9921d-1c9e-492f-8faf-137181bd5baa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_700dbd63-2e40-4af2-b455-7a20ccec31ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_39345cbf-4b9a-4be3-bcac-f6e134aa6817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_95b9921d-1c9e-492f-8faf-137181bd5baa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_39345cbf-4b9a-4be3-bcac-f6e134aa6817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2effc27c-1fda-4671-9f40-950cb17394f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_887d88e3-a77c-4a61-9bd7-5be3b766f5b1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2effc27c-1fda-4671-9f40-950cb17394f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bf9c2573-5bcd-481b-a454-b434b0c6a889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_887d88e3-a77c-4a61-9bd7-5be3b766f5b1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_bf9c2573-5bcd-481b-a454-b434b0c6a889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_73af11d9-43bf-4799-90ec-c0b5f6f34593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_887d88e3-a77c-4a61-9bd7-5be3b766f5b1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_73af11d9-43bf-4799-90ec-c0b5f6f34593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_59a24b2e-9af4-4c99-8a43-8c3b340b17da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_95a34ef4-6340-40eb-aa33-612d1a24a79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_59a24b2e-9af4-4c99-8a43-8c3b340b17da" xlink:to="loc_us-gaap_StatementTable_95a34ef4-6340-40eb-aa33-612d1a24a79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14256e15-c75d-4586-a653-5a5b2d62e86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95a34ef4-6340-40eb-aa33-612d1a24a79b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14256e15-c75d-4586-a653-5a5b2d62e86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14256e15-c75d-4586-a653-5a5b2d62e86c" xlink:to="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_bb044665-264a-4e68-86f3-c2b615fb3cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_PreferredStockMember_bb044665-264a-4e68-86f3-c2b615fb3cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_071aeb6e-d70d-4f72-83b5-5566397b6925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_CommonStockMember_071aeb6e-d70d-4f72-83b5-5566397b6925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a0dfbef9-1a3e-4a9b-8e0e-d6f8b3698484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a0dfbef9-1a3e-4a9b-8e0e-d6f8b3698484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_99555159-461c-4a8f-8d40-6bc687320a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_RetainedEarningsMember_99555159-461c-4a8f-8d40-6bc687320a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5644a031-7927-45eb-be79-37d9e49a44c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5644a031-7927-45eb-be79-37d9e49a44c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_232869d3-f145-4043-b978-661c65623da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8bc002f-ee5f-44c5-91ab-a07f3d6b317f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_232869d3-f145-4043-b978-661c65623da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ae3dcfa-21e9-4ece-a09f-9e42b505e95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95a34ef4-6340-40eb-aa33-612d1a24a79b" xlink:to="loc_us-gaap_StatementLineItems_2ae3dcfa-21e9-4ece-a09f-9e42b505e95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ae3dcfa-21e9-4ece-a09f-9e42b505e95b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6405ead6-82ba-4524-8ef6-a2818c499abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_SharesIssued_6405ead6-82ba-4524-8ef6-a2818c499abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ee8bb6a-ae7e-4f06-8884-3b9c0898e492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ee8bb6a-ae7e-4f06-8884-3b9c0898e492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_30cd06ec-c58e-440c-bfd6-1e1fad0fc81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_30cd06ec-c58e-440c-bfd6-1e1fad0fc81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6bbc6387-5cab-432f-8e0b-13aa836e5333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6bbc6387-5cab-432f-8e0b-13aa836e5333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410541c3-5d20-46da-8ac1-1d46e0afd076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_410541c3-5d20-46da-8ac1-1d46e0afd076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_82c859ed-6a0b-4743-b2bd-3ddf07388c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_82c859ed-6a0b-4743-b2bd-3ddf07388c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bc429cd6-e7ef-4ead-87cb-b9a1071c7c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_bc429cd6-e7ef-4ead-87cb-b9a1071c7c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2b47230-ceed-456e-baa9-a8cf28af2227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2b47230-ceed-456e-baa9-a8cf28af2227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ff7949-9ca9-4441-8739-340c93304918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_94ff7949-9ca9-4441-8739-340c93304918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_6e4c32db-dc37-4efe-ba1d-c5fd158055ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_6e4c32db-dc37-4efe-ba1d-c5fd158055ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_7dcf4e73-83ec-41fc-932d-8d10c222513d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_7dcf4e73-83ec-41fc-932d-8d10c222513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0011bc10-9f99-4b2f-a78b-5cb21803d3da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_ProfitLoss_0011bc10-9f99-4b2f-a78b-5cb21803d3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_75f562b2-61f9-4173-b2dc-e5efc739e723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_75f562b2-61f9-4173-b2dc-e5efc739e723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c5f45d93-f11c-4710-b6bf-2782585585ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c5f45d93-f11c-4710-b6bf-2782585585ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5d2b270f-18c3-4302-91ad-9b577677709a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_SharesIssued_5d2b270f-18c3-4302-91ad-9b577677709a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ceb251b-23b9-4148-91f1-4283e5431d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_efd7071b-4c35-4f8c-9026-9dbdebcbbc2e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ceb251b-23b9-4148-91f1-4283e5431d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5b835fd9-21df-4327-867d-5b32bba5cd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_96c7cb4a-a941-44e5-a292-906ed808392b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5b835fd9-21df-4327-867d-5b32bba5cd8f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_96c7cb4a-a941-44e5-a292-906ed808392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20210630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f9679dd2-5391-4b42-9aaf-d1e37703a26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f9679dd2-5391-4b42-9aaf-d1e37703a26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_406522a6-8e5c-424d-a7c9-c4215c0b8852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f9679dd2-5391-4b42-9aaf-d1e37703a26b" xlink:to="loc_us-gaap_ProfitLoss_406522a6-8e5c-424d-a7c9-c4215c0b8852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f9679dd2-5391-4b42-9aaf-d1e37703a26b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2b348af6-eee0-44ee-9ae1-2895b6a8c733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_Depreciation_2b348af6-eee0-44ee-9ae1-2895b6a8c733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ec49d65a-1502-4e44-bc51-367cef959fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ec49d65a-1502-4e44-bc51-367cef959fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_7f4cf954-57bd-463a-b4fc-18f23e13b216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_7f4cf954-57bd-463a-b4fc-18f23e13b216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_544950b1-eddc-45da-abc7-29720c27acc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_ShareBasedCompensation_544950b1-eddc-45da-abc7-29720c27acc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_90f2003b-0edf-4638-ae48-320f3c8e41ff" xlink:href="ino-20210630.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_ino_NonCashInterestIncomeExpense_90f2003b-0edf-4638-ae48-320f3c8e41ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_0938742d-3c77-42eb-a512-111efe94b507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_GainLossOnInvestments_0938742d-3c77-42eb-a512-111efe94b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_d3195ffc-5792-4df9-b54f-dabc2341e13d" xlink:href="ino-20210630.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_d3195ffc-5792-4df9-b54f-dabc2341e13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_526d74a5-7f88-49b8-9724-d51abfc4defe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_526d74a5-7f88-49b8-9724-d51abfc4defe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e0eddcd8-496b-4b36-b6b6-76ad17d59d96" xlink:href="ino-20210630.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e0eddcd8-496b-4b36-b6b6-76ad17d59d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b94b9a62-3f78-4e03-9a7a-8e3b0b78c1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b94b9a62-3f78-4e03-9a7a-8e3b0b78c1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_ff7d0a67-eed3-465b-9438-1c8233793da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_ff7d0a67-eed3-465b-9438-1c8233793da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_b3ff51bc-b839-4e78-8790-1ae8b384bbd6" xlink:href="ino-20210630.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_b3ff51bc-b839-4e78-8790-1ae8b384bbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_dc2641d1-c14c-4f8c-8047-1dbf4eec2563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_dc2641d1-c14c-4f8c-8047-1dbf4eec2563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_12c1df02-9864-4bee-9e71-c95954ab0128" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_35bf3499-8a97-484f-a812-ca9cc7a4576b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_35bf3499-8a97-484f-a812-ca9cc7a4576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_a8f36fb7-d64b-474e-ad2c-a3aea73ccb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_a8f36fb7-d64b-474e-ad2c-a3aea73ccb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba4bc6ff-7c13-43e7-9b84-6b843148fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ba4bc6ff-7c13-43e7-9b84-6b843148fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_774c0231-349c-4516-b021-98462a7f14f2" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_774c0231-349c-4516-b021-98462a7f14f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a7cf4129-cb51-45e9-86e9-f03c39ff58d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a7cf4129-cb51-45e9-86e9-f03c39ff58d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_03e52dc2-2922-4dd1-9fc3-fbad20946533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_03e52dc2-2922-4dd1-9fc3-fbad20946533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_b7b7ce85-1077-4420-8977-2244ffb1781d" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_b7b7ce85-1077-4420-8977-2244ffb1781d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1716c849-85f6-48b5-8f30-88765ea69ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1716c849-85f6-48b5-8f30-88765ea69ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_687eeaab-01f1-4fc3-adc2-2b89dd3fceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_687eeaab-01f1-4fc3-adc2-2b89dd3fceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_8e3908d0-ef3b-4263-892b-04d526698c2a" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_8e3908d0-ef3b-4263-892b-04d526698c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_55919e78-ee22-4c0e-89ef-b135c15c873e" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_55919e78-ee22-4c0e-89ef-b135c15c873e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_bebe8143-1487-4881-a448-0dcef1932457" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_bebe8143-1487-4881-a448-0dcef1932457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0b6ef9ae-39ed-4e30-ba5d-296c36d10363" xlink:href="ino-20210630.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0b6ef9ae-39ed-4e30-ba5d-296c36d10363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2eaa298f-4d06-445a-a830-6871e99df8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8808e89-2a97-4137-8470-c6f78e7ee17f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2eaa298f-4d06-445a-a830-6871e99df8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_703973af-6887-4b4e-a213-863bd1804d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f9679dd2-5391-4b42-9aaf-d1e37703a26b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_703973af-6887-4b4e-a213-863bd1804d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d9e95d57-5949-4ef3-9eb0-0f57408da5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d9e95d57-5949-4ef3-9eb0-0f57408da5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d3ed4e26-18d4-4543-af53-b252b257f892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d9e95d57-5949-4ef3-9eb0-0f57408da5f0" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_d3ed4e26-18d4-4543-af53-b252b257f892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_c3224fc2-f49f-4d04-9d6c-e27f437b0b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d9e95d57-5949-4ef3-9eb0-0f57408da5f0" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_c3224fc2-f49f-4d04-9d6c-e27f437b0b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8173afe5-b674-4c9f-9931-a4bd6c908833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d9e95d57-5949-4ef3-9eb0-0f57408da5f0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8173afe5-b674-4c9f-9931-a4bd6c908833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_8ac36f8b-84ed-460c-a244-5fa197eea301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d9e95d57-5949-4ef3-9eb0-0f57408da5f0" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_8ac36f8b-84ed-460c-a244-5fa197eea301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8e4c833-95c7-40c8-bafb-95834e32594f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d9e95d57-5949-4ef3-9eb0-0f57408da5f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8e4c833-95c7-40c8-bafb-95834e32594f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bcf4e1bf-bb45-4c83-b090-cfebebd01025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bcf4e1bf-bb45-4c83-b090-cfebebd01025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_04efcc7e-4c2c-460f-8ecf-ba3a020bb872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_04efcc7e-4c2c-460f-8ecf-ba3a020bb872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_11eeeed8-8dec-4593-970c-5a54dc8e939a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_11eeeed8-8dec-4593-970c-5a54dc8e939a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_3616709c-cd45-4541-b6ba-f58afb4b4799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_3616709c-cd45-4541-b6ba-f58afb4b4799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_18811349-dfe6-44bf-8f5a-0a57420a3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_18811349-dfe6-44bf-8f5a-0a57420a3aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cfc769b-f9ea-47fb-9c1a-850f2a5e1531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77076048-f2ed-4cef-96bb-b3625a892025" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cfc769b-f9ea-47fb-9c1a-850f2a5e1531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18685880-fec1-4c0c-8ea0-bd25571e4da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18685880-fec1-4c0c-8ea0-bd25571e4da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5df20932-3e27-4658-bb7c-c19c19b34007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5df20932-3e27-4658-bb7c-c19c19b34007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2bb96664-0993-4bee-bfb9-06cbe30563a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2bb96664-0993-4bee-bfb9-06cbe30563a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d225a98-be04-4b74-82b7-97898f534dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1d225a98-be04-4b74-82b7-97898f534dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2901a8f0-5b35-42ba-848a-88960f1b1488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e633cbc3-5283-476a-b0e3-16b3af01ce6b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2901a8f0-5b35-42ba-848a-88960f1b1488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_6ca14c57-6791-45a3-9c70-3e120d86c0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2901a8f0-5b35-42ba-848a-88960f1b1488" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_6ca14c57-6791-45a3-9c70-3e120d86c0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b94f62e4-a87a-40b1-9cd2-bf45feb01d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2901a8f0-5b35-42ba-848a-88960f1b1488" xlink:to="loc_us-gaap_InterestPaidNet_b94f62e4-a87a-40b1-9cd2-bf45feb01d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20210630.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f310599-8805-426d-962b-cb9056361f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_a9402f42-63ef-412f-9006-760832b1c396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f310599-8805-426d-962b-cb9056361f0f" xlink:to="loc_us-gaap_NatureOfOperations_a9402f42-63ef-412f-9006-760832b1c396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20210630.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6aa751f-cc45-4114-b564-c29c17a0928b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_24d82175-9b1c-4607-9871-16aa596d03c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6aa751f-cc45-4114-b564-c29c17a0928b" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_24d82175-9b1c-4607-9871-16aa596d03c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20210630.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f5c32875-54dc-49b8-a8d2-3e04ac258fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f5c32875-54dc-49b8-a8d2-3e04ac258fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_3d582fd9-01a5-4223-9fc5-3fc63bc1bc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_3d582fd9-01a5-4223-9fc5-3fc63bc1bc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f4ee04fe-9627-42af-a918-4c6b1513f830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f4ee04fe-9627-42af-a918-4c6b1513f830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantPolicyPolicyTextBlock_7325f2c3-c18b-42c7-8768-e35febf6d17c" xlink:href="ino-20210630.xsd#ino_GrantPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_ino_GrantPolicyPolicyTextBlock_7325f2c3-c18b-42c7-8768-e35febf6d17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_160fcb17-4664-48ea-b651-2ce4b1a44504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_160fcb17-4664-48ea-b651-2ce4b1a44504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_57c0d763-940b-4fd9-bc4a-3036799bbb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_57c0d763-940b-4fd9-bc4a-3036799bbb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1f249ff2-220a-4c16-957d-0002099f776d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1f249ff2-220a-4c16-957d-0002099f776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8f2c3ed0-744b-463d-80dd-a2630a62aaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8f2c3ed0-744b-463d-80dd-a2630a62aaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_133e9453-2544-4a97-bb8c-d3ac92e8dae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_133e9453-2544-4a97-bb8c-d3ac92e8dae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_9304bb8d-96e7-4686-9bd9-a9b7a82f3625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_9304bb8d-96e7-4686-9bd9-a9b7a82f3625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fabce940-29ae-4117-996c-b61c06bde254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a4fc83c-0fe9-44c1-beb2-1bfee741b8fc" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fabce940-29ae-4117-996c-b61c06bde254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c723930-2ea7-404b-bb5a-1ce81c9c05bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c723930-2ea7-404b-bb5a-1ce81c9c05bf" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8b23673d-5ccf-4d02-a1de-2e9d1948792e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8b23673d-5ccf-4d02-a1de-2e9d1948792e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2d50c3f7-2d8c-4b43-a000-a1831f06d362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8b23673d-5ccf-4d02-a1de-2e9d1948792e" xlink:to="loc_us-gaap_ClassOfStockDomain_2d50c3f7-2d8c-4b43-a000-a1831f06d362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_928f625c-2775-4dc7-9e0e-2cc781d04c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2d50c3f7-2d8c-4b43-a000-a1831f06d362" xlink:to="loc_us-gaap_CommonStockMember_928f625c-2775-4dc7-9e0e-2cc781d04c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e6bd0128-4aa6-49fd-bdd6-4933ba8c42b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_6f06ad49-fe78-48fb-b359-6c0f208cf5cb" xlink:href="ino-20210630.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_6f06ad49-fe78-48fb-b359-6c0f208cf5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_21d5da0d-5b9f-437b-8f08-7e62267c98c3" xlink:href="ino-20210630.xsd#ino_SalesAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e8d2430d-09b2-452e-bbbf-5b314cc4c6c1" xlink:to="loc_ino_SalesAgreementsMember_21d5da0d-5b9f-437b-8f08-7e62267c98c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_48be2631-2175-474e-b7d6-a396f2148056" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_968d8baf-8670-4c0f-b9b6-6f81414cc707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_NetIncomeLoss_968d8baf-8670-4c0f-b9b6-6f81414cc707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_b6a9cc47-9a3c-4fa4-a118-a9e8ab8c14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_Capital_b6a9cc47-9a3c-4fa4-a118-a9e8ab8c14bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cd50cd5e-fca2-419a-9838-1edaa4d4f8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cd50cd5e-fca2-419a-9838-1edaa4d4f8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2f9d7ec-a082-4f5c-a8ea-bf897e45a591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2f9d7ec-a082-4f5c-a8ea-bf897e45a591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bb625267-1346-45cc-a922-be1a835957d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ae96142a-67ab-4863-a175-6f99fd66de6d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bb625267-1346-45cc-a922-be1a835957d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20210630.xsd#CriticalAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7816afc0-2bde-4e30-9f01-320f31007ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3317b6b2-481c-4c26-901c-19e907f26973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7816afc0-2bde-4e30-9f01-320f31007ed2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3317b6b2-481c-4c26-901c-19e907f26973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#CriticalAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e3dc282b-b1a3-4847-84a1-fba360dd379a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11217b88-dc3a-464a-ac21-30acf8940ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e3dc282b-b1a3-4847-84a1-fba360dd379a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11217b88-dc3a-464a-ac21-30acf8940ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9a2c3d16-b6b5-4208-a2b5-0983fc447e18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11217b88-dc3a-464a-ac21-30acf8940ecd" xlink:to="loc_srt_RangeAxis_9a2c3d16-b6b5-4208-a2b5-0983fc447e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9a2c3d16-b6b5-4208-a2b5-0983fc447e18" xlink:to="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ed0983ff-1c0c-4731-b49b-5658c90d6268" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:to="loc_srt_MinimumMember_ed0983ff-1c0c-4731-b49b-5658c90d6268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_17f11015-b0cd-40ba-9205-8726a444cb1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5958334c-cca2-4ccb-9377-61f979288826" xlink:to="loc_srt_MaximumMember_17f11015-b0cd-40ba-9205-8726a444cb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11217b88-dc3a-464a-ac21-30acf8940ecd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ad7ee67a-91eb-48e3-ac8d-fc1612111ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ad7ee67a-91eb-48e3-ac8d-fc1612111ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_49eb7bf5-7654-4e81-b435-61e0bbb377ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1d5333b6-f50a-4bbe-9166-fc950b644ffe" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_49eb7bf5-7654-4e81-b435-61e0bbb377ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20210630.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3a551af5-a735-46e9-9b97-996d303be450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_64db5c02-bbd8-4f7e-b935-25b994034edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a551af5-a735-46e9-9b97-996d303be450" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_64db5c02-bbd8-4f7e-b935-25b994034edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20210630.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5bc96c21-980e-410a-83c5-02ee9afd5de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_eff783e2-a7f6-4706-9c49-854a2d46440b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5bc96c21-980e-410a-83c5-02ee9afd5de1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_eff783e2-a7f6-4706-9c49-854a2d46440b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#RevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fa25ff7d-4b03-4711-b6ce-9a7a7bb1cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_ae3c6fc7-79cc-4ad7-a0a6-8155876b73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fa25ff7d-4b03-4711-b6ce-9a7a7bb1cc62" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_ae3c6fc7-79cc-4ad7-a0a6-8155876b73a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_148020b8-520a-4176-a62c-f776dac9119e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ae3c6fc7-79cc-4ad7-a0a6-8155876b73a3" xlink:to="loc_srt_CounterpartyNameAxis_148020b8-520a-4176-a62c-f776dac9119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_148020b8-520a-4176-a62c-f776dac9119e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_74493d44-7008-43cb-8cdf-4806886ef3dc" xlink:href="ino-20210630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:to="loc_ino_PlumblineLifeSciencesMember_74493d44-7008-43cb-8cdf-4806886ef3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_cefd4b19-c690-4363-baeb-4694f502254d" xlink:href="ino-20210630.xsd#ino_OtherCounterpartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76f2d55f-a64f-453f-88d4-54e0c1e88bc6" xlink:to="loc_ino_OtherCounterpartyMember_cefd4b19-c690-4363-baeb-4694f502254d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_ae3c6fc7-79cc-4ad7-a0a6-8155876b73a3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bc62b38a-75da-454c-b1be-416e595687d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bc62b38a-75da-454c-b1be-416e595687d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f4c5c66-c057-484a-bcad-2f7765c5dfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ee08fa4-8aaa-48ab-8836-9409a152e81a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f4c5c66-c057-484a-bcad-2f7765c5dfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20210630.xsd#ShorttermInvestments"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_824f5be9-df20-47d3-8aa2-2bfd4dc8f1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_995ef53a-ce45-45e4-bcd7-118aaa8fe51b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_824f5be9-df20-47d3-8aa2-2bfd4dc8f1e7" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_995ef53a-ce45-45e4-bcd7-118aaa8fe51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20210630.xsd#ShorttermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_41cad504-3844-4057-91d0-8013572d8cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79b62cd9-149f-43ff-82dc-c2e54fd59be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_41cad504-3844-4057-91d0-8013572d8cbc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_79b62cd9-149f-43ff-82dc-c2e54fd59be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7de47e3-dea3-4d1a-836e-c66542ed0ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ab9fffae-30cd-409f-8f29-eab5d52a27e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7de47e3-dea3-4d1a-836e-c66542ed0ad7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ab9fffae-30cd-409f-8f29-eab5d52a27e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_28cc9064-e7a4-409a-9a87-95bafd8e9820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7de47e3-dea3-4d1a-836e-c66542ed0ad7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_28cc9064-e7a4-409a-9a87-95bafd8e9820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8472b216-18f2-4039-a823-240f15fd4e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7de47e3-dea3-4d1a-836e-c66542ed0ad7" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8472b216-18f2-4039-a823-240f15fd4e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f8171871-8c82-42c7-8765-442679395298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7de47e3-dea3-4d1a-836e-c66542ed0ad7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f8171871-8c82-42c7-8765-442679395298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_68715355-13db-4c4a-81d5-9d03abfdfedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7de47e3-dea3-4d1a-836e-c66542ed0ad7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_68715355-13db-4c4a-81d5-9d03abfdfedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_335830d7-6168-4a36-b8e1-d21b09e01dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7de47e3-dea3-4d1a-836e-c66542ed0ad7" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_335830d7-6168-4a36-b8e1-d21b09e01dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_94b7d28c-c66d-4731-b143-cf2bcf1528c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d7a6e338-be5d-43e0-b27e-675feedd803f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_94b7d28c-c66d-4731-b143-cf2bcf1528c0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d7a6e338-be5d-43e0-b27e-675feedd803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3bf77d01-a202-4314-86d4-ac57864f23ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d7a6e338-be5d-43e0-b27e-675feedd803f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3bf77d01-a202-4314-86d4-ac57864f23ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3bf77d01-a202-4314-86d4-ac57864f23ec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_97252e20-2c0b-43ef-aad6-1c3adeb40d36" xlink:href="ino-20210630.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_ino_MutualFundsMember_97252e20-2c0b-43ef-aad6-1c3adeb40d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_36f19def-7859-493b-ad29-ca81bd4656cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_36f19def-7859-493b-ad29-ca81bd4656cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4b0822e8-59a3-4507-a244-18c3a2079465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4b0822e8-59a3-4507-a244-18c3a2079465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_97bf7303-0245-4122-80ef-1807cc95c91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46304a42-cb8b-42e0-8952-f77705bf5f8c" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_97bf7303-0245-4122-80ef-1807cc95c91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_d7a6e338-be5d-43e0-b27e-675feedd803f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_75c900d0-ae21-474c-9bee-0354a30919e9" xlink:href="ino-20210630.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_75c900d0-ae21-474c-9bee-0354a30919e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_aabeb012-2823-45fa-9b5c-a57752248f62" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e770f919-4a08-43ee-b1f2-d6a4168c1d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e770f919-4a08-43ee-b1f2-d6a4168c1d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_772cf4b8-9146-4c75-89c9-f59263fb59ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_772cf4b8-9146-4c75-89c9-f59263fb59ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12e7ffd9-470c-4b58-85fd-07d643dc91d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12e7ffd9-470c-4b58-85fd-07d643dc91d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b9ad5b9-005e-409b-b921-3fdb793bf0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dd5fdac2-22fc-4ec1-8fea-640d70f5f8cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b9ad5b9-005e-409b-b921-3fdb793bf0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f5ad3fc0-25e9-443f-b9b9-e310f5044fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ab866c7c-ad4e-4836-b244-b024019c0d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f5ad3fc0-25e9-443f-b9b9-e310f5044fc3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ab866c7c-ad4e-4836-b244-b024019c0d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbb6931b-6670-4088-a5e5-1d8de2d7aa63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c5d89665-5242-4aad-8ec6-a8cc807c564d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbb6931b-6670-4088-a5e5-1d8de2d7aa63" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c5d89665-5242-4aad-8ec6-a8cc807c564d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1da30d8f-c3c4-4697-872f-c7cd1118ad7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1da30d8f-c3c4-4697-872f-c7cd1118ad7a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9d4be168-3707-42fc-8f3d-67c9e91ae8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9d4be168-3707-42fc-8f3d-67c9e91ae8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3785e8fb-183a-4881-8c48-011bac051e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9d4be168-3707-42fc-8f3d-67c9e91ae8d4" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3785e8fb-183a-4881-8c48-011bac051e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_020e5333-3757-4806-97ae-ac292851b27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3785e8fb-183a-4881-8c48-011bac051e4f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_020e5333-3757-4806-97ae-ac292851b27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ae2ad3de-769f-46ab-8470-cfe713d092aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ae2ad3de-769f-46ab-8470-cfe713d092aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ae2ad3de-769f-46ab-8470-cfe713d092aa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_8cb64d47-9e41-422c-bba9-d107f7ddba5e" xlink:href="ino-20210630.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_ino_MutualFundsMember_8cb64d47-9e41-422c-bba9-d107f7ddba5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_8cf2315b-3b38-439a-9783-3e916ed0fe4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_8cf2315b-3b38-439a-9783-3e916ed0fe4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e787388c-d8c1-459c-8e7c-6aa5956481b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e787388c-d8c1-459c-8e7c-6aa5956481b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_8136f735-c1e0-4aad-a5ce-077a95ea24ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_317c8c43-5e5d-4d84-bb77-4266e5650555" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_8136f735-c1e0-4aad-a5ce-077a95ea24ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ba8b3ad5-8920-4ca4-a6f3-ac22945a6882" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_421471e8-bfdb-4dd1-a70a-71ebd9eeb0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_421471e8-bfdb-4dd1-a70a-71ebd9eeb0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94d12c19-9474-48ef-8380-ec145729b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94d12c19-9474-48ef-8380-ec145729b40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1f95145b-2a4b-4d76-95ea-717c89d7c700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4c2536e1-b0d1-4c35-a3a2-51154ee89f26" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1f95145b-2a4b-4d76-95ea-717c89d7c700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca6083c6-0943-4234-931c-2e2d177f6bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_83590faf-cbe0-4d22-b9a8-317abf1a7873" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca6083c6-0943-4234-931c-2e2d177f6bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca6083c6-0943-4234-931c-2e2d177f6bff" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d941e680-8726-4922-8f5f-55ac57ab3b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d941e680-8726-4922-8f5f-55ac57ab3b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ec95de69-0ebe-4c23-b239-09caee13d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ec95de69-0ebe-4c23-b239-09caee13d46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_da70bb9c-9f3f-49ef-a22a-572988941244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_da70bb9c-9f3f-49ef-a22a-572988941244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e13dd803-8053-40dc-97d1-44a3518f7f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_283dc55c-72c6-4ee7-a3a6-be22a09f153e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e13dd803-8053-40dc-97d1-44a3518f7f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_257d8347-162a-42e6-af24-f0c2d212e026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_257d8347-162a-42e6-af24-f0c2d212e026" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e570ff87-180b-4b6a-b08c-7666ef95194e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e570ff87-180b-4b6a-b08c-7666ef95194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_28b11c4a-cc20-4481-8d39-32919da85b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e570ff87-180b-4b6a-b08c-7666ef95194e" xlink:to="loc_us-gaap_ClassOfStockDomain_28b11c4a-cc20-4481-8d39-32919da85b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f30afde3-b901-42b2-bb5e-66731e0b3b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_28b11c4a-cc20-4481-8d39-32919da85b99" xlink:to="loc_us-gaap_CommonStockMember_f30afde3-b901-42b2-bb5e-66731e0b3b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ade405a6-c0ae-4af3-9a43-82ea0a517bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ade405a6-c0ae-4af3-9a43-82ea0a517bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db9d123-bc21-4011-bd59-a002a451a03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ade405a6-c0ae-4af3-9a43-82ea0a517bb9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db9d123-bc21-4011-bd59-a002a451a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4e5fbeda-640b-419c-a3f7-42c99ac47998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6db9d123-bc21-4011-bd59-a002a451a03c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4e5fbeda-640b-419c-a3f7-42c99ac47998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e4dc1e73-e5bb-483a-90e8-28b11a428e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_0f6ffd3c-b94f-4da1-b5bc-44b15e041a60" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e4dc1e73-e5bb-483a-90e8-28b11a428e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_d5f5bbf9-512b-43d6-9936-2b1f445895dc" xlink:href="ino-20210630.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_e4dc1e73-e5bb-483a-90e8-28b11a428e18" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_d5f5bbf9-512b-43d6-9936-2b1f445895dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_46bd1eff-78fb-4d60-9491-10b2849ae0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_d5f5bbf9-512b-43d6-9936-2b1f445895dc" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_46bd1eff-78fb-4d60-9491-10b2849ae0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20210630.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_405ab8e7-eb26-4879-a1e9-9a857d602c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f769f2e9-3316-49d2-9b4f-33b3c6bff2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_405ab8e7-eb26-4879-a1e9-9a857d602c24" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f769f2e9-3316-49d2-9b4f-33b3c6bff2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20210630.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3233ea36-88a1-49d3-950d-bcd81a97a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ecbd8ac2-8802-48bb-a1bb-301834b99639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3233ea36-88a1-49d3-950d-bcd81a97a71b" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ecbd8ac2-8802-48bb-a1bb-301834b99639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91bb3ca8-a79d-4fa7-8d26-45dd3010b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91bb3ca8-a79d-4fa7-8d26-45dd3010b89f" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13e0041c-e4f9-459e-997c-08df8e20f711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:to="loc_srt_RangeAxis_13e0041c-e4f9-459e-997c-08df8e20f711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47754f0d-6caa-4733-a772-0fabe3ea3e1b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13e0041c-e4f9-459e-997c-08df8e20f711" xlink:to="loc_srt_RangeMember_47754f0d-6caa-4733-a772-0fabe3ea3e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_5b306c0d-3251-43fe-bfef-212f3d02ff1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_47754f0d-6caa-4733-a772-0fabe3ea3e1b" xlink:to="loc_srt_WeightedAverageMember_5b306c0d-3251-43fe-bfef-212f3d02ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2c576e8-62f6-4d51-b5be-aeda72f28d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2c576e8-62f6-4d51-b5be-aeda72f28d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b2c576e8-62f6-4d51-b5be-aeda72f28d15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_1bce2223-1917-4afe-934a-21cb3c979dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:to="loc_us-gaap_LicensingAgreementsMember_1bce2223-1917-4afe-934a-21cb3c979dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_106e9220-5390-473e-8871-fd6739b5238f" xlink:href="ino-20210630.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:to="loc_ino_BiojectMember_106e9220-5390-473e-8871-fd6739b5238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e0109645-5b2b-49f0-b5f4-e2473c627ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7a91df2-52b5-4e46-8d0c-891d013ec7b0" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e0109645-5b2b-49f0-b5f4-e2473c627ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ea24c830-b961-4f97-b1e4-4a55d32bb60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_18457687-5ec7-4dcf-a834-bade7b552b74" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ea24c830-b961-4f97-b1e4-4a55d32bb60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ea24c830-b961-4f97-b1e4-4a55d32bb60d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_9eeec5a4-2ad0-4b30-a9af-397d995fb8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:to="loc_us-gaap_GoodwillGross_9eeec5a4-2ad0-4b30-a9af-397d995fb8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bd17e4f3-545c-464f-806d-4c87a4b9ae6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d76d8008-ac85-43b8-9ae1-20421f872b34" xlink:to="loc_us-gaap_Goodwill_bd17e4f3-545c-464f-806d-4c87a4b9ae6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_307bb6ed-985e-486a-b1cf-9bf557b9382a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_307bb6ed-985e-486a-b1cf-9bf557b9382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d914649-3af0-41ef-9d36-af1d0945fab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d914649-3af0-41ef-9d36-af1d0945fab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_501eb59c-2336-408f-9bde-ba010828c689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_501eb59c-2336-408f-9bde-ba010828c689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e85e4c6-60ab-4fa4-b5c8-282b7375faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5fb1a9df-1caf-47d0-a859-961851b15951" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e85e4c6-60ab-4fa4-b5c8-282b7375faf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_91b6775d-740e-47fa-8c11-5b03c22b9694" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_91b6775d-740e-47fa-8c11-5b03c22b9694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_cac05e11-c2a9-4eb1-9de7-c7c9f44b017f" xlink:href="ino-20210630.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_11d36d05-d11f-47ef-8d73-9d61b72ac51d" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_cac05e11-c2a9-4eb1-9de7-c7c9f44b017f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a796bff4-3fb4-4321-8d6c-8c2ecd2daf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a796bff4-3fb4-4321-8d6c-8c2ecd2daf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_333a7a37-6464-4833-8e96-d5b456e7d538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_333a7a37-6464-4833-8e96-d5b456e7d538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0a13d735-5af9-44a9-8d49-6fb3a27140b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0a13d735-5af9-44a9-8d49-6fb3a27140b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_38c168af-bcf9-49a0-9022-09b5a1f1fce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_38c168af-bcf9-49a0-9022-09b5a1f1fce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e5d2712d-d5bd-4b68-a383-48703fbb9e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e5d2712d-d5bd-4b68-a383-48703fbb9e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b87fe60c-7fba-4a4d-88e0-a4f57613d72c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b87fe60c-7fba-4a4d-88e0-a4f57613d72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_aa6ecedc-4f00-4e39-9160-164d581269c1" xlink:href="ino-20210630.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc08edf4-11c7-40bd-a56e-930f0c59f481" xlink:to="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_aa6ecedc-4f00-4e39-9160-164d581269c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3cf4f37b-2678-4611-b300-c51510229206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_dbb60d1b-3520-42fa-b4b0-047a73c36518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3cf4f37b-2678-4611-b300-c51510229206" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_dbb60d1b-3520-42fa-b4b0-047a73c36518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9659f897-920f-4709-8f8f-5d51e03394f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_3d662803-322a-4995-9111-1111bc2eafe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9659f897-920f-4709-8f8f-5d51e03394f1" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_3d662803-322a-4995-9111-1111bc2eafe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_33ad72bc-f5fb-4a2e-a7ae-728f2ca437d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9659f897-920f-4709-8f8f-5d51e03394f1" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_33ad72bc-f5fb-4a2e-a7ae-728f2ca437d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7a595782-6253-413d-b73f-fe194ed9e705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7a595782-6253-413d-b73f-fe194ed9e705" xlink:to="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_411eafce-8750-4a97-b7ce-85aef05c6a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_411eafce-8750-4a97-b7ce-85aef05c6a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9a08a8cc-7ea7-44b6-8def-c70d5b11a5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_411eafce-8750-4a97-b7ce-85aef05c6a40" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9a08a8cc-7ea7-44b6-8def-c70d5b11a5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_01bdc572-51a2-4145-ad8f-4f891a0e7fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9a08a8cc-7ea7-44b6-8def-c70d5b11a5a3" xlink:to="loc_us-gaap_ConvertibleDebtMember_01bdc572-51a2-4145-ad8f-4f891a0e7fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_372fdcc3-cbe7-44df-8cf3-512320eca230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_DebtInstrumentAxis_372fdcc3-cbe7-44df-8cf3-512320eca230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_372fdcc3-cbe7-44df-8cf3-512320eca230" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ddc8f475-b3e9-4cb2-840e-3495f9fb8650" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ddc8f475-b3e9-4cb2-840e-3495f9fb8650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_1aac783d-dc52-4192-a483-ebe788b74bd2" xlink:href="ino-20210630.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:to="loc_ino_August2019ConvertibleBondsMember_1aac783d-dc52-4192-a483-ebe788b74bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_ef816839-f007-4847-a08d-db8facd36779" xlink:href="ino-20210630.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1cc90a95-458e-4d15-9503-b850b97917f1" xlink:to="loc_ino_December2019ConvertibleBondsMember_ef816839-f007-4847-a08d-db8facd36779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_c8f4ad81-95b9-435a-8774-f87901d2007d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_c8f4ad81-95b9-435a-8774-f87901d2007d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_f834e4ba-43ea-41b4-b58f-b56103a66441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_c8f4ad81-95b9-435a-8774-f87901d2007d" xlink:to="loc_us-gaap_DebtConversionNameDomain_f834e4ba-43ea-41b4-b58f-b56103a66441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_d41b1ed6-e752-4025-8fe5-b9332c04dbeb" xlink:href="ino-20210630.xsd#ino_InitialConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_f834e4ba-43ea-41b4-b58f-b56103a66441" xlink:to="loc_ino_InitialConversionPriceMember_d41b1ed6-e752-4025-8fe5-b9332c04dbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f1dff7dc-69c0-43f6-965a-63b791f59d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f1dff7dc-69c0-43f6-965a-63b791f59d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69f5ea6a-b008-4066-9120-825449aa0513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1dff7dc-69c0-43f6-965a-63b791f59d4f" xlink:to="loc_us-gaap_ClassOfStockDomain_69f5ea6a-b008-4066-9120-825449aa0513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d4cd4ac9-8e8b-4681-99a7-fe351d2fce4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_69f5ea6a-b008-4066-9120-825449aa0513" xlink:to="loc_us-gaap_CommonStockMember_d4cd4ac9-8e8b-4681-99a7-fe351d2fce4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b7183a5a-588f-4c3e-8ebe-44a79ebf994d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_56521b83-d889-44a2-852f-25c034c624d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_56521b83-d889-44a2-852f-25c034c624d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c57e28-3019-4e91-95de-942a9132f16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c57e28-3019-4e91-95de-942a9132f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_9065aee5-fa1f-40ff-be61-910a9e61df58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_9065aee5-fa1f-40ff-be61-910a9e61df58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_aa4c629d-cfe4-413c-88e7-93c919bcf18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_aa4c629d-cfe4-413c-88e7-93c919bcf18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5f9cf1b8-4f97-4e28-b1e9-47ab39f6b0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5f9cf1b8-4f97-4e28-b1e9-47ab39f6b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eafeae2a-8f57-4a91-82db-404774986a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_eafeae2a-8f57-4a91-82db-404774986a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_adda57d8-0a87-4c02-9e5c-a2a7b66cf3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_adda57d8-0a87-4c02-9e5c-a2a7b66cf3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_e55a575a-8a8b-4c73-abfb-9fd9b4c11bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_e55a575a-8a8b-4c73-abfb-9fd9b4c11bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d325d09e-d6f4-4516-9c67-3d909e2dbddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d325d09e-d6f4-4516-9c67-3d909e2dbddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9ca2ac5f-7daf-40a0-ac85-1556f00f2672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9ca2ac5f-7daf-40a0-ac85-1556f00f2672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_7654111a-91d4-4917-809f-b08ddbc1931f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_7654111a-91d4-4917-809f-b08ddbc1931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_69a4abec-ee77-4346-a1ce-d231fe0f70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_69a4abec-ee77-4346-a1ce-d231fe0f70f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6ad34350-c018-478b-8cac-7f06f22fba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6ad34350-c018-478b-8cac-7f06f22fba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2d923de9-0fd3-48b0-8590-c6128e5164ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_2d923de9-0fd3-48b0-8590-c6128e5164ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dac39901-723e-45d1-a56e-b8d2afa86995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_dac39901-723e-45d1-a56e-b8d2afa86995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6cdc9a59-881e-4dcd-a888-0d914b8d53b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6cdc9a59-881e-4dcd-a888-0d914b8d53b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_679246d9-f8b3-4442-8f39-cd5e35058ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_679246d9-f8b3-4442-8f39-cd5e35058ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0f422179-0de7-4e62-a39f-70441dd98a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_InterestExpense_0f422179-0de7-4e62-a39f-70441dd98a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7d1c3801-d71e-4bd4-a0ab-64f4f0207198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_InterestExpenseDebt_7d1c3801-d71e-4bd4-a0ab-64f4f0207198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_350347ab-eb54-44ac-8df9-033dfac52b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_350347ab-eb54-44ac-8df9-033dfac52b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7b3474cd-d669-4886-95d3-468da6fe24a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_7b3474cd-d669-4886-95d3-468da6fe24a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2492b82e-52d3-435b-bb1b-0be67e9c20a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2133d160-9f6b-4954-9f5a-dfcf1fdbe0a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2492b82e-52d3-435b-bb1b-0be67e9c20a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f5aa07f-5626-46f8-a3ae-ba2deb3f75d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_98163654-41c1-487f-ab0b-18c7850233f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f5aa07f-5626-46f8-a3ae-ba2deb3f75d0" xlink:to="loc_us-gaap_DebtInstrumentTable_98163654-41c1-487f-ab0b-18c7850233f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98163654-41c1-487f-ab0b-18c7850233f7" xlink:to="loc_us-gaap_DebtInstrumentAxis_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8c149ed-2789-4708-b02c-f522bcd3410a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9b5ea816-4e0e-4ee7-b034-f1aca3978dfd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8c149ed-2789-4708-b02c-f522bcd3410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c2c66298-535b-4f96-9f49-4c43b8e90b70" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8c149ed-2789-4708-b02c-f522bcd3410a" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_c2c66298-535b-4f96-9f49-4c43b8e90b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_98163654-41c1-487f-ab0b-18c7850233f7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_44ed22ad-6dcf-48ee-bdd1-333a6ee29747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_44ed22ad-6dcf-48ee-bdd1-333a6ee29747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_dc772134-3703-4e52-931f-88ebf275b056" xlink:href="ino-20210630.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_dc772134-3703-4e52-931f-88ebf275b056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_069ed325-11fe-4114-a0a4-711e123a614d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_069ed325-11fe-4114-a0a4-711e123a614d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_9536c3bb-59a5-4c47-918f-4c910c9d1fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_9536c3bb-59a5-4c47-918f-4c910c9d1fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_834191ae-e554-43e3-85bb-3e35acbac5f5" xlink:href="ino-20210630.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_ino_DebtInstrumentAccruedInterest_834191ae-e554-43e3-85bb-3e35acbac5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a6b6ba76-7716-4b09-8bdc-4c8c3af97afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0fcbc0e9-bbab-4eeb-ae91-67420cc3a676" xlink:to="loc_us-gaap_LongTermDebt_a6b6ba76-7716-4b09-8bdc-4c8c3af97afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_98cfbb2c-7313-4087-bc99-d861e2219ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_98cfbb2c-7313-4087-bc99-d861e2219ee9" xlink:to="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe879c7b-c472-4e83-96be-90f35ebb5111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe879c7b-c472-4e83-96be-90f35ebb5111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5cb0cf46-c775-4aaa-a1bd-f5c7e7e9c0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe879c7b-c472-4e83-96be-90f35ebb5111" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5cb0cf46-c775-4aaa-a1bd-f5c7e7e9c0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_79200d2d-c16b-4778-98d0-0406fb9381d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5cb0cf46-c775-4aaa-a1bd-f5c7e7e9c0d6" xlink:to="loc_us-gaap_ConvertibleDebtMember_79200d2d-c16b-4778-98d0-0406fb9381d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cac6233e-45ee-4d82-8490-143336974f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:to="loc_us-gaap_DebtInstrumentAxis_cac6233e-45ee-4d82-8490-143336974f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_85d9d422-98ff-4220-9ab1-90203a505611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cac6233e-45ee-4d82-8490-143336974f77" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_85d9d422-98ff-4220-9ab1-90203a505611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_24a38e5c-cf8e-4fe4-9aed-ed6d53675deb" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_85d9d422-98ff-4220-9ab1-90203a505611" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_24a38e5c-cf8e-4fe4-9aed-ed6d53675deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c3ccfe47-e9d4-4d63-84fa-50a06c2e4601" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d398cca2-cd2e-4ce7-8782-0590a116aa41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_d398cca2-cd2e-4ce7-8782-0590a116aa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0074ab76-c1b6-4c8f-b80b-b4840682ca72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0074ab76-c1b6-4c8f-b80b-b4840682ca72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_014f84bf-e3c4-4292-831e-98676b8530ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_014f84bf-e3c4-4292-831e-98676b8530ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1d38ec8f-a11a-4fc4-be57-e823912a6154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1d38ec8f-a11a-4fc4-be57-e823912a6154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2533f1c4-90a4-43c0-b665-9c6ea1ad3719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_LongTermDebt_2533f1c4-90a4-43c0-b665-9c6ea1ad3719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_91d2b817-32ab-4844-80f1-1a90e3663cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d5541169-25d3-41d9-832d-aba0791b24b6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_91d2b817-32ab-4844-80f1-1a90e3663cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2c2de713-f589-4220-a739-14f4f48c8b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22e2a7da-e8d0-4b30-a83a-38e2f3914281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2c2de713-f589-4220-a739-14f4f48c8b9a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22e2a7da-e8d0-4b30-a83a-38e2f3914281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20210630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3349bca9-8313-41f4-9d6f-4ff97ef20200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_d204436b-67bb-4e8b-80b9-b51afa48eb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3349bca9-8313-41f4-9d6f-4ff97ef20200" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_d204436b-67bb-4e8b-80b9-b51afa48eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a9045a9f-e87c-43e8-83b4-34b457172c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c74c28bc-feb2-4496-900b-feffa52b110c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a9045a9f-e87c-43e8-83b4-34b457172c42" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c74c28bc-feb2-4496-900b-feffa52b110c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aea7f2f2-25a5-405e-82a4-d14b63df7231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c74c28bc-feb2-4496-900b-feffa52b110c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aea7f2f2-25a5-405e-82a4-d14b63df7231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1190ecd-ef69-40ad-b710-0126e3440825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aea7f2f2-25a5-405e-82a4-d14b63df7231" xlink:to="loc_us-gaap_ClassOfStockDomain_e1190ecd-ef69-40ad-b710-0126e3440825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1a14a762-3410-4c2b-96d2-2f45b8c26e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e1190ecd-ef69-40ad-b710-0126e3440825" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1a14a762-3410-4c2b-96d2-2f45b8c26e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2ac0faab-f621-4a23-82a2-22d4faa5d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c74c28bc-feb2-4496-900b-feffa52b110c" xlink:to="loc_us-gaap_ClassOfStockLineItems_2ac0faab-f621-4a23-82a2-22d4faa5d3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2ac0faab-f621-4a23-82a2-22d4faa5d3c6" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a975dcac-6d3c-49e7-8fa1-1e0dc087a2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a975dcac-6d3c-49e7-8fa1-1e0dc087a2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cfd55239-1572-4fb1-acfe-a9fa150ad450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cfd55239-1572-4fb1-acfe-a9fa150ad450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_58e87038-2b7a-41eb-9424-1562471404ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockSharesIssued_58e87038-2b7a-41eb-9424-1562471404ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8df3ba21-c78e-4739-bcdc-eddabda3907e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8df3ba21-c78e-4739-bcdc-eddabda3907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c79b7b04-666d-4528-bcd1-d5042d7c0746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c79b7b04-666d-4528-bcd1-d5042d7c0746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f442cac6-5659-4727-b3bd-b17cd865e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f442cac6-5659-4727-b3bd-b17cd865e73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dcd73dbe-8899-4c2d-8a8c-c51d471c3166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dcd73dbe-8899-4c2d-8a8c-c51d471c3166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5c9757f9-8b91-4836-a1cd-ec808b5569be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_66661ef2-34a7-4551-be61-5f037308a1db" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5c9757f9-8b91-4836-a1cd-ec808b5569be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9b6e4513-6c44-4a66-9bd7-765f73892467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9b6e4513-6c44-4a66-9bd7-765f73892467" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_85a52bae-5a8b-4252-82a3-d84065e7c469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_85a52bae-5a8b-4252-82a3-d84065e7c469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_85a52bae-5a8b-4252-82a3-d84065e7c469" xlink:to="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1910761e-2c1c-4de1-a7f7-ff0c1fae4fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1910761e-2c1c-4de1-a7f7-ff0c1fae4fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_af6add71-3446-472b-b1c1-8116b6f44724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8872d381-5491-441d-a520-a1424c5e533f" xlink:to="loc_us-gaap_CommonStockMember_af6add71-3446-472b-b1c1-8116b6f44724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_44fea718-9975-470a-a1ea-f49ff2b35273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_44fea718-9975-470a-a1ea-f49ff2b35273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_44fea718-9975-470a-a1ea-f49ff2b35273" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_684290a2-6c32-4122-9f2a-60ebfb7bb124" xlink:href="ino-20210630.xsd#ino_PriorSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:to="loc_ino_PriorSalesAgreementMember_684290a2-6c32-4122-9f2a-60ebfb7bb124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_8a71f2d1-40de-4813-b7ad-cf17fc017506" xlink:href="ino-20210630.xsd#ino_NewSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_50bb20e9-ac23-4cd5-bd07-52d93837aa6d" xlink:to="loc_ino_NewSalesAgreementMember_8a71f2d1-40de-4813-b7ad-cf17fc017506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:to="loc_us-gaap_PlanNameAxis_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ebc17901-9fbb-40aa-8c2b-7c130e0b48bf" xlink:to="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_31659b8b-debe-496d-bc79-5b89633a84bc" xlink:href="ino-20210630.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:to="loc_ino_A2016IncentivePlanMember_31659b8b-debe-496d-bc79-5b89633a84bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_ce4ed9b3-fde8-4245-8bb5-d060a9d269db" xlink:href="ino-20210630.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4e8045eb-7fb3-4ad6-83ac-d1bf8204b39f" xlink:to="loc_ino_A2007IncentivePlanMember_ce4ed9b3-fde8-4245-8bb5-d060a9d269db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7956ca04-4dd0-4087-8afc-a26b98a538fd" xlink:to="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ea9cec9b-de04-4c95-82ed-e755da998b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ea9cec9b-de04-4c95-82ed-e755da998b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_f3ff04d0-4dff-49a5-84d9-85d714caa86b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_f3ff04d0-4dff-49a5-84d9-85d714caa86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38387343-0def-4d23-b100-8c4ffa634130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_38387343-0def-4d23-b100-8c4ffa634130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b7fc5d95-5aa4-4233-a108-1f0617020e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b7fc5d95-5aa4-4233-a108-1f0617020e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_7b7585ae-759e-42b3-add0-cde32c6486af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_7b7585ae-759e-42b3-add0-cde32c6486af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_e0e81b53-22f3-40ec-8081-e4b5d5e30e6a" xlink:href="ino-20210630.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_e0e81b53-22f3-40ec-8081-e4b5d5e30e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_4218f4b7-11a0-4bc7-918a-f84b8bec2d9f" xlink:href="ino-20210630.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_4218f4b7-11a0-4bc7-918a-f84b8bec2d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_14c33103-2dbd-43b7-9779-e617f53d0e69" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_14c33103-2dbd-43b7-9779-e617f53d0e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_a54b53ae-b34e-429a-9010-be151ffb5897" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_a54b53ae-b34e-429a-9010-be151ffb5897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e1c300a4-5d58-4719-bd12-9144478be92e" xlink:href="ino-20210630.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e1c300a4-5d58-4719-bd12-9144478be92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_02d73759-e72e-4b96-ac1a-60573011d8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_02d73759-e72e-4b96-ac1a-60573011d8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_817372c2-d702-4cfc-8a11-a61278fb9e99" xlink:href="ino-20210630.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_817372c2-d702-4cfc-8a11-a61278fb9e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_9938c378-14c1-4656-a1ef-a359b08fb28b" xlink:href="ino-20210630.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_9938c378-14c1-4656-a1ef-a359b08fb28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e93e7e80-baba-4892-a95e-75c01cdb6e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e93e7e80-baba-4892-a95e-75c01cdb6e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ccf088a-9b54-4bef-8db5-1f357c710e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ccf088a-9b54-4bef-8db5-1f357c710e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_f91d3b32-c67f-4951-a2a5-105c7f2dd3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_f91d3b32-c67f-4951-a2a5-105c7f2dd3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcb96798-4017-4f77-a049-04d62220d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcb96798-4017-4f77-a049-04d62220d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ac8ca4e3-532c-4e51-bc76-bed0e521f523" xlink:href="ino-20210630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1ce92f76-396e-4d01-b508-08cf4592eb42" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ac8ca4e3-532c-4e51-bc76-bed0e521f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20210630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d687804d-9c28-4c78-958b-d612964dcb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_cc8a4b86-b59a-4051-b0ce-432ca906c7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d687804d-9c28-4c78-958b-d612964dcb13" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_cc8a4b86-b59a-4051-b0ce-432ca906c7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20210630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_69f00954-bb9b-4d90-b208-9b93bd4eb350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_281c54e0-ac63-4bcc-a17d-0d0e14892f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_69f00954-bb9b-4d90-b208-9b93bd4eb350" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_281c54e0-ac63-4bcc-a17d-0d0e14892f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fefa3b79-4ca1-4450-b1a3-c92e868801d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fefa3b79-4ca1-4450-b1a3-c92e868801d5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0cc4934a-cc7d-411e-9f9a-1146cfd46466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:to="loc_us-gaap_DebtInstrumentAxis_0cc4934a-cc7d-411e-9f9a-1146cfd46466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0cc4934a-cc7d-411e-9f9a-1146cfd46466" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7b27cf9e-58c9-4208-ae3c-f5149b7badbc" xlink:href="ino-20210630.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7b27cf9e-58c9-4208-ae3c-f5149b7badbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_9bf605b6-661f-463e-b990-c2f0d2c238e1" xlink:href="ino-20210630.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:to="loc_ino_August2019ConvertibleBondsMember_9bf605b6-661f-463e-b990-c2f0d2c238e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_c9c2b7f5-46e1-4d5e-8a1f-8accdcc50f60" xlink:href="ino-20210630.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_61eab2bf-3efa-48f2-bac3-c42c3e9d6a1b" xlink:to="loc_ino_December2019ConvertibleBondsMember_c9c2b7f5-46e1-4d5e-8a1f-8accdcc50f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b96fac23-65c8-47aa-8440-717a14f87b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b96fac23-65c8-47aa-8440-717a14f87b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b96fac23-65c8-47aa-8440-717a14f87b1b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db564693-f27b-44c6-9220-29de3d0e30a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db564693-f27b-44c6-9220-29de3d0e30a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_2c4e661f-0ff1-459f-9d45-d0f13d764848" xlink:href="ino-20210630.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_2c4e661f-0ff1-459f-9d45-d0f13d764848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_097ba226-7f50-4090-834b-6268ed150e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_097ba226-7f50-4090-834b-6268ed150e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_b43b3e70-d526-4bfc-830f-45b39be10b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_b43b3e70-d526-4bfc-830f-45b39be10b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_53d3e4ba-76e0-47fd-bcb8-e6fa7fc6afd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_86d732cc-3b00-41eb-9c27-67117187bfcf" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_53d3e4ba-76e0-47fd-bcb8-e6fa7fc6afd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38a08494-ee8c-4fe3-8667-1fd08c959546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e87ab1a1-e7fa-488e-84d1-821a1e2c1ce3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38a08494-ee8c-4fe3-8667-1fd08c959546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f3abdf10-98a9-4d44-a895-c3495bd5d207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_38a08494-ee8c-4fe3-8667-1fd08c959546" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f3abdf10-98a9-4d44-a895-c3495bd5d207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20210630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_552d5e99-5270-4abc-a652-4d4fd4dcef79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5d065c2f-aadf-4041-9be4-26209689fa28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_552d5e99-5270-4abc-a652-4d4fd4dcef79" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5d065c2f-aadf-4041-9be4-26209689fa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20210630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f45d8686-de54-4016-a445-6c5584f30862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30e5dc43-a0bd-46c8-af7d-04c2f1c43799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f45d8686-de54-4016-a445-6c5584f30862" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30e5dc43-a0bd-46c8-af7d-04c2f1c43799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dacd71b9-6be0-4a8a-b30e-62d3d274c9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dacd71b9-6be0-4a8a-b30e-62d3d274c9c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_AwardTypeAxis_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ffdd7151-9d5b-4dff-bbcb-34f9d346d8a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e28186b2-9b23-41a9-a1b0-f17fe9630b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e28186b2-9b23-41a9-a1b0-f17fe9630b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2675a128-36e5-4f68-acd7-71918ea2e51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9ed9bc5-552a-4a41-90df-5d394913a95f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2675a128-36e5-4f68-acd7-71918ea2e51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b0b09a55-19d8-415a-b7c1-00abecacffd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_srt_TitleOfIndividualAxis_b0b09a55-19d8-415a-b7c1-00abecacffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b0b09a55-19d8-415a-b7c1-00abecacffd4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_fd273ff8-51c9-4f33-b175-251fc5dac630" xlink:href="ino-20210630.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:to="loc_ino_EmployeesAndDirectorsMember_fd273ff8-51c9-4f33-b175-251fc5dac630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_30cfcf37-f53e-4165-8f68-ca692e7015c9" xlink:href="ino-20210630.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d3501c8-e7fc-414d-a846-1fc1843fc485" xlink:to="loc_ino_NonEmployeeMember_30cfcf37-f53e-4165-8f68-ca692e7015c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e389dbef-7a94-4db2-b7af-f268ae6acdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e389dbef-7a94-4db2-b7af-f268ae6acdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e389dbef-7a94-4db2-b7af-f268ae6acdfe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_79d33d60-c155-45a4-931b-f818714c314a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_79d33d60-c155-45a4-931b-f818714c314a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ec96649d-374b-4274-9394-529ba304ed5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0e3ed2a2-e7a5-476a-b229-c087f6ac37df" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ec96649d-374b-4274-9394-529ba304ed5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_45c5129f-d62d-49c9-ad68-a3567ab2dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_PlanNameAxis_45c5129f-d62d-49c9-ad68-a3567ab2dec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a30b8391-f9ae-424c-827e-af5afcdc8137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_45c5129f-d62d-49c9-ad68-a3567ab2dec9" xlink:to="loc_us-gaap_PlanNameDomain_a30b8391-f9ae-424c-827e-af5afcdc8137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_38484c3e-42d4-4262-b44c-1c6adb04379e" xlink:href="ino-20210630.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a30b8391-f9ae-424c-827e-af5afcdc8137" xlink:to="loc_ino_A2016IncentivePlanMember_38484c3e-42d4-4262-b44c-1c6adb04379e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_beaba38a-0101-4d7f-9060-14fefebdf2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_VestingAxis_beaba38a-0101-4d7f-9060-14fefebdf2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_beaba38a-0101-4d7f-9060-14fefebdf2ea" xlink:to="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_47755caf-ae44-4d38-b379-900bbfb2487c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_47755caf-ae44-4d38-b379-900bbfb2487c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d1a3d8-8264-4670-9b34-4964bd451805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_0b243e58-fdde-412f-a0f2-27c5b9c0968a" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d1a3d8-8264-4670-9b34-4964bd451805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eb64c724-d275-4ec7-b99c-5266d424b667" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645bc0f9-50c2-4b06-9f43-37b4222f352d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645bc0f9-50c2-4b06-9f43-37b4222f352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6784ad10-eaba-460a-920b-92484aae0753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6784ad10-eaba-460a-920b-92484aae0753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_192e6987-6a2d-43bb-bab6-5326e30cc934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_192e6987-6a2d-43bb-bab6-5326e30cc934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_78e7c7ee-59c2-4a74-b4e0-150b366b3e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_78e7c7ee-59c2-4a74-b4e0-150b366b3e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_03ce192e-95ff-4da0-8c9a-984b5cbad274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensation_03ce192e-95ff-4da0-8c9a-984b5cbad274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e65e02-9006-4a08-8041-f50d4ae5d399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e65e02-9006-4a08-8041-f50d4ae5d399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f61d78aa-2f70-4d65-9b35-ef5451f76e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f61d78aa-2f70-4d65-9b35-ef5451f76e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7266523-1dc4-4394-b295-2d6ef821e8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b7266523-1dc4-4394-b295-2d6ef821e8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96812ddd-66be-4668-9de8-e7322548f4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_96812ddd-66be-4668-9de8-e7322548f4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c3d9ad2-2723-4f17-a770-56af3499b6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c3d9ad2-2723-4f17-a770-56af3499b6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77581068-0abd-4ba4-9c14-226f85aa32b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77581068-0abd-4ba4-9c14-226f85aa32b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7bdbeb13-a31f-4019-ba08-81657fe6de91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7bdbeb13-a31f-4019-ba08-81657fe6de91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a4472dc-5d10-473e-9477-0f0644e707f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4a4472dc-5d10-473e-9477-0f0644e707f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_d164cf6d-447f-4e59-be8e-3816e487f971" xlink:href="ino-20210630.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a40bf5cd-0cc0-4bf3-82dd-fb7e6e903682" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_d164cf6d-447f-4e59-be8e-3816e487f971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20210630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_00e02dbf-1f6f-43ff-b913-2d18d4f5e762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9cfe0e15-8442-4939-90c4-322b9e99a9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_00e02dbf-1f6f-43ff-b913-2d18d4f5e762" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9cfe0e15-8442-4939-90c4-322b9e99a9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_b9d63193-1a84-48b6-853c-01af1667eed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_b9d63193-1a84-48b6-853c-01af1667eed3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_07494dac-a35e-4044-aa20-8f6eb235e59b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_srt_CounterpartyNameAxis_07494dac-a35e-4044-aa20-8f6eb235e59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c817af6c-a5b3-4963-b7db-5d4a4cbfdf61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_07494dac-a35e-4044-aa20-8f6eb235e59b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c817af6c-a5b3-4963-b7db-5d4a4cbfdf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_1e215744-97c9-432d-9cea-0ebeb9183c4b" xlink:href="ino-20210630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c817af6c-a5b3-4963-b7db-5d4a4cbfdf61" xlink:to="loc_ino_PlumblineLifeSciencesMember_1e215744-97c9-432d-9cea-0ebeb9183c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_90a066f8-56a5-4caa-a750-6505f1ea015b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_90a066f8-56a5-4caa-a750-6505f1ea015b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f94d0ede-4d69-4f7a-87d8-eae7057698ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_90a066f8-56a5-4caa-a750-6505f1ea015b" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f94d0ede-4d69-4f7a-87d8-eae7057698ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_fdf37a5e-5246-431b-8013-c09221c7cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f94d0ede-4d69-4f7a-87d8-eae7057698ca" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_fdf37a5e-5246-431b-8013-c09221c7cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b70b29b1-6d56-4ed7-bc64-c2e728b216fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b70b29b1-6d56-4ed7-bc64-c2e728b216fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_513cda8c-4c41-49e4-9159-30d082a5a838" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b70b29b1-6d56-4ed7-bc64-c2e728b216fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_513cda8c-4c41-49e4-9159-30d082a5a838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_7337a399-4615-484c-b273-4203499ec20f" xlink:href="ino-20210630.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_513cda8c-4c41-49e4-9159-30d082a5a838" xlink:to="loc_ino_PlumblineLifeSciencesMember_7337a399-4615-484c-b273-4203499ec20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bfed0cdc-8f6a-4c58-bb77-5f183efe8ee0" xlink:to="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2c245883-3a44-4bd0-b28b-c45ab5be9f71" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:to="loc_srt_DirectorMember_2c245883-3a44-4bd0-b28b-c45ab5be9f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_7c67b5fd-efad-4487-97db-c2ebf84ed0e1" xlink:href="ino-20210630.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2882b6bf-f1c0-43e4-a58e-e21b34520c10" xlink:to="loc_ino_TheWistarInstituteMember_7c67b5fd-efad-4487-97db-c2ebf84ed0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_dc73301e-660b-46da-95aa-8fd042790af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4355666-9eb8-48ed-a831-8dc266742b79" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_dc73301e-660b-46da-95aa-8fd042790af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:href="ino-20210630.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_dc73301e-660b-46da-95aa-8fd042790af5" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_70ccd0b7-b7b0-4afd-8d70-ef8218308f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_70ccd0b7-b7b0-4afd-8d70-ef8218308f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d58b2c80-de84-4fc8-a788-0138c3828771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d58b2c80-de84-4fc8-a788-0138c3828771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a0f414a-439a-443c-88e0-51c684894368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a0f414a-439a-443c-88e0-51c684894368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_dabac162-2a91-47a7-aca5-bdf123b23d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_dabac162-2a91-47a7-aca5-bdf123b23d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_4ebac7f7-edc7-4411-acf2-cbc1d06353b5" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_4ebac7f7-edc7-4411-acf2-cbc1d06353b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_3424fdcf-9447-48bc-b733-5476dd081c6b" xlink:href="ino-20210630.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeArrangementTerm_3424fdcf-9447-48bc-b733-5476dd081c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_301c47a1-3a1c-473b-bc92-77ae53d28d00" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_301c47a1-3a1c-473b-bc92-77ae53d28d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_9ca225ce-c523-45a9-87b0-fc644cc98b86" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_9ca225ce-c523-45a9-87b0-fc644cc98b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_6298547d-a6ea-408d-8dab-84400d53169b" xlink:href="ino-20210630.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_GrantProceedsReceived_6298547d-a6ea-408d-8dab-84400d53169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_17dfb8a1-2b88-41e2-b1f2-a54b892ed2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_17dfb8a1-2b88-41e2-b1f2-a54b892ed2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cd7e18b4-5ca9-4263-936d-3eb581cecf39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_cd7e18b4-5ca9-4263-936d-3eb581cecf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_37a8b85b-d513-4c6a-b65c-69042db39747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_37a8b85b-d513-4c6a-b65c-69042db39747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_adaa951a-7444-4ecb-aa33-17880d245b98" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_e8f8c28a-db60-4583-95ee-d82e25a051d8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_adaa951a-7444-4ecb-aa33-17880d245b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_15d2dbf8-b29c-4990-9dbc-414ffccf320f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ebd6e079-7f2f-4375-835c-1bdee6e9c00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_15d2dbf8-b29c-4990-9dbc-414ffccf320f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ebd6e079-7f2f-4375-835c-1bdee6e9c00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bd0be01c-a96f-4db7-87ae-b130e5c21945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8b3296f5-b0ec-4463-9cfc-424b70ece53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd0be01c-a96f-4db7-87ae-b130e5c21945" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8b3296f5-b0ec-4463-9cfc-424b70ece53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cbade427-8c8f-4d05-bb84-526bf4502375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cbade427-8c8f-4d05-bb84-526bf4502375" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c697519d-2432-441c-af43-3757d3048d97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c697519d-2432-441c-af43-3757d3048d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c697519d-2432-441c-af43-3757d3048d97" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_2ea05f44-f977-4f8f-8269-4b68cd6fecfe" xlink:href="ino-20210630.xsd#ino_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:to="loc_ino_SanDiegoOfficeMember_2ea05f44-f977-4f8f-8269-4b68cd6fecfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_02d61241-9667-4f81-af08-54ac242d93f5" xlink:href="ino-20210630.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_dc2e1bac-fd72-40e1-96a6-dcac0084ef67" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_02d61241-9667-4f81-af08-54ac242d93f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c548445b-6960-4628-9797-b5362020445c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:to="loc_srt_RangeAxis_c548445b-6960-4628-9797-b5362020445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c548445b-6960-4628-9797-b5362020445c" xlink:to="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6d649f7a-21af-48e3-9773-a16dfa0bc8ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:to="loc_srt_MinimumMember_6d649f7a-21af-48e3-9773-a16dfa0bc8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f3c879d3-7f81-4212-ac66-3f7deb5ddd21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40e985ad-ce5b-4cf0-8791-d645a3b0ef38" xlink:to="loc_srt_MaximumMember_f3c879d3-7f81-4212-ac66-3f7deb5ddd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aa5f48da-eeab-4cc2-b6cc-e4d95243377a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_6803f615-3044-4128-84da-86d6ae417a72" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_6803f615-3044-4128-84da-86d6ae417a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8897d800-dbd2-4058-85f5-ab8c2b3ed755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_8897d800-dbd2-4058-85f5-ab8c2b3ed755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ca2f1f95-8878-4fb1-b524-10bf2d895ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_us-gaap_LeaseCost_ca2f1f95-8878-4fb1-b524-10bf2d895ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_a2c55d78-e115-40d2-9fc7-a17eaa560f35" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a6b72e08-3632-43ec-9775-bbba970fc015" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_a2c55d78-e115-40d2-9fc7-a17eaa560f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a31494c5-5551-44a1-8fcb-418dec15aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a31494c5-5551-44a1-8fcb-418dec15aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d2eafc1c-f9e7-4e1d-ab52-94eaac1172dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d2eafc1c-f9e7-4e1d-ab52-94eaac1172dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2abb8136-0097-4d3e-87d5-b37c3257a1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2abb8136-0097-4d3e-87d5-b37c3257a1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9fd82cf0-7f53-4691-aef3-3fc181271e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9fd82cf0-7f53-4691-aef3-3fc181271e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a30a519e-4659-4086-b003-5028b431b205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a30a519e-4659-4086-b003-5028b431b205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_775909a9-3291-471a-a921-d4333062ccc8" xlink:href="ino-20210630.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_775909a9-3291-471a-a921-d4333062ccc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37c85555-3862-482a-9910-3c05dafbd029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37c85555-3862-482a-9910-3c05dafbd029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_265f9776-e9d5-4cc1-a9f9-6e6ad95ff2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_265f9776-e9d5-4cc1-a9f9-6e6ad95ff2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8d7f155a-9bf2-4be3-85cd-53eed3e37494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_OperatingLeaseLiability_8d7f155a-9bf2-4be3-85cd-53eed3e37494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b86a0e3f-0b3a-4123-a644-d3958850fff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b86a0e3f-0b3a-4123-a644-d3958850fff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02db9b79-2f38-498f-a19f-cefb4ca27ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02db9b79-2f38-498f-a19f-cefb4ca27ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_269f4f29-e99a-4fec-8f2a-215e60f98f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_269f4f29-e99a-4fec-8f2a-215e60f98f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8deb26fa-bbdd-4d4a-8de1-18b5db0542b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_493e4be4-045a-490c-96ca-a1c97c089628" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_8deb26fa-bbdd-4d4a-8de1-18b5db0542b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20210630.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e68cc38-075b-4b00-ba63-0f2b2e96348e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b743982c-7fe9-41d0-8ef6-93b76ce79f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e68cc38-075b-4b00-ba63-0f2b2e96348e" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b743982c-7fe9-41d0-8ef6-93b76ce79f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bbce2aa-bf24-4288-bcff-2fb2c0fc7c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bbce2aa-bf24-4288-bcff-2fb2c0fc7c18" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_srt_CounterpartyNameAxis_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_694afb3a-c75c-4cf3-a49c-f8fcae11ea5c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_6c78007d-2794-418e-803c-3234ffeea5d4" xlink:href="ino-20210630.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_AdvaccineMember_6c78007d-2794-418e-803c-3234ffeea5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_7cf5f432-c8b5-4fcf-9890-3a144100a15a" xlink:href="ino-20210630.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_ApolloBioMember_7cf5f432-c8b5-4fcf-9890-3a144100a15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_cde7c2a4-6e9b-4c85-97fc-2ba4317aac4d" xlink:href="ino-20210630.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_AstraZenecaMember_cde7c2a4-6e9b-4c85-97fc-2ba4317aac4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_492c194d-1a2f-409c-a640-3ee376048967" xlink:href="ino-20210630.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_492c194d-1a2f-409c-a640-3ee376048967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_28537954-bb62-4914-ac8b-104325eb434e" xlink:href="ino-20210630.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_28537954-bb62-4914-ac8b-104325eb434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_b9cb3c0f-7305-4172-993b-a7034b39810d" xlink:href="ino-20210630.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3d1dcfcd-00db-47c2-abab-d63ef8d55046" xlink:to="loc_ino_DepartmentOfDefenceMember_b9cb3c0f-7305-4172-993b-a7034b39810d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_52a6ed14-79f3-426b-a443-f6f5c81f047b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_52a6ed14-79f3-426b-a443-f6f5c81f047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffbfddea-f83c-49c1-86f0-1f58d0a05cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_52a6ed14-79f3-426b-a443-f6f5c81f047b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffbfddea-f83c-49c1-86f0-1f58d0a05cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_1a3499a2-5525-4070-9ab7-591399c54a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffbfddea-f83c-49c1-86f0-1f58d0a05cd0" xlink:to="loc_us-gaap_CollaborativeArrangementMember_1a3499a2-5525-4070-9ab7-591399c54a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_77d6f14d-4bd5-4aae-8f86-b0024db55729" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_srt_ProductOrServiceAxis_77d6f14d-4bd5-4aae-8f86-b0024db55729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_77d6f14d-4bd5-4aae-8f86-b0024db55729" xlink:to="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b9d8bc94-dc8f-43f3-8ab3-a1cc3792f128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_us-gaap_LicenseMember_b9d8bc94-dc8f-43f3-8ab3-a1cc3792f128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_b5c6d2b6-dfed-4fdd-9d06-f11ffd1022c4" xlink:href="ino-20210630.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_b5c6d2b6-dfed-4fdd-9d06-f11ffd1022c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_980ace13-c545-4936-8964-ff5810d6a8cc" xlink:href="ino-20210630.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_980ace13-c545-4936-8964-ff5810d6a8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_a9cac55c-f116-42c3-b759-b4acb75dd446" xlink:href="ino-20210630.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_a9cac55c-f116-42c3-b759-b4acb75dd446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_c8ac043a-73b7-4c3b-8268-1ac0815b2f73" xlink:href="ino-20210630.xsd#ino_INO4800Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_INO4800Member_c8ac043a-73b7-4c3b-8268-1ac0815b2f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_3b2cb333-a5fe-4922-ac35-8688dae9aab8" xlink:href="ino-20210630.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_3b2cb333-a5fe-4922-ac35-8688dae9aab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_9ba44b33-243f-41f5-abdc-5663b4b840f2" xlink:href="ino-20210630.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab50e5a4-4992-4395-9764-9afc041a8f67" xlink:to="loc_ino_CELLECTRA2000DeviceMember_9ba44b33-243f-41f5-abdc-5663b4b840f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f00a9ab7-74cb-44ad-a035-77383efae3e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_srt_MajorCustomersAxis_f00a9ab7-74cb-44ad-a035-77383efae3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4f6e641d-fdfd-4af3-b02e-133348ff9a5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f00a9ab7-74cb-44ad-a035-77383efae3e7" xlink:to="loc_srt_NameOfMajorCustomerDomain_4f6e641d-fdfd-4af3-b02e-133348ff9a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_b18ce1df-c625-4df6-bc14-b700bb3b0982" xlink:href="ino-20210630.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f6e641d-fdfd-4af3-b02e-133348ff9a5d" xlink:to="loc_ino_AdvaccineMember_b18ce1df-c625-4df6-bc14-b700bb3b0982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a794045e-4e98-43f8-9ec7-122d4156ba23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a794045e-4e98-43f8-9ec7-122d4156ba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_918a2d34-cc5e-4732-b3bb-47446766250c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a794045e-4e98-43f8-9ec7-122d4156ba23" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_918a2d34-cc5e-4732-b3bb-47446766250c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2e644741-d7be-4807-9364-1fe715782b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_918a2d34-cc5e-4732-b3bb-47446766250c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2e644741-d7be-4807-9364-1fe715782b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_fdf59fcf-8b28-4236-884e-58d8db78df69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_fdf59fcf-8b28-4236-884e-58d8db78df69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a855e8dd-bed4-4dcb-9eea-72627a79ffdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fdf59fcf-8b28-4236-884e-58d8db78df69" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a855e8dd-bed4-4dcb-9eea-72627a79ffdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_17e01ca4-0b9c-4b1b-9ace-973ae566bebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a855e8dd-bed4-4dcb-9eea-72627a79ffdf" xlink:to="loc_us-gaap_ForeignCountryMember_17e01ca4-0b9c-4b1b-9ace-973ae566bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ba3bdce2-58f2-4c2e-9cf8-dc20c5102d00" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_04431ae2-2641-4335-9e85-e78df6d8ffcd" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_04431ae2-2641-4335-9e85-e78df6d8ffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bfaadb35-cfc8-47e2-a027-e97ea47e4d5c" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bfaadb35-cfc8-47e2-a027-e97ea47e4d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_bb0b7f5a-fd9a-4cb2-8aad-6e8a4f200372" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_bb0b7f5a-fd9a-4cb2-8aad-6e8a4f200372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_a9098e2e-fb3a-4f59-87e9-26568af9eedb" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_a9098e2e-fb3a-4f59-87e9-26568af9eedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_aac94cab-62a0-4b7b-926f-a47d227edb60" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_aac94cab-62a0-4b7b-926f-a47d227edb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_683c29cc-8f18-4b94-b26d-cbf27e13bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_683c29cc-8f18-4b94-b26d-cbf27e13bd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_a9f641f6-4b2e-4787-b0af-dbbea4bf16d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_AccountsReceivableNet_a9f641f6-4b2e-4787-b0af-dbbea4bf16d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_0901113f-6c44-4e0c-b085-e0bd4695f1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_CostMaintenance_0901113f-6c44-4e0c-b085-e0bd4695f1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_2c17f406-7ba8-4d0d-83cc-9b2de56f3dc1" xlink:href="ino-20210630.xsd#ino_AnnualMaintenancePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_AnnualMaintenancePeriod_2c17f406-7ba8-4d0d-83cc-9b2de56f3dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_d13296a1-166f-42b2-81b1-be7f76ca1a6e" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_d13296a1-166f-42b2-81b1-be7f76ca1a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_63e40f19-1a56-4c88-8463-e4cf9bcbe555" xlink:href="ino-20210630.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_63e40f19-1a56-4c88-8463-e4cf9bcbe555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_fe181e9e-892c-48bb-a79f-cca005c41e9e" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_fe181e9e-892c-48bb-a79f-cca005c41e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_713ab735-f3aa-4fa3-b573-8fcc1e57ee10" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_713ab735-f3aa-4fa3-b573-8fcc1e57ee10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_896db0ef-28d1-4c32-87f7-578d06675e71" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_896db0ef-28d1-4c32-87f7-578d06675e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_de8fc034-c5ca-44f6-a75e-007c839b8bd5" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_de8fc034-c5ca-44f6-a75e-007c839b8bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_29624645-da9b-4d2d-ac15-f028caf98a23" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_29624645-da9b-4d2d-ac15-f028caf98a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_4bcd3d2c-f3dc-4713-9341-b50be8d4092f" xlink:href="ino-20210630.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_4bcd3d2c-f3dc-4713-9341-b50be8d4092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_41104cb7-8497-442a-9796-5ebb0e86b84e" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_41104cb7-8497-442a-9796-5ebb0e86b84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3243b756-e158-4c2a-bec3-d47fe18512fa" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3243b756-e158-4c2a-bec3-d47fe18512fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_6aea22d3-76d2-48dc-9602-042bab63a406" xlink:href="ino-20210630.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_6aea22d3-76d2-48dc-9602-042bab63a406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_773a841e-6bf0-4a81-9438-57372aba483b" xlink:href="ino-20210630.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_DeferredGrantFundingCurrent_773a841e-6bf0-4a81-9438-57372aba483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_1d470900-e15f-421e-978b-450e9bac1ff8" xlink:href="ino-20210630.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_1d470900-e15f-421e-978b-450e9bac1ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_1d501f46-cd43-46e1-92de-d337cae0f88c" xlink:href="ino-20210630.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_ino_GrantProceedsReceived_1d501f46-cd43-46e1-92de-d337cae0f88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_c7b458b1-79a4-4031-aecd-3c07d9f26553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_c7b458b1-79a4-4031-aecd-3c07d9f26553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_2434d5f3-3d08-4eb3-82a3-724893a69988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_30a73ac7-64d7-4651-8f8e-1ce806e130a3" xlink:to="loc_us-gaap_GrantsReceivable_2434d5f3-3d08-4eb3-82a3-724893a69988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7b4c0b92-059e-42a6-b939-49abaf9a14ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ff0dd42d-4b8e-4428-a9fa-0bf396d29885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7b4c0b92-059e-42a6-b939-49abaf9a14ad" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ff0dd42d-4b8e-4428-a9fa-0bf396d29885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_afa097dc-fa6f-45cc-96d1-c6dc8fa8c676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0f10dbe7-45e0-4426-9cdc-10019ca51931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_afa097dc-fa6f-45cc-96d1-c6dc8fa8c676" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0f10dbe7-45e0-4426-9cdc-10019ca51931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_518560f9-b026-410e-8515-0b17823a9950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_c7514206-cd37-4344-a2ac-c154903790af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_518560f9-b026-410e-8515-0b17823a9950" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_c7514206-cd37-4344-a2ac-c154903790af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ca7cd024-fed1-41f9-98a1-9c0008892f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_518560f9-b026-410e-8515-0b17823a9950" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ca7cd024-fed1-41f9-98a1-9c0008892f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_e2f3deb9-b04d-4c2a-910a-62831d46a2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_e2f3deb9-b04d-4c2a-910a-62831d46a2ac" xlink:to="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_37518877-a4ca-4480-8e31-faa675b25afb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:to="loc_srt_CounterpartyNameAxis_37518877-a4ca-4480-8e31-faa675b25afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_430afebc-d076-44f1-bd6e-e0a386cf79e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_37518877-a4ca-4480-8e31-faa675b25afb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_430afebc-d076-44f1-bd6e-e0a386cf79e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_b23f7794-b6f7-497d-8c4b-254424c75879" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_430afebc-d076-44f1-bd6e-e0a386cf79e9" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_b23f7794-b6f7-497d-8c4b-254424c75879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0ff2baac-1b85-4bcb-8fc5-a098aad9e786" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:to="loc_srt_OwnershipAxis_0ff2baac-1b85-4bcb-8fc5-a098aad9e786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_84b5eae2-a7f5-4e58-a7da-a0d2d98097f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0ff2baac-1b85-4bcb-8fc5-a098aad9e786" xlink:to="loc_srt_OwnershipDomain_84b5eae2-a7f5-4e58-a7da-a0d2d98097f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_68814f2e-1e8c-4286-9a38-d587eed753f0" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_84b5eae2-a7f5-4e58-a7da-a0d2d98097f2" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_68814f2e-1e8c-4286-9a38-d587eed753f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_69de3b02-d567-4036-8d0a-b510269febb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:to="loc_us-gaap_StatementClassOfStockAxis_69de3b02-d567-4036-8d0a-b510269febb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_69de3b02-d567-4036-8d0a-b510269febb7" xlink:to="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f72620b0-740f-42aa-a496-d165a35df53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:to="loc_us-gaap_CommonStockMember_f72620b0-740f-42aa-a496-d165a35df53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b1015538-f77d-4f2c-85fa-567900ed4306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:to="loc_us-gaap_PreferredStockMember_b1015538-f77d-4f2c-85fa-567900ed4306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_f2b5a998-4976-4b1d-9da3-0676a8915007" xlink:href="ino-20210630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e1428f3f-be72-4481-a817-e091d5e9a225" xlink:to="loc_ino_SeriesAOnePreferredStockMember_f2b5a998-4976-4b1d-9da3-0676a8915007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_647560a2-0ce7-4471-8983-e0d870d1d860" xlink:to="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6d0c585c-89ed-4738-bb8f-aacecef92f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_6d0c585c-89ed-4738-bb8f-aacecef92f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_46b0e823-6d86-4fc9-a8a6-38a8cdf09fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_46b0e823-6d86-4fc9-a8a6-38a8cdf09fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_53ae3666-5ba7-4d32-9256-ccfba684556a" xlink:href="ino-20210630.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_53ae3666-5ba7-4d32-9256-ccfba684556a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24227628-6037-4923-8bb5-4e7032f62579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_24227628-6037-4923-8bb5-4e7032f62579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_ea76177f-d029-43ce-81cd-13fc2c470d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_ea76177f-d029-43ce-81cd-13fc2c470d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_51f02a28-d703-4e3f-84c0-32d33edea37c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_51f02a28-d703-4e3f-84c0-32d33edea37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_4397af84-3241-4c54-a1cc-1a7c5a2c21aa" xlink:href="ino-20210630.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_4397af84-3241-4c54-a1cc-1a7c5a2c21aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fef3a3e2-59c8-4416-a6d6-081e887aad66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fef3a3e2-59c8-4416-a6d6-081e887aad66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8646f532-0407-49fd-aa99-f9b543bbfe9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_55db27ad-009f-4c26-93ff-ce8bfa0f4120" xlink:to="loc_us-gaap_EquityMethodInvestments_8646f532-0407-49fd-aa99-f9b543bbfe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_bc840a4e-999a-4713-a517-e9f6a7f6b33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_2c7e8c7e-e45b-4a5f-9ede-e77d5e58bdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_bc840a4e-999a-4713-a517-e9f6a7f6b33a" xlink:to="loc_us-gaap_MinorityInterestTable_2c7e8c7e-e45b-4a5f-9ede-e77d5e58bdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f0f77ec9-5667-42d4-b626-00e7b6e0859d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_2c7e8c7e-e45b-4a5f-9ede-e77d5e58bdbc" xlink:to="loc_srt_CounterpartyNameAxis_f0f77ec9-5667-42d4-b626-00e7b6e0859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_585e87de-30b3-4088-afe0-5c9ac3681922" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f0f77ec9-5667-42d4-b626-00e7b6e0859d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_585e87de-30b3-4088-afe0-5c9ac3681922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_4942a564-ebe0-44e5-a494-a4d26f960ded" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_585e87de-30b3-4088-afe0-5c9ac3681922" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_4942a564-ebe0-44e5-a494-a4d26f960ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_2c7e8c7e-e45b-4a5f-9ede-e77d5e58bdbc" xlink:to="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_d75f982d-734c-4199-a8de-8ae20be8d464" xlink:href="ino-20210630.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_ino_WorkingCapitalExcludingCash_d75f982d-734c-4199-a8de-8ae20be8d464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_b1259be0-d0b8-4a53-b034-81883cc13834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_NotesPayable_b1259be0-d0b8-4a53-b034-81883cc13834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f033486a-c119-4317-9000-2c1cb3165ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f033486a-c119-4317-9000-2c1cb3165ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9ad90a0f-16dc-4a8e-a657-37d88885e503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_MinorityInterest_9ad90a0f-16dc-4a8e-a657-37d88885e503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_b8a694be-eec5-47f4-a1ba-720d47dc9826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_b8a694be-eec5-47f4-a1ba-720d47dc9826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_26db39fd-9296-420e-ae81-1e8379473444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_26db39fd-9296-420e-ae81-1e8379473444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_3d0dd0fb-5313-431f-ade5-fe74dbb1bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_9bb82f76-0dc2-4b8e-a752-2bbca920ca5d" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_3d0dd0fb-5313-431f-ade5-fe74dbb1bd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_d4c1ed65-490a-4e34-a338-2b8b7738fe8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_d4c1ed65-490a-4e34-a338-2b8b7738fe8c" xlink:to="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fa96f3a6-f72c-4190-bd28-f7389b1dda86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fa96f3a6-f72c-4190-bd28-f7389b1dda86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fa96f3a6-f72c-4190-bd28-f7389b1dda86" xlink:to="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_18e8eb27-263d-439c-a3f0-7e59bd54da69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:to="loc_us-gaap_CommonStockMember_18e8eb27-263d-439c-a3f0-7e59bd54da69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b44c8189-aef3-4065-a1ee-d3ed2e63cf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_51f7eb33-c0d5-4524-b928-a84e6c71fb35" xlink:to="loc_us-gaap_PreferredStockMember_b44c8189-aef3-4065-a1ee-d3ed2e63cf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:to="loc_srt_CounterpartyNameAxis_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd8f560f-d54b-4f7f-8608-1321666ae6dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4e7d037f-0bd6-4879-88ac-15a7eb98d1f0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd8f560f-d54b-4f7f-8608-1321666ae6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_e017cc95-01e4-4c73-8b0f-0f0602dc31a5" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dd8f560f-d54b-4f7f-8608-1321666ae6dc" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_e017cc95-01e4-4c73-8b0f-0f0602dc31a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_a0149a94-ddc5-4e24-bf05-e421edf1aad6" xlink:to="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_43c9f76e-c49c-4d70-b747-f3503621e977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_43c9f76e-c49c-4d70-b747-f3503621e977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0541f359-1560-45de-be4e-ac810af0828b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:to="loc_us-gaap_SharePrice_0541f359-1560-45de-be4e-ac810af0828b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b0aeefcf-b427-443c-b7b3-47b46f80b9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f61db578-2fc7-4077-a2b9-7cdba0dde0fd" xlink:to="loc_us-gaap_EquityMethodInvestments_b0aeefcf-b427-443c-b7b3-47b46f80b9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_d9fabd75-c76d-4c2c-9587-c4b369958f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_d9fabd75-c76d-4c2c-9587-c4b369958f7d" xlink:to="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9237f045-2846-4376-a68b-eafca763620c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:to="loc_srt_CounterpartyNameAxis_9237f045-2846-4376-a68b-eafca763620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f44fb0-5743-41d4-b479-0e9f5da82a05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9237f045-2846-4376-a68b-eafca763620c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f44fb0-5743-41d4-b479-0e9f5da82a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_f1c25ee0-271f-4c4a-8cb0-bd88fb55a5f3" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_05f44fb0-5743-41d4-b479-0e9f5da82a05" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_f1c25ee0-271f-4c4a-8cb0-bd88fb55a5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_749af9cf-be3d-41b8-94e2-134d74f81cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_749af9cf-be3d-41b8-94e2-134d74f81cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_749af9cf-be3d-41b8-94e2-134d74f81cc5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_5e3545be-5713-45cd-b25a-5cfdc39f9ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_5e3545be-5713-45cd-b25a-5cfdc39f9ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_3630493e-177c-402a-b0a1-f4c5a6f887c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_3630493e-177c-402a-b0a1-f4c5a6f887c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7846729b-7e5c-47bf-9323-6d2428b44afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3c8b5cad-8a62-451c-82fb-cfd218d1390a" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7846729b-7e5c-47bf-9323-6d2428b44afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_cd07f89b-8e54-45ac-ad26-fcd56435cda7" xlink:to="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_57c3bb46-42dd-4792-b676-3d356cc3b946" xlink:href="ino-20210630.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_57c3bb46-42dd-4792-b676-3d356cc3b946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_505a19bb-0917-4abd-badd-ef223839aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_505a19bb-0917-4abd-badd-ef223839aa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_45cf8cf8-87e1-4647-aaaa-15aa65e6e3a3" xlink:href="ino-20210630.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_48323bae-5638-4fba-90a6-069c874f5cf6" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_45cf8cf8-87e1-4647-aaaa-15aa65e6e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20210630.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_54c77f70-2831-4c7f-905a-44db83c74e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_54c77f70-2831-4c7f-905a-44db83c74e66" xlink:to="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19fd5535-d2f2-44c5-83a2-2f6e47721724" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:to="loc_srt_CounterpartyNameAxis_19fd5535-d2f2-44c5-83a2-2f6e47721724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b91a636-b936-4285-ad32-e6466ba06eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_19fd5535-d2f2-44c5-83a2-2f6e47721724" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b91a636-b936-4285-ad32-e6466ba06eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_80ac3aef-ec20-4b28-ad0b-f460fc16a8e5" xlink:href="ino-20210630.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b91a636-b936-4285-ad32-e6466ba06eec" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_80ac3aef-ec20-4b28-ad0b-f460fc16a8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11dac6bb-87d0-4c5d-82f4-d5e112eba83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11dac6bb-87d0-4c5d-82f4-d5e112eba83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a9344a07-7bc6-4a7b-b464-7062c55dfd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11dac6bb-87d0-4c5d-82f4-d5e112eba83f" xlink:to="loc_us-gaap_ClassOfStockDomain_a9344a07-7bc6-4a7b-b464-7062c55dfd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_350fd207-282f-471f-bd92-d0b817d93954" xlink:href="ino-20210630.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a9344a07-7bc6-4a7b-b464-7062c55dfd00" xlink:to="loc_ino_SeriesAOnePreferredStockMember_350fd207-282f-471f-bd92-d0b817d93954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_4b668468-981b-4ea0-9a0b-c8e24ba20e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_7212f733-4fec-4c82-a5b0-0968a913d47e" xlink:to="loc_us-gaap_MinorityInterestLineItems_4b668468-981b-4ea0-9a0b-c8e24ba20e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_4b668468-981b-4ea0-9a0b-c8e24ba20e64" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_46ed3295-7075-48e9-9412-2f7eef0b29ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:to="loc_us-gaap_EquityMethodInvestments_46ed3295-7075-48e9-9412-2f7eef0b29ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1622179d-f788-4b48-a397-7774375d2984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1622179d-f788-4b48-a397-7774375d2984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_865a480e-26e2-4a76-a9ef-486dcdd3a596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_e399651a-3179-40d9-8ee3-b51e6161ade0" xlink:to="loc_us-gaap_EquityMethodInvestments_865a480e-26e2-4a76-a9ef-486dcdd3a596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  !7D   "," 8    I\JJA    "7!(67,  $SE
M  !,Y0%USO"5   <'TE$051XG.W="=!=\_T_\#;V/7:BEHK8:E\22U#$EC(U
MVMI%*<J@J$HMI8RMQM:9HG9M&3IHC:6V(":,I1I$TC2V$DLM%7L%"><_G_.?
M^-US[GV>W'/ON<]SCWF]9NX\S9/[_9SON><X,WWG>S_?;R0      %36-_I[
M @      M$[("P    !084)>     ( *$_("     %28D!<     H,*$O
M    %2;D!0    "H,"$O     $"%"7D!     "I,R L     4&%"7@    "
M"A/R @    !4F) 7     *#"A+P      !4FY 4     J# A+P    ! A0EY
M 0     J3,@+     %!AO8:\'WWT47+OO?<FIYUV6K+[[KLG:Z^]=K+44DLE
M\\PS3S+??/,E@P8-2M9;;[WD)S_Y27+UU5<GTZ9-ZZMY]YF''WXX.?GDDY/A
MPX<G*Z^\<K+@@@LF<\TU5[+$$DLDFVRR27+444<E8\>.[>]I=LS,F3.3N^^^
M.SGFF&.2+;;8(EEVV673:Q^?P9)++IFLNNJJR;!APY(]]M@C.?OLLY.[[KHK
M>>.--UHZUCOOO)/<<LLMR>C1HY-==MDE66VUU9+%%U\\/=;\\\^?WF_KK+-.
M,FK4J.1WO_M=\LHKKY1\MOWGRR^_3.Z[[[[DA!-.2+;99IMDI9562@8.')C,
M.>><Z<_X<_S^^../3\:,&9.^G[[C60@   !TL[J0=\J4*<DYYYR3;+;99FG
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M,\\\D\P[[[R9.K_ZU:^:&AN;Z?WPAS],/Z=87?KIIY_6O4=XV/_/0M<)
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MS2/^ 2"_,KB,7LVAO_][FIVXOK7S&SQX\%=_%_^[]N]BA7D[NOE9V.W7"0
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M6=,]A-M55G 6*W8'#AS8UKG'^*C3[CE4-3P\[KCC>IQ3W,OMZ(9GX=?E.@$
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M"P    !084)>     ( *$_("     %28D!<     H,*$O       %2;D!0
M  "H,"$O     $"%"7D!     "I,R L     4&%"7@    " "A/R @    !4
MF) 7     *#"A+P      !4FY 4     J# A+P    ! A0EY 0     J3,@+
M     %!A0EX     @ H3\@(     5)B0%P    "@PH2\       5)N0%
M *@P(2\     0(4)>0$     *DS("P    !084)>     ( *$_("     %28
MD!<     H,*$O       %2;D!0    "H,"$O     $"%"7D!     "I,R L
M    4&%"7@    " "A/R @    !4F) 7     *#"A+P      !4FY 4
MJ# A+P    ! A0EY 0     J3,@+     %!A0EX     @ H3\@(     5)B0
M%P    "@PH2\       5)N0%     *@P(2\     0(4)>0$     *DS("P
M  !084)>     ( *$_("     %28D!<     H,*$O       %2;D!0    "H
M,"$O     $"%"7D!     "I,R L     4&%"7@    " "A/R @    !4F) 7
M     *#"A+P      !4FY 4     J# A+P    ! A0EY 0     J3,@+
M %!A0EX     @ H3\@(     5)B0%P    "@PH2\       5)N0%     *@P
M(2\     0(4)>0$     *DS("P    !084)>     ( *$_("     %28D!<
M    H,*$O       %2;D!0    "H,"$O     $"%"7D!     "I,R L
@4&%"7@    " "OM_+;D^5@\AWF@     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ino-20210630_g1.jpg
<TEXT>
begin 644 ino-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$<7>K[M
MZET1LYE]0:3S%K!9J#,:=KPY&F,!3QPV\M7@LQBUF&>+IFA,HRYC=^'Y%V?A
MVJW_ ));OU_9/U!_@L/_ +K5DSOJOB$SGV>TI^'*JIH(#./\DMWZ_LGZ@_P6
M'_W6GY);OU_9/U!_@L/_ +K6#B(#./\ )+=^O[)^H/\ !8?_ '6GY);OU_9/
MU!_@L/\ [K6#B(#./\DMWZ_LGZ@_P6'_ -UJVOW=6XN<U9LOH74.I,E/E\WD
MJ62DOY&TT33VCASN4K1%(T$<,3.$$$43=$8MT@W+<\N]$57ANZG^E^VX^Q^7
M_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %66[\[O9I-$5;>S6VN38-
M996G)#K//T9C&?26+NP!X>+Q]F Q*#4>3KS/(<P$TN'HN,HO'=MUI:TEG>N=
MX'4V VTM9:D5>SKC4+R8?1.,F<2%\@8-ZSFK<+\N>.P-<_79@<>FW:]2QSE'
MZX\T5!+;#;O-;A9W(YO-7;=M[F1GR>H,W<,YK>2R%Z<[=M_'/SFO6Y3DEGE=
MW:!I/%-O:BC.N/C[XN4Z%A6XM=ZINE5SY5R?O8]$^D:Z]GO](O>RC%>\H--+
M>R$EJW%/$-.!CV666*N,8[SGZQ3Z*,5W<YMI12Z]5MU:/A[0;-W-13=0L5;'
M1%TV+KBS^?O>&!BY\2<O>[NSA'SU2>;B!R2Z7T72Q-6.G0@&&$/-^/,Y3=F9
MY99/HI)"X;DR^1F%N!9F7-,'I>K0K0U*<$=:M #!%#$+" M^U[R=W=S(N2(G
M<G<G?E<CAQWUEQZXS\0[]4M?5U8T9?54)_\ 7M:^W8U_LP3<8_>E*EO%O%N1
MJMKWWKQ82^JH3_)3MVZ2L:_V8=5#NY2XO#CO=Y+H3%0O#G,C"[<.UV9G;EO>
M3]?R?5ZO_/S4EG9O[-V:W*U-5TYAA:(2;UC)Y*2,I*V)QH&(SW9V%QZW;J:.
MM7ZXWLV"CA&2-G.0,>NVMM%0T#O;K'2F+&9L?C9<,51[!E+/)'<P6,NO-*91
MQ]4DQSG(3@#1MU<1<@PKKA_<:=(U):]Q3J<Z90TK*T:K$JOF^59&;CZA19)4
MQ:WLC17;*-MFZC&=L81<I<ZAB9Z!D?HK+SG7MBN4<:-C^_<U*;4%MUC",7SR
MZ)2E&*;>_+D7W16::CVBM.QN3#\)X75&-9G=FZ^<=Z_T^;/U?\W]7 \/[///
M#/S<Z94<.[QS/P=VBMK;#DXA+G<A0-F(A8VR>GLSCHQ+I9^IFGLQ&PNW2Y@#
MNXLW4-X]ETH]I/'Y-<QI[=+=-J;?[4<G*BU^*CR_O+0^ &3SZ%L_N95B7X.F
MB7];?[CRB(J]$X$=/>S_ $O.Y?V*H?AO&*EOBO\ FL_^Z'^AU=/[UZK)+V>]
MS1C%R<<-6E)FX;B.'+XZ64O/CR&,")V][LW#,[NJ6&+_ .:S_P"Z'^AU=CV9
MW_ZGS?\ \1G_ /IL8J-[1_\ RS3O]%#_ ']I;-[BWXC7^W74W^FBID5#=W%O
MQ&O]NFIO]-%3(JL/B;_[0ZS_ /B&3_O&60X(_P #Z9_J6-_NHA>'7E%HIM)2
M0[T+*>N=I#71"0\U"P--G!RY$J^#H/YN[^1MU^?2[,S\<>:^%V>]:9C4NI*>
MBX*4V4R=Z.T^**#I]9F>C4FN303,1"TAO7KR/ ;.TDD@C#TRR&#KC_;RR'KG
M:'W4F?KZ0U.-<6-V=Q:IBL=6=FXY;I<XC(6YY9B;GSY9=Q]TUC?7.T7I7WOZ
MKCM2W7X)F9O"Q4L?+\^]N9F9V;S=W;RX96A\>?9ZX5X]\-8:7Q-IU>3]"T*&
M5IN?7RU:CI.:M/A*.1@97*Y5-RC!7TR4\?*A%5Y%-L%%*@7$W#>/KG%N1@Y/
M,J\C,LJ=E;2LK4\B47.MM27,HK=*491?:46NA[FZ>S^.U10FQ&8KR0S0R&,,
M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/B
M:EU#3Q&.OY;(SQU<?C*5K(7K,I,$5>G2@.S:GD(G81"&"(Y#)W9A$7=W9F5*
MO=3O4-Y<OJ7.Y/!:ZS.#PEW*6Y\1B*L.-:#'XQY2&C7%K&/EGZAKC&4KRR&;
MS%([NW+"TXW?:]I1M*[=5M$4+'1E]P)I:UD8C9I(=-XXH)<H4C-R01WYI:F.
M;EQ:Q#+= >L(YQ:HP@,X_P DMWZ_LGZ@_P %A_\ =:?DEN_7]D_4'^"P_P#N
MM8.(@,X_R2W?K^R?J#_!8?\ W6GY);OU_9/U!_@L/_NM8.(@,X_R2W?K^R?J
M#_!8?_=:?DEN_7]D_4/^"P_^ZU@XN6:#T1D=39O$:=Q$/CY3.9&IBZ$7!.Q6
MKLP01.?2SDT8.?B2N+.XQ 9,S\<("V/W.VLMTM:8#46N-PM6YC.XRY;BPVEJ
M5\:$<'%!SDS&58:M."21Y+)U\?5<S9HWIY!WC-IHC"9U=2[#[18_06C=-Z.Q
M;-ZGI[$T\<TO2P%;GAB;UR]*+.[-/?ME/<GX?CQ9SZ>!X9NVD 1$0!$1 %AS
MW@6O\SI;9O7NH-/9"?$YK%XB*QC\C6:)YZLSY&E$\D;31RQ.[QR&#L<9CP3^
M2S&6!7>@?$'N9]@X?PKCT!5'_)+=^O[)^H/\%A_]UI^26[]?V3]0?X+#_P"Z
MU@XB SC_ "2W?K^R?J#_  6'_P!UI^26[]?V3]0?X+#_ .ZU@XB SC_)+=^O
M[)^H/\%A_P#=:?DEN_7]D_4'^"P_^ZU@XB NF=T7O1JK7>U,^<UAF[>?RPZL
MS5$;]T:XS-4KUL8<$#-6@KQ=$932N/SOJY-^2?RXE$4-O<8_$I8^W?4'[TPZ
MF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1%XY0'E%A'V@^\0VEVU>:OGM55+>6AZA/ X%QS.8&06
M?YS8KU#**A([\-QD)ZG'6)/P#]30@;[]_)JK)^/4V]TO3TU6)G"+*Y^0,QEW
M%^KYZ-"#P\73DZ7'B(YLJ &+EXL@ET,!:+RF6JT8)+5VS7IUHFZI;%J:.O!&
M+>;E)+*01@S-[W(F91P[U][7LGHPYJH:E?563A=Q*CI. LM&)LS^4F69XL*+
ML3>')''D);$1^4D#>?%03=OM%Z\UY8.SK'5N=U 1D1>!>OR_!\/6[.0U<5!X
M.+IQN[,_A5*<$7+<]'/+KIAD!/GO+W]>L+[RU]"Z1P^G:Y,0CD<_+-G<IQSR
M,L52L=#&U)6;@7"=\M&7M/Y.X],5^\';5W5UWXH:FUSG[=.9RZ\95N'B\20G
MYO%)CL9ZI5GB_I0LQSL/R<<+%Q$!_ QB/N%F_69F_P!"_M$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'\D+/[V9_UVY7=&U'
M:*UYH4V/2&KL_I\&+K>KC\C.&.D/EW<IL9(4F.F)^7Y*6J9<$3<^T_/3*(":
M_9[OS]T<(\,&JL3I_6=$/*25XI<#FB%FZ1Z;U+UC&ET^1.TN&*25V=BL!RYC
M+-LSWU>SFI/!@SUC*:(O2O''TYNE)9QOB'PW_.N+&W##$)<\SWXZ4(1\'(8<
MDP4ZD0&Q@T7N#@=24H\CI[,XO.4)18X[F)OULA6,2YZ7::K+*'GP_'M-[N%S
M!:Z/0FY&HM+7!R&FL[F-/WA?EK>&R5O&SN_RL9U)HGD$F;I,).L#'V3$A=V4
MMNPW??;GZ;\"KJ^GC=>8\'83GL-'A,YX;-QY7Z%8J$IMPSL4^+(S]II)'(FD
M "W>BC&[/O>V[.Z[:"M8S1Z-R\K1B6-U;X&/A>8N&<*^7":7$S Y\M$1VJ\I
MCT.=>(R\)I,JUF.:,)89 EBD%CCEB(9(Y )N1,#!W$A)O-B%W9V\V= ?NB(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"HM=YM\?>YOV<J_@/$J]*J+7>;?'WN;]
MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
M^(/<S[!P_A7'H"C(B(@"(B (B("W]W&/Q*6/MWU!^],.IDE#;W&/Q*6/MWU!
M^],.IDD 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 %^4TH )&9"  +F9D[" B+=1$1/P(B(L[N3NS,S/R[-RL,>UGV]
MMO=GJ?\ ]D62]<SLT1'C]+XKIM9FV_3U <T8OX6,J%RWYMR,E>$FY&OZQ+Q$
M54WM@=Y7N)NZ5K'6[;:=TA(?$6EL/)+'!8A%WZ/AN\[C8R\I-P\D1^!CF)A\
M.@)#XA@3U]KOOF-#:&*UA=%1AKO4L?BQ%8JSC'I?&S@[AQ:R<9%)D91/_P"U
M\5'+"0L?BWZQ, R5G^T7VO=PMU+Q6]9ZAM7JPRO)3PM;BE@L>W/L!4QE?IA(
MXV\O6[?K5Z3WRVI/+C&AFX\EY0!$1 $1$ 1$0!$1 $1$ 1?8P&GK^5MQT,51
MN9.]+_0J6/JSW;4GUPKUHY)79OE?IX9O-W9F=2+[.=T=OAJYXY9=,Q:3QTG2
M_P (:KO04#<7X<O#Q-9[F:ZV%V(6LT*D$G/2-AG8^D"-!>')F\W=F;Z[\*S_
M +4]P/IR!HIM;ZYS63E9F>2EIJK3Q%5S9V?I*YD8<M:DA=N1)HH:DWN<)@?R
M4F^U?=R[*Z.\(\1H#"S68O,;N:"7/W.>..7GS,MUV\_:9@81$GY 1X9F I%[
M?;2ZJU9+X&E]-9[44C$P'\#8F]D8XB?CRGGJP205F\VY*Q)&+<MR[+/G;WN?
MM]L^P%)IFCIZ(_?+J/,5*CASQQUUJ+9*XWOY]FL7''!,Q>R]TVG3AKQ1P5XH
MH((@:.*&&,8HH@%N!".,&$  6\F$19F;R9F7LH"L;M[Z/_FY/#DU9N+C*?T'
MBU-.8>UD/J]?A9+*3XYFX?R!SQ3]7O=AXZ7S1T3W%^T&/$7R][5FH)!XY\?*
MPXZ$_)^>J+&U8)&Y?AVZ; \<<>?+J:%$!@=HWNQMAL'TO4VSP%HAX=BS;W]1
MOU-^BXS]S) +\^? "PL_'2+,(LV4NFMF-(86,8L1I73N,C#IZ0H87'51'HXZ
M.&@K!QT<>SQ[ODX79B(#\XHA 6 !$!'R819A%F^HS,S,W[3+]$1 $1$ 1$0!
M$1 $1$ 1$0'AVY\G]RX;G-N=/9,#CR6"P^0"1G8PNXRE:$V?S=B::$V?E_/S
M^5<S1 88ZR[N_9#/,?PAMCI,3D^CFQF/;!V3?EBY*UA#Q]ERY;CK>7JZ>1YZ
M7=GQ0UIW(VR628WQM;4FG3+GH;'Y^S=@CYZ?^KS39*4^.'XYL?HGZG?R9I?4
M0%;G7_H_8.TAZ5W(D!V;F.KJ+!!.QOS]"5_&6ZSPLW].V.L._#-T>;DV#NX/
M<K;X81CDITM-ZGB#DN<#G'&5Q^1O5LU2P\KF_DQ!%XK"_/!D+=3W*$0&O=W.
M[-.X6B_$+56BM2X.&)^#N7,3;^#A?ZGPI#'+CG?Y>!M._'R+H\3$OH79_P!9
MV?\ T+9)+%_=+L6;4ZS:7YHM!Z<NS2L77<BQT5#(=1>^1K^/:K;:7_[IXW7Q
MY=7" H'HK7NZ_<.;<Y)Y9](ZCU)I:<NMXZ=N2OJ#$@_OCC ;4=?+@W/LD<V6
MMOT\<!U,_7%MO+W*V\NF_$FP5;$ZYI [OSA;\&/R0QL+D\DF,S4M(3XXZ1BH
MW;UB0O(('Y0$1:+G&O=LM2:5M^HZFP&8T_;ZG!H,QCK6/,R'Z(8O68HQE<?T
M7A$?'RK@Z (B( B(@"(B (B( NS-I]YM5Z%RH9O2&?R6G\F#AU6,=/X8V C+
MJ&&[6-I*E^OSSU5KL$]<A(A*,F)V?K-$!9T[(_?DXV^]3";MX\<3;+B(=7X>
M CQ$A]7 GEL6QR6L;R+\%9I>NUNMG*2"G"[D$_NE]4XW-T*N5P]^GE,9=B::
MI?H6(K=2S$[NW7#/"9QFS$SB_23N)"X%P0NS:XY9/]F7MB:^VCR/KNC<P]>K
M-,,^0P-X3MX#*$PL#O=Q[2P\2E&S1O;IS5;K",;#9%HP9@+^**+#L8]ZYH+=
M)JF&RTL>CM:RB(_ V1F?X.R<O'!O@\L8QU[!.7#CC[;ULDXES#!:"*:4)3N4
M!Y1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY5_ >)0&"
MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
M?"C\_,?#"07=O)VDD+W.W"H9QI@:IX@<;87#.B3K^E9^7/2M-G=+:C&IQJ[<
MC4-2MY=VZ<>BG)RY<JE9.$*JHQE-QB5\\6>+?HE-MD&W;+FHQHKJURINRU+]
MA;SWV[^6GTVV[APF+$1BKUX^>CPX8H8F8G^0(XQ >7<G?@1%FY=_)N>5=R[#
M_9R@VQV\PV >$0RUD/A;44WLO)/F;T<9V ,A\G"C$,..@9N6:&H#\F9'(=)+
M9C7<.WNO=-:NN8I\[B\-FZ&2R.'\7P?A"O4L#,SQF0F'K54V&W4:5O"EGA&O
M,0032&U^#:7=G :YT[BM5:8R,.4PF8K#9I6X'9_)W<98)PYZH+=683KVZTC#
M+7L1R0R"Q@[*R_"7L/9'A;K>=J.7J%>N49F/CXNE:E'%EB3J<H^9J561CRNR
M8T7V6QK5$HY%GF8L9-34IW55X'V?=+Q)69F=YT+LGRX5U0:VLKKL]Z^UI[[N
M<U"OF3<HJ,E+96+?L=$12X6A/#LJOG?0=A<\'D3WHTA2?X/R-@ U_1K"S-3R
M$SB%74P1,W] OGQ5S)"[N%XJMTA,;5V:&T(OA:GTQC\UCK^(RU.OD,7E*=C'
MY"C;C&:M<I6XB@LUIXBY$XIHC.,Q?WB3K<>!>,LC0]1ISJ=Y07U>33NU&_'D
MUSUO]I;*=<G]FR,)--)IZWQ9PS1JV%;AWI>^MZY[;NJU)\LU\NKC)?>@Y+=-
MIK7@Y*I%E*;GP)NX.,@OQP0NW#\MQYL[>3^7'U5:8[G+MWGKC %MKJNYUZQT
ME4C^"+5B1REU%IF 1ABE<SY>7)8;YW5O]1/)8JR5+@^(?KG@P/=MWLDY'8O<
M"?!<6;.D<QXF1TCE9F(QL8\C=IL59F=W8LCAC(:]AC?KGKG4O<?FDF#&S36L
MLQH_4&%UGI>X=#,X.]#DL?9C<N/$B?YY6L"+MXU.Y"4E2[6+F.U4GF@D8@D)
ME>/B[AW!XNT.$\>R,G96LG R?6J[EVY9[;N,9-.G(@]W%I^[YE<=J;\(ZWE\
M):W/$R8R5$K'5;7Z2KW^[V3<=U93+M*+V349/?8;,Z\K%7L;=JS";Q:%Q>K\
M3X=>U(+5,]AVE:2?!YN 6:Y0FY83>+JXL49R$6M49J\[,SF0!E4N>^H8%V+?
M;C9%<JKZ+)56URZ2A.#VDGZ/JNC6Z:V:;33+R8N57?57=5)3JMA&<)Q[2C);
MIK\O3NNSZA<2UYH?%ZFPV5T]FZD=_$9JA9QN1IR_T.>I;B*&8'=O:$N@N0D'
M@XS83 A,6=N6HO-79*$HS@W&46I1E%M2C*+W4DUU332::ZIG[2BI)Q:33333
M6Z:?1IKU371HH&=H/8/*[0;@9S0.9(YXJ<OK&&R!BPMEM/W#D?%Y%F;V?$.*
M,H+;#[,5^M;B'V09>UV:>T'DMG=QL)KK&M)/3KR^IY['QO\ \Z:<NG$V3ILS
MNPO.( %RCUNPC?JU7-V!C9[,??%=C,MQ=!MJ[!4WFUGH""SD*@01]5G+Z??H
MFS.(9A9BFEACB^$\=%P9O9KRUH!8[\G54GQUJ/)T>GGDA#D7]_+<>[G_ #^2
MZ%^'G$]'%&A.&5&-EOERPM1I>RYI.'*[$EMRQO@_,@UMRV<\8O>K<H[X@Z!=
MPSKE>;B<T,>RR-U4ENU%<W2+^+JEO"6^[E#E<NDC8;Z+UCC-0XC&9W#6XKV*
MR]&MD<=<A?F.S3MQ#/!*//#MU1F+N),Q@7(&S$+LW)U6Q[C;MA/&]S934-OV
MX?7<SH66S+[4E?J>SF=/0];OUE6)YLQ1A9^IJQ9(0'P*@-'9.5'N..$[M%U+
M(P+=W&N7/1:UMYV//=U6KTW:]V:6ZC9&<-_=+A\+<0U:I@T9E37UD4K()[^7
M:DO,@_P?6._5P<9>IQ/76B<9J3#933^9JQWL3F:%K&Y&I(WL6*ER$H)HW?WB
M3@;N!B[&!L)@[$+.U"K?38S)[2Z_U!M]F#.=L99YQMZ1F%\M@[?5)BLFS"PC
MUSUV8+# +!'=ALPA[,;+8 J#SOM>R&^KM%P;E8.F\NIM 0&^0&M%U6LEI"2;
MQ<A"3C[4C8*623,PBXGX5=\JT/!V"&21/ GCC]%ZHL.^?+AZDX4RW^S5E)M8
M]O7[*FY.FQ]%M.,Y/:I;:/XP<&1U;2YSA'?)Q(SMKV^U*O;>R"^+7*IQ]=XM
M1ZR97T[(W:/N;,;FX36,3R'A9)&Q.JJL74[V]-WYH6O$ -Y26,>X19.H+L_7
M/4&!G!IG,>V>]\W[JZRWJRLF-N17</@,-@L%B[,!]<$\?JGPS:G#CV7<KV7L
M0N?D11UXF+CH9FQFT/MI)JG$E:.<:L8,XPF\/K!V..>MQ'Q8>(P?RZ^HNHF=
MF'@7=8][F;:VM/O&9V/6H93>/Q&B*/PSXY "ZI).6(6?H?D?H''A^%63^Z5<
M8<-:KA+3M)UC&NX@TK4Z*M<TVJG,<WBPHNG!O)CC_079AWW5*ZKZ0[5S.N24
M\6=:K=H.J9LM(6F9,91I>5&^N4FO>\N-D'%);OELDX6)227-#>._-N^.4M43
MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
MQ<3!V+Z)G9W;W>7R?7ZATWH+26A:4]R*.EBH(P<K>5OSBTOAMR3M+<L$S@#>
M;^%&X@_N8'X94VXW]H?Z91IVF8\\C6LNB*Q<3 Q(RL@[IRY:][*XS>1;+>-5
M4:8W3Y81K7)SMN ^).,[[XXV(LAY5>+'RL>$-VES/HN:*?F3Y>6N.W,XPC&"
MVZ[XE;/]CV:;PK^K/G,#LQQX:"4AL&W+.WK]B)V\ 7;GF"O(\O#LQRQ/R"G/
M[(/8CSFXDT$>.K1X/2&/E:M<R_@M%7B")F>2CB:["PV[W!,+BW36K.3G8EZV
M&&7#KL4Z-U%VCM<'IS0<5_%;?X,VEUSN?-4$(ZD7SIXL!I:M<%QFU+E1D(JM
MB[5L5<;3@GR%NF;%1AMW7M!Z%Q6F<-C<!A*84,5B:D5*C5C(S:*"$>ENN20C
MEFE-^3FGF,YIY2.6:0Y#(GES@#V+^(]8RL75O$CS-+QMH9.-PI&3JS_*GM.O
M])5QDY:5&V/+OC6R>KV5[_2(X,?(E;O? /@WE:E.&;K7/1B1:E7AK>-U_7M/
MUHJZ;2_Q\EO%>5LI''-H-G,!H;"5<!IVD-2C6%G,W?Q+5VPXLTMV]8=F.Q:G
M+VC-^ !N(H(XH CB#M%$71W3-,Q\+'IQ,2BK&Q<>N%-&/1"-=--5:485UUP2
MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
MX3/>&#,,6<QP$="Y(X\>>3QO-=W=N&DQ;.1$=AF: M $1$ 1$0!6V^Y![2/S
M3;>6]"9"P\F5T'9Z*32%S)+IK*2S6,>S._+F./M^N8\?<T54*,+-P+$]219J
M]WQVD/YENZNG-1V9V@PMLST_J1R)QB;!Y>2$)[$WF+=&.MPTLIR[^SZER[./
M4) 7NT7\@3$S.+LXNS.SL[.SL_FSL[>3L[>Y_E9?T@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B+^2)F9W=V9F;EW?R9F9N7=W]S,S?+[D!#CWTW:5?1
M^V8:3Q\_1F]?63QAL+LQU].U!:;,V?)^1>R3T\7&SLW4%VQ(Q<UR$J?S+/SO
M+NTB6YF[6H,C6G:7 X*3YFM.B)=494<81!;NB_N)\EDWN6Q,1;\RE4B+J>'K
M+ 1 $1$ 1$0!<FT3H^_J'-8C3^+A*?)YW*4,/CX1;GQ+N2M14ZPO\C#XLPN9
M$[" ,1FXB+NW&5.7W&_9M;4.N,KN%D*W5C-$P#4Q1R SQ3ZCRT,P$<3O[Y,7
MB_$DD?R>,\E3(>2=^@"S)V?]G,=M]HO3>C,4(M3T_BX*3&+<>L6?:GOW3\F=
MY;]^:S=F)V9REG,G\W==PHB (B( B(@"(B (B( B(@"(B (B( B(@"P*[T#X
M@]S/L'#^%<>L]5@5WH'Q![F?8.'\*X] 49$1$ 1$0!$1 6_NXQ^)2Q]N^H/W
MIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B *";OS^T>
MV"T5B=NZ,_3D=:6/7LH /[46GL-8AE8979^0'(93U>.)G'B:.E=%B9HC$IV'
M?CS^3Y?K?75$+O!NT-_-,W8U3J"O-XV'JVRP.GR8G>,L-AY):T%F+GCB/(3^
MLY(&80?HMBQMUL3N!A:B(@"(B (B^[I?3-_-Y/'8;%USMY/+WZ>,Q]6-N3L7
M;]B.K5A%OJR32@/+NPBSN1.PL[L!/+W&'98;*Y[*[K96NQTM///@],M(S])Y
MNW7#X4R -T\&^/QMAJ<3N3@TN1G)A>:N!Q6CET/V9-BZ&VN@]-:*QS"\6$QX
M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
MG7_X3:-5+<<\44\)A+#-&$L4L9,0212"QQR 3>1 8.Q"3>3L[.R_B[?AK0RV
M+,T5>O!&<LT\\@10PQ SD<DLLCB$<8"SD1F3"+,[N_"J,:"[\36^"VTTAH_!
MZ0HV-483!5\/D]59Z[-;IS/08JE.Q2P]1J\LTTE".J<\MS(PQ16VFC"E/78#
M>/3>CM";I;I3E+KK6.9RE-S<PPP62QVGH'<G)O#PE)X,>11\],<]B&Q:$'Z&
MG=G=GOSHOLZ:OD7365;1A8T+9PC:VK[K81FXQLKIKERJ,TN9*VVJ233<?0L1
MK_C;I&%6G&4LBYQ3=<?<C&32;C*<ENVM]O<A--^I:Q[1'?"[+:!*>C7S4VM<
M["YQOB-(1!D8XI1Y;IN9F62#"UA8V89 "[8N S]8TY!4(6_7?6;P:Q*6EHVK
MCMO,1)U TU.,,QJ.4'Y;DLI>B]2I]0.W+4<8%F(QZH[[<\-%/6PF.HBW6XN[
M?H1Z6;C^7R,RY#I>OE]07H\1I7!Y/.Y.4A&.CA<?:R=PG+GI^<TXII!9^'?J
M)A%F8G=^&=VGOAWP1X?TJ*NR*_IED%S2OSW&54=N[5&T<>,5W7F1LE']?U(-
MUGQJUO4Y.G3ZI40F^6*HC*,GOV^LZVR?\SE3_51\W4=;+:@R$F:U3F,AFLI,
M[O+D,Q>L9"V3$3DX#+9DD,(NIW=H8^B(>?8 ?<O4DM8VB/DPDX_*7#,W'UO)
M2W;#]RKNSJYH;NL[U#;W&S-')ZM8\/.:@*(_-V+'T;04:DO0XOT6LEXT1$XS
MUPDC*)3==GONDMF= M!9DP):QS,/!/E]9/!EW\5N?;@Q7@0X:MTN_P [\/'O
M*+"!%,<K>([B+QOX?TN/DX]GTVVM<D:<",94QVZ)._W<=07^:E:U^H?&C^#6
MOZK)7:A;+&KF^:3NDXS>_?ZI;W-_Z3R]_P!8JM;&]F7=+= XWT1H_)9#'R/P
MV9L .+P M[3]?PM>*O6FC%Q?K]4DL2\B4<8%-TQE,[L#W",+M!>W6UA+>E]D
MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B Z*[2VQ.-W*T1G]&Y/B.++U.FK;Z&.3'Y*N8V
M,=D(>?/KJVXXI"%G9I8?%@/F*:02U[7:-VTR>D]69+"YFL=3*8ZU/C,C"8DW
M%S'2O 9BY-[<,T/@3UI6Y">J<,T1%'(#K9,NJ[??I=ADM08%]VM-U&/*Z>A%
MM75XA-Y+F%KAT0Y@! 28IL1'S#=9^GKQQ1V"-O@UHYOOP+".D<<</\3U;0VA
M=P_K.W1W:/JDH^39*791TS5(8F=.3V4<19G7FY8N)_$GA9W2HU6B.]^+"=&3
M%+K;A6;O?YO%MVN7^:=W>2@BH1=CZ9'?Y"9B;^\[/_G9_P!IU(SW8O;BM;'[
MAULC;.:71NHGK8G6-(")V"EXI-5S<$3<B=S!RSR66'IZYZ4EZF! =@#&/G(U
M^J(9&\^E^'_[I>Y_UF?C^^O0B9WX9F=W^HS?773K7-)HS\:_#R8<]&1!UV1]
M=GVE%_=G"24X2^[.,9+JB*\?-LQ[:[ZI<ME4E*+_  ]'\8M;J2]8MKU-H%@L
MY3R=*IDL=:@NT+]:&Y2N5I!FKVJMF,98+$$H.X2131&,D9B[L0DSLOK*F?W<
MG>^Y#:32%S16J\%EM6XG'LTNC&HVJM>QC/%E<[.'MSW"9PQ D9V:4D(6YJ<C
ME4"KZJ43UN0;S=];O7JKKK:4@PNWU"3D?%Q].+.9L@<GY9\AFH)Z,'7&_2[U
M\2%F(G\2"W&; 0TR?@#KL\V['IA3]&A9M7G76QKJLK?6$O+AYEZERM*<8U24
M9II2<=I.7K_%K2*,:%U]SC<X[SQH1<IQDNDES2Y*]M_LMS6\=GLGNE;JU9K/
M#X"E-DL[EL9A<=7%SGOY:]5QU*",>.HYK5R6&",1Y;DCD%FY;E_-E%SO9WTV
MR.DVFAQ67NZ\R$;N(UM(56MTY#;GW9JW)4Q!Q_0\RU[=@2%^8FD=G%5*M<Y?
M5&L;39#6>I,SJ*TTA2C+G,G9O-%(?#F5>&>0H:SEY,[5XHFX9FXX86;X4=#&
M4VY=V(F^I[O+Y//S_P S*6.'_9IPZ^6>I9MV3);-U8T5CT_S79+S+9KYQ5+]
M.A$FN^T7NY5Z;B)OLISWME\GM'EKB_DW-?B3 ;P]^INKJ)IJVB]-8/0]23J"
M*W8DDU/F6!V<6E:6Q5QV,AD?R,8_@RR,)/T/-89F-XN]R=Q]P-?3G:UUK/4>
MHWD)S&#*Y:T>-KD7D7J6'"2/$4@(>6**E2KQEYN[,[N[\5TU/?S=^/#Z9Q%[
M,Y6;^A8[#T;&2O$//#GZO4CFE&-N?GDI",4;<D9BS.[2/[.=T1OMK&2O9R6/
MQ6A\9(0R26-47NO(-&Q,WSG"8R*]8DF9GZVKWY<9%* N+VHR?E2E7IW"W#,.
M;DT_3Y);QG;)2RI)?JSME9EV;[=H.6_PW(_EJO%O$,MJUDRJ;V?+%JJ._P 8
MUJ%$'L_O-?CL1FQZ?QM+D3<'<'=G$6%F;I?CC_R9F\OKKV*67]8G"EBJ,]ZY
M([#%4HUIKMN4G=A$8Z]>.28R)^!$0!W=^&%G=^%:(V;[A[;;%M#/KC-Y_6]H
M>'EJ169M-88R^IX6)L#E^AN&<6;,#\K'UCP+2U[3]GO0^A:HU-'Z4P6G81'H
MYQF/KP3R-QPY3VV![=B0O?))//+)*3N<AD1.ZC[B#VD-*Q^:&GXV1G36^UDD
ML7'?P:E-3N?X.B'3M+X;=HWL\YN0U/5,R-:?5UQD[I_-.,>2I?CYD_P^-0#9
MSNP]^=>-%/\ ,J>D<9,S$-[6<QX67I<F%W;#%%+G(W;GE@LXZKUA[4;DW',K
M6RO<&Z9I/':W#UKEM43^1EB\#6;3N*!^/:AEMR6,CE+K"7T,\,V)8Q\BJM\E
M@E%!_$/CUK^=S1JNKT^J6ZY,2M*S;TWR+?,MC)>LJI5;OT2Z*9] \'-#P.5_
M1OI-D?O9#WCOZ_50Y:VO@IQGM\7W,:ME>QWMAMX+/H_1&GL/:\,8Y,I'CX;&
M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
MCT,?3_Q^\]$_<O0D]S?R^JO?/W+B&HM34\;'U69/;XY" /:F/]8?T(\^\CX%
MOJKWTQ;V26[^1E\2J4Y*,(N4GMLDMW_Q_4?7&"24PCBC.660QCCBB I)))#=
M@"..,&<SD,B80 6<B)V$6=W93W]@[N.M0:N>CJC=KUS2NFS$;-?28"=;5&7C
M)V>-LD1=):=J&/M'"<<F6,7:,HL<?)JKKG-R\E-/%+5L38[U>6.>L5.:2"Q%
M-";'#,-J)PE&:(Q$XSC(/#-F(/;9B5A'N]?2%=6Z1]3TOO %K6V!CZ8:NHH?
M '5E*/J9FCL2S2UJF<C 7?PVO25;WETED)A\*$-8\0,/7_H#_0;J5SYO.6^V
M5Y>R6V(Y?4JSOS.35BZ>2_,V)5X5T+$KL5FI*4HK;EA'K5%[_P"/Y?>DET]V
M.\/U]X[ESC;3:[3NC<-2T[I7#8_ 83'Q^'4QN,K!6K1,_P!&;B#=4L\K^W/9
MF*2Q/(Y2S222$1/SU=+;%=H;1FY>$BU#HC/TL_BS<0EDJD06*<Y QO5R%*<(
MKE"T+/[5>W!#*W#^R[-RNZ50C.KOA=9')C;'(4Y><KU)7*S?>7F*?O\ /OUE
MS==^Y87'E6X0=3@Z^5<CKVY.7;IR\ON\NW;;H$1%Y3]@B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B _"Q5CFCD
MAFC"6*4"BEBD 3CDC,7 XS F<3 Q=Q("9Q)G=G9V=V5;3O'^YFAOQ6]6;4T.
M.EI+%_1M.(?$KNPD9V-, SMUQD[?/-/LWF3C\%D+\5'LI*&7M]][OIO;)[FE
M]&-4U7KN-BAL>T4FG].2D+MSE+$$@%=OQ/P38FG(Q!_]NV:C] 2[_P"'.HZQ
M1J$5I$9663V\^F6[QK*D^^3U480CO[MN\9P;VA+FEM+4.-:]->'*6I3C77'?
MRK%_+1L:Z*A;.4Y/;K!)QDEO-<JW5)'4FALG1NR4+%:2.:,C9W,#C%N@G$NO
MK$2C,"9QDB,1EC)NDP8E[N*TI7JNTALTT[>?60^R#N__ %8OY,__ &W]KZG3
MSPN\]T=S,[K'.Y+4NI<@>4S>6L%:OW3AKU_&F/WN->I%!6@ 69A"*"&.,!9F
M86X76I^Y7EKRK)1CSJ,)-1YXPDYQ4MO>49N,'**>ZBW"#:V;BGT55,C4I3<H
MUN2JW>S:49SCOT<TI246UMO&,FEVYI=WZ<GR_M_Z%Z$WO?\ ;_\ %>_)\O[?
M^AEZ$WO?]O\ \5Z:N_[CYI_X_<?,E^7]K_P7SI?Y?WW7T9?E_:_\%QC/YRKC
MX"LVYAAB#Y7\R)_/@(Q;VC,OD$6=_J\-YK*4K?HO^.IE<6+DXQBG)M[));MO
M?LDN[/JX_%6K]JM1HU;-V[;FBK5*=."6U;MV9W\.&O6K0@<T\\IDP1PQ <AD
M["(N[\*W3W5O<U5]%%C]Q=UZ=:]K!NBW@-*3!'9I:4+Z*&]DGZI(+VH.'8XH
MF JV&)A*(Y[S>+5JZ=W#WGF,V3W/CU3G-$4-3:<M0!C+$_@A)JK3M<I7>;,:
M:EFF"B-PXS<+E*80*Y6C"O7R-)WE*QL3]@]_M([G:5Q>M-#9JIG].YB)Y*MZ
MJ3\A('E/3N0&PSTK]23F&W2LQQV*\K.)@WD[U^\>>*-8P:H8>/19C8&3'EMS
MX2W=\I1WEBJ4>N.MD^=2:LOCNHM5*Q3FW@GA6J+5^3M.^+WA0^U?PG+TG+]5
M+>,'UZSV<>Y&9>414_)7"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@,5^VIV>X=T-L]4Z1(0:];H';P<YAU^JY['L]O%3-^B8#LQC6L='!E4L6
M %V<^50BOT)ZD\]6U"=>U5FEK6:\K.,D%B RBFAD%^'$XI!(#;Y"%V^1;(54
MU^^-[-+:'W4L:@H5_!P6OXY<Y78>?"@S<7A1:@KCY<-XUF2+*,/4_261D &"
M&.,6 B71$0!$1 %X(6=G9VY9V=G;ZS^3KRB NW]U?VEOYH^TN&*Y9>?/Z48-
M+9SQ9.NS*>/KQ?!U^;GVS>_C2KR'.?4\UF.WU&4H2\20,ZIL=SEVDVT/NK7P
M%ZP\.$W C@P,_4[>%'FXCEDT].?+MP\MF:?%@3<OXF2#J;HZB&Y0@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
MP$[RWM)OMEM-J')U)QAS^:B?3>G?;$90R.5C.&2]$S\N1XNCZUD09A(7GKPA
M(S1F1CGVJ?W?4]I)]7[F1:1H67DPV@*\E"2,';PI=1WO#ER\SN/T9588Z6.'
MJ<O5Y8;HAT//,S@0X?MN_P!5W=W=_KN[^;N_O=W\W][HB( B(@"(B _N*(Y"
M&..,Y99"$(XH@*2660W88XHHP9SDDD-Q  %G(R=A%G)V97Q>P3V<0VNVNTUI
MF6((\N=4<MJ(@9N3SN3$+%X"-G?Q&I<QX^,^78H:D;BP@[ -7GNC^S7_ #0-
MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"BL[Y^XT?9_U/&XN[V<QI&$7
M9V9@<-3XNSU/]5G&NX<-Y]1,_N9V4J:A\[\+(>#L><7),US5^G*[L+^R3 ]V
MYQ(W+<AS48F;A^)!C+CRY8"GDB(@"(B (B("Z_W/E7PNSOH)W!P.6;6$Q\\L
MY=6N=2M$?#_(4 Q.+MPSATEQY\O)BL".Z]Q+TM@MLXG8F\3!SW6ZG%WXR.6R
M.0%VZ?+I<;+.#/[0@XB?ML2SW0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M46N\V^/O<W[.5?P'B5>E5%KO-OC[W-^SE7\!XE 8*(B( B(@"D5[I7Z8O;/^
MWZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0$5'?1?$#J3[,Z2_&3'*F,KG/?1?$#J3[,Z2_&3'*F,@"(B (B( KM/='?$
M)HK^['X9O*DLKM/='?$)HK^['X9O("2=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$$/>Z]W;\UU"SN?HJBWS4XF
MJ4FIL96!W/4>*JQ<M=KQ1B[GF<9%&_LBW7D*3/#[5BO6$ZI@DSLSL_+.S.SM
M[G9_E;CR6R055+O>>[P?2=^WNEHND7S,96RTFJ<76C#PM.Y2P3#\*5XXA%X\
M/DYG'U@>#:CDI2+Q!JW((JH$#J(B (B( B(@#JRWW/7>)%:&CM!K:Z9V@%XM
M#9FT8<35XPZFTQ=G(A,K$+,1824VD*: 3QIR"<%".>M(OWK6I8)8IX))(9X)
M(YH)H3**6&:(VDBFBD!V..6*01..0'8P,6(79V9T!LB4427=;=X-%NO@&TSJ
M6S''N!IZK&UIS=@^:3&1,,09JL/+,5P'80S$ ,WASF%J(&@L,,,MJ (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@(GN^J^(3.?9[2GX
M<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$ 5X;NI_I?MN/L?E_P 9,RJ/*O#=
MU/\ 2_;<?8_+_C)F4!(4B(@"(B (B( B(@"(B +I/M&;WXO;?1&I-;Y@OS#I
M_&R6_";CKMW)#"KC:$7)"SS9#(SU:4+=0\RSAYLW+MW8JR_?_=I-Q/2>U%"?
MSEC'6.HP O=$TUK'Z?JR.S]+N<T&3O20EP<?J]&9VZ9HW?<_#[A=ZQJ^'@[/
MRIV>9DR73EQJEYEW7[KE%>7!OIYDX=^QKW%6M+3\#(R5MSQARTI^MT_=KZ>J
M4GS27ZL9$">J-?9/56H,QJ;-3E9RV>R=S+9"8GYZK-V<IC &\F""%B:"O$##
M'#7CBAC$(XP%N78'WC_+ZJZ?P7R?M?Z5V_@_D_E]5=)JZHUQA"$5"$%",(Q6
MT8QBN6,8KT44DDNR2.?7$ECE*<I-RE)RE*3ZN4I=9-OU;;;;.?6I!&L1$["(
MB3D3OPPLS<N[N_DS,S<N_P C+K+0^B<]N)JC&:1TE2/(9/+VAK4X6?PP+CVI
MKEJ7@FK4*D3'8LSFW$4 %(0D72"XKK'5L^5L0X7%A)8:6Q%68*X%)-?MRR#%
M#6K@')2,4I#'& ,3S2N/3RS#U7!NZT[ $&S^EAS>>KB>X6IJD)YLR\.3X!HD
M33P:=IR!U-\Z=HYLM-&9#:R , D=:G5)1EXF<>4:'A^<^6S+MYH8=#?V[$EO
M9-+JJ:4TYM;<S<:U)2FI*1?"+PPLRKE?DQ<%TL>Z_D:W]EM-->?;M]7%_P G
M%.;3DG&/6&T/<9[18NC1+5[YS6&6""-\AU9O(8;#R6^AGE:K5PDN-O#6"5W\
M)I[\A2 (^,/#E&\BNV78XVKT:(MIK;_2F*D$1'UF+#U)KQL/T)37[4<]V>1O
M_B36))/^TLD^%Y5&]6XVU?.YEE:CF6PDV_*=]D:%N]_=HC*-45\HP7I\"X^#
MPY@8SYJ,/'KG_E%5!VO9;=;6G8^GQD_XGYQQ" B("P@+,(@+,(B(MP(B+,S"
MS,W#,WDS>3,O[9EY1:N9H(B^9ELS4H0E9O6JU*N'T=BW/%6A#R=_:EF((Q\F
M=_,F]S_47S%-O9)MOLEU;_(^&]NY]-? U3I;&9S'7<1F<?2RV)R5:6GD,;D:
ML-VC=JS#T2U[56P$D$\,@NXG'*! 3>]E@UNMWI6P^CREAR.XF(R-V'D7Q^F@
MM:FM/*/O@-\)!=JU9O\ LWK-46\NHFY;F-S=7T@G3\'BPZ%V^S.;D9W:*[J*
M_7P5-VX]F3U:G'EKA]+^;PFU?J;R:8'?EMYT7PWU_-<)8NF9:3:<+;(?1:_B
MI1MR'5![=TXR?R-:U/C+2L1/Z1G8\6N\(S5LU\G"KGDOS1$-WMWH^^0T(.3W
M&V+I6LOHB")[><T$TMW):@TR+2$]BYIZ29[%K.8&*(FDGH3SGF,5'%))#)E*
MA=&/JT0MXCBT?MN?'0P-U.?/NZ&'ER=_D9O-6\MR.^,[06J/$CI9/ Z/K2>0
MQ:9PK>L"+._2[WLW9S%CQ>/HRB>",G;J&$&]E1>S:!.[D+V6N1PGD<K;GOY&
MX->M7DN7+<I3V;$K5XH8WDFF,Y).D!9S(GZ?-7F\.\37Z,/R-=GC7V5\JHOK
MMLLR7#LX93=2KLG'IM=&R4Y?XSGEO-PGQ%XN:+3)O&5DWUWB^2N&_IR=9R7\
MUP2^&W8B.PVUF?O</#C9Q%_<=AFKC_\ ]7$O_P 7E?=U!M%J+ P!E9 C>*N<
M<I6*<IR%3,3%XI)&.&)QZ3Z7:0&DC%^.HF\E+K7TC2@X\22-N/D;S_T,_P#Y
M+Q?;#O!-6F!IHIXI()8RXZ3BE%XY!=G9V=B$G9V=G;ZK*0>5^NQ'<O&JV5L?
M)PU;4I+GBHS;E#?JE-M14MNSVVW[IKH<!V5W&DS.(Q><K3'6R,$D3R2US>.6
MIE*,@GX\!@3%$8S %JM(SL8,\;L[&+\7P.[X[5T>[>W=#,V2$=18J1L+JB!F
M ?\ E2M#&8WXXPX9JV5K'%=B<1&,)CLU0;JJFS:X/LM:G#&ZDS&G?$8JEN2R
M5-W+EO6*$QB/2_N?QZG5U._+D4$?''+JR1W3':*/0NZE#&6YA# ZW =/9%I'
M=@@R!=4N#NCYLS&U_C'R.7 M7R,TC\O$#*#/&C@V.HZ9;97#?*P(SRL=K[4J
MDM[Z?BU.N/-%+J[:X);;O>5^'-2_1FJJK=K%S'!;/HHJWK3/;T=<VZY-O[+F
MWV1<91>&7E41)_"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"\.Z\K#_ +<?:FI[1[?Y34QO#)F)^<5IFE-YC=SUN*5ZC'&SB9UJ81RW
M[K"XN]6K(#&!&+KW:7IMV9D4XN/!V7Y%D*JH+UG-[+?X17>4GTC%-O9)GCU#
M/JQ:+<B^2A337*RR3](Q6[V^+?:*763:2ZM$8'>Z=MMX"DVDTO<()Y AGUI?
MK2#S'7D;Q:VFPD%W,9)Q\*YEF#H)J[U:;F06;L#0- WS@OUF_P!''"X.^=NY
M6];R>2LRW<AD;4]Z];G+JFLV[4A3V)Y'9F;JDE,B=A81'GI 1%F9N=!_0'_6
M9='>"N$,?1--JP:-I224\B[;9WY$HKS+'Z[;KEKB]^2N,([MIM\W?$OBN_6-
M2GEW-J+ER8]6^ZHHC)\E:]-^\K&OMV2E+HFDNL<Z_P!%^NZZ=SMR.'Z,N'=W
M<1;S(O/Y&^M\K^[ZZY%K[7L-:4ZM1PGM,[L;\\Q0._\ 3.WD<C?T@OP/EU^?
MLKCNU%;3\FH,9;UU%J"QIA[+'EQT[ZF.9L5P%R:"G+?(*\(RR],<TS=4D4!2
ME6!YV#CUY.$Y<]DHSE&"E/DK2E9/EZ\L%NEO+LMVMVTNG=;'PKP\Y5UVY4XX
MU,W%0=C4'/FVV?7[,&NO-LVX[N*:]Y9%=D+L7ZYWNS9XW2]0*^+I30#F]17V
ME##X:*7@W"66,"*[D7@YDKXNO\_EYB><JE:3UL;EO8W[!.A-EL7X&GZ?KV>M
M0B&7U5D &3+9%_>443^U'CL>Q,SQX^EX<7D,EA[%CJG/%SLL]YCV8J6$Q>D]
M-9RIM]1HPA#4P^H\7<P%>)WXZY9\Q-%+AIK$LCN<]FSERLV9'*64B=R)2H:1
MU[@]05PN8+,XO,U9 8PLXN_5OPD#OPQ-+5EE%Q=_+GGCGR5-_%3C+6LJ4L6W
M!R])TV,MH8UE5E3R-NT\BUQ4;FVN95Q;J@]OY2<?,=Q.!N'M+QJXSQ[L;+OV
MZV53A-5[]&JXIN47L]G.7OR_93Y5RUDX7E%")(Y\K+8.E?C\&]4JW8>>?"MU
MX;,?/_<F Q\_UEBSN#V!ME]4^(6;VSTA9FEYZ[=?$08R_P"U[^C(8MJ=Z/GR
M?F.P+\LS^]F=LNT7NPM4R<:7-C9%^/+]:BVRJ7[ZY19YLG#IN7+=55;']6RN
M$U^Z2:(>-:=QOL5D>LL34U1I@W\Q;&:FR-^$7^7F/41YJ1Q?GZ$9PZ>&8786
M<7Q UMZ/P#<GI?=&W"3,Y##J'3\-T")F?B-Y\9>QQ1@1<,\G@2D+<_.Y/<]D
M9%O&G^+?$>-MR:MDSV],EPR]_P 7DPMD_P!YJN=X>:)D;^9IV,M_\E%T?[EP
M*?>L.Y+WZQ)2'C+>B-2PL3^$V/SUVA>,>?(IJV9P]"G"9MYN 9.P+/Y>(_O6
M _:#V&W+VDJ5\CN)I>[IW$V[T>-K9BQ-2L8F7(2PR3Q4_7JEF>".>6*&8X8Y
MRB>9H96B<WC-FO\ ?"ZMWLV7TUN)I3.:*U?C(,QIW4-&3'Y.A.S.,D1NQQRQ
M$[.\-JK.$5JG9#B6M:AAGB)I(Q=I%T/VD-6KMJ6=3BY./S15SKJE5D<G:4JV
MK?)YTNJBZU&6W+O'?FCHNI^ NB71EY<;J9[/E]Z$X;^B:E7S;?[>_P")KU\=
MN33M#U 4%@/+DHRCD;S]WM1N_O\ U_K+]<Y)A\M1MT+<(O#<K2UY>'X9AE!Q
MZFY?R<'=C!^6<2%G9_)G6(/>0=@34?9PW*MZ0R,MB[A+K3Y31&INCP'SN \;
MPQ>5XG:./+XPCBIYF")V$+!16HP"K=K,L)X]=YH89*[96^\,H%'(!69#Z@)N
M"'J,B)F=O)^DF\O+W>2N3IFJTYF/3E8UD;L>^"LJLCVE"7R[IKK&46E*$U*,
MDI)I15E>!T*;4Z,R=-E<TU[LH.$HO=-.%DE)KHXO9)].NW4[G['G:>SFS>Y.
MD=R< 4AW=-9$)K52&3H#,8>S&53-X>7K< DAR6-FL0QM,XC%9]5ML\<U:*6/
M:K[+;N837VDM-ZVTW9:Y@=5X3&Y_$V.&$RI9.K':A">-G)X;,(R>#:KD_B5[
M,<L$K#)&3-J%65UOT7KMK2Y3!ZJV-SEH2GTRPZKT04I_/)L)DK,L>HL5&QF[
MNV'R94\A (,_5#FYQ80CHN10#[0W!JR\"&KTP_OC3]H7[=YX=D]ET[OZ/=-3
M6WV:[+I/I'I9/0LSEL=3?NV=8_*27\-TMOQ44BVZB(J4FWA$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5=COX.S5ZUC].[IXV!O&QA?,UJ9P;VI*%
MN3QL%>)F;C\Q7'N4IC?J.0,C49W&.JK$ZZLWNVGQVN](:CT=EF?U#4>'NXN:
M06'Q:Q682&O=@<A,1LT;/A7*ID!,%B"(W%^GAP->$BYEN+H'):5S^9TUF(O!
MRF!R=S%7H^.&\>G,<)&#.[OX4S"TT3O[XI ?Y5PU $1$ 1$0'?\ V6=]+6VF
MX.EM;5GD<<)DA._#'P[VL1;CDHY>JX.SC(\V.LV6B%VY&PT,L;A+''(%_C3N
M>IY7'T<ICYX[5#)4ZU^C9A(3BLT[D(6*T\1B[B<<T,@2 0NXD),[.[.M<0K>
M/<F]I1M6;;3:+O3L68V]E@HP@9/XDNF\AX\F&D#J\R"G)!=QCB+DT$-6H+M&
M$L#$!,^B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@/2R60@J5Y[=F08:U6&6Q8F-^ B@@ I)9#?Y!",2(OK,ZH,=L?M!V=S]
MR-4:PE,WI7<A)5P<)\-ZKI^@15<1#P/+#))5 ;=G@B9[EFPXET.+-9][Y?M)
M?,7M7/INA9\'.:_E+"0]!<30X.+PY<_8%F?J9IJI1XOK\NGX2<P)I0!4YF0!
M$1 $1$ 1%R'26D\CGLKC<'B*Q6\KF+U7&XZL/D\]R[,%>O&Y>X >0Q>20O8B
MC8I#=A%W8"Q%W#G9MZOFCW5R-=N&.32NF3D%^I^EHK&?O0\\-T=14\;'*/4Y
M219&%^CPR\2R:NF>SULQ0V]T5IO1N.=CKX'&5Z93]+ ]NVS>)>ND+,W!7+AS
MV'9^7;Q.EW?CE=S( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B + KO0/B#W,^P</X5QZSU6!7>@?$'N9]@X?PKCT!1D1$0!$1 $1$!
M;^[C'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@/
MY,&)G%_<3.S_ *SMPZUV^\6+>CJ_5E-VX]5U/GX&9WY=ABRUL!9WX'E^EFYX
M9FY^1O<MB4J"7;>P7P9O%N;1Z>EH=:YX@;_[E8NR6H2]Y?113@7'//GY^?D@
M,7$1$ 1$0!3P]P7F?"W!UO0Y_/NDJMCIY#S>AEHQYX=NM^GU[]"["W5[3/R/
M$#RE][D#4+4M\1JN7#9?1NH: B[^12PSXK*"3-RW)#%CIV;W^R9^7/#L!<31
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
MOW^TF]S+:=VNQMC\S8J/YI-2B#E\\R%D7AP=(^.!XIU/7+TH/XC')=HDSQG6
M=CKRKLO>7=/(ZXU9J+5^6-RR&HLM<RDPN1$-<+$K^JTHG)W=J^/J#!1K"[^Q
M7KQ!^A76B (B( B(@"S [!W9S/=+=+3.EY(2EQ+6"R^HC9N0AP6*Z;%L97Z2
M9AO3>K8J-NE^9K\7/2'68X?JV%W&_9L?3^ALEN%DJS1Y/6MEX,2\D?$L6F<6
M91PRB1/RPY/(^MV&86Z9*L%&=C)I>  G)@A", CC%@ !$  6X$0%F$1%OD81
M9F9OD9E^J(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"P*[T#X@]S/L'#^%<>L]5@5WH'Q![F?8.'\*X] 49$1$ 1$0!$1 6_
MNXQ^)2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( L/
M^W[H)]2[,[C8L0:25],9"_ WERT^)C;*1$//O(2J<BWO=_)O/A9@+T,KC(+M
M:Q3M1C-6MP35;$1?0RP3QE%-&7_9.,R$OK.@-;Z+\LS_ %69>5R?6VC;.G,U
MF-/7.I[>!RN1PMDB'I<Y\5<FHRGQ[N)#@<Q<7<7$F<7<79WXP@"(B (B("VS
MW$FX0Y+:K-8 C'Q],ZKN ,?GUM2S%6MD8)7Y=V8#M/?BCXX\ZY^7RO-NJK?<
M%[A-2UOKG3)R,(:@T[C<G$#OYE9T[>LQ< /R.5;.V"D)G;EH8V)BZ1Z;4B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@GWCO:2;;#:C469JS!'G<I#\S^G!<F
M8_A3*B<'K8#SU%\%T_6LD_#.+G5CB/I\5G6=BJ']]IVD2U5N16T70L$6'T%5
M>"S&+MX4VI<D(39&9^GS-Z5%J-&-C=WAF:_T<-.7($,!$Y.Y$1$1.[D1$Y$1
M._+D1/RY$3^9$[N[N[N[\NO"(@"(B (B(#^A B=A #D,G80CC$CDD-WX$(P%
MG(S-W80 6<B)V$6=W9E?![ 79O':S:[3FFI81BS$U=LSJ-V8.LL]E CFNQR&
M'+2/1%H<;&?6;/#2C8"\-@9JNG=+=FW^:%NWC+-VNTV!T7&.J,J\C.\4MJO*
MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB + KO0/B#W,^P</X5QZSU6!7>@?$'N9]@X?PKCT!1D1$0!$1 $1$!;^[C'X
ME+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B (B(
M"!OOW=A7RVB<!N!3@Z[6DLDV-RD@CR8X3.F$,<I\>\*V7"C'QQ[+7CD=Q #=
M54UL1-Y=L*.M=*:ATGDA9Z6H,3=Q<Q$+'X7K4)!%8$7=N3K3>'/'P[.QQB[.
MS^:U\6MM'9#3N9R^G\M"5?)X/)WL1D(2]\=S'69*D[,[>1@\D1%'(/(21N,D
M;N!"[@<81$0!$1 %:][C'M&MG=#Y7;R]8ZLCHJRUO& ;MU2Z=S,\THM%R7)M
MC\HUJ*5F%F@BMT1ZG\41&J$LP^P;VCRVLW0TWJ>60AQ!V6P^HA;GA\%E#C@N
MS.+?1O0+P<D <.YE38!X(A)@+YJ+\:]B.:,)8C"6*4!DCDC(3CDC,6(# Q=Q
M,#%V(2%W$A=G9W9U^R (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"P6[QSM&_S,
MMIM2YJM/ZOFLG ^G=.D+LTHYC+PS0Q686=VYDQU4;63'R-F]39S @8F?.E5%
M.^T[2HZKW%JZ)Q]AI<3H"&6&WX9<Q2ZDR<<$N0ZG'V9#QU0*M'WD]>R5^#V)
M/'% 0L"/#,S>YF9O[W^?^^OZ1$ 1$0!$7\D3,SN_DS,[N_U&;WN@)QNXOV$;
M.[@Y?75N'KIZ)QSU\>9?0MG<]%8J,8^YG.MB1R O]$P>N1DXL3QDULQ1[=U_
MV>GVZV>TY1LP>!F-0"^J\VQ!T3-=S,-<J\$S<\M)3Q<./ID!,+@4!"0"?7S(
M2@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*OX#Q
M*O2JBUWFWQ][F_9RK^ \2@,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[I7Z
M8O;/^WZN_@]U<@+O:(B (B( B(@"(B (B( B(@"(B (B("*COHOB!U)]F=)?
MC)CE3&5SGOHOB!U)]F=)?C)CE3&0!$1 $1$ 5VGNCOB$T5_=C\,WE265VGNC
MOB$T5_=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/XDC$A(39B F<2
M$F9Q(7;AQ)G\G9VY9V?R=G=G51'O8>[Q_F<98]=Z/I,.A,Y:_-U&L!=&ELS9
MD=W@8&Y&/"Y&0NK'.+C'2L/)CO#BA]1\2WBN+ZUT7B]1XC(X'-TH,EB<M3GH
M9"C9!CALU; .$L9MY.SNS\@8N)QFPR1D)B),!KET6>?> ]B'*;+:N.D(SV](
M9F2>QI3,2>V4M<>DI<5>D86$<IC>MHY.69K=?PKL;-XDL4.!B (B( B(@"^G
MA<U<QMRID<?9GI7Z%F"Y2N5I'BL5;5:09H+$$H\$$L4H"8$WN)F7S$0%UONT
MNWM4WCTQZAEI(*^O=/5H@S],.F,<G69Q@AU!0AYY]7LD\87HA9QI7S\+RAGJ
MN<FJUX&R^\FH-O\ 4V*U;I>YZEF<1/XT!F+G6L1%[-BC>A$XWL4+L75!;@:2
M,CB)WCDBF&.4+SO9$[5FGMX-'4]58(VAF8FIYS$&?5:PF7CC [%&?D8WDCZ9
M!FIVA!HK=62.:/AW,  RB1$0!$1 $1$ 1$0!$1 $1$ 1$0$3W?5?$)G/L]I3
M\.55305R_OJOB$SGV>TI^'*JIH( B(@"(B *\-W4_P!+]MQ]C\O^,F95'E7A
MNZG^E^VX^Q^7_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 %_+CS[_ '?4_P W
M\F7](@(1NW7W.^ UR5S5&W/J.E=6RN5BWBB$H-.9^9W(I3*. 2^!LC-SSZU5
MA.G8E%FM5@.:6\%6G>38K/:3R]G3VL,+=P>:J._SJW$\921]72%FI.W,%ZE*
M[.\5BO)-7DX=F-C$A'8GKI??+L]:.W(PYX/66#J9FEQ)ZN<HE'=H2RBPE8QU
M^%PMT;'L@[R5Y0<GC#Q&-A85./ ?C7F:<H8NH*>=A1VC&7,OI5$>R4)R>UT(
MKHJ[6FELH6PC%0<=<3>'M&7S78SCCY#W;6WU-C_:BEO7)OO.":?5RA)O<UQ^
M4TU8I\D[>+"S_P!%!G=F;_MC[P?Z[\C\C$Z^2+>Y63^U/W)^J=/O8RFV5L]7
M8EG,WP5^6K5U+5BX<G:"8AJX[,"#-PXCZE</V1AJVI"=08:YVCM8N]8QN4Q]
MW!9>J739H7JLM6>,N7;Y]5G&.06=Q+ID!F ^.1<V\VM+H7%.GZK5YN!E5W;+
M>=>_+=5\K*9;60ZO9-QY9/[,I+J0;K&@Y6%-PR:95[]%+O7/^98MXRZ==D^9
M>J78ZWT_I$[HC)RY [^YO<SL_#L_'RM]?_Q7:=/3E.D+/,0L[?H6X=_V_J?R
M\EUG%7RV(<WB<O!/Z,H_GD)LS<=1"WM _'O=V!^/<3LN/9/4%F?ES/C_ +O/
M^;EW6ZT:A5""3BXR71I+HW\5^/S_ (]R,-4TG.R+G%Y$88_390W4]OA)=MUV
MWCONMFVNR[7S.OJ]42"!A#WM[/#D_P"W[_[RZ5SNNK5AR8"<6\_:?S?^][O[
M[O\ K+X%DG=W=_-_JKXLW_FO/=J<Y](^ZM_3O^_T_+]YG-(X8Q<?9J"G/UG/
MJW\^NY\FY.<C]1D1D_O<G=W_ /J^M[ES'05!_P T62;R?B /K^?7(_[7$;-_
M]]RN$6/=_?\ ]"[NT_CO5Z->/C@G!I#_ ._+P;_WN6']I8G-MVC\Y/;\N[_L
M7YF;U?(\NCE71V-1Z=/=75[?P7X,]@P7IFW]YU]20/K+TS%8V$MC7*Y_\?(^
M88?^RQ@W-S/K-XH0?F&H/A,WO9Y>>92_O\ WU&'GY799"ZMS+4*,T_EXG#A"
MS_+*3<!Y?*PO[3MY<LW'RK#RT3OU.[NY/R[N_F[N[^;O]5^>>7^59W3J]_??
MX+^U_EV_,WOA7$W<KY+I'W(?-O[3_)=-_F_@?#L-_+^^OBROQYM[+\^]G=O\
M[>:^W8]W\OKKG>W>VDN;F:29I H [LY@["<YL[?.XW=GX%O/KD;W<=(^T_(Y
MRM&^W9E=%<K;9*$(+=M_U+XM^B.H?ABY#YQ6K4;M[O#L3!^MQTFWU&_O,OJU
MMT]1U'^<9O("S>X9)WL W_Z.PTH?M=/G_>4EVE]BM-PU^NUB*4D;-YO/'XIG
MY>YR-W(G?ZO4L,.TOHG3V*L59,-&U*6R<K3T0D*2%HQ%G:Q&!N10^T[1N#$T
M9\LX@+@?/J\I)=4OW?\ T-7T'CW U+->%7BVR?O;6RKJG3O%.34O><H[I=-H
MR2Z;M>G$\3VH-45G9II*=X6XY\>J$<A?_?U7A%OVH_\ 0NX=/=L*L[B.4PT\
M3<MU38^P$S-]=H+'@%PWO?\ -#OQ[A=_?@H?O7CE?G+'@^\5^73_ .AO-_#^
M'9WHC%_&&]>WY1:7[TR7C2.]VF,PX!5RL$4Q^ZO<?U.9R?\ 0BT_0)ER_#-&
M9<O]#RLF-O\ <C4.EK89#36<RV!NB76UG$Y"S0,BXXY-Z\D8RLX^RXRL8N/L
MNSL_"K_XO%3WIXJM6%YYYBZ8XAXY)_-W\R=A$6;ER(B$19G<G9N765^E\%N=
MI>NUG'"=ZC"W7)0:8<E" ,WFSU#*.P(,S>;T29P9G+EFY=_#DZ7"R,H-1G&2
MVE79%2BU\))IIKY..QJ.JZ%CXTH.&=7CV2>]4<BV%4F^RY;$XM/?HO=ZOION
M6V>SGWV&ML$]>EN#CH=9XT7CCDR=*.MB=111,[L4I!#'#B<C*P.SC&<..*5X
MV:2TQF<RL'=G?M::#W1H/<TAG(+DT8==S$V6:IFL?YL+^N8V0O& &)V%K$7C
M5#)V\.P?++7*;:]JS#91XZF7#X&OD[1L<A$>/FEY87$;#LQ5G=_<-IA!N>CQ
MR)AZLT]':NR6$R%/,X/)6L9DJ9M/2R6.L'!9A)V\CAGA=GZ#%^"'EXI0)P,2
M G9X+XQ\$--S%*>+#]&Y3W:=,?[UL?PGCIJ,%Z<U#KVWW<)OH9?3N.-3TV:J
MS8RR*O\ .OZWE_6KOZ^9^$W/?MS0-A0SKRJW79*[ZJS3*##[OU_6:74$4>M,
M/1,K52)Q$>O/X:FTAW(P-G*3(86NU@8C%I,3*\,UV6PUH?7.&U+B:&=T_E*&
M:PV3KQVL?E,9:BN4;E>1N0E@L0$<9B_N=F+D"9P-A,79JH\4\%ZAH]OE9M#C
M&3:JOAO/'NVZ_5V;)<VW5UR4;(KK*"31,^B:_BZA5YN-9S;?;KELK*W\)PW>
MWR:WC+[LF<K1$6JF9"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(N$;B;DX#26)M9W4V7Q^#P],>JSD,E9CK5H^
M>>D>N1VZY3X=HX8V.60O9C G\E^E54[)1A",ISFU&$(1<I2DWLHQBDVVWT22
MW;['TLLC&+E)J,8IN4I-*,4NK;;Z))=6WT1S;E<6UEKG"Z=H2Y7/97'X;&P^
M4M[)W(*-42Z2)@\:P<8/(8@3QQ"[R2<.P"3^2KS=J+OTQ,K.(V@Q(RL[G$VK
MM1U)0CX\A:QB<!(\,Y._F<,N9\+H=A>?%2,Y1M!YN'NOJO7>3^%]7Y_)Z@R'
M+O'-D+!2QUF+ABCI518:M&)V$6>.K!")=(]3.[<J?.#_ &?-3S5&[49K3*'L
MU7*/F9DE\ZMXQIW[?6S\R+[TLA?B[QLT_ YJ\.#S[E]Y2\O&B_\ 2[2E;MW^
MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
MNIF<@]KB/S7'?'[DY1S;!8K3VFJ[];"9039FZ(<^R_BVSAJ>*+>]WI&#OY]#
M*&W$X_W>7\OY<+[>0M#$'2/U//\ 7XY_E]56 T?P4X=P(IRPWFV+O9FS=V_X
MU+DQ]OA]3\FWL5CXF\<.(<V;KIS/H=<ON84%2XKY7/GR$^W:U=>R2Z&3^ONW
MWO!EB(K6XFHXN>6Z,9/7P<?3P3=/AX2OC@<>"=G8A=RX;J<G9G6(NI]]=872
M(K>K-36'Y=^9L]E#=WXXY\[?GY<M^MY+AF8R/OX?]?S_ )>Y=;Y&YSS\JSEN
MG8-"Y:,/$HBNBC3CTU))?*$(K;^HU[#SLZ_:61FYE\GUYK\F^Z3?S=DY-_FS
M[-[<+..__/>8^K_SI?\ _4+Y@;AZ@C+KCS^<C-N68X\QD0)F=N'X(+(OYL[L
M_N\G=GY;R7%9#Y=UZ<AK'/'A)]80Z_LQ?]ALE$YK[\^G[4O_ #.W,5VAM?X]
MP*CKC5]0@Z>AZ^I,Q'T=!,8<<7/+I+@F?WL_FNU,'W@6]^+=O4]U-:\#PPC<
MS4^3C%FXX9HLHUV)F9F;V>CCWL[<._.(AEY+U#)?2S1L2SI9BXUG^DHJFOSY
MHLS>-J.57]C)R(?S+K8?]V2)!=1=ZAOCFM/YG2^HM75]183/8RYB,E4RNG--
MB<M"]7*M/&-G%XO&6@D:,B*.P\Q3A*_6TCN(],7UK1]<_H9)0^LSB_#?MC\G
MU%S$B^5>J1>_ZJ]NEZ7C8:FL3'IQHSDI3C15"F,YI;<SC7&,7+;IOMN9.>K9
M=KB[LF^YP6T976SME&.^^RE8Y/;UVWV.L+NW[NS^';X^L<7/]]Q-N/\ Y77$
MK>W-UW=AFKDWU>HV?]MNCR_ONN\#->E(:V&J^?Q3_%+^S;<R.-JE\?O)_C&/
M]B1GGW3';LN=G'/:LDS&-N:CTMJK&4PGQ.+M5X+-;/8RTST,I&5[PZXPEC[.
M2IW1$ADG=\>7)#485,)JCTCJ)HR;#[4GXGET29/5T3CSY<]5:GA'?R^JUKW>
M?#>Y5>9#_E]1>C(?_P!2T[6?#31=2RYYN9AJW(L5:G)79%<9>7!0BW"JV$7+
MDBH[M=5%;FUX?&^I55*FJY0@M]DJZY-<S;>SG&3[O=$NW:I[WG.;KX\\;G-M
MMM/5G$PKV;V+R&8R^/ZV<?'QF7]=Q]S'6F%^&FJD#>]B @=Q>*LM5FW/$LS#
M_2QN0BS?(WF3/TLS<-R1/\KN[^:X?(:]&0__ '6UZ)PYB8%/T?#K>/3OOY4+
M+''?U:YY2>[]>N[]3#ZC.>=/S<N7G6=N:48)[?#W8+MZ'V;V>\1W=@=W?Y3+
MDO\ -S_K.N,6;3E[^&20U\BU/PW"V*G#K77E73X]?Z]S]<;#A';:/[^O]9ZE
MN=FY7%;ECW^:]RY9]_G_ "_E_)UQ2Y9]_G_+^7O^M^VO:EMVZ&P8U/;I_P ?
M\?\ '0].W8]_[?\ H7$[UIF9W=V9O=Y^7'U/_)OKK.3LE=WUNUOG=&';_2\]
MK%#-X5W564/X+TKCN)'BD*?+3 7K<L)B8G2Q$&2R'4!MZHS!(07*.[W[B/;+
M9R:GJ?4Y!N+K^OT3093*50#3^!L, LY8#!GXD?K(EU=.4R<ER\ NWJC46*49
M8WXV\5-*T.,H76K(S$GRX6/*,KN;T\Z76./'MN[/?<>M==FVQN>D:%=?LXQY
M*_\ *234=OV?UW^'3?HW$K\]V+W"&K-U2QNM=U8\AHO;J5J]VEB"&2GJS5U<
MW:0&B@D 9<!A[$3,[Y"R(Y&S#+&6.K!&;7H[R>U&TNF="Z?QNE='X3'Z=T]B
M(!K8[$XNN->I6B'S?@1Y*260G>2>Q,4EBQ*133RR2F1OV'PO*I)QSXBZCK]_
M/E3Y,>$FZ,.IM44KLGL^MENW25L]Y/JHJ$-H*2L#3:\>.T%O)_:F_M/_ ,E\
M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
MW.67 6S)G-H1!GDQ%B4S*Q6&2O*96*IR319K8D[N;3X'7.G,MI74M&/(8;,U
MGK6ZY\,3<$,D%FO)P[P6ZE@(K52P'MP688I0]H&5&OMG]D?.[-ZSMZ;RC26L
M78>6WIK-O&X0YG$];,$GER 7ZG6%?)5A)_ GZ3'FO/ 9@8E(B( B(@"(B Y3
MH?6V5TUF,9J#!79L=F,/<BOXV] 73+6LPN_23?(0&+G#/$3/'/!)+!*)12&+
MW>.P'VVL3O1I".^)04]5X@(*NJ\*#NWJMPQ)HK]02?JDQ>2\.26J?M/#(,U2
M5WEKN1T7EW]V9^T?J+:K5^.U?IN;\T5'\"_CY)) IYK%R&!V\5>8/HH)VC H
MSX(JMF."W$+R0CR!L$D71W9T[0>G=S])8S5^F;+3T;X.%BN1"]O%Y")A]<Q>
M0C%^8;E0R9B$F9I83AM0]5>Q#(?>* (B( B(@"(B (B(")[OJOB$SGV>TI^'
M*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1 %>&[J?Z7[;C['Y?\9,RJ/*O#=U/
M]+]MQ]C\O^,F90$A2(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M*JW>Z99I-Z)X7D<O5M*:?KN+L_$?5)DK70/+-[/YI:7D>6ZI';GJ8F:*O,X]
MG9W9N6?E_+^7\G4D7>]D4&^.1ZN&:?3>FY@X?]!X-F#S;Y':2"3R^IP_RJ/6
MM(,T?2_OX\OU_P"7"Z0^'=,9</:0E_\ 9^,_S=46_P".YS4\3U*OB'5K.NSU
M#);[]O-EM_ Z0RU#AW\OJ_R_66/^-J-;U"$3LW!7#'W/PS0B;O\ M-X;N[^7
MU5EWF<:_+^2QAVJTGF-1:JQF(T_0L93-9?(24\;1JAUSV;-H9@%AX\@ !(II
MYCXB@@CEFF((HS)L]BUQIG;98XPA".\Y2:C&,%[TI2;Z))1W;;226[-BX*E.
M^C.\K>5OT5UU)+=NRV-B@DEU;<HI)+K\%N9(Z)T+G-69O&:.T=C9LMG<M.->
MI5@X9G?WR6+,Q<1U:54.9K5J8@A@B$I#+W,]S3L%]A/ [):9>E 464U7E6"?
M4^I'CXDN3LS.%"@QBTE;#47;IJ5_(II/$N66>>8A#A?=T]WWB=EL ]N]ZMD]
M?YRL#:BS@#U!6A(QG;!8@S;KBQE:08GL2-T%D[<(VYQ$8ZD%:254Z\8O%J6L
M6RT_ FX:73/WIK>+SK(/I.79_1X-;TUO[3VMFN95QKM%X4>%U>C4K*RHJS4;
MH[R<MI?1U)=8Q?\ E6GM9)=E]7#W>9S\LB+!KMY]N' ;(:1/,76BR.H\GXM3
M2NG&D<9LKD!'EY['0_B08G'L039*W[+,+QU83>W:K@4*Z5I>1FY%.)BU2NOO
MFJZZXKK*3^/I&,5O*<I-1A%.4FHILEW-S:L>JR^Z:KJJBY3G+LDOXMOLDMVV
MTDFVD=-=YKWB%'9?3S8K"E6O[CZ@JF^ QLHO-#BJA&\$NH<K&! [5:Y#(%"L
M1@>1NQO$/%>"W+%3RJ-;RES(Y[.W9KV4R=NQE,CD;LAR6;UZU(<UN:4F!V*>
MS*;&Y/T +"PCT@PBWT]4ZOU!KC464UAJ[(2Y/-Y>R5N]<F]D1;W0U:T7+A6I
M5(V&O3K1\1P0@(-U%U$7=?9K[-^H]Y-85-&:7!X*L;!9SV:.-SIX'$-(P37;
M'#BTEB7VHJ%-B$[EEV!NF$)Y8K^\"<%8/"FEVW9-E:N\OSL_,ETC[BW\NMM<
MRIKWVKCMSVS?,X\TXPC2GCSC+,XFU&&GX$9NKG\NJN/HI/9SEL^7S)KJVWRU
MQ2Z[)R?9_8B[%^;WUU8-")YL=HG#R!)JK/0N G!%Y%'B,=U,;%E\BSOX/5&\
M52LTUV;GH@@LW5]O-OL-I3"8S3FGL?!B\+AZD5''4*S.T5>O"/2+<DY222&_
M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
MXNTBNRBRMSE6[]/RTOL3DNL)].=5S<57?4US0E%-Q\RM(J1PCQ%F\(ZM/$RH
MS^BSL55U4GZ;]'%OIS13YZ9[[2B]M^26YL.T6"W8%[;F%WLT='E8/ HZHQ(U
MZ>KM/A(Y'C<B<9=%JL!\2GB,IX,T^-G+JX8)Z<DAVJ=CC.AG7/W5M*R,')NQ
M,JJ5.11-UV5R[J2]4^THR34H2BW&<'&46XM,N[@9U6337D43C95;%3A.+Z-/
M^II]))]8R332::,?.TYV9]+[L:1R&D-55/%J6Q>2E>A81R.&R4;/ZIE<9.0E
MX5NL;L[B[%!:A>2I;BGJ3S0G28[2?9IU=LGJV72NJH?%K6"GET_G( +X.U%B
M@D80M57+SAM1#)%'DL>;O/1LET<S5Y*UJQ?J=8T]JSLIZ5W?TG:TMJ>N[,3'
M-B<O7&/X3P62Z'&'(X^4Q=F,7=AL5SYKW8.J"P! [.,G^%/BG=H.0J;G*W3+
MY[W5+K*B;V7TBA?K))>;#M;%;=)J,EH'B-X=X^N8S]V,,RN#5-G1*:7556/X
M;[\DN\)/?K%M.AUEL;( 27,?-+6GFKVJAG"91R>J7:\U.]7)V_ZNU!++7F!^
M.J(I(R%Q-V4/6ZFUUG3=OH?JEH2D_JMAV\VX?^@3.S,S2BS>3_0R#YCYL0C/
M)V@-@M5;-ZPN:-U; Y$',V+R\<,L>,U!BS?B'(XZ0^L7%_.*U6\4YJ%H9*T[
MN0@9XZ[@Z!I9BE,!Q!/7G!V,'9G<7][.SMYB8OY@;<.+MU,ZOO@9=&557E8T
MZ[:KZXSA;7LU9#JX-/;?9;R]U]8MR32>Z*L<,<29G#N;+3\^-GD<[@XS[Q>^
MVZWZ*:79KW9Q277HU">Z_@VY%V^JSM_?9=H[G;96].7"CD$CI2F7JEGCR)OH
MO!EX\AG!O)V]QLW6/EU,/6"]19K%RJ[ZX74S4ZYI2C*+[K^QKLT^J:V?5&R=
M[B?<(LYL5CX9#ZY,5DY(B?RY8<GC<;FA;@7<6'G(%T]+"/O86=FY>9M5K/1O
M=2E)HG4>(<OG=?!;;9*(>7=GDMX;*TK3LWN8A;&5!+EV)^6;CV'XLIKG%XKX
M*Q^(M4K2V4LB-W_YBJN]_P ;'^'8W+@^[GT[&_85M/\ T%UE*_A!?D$1%'AL
MH1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!?Q)&)B0&+&),XD),SB0DW!"3/RSL[.[.S^3MY/
MY+^T0%$SO$.S>>U^ZVI,%#"\>$R$[Z@TV?GT/A\J1S-69W]Q8RYZWC79W<GC
MJPSNPC. MA$K</?<]FKYJ=O*>N,=!U9C0=DI;C@ N=G3.1Z8LC&3MP;OC[8T
MLA&[N01P!D!:-SG8QJ/( B(@"(B *P)W$G:2^#=09_;#(67:KJ$"U#IZ(W;I
MCS&/KM'EZ\3N[/U7L7#7M>&W4S?!<L@ +G.95^US_:G<C(Z.U-@-5XDR#(Z>
MRU++5>DG#Q#ISA*=8W;Z*&W"TE2Q&7(2UYI8I!.,R%P-BBBZ[VEW,QNLM,X'
M5>'E&;&:@Q=/*5"$F)Q"U",A02>3.,U:1SKV(R$9(IXI(Y  Q(1[$0!$1 $1
M$ 1$0!$1 $1</W!USCM,8/+ZBR\S5\9A,=;R=Z9^/8K4X3GEXY=F<R$.D!Y;
MJ-Q'GS0%<KOX.TH\][3NUF-GYBI@.IM3,!>16IF.#!4#^O!!ZWD)A?RYL8\A
M?D)!:NHNT][]V\EKS5^HM8Y8G]=U#E;61.+J<@J02R.U.C"Y>?@4*8P4X>>'
M>. 2+VG)WZL0!$1 $1$ 67'87[.Q[H[H:8TH<)2XLK+Y74),S]$6 Q?38OM*
M3,_0-PO Q@/Y<SWH0ZA<NIL1U:Y[C3LUO@=%93<7(UO#R.LK#T\0\@,TD>F\
M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
MO$Y?YF8?U_?^VOQ?45EOH6C;_P"]?W_5\W7WM2Z3+'2=#S#+Y\<B#AY_K.1<
MMY?5\EQ)XED)2<7M);,_'$SZ[H1MK?/"2WC+9K=?A))K]Q[WS3W&]SQ_X-O_
M #7TL?J:_+*,0# Y$_Z(7%F;Y>>'Y^OY<_67XZ4T=E<]?CQ6"Q>1S64F\XL=
MB*5G(WI!Y9G(:M.*:;PQ=VZI/#Z!YY(F;S66>NNP5NMH/3=?7&L=)V-.8&?(
M5,7 63N48\C+;O!++7'X+BLRWHXW""0CDFBB .&$O;?I7CMU3%JMJINOHJMO
MDH4U66UPMME+LJX-J4V_39,]LJK)4W6UU2G&J$I2G&N4H0Y4WO*26T?S:.K@
MPV2"IZT;T)&;_JP*Q&3_ "_1$$C,_P"N/"X=#KZL)O'9AE@,7<2Z7:8&=OKC
MTD[-]7H\V7=4O_-/[?\ ^2K 78R[D_9_7.W6C];ZEM:PMY/4F'@RMRI5S5:A
MCHIIS/JB@C@QKVFC9@86ZKA%[WYY=NG#\;<7:?H5%61FJ[R[K/*@J(>9)SY)
M3[.48I<L7U;VW,#X;TYNMVY=+=<G0W)-[5*,%)12]U/?JU]UOYE<K&9:K:;F
MO8BEX\W$2;K'_O1OP8_KD/#_ ".ZY%7+IX?AG^L[?R_S*W;1[BCLWPL/.E<]
M-(+N[3GK?5T<OF_DW%7,5XFZ6\F<8F=V^B<G\UU[O?W&VWN0QA-M]D,II/,0
MQ\5PR>1OZ@Q%LV=W8;I9"6SE8'-GZ?6*ULQC9A+U25V)CC'%\?- G;&">?0I
M/9VW8U:JC\Y.G(NLV_"I[>JV)+S_  KSG7+=8UZVW\I62YW\H\]4(;_[4?D5
MA\2$4[](^R?](_#._E^A_IN/E9O/ZK,N85\-_P!G^7\OY>]?(W2VVRFBM4YS
M2.:\"/-Z;OOC\B-2=YX&F:**Q#-7G<(CDKV*TT-FN9Q0R>%*'BQ0R,48?OAM
M8&(M%8X=V^@EX9GX^1I./E_[3-_WO/DE..)J<+:X34E.%D(SKL@]XSA.*E&2
M:Z-2BTXM=&GOV*X<4\)Y-+LGB\TE!RC;1+^5KE%M24=^L^5IJ47[\=OO==N:
MXRG+5ECLP2R5K$1,44\$A031$W#L4<T;A(#MY<.),[/YL[.S*238+O0MQ]#M
M#4RE[YML/%T#ZGJ"S*>2CB%VY&OG^F>\Q=/(B=\,D(OQP#B/0HN+6>^NRX]9
MSGO\_P#/_+E877],T[4:G3G8M.57Z*V&\H[]W78MK*I/]:N4)?,U+0-7U7 N
M5^%F7XEGJZI-1E\%96U*NV/[-D)QZ+H73NS-V_\ ;S<]H:>-R88C44@OU::S
M,L-;(F8MU2-CSZ_ RH"+.?YB,YAC9SF@A838<W5KN_FBEBDCFAEDAFB,)89H
MI"CEBEC)B"2*0'$XY )F(#!V,29B%V=N5,YV,.^=S>ERJZ>W/];U+IYBB@KZ
MBAC"34.'AY:-O70%XVSE*$>#(W_Y7 &D<9,B?@UVJIQQX).GGR-'G*ZM;REA
M6R3NBM_\19T5J7I">UFRV4[9/8MQP'XX>=R8VM0C38]HQS:H[4R?^?JZNIOU
MLKWJW?6%,5N6J$7"=O=Q<'JS$4L_IO*4\SA\A$TU/(4)AFKRA^B;EO:CDC+V
M)8)6":&1BCE #%V7-E7NRN4).,XN,HMQE&2<91DGLTT]FFGT::W3+$UV1G&,
MX24HR2E&46I1E%K=.+6Z::ZIKHT%TWV@]Y<?M[HG5&M<HX>IZ;PUS)E&9]'K
M$T,3M4IB7O\ $NVRAJQL+$9'*+ )F["_<BKB^D.=H;X.TEI3;.E.XV=3Y+YH
MLU$'O+#8(F&A7EX?RCLYF6&V+$S$4F*!P)Q&05M/ W#KU;5L+!Z\EUR=S7>.
M/6G9>U\'Y4)*/[31C=<U%8F)??ZP@^3?ULE[L%_2:W^6Y5CU;K#)ZES67U#F
M;$EO+9S(W<OD[4A.137LC9DMV"Y]PAXDI#%&##'%$P11B$8"+?)&'^7\O_J7
M\0,,8"S^_P!Y?KNW_A[O\ZYK!I68J WG?I:7EX@;S]AG=F(O^]QR+?TG!<^T
MRZ'<CLEY=,4H5QY8Q2VC&,=DMEVVZ)+;LMD4^U;581FI63Y5.?)!R?VYO=[[
M^K>SDW\%U9Q/H9O?_P#7^TIT^X;[-T6J-Q\IKN_6:7&[?4H?4#EC8H9-29R.
MU7JE$1<"<V/QL-ZR?3UE6.U1D(0*: U G:M.#DQ>RX\\\_)Q[W_O*^=W1W9^
M;;_8[24<\'@Y?5=8=9YAB'B;Q\_##8HPSL_#C+4Q#8ZM)$0B4,D9Q$SF!$4/
M>,O$#P-&MKC)QNSI_1(;='&N2<LA[=]O*4JG\';%F^^'.B?2M1KLFDZ\5?2)
M+T<X]*5^/F-6+XJMD,7?3=C1]%:IAW9T[5>/3NL+\=34M:O"[08G5!PD\>0=
MHV<(*NH8X#.:0Q")LT$CE(5C*P@\.>1![=>.W7DDAM0$$L<\)E%/#+$0G%/#
M+&XR12Q&(F$@$)@8B8NSLSK8&[R;2837>E\UI'4=7US#9ZC+1NQ-PT@,?!16
M:YNS^%:J3C%:JS=)>%8AC/I?IX>AIN[LYG-J];YS06I&8[F(LN,-H0<(,KB[
M#/)CLK7$O,8;U7ID>-G+U>=IZSF9P$[^GP%X_P#TC@O2\J>^7@5Q5;D]W?A]
M(0?SEC^[3/\ 8=,O>DYM:YXY<#RQ,F&L8<>6-DW*Q137)=]J:>WI<MYQ_;4U
MLDEO;J[KKMH#N]M_"&6LQGK?20U</JJ)S'Q[A-$0X_4'A>3C%FH8)))2%O"'
M(P7X8W88F!I+E0Q[*':5R.R^XN)UI1::?#RD..U1CH7'JR>G;4T17(XP)VC*
M[3( O8]R(6]:KC"4L44TI->MTIJK'9S%X_-8FW#?Q>5IULAC[L!=4-JG;B&>
MO/&[\/TR1&),SLQ-STDS.SLU?_&?@#]"ZF[:(;8&<YVX^R]VFSH[L;Y*#DI5
M+HO*E&*YG"3)M\*N-XZSIM<IR3RL>,:[UOUDNJA;^,DFI_YR,GLE*)R%<=U;
MI+&9[%W\+F:5?)8K*5)Z.1H6HVEKVZEF-XIX)8W]XF!.W+<$+\$#B3,[<B10
M_";BU*+<91:E&46TXM/=--=4T^J:ZIDG2BFFFDTTTTUNFGT::]4_5%$3MJ=D
MS)[$[@3:<D*S<TQE /):1S,X$XW<64I!)C[$_#QGE<.?36OAU>(<4E.^4817
MHF72&C];YC2&H<-K72UZ3'9G!VQR%*Q#STD<0D\E&T#<--1R$3G1NP'R$U2Q
M*!,_*NQ]N7LAXK>;0E[3%MX:F8K%\)Z7S)QL98C.5Q?P)#;A_$HW0<Z.3KN)
MC+3G.0 :U!6EBI"6\9E--YC-Z3U'1]0S6'OV<3EJLK$QUK=:1XY1BX<8C@DX
M&:K/'&X6*LL4T!/#*#J_?A-Q_7Q#IL\7,Y9YM%?D9E<U%K(JG'D61R-<KA;'
M>%T4FE9S;QC"RM.E?BMP3;H6H5ZI@<T*)S\R')NO+E&7,ZMUU4H/:53>V\/5
MN,FKT78_[4N#W?T-BM889QAEG$JF:Q3R,=C"9NMP-[&V6\B;I)VGJ2D(M:HS
M5K0>Q,*R@5'GL#]L2WL9KX+]N6S-H;4+PT-6X^$7E:*#J9JFH*L+>T]W$$1&
M8Q\G:QTMNLT<DSU'BNYX;,5<A3JWZ-B*W2NUX+=.U 8R06:MF,9J]B&07<9(
MIHC"2,Q=Q(28F]ZJGXK>'T] U&4(*3P,ESLPK'N]HIKGQYR?>RCF2WW;G7*N
MQ]924;+>'/&]6MX$+E*/TBM1ADP6R][;I9%>D+-FU^K)2CV2;^FB(HN-_(%N
M]^[NHM64;&ZVA:#_ #6X2G)+J;$4*KR3ZKQ%2,2:W7A@;Q9\_B8(C\&.*.:Q
ME:?YB )+4%$"K%XN]#DZS1FXN?3[+OY^?GPWZS_WEL6W_E_[_6547O>.[U+1
M&3M;M:'HD.ELM<\35V(I@3QZ=REIVZLS7A%G>+"Y.QR]P1?PL?D;#%&$5*R(
MU;7^!'BIMY>A:A9T?NZ=?-KI\,.<G\?_ '9M]']0NGE15</&GPR63"6JX4.6
M^OW\B$%U>W^/BE^7G+LU]8_OM\>[IOO!9-MLS!MCK2Y(^B,[?<<!E+<[^%I+
M,7"X:L93/Q!@,K8X8Q$ABQV3F>WT-!<NRQ6VP)G9G;AV=N6=O-G9_<[/[G9V
M]RUTUB"#+5'\A<V!V=G_ $3?*W'R^7O^JW*LD=SYWB4F8BK;/Z\OD6=QU=HM
M$YFY)U%F\;5!Q^ ;<YDQ'EL; (%CY#ZRR%".2.20;50/6_V\=_"O?S-=TZOJ
MMY:C1!=TN^9"*]5_[RHKLO/?:Z3\_@KXF^=&.CZA+EOK]S&G-]]NU#;[I_XE
MO_1_J(L)JDYZ63_TNV+^UO<;\)Z)5V+E48_2LL\,NZFUF,9^2H;?96^3<EPS
M9?49UQ?I=NENI\*7+B_472W7PP1\Q=X!P;XGPGZ0ISI/\'A7UK^,T6!UM_WM
M/\8?PG%_V%6CQ2Z7'EV%_-Q9W87=O<[C]"[M\C\<M\BY-HG$ED,SB:0CU/:R
M-.'I9N7<3L QLW_WG4N*K)#LIZ;>_K*A,0\PXN&UD)>6?CK&$J]9N6]Q-9L1
M3"S^]H3^HK\V3Y8R?PB_ZNG\2.L^_P JBZSMR5SE^:B^5?BWLE^1==[AS#=6
M=W*O,+=-+#Z5I,_#<M\(7,[,PL_5SP[8ODF829W$7<AX%CLEJ"[N*M(/7T;K
M?.D/!9;4M+'QE\IU\-C1E%^?J-8RUH&;Y'$G^53HKG=XP92MXBU!KJH/'J7X
MUXM,)K_I%,VCP^H=>D8B?>2ML_*=]DH_]1Q"(BC,W,(B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"ZFWUVCQVO='ZBT=EA$J.H,78H2$0,?J\QCUU+@"_NFHW(X+D!"[$$
MT &! 8B3=LH@-<WKS160TUG,SIW+0E7R>"RE_$7XC%P<;6.LR59G%G]\4A1>
M)#(/(2PG'+&11F)/Q-3M=^=V;?@+66&W&QU;IQVL8"QN9.-O8AU%BH8VK22M
MY<%E,4S>$[=7)XFRY]+E'UP2H B(@"(B \.KA?<O=I9]9;8OI;(V&/.:!LCB
M>#E8Y[6G[ >/A;;B_M\5_P U8D_(F9L?#*9]5E@&GJI!^[$[2);:[MX"Y:L/
M#@-1'\S&H1=V\-JV2)@Q]PF?EA?'99J5@Y&;K:GZY$']&=G O$HO#/\ 4]WU
MEY0!$1 $1$ 1$0$3_?#=I5M";4VL+2L>%G=?G8TY2$#Z)H\5X+'J&X+,_5X4
M=&6+'D8L_3-E*[.X];$U,YO\RDL[USM*MN+NUEXJ4_C8#1KRZ6P[BXE%/-2G
M)LU?C<.1,+64&:&"5B-IZ=.K,),$C ,:B (B( B(@"Y!I/2][.93&X7%P%9R
M67OU,;0K@SD4UR].%:O&S"SD_5+(+/PSNS<NS/PN/J;3N0^S6.I]P+NO,A7:
M3%Z#A8:'B#S%+J3*P30UB9G]DRQV/>S:XX=X+$]&?V3&(D!9J[->R-#;G0NF
M-%X]A>+!8JO6L3B+ ]W(F/CY/(2"SEQ)>R$MFT3=1,'B^&#] BR[R1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
M M_=QC\2EC[=]0?O3#J9)0V]QC\2EC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$!@1WB'8SI[R:$M8V ((=6889<CI/(RBS=%X1%Y\7/(
MW!#1S$4;5)GY<:\_JMYXY7J-%)1ZS>#N8R[<QN1JST<AC[5BE>I68RBL5+=6
M4X+-:>,V8HY89@*,Q=N6(79;'Q5R.^?[!?CQS[PZ2I#X\(BVNZ-<79YJ\8#%
M7U)%&+.+R5A :^7X82DK^!=)W>O8(P*TR(B (B( B(@) .[W[<^4V6U6TTKV
M+VC<U+#!J?# 9/TART<>:QT3OX392@#\\<#Z_5$J4L@/X$T%V;0^M\3J3#XW
M/X*]7R>'R].&]CK]4VD@LU9P8XY )O-G\W&2,F&2*03BE$) (6US*EH[L?O&
MK6TF5'3&IYY[6W67L\RBPO-)I?(3G[>7I (O*=&=W9\M1CZG=A:]4C:R$\5T
M"Y0B^=A\O5R%2M>HV(;E*Y!%9J6J\@35[-><!DAGAEC=PDBEC(3 Q=Q(79V?
MA?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!?Q)(("Y$["(LY$1.S"(LW+D3OY,S,W+N_DS>;K^U6O[V?O,NOX2VIV
M\R!,+//C];:BJGPQ-PP3Z=Q%F,^7]\D.:N!Y"[%CH#<O6R #'[O8^\<?7EZQ
MMSHFZ[Z+Q=H6S66J6.8M69&N[.U>$H^&DP6.G;D/GAQ9.[&-KH]7JU))H0%X
M9F;R;W-Y-]3CZS?(O* (B( B(@"._'O]R*7/NG^P>^Z&J/FKU'3Z]":4MPR3
M13=31:ASD3C/5Q(BW'C4:G 6LOR7AF#UJ!C*%NPT0$J7<V]A8M'8+^:9JBB\
M6J=34WCP5.W!TV,%IR=P,9G&1NN"_G& )Y&80E@QS5X")BLVH1G+7\@#"S"+
M,(BS,(LW#,S-PS,S>3,S>3,WDS>2_I $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!46N\V^/O<W[.5?P'B5>E5%KO-OC[W-^SE7\!X
ME 8*(B( B(@"D5[I7Z8O;/\ M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.
MDOQDQRIC( B(@"(B *[3W1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;R DG1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!\#56EL=F\;>P^7
MIP9#&9*K-2OTK4;2U[56P#QS0R@_DXF!.W+<$+\$+L3,[4D>\,[#&2V6U8\%
M<;5W1>:*2QIC,2_/'!F(BFP=^5N';)8T>AVD,1:]3.&U&9S#<CKWC5TAVB>S
M]IW<[264T?J:JT]#(QL\-@&%K>,OPOUT\G0E=N8;=2;@Q<789HWEJSM)6GFB
M,#7O(L@.TWV<-0[5:OR6D-1P\3U#*7'7XQ?U3,XJ20QI92F3_P#5S@/$L+OX
ME2P,M:7VXN2Q_0!$1 $1$ 79.T&[6=T)J7$ZLTU<*CF<+9:S5E;J>*47$H[%
M.W$)#ZQ2NP')6MUR=FFAD(>6+I(>MD0%]WL9]K; [QZ-IZEQ+QULA$T=346$
M\7Q)\)EVC8IJQN["4E6;SGQ]IP$;54A+@)0FBBRS5"'L:=K?.[.:RJZEQ7B6
ML=.\534>$\7PH<UB?$ZC@Y<3"*[6ZCFQUIP)Z]CD28H)IXSO*[1;M8'7.G,5
MJK35Z/(8;,5ALU9P<>L'Y<)ZMF-B+P+E289*UNN3]<%B*2,OH>7 [)1$0!$1
M 1/=]5\0F<^SVE/PY55-!7+^^J^(3.?9[2GX<JJF@@"(B (B( KPW=3_ $OV
MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B *BUWFWQ][F_9RK^ \2KTJHM=YM\
M?>YOV<J_@/$H#!1$1 $1$ 4BO=*_3%[9_P!OU=_![JY1U*17NE?IB]L_[?J[
M^#W5R N]HB( B(@"(B (B( B(@"(B (B( B(@(J.^B^('4GV9TE^,F.5,97.
M>^B^('4GV9TE^,F.5,9 $1$ 1$0!7:>Z.^(317]V/PS>5)97:>Z.^(317]V/
MPS>0$DZ(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
M5TMH/<S-Z"U1@M>:5F:#+82X%R!BY>O:BX<+F.N WT=/(5BDJ61;VFBE<XW&
M4(S&Y+WC_8YK[R[=7L36CC#5>$\7-:.N'TAT9>"%^O&S2DSN%+-0B]"R[.+1
M2%6MNQO48"I/X<IXRM8G)025+M2>>G;J61Z)ZMRM(4,\$P/RXRPS <<C>;,0
MOYOY._0+PGXVJXBTB5&9R6Y5$/HN=7/9J^N<7&-SCZPR*]XV>GFQL6RBX[TH
M\5N$[=!U6O4\)2A3.:MKE#=>6XR3E#=?>JEM*'[#CW:9?S[.^^V$W+T;@M:Z
M>D<L;FZ;3M"9 4]&U&10WL=:Z'<1M4+<<U6=F\NN-R;V29=U*H-W/_;#?;77
M)[>9ZPT&D->Y 7JV)CZ8,/JXX(JM.R3N_1'6SD5>MB;,GN"S'BY9'&N$\L=O
ME4\\2N"+-!U2W%VD\:S>[#L?7GQY-[1;];*FG79V;<5/91G$M/P+Q95K.GTY
M<''S-E"^"^[:DMVE^K-;3C\$^7=N+"\.R\HH_-Q*M'?1]A7YG,F>\^D:71BL
MM;CCUY1K"_30RL_3'6U+'"WL!5R1LU;,.'2(9(Z]TP,K]V:.#JW!%E:;^3/(
MP>;/^B'ZOE]3Y?EX_66P]U3IC'YO&W\/EJ<%_&92G8H9"C9!I*]NG:B*&Q!,
M#^\)8C('^5N>6=GX5&GMM]DG);%;@3Z?)K-G2N5&3(Z/R\_SSUK&%(XR8^S,
MS,+Y3$&[5;@&PR2PO4O]/AW!5TO 3Q)^F4+1LVS?*Q8?WI.;ZY&-!?R6[[VX
MRV22W<J-GM]5.3JEXX>'LJIK6,&/+O/FOC%;*%K^]T[0N?VF^BL_GQ2G][G;
MMX'KO3Y;;ZKMD>M-'T8FQ]RS(+RZDTU!Q7@L.3EXDV3P_$53)$8]=B"2C>>2
M>:6Z\,W"UYVE]:9?26?P>MM+6GI9K WX,G0G'S#Q8G^>UK(<MXU*[ 4M.[7)
M^FQ3GFA?R/RO%=CKM4X7>'0N+UAB.(+$K/3SF)(N9\+FZS"-ZA*SOU/'U.UB
MC._E:HS5K#</(0#%GCGX;_HO+_26'7M@9MC\R$%M'%RI;RE'9=(U7;2G7M[L
M9*=:48JM.1?!WQ"CJV&L6^?]^XL>5\S]ZVJ.T5)^KG7TC/NVN6;;;EME.HTN
M]8[?^,[/.U.4U.\D4NKLP,^#T'BC\.0KNH[%8WCNS0&8O)B\)'_REDR9G9XH
MHJC?/KD#%FIOIOCI?;;2>;UOK/*P873>GJ1WLE?G8SZ0%V"*"O!$)SV[MN<X
MZM*E6CDLV[4L5>",Y9!%]:+W@W;9U?VH=U;6HSJ30XBH\^*T/IP7;P\!IH;#
M.,MV5R>+X2R)!'?S=MR:+UD@J0?F:I6!]?\ "#PYGK>=&[(@UIF'-3R9R34;
MIKWH8D7ZN?1W;/W*6]VI65<THZQJ4<>M^\E-Q;3;248KO.3?1)>F_=_),P%E
ML9G4N8FGLSVLSG<W?GMV[=@V.YD<E=E.S;MV#X /%GF.6><V8(@Y,F$(QX:4
M#9G:JOI7&^%[$V1M-')D+8\NQ2"WLUX7+AVK0=1,#<"\A.4ILQ$PC\'9S9NE
MI>#Q3Z;66G#ILW''V0!^']6JL[,X0MPW43^W.3=1\#T1QS"=WGV#<MO+J,)[
MD5JAH7#V(RU!F(V&,K9CQ(V#Q<DC.QWK0?GB<(Y8\=7+Q96::6K'+=KB'7\;
M!Q;<C(G&G%HAO*6VV^W2,*X+;>4GM&NN*WE+9)=DH&U+4+M2OAAX<93C.27K
M]8T]^>3?V:H?:Z_#FEU22SU[F/L6'ELD.[FHJK?!.+.>MHRO*+_FW+QR%7NY
MQF=F$JV+Z9J5-_::6_)8D?H+'QO+9Q9?#TQIG'X7'4<1BJ<%#&8RI7HT*58&
MC@JU*L8PP01 WN".,!$?E=FY=W=W=?=7/3C?BZ[6M0MS+4X0_D\>G?=4T1;Y
M(;]G)[N=DELI62DTE'9*<^'-"KT_%ACPVE+[=MFVWF6R2YI?)+91@O2*2;;W
M;(B+43.A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!"5WWO9M'4NWM77E&N
MQY;0<_7=(!^>3:;R<T$%]GX\S#'V_5+[\^4%8;TK.(N?54D6QRU1IJGF<9D,
M1D81L8_*4K6.NUS9G&:I=@.O8B)G9VX.*0Q\V=O/W.M?]VE=D;NW&N]3Z+O"
M?5@\K/7J3&WY\Q4K^L8F\+_*US'35IBXYZ)2DB)V.,V0'1R(B (B( NPMIMS
M\GHK4V"U9ACZ,GI_)5LG59WX"9Z\C%+5E?A_G-R%Y:LWD[M%,;C[3"[=>H@-
MBGM;N/C-7Z<P>J,/(\N,S^,IY2D1=/B##;A"5HI6$B$9X")X9P8G\.:,PY?I
M7/57_P"XF[27PGIO/;99*PQ7-.6"S>GV,WZY,'DC$;U,&)WY;&Y3JG;@N?"R
MH1L(QUF(K " +B.O];X_3."S&HLM,-;%X+&7LOD)R]T5/'UI+5@F;AW(O"B)
MA 6<C)V$6<G9GY<H)._,[2C8+1F)VXH3?\HZSF>]EQ%W8H-.XF>*00DX=F;X
M3RC0QQ"[$QQ4+K/TN(]0%:+?;=W(:^UEJ3663<_7-196Q?*,RZBK5G88*%)G
M;ENBCCX:M*-AY%HX!%N69=3HB (B( B(@"M:=QEV:O@'1N6W'R$3-D=:2C0Q
M#DS]5?3N(GF S#D6X?*93QI9G$C$X<?C^.@PD8JT>Q6T60U]K'3FC<8Q^N:A
MRD% 9(V8BKUGZIK]S@F<>FCCX;5PW)G%@@)R]EG6P+T%HG'Z:P>'T[B8&K8O
M!8RCB,= /+M%2QU:*I6#EW=R<8H@ZC)W(RY(G<G=W Y:B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"P*[T#X@]S/L'#^%<>L]5@5WH'Q![F?8.'\*X] 49$1$ 1$0!$1 6_NX
MQ^)2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"B&[S?NV:FZV.DU7I.O5I[BXRL(LY$]>OJFA7Y)
ML;>,>8@R4(%)\%Y"2/J(VCQ]V8*3Q3T9>40&N!S6&MXV[<QV0JSTK^/M6*-Z
ME:C*&S4N592@LUK$)LQQ303 <<D9,Q"0NSKYJN'=YGW9]3=2E-J_2,,-+</'
MU2ZH6>&O5U;6@B;PL?>DDZ ARD01C#B\C)+%$PEZID">MZO/0J"YS!W<9=M8
MW)5+%#(4;$M2[2MQ'!:JV82<)H+$)L)QRQFSB0DS.S_6X= ?+1$0!$1 $1$!
MW=L!VBM7[8Y^'4FC<M+C+P>&%N%V:;'Y6H!]94,K2/YU;JGR3-ST6*Q&4U.Q
M5L,,PW!.PQWDFD-Y:L>.?HT]KB"$CO:9M3"36QA'JENX"R3M\(TNCYY)"XQW
MZ?3(T]<JX!<GI&KW<;DK-*S7N4[$]2Y4FCLU;=6:2O9JV(28XIZ\\1!+#-&;
M"4<D9B8$S.+MQR@-D&BK9]A3OI^&IZ6WDE%F;P:M#7,$!^;/Q&#:HK0L;,75
MQU9FG$$3"_7?JQL$UX[&^$SE/)U*U_'6ZUZC;B">K<IS1V:MF$VY"6">(BCE
MC)O-C G%T!]5$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=^/-_)F][_
M %$!Y6+7:I[8.BMH,$68U7??UF8)/@G!4GBFS6:G#AO"HU3DC%HQ(A:>Y8.&
MG6%^J:9G<1*/SMV=[_IO037=,[?'1U7K*-RKV;O)SZ;P$KB_5X]F P'+Y"#E
MN:%&=X()6>*]:BFBEJO56W/W2U#K3.7-2:IRUO-9J\X^L7KAL9M&#N\5> !8
M8JU2!B)H*M<(X(6<NB,7<N0,FNV7V[]9[SY9YLQ.^-TW4F(\+I6E(_P?1;EV
M&S;-A LGDR%_GERP/3%R\=.&M&Y">$R(@"(B (B( B(@/!$S-R_DS>;N_DS-
M]5U9#[J'NPNOX+W5W%HNS,X7M':8MQNSO\M?4&:KR"WD_P#1\10D9V=O"R%E
MN?5XF^=W7?=4G8/';E;H8UPK#X-_2ND;L8N]EWXEK9K/UI&)Q@9NB7'8J41.
M5W"U>!HVCK267T 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 %1:[S;X^]S?LY5_ >)5Z546N\V^/O<W[.5?P'B4!@HB
M(@"(B *17NE?IB]L_P"WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0$5'?1?$#J3[,Z2_&3'*F,KG/?1?$#J3[,Z2_&3'
M*F,@"(B (B( KM/='?$)HK^['X9O*DLKM/='?$)HK^['X9O("2=$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
M?0,X$1%2XML0S=^QAO6-BSM=/46.U?IFPWT7(M/9EI$7L^7##:\W-NGCGW%P
MJG0OUXIV]_'_ ).KC??(X3UWL^:U-AZO4)<!D/<;]+09['@Y>Q[N&E\W/D&;
MWM[E3BQ#]>,D;W\,S\?W_P#S_E\MY/9OOYM!OAW=>H9"_!2IQI)+\VW^93WV
MBJN74<*S;O51^]76QW_=LBZMW5&8]<[/^VQ>_P!6P\]%_+CSI9&[7^J_/'0S
M<MPS\>3-[E(4HGNY2RCV.S_IR,F=CI9K5E,VZ>EN!U!>GBZ?-^IO L1<EY<G
MU-QPW+RPJH_'E'E:WJ]?I'4\Y+\/I-FW\"TG"UWF:9I\_P!;"Q7^^F!\C4&'
MBR-"[CY_Z#>J6:<WES\ZM0G!)Y<MS[)OY<MS[N6]ZUV.GL7)C<CD\3./1-CK
M]_&3 [_02TK4U24'][>P<1#^U\JV,CJA+VPM(?,WOMNKBF#PXWUSFLK$/GTM
M#J&Q\T,;!S^@$,JP"S>R+#T#Y!PT[^S%G\N7JN+O_*48]Z7^ALG5)_\ Q$/X
M$,>T3I_F:9CW)?R=EL-_G.$9Q_W4B3?N$]8O3W(W#TVY/QF-)4,W&/+]#'IW
M,A1D=AYX8S'4T?4[-R81#R_3&*[(])L[20:>VET]MO7L,-_<34$5N[7&1AD/
M3^D)JF6F(X_)S@?.'@A?Y.L!Y\N5@[W3.JVPO:)TV)&X19S%:AP9LW_6//0]
M?@!_K/:QL!/]3I43'?I=K*+=/M$ZJEQ]I[."T-!#M[AN@V*N3X"W?FS=J)@9
MA([&H+V2B*<F>66"G5B<RAKP<;IJ7!GTKQ AE2B_)HPL?4[);='=3S8F-'?L
MI*VFNQ+UC3+\3W>%NK>;PO3!-<RMMQU\HRVNE^35C7^TB//2N\5R@T=:VY7*
M0.PBTC\V*\?/T,,CO[48>;C!([BWT,91LZR6Q&?JWX!L5)@FB+Y1XY$OE"0?
M>!M\HDS.W/+>3L[QUG8+]9?:TYJN]BI_'IS/&[\,<9-U12CS]#)&_D7U&)N#
M'WB3.I]MQ$^L>C_@S\]4X6KNWG7M7;W?3:$W^TDNC?ZR7QW3[J0DI5^3RKB&
MV&=M:J@NR8_&7YI<76>WDQJUIK4=6J '));,X0-PK11QR2S2RB(UX@DEE<8A
M*1ON>*SLSL_+/\OR.WU>?E7B4-FUTYEMNM^JW[;_  W]#0[<&=4Y0LCRRB]F
MGL_3?OV?1I[K=--'O/+_ "_ERO3G 3;S;ZS/_+W_ *WU/J+\7E_DR_(I?Y<^
M:_6$'W6Z?R/M"O;KV/OX35%[&2,=>9^EGYZ";JC?]<'?V?UQ=OUW7=6FM^;.
M/RN+SV/.7#Y["WJN2QN0JDYC#>IRC-!,S-T2 W6##)'R8G&Y@1=)N*QP>5?D
M\GRM_F7K:4HRA9%2A*+C*+2<91:V:::V::;33Z-/9GER-%QKK89$J_+R*VG"
M^INNU-/=-N+2EL]MN=2V]-F;&WL3]LS3&\>BL+J#%Y+%CG9<?!\T>G(<A7FR
M.#RT?SB[#/48AM#4DL@<F-M2UXAMTI()A$"(HQS*Y6K;PV?M8ZU#>H6[./O5
MRZJ]VE8FJ6X"_IH+58XYX2\F]J.07;C]921[-=[QO_HQH8:>O)\Y1BZ>,=JR
ME4U!7,0^A K<XQ9F.-OE&KEJ[E\KN[#Q4[B;V;KO-MMTK-I\J<Y3AC94;*W5
M%MM51O@KO,Y5[L7.%;Z+FDWO)S?IGB)!0A#*IL<HQC&5U?++G:23G*#Y.5ON
MU%M;]DET-@$JJG?:]C+YF,_#O'INHX8C4ER"CK.O6BXAH9\X^BGG#"-F&"#-
M!"U:],[,!9AH992*UE2*3UMJ_2.\K&,46M=MZ-MV86EN:7R\U-Y"_1&&.RL=
ML8F9^':-\E+U>;/(S^:S O=]7V;]R-.Y72FN*NK<%BL]CYL;DX,MIZ7(5BBL
MBX$]>SIJ?-6@D@)QF@LE3@."8 E!F(&=:QPEPEQ1PSJE.:M,R,BA/RLJO#E7
MD^?C3:YU&%,YSYH[*RO>":LA'FZ<R/VXER=)UK MQ+,FJ$I+FJE<G7Y5J3Y)
M-S2CL]W&6SZQD]NNS*R^1A'(U&EC=QFC9G8P)QD$A=B"0#!V(3$F9V(79Q=F
M(79V97#.ZA[:G\U?0(8K-VVEUUHJ*GBM1>*8^LY6KX918O4?2S#U/DHZ\D=\
M@%@')U[+\1QS0"].7)7</@L]E,3C-05-18:K=FBQ>=A">M%E<:[\U+9U[4-:
M>K8. @:U7EA!X+0S1CU (&7??9C[35S:'<+"ZZPM@+-.*4:FH<;#-&_PMIVW
M+%\)4NGEV]9CC$;= WX:._6KN3^$\HG9+Q2X*KXATEJJ/]^4Q^DX,I1<)\SB
MG*B:FE*"R()0E&2CR6JN4]O+:*U>&NO9'#FK2Q<B,_H5\G78TG*M+F>TXR6\
M7Y4O>BXM\U;E&._,MK]Z+JO1V]VDL]B<;F\7J'#V,=E:5;(4IOA&F+G7M1#+
M&Y \W5&;"3#)&7!QR,49LQ"[+[MG<O3D(]<V?PD0<LW7)E:$8<O[FZCL,W+_
M "-RN>\\.Z,G"55BE%N+BX234D]FFMMTT^C1=J-\&DU.+32::DMFGU33WZIK
ML<W6'7;B[(.'WGT)?TM?>*IE87?(:9S91,<V&S< OX$S.W!O2MCS3R=<"9IZ
M<INS-/'!)'V1J/M5[9X@'/):_P!'5!'GGQ=1XGEN.KGD0M$3<=)?)\CLL4]?
M][MV?L !]6OJV9F%N0KZ<QV5SA2OS]"%FC3/'@[-R[E8N0Q^7'7U.(OL/#^E
M:Q#)HR=.P\Z6119&RJRC&NGRSB^C]V#CR^DE+W7'=2WBVC&:IE8,J;*<N['5
M5D'"R%EL(J49+9KK)/?X;=4]FNNQ3BR6GLKIK,YC2>I:4N/S.$OV,7DZ5@2$
MX;58W!S#K$?%KS#T6*=D.8;=2:&S <D$T9EEUV"NV'>V+U\&1LG:L:(S[14-
M6XR'KE$(.L7JY^I6;GKR.(?K=F#@[5">W5=CE*J4/T^\U[7^VN\&I,1J71&G
M=0X?-TX),?F,ME@Q]6'/8Z-F*@\N/J6KT@VZ$GB!7MG8CDDI6'@LQ.4%0:\;
M-S/V+(B$I\QC]"(LS-^V_'47[;NS/SPS+H#1MK.C1IU;"G1/+H\O*Q)[;US3
MV<H23ER[3BKJ)?;A[G,E.+13A<.9&DZX\K2LJN6/"SF5F\MIQVWVY%'WGLW7
M8FXPFN;:336_;W>2=NW7G:KU+7KC5OZ'VDT_;F^ M/W)">_E[ 2''\T6;JAX
M<<^3E@X"C4=SHX6(YA@LW;$DUB3'C0VA,7I^KZMCJXQ]3,\]DN"LVB']'/+Q
MR_'GT@W$<;<L(MR_/:^V&VVH-9YRCIO2^*MYK.9 G:KCZ0,<K@) ,EB8R<8:
MM.!Y \>[9DBJP=8-+,#F'-F#L5]R)C,,534.[TU7.Y(/"LU](8^:0\'3E;ID
M <S<88BS,L;\--2A8,4YL44AY.L_5)K6K\3Z+PM@U8N\**ZH?WO@T^_D7;M[
MS<6^9N<MW.^Z48.6ZYM]HDLJ&IZY:^6+56_O2>\*(;?K2V?/)=-H1YFNC4(]
M61@]@+NTM2[P7*^:RK6M/;?03<VLS+"06\YX1<24-/1RL+2=3L\5C+.Q4Z;M
M(,;6K43UAN([8[88+1N"QVF]-8VOBL-BX!KU*=8.D1%OHY93\SGLSGS+9LS$
M<]B8SEF,C)W?F-#'5ZD$-6K!%6K5XPA@KP1A#!!#&+!'%#%&PA'& LP@ "PB
MS,S,S+W53GCSQ$S=>N4K?J<6MMX^)"3<*_3GLELG;<UT<VDDMU",$VG+_#7"
MV/IM;4/?NFOK;Y+:4OV8KKR5I]HIO?O)R>VQ$11^;.$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 %7)[^'LV/+5TYNGC:[.=0FTSJ<HX^2>M.138*_*
M8^Z."SZUCY2/GDKM$1<6 NJQLNI=]MHL=KW1VH]'Y1OS'J#%6\>4G')59Y8W
M>I=B;R^?4K30VXN>1>2$6-B!R%P->2BY9KS1&2TSF\MIW,0^KY7"9"WB\A#Y
M\#:IS%#*X._OB-Q\2$O+KB(#X]I<30!$1 $1$!DSV.^T!8VPW(TMK*(S:IC[
MXU\U"!$PV\#D&>IEH)!;R/HK2/<KL3$(7:M6?H(HA97Z<7DX+M:O<JRA/5MP
M16:T\;L4<U>>,9890)O(@DC,3%V]XNSK6^JXGW,?:3^;/:V/3%ZP\V:V\D@P
MDG6[/+)@9QFDT[,_M<O'!6@GQ0%TB_3C!ZNH^J0P)=K5J."*2:8PBAAC.666
M0F"...,7,Y#(N!$ %G(B=V9A9W?R94+>W-VBYMT=SM3ZI8S?%O</%Z>B,G=H
ML!C))*V.-A]T9WA8\E. \]$UPX^N3H8WM!=[_P!I0M![47<5C['@Y_7$KZ=H
M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B^%J35&-PU*?)9?(4L7CJH>)9OY
M&U!2IUP]W5-9L''#&//#,YFW+NS-YNH9NTOWW>W^F/&QV@Z5C768%G%KXN^/
MTQ7/EV?KO2MZ]D#;AB8*%/U8Q?CX1C-G! 36W+L->*2>Q+%!!$+G+--(,448
M#YN<DAN( +-[R)V9OE=0\=JSOF]O-$^N8K1K#K[4<+G#U4)_!TS4L-RSO9S0
MA(-]HGXZH\0%H)"^<O;KGXAQ5O\ M+=NS<W=>60=4ZAF#$.1>#IK$,^-P$(/
MY,TE.(GDR,C-_P!?E)[LHN1-$\,1>&V'[,@,JNTQVTMQ-VKGC:OSLLE".1SI
MZ>QSR4=/TG=_(H\<$A#9F!FX"W?DMVQ'J89Q8C8L5>41 $1$ 1$0!$1 $12(
M]B#NX-9;S6HKX#)I[144SC=U3;@)VM-%)T3U,!6+I^$KHNQ1E,[C0IF)>/,<
MP-5D Q5V'[/VK-RM0UM-:/Q,^4R,[L<TC,\=#&56_HE[*W2'P*-.)F?YY*3'
M/*X5:L<]N6&"2X?V$>[CTKLQ0&\3Q9_6]RL(934<\(L-7K;F7'X&$V<Z./%W
MZ#E=_7+[ TEDP!PJPY-]G/LR:.VKP$>GM'8J*A7=QEO7).)LGEK;"P%<R=TF
M:6U.XLP@+N,%<.(:T4,(B#=_H B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"HM=YM\?>YOV<J_@/$J]*J+7>
M;?'WN;]G*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_P"W
MZN_@]U<@+O:(B (B( B(@"(B (B( B(@"(B (B("*COHOB!U)]F=)?C)CE3&
M5SGOHOB!U)]F=)?C)CE3&0!$1 $1$ 5VGNCOB$T5_=C\,WE265VGNCOB$T5_
M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
MN7Z__%/+("NIV;MVNV5NQB[^8T7KP[M'&WFQUL[D6B:!C:>".RPA%-I[J,?"
ME!W-O)G?CWK(O^9CV_/TX5_\:T)_%U=O]P7\7NL_MP#\#TE/$@(D>SA!VAM,
M:"W=R>\.>&YE:>FK&0T9:A/3]@J$]#"Y^Q=F8,5C*D#D-D<9((W8K &\7 BP
M>*)P?]G?O;]W,3J_3N2UOK"_J'2 WXZ^?Q\^+P-:,Z-J,H)[(3XW#5;36,<,
MK9"**.9O%>NT1 82.+VPNTM\7&O_ +2=5?@*^JGW8Y[*?\U/87=:&A%UZETO
MJ/$:BT\XM\\L2UL%.U_%.[,Y$&2HO($0-[KT5,_<),0%R''Y""W7@M59H[%:
MS#%8KV(3&2&>"8!DBFBD!W&2.6,A,#%W$Q)B9W9U[BA=[EKM7/K/0,NA\K,1
M9_0(5JM9Y"9SN:8GZ@Q4@\^TYXR2*7%V&X=HX0QY=7-CH":) %X=^/-_)F][
M_47E1I]ZCVKVVNVQOAC[/@:GU>-G3VGWC)FGJ^-7=LIF(V\W'X*IR]44S"XQ
MW[% 2_H@LX$*7;D[UK<F7<?4-/;;5MC!:0P,XX*H]"AA;T64N4WE:]E9;&2Q
M=XQ>U;&S!3BBF&(J5*&9A>4YG:QWV+M<Y;4VU.@L_GKIY+,9;3E&[D;TD=>&
M2U:E$GDF.*K%!7!R=O,888XV_0@RJQ[M]E8]!]EC36I\I6:'4.O]R]/Y203Y
M>>II^'2FMO@*G)U"SA)/'--E)P9_)[L44CO) [-9Q[O3XD=L?M3QO^H2 S)1
M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
MB(@"(B (B( B(@"(B (B( B(@"K^>E#_ $DF[/V3VO\ X6-$JP&J_GI0_P!)
M)NS]D]K_ .%C1* U22(O3R,Y15YY!XZHXI#'EO+D <FY^MRWGYH#W%_)@)"X
MDS$),XD+MRSL[<.SL_D[.S\.WU%++WP_=]%V?]Q]/U\54GBT+N-H33&NM%3R
M%-,$7K6)H0:GP969BD*6WA\XY6#8YCD^#LQBI7$&E8 B<0&TA]&#[Q+^;-L#
M2T5J#*M>W V=]7TIE_6)WDR.2TL[3?,7G;'B&4\Y'BX"PERZ75ZSD,-9GDD>
M>>01LGK3S]RUW@;]FSM Z3U[>GEBT?E1/1FX,<?60/I+.VJCRY*2(&=Y?F=R
M5:AG6Z6*5J]*Y'"!G.\4FX-H7X+4$-FK-%9K68HYZ]B"0)H)X)@&2*:&6-RC
MEBEC(3CD B P)B%W%V= >VB(@"(B (B( B(@"(B (B( B(@"P,[S/MNXGL\;
M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
MB(@"(B (B( HRN][[?%/LW["ZUW&>6O\T34CP&A*4[@[9'6^:@G@P,/@D_58
M@IRC)E[\0-Y8W'7#,HXP.4)-5K!?2FN\2@W?WSAVWTYD!N:+V3?)X.26M*3T
M\EK^^5:/5D_ DX6"T\]*'344[CS7N09V&#B.8Y;(%9G+YB[DKES)9*W/?R62
MN6LCDK]J1Y;-[(7[$EN]=LR/YR6+=J:6Q,;_ $4DA%Y<KY[OQ[_)D4F7="=@
MF[VC]_-$;>>JSRZ7BO!J3<&['X;18_1>#,;>1BE.7D?%SU@:NG*<8!-*4^5]
M8> JM2W+"!>-]%#[O&/;7927>+.T/!UCO5'4R-"2<3]8H;=T))RTO7A8^&@C
MSY33ZFE>(6*Y5N8=YY)1IU0KVL5\_$8JM0J5:-.".M3I5X:E2O$/3%7K5HQA
M@AB%O(8XH@$ %O<(LR^@@-'/O]\8&X'V^ZU_&?*KJ==L;_?&!N!]ONM?QGRJ
MZG0&R5]#5^EHW&^[_J3^#/:96VU4D]#5^EHW&^[_ *D_@SVF5MM $1$!B_VW
MOB6W>^Y?K_\ %3++2/8?\Z5?V/!^Y"MW#VWOB6W>^Y?K_P#%3++2/8?\Z5?V
M/!^Y"@/HK;0^C5_22['?L/6_\)FLUJ7EMH?1J_I)=COV'K?^$S6: G/1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!H?,+^<ZO]HB_U!7TU\S"_G.K_:(O]05]
M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
M<9?0R"0%QY/TFSB_#_(_#^2W,'=']HNSNQV:-E-=WYRLY?,;?X"#/V#<7DL:
MBPU0<'GK1B'E&]S+8ZW<&-^'".<&?ZKZQK\@0[9/ZGS6G^/:1_C*M@'Z-OL1
MNEMAV;ZV@=V='971>?T_K/518_'Y::E8L6<+EK<>8J68Y*%_(5_ ":[9J  R
M1/&]8A\+I89) )^$1$ 6H%[^_P"G'[0'VY5/Q8P"V_2U O?W_3C]H#[<JGXL
M8! 1$J\'Z%-_TC[2'V%VE_?VY*H^*\'Z%-_TC[2'V%VE_?VY* OVHB( N&[B
M_P#1[._8;*?O&=<R7#=Q?^CV=^PV4_>,Z T6&'_.E7]CP?N0KZ*^=A_SI5_8
M\'[D*^B@-J%Z*U])KHC[9]?_ (UY%6+E71]%:^DUT1]L^O\ \:\BK%R A3[[
MSNB\)VJMLIJ5&/'XS=72=:Y?VWU-:9X@"Z8C)8TSF;44<D[Z<U \$5>W\[G^
M#;;5LO7KRSU/"FU-NXVW>=TAJ'.:3U/B[6$U)IK*W<)G<1>C>*WCLICISKVJ
MTPNWGTF'5%*/,5B HK$)'#+&9;SY5-O23>X^DWLP<N]NUN,8]VM)XUPU#@ZD
M=>,]Q=+4(.6B9W$))M6:?KP-\ N<K_"./]8P;@4Y8PZP&M84D7=8]Y7J_LM[
MJ8W7FGCLW]/W2JXW<#24<D80:LTP,Y'+7#QOG4.;QGBSW=/7S<&KW2DKS'ZC
M>N@<;4<C$S$W/#_59Q=OJL0DS$),_D0DS$+L[.S.SLO[0&[][-/:0T?N[H73
M>XV@LO#F]*:JQX9'%7XO9-FZS@M4KD+NYU,CCKD-C'Y*E)\]IWJUBM*W7$Z[
MS6JI]'^[Z*SV8=<'I;6U^S)LAK:Z):CA:":X6B\[*T4,&M,=!7&2UZGX<8U]
M2T*L-@[=1HLA7KE<HN-G:C8G+5;]6M>HV:]VE<@BM4[E2:.Q5M5;$8RP6*]B
M(CBG@FB(9(I8B*.0"$@)Q=G<#Z"(B (B( B(@"(B UZ/II'QF[#_ &BZU_#^
M#5+U70O32/C-V'^T76OX?P:I>H";'T<GZ=G87[*ZX_@JUXMM^M2!Z.3].SL+
M]E=<?P5:\6V_0!$1 %JT/2NOIQ]0?<\V^_>V46TO6K0]*Z^G'U!]SS;[][91
M 5OE:\]#O^F<UC]QC/\ XWZ*54-6O/0[_IG-8_<8S_XWZ*0&RT1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 %6&]+CPUBUV1+$\(=4>-W.V_NVW9B?PZYW+^.$W<1
M=F9[5^M'R3B/)LW4Y.(E9Y457?=]FVUNSV5=Z-&8^ K.6ETK\T&%@CZ6DFS.
MC<E0U?C( (G'I]9N8.*M(_4W5#-)&3$)D! :>1%^4$PR $@/R!B)B_NY$F8F
M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
MW>Z+2$?SUFZW]E7<[_*%K#_?*?SUFZW]E7<[_*%K#_?* W>Z+2$?SUFZW]E7
M<[_*%K#_ 'RG\]9NM_95W._RA:P_WR@-WNBTA'\]9NM_95W._P H6L/]\I_/
M6;K?V5=SO\H6L/\ ?* W>ZXYF-8XC'"19#*8ZB(,[F5R]5JB+#SU.3SR@PL/
M#\N_''#\^Y:22QVHMTI1Z9=T-RY0Y8NF37^KC'J;EF?@LR[<MR[,_'/#O]5=
M9:GUMG,XQ-G,[G,XQ%UD.;S63RXN?4Y];CD;5D>KK=SZN.KJ?JYY\T!MZ>TM
MWY/93VI"R&I=Z-'WLI5ZQ/3VD+XZUU TP ,GJ\N,TNV4DH2D!"8?"A48S9QX
MD?J'FH]WD7I<NL=85+^E.SQIZSM_B+(2UK&X>HWAL:SGB-S!RT[A87DQNG7*
M/IDBR.1L93(,1<!C\=+$TLM,Z&$(Q8(P$ ;W" L(MSYOPPLS-R_+^[Y5^B ]
M[*Y2U?MV\A?MVK^0R%J>]D,A>LS7+]^]:D*:U=O7+,DMFW;LS&<UBS8EDGFE
M(I)9#(G=>BBEC[K;N;]VNU9G #2E,]-[?U)SBU#NAF*4TFGL=X/0\U#"Q,4+
MZFS_  8M'C:,PUJI.TF6O4(NEI0/R[G7NN]0=J?=K':5AAM5= 8"Q1RNYNHX
MA(8L;I_Q7D;"U+'#A\/:E&"7'XV-G<JL)6<K(+Q4ACGV].B-%XK3>&Q.GL'1
MKXS"X+&TL1B<=4C&&K0QN.K1U*5.O$#,,<->O#'%&(MPPBS+%SL(=@[;OLZ;
M?8W;K;C$M0QE5_6\IDK#M-F=2YJ:,!NYW.779CM7[9 +,/LUJ5<(:-&&O3@A
MA#,Q %C?VQ]4E@]H=U<T+F)8?;?7&4$HQ$C8L?IC*6V<!/V"-GAY$2]EWX9_
M+E9(+#[O#/B!WQ^X_N9^)>;0&E!Q0NU6LS^]J\+/^NT8LO?7J8]_G$']JC_U
M&7MH"_MZ%;I@ TCO]F^1>6YJ[1F(=O:ZVAQ6!R%Z)G_0=/B9N=QX;JZG/J=Q
MZ&:[TJ:'H7UFL^S^\T(L/K@;K4Y9R8.#>M+HK3XU6*7CVQ:6&XXQ]3^&Y&7#
M>)R]R] $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!5V?2HM+A?[%VX-LNGJP>I=L
M\I'U=7/7+N#IW"OX?3Y=7AY<W=C]GHZ_T?0K$R@7])LFA#L2[RO.+$)'MY&#
M.#'Q8EW1T7'6+A_<X6"B(3_ZMV8VX<>4!J=T1$!MAO1E<Z>0[%6STDG/-5]<
M8L.6%N(L3N#JG&0BW3[Q:*J#"[^TXLSG[3NIZE7W]%T^DFVI^RVZ'\*FLU8(
M0!$1 4<_3,>R<=G [4;W8ZJ1/A<G?VZU/-%&[O'1SL19C3=RP01^Q##DL9D<
M:\\Y]'K.6Q]>/I.5A.@VMRSWM/9._FV]G3=?;N"K':R^6TI?NZ;C.+Q2'5&#
M%LSIXH!ZP8;!92C6AAD<F\(Y6D\^GA:9ZI8:6*.5FX:2,#9OE;J%BX?CY6YX
M= <JT?K'(:<S.&U'B3>++:=R^+U!BI!)P>/)82_7RE F-G9QXMU(7<A<29O-
MB9^';=D]DO?_ !FZNV.@=R,/*$V.UMI/!ZC@>-VXC+)X^"Q8K&+.[Q35+)35
M;$!\2UYX9()1"6,Q;2*+91^B#]JJ'579]SNU]FT\F6VEU9?&"M)*)2QZ9UM:
MNZCQ<D<7'7'4;+GJ*K"1D['+6GCC80A86 MFHB( B(@/0RF3K4JUB[<GBJU*
MD$UJU9G,8H*]:O&4L\\TANP1Q11 4DAD[" "Y$[,SK2M]OSM56-[MZ-R=U)C
ME*OJ_5%^[AHYNL3KZ;JDV/TW7>,W<H''"5*4DL'EX5F6=N&?EFV;7I'?:_?:
M#LJ:[FI7'J:BW!]7VSTX\<OAV7M:HBM#EIX.!)W]1TS4S=Z1G%@(8&A<P*8"
M6IECC$!$!;@1%A%F]S,S<,S?69O)OK(#^U>_]#2['S!%NCOSDJA>):>';'2=
MB0'8/4J\M+/:NGKGUN!O9R$6 I2<QC)"6*D$3<+,@M1 8)#<0AB.>:0ACA@B
M%REGFD)@A@B%F=SEFD(8XP%G(C(19G=V9;E+NCNR!%L5V=-K=M^@6R>,T['E
M-23,/!VM4ZEL3ZBU%,;N 2.(97)V:M49&<Z]&M4J,_AUP9@)'D1$ 1$0&O.]
M,<['P837^W.^&.J]%?6V,ET)J:>*+@#SVFX9LEI^Q.8 P^LV\%)D:@G+(4LM
M?"PQ1LT5-^*8"V\'?W]C9M[NR[N/IVK6:QJ'3=(-P-).P"<T>H-(1SWQC@<N
M7 LEB2RV$F>-BE*GE+,4+>+(+MJ&H)AD )!\QD$3%^./9)F)O+Y/)_<@.=;:
M;CY31NIM-:QP<A0YO2&HL%JO#2@[,<>6TWE:F:QQ@3L3"0W*4+L_2_'OX=;M
M3LY[UXO<C0.C-?X66.;%:RTSA=249(G=X_ R]""Z("Y>U\[>5XGZO:Y!V?S6
MCV6RQ]$2[67S8=GK+;97[;S97:/5-^E2BEE$IFTIJJ:?46(Z <BF]5J9*SG,
M?7(^(XXJT=. 0AK # 6OT1$ 1$0'HY/)5Z=:Q<MSQ5JM2&6S9L3F,4->O!&4
MLTTTANP1Q11B4DAD[" "Y$[,W*TJ_;Y[4\V]N].YFZLCR-6UEJS)7\-%()1G
M7TU6-L=IF XC,WAF' T\>=N-G$?79+)M''U] [0+TA?M@-LWV5=Q,I5MO4U!
MK.&';72S@3#,>9U?%9KV9(&)G8SQVGJV=S!QNSL=?&S,_DM2!%$("("W @+"
M+?4$6X9OVF9D!_:O&>AH]D<;&8W5WSR%9R;'5JVV.F)I ?H&6X5'4>J[$!$+
M@<KQPZ<I]8.$M8&LQ<E'=D%J-TTO0!'TD70+ET@W)%PW/2+?*1>X6^5W9EN&
M>Y'['P;']F3:[1DU>.#.6L(VK=6&'2Y6-3ZND?.9+Q#80>1J(VZ^'JD8#*-#
M&U(I&8XW0$KB(B (B( M*WWCWTQG:$^[OO'_  CZE6ZD6E;[Q[Z8SM"?=WWC
M_A'U*@,,UZMBC#*[/+#'(X^3.8";LS^]FZF?A>TO5GNPQ.S2S11N[<LTD@ [
MM]5F)VY;]9 >O\#5/ZEK_P"!C_V4^!JG]2U_\#'_ +*\_#%3^JJ_^'B_VD^&
M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
M$1$ 4/O?C=XM!V;-@M2ZKI6XHM<:CYT?MW4<N9Y=49>M8Z<D,0DQ^JZ=Q\5O
M.6YWZ8@]3@K]3V+=6">8):J[TEKO%2WR[061TS@KS6-OMG3MZ0T^\$_B5<MJ
M,FKOK+/N -X74&5A+3M$F*9_4L,=H90^$Y*M<"N[&+L+,1'(7Z*20NJ20W\S
MDD)_,I)"=SD)^7(W<G?EUYD-A%R)V$19R(G?AA%FY=W?ZC-YO]1E_2EW[C_N
M[Y>TEV@-,:4NQ$6BM+R5];;A2L)N$NG,-?K%'@7,';PY-47_  <.YN0O'1DR
M,\;O+  D!>?]%_[N0MF-AH-=:BQ\E/<#>7U35&4AM0-%<P^DXQF;1F"E8XQL
M12OCISSU^M,3/6R&:FJ%%')5D*2RTO7J5(J\44$$4<$$$80PPP@,<4,48L$<
M448,(1QQ@+   S"(LPBS,S,O80!$1 :.??[XP-P/M]UK^,^574Z[8W^^,#<#
M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
MB(@"IB=^+Z._OCVE-^;>Z.@-2;4XS3]C1^F=/#3UAJ#5^,S W,*63*S*5?"Z
M"U%2]6D]>!H";(O*70;R0Q^3/<[1 :TC\IS]J?\ 3GL!]^.XO_"138]PMW F
M]?9>WGS&X>X>H-K<K@LAH',:6AKZ,U!JS)Y8,E>S.G\A7EDK9S0FFJ;4F@Q=
MH9I1R!SA*5<0JRA)))#<&1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!Z&4Q=:]6L4K
ME>"W3MP2UK56S$$]:S6G HIZ]B&02CFAFB(HY8I!() (A(7%W94#>W%Z'[K_
M "6Y6?RNP.I=L\-MIEI&R.*TYKK4&K\?EM-6[4DTE[!T'P^B-40V]/TR>+X&
MGMY'X0BKR/2LA(U2.U8V *(#6D?E.?M3_ISV ^_'<7_A(O#^AS=J=_\ ]L]@
M/OQW%_X2+9<(@,8.Q%LIE=M=E]H=N<[8Q]O-Z VOT!HK,6L3+9GQ5G*Z5TIB
M<%D+&,GN5*%N;'S6Z$TE*6U1IV9*Q1G/4KRN4(9/HB U\?;.]&,[8N]FZFN-
MU-2ZUV!')ZRSMK)!2^;7<6:+#XH7:OA<%6D;:"$3KX;%15:(S-#"]N2*6[+$
M$]J5EC)^4Y^U/^G/8#[\=Q?^$BV6Z("FCW('HU6O=@=YX]V=X\YMUGWTU@\A
M!H?&Z)RVILN]?4N8#X.LYO*?#^D=+0QCC\'+D:F.BA:^Y6\F]UVJS8^K(=RY
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!0A[QOT3[=O7N]NX>NMHM1[1X?0NL
M<Y\TE##:KSVL,5F,9D\I4K6-1P'6PV@M14"JV-0ED[].0,B\CU[D<<T(2QD1
MX3?E.?M3_ISV ^_'<7_A(MENB UW/9F]%G[8VU&XFBMRM+:Z[/\ !G]$:BQV
M?Q_5K'<9HK+59>F]C;/&T;N]/+XV6YB;K,SEZI=F<.)&!VV']9Y'CC>8 "5P
M%Y0CD*6,)'%G,(Y2BA*0!+E@D*&(C%F)XP=^EOW1 $1$ 1$0!$1 $1$ 477?
M,=BC5G:'[.NN=I-$7]/8S4NI;>CK&/N:JN9*A@HAT[K;3VI;@W+>(Q&=OQ%-
M2Q%B&MX.+LL5HX0E\&(CFCE%1 :TC\IS]J?].>P'WX[B_P#"1>M<]#?[4\T,
ML7S:]G\?$C./J^;#<5^GK%QYX_F2MSQSSQRW/U5LP$0'7NT>E+.!TIIC!W3@
MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
M1$0!<?U9BI+V*R=&%P&:YC[M6(I7(8QDL5I(8WD(0D(08C9S<0,F'EV G\GY
M B UH%/T-_M3Q0Q1?-IV?R\*,(^KYL-Q6ZN@6'GC^9*_'/'/'+\>[E>Q^4Y^
MU/\ ISV ^_'<7_A(MENB B=[E/L+:P[.6P&G-J]=W]-9/4>(S&J,A9MZ2O93
M(X0X,WF[>2J#!:S&%T_>.6."< L#)C(@"5B&*24&:0I8D1 $1$ 1$0!$1 $1
M$ 1$0!$1 %@#WE/=XZ*[3.UV8VXUA"\$LK/D-+:BKB+9+2NI:T9_!V8HF[/U
MQL;^KY*C(Q09''36*DHLYQRPY_(@-:7)Z')VI6(F#6VP,@L[L,A:MW$A(Q9^
M&,H6VIG:)R;VGC::9@=^EI39NI_X_*<_:G_3GL!]^.XO_"1;+=$!1=[I?T9K
M?_8KM$[9[MZRU1L]>TUHN[J.SE*>F-2ZUOYVP.7T7J73=8:%7*[=8.A(07<S
M6FG]8RE5AJQSE&\LK1PR7HD1 $1$ 5)?OS/1\-^^T7V@LIN?M[>VX@TY=TII
M7!Q1:GU+FL5E&MX6"V%HRJT-*YB!H".R+0EZWUDP.Y1ARS*[0B UC/Y4,[6?
M]<]E_OWU-_$!/RH9VL_ZY[+_ '[ZF_B MG,B UC/Y4,[6?\ 7/9?[]]3?Q 3
M\J&=K/\ KGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_P!^
M^IOX@+9S(@-8S^5#.UG_ %SV7^_?4W\0$_*AG:S_ *Y[+_?OJ;^("V<R(#6,
M_E0SM9_USV7^_?4W\0$_*AG:S_KGLO\ ?OJ;^("V<R(#6,_E0SM9_P!<]E_O
MWU-_$!/RH9VL_P"N>R_W[ZF_B MG,B UC/Y4,[6?]<]E_OWU-_$!/RH9VL_Z
MY[+_ '[ZF_B MG,B UC/Y4,[6?\ 7/9?[]]3?Q 3\J&=K/\ KGLO]^^IOX@+
M9S(@-8S^5#.UG_7/9?[]]3?Q 5N?T>/NR=R.RWMAKG2&YEG2MG+ZDW#EU30+
M2>5OY>B&-/2^G,,(6+&0P^%E"UZUB;)O$%:2-HBB+QG(B$9_T0!$1 $1$!_$
MD8F) 8L0$SB0DS$)"3<$)"_+.SL[L[.W#MY.H+>W9Z.MV9M]+%[.6])R:!UK
M=&0I-7[?3#@K%FP0$(6,O@V"73>9EC)V-Y[>*]?-@&)[S0\QO.JB UO':J]#
MVWRTW//<VFUGHW<K#LY/#C<[/8T5JT&=R<(^):^1TUD&$&;Q;3Y?"D\A"T6.
M(7(HX&M\>ZA[2VVY2OJ_8_<6E7B<^K(8S3]G4V-\,"(/'*[IGX7A@KDX.XRV
MWKL[$#/TF8B^YL7A :(BY;CK2R063&M8A,HYJ]E_5[$,@/P<<T$W1+%(#L['
M'( F+L[$+.OZBLQFW(2 ;?5$A)OJ^]G?Y%O,->[/:1U5&T6J-+:<U)$P]+1Y
M_!XS,1L/OZ6#(5; L/UF;A8=ZT[IGLR:A(RR^P^UEIY.GK8-&X6H+],CS#[-
M*K7%N)'ZO)F^1OH69D!IF46X-E[BCL?&1$79XVS<C(B)VP0MYD[N_#-*S-YO
MY,S,S>YF9E\S'=PGV.JH%&'9[V[D8I#D<K.*DLFSGQR(R36#,8QX]B-G8 \^
MEFY= :@$Y1'Z(A']=V;_ $KTGR]1O?9K^7O;QH^?+ZW5[UN4=*]S3V5,)(,N
M,V VNK2#T<$^E<?8;D'<A<ALQS"7#N[^TS\\OU<K,G;OLX[>Z0,9=)Z$T;IB
M46X:73^F,)AI6;CCAI,=1K'YL_#^UYL[\\\H#3E;%=V]V@-S2B^879K<7/5Y
MQ8XL@VF<ABL1(#OYG'F<Y'C,7,(MPYM!;E,1<2<>DF=YVNR_Z(EVC=6V*UG<
M7.:(VKP9=)V(WR$^L-6%&3"0A7Q&)@@P4)$/4,DMS4PRU)>EGQUL>L0V82("
MO=V&O1G^S+LS:Q^>OX"[NEK''F$]?4&X-ALC0IVHS8X[.-TE7&OIFM/&XQE!
M:M8[(7JQQO)5N0/+*QV":M6*"*.""..&&&,(H88@&.***,6"...,&8 C &80
M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>ino-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:ino="http://www.inovio.com/20210630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ino-20210630.xsd" xlink:type="simple"/>
    <context id="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83ed6177c4804f6aa764dfbd829ecaa8_I20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="iad1208ba98074d448260b48944e05ebe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc098f58f8a041b08a33357d6648fbc0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i32b8bf36ec4d469591d90e39f3ec8e81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2ee9a992e9d4aecbed299eb5413def8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i06e1e9bb6dd649dfa52090802d4a0072_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ecf790ef87d429c90f4ebc744136636_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96d79f4dc5474687846e3b39dfca505c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4761e01b5c81478a816114b036289275_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7bf3b64ae03f46cfbeb3fc8dc8a97ca8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idb0126e377d2444cbed98c98dca66844_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id697003739b14dbabbe3d698b5c6670a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibeb6dd3bc70a471ab465c71da214cea2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i51b398cfbf4a4650b18fe5d6ea487fb8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icbfb78a03fb44fdfb83c5a956c89ea69_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i493fb6cfff2d460993ffab8a845aaa8d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if232bf82d12541779d14e8a336ace449_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibda3de1762204459935f37915d69c1b6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i12aac99aaaf741349f86a989fa764482_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i799a2702ab5a4bd4a435e11c1046de46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44709f40e8a943049398893f00a24be2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85e84c6e219d4b4ab6f799165f3ff3f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5bb1d8705d24b5cb342ad0d76c412f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id506e21662664607abb5ada53bef4c71_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i293a954b904244158be4beb19eadc1eb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6be5b29e6e640aeb3b3c6f8c8b4b46a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia305805348c642e181a5a220764cd0cb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie410c23f3d734e22a654add21f7dd4be_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd07f46a44cf47b29f251e9f8b53b448_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb3c65da07554ec0a475b65aec785e3e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifd8b502204b444ec8fc08ad865e94b35_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if9fc53bfe459451e93c099b12e3d7d7d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib97826d72ea649e4b70791285961ac6c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib69edae5e51e45c6a95fcd35749a9236_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3da144150804a6fbb5a9f2eb556643e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i108e0d957d844157b477393aead9cc52_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1439ad58b8a4b8d80f168ebe9e96082_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fd181698642459c9825e12bed9aa37d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icb3abe12b5c3451b84594cfcc6853c43_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i254bd042051242849bc85dee66371184_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i42516c7d860c496fa39ae9ebb52897c6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5ebf817b5d604254a7317c1108eb9e22_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if20cd84b26984f8f9e8f6f29f783d43c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica81cf786c5d4fff8fd605675e3eac0a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i79f44eaa8aa2459ca2f8c8563adf249b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2c97a020ced432dba7dfa7f21e090af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7027e5aeb5e64cd7ad992e12c7a0fb56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a7c265546d74b3c8712996af91049b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1879c69872f8418ab00a9d6a48983451_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0493a38b630a49bc902812a2465a3617_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie8eecef92b9240d5bfdf9e6810786a6e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7ff215ce28014289ac0323b81097347d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i005c775b4401470a90ee91adfbb417b8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic1a0656da9344a8a8b854e2ca77a6732_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifa58a8fc43214b7bbd63cc831b027ff0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2ee8db81f57e4c278a66fdfcba5073cc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia4fb0140f8414f75b8e619c79cf2a649_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie0caffc4cfd24e629b7a9fa306e19b99_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iddb00ed027cf4a6bb677b4122123ec1a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibfc901c89fb3492ea30e005f1f9c9e8b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icabb95078cd04d3b859cdd387e239ad7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i886aa86a8ef3444899784ec9f609e6e7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id0963ef6fa894e47b9e2458dad5bd538_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idbfee2e1b2af4f098563291bfb7a6e6d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4152dc4545d04bab8fe2acc7fb1b3424_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if1eb417f6f754a2ea880089bb2a38945_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id92715916320442a9ca37398433d7c01_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5677a5c642824f42ad93623935b5b5bf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6030a2333ec842288f8ea1f6eea367a2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0ae8485bffe44645bcc2d2d69167e061_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6b7911f846a04e46825317fba23a0d2e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i11839e6989af49a292b4e10ab48b712a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic6c3eb7929d54a7db36dd6d7dbc2b7dd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i58f2d9f6575543589f663ac5ade5d146_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice4430b09f8f4a3d9c5b6e2ef7fa048f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4cf6343817df4d51b56069690f181906_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8419a4c84d46487aa9709be5474b797c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5bc7989f3223430dbcc2ce0a18701c95_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if83d3a2efc6e49fa9fd97fa96d8adcec_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i42c406f875024b2bb0c68f572a31cd9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i510a549b3ec34defbede167e3f43db38_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib4f229a241b946588368e702a0bfb111_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2706bc18dc264d7f80c2c3df55033508_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6816a859d85847e482e3a9f0779b70fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e7cf41bc39a400f8c65d4ac89cb740f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4379956285af4a64828e8aed46e6fc8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59b2f82a49c24e32adbb66d496dda53e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8cfaf8d38f5648c19f2ea139b9b26baf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie51d461609384e719322b34eb0028974_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4f3ac792a0624a46adde92d9a011757a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5dc69a851d9e4e609cc585a27766de44_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7015122ae2124cc496b05b2e9f7e4d96_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i58a6f1f19ef548cca073dbd3bb6f4e78_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia791cbcc956646499769e8fd73d3f0da_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if19edaa6e2cc4d4bac4bd7a20b22e0ab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8a1e910e01534d50ada88b9157528ea0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaa3846d736e946a395c5e4a35be5dda3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i195cff6b53c543e79e1b7a11b9e1e066_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if1713bb34c3046b5b8c3fb55489e9da9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9ae0695b197b427cb51e9553cf7567c3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8730b43b27914e7aad78d1a3e3c967ea_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8ca670336a984af492bfea37611a6fc6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc709f4b94bc48ed922b211843a64806_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7bfff0eba5124813b5d1d472946eca2b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2063a61ba08e4166b1cddf9ccca281e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie423d6a2d8714a8f9455c1d4c07b71ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b0fd8f591c349f3a5e3a09df3fda89c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d1fecace3114e4e8dc9bbf39dbc9e69_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5efcc9635b543f288d5ac148668e8be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b14d9a9f0a04ed881500352253a7910_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee92b5ff60e34bdc86aeec302d9c2bf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79c69a9ae1284a36bb632aed6602a513_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb94388dbd194288ba834bcc4e711204_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72086878455242579c997bb7d0dbafca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28d2855764184d899799d1f6e766ef05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd724b7e4b434a0299f128f23b08a6f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie555d9e8436b4b7c816532c5dba1b774_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41fa24018fea4d7789e40b137a122c1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77e632e4521a403eabd9a0d1cd065f58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0dae7058a7c24aad9e604be62fc80f77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i885b976e592548cab96e1ad94a5f5ca6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98ee59d71b964e1b903875f0effd8913_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bd6370c584d45d1980fe5eae38e0f14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if15f13a0132e4e6a88992dc32184349a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cdd7b8ef815473385e371284b1691bb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i658f1d80d9ae443e8ed687c6a2037b8e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25b5d1ccf26e443ea857b84e229ce359_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie0f8942f622e48a99283907789ffa607_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f14f4877fcc414dbb3be5f50ae03388_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i449fddef645f4a30a1891aa40c4f6f0d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0f168c1581a04f49b0e144ce91a5b415_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90cb8338f9474cb7b4f4e085bba18709_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9694c3b5185b4167946bc4ade85f653b_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="idb65bbc9382a4813ad514235377b41b5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cbf958eded24955b7f7345d5fff5691_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife6839a934ca45f6a9f657888e33b403_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4d7b13bbac7745c18bcb6916ba590376_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ied29f23ff8a24d14ba72e1520dbcbe12_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0cb6494a5734438caccf162208d9c9e9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="i586e28029d9349b8990dda0e65156664_D20190801-20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="i4387c26933424d9096e5a67cc6e310e0_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i17e32422bc844eba90a640f03b45dce5_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="idaad05c89c7a4003898310c3fcc4bef8_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="ibb48eed1dd1d450f97688eeb9d9b1075_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i48cbe06ea9db47109f2c6aa21e985ed6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3325f0757ae043c6b5ac88744b9c348b_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i0d8ee829033246dd9adf6d9303496b62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icaaf8fc6a6c144978817e6793fd2365a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28f211979e784e9bbb20076cc52f7e54_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i8a26ab4a585a46dca8422a60ddfe24b4_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i2908c92d06bf4769bdd733e5d00c8200_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i6d34dff54d0e4a038bfa48e0e67a8e99_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i442ae70cad5c4076acaead0487e51e18_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0f6c67ea61a42c8a33b20a0edfa3e86_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab4e7c41161447e1a1a8d07237954cb4_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i93769b4e1cd94005890eb64e29ddbcd8_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i689dc147815948f0886fb748641b715b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i77178543290247baada87cc58713a47e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5014003f2f6f483b8391af1fa2db26e8_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i59c22ff37c374753ade05595b7204ddb_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i35a378f1adfd4003a890450ab84a2bd9_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i9f31aeb778524005bde1396b19356f60_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i6a0d7c5a50ca41b28dad429b0cb851a4_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i78ee577f7a7e4579bb39bba035abaee4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i33badcdaab9f4b948718c8bce4d00c22_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8bbbdeacd5fc468588e3dc03b0a7861e_D20200403-20200512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if44318d1ef4e4fd298cb0d5f9506f23a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2005c7bb31a94776aff831320305c606_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="ifbea9bf1e25743b78635a4f7dced6bd6_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ia838f5b6a3354692a049e285a3f8c1ab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i23ce38f7c67443e49e518a149cc81961_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0da088e105ad4f18ad8b9d31ec870555_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iacd59942851345caa9bfa5f0f8f2c395_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7720390ee14d46e0af301a676fc1e147_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idcbd43fff7ff49d2b5186181ccc1ee3e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0df4c9eb1a604d84a5994034871feeb9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45c9b4d010164a689b6d9c3c41f23c03_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i36d2d9234b5a431cbf09724c62882b4e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i59ae4261b99c4a6e810082721dff0e62_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6c583306369d41e29983388433b751ce_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib9fb06d2b7b14b53aa4aa3861c628292_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i97026c92ba624f5eb88dedb4f4fd222a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b6b2ddbdd8e403393dd968eb554812d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i409887a8fa6a4346a1975b51ea0e7e16_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id1b2caeab20c408da8ce4dbb3e47ca39_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f3835a374c242d7a7e25920391ff721_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc6843efcb854eb59c1d1c8cfa5945bb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6840ef28448241779743cf158cd253ec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9220dabb97347baaad3b955c7ca131c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice27ffbaffd34874afe23deb45a41f1d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75baa0c985dc4a80846a6c09d447a541_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib01f6e99b41046cea288d454a397131b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c4a44eb23a64f2a8177b06eccfd5462_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf811d4883d349a090d95c8c69bfc003_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9e764caa439a41a78c114122d5dd11fb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i516d344bdae6478b9cbb0eb47830b5bf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i56a074845daa435895695e2ec5b8a0a9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if7fe878a23244e578b1d0fe5755cc0fa_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6adba9b5cfe8432498fb5b3d434a4541_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c44a7a4bb0e423fbd2ec314824724ad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i084bec39b5ca4a51a9902a9ff9ad928f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2eb3f0be101b47a18fcc503057ad42f1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7334687cb4a947de92ae0eb9f74ab59d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc5e991cb67b41b5987aee77b9140631_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i73f8e4b6b88849388af7af4775429f82_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cfb07957bc8448e898eec6cc1d4f178_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idab9cee1a62047fb8051e1d941df796b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0e3baa7582b441aab8b2cad5aea5a16d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i3e5ffc18c04b4a18bc872e736b8e3274_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i2ff71523015949a3a75328d8f76bc7c6_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="iec5758f42e8641cca8f706945d684248_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7bfa0efcd5e94977acef14e343d8c32f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9758e3169bf42408ff0026a43dd6c32_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i39000bc0ed2f4334bb3f0d81cbac8fef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6b00238ffc3b48c5a7ddb81b78793302_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee4bc461464046a39879834a877ac90d_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i9aaebaef4a484e99a1f72fd27c49260c_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i0db0b6c7420847968706776cec806a32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8fbd471a37474f43870e9353685a3362_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i647dbd99928840369aa848a876ffaef7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifc72a58c0cfa4fec9b889e44cf304615_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id9cf11cba38341b4909eff0dd1632ec2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id242696b659b49afadf87dff3bed0cc3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i79aa827c9e8f4b358c9a1724e62d1c61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66a148722afa41b185cd4eef30e25fdb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1b665a2cbce54f4a94dd8ecf309380fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ae75de8f5854856a0f90d658ba0bcd8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i110b3be318af4daab8582df0596dd792_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0dc2a7ba5e24419aa07ad87b72b18c9c_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8db89a2c66514d7498b690857971a626_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c8ad24eca624a71a7fb21cdcced5abe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica98223bf1ed447193c67fa870204517_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i71ccd78a11244d749d8dd9859e9ce310_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic44786c100124c789efc53e8f92bfde9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i95c7a96f00054646b6f751e13b02c56e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72b40649a6a84f138cb3a6dcb7498815_D20171229-20171229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="i537aa32e3c5f4baf82bacfc6e7b0d869_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i564bbcf0dabf424f86f296be903e20b0_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if69d1eee3fca4367a054a928d24cff8d_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia92556534d574bbc94e10cc84341c759_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if9ad39f285414f30b79535cfaba7daa2_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="iba45b8937a894f6b9a5129658feedbc3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie861c939ef624bffbd0b88dbfdf9c693_D20171231-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iafce45fcd5d548d596dd6d619e8eacd5_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i46c98d6b5b8a4c33898800f47a20e3ff_D20190302-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-02</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i42ff72c6a8dc403c95f8ee874839211b_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i3df90724be6143258a8fdee15d4e93e6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6407575bd8b340a1a2a8f8810560320a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icaeaf41dd77446d3927ea1c114867dba_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i192e249f20ad47fd87c6efd63533083b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaca810872ff8493db0d62372edb6bd01_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8220fcd140d74557b083a926e4253873_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i03b88e02327942f9ae78274a728a6c7a_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i761da9fe1ff8435f937cde9607056cae_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="id78961ef0362494d9ca8a3a24f0402d9_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i63751304353e47dfa5578ae4af319b3b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae69df542d9c4fbab5f22042b834a657_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5944f9592ca4638842dcafe5504d740_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7f7c6a9e4960494e8081fc7f145ad847_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifa54cd5e2c5b4aee983f8f582c668686_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ieda7c74c79e1485082bb7462bb0aec90_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i02069efe34d14945a75f312034c48d56_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i97a4ecfa456040578debe0c705bb0cb0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i904f52b9d85542868818618a457d155a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7e44b859e87640b9887e249f509f22b2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia079900790b44ee39d2535ab8a76f7c7_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i01f7a9d3dc10499f8b65f4f3b1c7d04b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8772e190853b4c34b869b43e00154114_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f531494334b4657bad6357a54553f03_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1282eb1a458f4357a1ac8a3d8b4fa3ea_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iba1c591d1f53449fb9a0ca78b60e0636_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i40b6bab09ed848df86ba826cc4961c16_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i56b4d555b69d4dca91e2e11a14be2165_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b1efaad3a5848b9b2664bb608171aa6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id32424115c5249fdab21269b2a97590e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i44b465568e394137b0167411e7b5c097_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifdf3e49c10cc4f94a383960947e82228_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7e127c1524564bae89ca80e255ad2678_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e185f6790bc47528495934e156680eb_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i4df2a303132e4f7f96ff6997a31a1212_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="iccb9c884d87d48218ffe7d83101d494f_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i5c02b65034ce49e890afd34400d720ae_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i667c2fdb4d5345df8d39328da874e2ad_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2fb35c7b8b7e4a2a8b77665cb4247493_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="icb812a090bdf454a8d614a22e3087514_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="iea7c36741569485ca8d859069b46f092_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i02456b81a37f4ae6a5c063b014c525f2_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i196f4528a0a9490b9a924875a4215545_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i8ac9bc58c8414810ae3dff09c8e549af_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="if173908cc8354a3187bf1e82e65a5550_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="ife9ba1ec7a1a485a8b2bda6032474f24_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i230f14716d1a4c2e895e45f0ed84c399_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i9dcc915ba16e470c810717cdca71bc8a_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i751954486ff04a2585b50cca7a7a1f66_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id548d70b807a41cdbafa0a873651db92_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i603b348bf030425286b8663a7233f3b2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie7eefa6dfb474f59a56c5498e9af5934_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ddd5fa80e1f4d619dac2b863cd3a051_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id0b994018688462294e9fc2216b8b645_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7eed2f09111e4adc973bc8d68b9050b1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i565b71404f58429384bf7e01598dd420_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i1ec0c50e342949c6b66d38190dde51e1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc6d252ee23a41b88a2b37888e87aff6_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="agreement">
        <measure>ino:agreement</measure>
    </unit>
    <dei:DocumentPeriodEndDate
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV8xLTEtMS0xLTA_c229cdaa-6c8e-4653-b44b-761158b216d5">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV80LTEtMS0xLTA_9b6349bf-7b12-4f5c-a39a-90b872187bc1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV82LTEtMS0xLTA_ef2a07b0-c4a3-4f52-bb19-277f48dae386">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV83LTEtMS0xLTA_da88fecc-10d7-4578-96c6-63d7ceee369c">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV85LTEtMS0xLTA_5e3c89aa-9bae-4fa9-9e14-b6a280376842">0001055726</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80L2ZyYWc6NWYzOTMwOWQ4N2U4NGY3Yzk0NTNlNjc2YjlmYzA0YjgvdGFibGU6MTRmMjM2NjZlZWUyNDI3YmFlYjc3MWU0MWIxYTVhNjUvdGFibGVyYW5nZToxNGYyMzY2NmVlZTI0MjdiYWViNzcxZTQxYjFhNWE2NV8xMC0xLTEtMS0w_0aa83c02-67ef-4307-83c2-cdc29bbf4c88">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i11839e6989af49a292b4e10ab48b712a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1Mg_7c2a02d6-d7ff-4cb3-9069-106f0e2331f1">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfMi0xLTEtMS0w_a96a096d-fa83-4ae6-b9b8-49d42b190057"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="iab4e7c41161447e1a1a8d07237954cb4_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfNS0yLTEtMS0w_fd2066bb-c8dc-43f2-880e-61c1cd8cb772"
      unitRef="number">0.0002110595</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i4387c26933424d9096e5a67cc6e310e0_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfNi0yLTEtMS0w_a3dd577c-a8de-4fae-8029-8143d6d4db49"
      unitRef="number">0.0002756873</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i93769b4e1cd94005890eb64e29ddbcd8_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82NC9mcmFnOjNlYTY1NmExMmRlZTRmZjc4MzhjYWQ5NDViODhlNmUyL3RhYmxlOjBkODI0ZmY2ODljODQ3ODk4ZjYzMzA5MDlmZmY3NzBjL3RhYmxlcmFuZ2U6MGQ4MjRmZjY4OWM4NDc4OThmNjMzMDkwOWZmZjc3MGNfNy0yLTEtMS0w_f10fc8b6-a3e6-4e37-ad92-c7975335b7ff"
      unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEz_c226ff12-2ce2-4670-b4fa-30decfd01c0c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6MTJlMTU2ODg0ZDNjNDg3NmIwMDIzYzExMDU1ZjBmMmIvdGFibGVyYW5nZToxMmUxNTY4ODRkM2M0ODc2YjAwMjNjMTEwNTVmMGYyYl8wLTAtMS0xLTA_ff19112d-4900-49a9-abf3-2535bf82616c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6ZGMyZTI5NDZiYTAzNDc0ZDkzOWY3ZGEwMmVmNzA2MmQvdGFibGVyYW5nZTpkYzJlMjk0NmJhMDM0NzRkOTM5ZjdkYTAyZWY3MDYyZF8wLTAtMS0xLTA_aa2e9b97-be79-4b48-b127-e8504bdc7da8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE0_9638b7ba-9b0d-4451-9a6c-ac61d5e8928f">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE1_81350c95-5492-4ddc-bda9-b0a86b9ac967">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NGYyYzA5MDBlNmFhNGRhMTkwZDIzMTcyMDc2MmRkODgvdGFibGVyYW5nZTo0ZjJjMDkwMGU2YWE0ZGExOTBkMjMxNzIwNzYyZGQ4OF8wLTAtMS0xLTA_e7f98c2e-0147-46ee-accf-95d2ad17749d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NGYyYzA5MDBlNmFhNGRhMTkwZDIzMTcyMDc2MmRkODgvdGFibGVyYW5nZTo0ZjJjMDkwMGU2YWE0ZGExOTBkMjMxNzIwNzYyZGQ4OF8wLTItMS0xLTA_66d8c4fb-7ca4-4fb7-b2b0-4c5917f34429">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA4_fbf7203c-6397-4a76-a929-9725d6c9a3f4">660 W. GERMANTOWN PIKE, SUITE 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA5_2db64d1e-f163-40a2-a730-f580ded4d9dd">PLYMOUTH MEETING</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEw_32cdbf57-b27b-4f72-93f4-b67f699d751a">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE2_2ac7be9c-663b-418b-a11a-b967a0d95e24">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEx_23a5fea3-f419-4d98-8cc6-35ae41a096d2">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTE3_7de4135d-30b7-4b95-b784-061e0c340d69">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6YWVlNzg3MjBkMTVhNDdmYTk2ZDgyYzM3NWIwZTBiMzcvdGFibGVyYW5nZTphZWU3ODcyMGQxNWE0N2ZhOTZkODJjMzc1YjBlMGIzN18xLTAtMS0xLTA_724ff894-325a-4aac-923b-ae423447536d">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6YWVlNzg3MjBkMTVhNDdmYTk2ZDgyYzM3NWIwZTBiMzcvdGFibGVyYW5nZTphZWU3ODcyMGQxNWE0N2ZhOTZkODJjMzc1YjBlMGIzN18xLTEtMS0xLTA_4021fe4f-bdbc-4b17-a318-b8324cb9a22f">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6YWVlNzg3MjBkMTVhNDdmYTk2ZDgyYzM3NWIwZTBiMzcvdGFibGVyYW5nZTphZWU3ODcyMGQxNWE0N2ZhOTZkODJjMzc1YjBlMGIzN18xLTItMS0xLTA_a68ecf26-faa5-46b5-88fb-90ce916be2b1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTEy_75fdc898-41a6-4c5a-b41b-fa48accd588d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA2_02614417-cfd3-4cc9-8f97-50a28cee67b3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NTk3ZjI0YmI0NjZmNGZmZTg1ODM3NmVkNDkxMWQzZTAvdGFibGVyYW5nZTo1OTdmMjRiYjQ2NmY0ZmZlODU4Mzc2ZWQ0OTExZDNlMF8wLTAtMS0xLTA_ee23d0fe-7060-4404-9bbc-89f3b535ca17">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NTk3ZjI0YmI0NjZmNGZmZTg1ODM3NmVkNDkxMWQzZTAvdGFibGVyYW5nZTo1OTdmMjRiYjQ2NmY0ZmZlODU4Mzc2ZWQ0OTExZDNlMF8yLTQtMS0xLTA_e8e498df-c97c-470d-9fa3-92c948cf3863">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGFibGU6NTk3ZjI0YmI0NjZmNGZmZTg1ODM3NmVkNDkxMWQzZTAvdGFibGVyYW5nZTo1OTdmMjRiYjQ2NmY0ZmZlODU4Mzc2ZWQ0OTExZDNlMF80LTQtMS0xLTA_a6b8695f-493e-4cf8-8ec0-e1e8835ca3bb">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMTA3_3b9c04fd-8bd1-45a0-93c3-a6cb34cd8fef">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i83ed6177c4804f6aa764dfbd829ecaa8_I20210806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xL2ZyYWc6OTYxYmYwMTVhNTIzNGY3NWJkOTRhNjZhYTNmM2I5MzUvdGV4dHJlZ2lvbjo5NjFiZjAxNWE1MjM0Zjc1YmQ5NGE2NmFhM2YzYjkzNV8yMDky_e0d298ab-e9bf-4e5a-b636-4aa20fb00f96"
      unitRef="shares">210356896</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNC0xLTEtMS0w_739ade15-9953-46ec-a6e1-baf6722874eb"
      unitRef="usd">58925302</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNC0zLTEtMS0w_39cac9a8-6090-495d-80f3-6442003a80a5"
      unitRef="usd">250728118</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNS0xLTEtMS0w_f3cf9f3c-be2d-4ca7-bb60-402d3846b095"
      unitRef="usd">384752382</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNS0zLTEtMS0w_fa82d8df-5419-423c-9244-f84684722c54"
      unitRef="usd">160914935</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNi0xLTEtMS0w_5eb933b3-fcc3-4afd-b623-a00772fea51e"
      unitRef="usd">13128330</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNi0zLTEtMS0w_0cd99ff3-6cb8-4d67-be24-19fa395db4b1"
      unitRef="usd">18559967</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNy0xLTEtMS0w_a9077a44-599e-4afd-b6d1-83f9fbce222d"
      unitRef="usd">722941</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNy0zLTEtMS0w_665c2499-6f3d-40c3-b82d-71b4a1e2440a"
      unitRef="usd">503782</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOC0xLTEtMS0w_7994b227-4c36-4aed-9a6b-d1c33020e5a4"
      unitRef="usd">84592179</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOC0zLTEtMS0w_6d66c195-7302-4f6d-b55c-f305702ac91d"
      unitRef="usd">40357456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOS0xLTEtMS0w_a5e76e10-d176-43eb-97d5-7173457e0ad6"
      unitRef="usd">303491</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfOS0zLTEtMS0w_54cbbe83-454d-4323-a3b5-60c141d8f608"
      unitRef="usd">106432</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTEtMS0xLTEtMA_d5604903-4ef5-4ce6-a511-e956dfbfda93"
      unitRef="usd">542424625</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTEtMy0xLTEtMA_3f0578db-ae1a-4067-ba1e-3e3c5e1037aa"
      unitRef="usd">471170690</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTItMS0xLTEtMA_4d63c6be-f20f-42da-bdd5-2ad40c703172"
      unitRef="usd">18111288</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTItMy0xLTEtMA_4173ac08-b358-41ca-8f13-0ada177e1b88"
      unitRef="usd">11348144</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTMtMS0xLTEtMA_26f1f788-dfb3-4a19-830c-b9534ca08126"
      unitRef="usd">3908709</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTMtMy0xLTEtMA_f85a384c-c08a-49ac-80e3-6606b7f5fc18"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTQtMS0xLTEtMA_858db244-4a37-4521-ae91-f30b509caad0"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTQtMy0xLTEtMA_f24393c0-d047-4f29-874b-ffe7e48425cb"
      unitRef="usd">434387</us-gaap:EquityMethodInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTUtMS0xLTEtMA_5caffdf1-79b5-4f33-88d3-f9e5db281220"
      unitRef="usd">2879896</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTUtMy0xLTEtMA_0155ef40-0a6a-441c-8167-6647d2fa739b"
      unitRef="usd">3146770</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTYtMS0xLTEtMA_66c095d2-93b1-473a-9316-a0df1f30a143"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTYtMy0xLTEtMA_3f737805-2f91-4e78-8f69-9985f56909ec"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTctMS0xLTEtMA_9f0043c0-494c-47f6-a3cf-9bc0ec11ba1b"
      unitRef="usd">12173414</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTctMy0xLTEtMA_32debae0-ee9a-422b-9ac1-5139463e0896"
      unitRef="usd">12741296</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTgtMS0xLTEtMA_6f3ba18c-4d6f-46a1-8cff-24763ea1a8a2"
      unitRef="usd">1830866</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTgtMy0xLTEtMA_3802bbc1-8147-4bab-960d-016ed5e535b1"
      unitRef="usd">25957448</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTktMS0xLTEtMA_8f67a75b-dbd7-47ce-8a1d-8d65ed954d66"
      unitRef="usd">591842169</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMTktMy0xLTEtMA_b0c0c67d-0124-4f4f-974a-50f170819c0b"
      unitRef="usd">539772472</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjItMS0xLTEtMA_5ae47cf6-404b-43e4-83e7-a686d9b9bd7b"
      unitRef="usd">30095578</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjItMy0xLTEtMA_bf2ca63d-0446-4a29-871d-63b388f2efd7"
      unitRef="usd">21203808</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjMtMS0xLTEtMA_a09068bb-6cbc-4825-a37a-acfd14be1120"
      unitRef="usd">1773846</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjMtMy0xLTEtMA_e9698a3b-9bbf-45d8-afa4-892fece2eb47"
      unitRef="usd">642969</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjQtMS0xLTEtMA_e53bcbda-f2b5-411a-aa43-b5869cf8baba"
      unitRef="usd">10416164</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjQtMy0xLTEtMA_68cf4647-5fb3-42e4-be8b-d3f4740ef98b"
      unitRef="usd">9950345</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjYtMS0xLTEtMA_b132271f-bfec-4603-9c41-48a43bba9795"
      unitRef="usd">109128</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjYtMy0xLTEtMA_44a90d11-7789-4386-ae91-e27ce3a16ac3"
      unitRef="usd">46628</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjktMS0xLTEtMA_e7e3a8bd-b209-4fba-a6f6-3a050873d991"
      unitRef="usd">2463878</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMjktMy0xLTEtMA_eb5b3ff7-704c-4f12-aebf-a92f03b12384"
      unitRef="usd">2329394</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzAtMS0xLTEtMA_98cf5dfc-c2bc-4558-bc4e-253856e1ba4d"
      unitRef="usd">6859155</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzAtMy0xLTEtMA_137b56e0-b6ac-4be9-8250-986b495f0dc3"
      unitRef="usd">7474310</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzEtMS0xLTEtMA_171b9508-b62d-4efd-a9eb-69a6ceb2a987"
      unitRef="usd">31250</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzEtMy0xLTEtMA_04e00484-6738-4e1f-85c6-cea88c37f456"
      unitRef="usd">58500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzMtMS0xLTEtMA_c5f656db-8c53-439d-86ea-a8ea29b1bae0"
      unitRef="usd">51748999</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzMtMy0xLTEtMA_006c9d23-f0b8-46fa-b6e9-26a64b9b3b28"
      unitRef="usd">41705954</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzQtMS0xLTEtMA_a8ec0e01-606b-4292-960c-6512ce0f4bb0"
      unitRef="usd">71788</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzQtMy0xLTEtMA_d6f89ea1-29c6-424d-8882-472efa104194"
      unitRef="usd">79214</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzYtMS0xLTEtMA_3ddaf106-b069-4b00-bb5b-55bd392540d9"
      unitRef="usd">14536448</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i32b8bf36ec4d469591d90e39f3ec8e81_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzYtMy0xLTEtMA_55298f13-de44-4a8f-b47c-90076f9a1cef"
      unitRef="usd">14139988</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="id2ee9a992e9d4aecbed299eb5413def8_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzctMS0xLTEtMA_5541887b-0892-4abc-965e-5224e790f893"
      unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i06e1e9bb6dd649dfa52090802d4a0072_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfMzctMy0xLTEtMA_789aea76-3b9e-43fc-ae79-77fa208946ce"
      unitRef="usd">4515834</us-gaap:ConvertibleDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDAtMS0xLTEtMA_6700502b-203e-4910-8191-ed5f5d13e429"
      unitRef="usd">16797476</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDAtMy0xLTEtMA_c6767dbc-e3f1-4782-acfb-d56bc3a89239"
      unitRef="usd">18063515</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDEtMS0xLTEtMA_ba851d9c-f779-4189-bfbd-e677a114a90f"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDEtMy0xLTEtMA_16ebc96b-7731-4dc4-806c-83d307bbc327"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDItMS0xLTEtMA_9fcc0ea4-f2a0-4f7b-9e59-22f36c5deb4c"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDItMy0xLTEtMA_3fe16c63-b1d2-4d3b-a1ae-1e4bce68fedf"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDMtMS0xLTEtMA_334a2750-9345-46eb-967a-dbd19713b704"
      unitRef="usd">64141</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDMtMy0xLTEtMA_200626f9-08aa-4303-9df3-993e8c1700a6"
      unitRef="usd">57663</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDQtMS0xLTEtMA_f7e27ac9-3fb1-4361-8139-186d8a3c74ae"
      unitRef="usd">83288398</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDQtMy0xLTEtMA_b2c78578-59d1-4c17-9332-a768119448f7"
      unitRef="usd">78631714</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDYtMS0xLTEtMA_d9f14bb3-76cd-4e27-bb4b-3c1119f28935"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDYtMy0xLTEtMA_f9a77bb5-3392-40b4-8a28-e9f90dcb9161"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDctMS0xLTEtMA_023506bc-c1bd-4721-8f9a-4bb19c9a2a84"
      unitRef="usd">210146</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDctMy0xLTEtMA_25543f70-f5ba-458a-a5d8-d3a04976284e"
      unitRef="usd">186851</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDgtMS0xLTEtMA_b2e9396e-7350-4656-98d9-8906a3adb333"
      unitRef="usd">1551348435</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDgtMy0xLTEtMA_8a5bf5b8-e52d-43df-9e37-19808f1dac3c"
      unitRef="usd">1367406869</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDktMS0xLTEtMA_fb095f10-b74f-47cb-8783-f618e3bec085"
      unitRef="usd">-1042738901</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNDktMy0xLTEtMA_c11cb022-3d22-407e-bcf9-90c969e5757f"
      unitRef="usd">-906196812</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTAtMS0xLTEtMA_942ab5b5-dbb3-4a18-9684-359135c7b51a"
      unitRef="usd">-265909</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTAtMy0xLTEtMA_be0675ec-2f2f-4817-a0c1-284ed4cc3694"
      unitRef="usd">-256150</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTEtMS0xLTEtMA_d63d5b6d-9016-4a50-9495-24ef69970f65"
      unitRef="usd">508553771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTEtMy0xLTEtMA_8d412271-a8ea-4ee1-899f-773cf7767317"
      unitRef="usd">461140758</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTQtMS0xLTEtMA_ca2e8d16-3235-40b5-8a6c-bdf503a50272"
      unitRef="usd">591842169</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xNi9mcmFnOjYzYzU2NzFmYzQwYTRhN2JiOTUxN2Q2ZDZjZGUyYTU4L3RhYmxlOjVmZGYyZmJhNjQzYTRjYjc5OGNjYTFiZTljODM4YzVmL3RhYmxlcmFuZ2U6NWZkZjJmYmE2NDNhNGNiNzk4Y2NhMWJlOWM4MzhjNWZfNTQtMy0xLTEtMA_ef271da6-4938-4f9e-90f6-083243b9fed0"
      unitRef="usd">539772472</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ecf790ef87d429c90f4ebc744136636_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy0xLTEtMS0w_6189240d-553c-46a2-bc22-25b9b245f754"
      unitRef="usd">82923</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96d79f4dc5474687846e3b39dfca505c_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy0zLTEtMS0w_defe504a-a32b-4984-800e-50697613138f"
      unitRef="usd">74102</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4761e01b5c81478a816114b036289275_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy01LTEtMS0w_40503389-8c4a-4e04-963b-d6f961821eb5"
      unitRef="usd">122538</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bf3b64ae03f46cfbeb3fc8dc8a97ca8_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMy03LTEtMS0w_71d798ce-1a08-4695-aad5-4e2615e68c36"
      unitRef="usd">145602</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb0126e377d2444cbed98c98dca66844_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC0xLTEtMS0w_5fad1dc2-8287-48f8-b1c9-b1f668fdb6a9"
      unitRef="usd">74787</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id697003739b14dbabbe3d698b5c6670a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC0zLTEtMS0w_8c4abe77-6f61-443c-8dcc-9ca41c371862"
      unitRef="usd">95146</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeb6dd3bc70a471ab465c71da214cea2_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC01LTEtMS0w_035052ba-de77-416e-93e6-7e49974e83fd"
      unitRef="usd">124736</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51b398cfbf4a4650b18fe5d6ea487fb8_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNC03LTEtMS0w_2bf044df-9580-4d01-9458-437e1f6de508"
      unitRef="usd">1267272</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbfb78a03fb44fdfb83c5a956c89ea69_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS0xLTEtMS0w_c5c54da1-baa1-4ee6-b6f4-ce5358902636"
      unitRef="usd">115114</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i493fb6cfff2d460993ffab8a845aaa8d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS0zLTEtMS0w_ba838034-5482-4da0-93dc-8c5cad874e97"
      unitRef="usd">97939</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if232bf82d12541779d14e8a336ace449_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS01LTEtMS0w_959c6580-dfdf-43ef-b561-21c7c01fd558"
      unitRef="usd">396671</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibda3de1762204459935f37915d69c1b6_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfNS03LTEtMS0w_96d7b971-0c24-4bd5-87e8-0d6f69869813"
      unitRef="usd">181587</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC0xLTEtMS0w_1a89a032-3fff-4d64-8f7f-d8954f2edd50"
      unitRef="usd">272824</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC0zLTEtMS0w_238fa39e-95d8-4ac6-b893-fcd1dd018944"
      unitRef="usd">267187</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC01LTEtMS0w_757cd839-478a-4037-830f-479c1932f81e"
      unitRef="usd">643945</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfOC03LTEtMS0w_4ea2bb2e-1779-42ad-81df-07bd32cfc845"
      unitRef="usd">1594461</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtMS0xLTEtMA_7a63c17f-951d-4ff2-8f6a-9fca7829e3cb"
      unitRef="usd">70808418</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtMy0xLTEtMA_edd13d93-fcee-481e-9ca9-09ead0dbc29a"
      unitRef="usd">22376575</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtNS0xLTEtMA_4f5fce7f-fb30-48f3-a281-a744ad625654"
      unitRef="usd">109852836</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTAtNy0xLTEtMA_38e2fcc0-cd35-416a-be8a-eb2fac79ed60"
      unitRef="usd">41487763</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtMS0xLTEtMA_b9c16f5e-1bbd-4e97-b5d8-9a2868010161"
      unitRef="usd">12666341</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtMy0xLTEtMA_14533849-b208-4fdf-a8ab-b8f111918379"
      unitRef="usd">11071510</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtNS0xLTEtMA_b93ba9cf-69d0-4a59-9010-af4f72f3e0f5"
      unitRef="usd">26547535</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTEtNy0xLTEtMA_db3b4bf6-8558-4537-a49b-2f02696a8b20"
      unitRef="usd">18519864</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtMS0xLTEtMA_6eaee500-a375-41b3-ac0a-c29ca51104e2"
      unitRef="usd">83474759</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtMy0xLTEtMA_342c470d-0d19-474e-9d8d-a2d31ce02083"
      unitRef="usd">33448085</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtNS0xLTEtMA_31c553a6-f30f-43e4-97d7-e5ac7ba4c371"
      unitRef="usd">136400371</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTMtNy0xLTEtMA_e1758c4b-15a8-41bb-baf0-4d884c7cc965"
      unitRef="usd">60007627</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtMS0xLTEtMA_ae1d1190-09ab-4b79-984c-a53176253a1a"
      unitRef="usd">-83201935</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtMy0xLTEtMA_f5976086-e1c0-4de5-a852-ba73dee95710"
      unitRef="usd">-33180898</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtNS0xLTEtMA_b0422dcc-dbb0-4e2a-a2d4-f640629f9b92"
      unitRef="usd">-135756426</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTQtNy0xLTEtMA_27ad989c-8f32-435c-92ec-4cfac330c251"
      unitRef="usd">-58413166</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtMS0xLTEtMA_2901343f-5734-46ad-bf10-1c28e647b774"
      unitRef="usd">928111</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtMy0xLTEtMA_abb816c5-5ab6-4fcd-b587-78b04ae0cae2"
      unitRef="usd">1067399</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtNS0xLTEtMA_42cbed2e-afb5-4664-ad29-05ff42a66018"
      unitRef="usd">1697347</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTYtNy0xLTEtMA_b1c766a9-d035-4c72-8e6a-48fcc31f9770"
      unitRef="usd">1483968</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctMS0xLTEtMA_5629ae22-7823-4d51-946b-d0149c535dec"
      unitRef="usd">466726</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctMy0xLTEtMA_17257e68-cec0-4d50-9d48-e7d9226870be"
      unitRef="usd">2846641</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctNS0xLTEtMA_c9134a7c-2b38-4b5d-a9ec-77fb67f1e592"
      unitRef="usd">979760</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTctNy0xLTEtMA_7df67515-8245-4a0a-8389-9a9ecaaa34f3"
      unitRef="usd">5650396</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktMS0xLTEtMA_8ee15d70-25e8-4405-a89f-0f327796d9a0"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktMy0xLTEtMA_e3e928a3-ee7d-47f9-8850-caa7f2dfd07a"
      unitRef="usd">-97755000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktNS0xLTEtMA_c90bc00f-2825-4f6a-a598-bc73ca2a8a9a"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMTktNy0xLTEtMA_6323998e-4e68-42ad-ac9b-9b8253dc2f46"
      unitRef="usd">-110976977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtMS0xLTEtMA_2bfbbba6-8749-4168-9433-806ce0db6b30"
      unitRef="usd">278818</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtMy0xLTEtMA_22e93bda-f6dd-4760-ba99-caaf7ccccea4"
      unitRef="usd">-3883176</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtNS0xLTEtMA_c02001e1-6566-4655-a22c-4a14984f3e87"
      unitRef="usd">-551657</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjAtNy0xLTEtMA_15e05d90-0d4f-4adb-8650-fdfa96029a95"
      unitRef="usd">9298443</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtMS0xLTEtMA_db99196d-4404-48cf-817b-5f3cccc47b3c"
      unitRef="usd">136493</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtMy0xLTEtMA_16abd1b0-0118-4ad8-87be-75f64b36a586"
      unitRef="usd">4358634</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtNS0xLTEtMA_f7984269-e8e2-4efc-acdd-f1b6da3595fc"
      unitRef="usd">-711465</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjEtNy0xLTEtMA_eaa700ba-3b8a-46a8-9e96-44fb2402dfe8"
      unitRef="usd">-691458</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItMS0xLTEtMA_f91ccd75-daa1-4eb8-849e-d7e5e9a2c31c"
      unitRef="usd">185281</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItMy0xLTEtMA_f7055b4f-04d4-46ad-a9b4-c9cf2bbedeb6"
      unitRef="usd">-152102</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItNS0xLTEtMA_db560e10-caf0-4bbd-b145-eaa5f8ae50e3"
      unitRef="usd">194259</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjItNy0xLTEtMA_f8a01a0d-db12-45f3-a3d5-b9398ea84ad4"
      unitRef="usd">-577602</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtMS0xLTEtMA_d62c4d23-54a8-48c6-a37e-a891618e6934"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtMy0xLTEtMA_63f77d19-311f-4f55-b69f-d39cbfdf22d1"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtNS0xLTEtMA_4bb414be-06ac-4300-a0a6-87f7a0d18e6f"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjMtNy0xLTEtMA_8a74fad4-bd65-4140-85b4-215a59a23538"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctMS0xLTEtMA_df2980e7-122e-4f51-965f-1fc24e454944"
      unitRef="usd">-82139958</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctMy0xLTEtMA_de61e8b4-c363-4755-8ca4-dbdc895ad758"
      unitRef="usd">-128270709</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctNS0xLTEtMA_484ffaf8-5c22-44e5-9438-b97bf891159f"
      unitRef="usd">-136107702</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjctNy0xLTEtMA_cf0c00bf-f3bc-4b99-9ca5-23c73043916f"
      unitRef="usd">-161406113</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktMS0xLTEtMA_17525e78-7d6f-44a1-8254-36eb5c1ffaf0"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktMy0xLTEtMA_f69afdf8-74a3-40b5-ad46-921af8bf1c41"
      unitRef="usd">-901757</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktNS0xLTEtMA_995a7c92-51b5-4d44-bef0-237622024a9c"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMjktNy0xLTEtMA_086e5ac5-6f02-426d-b30d-32db05b9ab10"
      unitRef="usd">-901757</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtMS0xLTEtMA_232c12fe-242e-49a6-bc53-8611e38703e4"
      unitRef="usd">-82139958</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtMy0xLTEtMA_4f959147-5968-431c-8274-a8ba0b952516"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtNS0xLTEtMA_0ee59537-318c-4299-ac15-9b2c71bba07e"
      unitRef="usd">-136542089</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzAtNy0xLTEtMA_475581e3-5451-464e-bc14-3aed32884fcd"
      unitRef="usd">-162307870</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtMS0xLTEtMA_fe4d69a0-1d42-4f97-a15b-b135bb301011"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtMy0xLTEtMA_57ac0018-60e5-4c38-80d3-b84543020f70"
      unitRef="usd">-469407</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtNS0xLTEtMA_9f465252-2c7a-440d-bde2-fbb061a22ddd"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzEtNy0xLTEtMA_1ef5e119-a8fb-48c2-8a8d-157b3b931237"
      unitRef="usd">-1063757</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItMS0xLTEtMA_cd41d7de-cb97-4376-a3ce-4c048932f4b3"
      unitRef="usd">-82139958</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItMy0xLTEtMA_496224fa-0e02-448d-be58-8e614a1ccdff"
      unitRef="usd">-128703059</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItNS0xLTEtMA_6de12d0d-8693-4a3c-9004-2313864eb8ca"
      unitRef="usd">-136542089</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzItNy0xLTEtMA_862ae637-7fdd-42bd-a552-9991370baadd"
      unitRef="usd">-161244113</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMS0xLTEtMA_77a3f73e-fbd6-4334-85e4-cd667d5bb5a3"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMS0xLTEtMA_a5efaadd-db5f-4afe-b2a8-307b6e6c5f1f"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMy0xLTEtMA_6da92e00-fe90-4e50-8f36-0687cf5bab12"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtMy0xLTEtMA_c3af9eeb-49e4-4873-b2d6-a003963024bb"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNS0xLTEtMA_22949fe9-eeba-4bf4-aa63-3fcbafb46c27"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNS0xLTEtMA_bf9e1c2c-c285-4783-a05c-1ec3cb805c6c"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNy0xLTEtMA_173de90c-1f29-4cba-893f-a445a363ea77"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzQtNy0xLTEtMA_c5c95ae0-8f82-44a3-9c44-136079f4babf"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMS0xLTEtMA_6926f7c8-718c-4fa6-ac14-cc577c310a8e"
      unitRef="shares">209561064</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMS0xLTEtMA_a9bb2cdb-03cd-46c4-a4a7-154f3dbf6990"
      unitRef="shares">209561064</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMy0xLTEtMA_625882e8-57f8-4856-ba29-f35dbadfb006"
      unitRef="shares">155807054</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctMy0xLTEtMA_643e9d9e-eadd-4ce5-9f5f-741ac9730254"
      unitRef="shares">155807054</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNS0xLTEtMA_eeeeddb7-bbd2-4e09-abfc-18f65e1a7f8a"
      unitRef="shares">206007497</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNS0xLTEtMA_fe8371e3-975c-44a6-a599-f4fe8ed07167"
      unitRef="shares">206007497</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNy0xLTEtMA_8e6a0024-a56d-4525-ac4d-882ec0a2f26d"
      unitRef="shares">140215158</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8xOS9mcmFnOmZjMTMyZTQwMjM5ZjRkNjNhNzBhNTA0MDZhZDg1Y2YxL3RhYmxlOmNkNTQyMTVkMzIxZTRlNjk5OTliNjA0Yjc3MDI1ZTA5L3RhYmxlcmFuZ2U6Y2Q1NDIxNWQzMjFlNGU2OTk5OWI2MDRiNzcwMjVlMDlfMzctNy0xLTEtMA_a011ba71-f9e8-4fde-917d-3517b78fd9f0"
      unitRef="shares">140215158</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi0xLTEtMS0w_32644c79-dc26-4350-8957-4464a9a11b81"
      unitRef="usd">-82139958</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi0zLTEtMS0w_f3f910fd-c1b5-4a17-9a76-ecc0b95e08fb"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi01LTEtMS0w_44f4ab9d-f602-4e13-81de-278e57e4587f"
      unitRef="usd">-136542089</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMi03LTEtMS0w_73302694-a67b-4134-a326-631b805632aa"
      unitRef="usd">-162307870</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS0xLTEtMS0w_130cf7b6-51b9-4bc7-858e-2137ff4e4354"
      unitRef="usd">2478</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS0zLTEtMS0w_6cc04836-63da-4bf6-81a6-b78e35243673"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS01LTEtMS0w_04921324-2036-42f5-abc6-93f5a25683cc"
      unitRef="usd">-11941</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNS03LTEtMS0w_87f04d03-b6f5-4f8c-80a9-3d09bdc8a797"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi0xLTEtMS0w_65293462-ea13-4e27-9b0d-e60c44f61321"
      unitRef="usd">-2679</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi0zLTEtMS0w_2966902d-a103-47fb-83ee-151de94a2564"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi01LTEtMS0w_d78ad60c-b9a0-4109-9d3a-515ca3e60e50"
      unitRef="usd">2182</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfNi03LTEtMS0w_4632ea03-7557-4081-8809-cf753713ba9e"
      unitRef="usd">-1082638</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS0xLTEtMS0w_a28dadab-9a2d-4da6-ae49-8ec3f2918400"
      unitRef="usd">-82140159</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS0zLTEtMS0w_a643d1c2-4b9a-4bf5-b1b1-982f92281d26"
      unitRef="usd">-128325566</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS01LTEtMS0w_0420ab5a-2f5c-497d-a97d-65894933337e"
      unitRef="usd">-136551848</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfOS03LTEtMS0w_83a6e019-7d58-4749-91ab-8fd8604a6a88"
      unitRef="usd">-163390508</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtMS0xLTEtMA_c2fb362f-dc24-46c3-a2e1-3b69ede3a517"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtMy0xLTEtMA_a77b7193-9efb-4cec-a1c4-efae9c5364c8"
      unitRef="usd">-469407</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtNS0xLTEtMA_c020e626-794a-4626-b35e-b4c54137739b"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTAtNy0xLTEtMA_e92fec6d-9f9e-4c80-9746-9316be7e99c4"
      unitRef="usd">-1063757</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtMS0xLTEtMA_37218585-b3ca-494a-8db1-6a719d8aed9a"
      unitRef="usd">-82140159</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtMy0xLTEtMA_98c4ac6d-6f0c-45f0-82e0-c5e1dfc1241c"
      unitRef="usd">-127856159</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtNS0xLTEtMA_c42f354d-8dd5-4c83-b69c-22b107b3dff0"
      unitRef="usd">-136551848</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yMi9mcmFnOjUwYmY1OWYzYzViMDQ2NDhhZmNkYTI0ZDJlOTBjODFkL3RhYmxlOmFiMTQzYzA4ODJhNDQ4ZDliMGExYzA5OGQxYWJiMGQwL3RhYmxlcmFuZ2U6YWIxNDNjMDg4MmE0NDhkOWIwYTFjMDk4ZDFhYmIwZDBfMTEtNy0xLTEtMA_29e87e4f-3072-4023-b5fa-32e3f4d6ccb8"
      unitRef="usd">-162326751</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i12aac99aaaf741349f86a989fa764482_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xLTEtMS0w_f8ef5a73-e5bf-4697-a412-8e81febd9d36"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12aac99aaaf741349f86a989fa764482_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0zLTEtMS0w_29f6d84f-c7a8-461c-bb11-8d29cb320c45"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i799a2702ab5a4bd4a435e11c1046de46_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy01LTEtMS0w_02adf9ab-e9a7-4472-a525-77478ec5d69d"
      unitRef="shares">186851493</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i799a2702ab5a4bd4a435e11c1046de46_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy03LTEtMS0w_5b39612b-10a0-4648-936b-2bd7df308eb2"
      unitRef="usd">186851</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44709f40e8a943049398893f00a24be2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy05LTEtMS0w_7570aaa7-0c13-43f7-b2f9-538f39f0becc"
      unitRef="usd">1367406869</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85e84c6e219d4b4ab6f799165f3ff3f6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xMS0xLTEtMA_84a4c4ea-c547-41e9-9ed3-736c6a502636"
      unitRef="usd">-906196812</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5bb1d8705d24b5cb342ad0d76c412f9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xMy0xLTEtMA_b5af81f5-a84f-463c-b41f-08a1911dbc6d"
      unitRef="usd">-256150</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMy0xNy0xLTEtMA_f834c594-fc27-4b42-addf-331101148d2e"
      unitRef="usd">461140758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC0wLTEtMS0wL3RleHRyZWdpb246MWQ2MDk0ZGFjNTBmNDkzZWI1ZDA4YWU0OWYyYTUxNDlfNjU_e002f314-6ae6-402f-8ff2-7ac0f2ca2849"
      unitRef="usd">531000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC01LTEtMS0w_86cf3d1e-b23d-4f74-b591-8ebd77ec31f4"
      unitRef="shares">20355000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC03LTEtMS0w_d7812302-1f78-41dd-a24b-f5afc98df449"
      unitRef="usd">20355</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC05LTEtMS0w_1c1664d0-82d5-4569-a329-99e6d8208cc9"
      unitRef="usd">162084675</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNC0xNy0xLTEtMA_c3ae4974-a2dc-45a2-9165-40afd308c6f6"
      unitRef="usd">162105030</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS01LTEtMS0w_72374c60-819b-4fbc-a19d-dd0dd2dd9461"
      unitRef="shares">1009450</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS03LTEtMS0w_1eab4dde-a4f8-46b6-b921-31b238157852"
      unitRef="usd">1009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS05LTEtMS0w_5cb8236a-5efb-479f-8ebb-4fbd4099153b"
      unitRef="usd">4376883</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNS0xNy0xLTEtMA_3664dbd6-641b-4d5c-a45f-f37614824a7b"
      unitRef="usd">4377892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi01LTEtMS0w_cfcb1b4f-6b06-4662-bd6e-dd65f59ddc45"
      unitRef="shares">1118093</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2e031a20ef884c0fa02339cdb8423fc4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi03LTEtMS0w_062dd984-32d7-437e-b252-31e093df0f0f"
      unitRef="usd">1118</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi05LTEtMS0w_9b3576aa-d0e3-43eb-a02c-81ffa6c85e7d"
      unitRef="usd">-1202907</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNi0xNy0xLTEtMA_655aea9f-7624-4599-9829-179c7027219a"
      unitRef="usd">-1201789</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i293a954b904244158be4beb19eadc1eb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNy05LTEtMS0w_c60e4d05-753c-44f8-8bfd-bc4ae9a5bc3e"
      unitRef="usd">9595947</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfNy0xNy0xLTEtMA_7a29274b-302f-4b02-9291-32c76b7888b3"
      unitRef="usd">9595947</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="ib6be5b29e6e640aeb3b3c6f8c8b4b46a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOC0xMS0xLTEtMA_0acb83c4-34ae-41aa-b4c8-0f3abee4996a"
      unitRef="usd">-54402131</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOC0xNy0xLTEtMA_da191c2e-9871-4eca-9035-006f95dd49a3"
      unitRef="usd">-54402131</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia305805348c642e181a5a220764cd0cb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOS0xMy0xLTEtMA_3c4e636a-c558-448e-87fa-8a2d52f93991"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfOS0xNy0xLTEtMA_5b9ced1f-450a-456b-aefe-b527e23b3401"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia305805348c642e181a5a220764cd0cb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTAtMTMtMS0xLTA_d631841c-d5b1-434e-b8c1-ac75d1b2ddd1"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id506e21662664607abb5ada53bef4c71_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTAtMTctMS0xLTA_6050d94d-0811-4688-ad00-8cc5d684a44f"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ie410c23f3d734e22a654add21f7dd4be_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMS0xLTEtMA_d0acd26d-b349-4cab-a7d7-f7d5826833cb"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie410c23f3d734e22a654add21f7dd4be_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMy0xLTEtMA_c8489efd-e120-4c1b-a15b-be504d8542b3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ifd07f46a44cf47b29f251e9f8b53b448_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtNS0xLTEtMA_28b968eb-a010-452e-bff9-a86d91155bbe"
      unitRef="shares">209334036</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd07f46a44cf47b29f251e9f8b53b448_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtNy0xLTEtMA_89fb5034-0507-4e56-a391-01706c303925"
      unitRef="usd">209333</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb3c65da07554ec0a475b65aec785e3e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtOS0xLTEtMA_76cd07d0-9068-44d2-8855-e6c9cfac6752"
      unitRef="usd">1542261467</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd8b502204b444ec8fc08ad865e94b35_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMTEtMS0xLTA_1e8bd1dc-2a95-4b7b-800d-d1ef3d96c9a7"
      unitRef="usd">-960598943</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9fc53bfe459451e93c099b12e3d7d7d_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMTMtMS0xLTA_4778d6d7-1ccc-446f-a695-0314b7054f73"
      unitRef="usd">-265708</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib97826d72ea649e4b70791285961ac6c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTEtMTctMS0xLTA_f32c18f2-d8bd-465a-91f4-5b9109e944b7"
      unitRef="usd">581606149</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib69edae5e51e45c6a95fcd35749a9236_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtNS0xLTEtNDI_28a20c65-324e-4031-a586-092ad5e6ea96"
      unitRef="shares">812844</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib69edae5e51e45c6a95fcd35749a9236_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtNy0xLTEtNDI_c8537d6f-0930-4448-9e93-56fd8f915569"
      unitRef="usd">813</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id3da144150804a6fbb5a9f2eb556643e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtOS0xLTEtNDI_5e560803-8226-47dc-8e30-a1c40e039646"
      unitRef="usd">3440610</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTMtMTctMS0xLTQy_e2a2c474-12c9-4e07-acdd-ead077765d3e"
      unitRef="usd">3441423</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id3da144150804a6fbb5a9f2eb556643e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTQtOS0xLTEtNDI_42aea164-4283-46d3-962d-fe55c429a84b"
      unitRef="usd">5646358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTQtMTctMS0xLTQy_4db49f3a-9e4d-46a4-9fbb-8d929dd030d4"
      unitRef="usd">5646358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i108e0d957d844157b477393aead9cc52_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTUtMTEtMS0xLTQy_63644812-bb55-4c07-bb03-96eebf62c68b"
      unitRef="usd">-82139958</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTUtMTctMS0xLTQy_e3011708-00fc-4cf4-9978-a27b0d6b5dc4"
      unitRef="usd">-82139958</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia1439ad58b8a4b8d80f168ebe9e96082_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTYtMTMtMS0xLTQy_78253903-fbce-4f18-8b7e-21d4f884bcd9"
      unitRef="usd">-2679</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTYtMTctMS0xLTQy_8c27ba3c-5e56-4e61-9150-85c0baf5a6d7"
      unitRef="usd">-2679</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia1439ad58b8a4b8d80f168ebe9e96082_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTctMTMtMS0xLTQy_b3df5628-c46e-461e-aefa-5e91b12d7d33"
      unitRef="usd">2478</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTctMTctMS0xLTQy_e0eee643-8c9b-489b-8685-3778a9097334"
      unitRef="usd">2478</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i8fd181698642459c9825e12bed9aa37d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMS0xLTEtNjA_ba20d384-0e91-4614-a344-0e4a1e990db4"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fd181698642459c9825e12bed9aa37d_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMy0xLTEtNjA_a94e5bac-ac97-44ce-9470-de631ad186d4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="icb3abe12b5c3451b84594cfcc6853c43_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtNS0xLTEtNjA_2e56ce5e-737c-4e87-886f-d488db7ef63b"
      unitRef="shares">210146880</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb3abe12b5c3451b84594cfcc6853c43_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtNy0xLTEtNjA_684635b7-6de8-403a-ad97-8815048e256d"
      unitRef="usd">210146</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i254bd042051242849bc85dee66371184_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtOS0xLTEtNjA_7f2cc302-70cd-41f5-8607-0d7505cd4be0"
      unitRef="usd">1551348435</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42516c7d860c496fa39ae9ebb52897c6_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMTEtMS0xLTYw_475bb6ce-de9d-42de-938c-21492038f600"
      unitRef="usd">-1042738901</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ebf817b5d604254a7317c1108eb9e22_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMTMtMS0xLTYw_de3777a1-d0d4-4d6c-aacf-187f708011d2"
      unitRef="usd">-265909</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmNGQzNGU5MWFmZDQ4NDY4MTM0ZWM5ZmI1ZDg4MDI3L3RhYmxlcmFuZ2U6M2Y0ZDM0ZTkxYWZkNDg0NjgxMzRlYzlmYjVkODgwMjdfMTgtMTctMS0xLTYw_cd2c7c5b-3df7-489d-8494-e20c4a6eff82"
      unitRef="usd">508553771</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="if20cd84b26984f8f9e8f6f29f783d43c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMS0xLTEtMA_f944f81b-4824-4958-8400-d015218b7ecc"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if20cd84b26984f8f9e8f6f29f783d43c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMy0xLTEtMA_41db982f-b66e-4fe3-ab8b-a4dbea5b9cb9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ica81cf786c5d4fff8fd605675e3eac0a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtNS0xLTEtMA_fba9e008-37f7-4bbd-a6f5-2f1b27a7b127"
      unitRef="shares">101361034</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica81cf786c5d4fff8fd605675e3eac0a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtNy0xLTEtMA_6520d879-c038-4550-82bc-ea8d7637065a"
      unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79f44eaa8aa2459ca2f8c8563adf249b_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtOS0xLTEtMA_6bb8796f-dc27-4b7e-9ca8-408c5397fab6"
      unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2c97a020ced432dba7dfa7f21e090af_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTEtMS0xLTA_0774c207-4484-4fb4-b0df-524994426db7"
      unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7027e5aeb5e64cd7ad992e12c7a0fb56_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTMtMS0xLTA_7617e612-146f-4d07-b04e-9df201ca2a38"
      unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a7c265546d74b3c8712996af91049b6_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTUtMS0xLTA_4c5e5168-2700-47a7-ad8d-5931dc33ecb8"
      unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1879c69872f8418ab00a9d6a48983451_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzMtMTctMS0xLTA_47e5b70d-1d10-43cb-8a2d-19dadb1d7412"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtNS0xLTEtMA_11da7a0c-29a2-4838-ab5a-e8b9e8fedb7d"
      unitRef="shares">43148952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtNy0xLTEtMA_5374f53b-287b-4913-8c18-ec01b0e59197"
      unitRef="usd">43149</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtOS0xLTEtMA_59c36025-afbc-4144-a879-66fea2409dd6"
      unitRef="usd">208198784</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzQtMTctMS0xLTA_61e26667-2e11-471d-b7be-ac97e1d451e8"
      unitRef="usd">208241933</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtNS0xLTEtMA_bbfeb133-592e-4b7a-a70b-2df88fa05d3f"
      unitRef="shares">1405114</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtNy0xLTEtMA_e39877a9-0d74-4c04-aff4-e346805d8d84"
      unitRef="usd">1405</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtOS0xLTEtMA_2e7d2c83-8f98-4b7d-abaa-ee8ae8284f72"
      unitRef="usd">3099298</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzUtMTctMS0xLTA_b90f9f4b-50bb-4066-b7d3-e33171ed6ab3"
      unitRef="usd">3100703</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8ea5046cfab54c6896a2bef89c2beac0_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzYtOS0xLTEtMA_fe715955-dc0e-45cb-b297-b6f7e898ca5a"
      unitRef="usd">4017761</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzYtMTUtMS0xLTA_b3f29857-010d-43f1-aa52-8c0ee8a3e8a8"
      unitRef="usd">-16208</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzYtMTctMS0xLTA_bde235d0-71cf-4fcf-9bed-658db7842926"
      unitRef="usd">4001553</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzctMTUtMS0xLTA_a1fbc84c-2e59-40ef-a937-f0ff53f764cc"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzctMTctMS0xLTA_0c8a43da-669f-4d97-9592-6f7c0d930145"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="ie8eecef92b9240d5bfdf9e6810786a6e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzgtMTEtMS0xLTA_0cb7acfc-5174-407f-a9c5-92fcc6073fef"
      unitRef="usd">-32541054</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i71d0db922fe44f74a3a8cb1b109d5dcf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzgtMTUtMS0xLTA_dd3f702e-9d6c-4bf3-802a-93dd473ffbd2"
      unitRef="usd">-594350</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzgtMTctMS0xLTA_fe8c015e-04eb-42c5-9590-f695080dfb2c"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7ff215ce28014289ac0323b81097347d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzktMTMtMS0xLTA_9a081950-0180-4fd0-8092-d28bc0431e55"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0493a38b630a49bc902812a2465a3617_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfMzktMTctMS0xLTA_d58a7d7f-ff1e-41d0-901b-447227154fe3"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i005c775b4401470a90ee91adfbb417b8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMS0xLTEtMA_d93dacb3-804f-45d1-9a53-2b7f38cf1e4c"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i005c775b4401470a90ee91adfbb417b8_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMy0xLTEtMA_ae88d82b-17fb-4090-9ddf-9a18512fae0f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ic1a0656da9344a8a8b854e2ca77a6732_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtNS0xLTEtMA_6f54c6a4-78fd-466d-a26c-461c01d0a2d1"
      unitRef="shares">145915100</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1a0656da9344a8a8b854e2ca77a6732_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtNy0xLTEtMA_9a84fdbd-cf36-4d99-97e1-26df2b2220b6"
      unitRef="usd">145915</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa58a8fc43214b7bbd63cc831b027ff0_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtOS0xLTEtMA_e6836fac-01ec-4f82-89c7-d607730ea43c"
      unitRef="usd">957962628</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ee8db81f57e4c278a66fdfcba5073cc_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTEtMS0xLTA_74185c72-488a-4864-a989-5a420fa1ebbf"
      unitRef="usd">-772326709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4fb0140f8414f75b8e619c79cf2a649_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTMtMS0xLTA_69f6890f-8487-4079-8043-e894cb891a89"
      unitRef="usd">-1456930</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0caffc4cfd24e629b7a9fa306e19b99_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTUtMS0xLTA_7288ec6d-ec33-45d8-9b90-281d19d5e300"
      unitRef="usd">3529199</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iddb00ed027cf4a6bb677b4122123ec1a_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDAtMTctMS0xLTA_dc757703-30f3-4e62-a599-0608ecc96f97"
      unitRef="usd">187854103</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtNS0xLTEtMA_dd819dd7-bdf8-42de-98e5-1d262fc7e1d2"
      unitRef="shares">12041178</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtNy0xLTEtMA_21552ab2-e30e-4b83-8f9e-72c63deea162"
      unitRef="usd">12041</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtOS0xLTEtMA_719edc34-23cc-42e1-8866-3a61c1b713ee"
      unitRef="usd">121706881</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDEtMTctMS0xLTA_9c338b38-07d9-4f76-8a7e-d29db595ba58"
      unitRef="usd">121718922</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ibfc901c89fb3492ea30e005f1f9c9e8b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItMS0xLTEtMA_e7d6a38b-2624-4082-a87f-fbeb8b6ea063"
      unitRef="shares">14</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItNS0xLTEtMA_2725b7d8-4453-482e-adad-515eb3433298"
      unitRef="shares">5147</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItNy0xLTEtMA_bbb12a9d-cc49-4451-94a8-9ca481c38d57"
      unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItOS0xLTEtMA_c5839a75-42ec-422a-a06c-4794d3fd9c7e"
      unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDItMTctMS0xLTA_fabe4158-3e9a-4bb6-8019-2126b024eae7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtNS0xLTEtMA_64dd57d2-ee96-4d94-83b9-f3d20b9cf8fb"
      unitRef="shares">794986</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i77040bbbee7543658175d6d8b9278c15_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtNy0xLTEtMA_e49bba61-483a-4690-82cc-534e36a7c1f8"
      unitRef="usd">795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtOS0xLTEtMA_5747fb49-8373-4019-af65-3ca0816d9398"
      unitRef="usd">4421449</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDMtMTctMS0xLTA_e2906e38-05cb-4c07-bb5b-822d79b1f052"
      unitRef="usd">4422244</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9ad647e5d5f04f4786720465ce518b65_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDQtOS0xLTEtMA_aef5b2d6-5573-41f5-a869-917071e48f24"
      unitRef="usd">3654289</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDQtMTUtMS0xLTA_ae423cd3-05d4-445c-82c2-70769a03abbe"
      unitRef="usd">8146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDQtMTctMS0xLTA_198406db-4a1c-43ef-a896-5a4256a23c08"
      unitRef="usd">3662435</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDUtMTUtMS0xLTA_0a854081-2ee5-4f68-b0b7-a3c0ee8dbad0"
      unitRef="usd">209971</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDUtMTctMS0xLTA_261fcc96-28ae-4959-a8df-3c61014700e4"
      unitRef="usd">209971</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDYtMTUtMS0xLTA_fbb47562-9bd7-455c-bf4b-c4d62270bb92"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDYtMTctMS0xLTA_a62529a1-d0fb-45e5-98a8-eb1eadfe1833"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="icabb95078cd04d3b859cdd387e239ad7_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDctMTEtMS0xLTA_7b3bd959-e493-45d5-83f8-8f21de98379a"
      unitRef="usd">-128703059</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5fd16f9b31184569926f2dbda4900c8a_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDctMTUtMS0xLTA_202a8aca-2239-46e7-a482-ef7b2daaf18d"
      unitRef="usd">-469407</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDctMTctMS0xLTA_54b4cfb0-9cf4-4332-ba61-033a5284dba5"
      unitRef="usd">-129172466</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i886aa86a8ef3444899784ec9f609e6e7_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDgtMTMtMS0xLTA_25c6e951-223d-41fe-9665-63248d0766c3"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDgtMTctMS0xLTA_ddd18b04-246d-4d1d-ae44-ae72a0e86897"
      unitRef="usd">846900</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="id0963ef6fa894e47b9e2458dad5bd538_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMS0xLTEtMA_0233d166-1108-4424-8866-a0a951e3ff2c"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0963ef6fa894e47b9e2458dad5bd538_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMy0xLTEtMA_1e56e713-c1b2-4374-8886-8ca76327cc4f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="idbfee2e1b2af4f098563291bfb7a6e6d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktNS0xLTEtMA_bbd811ce-b047-46d5-8871-56bc54d4da65"
      unitRef="shares">158756411</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbfee2e1b2af4f098563291bfb7a6e6d_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktNy0xLTEtMA_de652c75-9309-44fe-a0f4-445ec89c52a6"
      unitRef="usd">158756</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4152dc4545d04bab8fe2acc7fb1b3424_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktOS0xLTEtMA_695a124a-2180-4997-b765-2306073e1b37"
      unitRef="usd">1087745242</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1eb417f6f754a2ea880089bb2a38945_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTEtMS0xLTA_f9993ef5-c5c9-4f3c-8f09-0c6fc70281f3"
      unitRef="usd">-901029768</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id92715916320442a9ca37398433d7c01_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTMtMS0xLTA_ca7c3982-94e3-4d5c-a124-2f6a3ea850fb"
      unitRef="usd">-610030</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5677a5c642824f42ad93623935b5b5bf_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTUtMS0xLTA_fb39c22d-f127-4a4f-ac3b-9d5cd2f6cd71"
      unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6030a2333ec842288f8ea1f6eea367a2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yNS9mcmFnOmRlZGYxYzVjNDNkNzQ3ZGE5ZmE5ZTcyOTUyYmI1NTMwL3RhYmxlOjNmZDg4YjU2MzZlNTRkOTFhZmQ5OWI3Zjg3NDAwZjFhL3RhYmxlcmFuZ2U6M2ZkODhiNTYzNmU1NGQ5MWFmZDk5YjdmODc0MDBmMWFfNDktMTctMS0xLTA_986cc988-053d-4291-bf31-0b3990a12119"
      unitRef="usd">186360469</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMy0xLTEtMS0w_2530b86f-ebfe-4389-91c1-1cbda2442225"
      unitRef="usd">-136542089</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMy0zLTEtMS0w_e900904a-5cb7-48d9-95b2-ac4fafb0b604"
      unitRef="usd">-162307870</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNS0xLTEtMS0w_4d2ad9d4-b6b3-428c-b422-46bfffa7e54b"
      unitRef="usd">1361595</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNS0zLTEtMS0w_b4e57f8a-f628-4e44-a560-eb59f20fd2dc"
      unitRef="usd">1608060</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNi0xLTEtMS0w_e566ab15-9767-4375-9e76-273900177140"
      unitRef="usd">266874</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNi0zLTEtMS0w_5c132b92-5a99-4aa0-a2f0-43161584b9b4"
      unitRef="usd">273540</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOC0xLTEtMS0w_0b75be13-8811-4660-acb9-ffb5e009eb8d"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOC0zLTEtMS0w_9e0442e8-c2aa-4549-a38c-1dc7c2d87cc7"
      unitRef="usd">110976977</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOS0xLTEtMS0w_17d83ae7-2fd8-4e53-9455-3d383517af25"
      unitRef="usd">15242305</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfOS0zLTEtMS0w_f5468521-924b-459d-bc22-3e7f04880f00"
      unitRef="usd">7663988</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTItMS0xLTEtMA_41e092a4-bbef-4099-8c00-dba548a7f8ae"
      unitRef="usd">-435445</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTItMy0xLTEtMA_144599ba-0b36-46ab-8d02-c6e7602fdef1"
      unitRef="usd">-3013942</ino:NonCashInterestIncomeExpense>
    <us-gaap:GainLossOnInvestments
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTQtMS0xLTEtMA_84e2fc1b-a09a-4688-9503-f77ee4c09e8c"
      unitRef="usd">153252</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTQtMy0xLTEtMA_157128ae-80d7-4c8d-b050-0ded0752209c"
      unitRef="usd">-576001</us-gaap:GainLossOnInvestments>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTYtMS0xLTEtMA_a403e5c8-3a46-405b-9d75-694e5fc62a7a"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTYtMy0xLTEtMA_05aaa537-f348-4f86-a691-44f368f63aff"
      unitRef="usd">1713770</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTctMS0xLTEtMA_1f07a7f0-ebba-4c15-bae4-28c5e5f0f331"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTctMy0xLTEtMA_fd8f61bb-9eb1-435c-9b1c-92f5c694b750"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTgtMS0xLTEtMA_b002f112-67e3-46ce-bb8c-d6e2b50211bf"
      unitRef="usd">-551657</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTgtMy0xLTEtMA_ddf9fc1f-3bc4-44ef-ae13-8611745c4fed"
      unitRef="usd">9298443</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTktMS0xLTEtMA_47300142-e9ac-49f7-ac0c-720cc17c95d9"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMTktMy0xLTEtMA_4037282c-a164-4271-a149-64b314e66dc7"
      unitRef="usd">-901757</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjItMS0xLTEtMA_34eaf906-4755-4aa4-bebb-71909bd63d76"
      unitRef="usd">711465</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjItMy0xLTEtMA_e7a6f707-0b0f-456f-a844-623775687181"
      unitRef="usd">691458</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjMtMS0xLTEtMA_05a77eaa-fdf9-4d00-bf68-069a34217496"
      unitRef="usd">567882</ino:OperatingLeaseNonCashLeaseExpense>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjMtMy0xLTEtMA_8a0fbab7-7b55-45f3-91ee-e501d7a1c41f"
      unitRef="usd">517865</ino:OperatingLeaseNonCashLeaseExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjYtMS0xLTEtMA_f359fcc5-fd57-4674-9834-fd9c22dc4a49"
      unitRef="usd">176927</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjYtMy0xLTEtMA_b7f8eb79-f332-458d-ad78-643702da4b95"
      unitRef="usd">474071</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjgtMS0xLTEtMA_9474c4ee-b1f8-4083-ac0f-b8feb449cf68"
      unitRef="usd">-5431637</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjgtMy0xLTEtMA_c4383805-be05-4bb5-9e3e-266ccd457c80"
      unitRef="usd">2813086</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjktMS0xLTEtMA_29322e02-3917-4f7c-a749-60f376a69c14"
      unitRef="usd">219159</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMjktMy0xLTEtMA_ac147e1b-e34e-47d0-9ef4-7ff87c75cc0c"
      unitRef="usd">-865832</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzAtMS0xLTEtMA_141b69a6-f117-48b5-81cb-59c9abaa709f"
      unitRef="usd">51944060</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzAtMy0xLTEtMA_0cc7828e-db1b-472e-aa96-387c29a3695c"
      unitRef="usd">3084082</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzEtMS0xLTEtMA_bef7d456-a96b-4f64-9d90-8cbd5219da09"
      unitRef="usd">197059</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzEtMy0xLTEtMA_060067fc-9368-4b3f-baed-882e8c7b9198"
      unitRef="usd">1330601</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzMtMS0xLTEtMA_98f8a6d1-4514-4a21-a083-41a75ea530b3"
      unitRef="usd">-24126582</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzMtMy0xLTEtMA_b1f6c323-726a-4290-a56a-14d4c6931449"
      unitRef="usd">-116242</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzQtMS0xLTEtMA_e8d1a817-fee6-450e-a823-826fedb2b3bf"
      unitRef="usd">8891770</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzQtMy0xLTEtMA_a6965a1f-4561-47a8-9a97-d3ba18579267"
      unitRef="usd">-732774</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzUtMS0xLTEtMA_a8849c4d-af5a-4c17-b8d9-ab71af4277be"
      unitRef="usd">465819</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzUtMy0xLTEtMA_38fae5f9-8287-4e42-982a-01d8fada12f0"
      unitRef="usd">2882486</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzYtMS0xLTEtMA_cae0798a-19e1-477a-ab0e-57113cd4e4b3"
      unitRef="usd">1130877</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzYtMy0xLTEtMA_4190c41b-4bdc-484e-a1f8-68a994c452b3"
      unitRef="usd">4634</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzctMS0xLTEtMA_3c3d107b-c35c-4b05-a061-b7e949ed2a1b"
      unitRef="usd">55074</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzctMy0xLTEtMA_320a95b6-1b50-451b-a45c-c2b5214a6b21"
      unitRef="usd">-92426</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzgtMS0xLTEtMA_ac31812a-0381-4650-9c44-15677f2bdcd3"
      unitRef="usd">-6250</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfMzgtMy0xLTEtMA_12144346-229f-4aed-be77-a96aa6dca628"
      unitRef="usd">62500</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDAtMS0xLTEtMA_51a68a40-5507-4c8d-992a-373f5629c57d"
      unitRef="usd">-1131555</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDAtMy0xLTEtMA_c0b0e494-9867-4cf5-9a67-4d8846789668"
      unitRef="usd">-1022951</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDEtMS0xLTEtMA_9ced9efc-63d3-4bea-a3f5-15da03638011"
      unitRef="usd">-615155</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDEtMy0xLTEtMA_3504737f-f96e-43ec-bdbb-c7160d069704"
      unitRef="usd">4265023</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDItMS0xLTEtMA_ffbcf316-8274-45e7-8b73-fe2c3ab3aaf3"
      unitRef="usd">-21000</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDItMy0xLTEtMA_b6a754ab-c6cc-4549-b37b-2124806df63f"
      unitRef="usd">-63050</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDQtMS0xLTEtMA_37b0fe6e-f888-4317-a3c2-f0838baa48d8"
      unitRef="usd">6478</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDQtMy0xLTEtMA_a87228c1-0005-4514-8961-73910ff50745"
      unitRef="usd">29686</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDUtMS0xLTEtMA_001b92b4-5739-4f17-a12a-770b7fd88077"
      unitRef="usd">-131326659</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDUtMy0xLTEtMA_c88c3132-980d-45af-9361-02beb23a2868"
      unitRef="usd">-52604208</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDctMS0xLTEtMA_54c5c4e3-fddb-457a-9f0d-99efe2701868"
      unitRef="usd">307857113</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDctMy0xLTEtMA_923113b5-918f-40fb-aef1-d78f7c512c07"
      unitRef="usd">138698249</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDgtMS0xLTEtMA_6619282d-8de6-4e29-b341-4b13852efd63"
      unitRef="usd">83466967</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDgtMy0xLTEtMA_b95d9919-df84-4da6-9d66-19d68c6c3b98"
      unitRef="usd">47455067</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDktMS0xLTEtMA_bf82032d-7d75-49e7-a4ab-a53999a1f2c1"
      unitRef="usd">418734</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNDktMy0xLTEtMA_e0b375f3-83dc-4fd8-93cc-de6917617112"
      unitRef="usd">176534</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTQtMS0xLTEtMA_6588a940-075b-496f-b813-3c76e9c38c4d"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTQtMy0xLTEtMA_9fb785bf-a498-4334-be76-81166561390c"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTUtMS0xLTEtMA_8876393e-d74a-4a84-9686-597ae524fd21"
      unitRef="usd">-224808880</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTUtMy0xLTEtMA_9a704fd9-de52-4bb1-b060-655a68da07e6"
      unitRef="usd">-94194567</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTktMS0xLTEtMA_e564535f-ce20-499e-8fde-6c8d7a58d960"
      unitRef="usd">162105030</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNTktMy0xLTEtMA_6707d2cc-9b06-42da-beca-2075d7742442"
      unitRef="usd">329960855</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjAtMS0xLTEtMA_a3d3fdcf-8d0d-4d62-ae69-87bf71beb8fc"
      unitRef="usd">6154794</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjAtMy0xLTEtMA_ac516b4a-5f09-4712-baac-ebaa99ea851f"
      unitRef="usd">9599514</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjEtMS0xLTEtMA_6d7cbf2c-7fd8-478b-9579-fb47e819b990"
      unitRef="usd">3915160</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjEtMy0xLTEtMA_142ab2ac-fc79-49d7-b670-e50ba5a3d289"
      unitRef="usd">2076567</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjItMS0xLTEtMA_fbe057e5-193e-451b-b7e9-43ddecc21132"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjItMy0xLTEtMA_36cc8309-108b-41f1-8e01-a91d4596fd68"
      unitRef="usd">2379969</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjMtMS0xLTEtMA_10a2617b-1bf1-49d9-a11b-98da25b9350e"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjMtMy0xLTEtMA_46de8424-fe82-4926-a480-ae3215faca52"
      unitRef="usd">171620</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjQtMS0xLTEtMA_02bf7a61-7c39-4f82-9486-3e9ae4068080"
      unitRef="usd">164344664</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjQtMy0xLTEtMA_b3968129-9bfd-475d-925b-67cc8cfdea94"
      unitRef="usd">340035391</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjUtMS0xLTEtMA_517eaa27-3775-4ca9-bf0f-7a2e3dce537b"
      unitRef="usd">-11941</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjUtMy0xLTEtMA_91e0318f-d600-430d-beae-69d6d3219dbf"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjYtMS0xLTEtMA_caf1cad0-cd1f-4f9d-8b33-14e12317fccf"
      unitRef="usd">-191802816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjYtMy0xLTEtMA_c3c6d69d-2067-4e14-ab6e-1c716f1c0380"
      unitRef="usd">193236616</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjctMS0xLTEtMA_7c9f748f-a529-44c9-acea-deb46dc87982"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1879c69872f8418ab00a9d6a48983451_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjctMy0xLTEtMA_2d014439-f241-4ff0-b1d5-a167f7ee3dbe"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjgtMS0xLTEtMA_a55b3725-b3c2-4d06-9072-3e08594de3f8"
      unitRef="usd">58925302</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6030a2333ec842288f8ea1f6eea367a2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNjgtMy0xLTEtMA_3c3373df-6eac-498e-903e-428f446b07cd"
      unitRef="usd">215432713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzEtMS0xLTEtMA_6b2e894f-5edc-4f07-97e3-adf1156bcb80"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzEtMy0xLTEtMA_0ad8f1e6-7b91-4e9d-8667-26e3a905f686"
      unitRef="usd">1620</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzItMS0xLTEtMA_c23f00aa-4b27-4063-afef-c5cd84f4a8fd"
      unitRef="usd">544315</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8yOC9mcmFnOjViOTFiMGNmMTU0ZDQ3YmNhZjFhMzNmMjVmMDc0ODYwL3RhYmxlOjdhZWNmMGI5YTA4YjQyODJhNjNiZGM2NzFmNDM5OWNlL3RhYmxlcmFuZ2U6N2FlY2YwYjlhMDhiNDI4MmE2M2JkYzY3MWY0Mzk5Y2VfNzItMy0xLTEtMA_6ee1aea5-9317-4e8e-aa3c-4b3464135a0b"
      unitRef="usd">2636454</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNC9mcmFnOjVmYjM1ZGM4YTVkNDRhYmVhZjk4MDFkZmMzODM0YTRmL3RleHRyZWdpb246NWZiMzVkYzhhNWQ0NGFiZWFmOTgwMWRmYzM4MzRhNGZfMzUwOQ_72a72b86-98c0-4c99-a5f2-ed42081e60d8">Organization and Operations&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's novel DNA medicine candidates are made using its proprietary SynCon&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#x2019;s immune system recognize and destroy cancerous or virally infected cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's patented CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Human clinical trial data to date have shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart device in more than 7,000 administrations across more than 3,000 patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's partners and collaborators include ApolloBio Corporation.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; AstraZeneca, Beijing Advaccine, The Bill &amp;amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#x2019;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for COVID-19; Middle East Respiratory Syndrome, or MERS; Lassa fever; HIV; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNzQ0Mw_ca409aa4-25ae-4a7b-8e2f-b69b98d0a221">Basis of Presentation, Liquidity and Risks and Uncertainties&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2021 and 2020 and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and six months ended June 30, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s. As of June&#160;30, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority-owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $82.1 million and $136.5 million for the three and six months ended June 30, 2021, respectively. The Company had working capital of $490.7 million and an accumulated deficit of $1.0 billion as of June&#160;30, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $443.7 million as of June&#160;30, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the &lt;/span&gt;&lt;/div&gt;effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNzQ0Nw_46d21628-8ce4-4ce7-996f-01a579726d41">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2021 and 2020 and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and six months ended June 30, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s. As of June&#160;30, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority-owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $82.1 million and $136.5 million for the three and six months ended June 30, 2021, respectively. The Company had working capital of $490.7 million and an accumulated deficit of $1.0 billion as of June&#160;30, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $443.7 million as of June&#160;30, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the &lt;/span&gt;&lt;/div&gt;effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMjk1Ng_249a995d-0101-4d0d-8317-6be379c0b809"
      unitRef="usd">-82100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMjE5OTAyMzI2MzAzNA_65258f44-d316-4487-a295-0b632f8c25cc"
      unitRef="usd">-136500000</us-gaap:NetIncomeLoss>
    <us-gaap:Capital
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMzAwNg_612f7ea3-b77f-4fc9-ab91-c22fb4328a52"
      unitRef="usd">490700000</us-gaap:Capital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMzA0MA_49cb3c24-3f83-430c-8d31-9f9717b88ff4"
      unitRef="usd">-1000000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfMzM4Nw_99a7c669-a60d-45b5-ad25-16e3808be8f8"
      unitRef="usd">443700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0ae8485bffe44645bcc2d2d69167e061_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNDAyMw_8bb6c204-b9b0-4490-8f4e-8b5593bf05ad"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6b7911f846a04e46825317fba23a0d2e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV8zNy9mcmFnOjM4NTA0YTUyZTM0NzRkZWM5NGExMGZkNjIzOGU0ODQyL3RleHRyZWdpb246Mzg1MDRhNTJlMzQ3NGRlYzk0YTEwZmQ2MjM4ZTQ4NDJfNDA5NQ_ad1807ea-0805-4688-a87e-8f546dbf85fc"
      unitRef="usd">454500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0Mzc_109fb3a1-7860-4b5c-bbcd-bcae89494e98">Critical Accounting Policies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1Mg_7c2a02d6-d7ff-4cb3-9069-106f0e2331f1"&gt;two&lt;/span&gt; to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.9 million and $3.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations. See Note&#160;8 for further discussion of the Company&#x2019;s goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to estimate fair value using the net asset value per share (or its &lt;/span&gt;&lt;/div&gt;equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDc_f4583133-0180-4cfa-b1af-d7ebf73bfd8d">Collaboration Agreements &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt; (&#x201c;Topic 606&#x201d;).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NTE_3ac3bfa7-e3fa-4766-a194-49892469c46c">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ino:GrantPolicyPolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0Mjg_6af3b9df-05bb-48f1-8caf-0433c6d5ce1f">Grants&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.</ino:GrantPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDg_a6568855-6e51-4544-af5b-b427ad4c566d">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0MzA_26f35ab7-aeae-447d-ad56-70c75a2cf578">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0MzE_986490b9-ea58-4aec-8608-7788ee3e72d9">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1Mg_7c2a02d6-d7ff-4cb3-9069-106f0e2331f1"&gt;two&lt;/span&gt; to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.9 million and $3.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.&lt;/span&gt;&lt;/div&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic6c3eb7929d54a7db36dd6d7dbc2b7dd_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1OA_658068bc-f2b2-497a-91fc-5945e4b48643">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTA0MzI_afc7a56a-f17d-44f1-836c-ffeee42d8816"
      unitRef="usd">2900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTA0NDA_f2568e49-aa82-4858-bfbf-e365c3be91eb"
      unitRef="usd">3100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDY_a1fd3202-3456-403d-ad17-1432532185d7">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDk_c1881e2a-6dc2-473f-8edb-30b9f53355c3">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfMTY0NDE_ca468ae0-5ae9-4f42-87a6-18382f33d634">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to estimate fair value using the net asset value per share (or its &lt;/span&gt;&lt;/div&gt;equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80My9mcmFnOmU0N2QzM2FiY2E4NjQ4Y2M5ZDJhYTY4NDkyZWVjZGFmL3RleHRyZWdpb246ZTQ3ZDMzYWJjYTg2NDhjYzlkMmFhNjg0OTJlZWNkYWZfMTEzNQ_58ed8bf9-15cb-4026-b86e-8f899f2e9b40">Impact of Recently Issued Accounting Standards &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80My9mcmFnOmU0N2QzM2FiY2E4NjQ4Y2M5ZDJhYTY4NDkyZWVjZGFmL3RleHRyZWdpb246ZTQ3ZDMzYWJjYTg2NDhjYzlkMmFhNjg0OTJlZWNkYWZfMTE0NA_5d03c529-4c5d-4807-b23a-c2e826c55c52">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfNDE1_30367cbc-82d8-41d4-927e-be67494e8226">Revenue Recognition  During the three and six months ended June 30, 2021, the Company recognized total revenue under collaborative research and development arrangements of $75,000 and $125,000, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $198,000 and $519,000, respectively, from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three and six months ended June 30, 2021, $35,000 and $39,000, respectively, were in deferred revenue as of December 31, 2020.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58f2d9f6575543589f663ac5ade5d146_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMTUx_f1b62da8-231b-4adc-985f-9a5c96492744"
      unitRef="usd">75000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice4430b09f8f4a3d9c5b6e2ef7fa048f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjE5OTAyMzI1NjA2MA_7c0a06b2-8f5a-4311-a717-33116539ae94"
      unitRef="usd">125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cf6343817df4d51b56069690f181906_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjIz_c348a26c-693c-49cd-9a29-c12c896d554e"
      unitRef="usd">198000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8419a4c84d46487aa9709be5474b797c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjE5OTAyMzI1NjAzMg_2dd9d695-db9d-4990-99c3-cd3ee4244372"
      unitRef="usd">519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMzU4_deac66a7-dbb5-40af-9ece-d3c5dc941bf9"
      unitRef="usd">35000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80Ni9mcmFnOjBlODU5ZDcwZjU1OTQ5ZjA4YmVkNmYxZWZmNjdjOTY1L3RleHRyZWdpb246MGU4NTlkNzBmNTU5NDlmMDhiZWQ2ZjFlZmY2N2M5NjVfMjE5OTAyMzI1NjAyMA_d181b928-7503-47b0-bb28-7a2949a2f0bb"
      unitRef="usd">39000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMzA0Nw_2c9016df-4f3c-46c4-94b9-a61f711042e1">Short-term Investments&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Short-term investments at June&#160;30, 2021 consisted of mutual funds, U.S. treasury securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three and six months ended June 30, 2021, the Company recorded gross realized gain on investments of $358,000 and $358,000, respectively, and gross realized loss on investments of $194,000 and $204,000, respectively. During the three and six months ended June 30, 2020, the Company recorded gross realized gain on investments of $585,000 and $635,000, respectively, and gross realized loss on investments of $686,000 and $1.2&#160;million, respectively. During the three and six months ended June 30, 2021, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $136,000 and $(711,000), respectively. During the three and six months ended June 30, 2020, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $4.4&#160;million and $(691,000), respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2021, the Company had 22 available-for-sale securities in an unrealized loss position, of which four with an aggregate total unrealized loss of $211,000 were in such position for longer than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of June&#160;30, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,475,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,459,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,203,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,210,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,972,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,130,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,783,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(633,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,752,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2021&#160;were primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfOTY2_21cf23b2-e30b-49d1-a246-19b682bcdc01"
      unitRef="usd">358000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfOTcz_a7b2e739-c35a-4811-b3f8-96763edac64f"
      unitRef="usd">358000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTAzMw_36f03359-bfec-479d-8df2-80bbaabf2ff6"
      unitRef="usd">194000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTA0MA_97df5c47-9269-435c-825a-935df56634ef"
      unitRef="usd">204000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE0Nw_7ed70585-45f7-4173-b5bd-dea67a5d924f"
      unitRef="usd">585000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE1Nw_2874f97f-4033-4f74-a885-fd2172ff6777"
      unitRef="usd">635000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE2Nw_199aad22-7735-48c3-8c9c-02248e807e07"
      unitRef="usd">686000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE3Nw_3682f0cd-ee01-4ce8-9539-6f1ad6e257c2"
      unitRef="usd">1200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTE2NA_57338cbe-dd1d-4bfc-8b44-dd887a8c3506"
      unitRef="usd">136000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMTE3MQ_d24b3c8f-c46d-483a-b1ba-cc738697a045"
      unitRef="usd">-711000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTE5MQ_beca3b21-44ac-44a1-8d8a-58fa1da5b932"
      unitRef="usd">4400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTIwNQ_01b384ed-23ca-48a4-b924-b0964cf3e009"
      unitRef="usd">-691000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTY3MA_5f87c3ce-a303-4cf7-b1b7-b1b830f503a1"
      unitRef="position">22</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTY3NA_47653eab-27d4-4d33-9c41-2f6ed74cdb0f"
      unitRef="position">4</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMjE5OTAyMzI1OTY3Nw_da2748c0-5393-435b-b7aa-5ad0de1b7475"
      unitRef="usd">-211000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RleHRyZWdpb246NGY5Mzg0ZjEyNGJlNGI1ODkwMTU5MjlmMjc0N2FiMDhfMzA0Mg_9b187495-2dae-4814-a796-e94e544bd54c">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of June&#160;30, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,475,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,563,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,459,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,203,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,210,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,972,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,130,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,783,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(633,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,752,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi0zLTEtMS0w_c110f4d2-b90b-4956-9f0c-3e9d1f322e0f"
      unitRef="usd">207475699</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi01LTEtMS0w_0442b626-8495-46f6-b774-bc664baf91a0"
      unitRef="usd">1563089</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi03LTEtMS0w_37efd383-c7bc-4141-bd99-6864328f2eb9"
      unitRef="usd">579056</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bc7989f3223430dbcc2ce0a18701c95_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMi05LTEtMS0w_1ad0bb05-e51a-4b04-aed3-d1dd187517ac"
      unitRef="usd">208459732</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="if83d3a2efc6e49fa9fd97fa96d8adcec_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy0xLTEtMS0wL3RleHRyZWdpb246ZDZmOTdmNjZiMGJlNGNiYmE0ODc5MTVhMzIwMDY5NmFfMTQ_361d3728-850f-4a72-a8b3-bc437d76339f">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy0zLTEtMS0w_0925efbf-c3ea-4edc-95bd-29dfdd015096"
      unitRef="usd">170203940</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy01LTEtMS0w_e1cdd990-5fb5-4af6-b44a-dc69ae0b1114"
      unitRef="usd">10943</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy03LTEtMS0w_93771b03-d6aa-4243-a5d1-95ba9b2f2be8"
      unitRef="usd">4754</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i42c406f875024b2bb0c68f572a31cd9b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfMy05LTEtMS0w_cba269ed-5bd0-42d5-8fe3-7bc466b1f306"
      unitRef="usd">170210129</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i510a549b3ec34defbede167e3f43db38_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS0xLTEtMS0wL3RleHRyZWdpb246OWZhZWY3NzYxNGM1NDZlNDgzZWQyMTU2Yjk0YzNlMTNfMTQ_16921289-4409-478b-8234-728ab9c5b771">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib4f229a241b946588368e702a0bfb111_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS0zLTEtMS0w_abe60b91-a35f-4eaa-ae74-72042417261a"
      unitRef="usd">2972816</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib4f229a241b946588368e702a0bfb111_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS01LTEtMS0w_4b60c34c-d0e8-4e08-9c2a-4a411454281b"
      unitRef="usd">25684</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib4f229a241b946588368e702a0bfb111_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS03LTEtMS0w_dba3e86e-408f-4a12-ab39-7b387e28e668"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4f229a241b946588368e702a0bfb111_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNS05LTEtMS0w_e5066e8f-0749-4d77-ae93-b14bf74bb5f4"
      unitRef="usd">2998500</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi0zLTEtMS0w_eb89ed76-32d6-48fa-9cc1-27c4a29d8239"
      unitRef="usd">3130877</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi01LTEtMS0w_c2d8545e-a866-4f7a-99d2-226f1ad8c94f"
      unitRef="usd">2782</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi03LTEtMS0w_00b8b632-b7e7-4ca3-b3b9-15e06d9fc0b7"
      unitRef="usd">49638</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2706bc18dc264d7f80c2c3df55033508_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfNi05LTEtMS0w_ee8b04cc-ce7d-4fd1-91a9-d6d180dddb97"
      unitRef="usd">3084021</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC0zLTEtMS0w_920f65af-e949-407a-b221-f062bafe4a0e"
      unitRef="usd">383783332</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC01LTEtMS0w_a974e371-bdc5-493d-8c7d-9ff845a7c233"
      unitRef="usd">1602498</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC03LTEtMS0w_3674dc7c-20b9-490f-a566-303672f48db4"
      unitRef="usd">633448</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOmM4MGQ1MzdlM2M2NTRjNTBiZjU5ZWQ3ZTkwN2UxOTQ1L3RhYmxlcmFuZ2U6YzgwZDUzN2UzYzY1NGM1MGJmNTllZDdlOTA3ZTE5NDVfOC05LTEtMS0w_189cc30a-07f3-479f-b288-3766b6162058"
      unitRef="usd">384752382</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi0zLTEtMS0w_80259d76-66d4-4a8e-9054-199d02100241"
      unitRef="usd">153177675</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi01LTEtMS0w_d775f297-6b8c-43f1-98c3-f29016339b9d"
      unitRef="usd">2339639</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi03LTEtMS0w_9910cbaf-d05c-442d-b167-7d0b33791db1"
      unitRef="usd">644140</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6816a859d85847e482e3a9f0779b70fd_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMi05LTEtMS0w_ec2786fe-54a9-4038-88a1-15588c32338d"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i9e7cf41bc39a400f8c65d4ac89cb740f_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy0xLTEtMS0wL3RleHRyZWdpb246MTA4YWI3MjNlYzBhNDE0YmEyZDhhYWZlYzRmY2YxMzRfMTQ_3c87a2cd-af87-4ed4-8fbd-010e193608d6">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy0zLTEtMS0w_8c8fb323-f79a-4132-bc1e-6e3b0675884d"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy01LTEtMS0w_33bf58a2-855c-40ab-b1ac-a58d6fbd77ce"
      unitRef="usd">26260</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy03LTEtMS0w_f8581691-4719-431b-8f64-d13312a5ea8c"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4379956285af4a64828e8aed46e6fc8c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfMy05LTEtMS0w_4dba59a7-e20b-480b-b4d7-9f9986a7b72f"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC0zLTEtMS0w_6fa2d356-eecf-4d4a-a565-6fa0b23de834"
      unitRef="usd">3062256</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC01LTEtMS0w_d1588c6a-0c52-44cc-a942-1d72d2097fd2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC03LTEtMS0w_8f28f10c-f0ce-4bf0-a8f3-e857d880719e"
      unitRef="usd">36755</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c791d22a96a422ba56ca3c1a8e39a71_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNC05LTEtMS0w_30000b64-6b99-4916-a36e-7ce5394c2491"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy0zLTEtMS0w_55c107b0-0499-4596-9508-1b2c82ea0b3b"
      unitRef="usd">159239931</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy01LTEtMS0w_ecf7b215-43eb-4ec8-b4bf-c4971101c0d7"
      unitRef="usd">2365899</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy03LTEtMS0w_5088a972-6697-4581-a996-af3887b1033d"
      unitRef="usd">690895</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80OS9mcmFnOjRmOTM4NGYxMjRiZTRiNTg5MDE1OTI5ZjI3NDdhYjA4L3RhYmxlOjZlOTkxMDYwYjMyZTQ4YjdiMTkxYmU3Yjc2NDk5YjE1L3RhYmxlcmFuZ2U6NmU5OTEwNjBiMzJlNDhiN2IxOTFiZTdiNzY0OTliMTVfNy05LTEtMS0w_ffe98573-1e1d-4ef0-a292-b80c9dfa92fc"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RleHRyZWdpb246OTRkMzgyMzdhZTAyNDdiM2IxNTk0YWEwMzY5Y2I3NDhfMzQ2MA_185d6aeb-c9ec-4efc-a214-cb50f5332d5c">Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company does not have any liabilities measured at fair value on a recurring basis and did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the six months ended June 30, 2021 or 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,459,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,459,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,210,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,210,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,752,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378,669,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,082,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,661,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,578,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,082,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at June&#160;30, 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain (loss) on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain (loss) on investment in affiliated entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at June&#160;30, 2021 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RleHRyZWdpb246OTRkMzgyMzdhZTAyNDdiM2IxNTk0YWEwMzY5Y2I3NDhfMzQ2Mw_29411f56-dd59-4eff-abbc-9fc5e36597d8">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,459,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,459,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,210,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,210,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,752,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378,669,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,082,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,661,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,578,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,082,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59b2f82a49c24e32adbb66d496dda53e_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS0xLTEtMS0w_8ac55195-a412-4f10-899a-8380787737b1"
      unitRef="usd">208459732</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8cfaf8d38f5648c19f2ea139b9b26baf_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS0zLTEtMS0w_bdf88fdd-879d-4994-9700-4646d30710d9"
      unitRef="usd">208459732</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie51d461609384e719322b34eb0028974_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS01LTEtMS0w_ab8d50d0-da8e-46b1-bbe9-973fe1f24930"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f3ac792a0624a46adde92d9a011757a_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfOS03LTEtMS0w_62b66b6e-f76d-4535-b9bd-a627671974e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5dc69a851d9e4e609cc585a27766de44_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtMS0xLTEtMA_4291e7b5-b753-47e6-a4b5-483e68c64878"
      unitRef="usd">170210129</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7015122ae2124cc496b05b2e9f7e4d96_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtMy0xLTEtMA_e5b8058c-e070-4829-857c-b005a4d83867"
      unitRef="usd">170210129</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58a6f1f19ef548cca073dbd3bb6f4e78_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtNS0xLTEtMA_0ef7abf8-d5eb-4224-a3ea-d7a608b3a2ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia791cbcc956646499769e8fd73d3f0da_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTAtNy0xLTEtMA_58fa0a3f-4192-4af2-b7da-8d134cc6912d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if19edaa6e2cc4d4bac4bd7a20b22e0ab_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItMS0xLTEtMA_8dcc1fba-fc3d-4a66-bf43-b5b29290ad63"
      unitRef="usd">2998500</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8a1e910e01534d50ada88b9157528ea0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItMy0xLTEtMA_c52f0804-1a93-47ee-b33a-338eff19bbf2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa3846d736e946a395c5e4a35be5dda3_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItNS0xLTEtMA_f47f6123-de7d-48ee-9948-9a93f0feac4f"
      unitRef="usd">2998500</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i195cff6b53c543e79e1b7a11b9e1e066_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTItNy0xLTEtMA_f9aa83a5-761a-4342-9c70-90c26a3ff7e9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1713bb34c3046b5b8c3fb55489e9da9_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtMS0xLTEtMA_2fc068fc-fc29-4825-9e5d-670116a250a3"
      unitRef="usd">3084021</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ae0695b197b427cb51e9553cf7567c3_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtMy0xLTEtMA_f0fecc6e-1156-4b6c-a506-7a7c2a05313e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8730b43b27914e7aad78d1a3e3c967ea_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtNS0xLTEtMA_9a07c65c-ad4f-4c8f-980b-344efed2a40f"
      unitRef="usd">3084021</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ca670336a984af492bfea37611a6fc6_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTMtNy0xLTEtMA_0ca0d1e4-b679-4f80-be6e-40284a249bf1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc709f4b94bc48ed922b211843a64806_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtMS0xLTEtMA_83c950ac-7bdc-4fe6-9307-8dfc76c6a505"
      unitRef="usd">384752382</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bfff0eba5124813b5d1d472946eca2b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtMy0xLTEtMA_4c1b5736-c62b-4ea1-85de-105689f0d4ef"
      unitRef="usd">378669861</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtNS0xLTEtMA_16ee30cf-9966-4445-a529-185fc312bb13"
      unitRef="usd">6082521</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTQtNy0xLTEtMA_ddeb2ec5-9ed1-49b3-a763-afb59d794527"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibc709f4b94bc48ed922b211843a64806_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtMS0xLTEtMA_77da727c-89c5-4141-bcfe-05d5b156ad6c"
      unitRef="usd">3908709</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7bfff0eba5124813b5d1d472946eca2b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtMy0xLTEtMA_6c7dbff0-0b7a-40d7-8174-6b17c0117d70"
      unitRef="usd">3908709</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtNS0xLTEtMA_d9d03dd0-987e-4d09-8f06-2f7f75299c57"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTYtNy0xLTEtMA_f2bd1402-78f2-4ccb-ac3e-81bd240f3709"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc709f4b94bc48ed922b211843a64806_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtMS0xLTEtMA_a2274792-d935-41b7-a7ad-9d5c87dcf176"
      unitRef="usd">388661091</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7bfff0eba5124813b5d1d472946eca2b_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtMy0xLTEtMA_583292c1-9f8a-418b-99e7-395e20f86a39"
      unitRef="usd">382578570</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6ba1e155e6694c81b9af573a7d9c1a84_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtNS0xLTEtMA_30f29378-d3d5-4a0d-b300-93d7f8096924"
      unitRef="usd">6082521</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69a0f3d76e6a40b39e49e4c8132423ea_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjNjNzJiNGM3NDZkNDRkYmM4OWU0YzUwZTE2MWNmYjZjL3RhYmxlcmFuZ2U6M2M3MmI0Yzc0NmQ0NGRiYzg5ZTRjNTBlMTYxY2ZiNmNfMTgtNy0xLTEtMA_dd2f8340-a6a4-4623-ad04-b5a5ca2476ca"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2063a61ba08e4166b1cddf9ccca281e7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS0xLTEtMS0w_97465ec0-bcea-4500-b07a-92f944daf98b"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie423d6a2d8714a8f9455c1d4c07b71ce_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS0zLTEtMS0w_fec2e6a6-dda4-4480-9ba2-d0eb4b40f26b"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b0fd8f591c349f3a5e3a09df3fda89c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS01LTEtMS0w_0876f23e-db9d-42d8-8c43-134b29e73c6d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0d1fecace3114e4e8dc9bbf39dbc9e69_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfNS03LTEtMS0w_7e0b9605-eade-489c-996c-06fd6468c154"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5efcc9635b543f288d5ac148668e8be_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC0xLTEtMS0w_00851267-dcad-4efa-a69c-40574109d561"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b14d9a9f0a04ed881500352253a7910_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC0zLTEtMS0w_4de84fc5-8c4b-42ca-bb9c-d220b5fed0b4"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee92b5ff60e34bdc86aeec302d9c2bf7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC01LTEtMS0w_4e261db3-e917-438e-9f0a-5296ff4ec282"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79c69a9ae1284a36bb632aed6602a513_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOC03LTEtMS0w_1fb997f2-86ba-4254-84a4-7733925a9453"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb94388dbd194288ba834bcc4e711204_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS0xLTEtMS0w_82dce1d3-f1f6-4308-aa33-66987f24e247"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72086878455242579c997bb7d0dbafca_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS0zLTEtMS0w_2059f989-ab6e-4f39-9769-f431fd73333e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i28d2855764184d899799d1f6e766ef05_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS01LTEtMS0w_ecd4f714-9313-4302-a418-9907c1c3a0ce"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd724b7e4b434a0299f128f23b08a6f7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfOS03LTEtMS0w_830cd871-b3f5-49f6-97c8-90abbc2409fd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie555d9e8436b4b7c816532c5dba1b774_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtMS0xLTEtMA_a49ba1fe-7517-4e91-8eb7-98b5e589d925"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41fa24018fea4d7789e40b137a122c1f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtMy0xLTEtMA_e758c274-859f-465e-8379-86bce8052309"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i77e632e4521a403eabd9a0d1cd065f58_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtNS0xLTEtMA_d4c1dc77-f604-4783-9f81-25b5e41c2146"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0dae7058a7c24aad9e604be62fc80f77_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTAtNy0xLTEtMA_2c1227d7-eada-4654-b624-7cfdca1546d1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i885b976e592548cab96e1ad94a5f5ca6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItMS0xLTEtMA_2d6e77e2-0845-4b41-bd96-905832988557"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98ee59d71b964e1b903875f0effd8913_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItMy0xLTEtMA_f327ca27-657c-415c-910c-4305aa03ce9f"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6bd6370c584d45d1980fe5eae38e0f14_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItNS0xLTEtMA_fd52d72b-0f1c-4bda-9999-59ebf5d7f3fb"
      unitRef="usd">6041761</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if15f13a0132e4e6a88992dc32184349a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTItNy0xLTEtMA_c9324c03-2c24-4581-b4a3-85a8f3f825ae"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i885b976e592548cab96e1ad94a5f5ca6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtMS0xLTEtMA_814d9ef6-e338-48d9-b796-e5b536478af9"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i98ee59d71b964e1b903875f0effd8913_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtMy0xLTEtMA_e687e39c-4a96-4ba0-95c8-2e6512fca725"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6bd6370c584d45d1980fe5eae38e0f14_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtNS0xLTEtMA_4d7e1692-4c0b-4f70-b6f9-c8f740a64dd8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if15f13a0132e4e6a88992dc32184349a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTQtNy0xLTEtMA_621a1832-1ae3-44a4-a7f0-0c1cf19ffc36"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i885b976e592548cab96e1ad94a5f5ca6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtMS0xLTEtMA_8cf58e4c-a6fe-4b57-a070-755e4916204a"
      unitRef="usd">225372101</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i98ee59d71b964e1b903875f0effd8913_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtMy0xLTEtMA_461f2016-cfb3-445c-be98-b7af61cf2bbb"
      unitRef="usd">219330340</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6bd6370c584d45d1980fe5eae38e0f14_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtNS0xLTEtMA_bd8fb158-ac32-437c-8fd6-788122d90ff0"
      unitRef="usd">6041761</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if15f13a0132e4e6a88992dc32184349a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RhYmxlOjc2YTVkNzczM2EyMTQ2ZDRhN2U0OTVhMzMzYWQ1ZDZiL3RhYmxlcmFuZ2U6NzZhNWQ3NzMzYTIxNDZkNGE3ZTQ5NWEzMzNhZDVkNmJfMTYtNy0xLTEtMA_3cfc9be5-2f90-4b1e-bcff-8686e2313393"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i9cdd7b8ef815473385e371284b1691bb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81NS9mcmFnOjk0ZDM4MjM3YWUwMjQ3YjNiMTU5NGFhMDM2OWNiNzQ4L3RleHRyZWdpb246OTRkMzgyMzdhZTAyNDdiM2IxNTk0YWEwMzY5Y2I3NDhfMTc0NQ_8cf8d23f-f15d-4d14-ab8f-300c4bd451a0"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNzEz_10ccf709-c31b-4db7-af75-c994aa5109e1">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,291,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,608,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,491,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,693,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,593,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,879,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,593,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,393,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property. &lt;/span&gt;&lt;/div&gt;Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2021 was $130,000 and $267,000, respectively. Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2020 was $137,000 and $274,000, respectively. Estimated aggregate amortization expense is $254,000 for the remainder of fiscal year 2021, $493,000 for 2022, $276,000 for 2023, $253,000 for 2024, $253,000 for 2025 and $1.4 million for 2026 and subsequent years combined.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNzE2_a154e830-1b78-4080-9a05-89103835134b">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,291,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,608,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,491,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,693,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,593,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,879,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,593,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,393,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;(b)Other intangible assets represent the estimated fair value of acquired intellectual property.</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy0zLTEtMS0w_dd1ae8b5-9907-4202-8e83-608c6ebfb15b"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy03LTEtMS0w_ec285973-bd27-48e2-938b-13d3fea87f6f"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy05LTEtMS0w_eb27fa78-56c4-4647-8c3c-3277f0d7f0e6"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMy0xMy0xLTEtMA_4cc2bf43-6e1e-4972-9cd9-8ec525261e6a"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i658f1d80d9ae443e8ed687c6a2037b8e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0xLTEtMS0w_a3b3a1d4-9c8f-43eb-b84a-5be4133c861f">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0zLTEtMS0w_aa6736ed-2e88-4738-9760-3e02fc6fcfec"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi01LTEtMS0w_6f0c0e94-dc5e-4598-8fc3-fb63c02ea13e"
      unitRef="usd">1291226</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8cf350f910574dad9b9d76f4fa9e24dc_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi03LTEtMS0w_7580e26e-8773-4e98-b763-d6545974e1bf"
      unitRef="usd">32535</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi05LTEtMS0w_6b1713f6-777e-4ff6-9eb6-3bd6028a54c9"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0xMS0xLTEtMA_11de684c-991e-4d75-b4de-a6e295df75ff"
      unitRef="usd">1276852</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8b3fc7e2ac154fbeb6e10abe475c1f4c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfNi0xMy0xLTEtMA_5eb53892-69ba-411b-b223-51e0c13d73c6"
      unitRef="usd">46909</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i25b5d1ccf26e443ea857b84e229ce359_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0xLTEtMS0w_6b9cd460-78b4-40e0-9c6d-85d0d3854dc0">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie0f8942f622e48a99283907789ffa607_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0zLTEtMS0w_41d1d3f3-c4fa-4503-88a2-c74a18221b51"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie0f8942f622e48a99283907789ffa607_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS01LTEtMS0w_f503d8c2-6b09-4fb2-8dde-3fa0f35d2240"
      unitRef="usd">2608889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie0f8942f622e48a99283907789ffa607_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS03LTEtMS0w_9cfd8a8b-4306-4537-8926-81391563e3b0"
      unitRef="usd">2491111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS05LTEtMS0w_c5ff6380-054d-4ce6-82c3-35ca012c065d"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0xMS0xLTEtMA_1c80693d-8e9a-4308-a031-eba7ced1b685"
      unitRef="usd">2468889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i938f2c8416ca49c7bc6f0b0bdeac5d01_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfOS0xMy0xLTEtMA_09e98556-ffab-486b-a06e-560a6b3e0603"
      unitRef="usd">2631111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0f14f4877fcc414dbb3be5f50ae03388_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMS0xLTEtMA_20d4667b-6d1a-41d2-bf2a-98048926772d">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i449fddef645f4a30a1891aa40c4f6f0d_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMy0xLTEtMA_6c5772d8-30cb-456b-8194-54bf1bc0e3ed"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i449fddef645f4a30a1891aa40c4f6f0d_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtNS0xLTEtMA_7114567b-cd54-4b79-891f-822088febca3"
      unitRef="usd">3693750</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i449fddef645f4a30a1891aa40c4f6f0d_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtNy0xLTEtMA_b85f1b75-0286-4a99-91c6-0ef5070310ed"
      unitRef="usd">356250</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0f168c1581a04f49b0e144ce91a5b415_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtOS0xLTEtMA_034460ae-c811-4a4f-a6f8-6788ac438ae9"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0f168c1581a04f49b0e144ce91a5b415_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMTEtMS0xLTA_b703ad25-228e-4015-8245-2ef0e0d8c90c"
      unitRef="usd">3581250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0f168c1581a04f49b0e144ce91a5b415_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTAtMTMtMS0xLTA_1c4d6851-64f0-431a-ab1e-795d14850556"
      unitRef="usd">468750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i90cb8338f9474cb7b4f4e085bba18709_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMS0xLTEtMA_3f4e4927-a364-46fe-8ffc-070d4131c57a">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMy0xLTEtMA_4eb50091-c149-4292-9e22-5fc93e185663"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtNS0xLTEtMA_0fa6f392-142d-4cae-ad6d-87bc8d9bf3b0"
      unitRef="usd">7593865</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtNy0xLTEtMA_3ba9481d-8a97-4cf8-b90a-2d549a992397"
      unitRef="usd">2879896</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtOS0xLTEtMA_ffd2c01a-9211-45d7-9f69-aafec08be6a1"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMTEtMS0xLTA_54f50d6e-6be8-4e52-983e-96eae75f06b9"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTEtMTMtMS0xLTA_9e40c54d-8525-4288-acc9-59f4035ace55"
      unitRef="usd">3146770</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItMy0xLTEtMA_ed4190ea-27e8-44b1-8309-f83629894110"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItNS0xLTEtMA_098e9fb0-fedf-4ba8-9063-028dc9b6f0ea"
      unitRef="usd">7593865</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItNy0xLTEtMA_73d24fed-19df-496d-a74f-7209838250ca"
      unitRef="usd">13393267</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItOS0xLTEtMA_00cdb437-0b32-4417-9651-6600649ba660"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItMTEtMS0xLTA_a8de83f3-4bb0-45dc-867f-ec1b6ee44cd6"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RhYmxlOjVlZGJkM2Q1YTZiOTQ0ODY4ODQ3NTRmNmM1ODAyNjE1L3RhYmxlcmFuZ2U6NWVkYmQzZDVhNmI5NDQ4Njg4NDc1NGY2YzU4MDI2MTVfMTItMTMtMS0xLTA_8bb271cc-db78-49f8-8a9a-8b147d77e466"
      unitRef="usd">13660141</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNTI3_8ccc05d2-3f27-469b-ad23-d419bb905587"
      unitRef="usd">130000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfMjE5OTAyMzI1NjI5MA_11e90268-bd76-447e-a81f-0e741174a275"
      unitRef="usd">267000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfMjE5OTAyMzI1NjM3Ng_80aee7eb-9e58-4e37-bf74-6d530a5264d9"
      unitRef="usd">137000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfMjE5OTAyMzI1NjM4NA_3ab63536-77e2-4933-91ab-e7816cabdbd2"
      unitRef="usd">274000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNTc2_96119333-f517-43f1-b4e8-0790af8eee2d"
      unitRef="usd">254000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjE2_6ac940c6-93fe-451b-b4c1-ba32f63051d3"
      unitRef="usd">493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjI4_38e0fab0-8824-48ad-9637-76d7785eee7e"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjQw_1efbad8b-0972-4ba0-8115-7f08a6feb432"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjUy_372eda80-096f-4f2f-bbd6-bf84c9a8d398"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV81OC9mcmFnOjUzMzZlMmFhZmZmNjQ3NmE5YmIwMzkzZDcyMTJhMTBlL3RleHRyZWdpb246NTMzNmUyYWFmZmY2NDc2YTliYjAzOTNkNzIxMmExMGVfNjY3_bfc562ff-ff1f-4d65-a3a7-b2695d432ac8"
      unitRef="usd">1400000</ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI4ODk_61cfa3ed-d338-4abe-bdb3-d7786385eaed">Convertible Debt&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled for&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; an aggregate of 11,535,660 shares of the Company's common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8 million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at June&#160;30, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,963,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,536,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June 30, 2021,&#160;the Company recognized $467,000 and $930,000, respectively, of interest expense related to the Notes, of which $267,000 and $533,000, respectively, related to the contractual interest coupon. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized $2.1 million and $4.2&#160;million, respectively, of interest expense related to the Notes, of which $1.3&#160;million and $2.6&#160;million, respectively, related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;August 2019 Convertible Bonds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2019, the Company closed a private placem&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ent of the August 2019 Bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.69 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized $672,000 and $1.3&#160;million, respectively, of interest expense related to the August 2019 Bonds, of which $37,000 and $75,000, respectively, related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the August 2020 conversion in full of the August 2019 Bonds, the derivative liability associated with the August 2019 Bonds was revalued at $84.5 million. The change in fair value of the derivative liability was an increase of $75.7 million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#x2019;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#x2019;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds was 6.2%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the six months ended June 30, 2021,&#160;the Company recognized $50,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and six months ended June 30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized $60,000 and $122,000, respectively, of interest expense related to the December 2019 Bonds, of which $10,000 and $20,000, respectively, related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt; As of June 30, 2021, all outstanding December 2019 Bonds were converted into 1,009,450 shares of the Company's common stock. Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTM2_98ea9104-0578-4629-9dc1-b8e0358be535"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTcz_35900a79-15aa-42a3-bf33-35947335f19c"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDE5_ad4136af-019f-459e-8c0f-4b5ae68acedc"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNjI4_5d33f1d2-63f8-4b80-b496-ded3ec261dac"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTQ0MA_1c7d3397-0a19-4720-8761-523397c7ea2f"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTc1NA_03ba8f88-4ef7-42d5-82f3-90e85371c1b8"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTgwNQ_21a477e0-769d-419e-9818-2725aa4aca38"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTg2MQ_1cffd579-f9cc-48b9-98cf-1977157f39e6"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ib47fd93f8bda4882843895b551fb71f2_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjEzMg_20dc92c1-cffe-416d-b450-f054bbfd9815"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjY3MQ_2d212408-2cb4-4046-a128-d0af9eba3669"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjk4Nw_df5d1069-aad0-4257-86cd-cfcc5cefc58e"
      unitRef="usd">62200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMzE5OQ_4b8f7de7-82a4-46ae-b3ef-a84e173689d6"
      unitRef="usd">2800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i9694c3b5185b4167946bc4ade85f653b_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMzg2Mw_3d81b35a-b761-474d-a5a8-92f513bd59ac"
      unitRef="usd">18600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDA5Mw_11eb2ff9-f393-4cd6-a56c-3dde3f86264e"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDE5MA_91badd2d-2d58-46b9-b9dd-3bc839500d66"
      unitRef="usd">62100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDI2Ng_ab93946c-6b0b-49e9-af05-da5d06752761"
      unitRef="shares">11535660</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7cbf958eded24955b7f7345d5fff5691_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDM2NQ_d31f83d9-8141-4e27-a9b6-cfdc579b67ed"
      unitRef="usd">43700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i7cbf958eded24955b7f7345d5fff5691_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDQwMg_43ec5d8f-a8e7-4944-b39b-97b6a4aa0d3b"
      unitRef="usd">52500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i415596e6d77b4849a0aa783283c887ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDQyMQ_9086bbbf-ad06-4fba-9f33-2fd9f7e08389"
      unitRef="usd">8800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI4ODI_1c41fa46-2301-4b19-8f26-51c24741008f">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at June&#160;30, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,963,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,536,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMC0xLTEtMS0w_abce213a-1d39-4e2a-a527-33712a934671"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMS0xLTEtMS0w_6cbc79e2-d836-4ff6-811f-cf427de631d6"
      unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMi0xLTEtMS0w_75fd3f3a-2046-49f5-9ac1-9510dddd502d"
      unitRef="usd">1963908</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfMy0xLTEtMS0w_efe19bb0-d54d-4e61-9975-c490725e0ef9"
      unitRef="usd">270302</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccruedInterest
      contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfNC0xLTEtMS0w_c1cb5c64-ce32-445f-9d5c-4310be69a84a"
      unitRef="usd">355658</ino:DebtInstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="icc098f58f8a041b08a33357d6648fbc0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjljNzA0ZmI5YWNiMzQ2ODI4ODEzN2EyZmJkMWVhZGIxL3RhYmxlcmFuZ2U6OWM3MDRmYjlhY2IzNDY4Mjg4MTM3YTJmYmQxZWFkYjFfNS0xLTEtMS0w_3e068df2-9f77-4a13-8a20-0f8ca93ceebe"
      unitRef="usd">14536448</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="ife6839a934ca45f6a9f657888e33b403_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDc5Mw_7bd3765c-4b20-4d27-bf38-a46247c42b39"
      unitRef="usd">467000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4d7b13bbac7745c18bcb6916ba590376_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDgwMA_69b6ba69-453d-48c7-9323-e67e567b61b8"
      unitRef="usd">930000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ife6839a934ca45f6a9f657888e33b403_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDg2OQ_5d2c7ad4-9804-46be-9827-e5577a5a7d50"
      unitRef="usd">267000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4d7b13bbac7745c18bcb6916ba590376_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNDg3Ng_52c3fbe1-76b8-4676-ada7-2e40045f9f35"
      unitRef="usd">533000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense
      contextRef="ied29f23ff8a24d14ba72e1520dbcbe12_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc2Nw_97d8bf66-d019-4079-9507-d84ecdc772a0"
      unitRef="usd">2100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0cb6494a5734438caccf162208d9c9e9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc2OQ_3b683f3a-69a0-4563-899d-de3add2badff"
      unitRef="usd">4200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ied29f23ff8a24d14ba72e1520dbcbe12_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc4NQ_ff80652c-0745-4d28-a5e9-277c6b2f9639"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0cb6494a5734438caccf162208d9c9e9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODc5OQ_610931f6-e4fa-4dc0-89e0-41ef352ee904"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI4ODQ_48031256-a936-43a9-a8be-5ca2bbeaee28">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTA3Nw_2f1551bc-4595-49ce-9ca8-72f021cfca6c"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfMS0yLTEtMS0w_b6e26b36-e9e6-4fe2-bfb0-d2821451fab2"
      unitRef="usd">534000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfMi0yLTEtMS0w_4506fec0-314f-4ae6-9906-6fc9db787216"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfMy0yLTEtMS0w_f124cee1-57a6-43be-8f5c-7bd03690b954"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfNC0yLTEtMS0w_ae8f58a6-0c17-49a7-b9a5-9bfc86ddc7a4"
      unitRef="usd">16948000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="idb65bbc9382a4813ad514235377b41b5_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RhYmxlOjc5NGU4ZjVkZThlNDRiOWE4ZDk5MDExN2M0YzZiM2FlL3RhYmxlcmFuZ2U6Nzk0ZThmNWRlOGU0NGI5YThkOTkwMTE3YzRjNmIzYWVfNi0yLTEtMS0w_6cb8945a-7342-4849-8011-06a4cefa5981"
      unitRef="usd">19616000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTI2Mw_88105dc3-6e59-4b11-bcac-cebc35a7db99"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTMwMg_4f55d945-e407-4aa2-9c2e-f98b0a3604cf"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i586e28029d9349b8990dda0e65156664_D20190801-20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTU1Mw_236906cc-75f9-49b9-9d2c-e94e852c383a"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTcwMQ_e11fa5fa-dadd-407d-83d5-2754be3b884d"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i4387c26933424d9096e5a67cc6e310e0_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNTkyNA_aef7c1fb-28a8-40f7-ad27-2e93bc7c94eb"
      unitRef="shares">4962364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i17e32422bc844eba90a640f03b45dce5_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNjE1MQ_ead78133-366b-481e-aa47-341307364e84"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="idaad05c89c7a4003898310c3fcc4bef8_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNjYzMQ_165ca422-8abd-4306-b8da-e700dd5abbb3"
      unitRef="usdPerShare">3.14</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfNzA2Mg_54594d88-3092-4f0c-addc-3c68f80331a1"
      unitRef="usd">7100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i929bfbecbf9c499c8fefd99dfc4da4b8_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODExOQ_3cefdc55-76fc-4ffe-9186-ea33f92ce83b"
      unitRef="usd">7300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpense
      contextRef="ibb48eed1dd1d450f97688eeb9d9b1075_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODMzMw_85619367-6032-4a41-9eef-0198c0c3ab2a"
      unitRef="usd">672000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i48cbe06ea9db47109f2c6aa21e985ed6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODg4MA_40f05e79-0c7c-44ac-b8f5-db76a1bb2c28"
      unitRef="usd">1300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="ibb48eed1dd1d450f97688eeb9d9b1075_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODM5OQ_7ee6255e-b296-438d-93d2-80a23b41b350"
      unitRef="usd">37000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i48cbe06ea9db47109f2c6aa21e985ed6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2ODg5NA_0e72d527-45b6-40b2-bf94-4da5f5b43626"
      unitRef="usd">75000</us-gaap:InterestExpenseDebt>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i3325f0757ae043c6b5ac88744b9c348b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODU3NA_73aeb65c-c572-42a3-a86e-0f95ae849bc7"
      unitRef="usd">84500000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i0d8ee829033246dd9adf6d9303496b62_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODY1MA_cf2f73b9-9265-413b-a07a-a1af1967526f"
      unitRef="usd">75700000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0d8ee829033246dd9adf6d9303496b62_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfODkzMw_6312300a-ece9-40c1-85d7-06d55b88e854"
      unitRef="usd">8200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="icaaf8fc6a6c144978817e6793fd2365a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTMwOA_80de2a81-78f0-452f-81d0-6b7710c91d5b"
      unitRef="shares">4692364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28f211979e784e9bbb20076cc52f7e54_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTU2NA_00808b6d-bcd7-46ba-a786-4fd75b870eda"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i28f211979e784e9bbb20076cc52f7e54_I20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTU5MA_7c10f7c8-c051-408c-9455-2cf5d27de10a"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i8a26ab4a585a46dca8422a60ddfe24b4_D20191226-20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTc0Mw_2f1d8f5c-98f8-456c-b2d8-8273322c38be"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28f211979e784e9bbb20076cc52f7e54_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfOTg5Nw_45646053-5ede-490a-b984-93c82c98c458"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i8a26ab4a585a46dca8422a60ddfe24b4_D20191226-20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTAxMjk_38ff3c53-ebf1-4b98-936b-e086d11608d3"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i2908c92d06bf4769bdd733e5d00c8200_I20191226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTAzNjQ_7d962354-fe81-4bb8-9be1-7948f31c0af4"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6d34dff54d0e4a038bfa48e0e67a8e99_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI0NjI_7ad5d2b5-b72b-4f33-af24-b0b25965fa2d"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI1MDg_8f464e2b-77d3-4bfe-8d55-bd936970522b"
      unitRef="usd">50000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI1OTg_d2fb60e7-4ad0-4ffc-8555-27b7be8a4b2b"
      unitRef="usd">9000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense
      contextRef="i442ae70cad5c4076acaead0487e51e18_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTMyNw_4adffb51-881b-4db7-91cd-78a4de1b635c"
      unitRef="usd">60000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia0f6c67ea61a42c8a33b20a0edfa3e86_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTMzNg_06dc1ead-a5e3-4f1d-95e5-74319773462f"
      unitRef="usd">122000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i442ae70cad5c4076acaead0487e51e18_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTM0Ng_bd703c90-0128-45f7-b2fa-144344d083c8"
      unitRef="usd">10000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ia0f6c67ea61a42c8a33b20a0edfa3e86_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMjE5OTAyMzI2OTM1NQ_d2987351-07b0-4b61-97c2-da971e427690"
      unitRef="usd">20000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI3MzQ_b028737b-bdbe-46a2-82aa-8f522227a60f"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i33983d5482cc4cb4831ac0edc3ba7f58_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82MS9mcmFnOjk3M2JmYzRlZGQ3YzQwMDhhYWZmNTI4Mzg0NzY4ZjIxL3RleHRyZWdpb246OTczYmZjNGVkZDdjNDAwOGFhZmY1MjgzODQ3NjhmMjFfMTI3OTY_21d9bbde-7aa5-405a-bfe0-05b652092486"
      unitRef="usd">4400000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDM5NQ_acbb9274-cdc5-4242-9e54-b67250784223">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2021 and December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,146,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,146,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,851,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, 14 shares of the Company&#x2019;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $162.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#x201c;Placement Agent&#x201d;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#x201c;at-the-market&#x201d; equity offering program under which the Placement Agent acted as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0 million to $250.0 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, the Company sold a total of 22,919,934 shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2 million. As of December 31, 2020, there was no remaining capacity under the New Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the &lt;/span&gt;&lt;/div&gt;2016 Incentive Plan was 20,000,000 shares. On the first business day of each calendar year, such maximum number of shares is further increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares increased by 2,000,000. At June&#160;30, 2021, the Company had 4,998,253 shares of common stock available for future grant under the 2016 Incentive Plan, 2,516,102 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 7,814,677 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At June&#160;30, 2021, the Company had options outstanding to purchase 2,516,141 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDM4OA_ec06accf-81ee-4953-b6e9-b5ce0376a9c1">&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2021 and December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,146,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,146,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,851,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0wLTEtMS0wL3RleHRyZWdpb246ZjVhNTljMTk2MWZkNGVhYjg4OGE0OWQxMWJlYThlYTRfMjg_22c9f2db-2b46-4146-9774-08d7a39090ca"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0wLTEtMS0wL3RleHRyZWdpb246ZjVhNTljMTk2MWZkNGVhYjg4OGE0OWQxMWJlYThlYTRfMjg_edb68bea-e788-45f9-8744-c4df0028dcb5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0xLTEtMS0w_e0b1f838-7b50-4e93-b762-0b70fc194276"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi0zLTEtMS0w_b3d27168-6254-4fb9-9811-13c36cce4fb7"
      unitRef="shares">210146880</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi01LTEtMS0w_d69db047-ed15-4755-9f9b-4f2bdd813276"
      unitRef="shares">210146880</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfMi03LTEtMS0w_f76e69d7-a5ce-4b1b-860b-45efcf06e92e"
      unitRef="shares">186851493</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i689dc147815948f0886fb748641b715b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0wLTEtMS0wL3RleHRyZWdpb246MmNjNjA3YjRjOWNmNDdhYTk5NDNlMTJjNzM0ZGZiNjJfNDA_030da638-6412-483a-a2d9-580a8e0d28cf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i77178543290247baada87cc58713a47e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0wLTEtMS0wL3RleHRyZWdpb246MmNjNjA3YjRjOWNmNDdhYTk5NDNlMTJjNzM0ZGZiNjJfNDA_b5a276fd-82e3-4a62-940d-088eb26a7fef"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i689dc147815948f0886fb748641b715b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0xLTEtMS0w_c4846a73-f661-4bdf-bf5e-aea44f513c29"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i689dc147815948f0886fb748641b715b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS0zLTEtMS0w_4e06e22f-42f6-4dbf-9f08-7b0ed77dd155"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i689dc147815948f0886fb748641b715b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS01LTEtMS0w_ab2e9147-dbfb-4b5e-89a2-e5ff6289deaf"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i77178543290247baada87cc58713a47e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RhYmxlOmE2YjVkMDk2NWE1NjRiZGRhMTVjM2JlMmMwMzBlMGMzL3RhYmxlcmFuZ2U6YTZiNWQwOTY1YTU2NGJkZGExNWMzYmUyYzAzMGUwYzNfNS03LTEtMS0w_84ed23db-287d-4bc0-b458-50088d37a4c1"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i5014003f2f6f483b8391af1fa2db26e8_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTc0_5e7f6bd3-e203-4433-9b6f-64e9a22b5d88"
      unitRef="shares">14</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i59c22ff37c374753ade05595b7204ddb_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjYy_05e93dfc-677e-477c-b0db-8d613dbd9a49"
      unitRef="shares">5147</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i35a378f1adfd4003a890450ab84a2bd9_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzkx_75f0aa84-f1ec-4b31-b8ad-083885e55c82"
      unitRef="shares">20355000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9f31aeb778524005bde1396b19356f60_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDQ3_8e320a03-b8a5-4d69-bdf9-795fe22893c0"
      unitRef="usdPerShare">8.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes
      contextRef="i9f31aeb778524005bde1396b19356f60_I20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNTk4_4a54a282-7ce1-4bb2-bffb-b0749438f70d"
      unitRef="usd">162100000</us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i6a0d7c5a50ca41b28dad429b0cb851a4_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNzg5_6aa83111-ad4d-4131-b57e-9575f0773569"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i6a0d7c5a50ca41b28dad429b0cb851a4_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTE2OQ_be607ec1-2626-485c-a8a2-7b3cb6f8b8bd"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i78ee577f7a7e4579bb39bba035abaee4_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTE3NQ_3a937e0f-76ae-4755-b7eb-0b874b431771"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i33badcdaab9f4b948718c8bce4d00c22_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTIxMQ_0b7db0c1-fafb-45a7-afff-32405e0c9d93"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i8bbbdeacd5fc468588e3dc03b0a7861e_D20200403-20200512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTYyOA_e4ee986a-f461-41d2-b26c-c282b1457083"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTY5Ng_3f7da662-a95a-44ad-bade-c531277777ac"
      unitRef="shares">43148952</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTgxMA_3031815e-1f69-4e85-b367-0e18d642ff32"
      unitRef="usdPerShare">4.92</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="ia2e8764594a442abb2844eda642fc11e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTg2Mw_bc196bd4-af74-4923-8a11-457de60a955b"
      unitRef="usd">208200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i33badcdaab9f4b948718c8bce4d00c22_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMTg5OQ_1f819cdd-06b9-4857-9833-7b88103947a4"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjAyMw_0349ea0c-d12d-40f9-9e5c-6b07283c3f27"
      unitRef="shares">22919934</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjEzNQ_85977f99-1a9f-4b6a-ae14-4d2a13d2a4a2"
      unitRef="usdPerShare">10.91</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i275a0f60a4054ef2aba5d0c255536ae9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjE4Nw_acd27732-3514-4607-a100-8f9db675146e"
      unitRef="usd">246200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="if44318d1ef4e4fd298cb0d5f9506f23a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMjMwNA_5f6dd58e-f1c0-461e-913c-6d3bef29d0d9"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2005c7bb31a94776aff831320305c606_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzExNA_69ddd0aa-0203-47bb-adb7-6499bb4fa54c"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i2005c7bb31a94776aff831320305c606_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzIyOA_17e75c49-76c5-4668-ac82-272e32b2077e"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="ifbea9bf1e25743b78635a4f7dced6bd6_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzUxMg_4c2ed322-21b7-4ecf-ab36-0e5e2a46af5f"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia838f5b6a3354692a049e285a3f8c1ab_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzUzOQ_61c881e1-2bbc-4208-9057-d476f9acde10"
      unitRef="shares">4998253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia838f5b6a3354692a049e285a3f8c1ab_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzYyMw_3bcdb1e1-77a4-46cf-ae57-ada43fb376ed"
      unitRef="shares">2516102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="ia838f5b6a3354692a049e285a3f8c1ab_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzcyOA_da2d94dc-6979-4486-878e-615d8aae6d1b"
      unitRef="shares">7814677</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i23ce38f7c67443e49e518a149cc81961_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzg4NQ_53c796da-e5b8-40ce-8f57-97b463dc755d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i23ce38f7c67443e49e518a149cc81961_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfMzkyNw_47bd4304-d758-4ab4-8620-57cde8b3f6d5">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i0da088e105ad4f18ad8b9d31ec870555_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDIxMA_a98ebb2c-3bc5-42d3-ba8e-b41c3cb8d1f1"
      unitRef="shares">2516141</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iacd59942851345caa9bfa5f0f8f2c395_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDMzNg_ca086abd-b82f-49a0-bbaa-8b04948cd8ab">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="iacd59942851345caa9bfa5f0f8f2c395_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV82Ny9mcmFnOjAyYThkNGU1ZGYyZjQxN2VhOGNjYTU5YzVmZmZmNjc3L3RleHRyZWdpb246MDJhOGQ0ZTVkZjJmNDE3ZWE4Y2NhNTljNWZmZmY2NzdfNDM3OA_933320bd-4ad3-4e04-9eb2-8319657afb85">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RleHRyZWdpb246ZmY5OTJhNmFmN2JlNDZiNjk3YTdmNTkxYzJjNzYzNDZfMTY4OA_9a87be53-b378-49d6-a6e1-c3b685faf93e">Net Loss Per Share &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2021 and 2020, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three and six months ended June 30, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,330,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,193,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,962,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,563,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,622,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RleHRyZWdpb246ZmY5OTJhNmFmN2JlNDZiNjk3YTdmNTkxYzJjNzYzNDZfMTcwNA_1edcd22d-dbd0-4221-ba5c-1d6a7bb40d10">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three and six months ended June 30, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,330,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,193,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,516,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,868,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,962,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,563,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,622,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7720390ee14d46e0af301a676fc1e147_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMi0xLTEtMS0w_f3d99dbb-1856-46d7-b279-dfe33f1e935b"
      unitRef="shares">10330818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idcbd43fff7ff49d2b5186181ccc1ee3e_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMi0zLTEtMS0w_92f99fb6-b484-41cb-87ae-081bdd9dc7c6"
      unitRef="shares">9193096</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0df4c9eb1a604d84a5994034871feeb9_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMy0xLTEtMS0w_0344ba47-4bf0-48f9-b818-c481c806cde0"
      unitRef="shares">2516102</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i45c9b4d010164a689b6d9c3c41f23c03_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfMy0zLTEtMS0w_eeec3db2-6198-4a79-ad22-0fcb8e8c0322"
      unitRef="shares">2868665</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i36d2d9234b5a431cbf09724c62882b4e_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNC0xLTEtMS0w_576fd6c9-51fc-4241-9e39-d1e09102fcbf"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i59ae4261b99c4a6e810082721dff0e62_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNC0zLTEtMS0w_7ae202b5-8881-4ed7-b67b-aaa0d67a6a0f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c583306369d41e29983388433b751ce_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNS0xLTEtMS0w_0385d3f0-ab63-45be-923c-e85042a96630"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib9fb06d2b7b14b53aa4aa3861c628292_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNS0zLTEtMS0w_ed33e299-f63e-456e-9302-8f1e3adc3c80"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i97026c92ba624f5eb88dedb4f4fd222a_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNi0xLTEtMS0w_0c510df4-7a20-423c-85c5-a2040e446204"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4b6b2ddbdd8e403393dd968eb554812d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNi0zLTEtMS0w_845bf092-ab43-4527-982b-32d3a0aabcc1"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i409887a8fa6a4346a1975b51ea0e7e16_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNy0xLTEtMS0w_3a39d1a3-ba69-437d-af38-9bae657b34e3"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1b2caeab20c408da8ce4dbb3e47ca39_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfNy0zLTEtMS0w_81a187d2-9ea2-4a32-b8bd-9c51fa200c2c"
      unitRef="shares">4962364</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f3835a374c242d7a7e25920391ff721_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOC0xLTEtMS0w_d43beb5b-ed3a-4494-b68d-c97d407401d2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibc6843efcb854eb59c1d1c8cfa5945bb_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOC0zLTEtMS0w_c81f33e2-a572-4737-b31f-1b807d2aaeb5"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOS0xLTEtMS0w_1274b78f-3c26-4f8c-932f-c20b96c4f2df"
      unitRef="shares">16563562</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83MC9mcmFnOmZmOTkyYTZhZjdiZTQ2YjY5N2E3ZjU5MWMyYzc2MzQ2L3RhYmxlOjg3MWU3YTU1MmM1ZTQ1ODZiYjVkYWUzMTYwMzVhMmY3L3RhYmxlcmFuZ2U6ODcxZTdhNTUyYzVlNDU4NmJiNWRhZTMxNjAzNWEyZjdfOS0zLTEtMS0w_3613fc8b-cfd5-4359-b282-acfe948c4de0"
      unitRef="shares">32622537</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzQ2OA_ba86273c-94ee-4596-a359-f927a1bb3347">Stock-Based CompensationThe Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.67%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2021 was $5.3 million and $14.5 million, respectively, of which $2.7 million and $7.9 million, respectively, was included in research and development expenses, and $2.6 million and $6.6 million, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 was $3.4 million and $7.1 million, respectively, of which $1.8 million and $4.1 million, respectively, was included in research and development expenses, and $1.6 million and $3.0 million, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, there was $19.8 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $5.25 and $7.91 for employee and director stock options granted during the three and six months ended June 30, 2021, respectively, and $9.52 and $6.19 for the three and six months ended June 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, there was $16.8 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.1 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $6.81 and $10.64 for service-based RSUs granted during the three and six months ended June 30, 2021, respectively, and $14.50 and $9.12 for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2021 was $308,000 and $737,000, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2020 was $224,000 and $607,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 28, 2020, the Company granted 663,353 performance-based RSUs to executives under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The total grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the six months then ended.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzQ2MQ_47f9f521-238a-4c8d-8aee-3a2af73efbe7">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.67%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0xLTEtMS0w_6ca20cac-c17a-4bd9-b885-702639153b7b"
      unitRef="number">0.0099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0zLTEtMS0w_f1e290c9-e71d-493e-8700-fed03ae91475"
      unitRef="number">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0xMC0xLTEtMA_861b542e-fb42-4792-ae9b-a8c7911cbd3b"
      unitRef="number">0.0090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMi0xMi0xLTEtMA_58031023-9612-40e9-abc9-1d6db94b4298"
      unitRef="number">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0xLTEtMS0w_366f8b5f-adf0-4aea-830d-7f3697c72ed4"
      unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0zLTEtMS0w_9276f002-b897-44b2-96cc-fc054379a05e"
      unitRef="number">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0xMC0xLTEtMA_3f6033da-f35b-48e9-b15a-0cd99d0a47f3"
      unitRef="number">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfMy0xMi0xLTEtMA_e64742f4-26ac-4653-a238-75e7abcf26ac"
      unitRef="number">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0xLTEtMS0w_13ca4ba4-18b1-4ed8-a696-0399cf426b70">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0zLTEtMS0w_dcde58bf-2c2b-4d80-bfbf-ab84058264d2">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0xMC0xLTEtMA_92265260-98c2-4925-a4a2-8e083d9f2c10">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNC0xMi0xLTEtMA_927d5446-7b00-4735-8cdd-5e6b73f38dd8">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8c82d52150b4412bbdcc8383c97d72ee_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0xLTEtMS0w_b014b87d-4c66-42df-97a7-a2630de1110a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8dbda995783e41a0a6d0e95132df130a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0zLTEtMS0w_043c035c-7bf9-4076-9e42-812d293856ec"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2dd1a60f82d840b08ae5b2df79b49a97_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0xMC0xLTEtMA_91ce95b7-b2c7-4b9e-a544-7faa789b13de"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3a16d6d2ba204402ac461d5edc6697cc_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RhYmxlOjczNmUxMjZhM2NkZjRiMTRiYTg0ZjFhZDZjYjdhOTAwL3RhYmxlcmFuZ2U6NzM2ZTEyNmEzY2RmNGIxNGJhODRmMWFkNmNiN2E5MDBfNS0xMi0xLTEtMA_b46cbb72-9fbb-4847-ba99-802b4b12e5f1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="i6840ef28448241779743cf158cd253ec_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTU5Mw_e23da35d-6a10-4c67-95d2-13105b8e5d8e"
      unitRef="usd">5300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia9220dabb97347baaad3b955c7ca131c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTA0Mw_ee630796-2058-4bb2-86b7-69b108fc1d11"
      unitRef="usd">14500000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice27ffbaffd34874afe23deb45a41f1d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTYyOA_748daee0-5f9d-4561-a7af-85ce944ba868"
      unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i75baa0c985dc4a80846a6c09d447a541_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTA1MQ_b622ed32-1613-436c-a094-055ecf455296"
      unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib01f6e99b41046cea288d454a397131b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTcwOQ_95efca10-9ce7-4f65-9081-3c02ecedf689"
      unitRef="usd">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c4a44eb23a64f2a8177b06eccfd5462_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTA1OQ_4ea39423-08ca-4ac9-a03c-ecb57ef0e909"
      unitRef="usd">6600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="idf811d4883d349a090d95c8c69bfc003_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTU2MQ_e9104dd1-1fcc-48dd-9bde-9c366af025a2"
      unitRef="usd">3400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9e764caa439a41a78c114122d5dd11fb_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTU3Ng_6331f805-f344-4071-bacd-3c104832fa1d"
      unitRef="usd">7100000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i516d344bdae6478b9cbb0eb47830b5bf_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTU5MQ_f87b1275-f920-4e97-a2a4-55cfc278c8c4"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56a074845daa435895695e2ec5b8a0a9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTYwNg_1423cfed-ad04-452d-b0d6-b774e5b16cd3"
      unitRef="usd">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7fe878a23244e578b1d0fe5755cc0fa_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTYyMQ_36557eab-2f3a-4e85-9d32-9d0a1825a12f"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6adba9b5cfe8432498fb5b3d434a4541_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTYzNg_d3c03e12-87e5-4f9f-a152-5b104a4e5bca"
      unitRef="usd">3000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTgwNA_b274ed58-e0b5-42ce-af66-37a4e6a27bfa"
      unitRef="usd">19800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMTk1NA_a7b1be83-797b-4042-a569-ca967dd6bd46">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjA3Mw_1ec68efb-a513-4d67-a91e-9085a2eab919"
      unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTY3Mg_dd69aae0-c431-42c7-9c3c-6aa060dc4fe7"
      unitRef="usdPerShare">7.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTY4MQ_f0758b85-6649-4814-9d0d-da516f0337fa"
      unitRef="usdPerShare">9.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTY4OQ_e93758c9-9e61-420d-8ee9-1e12f2629087"
      unitRef="usdPerShare">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i4c44a7a4bb0e423fbd2ec314824724ad_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE4NQ_54c60ec4-5c33-4f19-9ab8-2dc7520b8f4f"
      unitRef="usd">16800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i084bec39b5ca4a51a9902a9ff9ad928f_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjM0MA_d2890122-7f97-4732-8734-83fe582354c8">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2eb3f0be101b47a18fcc503057ad42f1_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjQwOQ_1a46fc2c-74ee-4c37-a1a8-e34622208b3d"
      unitRef="usdPerShare">6.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i084bec39b5ca4a51a9902a9ff9ad928f_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTcyMw_18c82345-cb94-4968-958a-0723586f1d79"
      unitRef="usdPerShare">10.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7334687cb4a947de92ae0eb9f74ab59d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTczOA_8b2e6859-cc5f-446a-905e-e6c1c05cd803"
      unitRef="usdPerShare">14.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icc5e991cb67b41b5987aee77b9140631_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTc0Ng_c2b9ee2f-d780-4afa-aed9-a2261cb794a3"
      unitRef="usdPerShare">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="i73f8e4b6b88849388af7af4775429f82_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjcwOQ_845c8a17-1577-4818-8cec-81b7d9584caf"
      unitRef="usd">308000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8cfb07957bc8448e898eec6cc1d4f178_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTc5MA_f356b316-e003-4a04-ac2c-7b89edf846c6"
      unitRef="usd">737000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idab9cee1a62047fb8051e1d941df796b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTkwMQ_5bdddf2f-0e25-43e8-9707-b8dcd1109f04"
      unitRef="usd">224000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0e3baa7582b441aab8b2cad5aea5a16d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjE5OTAyMzI1OTkwOQ_b17baf67-fa76-48b0-9b0f-dda34fc86d3c"
      unitRef="usd">607000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjc3NQ_da6d55b2-c6f2-4c32-b674-19c9eccf24fc"
      unitRef="shares">663353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3e5ffc18c04b4a18bc872e736b8e3274_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMjg5Mw_467cf288-e0a1-4fbb-8874-ed7846a6622d"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2ff71523015949a3a75328d8f76bc7c6_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzAxNQ_0f2bd72e-4f4c-47cf-be2e-42d4fd3290de"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2ff71523015949a3a75328d8f76bc7c6_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzQ2Nw_aeb7db25-0eda-4587-ac1f-fa75a5e8d281">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
      contextRef="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzE4MA_c42d9ef5-a9ff-44c0-b550-86a775d2d840"
      unitRef="usd">8000000.0</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i780aa1f1696f415cbd91a5c56bc891cb_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83Ni9mcmFnOjc4MzU1OTI3NmFkNDQxODJiN2FkMzBiY2IzNjY0MmZjL3RleHRyZWdpb246NzgzNTU5Mjc2YWQ0NDE4MmI3YWQzMGJjYjM2NjQyZmNfMzIzNA_5ca6d13d-842d-49d0-9426-abb0bfe2ef07"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzAwMQ_20a3a806-a59b-4e1e-a5d7-5813d2a7e3e7">Related Party Transactions&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owned 597,808 shares of common stock in PLS as of June&#160;30, 2021, representing a 19.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the three and six months ended June 30, 2021, the Company recognized revenue from PLS of $75,000 and $125,000, respectively, and $64,000 and $1.2 million, for the three and six months ended June 30, 2020, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $99,000 and $67,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under the agreements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a dMAb against the Zika infection, with funding extended through December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and six months ended June 30, 2021, the Company recorded $381,000 and $610,000, respectively, and for the three and six months ended June 30, 2020 the Company recorded $73,000 and $691,000, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill &amp;amp; Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three and six months ended June 30, 2021 were $1.2 million and $1.6 million, respectively. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2020 were $408,000 and $770,000, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $617,000 and $425,000, respectively, and an accounts payable and accrued liability balance of $1.8 million and $643,000, respectively, related to Wistar. As of June&#160;30, 2021, the Company had a prepaid expense balance of $303,000 and recorded $69,000 as deferred grant funding on the condensed consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="iec5758f42e8641cca8f706945d684248_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfODQ_05b3d833-9369-465e-a58c-50df5a65a8cb"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iec5758f42e8641cca8f706945d684248_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTQy_d78f8991-1283-4b39-a71b-6366538e01b5"
      unitRef="number">0.197</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58f2d9f6575543589f663ac5ade5d146_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzg5_f1b62da8-231b-4adc-985f-9a5c96492744"
      unitRef="usd">75000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice4430b09f8f4a3d9c5b6e2ef7fa048f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODU2OQ_7c0a06b2-8f5a-4311-a717-33116539ae94"
      unitRef="usd">125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bfa0efcd5e94977acef14e343d8c32f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzk2_d875a8f7-c9c3-4b33-ae33-4d64d70d4be0"
      unitRef="usd">64000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9758e3169bf42408ff0026a43dd6c32_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODYwMg_bff310a8-2454-4221-a06e-9ccf4d614542"
      unitRef="usd">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i39000bc0ed2f4334bb3f0d81cbac8fef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfNDc4_50506fca-c2df-42f1-b37f-c6834ab6871e"
      unitRef="usd">99000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i6b00238ffc3b48c5a7ddb81b78793302_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfNDg1_d022ca21-9715-48c0-9492-206da951546f"
      unitRef="usd">67000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="iee4bc461464046a39879834a877ac90d_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTEzNw_a6af9b91-8dc9-4b2c-a8c1-443bd8b03f75"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="iee4bc461464046a39879834a877ac90d_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMzAwMA_d3dbf049-904e-45ea-9fdf-84619d4011b0">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i9aaebaef4a484e99a1f72fd27c49260c_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTQ5MQ_0c24aac8-0266-4124-b9b2-1b86144f631a"
      unitRef="usd">6100000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i0db0b6c7420847968706776cec806a32_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMTc5OA_9efb4de4-1e54-4e97-b92e-e0a32ca9329c"
      unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount
      contextRef="i0db0b6c7420847968706776cec806a32_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjAxOQ_ed8f1e69-da19-419e-b943-9be3901736e7"
      unitRef="usd">6000000.0</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:GrantProceedsReceived
      contextRef="i8fbd471a37474f43870e9353685a3362_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjI4NA_6f5a95b7-4759-4c31-ae28-0a9d3bcb63a2"
      unitRef="usd">381000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i647dbd99928840369aa848a876ffaef7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODYzMg_b3292c1f-280b-40f7-870f-3fa4efeeec09"
      unitRef="usd">610000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="ifc72a58c0cfa4fec9b889e44cf304615_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjI5MQ_fad80534-6ba6-4e02-80e1-fcb2062c4930"
      unitRef="usd">73000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="id9cf11cba38341b4909eff0dd1632ec2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODY1Nw_c1950bc0-20cf-4ba6-b7c2-37a0e66ac506"
      unitRef="usd">691000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i8fbd471a37474f43870e9353685a3362_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjY1Ng_b42af1f0-dbcd-4893-ad75-e1b5bfaca092"
      unitRef="usd">1200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i647dbd99928840369aa848a876ffaef7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODcxNw_a27078bb-2a7e-43e4-a55b-4f0bf94b5d99"
      unitRef="usd">1600000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ifc72a58c0cfa4fec9b889e44cf304615_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODc5NA_67f335bf-322a-4fde-867b-b13cb5ffad39"
      unitRef="usd">408000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="id9cf11cba38341b4909eff0dd1632ec2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODgwMg_c0daf182-45b7-4464-bb41-16cf974744db"
      unitRef="usd">770000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjc0NQ_e311e02a-05b5-46f4-8d28-998fbea5d82d"
      unitRef="usd">617000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i79aa827c9e8f4b358c9a1724e62d1c61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjc1Mg_a74eada0-adc4-49bb-aa24-8d284d68b692"
      unitRef="usd">425000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjgyNw_91a49798-f729-4a4c-b6ad-e4f7a9b76922"
      unitRef="usd">1800000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i79aa827c9e8f4b358c9a1724e62d1c61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjgzNA_5044466e-e3b1-4b36-9360-87e31bd3fc5a"
      unitRef="usd">643000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjE5OTAyMzI1ODkxNQ_e5998e4c-51da-4729-b305-03ee9cd1372f"
      unitRef="usd">303000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="id242696b659b49afadf87dff3bed0cc3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV83OS9mcmFnOmRkZmE5MzZmNWJkZTRlYmQ5YjBhOWUzNTAxMDQ2OWI4L3RleHRyZWdpb246ZGRmYTkzNmY1YmRlNGViZDliMGE5ZTM1MDEwNDY5YjhfMjg5Nw_5340306e-2b3c-4338-a81f-e0ae7e9b1abf"
      unitRef="usd">69000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzA4MA_835f5093-bae0-439a-9a69-f18d6083b729">Leases                                                  &lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 2.4 to 8.5 ye&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of June&#160;30, 2021, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,014,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,753,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,261,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,464,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,797,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2021 were $827,000 and $1.7 million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 were $814,000 and $1.7&#160;million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i66a148722afa41b185cd4eef30e25fdb_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMTAw_3024b95b-271d-4334-9723-21af44c75094"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i1b665a2cbce54f4a94dd8ecf309380fd_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMTkx_0fa56284-d401-45ef-8768-2873069e2e00"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i3ae75de8f5854856a0f90d658ba0bcd8_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzUy_a9c01808-9aaf-442a-9d34-45bfede6b5ea">P2Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i110b3be318af4daab8582df0596dd792_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzU4_35ea9eef-4f8d-40b2-827e-cbc29e39e553">P8Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMzA3NQ_a39ea3f2-841d-4ce5-9b86-a1b722dee5d0">As of June&#160;30, 2021, the maturities of the Company's operating lease liabilities were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,014,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,753,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,261,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,464,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,797,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMC0xLTEtMS0w_340339c0-f566-4087-b430-1cb1111919ce"
      unitRef="usd">1994000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMS0xLTEtMS0w_0c52723a-bd0d-42ae-b40d-423e82c29ffc"
      unitRef="usd">4045000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMi0xLTEtMS0w_cedb9b5b-6a19-4e97-a83b-6e788a574425"
      unitRef="usd">4023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMy0xLTEtMS0w_e3cdfe75-b735-4fda-adf3-b2c496de7dd9"
      unitRef="usd">3001000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNC0xLTEtMS0w_d0daaddc-27e3-4b66-a830-a3cda5b7fb3e"
      unitRef="usd">3063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNS0xLTEtMS0w_6a685fe2-6027-4485-80ac-677c22f6a5ac"
      unitRef="usd">9888000</ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNi0xLTEtMS0w_b0fa9b61-dd8b-4ac1-8478-21521da1e3d2"
      unitRef="usd">26014000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfNy0xLTEtMS0w_faf1f1c6-2dcd-4e18-9681-0b7c6d389bb4"
      unitRef="usd">6753000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfOC0xLTEtMS0w_8ebdb49d-3795-4ef9-a0e7-82fdd3fdac22"
      unitRef="usd">19261000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfOS0xLTEtMS0w_39d8b7db-8e4c-4b57-a557-b529bc36c9b4"
      unitRef="usd">2464000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMTAtMS0xLTEtMA_e0bb14df-f6d5-4742-8ada-af8e59385a35"
      unitRef="usd">16797000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMTItMS0xLTEtMA_689479df-31b9-4fa6-ba55-fb20459309c2">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iad1208ba98074d448260b48944e05ebe_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RhYmxlOjUwZWI1ZWFlMTE3ODQ0MTI5MGI4ZTk4YjE1NzdiM2FlL3RhYmxlcmFuZ2U6NTBlYjVlYWUxMTc4NDQxMjkwYjhlOThiMTU3N2IzYWVfMTMtMS0xLTEtMA_f18e896c-b86a-4d00-b711-b72d27f8d65d"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjAzMw_6e299373-fe4d-445a-b4b1-ddbde5d93ce3"
      unitRef="usd">827000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjA0MA_d61b0063-eea7-4e9e-ad2b-7203b43cec37"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia9162d7cd9cb4b96bfce32cbdebc2e93_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjE5OTAyMzI1ODgwNg_75cc8e3b-a8eb-475c-9ea7-c54e10ebc6a6"
      unitRef="usd">814000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7dc362b9ccc1419fa8c5dcd71b86986d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjE5OTAyMzI1ODgxNg_9d0e2881-04e7-46fc-acf3-b6705b53fac3"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseNumberOfAgreementsToSublease
      contextRef="i0dc2a7ba5e24419aa07ad87b72b18c9c_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMTA0NDUzNjA0NjcxNzU_e5efa4cc-f2c9-4724-b78b-9adab6c88f8d"
      unitRef="agreement">2</ino:LesseeOperatingLeaseNumberOfAgreementsToSublease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i8db89a2c66514d7498b690857971a626_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84Mi9mcmFnOjYyY2IyMzRkZDIxNjQwYzhiNjIyNjQ5ZWM0ZTg4Y2NmL3RleHRyZWdpb246NjJjYjIzNGRkMjE2NDBjOGI2MjI2NDllYzRlODhjY2ZfMjM3NA_1022eb1b-8898-4ad8-8244-9a7ac2046bc0"
      unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg5NjQ_4566662c-fb2d-4c3b-b4f2-84f5c8bb7fb0">Collaborative Agreements&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated on June 7, 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#x2019;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#x2019;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred in conducting the trial in Greater China. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#x2019; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $206.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#x2019;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, the Company will supply Advaccine&#x2019;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#x2019;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#x2019; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#x2019; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. For the six months ended June 30, 2021, no revenue was recognized from Advaccine. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company had an accounts receivable balance of $0 and $7.1&#160;million, respectively, from Advaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reevaluated the Advaccine Agreement under ASC Topics 606 and 808 as of the date of the June 2021 amendments and determined that the Global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore should be accounted for under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2021, no contra-research and development expense has been recorded from Advaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018 which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price. As of June&#160;30, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payme&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nt. In both December 2018 and March &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019, the Company recognized as revenue $2.0&#160;million in milestone payments from AstraZeneca triggered by AstraZeneca&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three and six months ended June 30, 2021, the Company received funding of $2.1 million and $4.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. During the three and six months ended June 30, 2020, the Company received funding of $1.8 million and $2.9 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of June&#160;30, 2021, the Company had $316,000 recorded as grant funding liability on the condensed consolidated balance sheet related to these CEPI grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three and six months ended June 30, 2021, the Company received funding of $1.1 million and $3.5 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. During the three and six months ended June 30, 2020, the Company received funding of $5.8 million and $8.1 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of June&#160;30, 2021, the Company had $2.9 million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Bill &amp;amp; Melinda Gates Foundation (&#x201c;Gates&#x201d;) awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three and six months ended June 30, 2020, the Company recorded $36,000 and $170,000, respectively, as contra-research and development expense related to the Gates dMAb grant. During the three and six months ended June 30, 2021, the amounts recorded were minimal. As of June&#160;30, 2021, the Company had $575,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device for the intradermal delivery of INO-4800. During the three and six months ended June 30, 2021, the Company recorded $0 and $893,000, respectively, and during the three and six months ended June 30, 2020 recorded $850,000 and $913,000, respectively, as contra-research and development expense related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5 million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 2000 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;devices will be used to inject&#160;INO-4800&#160;in the Company&#x2019;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6 million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2021, the Company recorded $13.4&#160;million and $21.2&#160;million, respectively, as contra-research and development expense related to the OTA Agreement. During the three and six months ended June 30, 2020, there was no contra-research and development expense recorded related to the OTA Agreement. As of June&#160;30, 2021 and December 31, 2020, the Company had an accounts r&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;eceivable balance of $12.9&#160;million and $11.4&#160;million, respectively, on the condensed consolidated balance sheet from the DoD. As of June&#160;30, 2021, the Company had $3.0&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to the Procurement Contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfODgw_63a704dc-cd19-4f2e-b558-b41508f4edde"
      unitRef="usd">3000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfOTc3_967c41fc-421d-4374-b753-52bfc8bbef63"
      unitRef="usd">206000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI2MQ_623f4004-90a8-4559-a60c-076194754f2b"
      unitRef="usd">2000000.0</ino:CollaborationAgreementPaymentEarned>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTgyMw_c800ef08-bb39-4faa-9aab-bd20340612b3">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <us-gaap:CostMaintenance
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY3MzA0Ng_48836268-f8a3-4ce2-97b1-23d0ca8915e8"
      unitRef="usd">1500000</us-gaap:CostMaintenance>
    <ino:AnnualMaintenancePeriod
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY3MzA1OQ_0c8f691e-7165-4d9d-a91c-b301d25a822b">P5Y</ino:AnnualMaintenancePeriod>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNTE0Mw_24cc1e0a-1ffd-48a7-9a52-7d1fd742360a"
      unitRef="usd">3000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i5227904b0a264b85bff5b99058ce869c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNTE3OQ_be403dff-14ca-440a-934f-19c28cd287ed"
      unitRef="usd">2000000.0</ino:CollaborationAgreementPaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c8ad24eca624a71a7fb21cdcced5abe_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjA1MQ_fb490a6d-dd71-4f5c-8425-aacc92717aa8"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica98223bf1ed447193c67fa870204517_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjMzOQ_8745c875-700f-4927-8702-6d9a8a69a920"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71ccd78a11244d749d8dd9859e9ce310_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjU0Mg_76385e7f-f090-49e9-b99e-fde92b9e3de8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="ic44786c100124c789efc53e8f92bfde9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjY2NQ_5efd3ac0-ec27-4e8e-8e54-9d9401db7dc8"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i95c7a96f00054646b6f751e13b02c56e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNjY3Mg_df278630-131d-49cb-a977-e2af841dd536"
      unitRef="usd">7100000</us-gaap:AccountsReceivableNet>
    <ino:CollaborationAgreementTerritoryExpansionOptionPeriod
      contextRef="i72b40649a6a84f138cb3a6dcb7498815_D20171229-20171229"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzMzMQ_3a93bcdd-4150-4872-b599-c14fa245fe57">P3Y</ino:CollaborationAgreementTerritoryExpansionOptionPeriod>
    <ino:ProceedsFromCollaborativeAgreement
      contextRef="i537aa32e3c5f4baf82bacfc6e7b0d869_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzQ1NQ_fb3c0a17-602f-4ed5-b915-07687a10cb7f"
      unitRef="usd">19400000</ino:ProceedsFromCollaborativeAgreement>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i537aa32e3c5f4baf82bacfc6e7b0d869_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzUxMQ_64139942-1595-4585-b055-6123a3f27d08"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementCorporateIncomeTax
      contextRef="i564bbcf0dabf424f86f296be903e20b0_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzUxOQ_c3e5173c-473c-45f7-ab79-2d7f30179fd4"
      unitRef="usd">2200000</ino:CollaborativeAgreementCorporateIncomeTax>
    <ino:CollaborativeAgreementForeignNonIncomeTaxes
      contextRef="i564bbcf0dabf424f86f296be903e20b0_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzU1MA_2f93122c-12cb-4779-a80d-4947dd00247f"
      unitRef="usd">1400000</ino:CollaborativeAgreementForeignNonIncomeTaxes>
    <ino:CollaborativeAgreementAdvisoryFees
      contextRef="if69d1eee3fca4367a054a928d24cff8d_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfNzg0Nw_d98c6654-459b-45ec-a45e-01e04cdbb718"
      unitRef="usd">960000</ino:CollaborativeAgreementAdvisoryFees>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfODQzNQ_a3c1a741-3221-41dd-9de7-c6ecd7eb7272"
      unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfODk3Ng_34251167-ef36-4b1d-8db1-575f9c39bf82">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfOTU5OA_a1b55f01-7353-453e-ae96-f801fdd538e7">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfOTY0Ng_6f2d5c56-feaf-4f96-b01c-7617a32ee41e">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i0483a57c827a4cc692e46b94a7b7a7de_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTAxMzk_be318aaa-a6ee-4599-bc4d-f8ff7509ac8d"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ia92556534d574bbc94e10cc84341c759_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTEwODE_da817e58-999a-4510-a74c-7e65c5efdb20"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="if9ad39f285414f30b79535cfaba7daa2_D20150901-20150930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTE3ODk_d67b0ea2-6274-4a75-99b5-4c877e309873"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
      contextRef="iba45b8937a894f6b9a5129658feedbc3_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTE5NTg_2e1131f2-5108-4063-853e-39ba8e5f7dcf"
      unitRef="usd">125000000</ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones>
    <ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones
      contextRef="iba45b8937a894f6b9a5129658feedbc3_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTIwMjk_fc2dc210-a5eb-41fe-a9a5-79a131cfbee0"
      unitRef="usd">115000000</ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ie861c939ef624bffbd0b88dbfdf9c693_D20171231-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI2NjI_27d510e1-f034-49b9-b51c-c765fe84644f"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafce45fcd5d548d596dd6d619e8eacd5_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI4NTk_4e722d95-06a0-423b-a52d-da644be9072a"
      unitRef="usd">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46c98d6b5b8a4c33898800f47a20e3ff_D20190302-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTI4NTk_f4e18242-c6ba-49aa-97b7-f7f20ca3f684"
      unitRef="usd">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i42ff72c6a8dc403c95f8ee874839211b_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTM3MjU_3addfadb-0c08-494b-b5de-9a06be1d4bec"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="i42ff72c6a8dc403c95f8ee874839211b_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg5NzA_f47e5e61-70d4-44f4-88de-00d47fc6778b">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i3df90724be6143258a8fdee15d4e93e6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQwMjA_f5214ea3-babb-4453-8529-bdd388db59e0"
      unitRef="usd">2100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i6407575bd8b340a1a2a8f8810560320a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NDU2Ng_1580d5e1-00c9-4c5e-bfbc-ac0c17fa5a60"
      unitRef="usd">4400000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="icaeaf41dd77446d3927ea1c114867dba_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQwMjg_faa85148-ec4e-42ac-9015-cc2bdbec3a78"
      unitRef="usd">1800000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i192e249f20ad47fd87c6efd63533083b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NDc0MA_82208bf6-c674-4fec-bf9d-8f3dce751f82"
      unitRef="usd">2900000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="iaca810872ff8493db0d62372edb6bd01_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQxNjg_36b8dd01-573f-404c-aa77-00b3cacc0957"
      unitRef="usd">316000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i8220fcd140d74557b083a926e4253873_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQzMzg_01e96986-9362-460b-8de8-71181b76c55d"
      unitRef="usd">9000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i03b88e02327942f9ae78274a728a6c7a_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ1MDQ_d25e38fa-9dbe-445e-ad16-d4db2bf5aa03"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i761da9fe1ff8435f937cde9607056cae_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ2ODI_e4474587-6dcd-4f04-b934-d4ffb4aff966"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="id78961ef0362494d9ca8a3a24f0402d9_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ4NjQ_fe9d8ec9-1737-4f04-9bcc-3301ef426e36"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i63751304353e47dfa5578ae4af319b3b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTQ5ODE_6f6eeff9-e327-4ff9-a2fd-c3f03163a87d"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="iae69df542d9c4fbab5f22042b834a657_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NDc2NQ_a4afe879-c2cd-416e-b482-5a7e138a8324"
      unitRef="usd">3500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ic5944f9592ca4638842dcafe5504d740_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTY4MA_7344b8be-da18-4a2b-a235-ab534c51281e"
      unitRef="usd">5800000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i7f7c6a9e4960494e8081fc7f145ad847_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTY5NQ_b9f3e579-2846-4e27-a09a-d08d33280488"
      unitRef="usd">8100000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="ifa54cd5e2c5b4aee983f8f582c668686_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTUxMjc_ca849f53-1dcc-48de-a747-f1dfdbe25890"
      unitRef="usd">2900000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ieda7c74c79e1485082bb7462bb0aec90_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTUzOTQ_1c08ffc1-9e52-4b9f-af16-d7b198088c6a"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i02069efe34d14945a75f312034c48d56_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTU3NTc_41150b0c-a5f8-4275-bc48-f0e1dcbaaa54"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i97a4ecfa456040578debe0c705bb0cb0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTgyOA_ed2f903f-5192-4ddd-87db-374cbb7e82ee"
      unitRef="usd">36000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i904f52b9d85542868818618a457d155a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTgzNw_b552e022-e5a2-4587-b9f0-d49767e716f5"
      unitRef="usd">170000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i7e44b859e87640b9887e249f509f22b2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTU5NDk_4133064a-a5b6-42c2-a084-711a74559ff4"
      unitRef="usd">575000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ia079900790b44ee39d2535ab8a76f7c7_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTYxMTY_fc1453ae-92e2-47ed-94a5-02beb9df5d44"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i01f7a9d3dc10499f8b65f4f3b1c7d04b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTYyNjY_3c44e4ab-8839-4c3d-80fe-d53feff0cee2"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i8772e190853b4c34b869b43e00154114_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTYyNzM_471a0ce2-4ea4-4a2d-9488-d1fc7fe20908"
      unitRef="usd">893000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i7f531494334b4657bad6357a54553f03_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTkyNg_140ca0cd-63ed-4337-9c63-8ae66fe08195"
      unitRef="usd">850000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i1282eb1a458f4357a1ac8a3d8b4fa3ea_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTkzNg_e5f596b3-95e2-4d94-b922-f71e0b776971"
      unitRef="usd">913000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="iba1c591d1f53449fb9a0ca78b60e0636_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTcyOTM_131b5ee0-fc32-4c56-bb86-0089524b125a"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i40b6bab09ed848df86ba826cc4961c16_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTgxNTc_afe4a9bb-ab02-40b7-ac25-6227b1359735"
      unitRef="usd">16600000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:GrantProceedsReceived
      contextRef="i56b4d555b69d4dca91e2e11a14be2165_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg0NDI_4e8905e3-c4de-41be-aea9-9c1339e7e796"
      unitRef="usd">13400000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i4b1efaad3a5848b9b2664bb608171aa6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI3NTk3OQ_60de2c7e-d9a1-4cb4-af87-53ab77c025a6"
      unitRef="usd">21200000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="id32424115c5249fdab21269b2a97590e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY1OTEwOA_2acfd21e-e90b-48d6-bcc7-e2f70965ceec"
      unitRef="usd">0</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i44b465568e394137b0167411e7b5c097_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTA5OTUxMTY1OTEwOA_65a154a9-e252-411a-8db1-96130f79ab7e"
      unitRef="usd">0</ino:GrantProceedsReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ifdf3e49c10cc4f94a383960947e82228_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg2MTA_236c0795-749c-4e41-881c-d10e5e466168"
      unitRef="usd">12900000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i7e127c1524564bae89ca80e255ad2678_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMTg2MTc_587afa05-4bf4-4fa1-b618-e91fa2a8806b"
      unitRef="usd">11400000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:GrantsReceivable
      contextRef="ifdf3e49c10cc4f94a383960947e82228_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84NS9mcmFnOmQ0YWQ2ZmY3OWRiYjQ5YjZhYThlZTFmNTgyMzIzNTliL3RleHRyZWdpb246ZDRhZDZmZjc5ZGJiNDliNmFhOGVlMWY1ODIzMjM1OWJfMjE5OTAyMzI5MzEyNg_24d3efb4-38ea-4ca9-9ebc-409a545ced82"
      unitRef="usd">3000000.0</us-gaap:GrantsReceivable>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV84OC9mcmFnOjU3M2IzNmMyNmE5ZDQwZTZhMWVkZTZmNTJiN2QzM2FkL3RleHRyZWdpb246NTczYjM2YzI2YTlkNDBlNmExZWRlNmY1MmI3ZDMzYWRfMTcwMg_ddb29823-ddc1-44c3-a9ad-7b9647717e49">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;For the three and six months ended June&#160;30, 2021, the Company has not recorded any income tax provision/(benefit) due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTkxNw_bf157bc4-d8f2-4761-a735-2405265299d6">Geneos Therapeutics, Inc. &lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations. The following table shows the amounts related to the deconsolidation accounting: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#x2019; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#x2019;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption. The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#x2019;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. Since the Company&#x2019;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the period from June 1, 2020 through December 31, 2020 was $4.6 million and for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos from June 1, 2020 - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos for the three months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i0e185f6790bc47528495934e156680eb_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMzc4_98688c49-3a98-4970-97a3-76bff4461a14"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i4df2a303132e4f7f96ff6997a31a1212_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfNTA3_1d0814b1-dfb0-4bbf-aebc-03aff23723be"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="iccb9c884d87d48218ffe7d83101d494f_I20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODAw_5f88b623-e9d3-42e5-9513-77bb7e6fb7c9"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i5c02b65034ce49e890afd34400d720ae_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODcx_5ece1031-6daf-4b24-85ca-5f8ce4cd06ba"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i667c2fdb4d5345df8d39328da874e2ad_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTEyMg_9223dcd7-70c1-412d-9898-091d3f192c9c"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2fb35c7b8b7e4a2a8b77665cb4247493_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTE3Mw_4057eedc-f69f-42ef-8043-d2d0d69e1802"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTg0Mw_c2193de1-938a-47eb-a9a9-5926bf939370"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMTg1Ng_33e89b9c-1286-4196-9eb4-09f013101df8"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTkxNg_a4a6e329-2d3b-4b51-9389-9a5df0e0ab5b">The following table shows the amounts related to the deconsolidation accounting: &lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The remaining $4.2 million loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos from June 1, 2020 - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos for the three months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <ino:WorkingCapitalExcludingCash
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMC0xLTEtMS0w_e7784b51-3be5-4a21-b60a-45278deb4519"
      unitRef="usd">59992</ino:WorkingCapitalExcludingCash>
    <us-gaap:NotesPayable
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMS0xLTEtMS0w_1eb2796d-802f-4003-b0b3-3d38f2862174"
      unitRef="usd">171620</us-gaap:NotesPayable>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMi0xLTEtMS0w_9478d92c-a063-4c13-952a-5a9c900419a0"
      unitRef="usd">16340</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MinorityInterest
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfMy0xLTEtMS0w_2b3aae85-4467-4a0e-8403-92f7dbc49f25"
      unitRef="usd">3181640</us-gaap:MinorityInterest>
    <us-gaap:RetainedInterestFairValueDisclosure
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfNC0xLTEtMS0w_2503c74d-7db7-4466-b5a9-1bd0746143f9"
      unitRef="usd">3618998</us-gaap:RetainedInterestFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfNS0xLTEtMS0w_0ffa9403-8789-43d6-b2ee-2d7a60e17571"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i43d2470250a44f74a3600ceaa77c0bfd_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjU1OTFkMGEyY2YwMzRkZTg4YjYwZWM0OWYxOWQyMDc4L3RhYmxlcmFuZ2U6NTU5MWQwYTJjZjAzNGRlODhiNjBlYzQ5ZjE5ZDIwNzhfNi0xLTEtMS0w_f0ea8a5a-d42f-4ec9-abfd-3128dc7024d5"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iea7c36741569485ca8d859069b46f092_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfMjE3NA_f993d316-c0dc-4ae1-a473-f3cb09b85fd4"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i02456b81a37f4ae6a5c063b014c525f2_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMS0xLTEtMS0w_32d7e5c6-be53-4efb-964f-e759722f8eb4"
      unitRef="shares">3000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i02456b81a37f4ae6a5c063b014c525f2_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMS0zLTEtMS0w_1f09932d-92cb-4c16-8f2f-37e2ce347449"
      unitRef="usdPerShare">0.273</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i02456b81a37f4ae6a5c063b014c525f2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMS01LTEtMS0w_e8c8ad68-72fd-431a-8191-d1ad8c9e070b"
      unitRef="usd">819000</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i196f4528a0a9490b9a924875a4215545_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMi0xLTEtMS0w_b7b317b1-f7dd-47c8-988d-6b72f68b032a"
      unitRef="shares">2113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i196f4528a0a9490b9a924875a4215545_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMi0zLTEtMS0w_8a57d988-1d46-4ba5-9130-9b3134e05ab8"
      unitRef="usdPerShare">1.325</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i196f4528a0a9490b9a924875a4215545_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMi01LTEtMS0w_81fdb2e9-58de-4c37-96e8-14368008d753"
      unitRef="usd">2799998</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMy0xLTEtMS0w_1d2360c1-cb8c-4395-9b05-50afc222919f"
      unitRef="shares">5113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestments
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjc0ZGY4NDY0NjFhYjRhOWJiNDE3MTcwOTdkOGM0NzY1L3RhYmxlcmFuZ2U6NzRkZjg0NjQ2MWFiNGE5YmI0MTcxNzA5N2Q4YzQ3NjVfMy01LTEtMS0w_0c66099c-a89a-486c-b6e0-472ec61b119c"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTkxNQ_01cfd171-ebcf-477e-af47-1ce9ccc920eb">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:AlternativeInvestmentMeasurementInputTerm
      contextRef="i8ac9bc58c8414810ae3dff09c8e549af_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMC0xLTEtMS0w_a0df14b9-2cb0-464a-991b-f8644c8dbc84">P2Y11M1D</ino:AlternativeInvestmentMeasurementInputTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="if173908cc8354a3187bf1e82e65a5550_I20200601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMS0xLTEtMS0w_0cdea95f-46ee-4fc7-a7b6-8f608bdedce9"
      unitRef="number">0.70</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="ife9ba1ec7a1a485a8b2bda6032474f24_I20200601"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMi0xLTEtMS0w_1212bc4f-b404-485a-87e8-d5bff2d6cb25"
      unitRef="number">0.0246</us-gaap:AlternativeInvestmentMeasurementInput>
    <ino:EquityMethodInvestmentEnterpriseValue
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjhkZDQ5ZDY4NzhmYzRiYzU4NmJkOTFkMzA2OGY3NGQyL3RhYmxlcmFuZ2U6OGRkNDlkNjg3OGZjNGJjNTg2YmQ5MWQzMDY4Zjc0ZDJfMy0xLTEtMS0w_a82ab5df-b644-480e-a3b5-e2d40dc9937e"
      unitRef="usd">4966531000</ino:EquityMethodInvestmentEnterpriseValue>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i230f14716d1a4c2e895e45f0ed84c399_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfNjg4OA_960b9b05-ff8f-47fc-bf36-fb8294db97ce"
      unitRef="usd">1400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i9dcc915ba16e470c810717cdca71bc8a_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfNzUyMw_d5425773-ab7c-4833-955f-2997907cbae7"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="i751954486ff04a2585b50cca7a7a1f66_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODUwNA_65511e8d-5966-4e6d-acc9-8ab61e4e7d0a"
      unitRef="usd">4600000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="id548d70b807a41cdbafa0a873651db92_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODU2NQ_b34276a4-e034-4dfb-8060-ae815124da4b"
      unitRef="usd">1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id548d70b807a41cdbafa0a873651db92_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODU4Mw_606216bd-3e9e-4354-9e1f-765ec4be7da6"
      unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i603b348bf030425286b8663a7233f3b2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODY1Mw_b6761ba2-cd1b-46af-87a1-bacbd6b9f139"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie7eefa6dfb474f59a56c5498e9af5934_D20200601-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODY3OA_727fbd2e-ef9c-4015-9365-534eebe3b5af"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3ddd5fa80e1f4d619dac2b863cd3a051_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODc2NQ_5a40828a-ecb0-4500-9a9a-5492adc3c0ab"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id0b994018688462294e9fc2216b8b645_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODgwNA_559472bc-897d-4c36-912b-4e36e3e60d6a"
      unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i7eed2f09111e4adc973bc8d68b9050b1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfODk3MA_9bd730e3-68e4-4261-bf86-4269793d2a80"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="icb812a090bdf454a8d614a22e3087514_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfMS0yLTEtMS0w_e6ddccb8-daf4-4993-984f-97ce24badcdc"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i565b71404f58429384bf7e01598dd420_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfMi0yLTEtMS0w_205f797b-8dbe-40ae-bce5-44d9eade9819"
      unitRef="usd">1399999</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i751954486ff04a2585b50cca7a7a1f66_D20200601-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfMy0yLTEtMS0w_36e1ee23-6e85-4c85-b6fc-68f856c3d83a"
      unitRef="usd">-4584610</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id548d70b807a41cdbafa0a873651db92_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfNC0yLTEtMS0w_2af7a53d-8a37-4d39-a4ba-89a7652900d7"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i603b348bf030425286b8663a7233f3b2_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RhYmxlOjFmOGZmNzU0NjYzNTQ2NTQ5OTZiNWYwZjZiNzUyNmEwL3RhYmxlcmFuZ2U6MWY4ZmY3NTQ2NjM1NDY1NDk5NmI1ZjBmNmI3NTI2YTBfNS0yLTEtMS0w_c316c179-294b-427a-a8ec-f06a5b1ece87"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1ec0c50e342949c6b66d38190dde51e1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTA3Nw_f524c872-6f14-4387-a012-db9d2b850cd9"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ibc6d252ee23a41b88a2b37888e87aff6_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV85MS9mcmFnOjE5Y2M5MmNhOGRkZjQ1NDNiMTI5M2MyZjlhOGM5YWJiL3RleHRyZWdpb246MTljYzkyY2E4ZGRmNDU0M2IxMjkzYzJmOWE4YzlhYmJfOTM4OQ_3d11bc91-d899-42f3-a65c-7025aba635f1"
      unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348127689848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. GERMANTOWN PIKE, SUITE 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">PLYMOUTH MEETING<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,356,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043513832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 58,925,302<span></span>
</td>
<td class="nump">$ 250,728,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">384,752,382<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">13,128,330<span></span>
</td>
<td class="nump">18,559,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">722,941<span></span>
</td>
<td class="nump">503,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">84,592,179<span></span>
</td>
<td class="nump">40,357,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">303,491<span></span>
</td>
<td class="nump">106,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">542,424,625<span></span>
</td>
<td class="nump">471,170,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">18,111,288<span></span>
</td>
<td class="nump">11,348,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in affiliated entity</a></td>
<td class="nump">3,908,709<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,879,896<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">12,173,414<span></span>
</td>
<td class="nump">12,741,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,830,866<span></span>
</td>
<td class="nump">25,957,448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">591,842,169<span></span>
</td>
<td class="nump">539,772,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">30,095,578<span></span>
</td>
<td class="nump">21,203,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">1,773,846<span></span>
</td>
<td class="nump">642,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">10,416,164<span></span>
</td>
<td class="nump">9,950,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">109,128<span></span>
</td>
<td class="nump">46,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,463,878<span></span>
</td>
<td class="nump">2,329,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">6,859,155<span></span>
</td>
<td class="nump">7,474,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">31,250<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">51,748,999<span></span>
</td>
<td class="nump">41,705,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">71,788<span></span>
</td>
<td class="nump">79,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">16,797,476<span></span>
</td>
<td class="nump">18,063,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateNoncurrent', window );">Grant funding liability from affiliated entity, net of current portion</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">64,141<span></span>
</td>
<td class="nump">57,663<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">83,288,398<span></span>
</td>
<td class="nump">78,631,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">210,146<span></span>
</td>
<td class="nump">186,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,551,348,435<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,042,738,901)<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(265,909)<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">508,553,771<span></span>
</td>
<td class="nump">461,140,758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">591,842,169<span></span>
</td>
<td class="nump">539,772,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">14,536,448<span></span>
</td>
<td class="nump">14,139,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,515,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043636456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 272,824<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 643,945<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">70,808,418<span></span>
</td>
<td class="nump">22,376,575<span></span>
</td>
<td class="nump">109,852,836<span></span>
</td>
<td class="nump">41,487,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,666,341<span></span>
</td>
<td class="nump">11,071,510<span></span>
</td>
<td class="nump">26,547,535<span></span>
</td>
<td class="nump">18,519,864<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">83,474,759<span></span>
</td>
<td class="nump">33,448,085<span></span>
</td>
<td class="nump">136,400,371<span></span>
</td>
<td class="nump">60,007,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(83,201,935)<span></span>
</td>
<td class="num">(33,180,898)<span></span>
</td>
<td class="num">(135,756,426)<span></span>
</td>
<td class="num">(58,413,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">928,111<span></span>
</td>
<td class="nump">1,067,399<span></span>
</td>
<td class="nump">1,697,347<span></span>
</td>
<td class="nump">1,483,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(466,726)<span></span>
</td>
<td class="num">(2,846,641)<span></span>
</td>
<td class="num">(979,760)<span></span>
</td>
<td class="num">(5,650,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(97,755,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(110,976,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="nump">278,818<span></span>
</td>
<td class="num">(3,883,176)<span></span>
</td>
<td class="num">(551,657)<span></span>
</td>
<td class="nump">9,298,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">136,493<span></span>
</td>
<td class="nump">4,358,634<span></span>
</td>
<td class="num">(711,465)<span></span>
</td>
<td class="num">(691,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">185,281<span></span>
</td>
<td class="num">(152,102)<span></span>
</td>
<td class="nump">194,259<span></span>
</td>
<td class="num">(577,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before share in net loss of Geneos</a></td>
<td class="num">(82,139,958)<span></span>
</td>
<td class="num">(128,270,709)<span></span>
</td>
<td class="num">(136,107,702)<span></span>
</td>
<td class="num">(161,406,113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(901,757)<span></span>
</td>
<td class="num">(434,387)<span></span>
</td>
<td class="num">(901,757)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(82,139,958)<span></span>
</td>
<td class="num">(129,172,466)<span></span>
</td>
<td class="num">(136,542,089)<span></span>
</td>
<td class="num">(162,307,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (82,139,958)<span></span>
</td>
<td class="num">$ (128,703,059)<span></span>
</td>
<td class="num">$ (136,542,089)<span></span>
</td>
<td class="num">$ (161,244,113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">209,561,064<span></span>
</td>
<td class="nump">155,807,054<span></span>
</td>
<td class="nump">206,007,497<span></span>
</td>
<td class="nump">140,215,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">209,561,064<span></span>
</td>
<td class="nump">155,807,054<span></span>
</td>
<td class="nump">206,007,497<span></span>
</td>
<td class="nump">140,215,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 82,923<span></span>
</td>
<td class="nump">$ 74,102<span></span>
</td>
<td class="nump">$ 122,538<span></span>
</td>
<td class="nump">$ 145,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">74,787<span></span>
</td>
<td class="nump">95,146<span></span>
</td>
<td class="nump">124,736<span></span>
</td>
<td class="nump">1,267,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 115,114<span></span>
</td>
<td class="nump">$ 97,939<span></span>
</td>
<td class="nump">$ 396,671<span></span>
</td>
<td class="nump">$ 181,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044003192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (82,139,958)<span></span>
</td>
<td class="num">$ (129,172,466)<span></span>
</td>
<td class="num">$ (136,542,089)<span></span>
</td>
<td class="num">$ (162,307,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,941)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(2,679)<span></span>
</td>
<td class="nump">846,900<span></span>
</td>
<td class="nump">2,182<span></span>
</td>
<td class="num">(1,082,638)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(82,140,159)<span></span>
</td>
<td class="num">(128,325,566)<span></span>
</td>
<td class="num">(136,551,848)<span></span>
</td>
<td class="num">(163,390,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (82,140,159)<span></span>
</td>
<td class="num">$ (127,856,159)<span></span>
</td>
<td class="num">$ (136,551,848)<span></span>
</td>
<td class="num">$ (162,326,751)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348040681496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 5,404,858<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="nump">$ 742,646,785<span></span>
</td>
<td class="num">$ (739,785,655)<span></span>
</td>
<td class="nump">$ 472,608<span></span>
</td>
<td class="nump">$ 1,969,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">208,241,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,149<span></span>
</td>
<td class="nump">208,198,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">3,100,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">3,099,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,001,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,017,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">2,169,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,169,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(33,135,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,541,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(594,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">145,915,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">187,854,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 145,915<span></span>
</td>
<td class="nump">957,962,628<span></span>
</td>
<td class="num">(772,326,709)<span></span>
</td>
<td class="num">(1,456,930)<span></span>
</td>
<td class="nump">3,529,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="nump">742,646,785<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="nump">472,608<span></span>
</td>
<td class="nump">1,969,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(162,307,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(1,082,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">158,756,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">186,360,469<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 158,756<span></span>
</td>
<td class="nump">1,087,745,242<span></span>
</td>
<td class="num">(901,029,768)<span></span>
</td>
<td class="num">(610,030)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">145,915,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">187,854,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 145,915<span></span>
</td>
<td class="nump">957,962,628<span></span>
</td>
<td class="num">(772,326,709)<span></span>
</td>
<td class="num">(1,456,930)<span></span>
</td>
<td class="nump">3,529,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,041,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">121,718,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,041<span></span>
</td>
<td class="nump">121,706,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">4,422,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
<td class="nump">4,421,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,662,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,654,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">209,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Geneos</a></td>
<td class="num">(3,181,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,181,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(129,172,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,703,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">846,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">158,756,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">186,360,469<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 158,756<span></span>
</td>
<td class="nump">1,087,745,242<span></span>
</td>
<td class="num">(901,029,768)<span></span>
</td>
<td class="num">(610,030)<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">162,105,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,355<span></span>
</td>
<td class="nump">162,084,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">4,377,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">4,376,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(1,201,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="num">(1,202,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,595,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,595,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(54,402,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,402,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(14,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">209,334,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">581,606,149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,333<span></span>
</td>
<td class="nump">1,542,261,467<span></span>
</td>
<td class="num">(960,598,943)<span></span>
</td>
<td class="num">(265,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(136,542,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">2,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(11,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">210,146,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">508,553,771<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 210,146<span></span>
</td>
<td class="nump">1,551,348,435<span></span>
</td>
<td class="num">(1,042,738,901)<span></span>
</td>
<td class="num">(265,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">209,334,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">581,606,149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,333<span></span>
</td>
<td class="nump">1,542,261,467<span></span>
</td>
<td class="num">(960,598,943)<span></span>
</td>
<td class="num">(265,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">3,441,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">3,440,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,646,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,646,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(82,139,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,139,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(2,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">210,146,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 508,553,771<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 210,146<span></span>
</td>
<td class="nump">$ 1,551,348,435<span></span>
</td>
<td class="num">$ (1,042,738,901)<span></span>
</td>
<td class="num">$ (265,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036614392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043780728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (136,542,089)<span></span>
</td>
<td class="num">$ (162,307,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,361,595<span></span>
</td>
<td class="nump">1,608,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">266,874<span></span>
</td>
<td class="nump">273,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,976,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,242,305<span></span>
</td>
<td class="nump">7,663,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest expense</a></td>
<td class="nump">435,445<span></span>
</td>
<td class="nump">3,013,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Gain) loss on short-term investments</a></td>
<td class="num">(153,252)<span></span>
</td>
<td class="nump">576,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity', window );">Settlement of receivable with shares of common stock from affiliated entity (PLS)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,713,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on equity investment in affiliated entities</a></td>
<td class="nump">551,657<span></span>
</td>
<td class="num">(9,298,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">901,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net unrealized loss on available-for-sale equity securities</a></td>
<td class="nump">711,465<span></span>
</td>
<td class="nump">691,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLeaseNonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">567,882<span></span>
</td>
<td class="nump">517,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction gain on foreign-currency denominated debt</a></td>
<td class="num">(176,927)<span></span>
</td>
<td class="num">(474,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">5,431,637<span></span>
</td>
<td class="num">(2,813,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from affiliated entities</a></td>
<td class="num">(219,159)<span></span>
</td>
<td class="nump">865,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(51,944,060)<span></span>
</td>
<td class="num">(3,084,082)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="num">(197,059)<span></span>
</td>
<td class="num">(1,330,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">24,126,582<span></span>
</td>
<td class="nump">116,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">8,891,770<span></span>
</td>
<td class="num">(732,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="nump">465,819<span></span>
</td>
<td class="nump">2,882,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">1,130,877<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">55,074<span></span>
</td>
<td class="num">(92,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties', window );">Deferred revenue from affiliated entities</a></td>
<td class="num">(6,250)<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(1,131,555)<span></span>
</td>
<td class="num">(1,022,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="num">(615,155)<span></span>
</td>
<td class="nump">4,265,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="num">(63,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">6,478<span></span>
</td>
<td class="nump">29,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(131,326,659)<span></span>
</td>
<td class="num">(52,604,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(307,857,113)<span></span>
</td>
<td class="num">(138,698,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="nump">83,466,967<span></span>
</td>
<td class="nump">47,455,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(418,734)<span></span>
</td>
<td class="num">(176,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,774,851<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(224,808,880)<span></span>
</td>
<td class="num">(94,194,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">162,105,030<span></span>
</td>
<td class="nump">329,960,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">6,154,794<span></span>
</td>
<td class="nump">9,599,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(3,915,160)<span></span>
</td>
<td class="num">(2,076,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Geneos issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">171,620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">164,344,664<span></span>
</td>
<td class="nump">340,035,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(11,941)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) Increase in cash and cash equivalents</a></td>
<td class="num">(191,802,816)<span></span>
</td>
<td class="nump">193,236,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">250,728,118<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">58,925,302<span></span>
</td>
<td class="nump">215,432,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 544,315<span></span>
</td>
<td class="nump">$ 2,636,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLeaseNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLeaseNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Receivable With Shares Of Common Stock From Equity Security</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036476760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicine candidates are made using its proprietary SynCon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date have shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corporation.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for COVID-19; Middle East Respiratory Syndrome, or MERS; Lassa fever; HIV; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044693976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Liquidity and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Liquidity and Risks and Uncertainties<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2021 and 2020 and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and six months ended June 30, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. As of June&#160;30, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority-owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $82.1 million and $136.5 million for the three and six months ended June 30, 2021, respectively. The Company had working capital of $490.7 million and an accumulated deficit of $1.0 billion as of June&#160;30, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $443.7 million as of June&#160;30, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the </span></div>effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038200904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting Policies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1Mg_7c2a02d6-d7ff-4cb3-9069-106f0e2331f1">two</span> to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.9 million and $3.1 million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through June&#160;30, 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its </span></div>equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038275208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Recently Issued Accounting Standards</a></td>
<td class="text">Impact of Recently Issued Accounting Standards <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036665768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition  During the three and six months ended June 30, 2021, the Company recognized total revenue under collaborative research and development arrangements of $75,000 and $125,000, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $198,000 and $519,000, respectively, from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three and six months ended June 30, 2021, $35,000 and $39,000, respectively, were in deferred revenue as of December 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036647352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text">Short-term Investments<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Short-term investments at June&#160;30, 2021 consisted of mutual funds, U.S. treasury securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three and six months ended June 30, 2021, the Company recorded gross realized gain on investments of $358,000 and $358,000, respectively, and gross realized loss on investments of $194,000 and $204,000, respectively. During the three and six months ended June 30, 2020, the Company recorded gross realized gain on investments of $585,000 and $635,000, respectively, and gross realized loss on investments of $686,000 and $1.2&#160;million, respectively. During the three and six months ended June 30, 2021, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $136,000 and $(711,000), respectively. During the three and six months ended June 30, 2020, the Company recorded net unrealized gain (loss) on available-for-sale equity securities of $4.4&#160;million and $(691,000), respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of June&#160;30, 2021, the Company had 22 available-for-sale securities in an unrealized loss position, of which four with an aggregate total unrealized loss of $211,000 were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of June&#160;30, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,475,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,459,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,203,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,210,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,972,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,783,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(633,448)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,752,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;June&#160;30, 2021&#160;were primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at June&#160;30, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044650456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company does not have any liabilities measured at fair value on a recurring basis and did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the six months ended June 30, 2021 or 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,459,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,459,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,210,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,210,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,752,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,669,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,082,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,661,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,578,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,082,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at June&#160;30, 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain (loss) on investment in affiliated entities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at June&#160;30, 2021 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of June&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038232552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,693,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,593,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,879,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,593,865)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,393,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property. </span></div>Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2021 was $130,000 and $267,000, respectively. Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2020 was $137,000 and $274,000, respectively. Estimated aggregate amortization expense is $254,000 for the remainder of fiscal year 2021, $493,000 for 2022, $276,000 for 2023, $253,000 for 2024, $253,000 for 2025 and $1.4 million for 2026 and subsequent years combined.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038288472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> an aggregate of 11,535,660 shares of the Company's common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8 million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at June&#160;30, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,963,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,536,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2021,&#160;the Company recognized $467,000 and $930,000, respectively, of interest expense related to the Notes, of which $267,000 and $533,000, respectively, related to the contractual interest coupon. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $2.1 million and $4.2&#160;million, respectively, of interest expense related to the Notes, of which $1.3&#160;million and $2.6&#160;million, respectively, related to the contractual interest coupon.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,616,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent of the August 2019 Bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.69 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $672,000 and $1.3&#160;million, respectively, of interest expense related to the August 2019 Bonds, of which $37,000 and $75,000, respectively, related to the contractual interest coupon.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the August 2020 conversion in full of the August 2019 Bonds, the derivative liability associated with the August 2019 Bonds was revalued at $84.5 million. The change in fair value of the derivative liability was an increase of $75.7 million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds was 6.2%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the six months ended June 30, 2021,&#160;the Company recognized $50,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $60,000 and $122,000, respectively, of interest expense related to the December 2019 Bonds, of which $10,000 and $20,000, respectively, related to the contractual interest coupon.</span></div> As of June 30, 2021, all outstanding December 2019 Bonds were converted into 1,009,450 shares of the Company's common stock. Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038361368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2021 and December&#160;31, 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,146,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,146,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,851,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, 14 shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $162.1&#160;million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent acted as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0 million to $250.0 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company sold a total of 22,919,934 shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2 million. As of December 31, 2020, there was no remaining capacity under the New Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the </span></div>2016 Incentive Plan was 20,000,000 shares. On the first business day of each calendar year, such maximum number of shares is further increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares increased by 2,000,000. At June&#160;30, 2021, the Company had 4,998,253 shares of common stock available for future grant under the 2016 Incentive Plan, 2,516,102 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 7,814,677 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At June&#160;30, 2021, the Company had options outstanding to purchase 2,516,141 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038216408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three and six months ended June 30, 2021 and 2020, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds would have been anti-dilutive.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three and six months ended June 30, 2021 and 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,330,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,193,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,962,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,563,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,622,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348213312232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based CompensationThe Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2021 was $5.3 million and $14.5 million, respectively, of which $2.7 million and $7.9 million, respectively, was included in research and development expenses, and $2.6 million and $6.6 million, respectively, was included in general and administrative expenses.</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 was $3.4 million and $7.1 million, respectively, of which $1.8 million and $4.1 million, respectively, was included in research and development expenses, and $1.6 million and $3.0 million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $19.8 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.3 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $5.25 and $7.91 for employee and director stock options granted during the three and six months ended June 30, 2021, respectively, and $9.52 and $6.19 for the three and six months ended June 30, 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, there was $16.8 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.1 years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $6.81 and $10.64 for service-based RSUs granted during the three and six months ended June 30, 2021, respectively, and $14.50 and $9.12 for the three and six months ended June 30, 2020, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2021 was $308,000 and $737,000, respectively. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three and six months ended June 30, 2020 was $224,000 and $607,000, respectively.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted 663,353 performance-based RSUs to executives under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The total grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June&#160;30, 2021</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the six months then ended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038181784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned 597,808 shares of common stock in PLS as of June&#160;30, 2021, representing a 19.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three and six months ended June 30, 2021, the Company recognized revenue from PLS of $75,000 and $125,000, respectively, and $64,000 and $1.2 million, for the three and six months ended June 30, 2020, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $99,000 and $67,000, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under the agreements.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a dMAb against the Zika infection, with funding extended through December 2021. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three and six months ended June 30, 2021, the Company recorded $381,000 and $610,000, respectively, and for the three and six months ended June 30, 2020 the Company recorded $73,000 and $691,000, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill &amp; Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three and six months ended June 30, 2021 were $1.2 million and $1.6 million, respectively. Research and development expenses recorded from Wistar for the three and six months ended June 30, 2020 were $408,000 and $770,000, respectively. At June&#160;30, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $617,000 and $425,000, respectively, and an accounts payable and accrued liability balance of $1.8 million and $643,000, respectively, related to Wistar. As of June&#160;30, 2021, the Company had a prepaid expense balance of $303,000 and recorded $69,000 as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038195320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases                                                  <div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2.4 to 8.5 ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of June&#160;30, 2021, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,014,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,753,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,261,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,464,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,797,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5%</span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2021 were $827,000 and $1.7 million, respectively. Lease costs included in operating expenses in the condensed consolidated statements of operations for the three and six months ended June 30, 2020 were $814,000 and $1.7&#160;million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038306360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#8217;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred in conducting the trial in Greater China. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $206.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. For the six months ended June 30, 2021, no revenue was recognized from Advaccine. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an accounts receivable balance of $0 and $7.1&#160;million, respectively, from Advaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reevaluated the Advaccine Agreement under ASC Topics 606 and 808 as of the date of the June 2021 amendments and determined that the Global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore should be accounted for under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, no contra-research and development expense has been recorded from Advaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018 which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price. As of June&#160;30, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.   </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payme</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt. In both December 2018 and March </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019, the Company recognized as revenue $2.0&#160;million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three and six months ended June 30, 2021, the Company received funding of $2.1 million and $4.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. During the three and six months ended June 30, 2020, the Company received funding of $1.8 million and $2.9 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of June&#160;30, 2021, the Company had $316,000 recorded as grant funding liability on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three and six months ended June 30, 2021, the Company received funding of $1.1 million and $3.5 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. During the three and six months ended June 30, 2020, the Company received funding of $5.8 million and $8.1 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of June&#160;30, 2021, the Company had $2.9 million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three and six months ended June 30, 2020, the Company recorded $36,000 and $170,000, respectively, as contra-research and development expense related to the Gates dMAb grant. During the three and six months ended June 30, 2021, the amounts recorded were minimal. As of June&#160;30, 2021, the Company had $575,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three and six months ended June 30, 2021, the Company recorded $0 and $893,000, respectively, and during the three and six months ended June 30, 2020 recorded $850,000 and $913,000, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5 million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6 million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2021, the Company recorded $13.4&#160;million and $21.2&#160;million, respectively, as contra-research and development expense related to the OTA Agreement. During the three and six months ended June 30, 2020, there was no contra-research and development expense recorded related to the OTA Agreement. As of June&#160;30, 2021 and December 31, 2020, the Company had an accounts r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eceivable balance of $12.9&#160;million and $11.4&#160;million, respectively, on the condensed consolidated balance sheet from the DoD. As of June&#160;30, 2021, the Company had $3.0&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to the Procurement Contract.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036665768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;For the three and six months ended June&#160;30, 2021, the Company has not recorded any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038205912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations. The following table shows the amounts related to the deconsolidation accounting: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneos's next financing and successful exit timing assumption. The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through December 31, 2020 was $4.6 million and for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 1, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348041241128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of June&#160;30, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of stockholders' equity for the three and six months ended June 30, 2021 and 2020 and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three and six months ended June 30, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. As of June&#160;30, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority-owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $82.1 million and $136.5 million for the three and six months ended June 30, 2021, respectively. The Company had working capital of $490.7 million and an accumulated deficit of $1.0 billion as of June&#160;30, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $443.7 million as of June&#160;30, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the </span></div>effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span> (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantPolicyPolicyTextBlock', window );">Grants</a></td>
<td class="text">Grants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div>Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmNhMGE3MGZlMmE4MDQ3ZjdiZGE3YTNkOWRiZTQ5YmRlL3NlYzpjYTBhNzBmZTJhODA0N2Y3YmRhN2EzZDlkYmU0OWJkZV80MC9mcmFnOjhhN2MzYTI1Yjc4YjQyYjVhYjc1NTIxZjllZDk0YTI4L3RleHRyZWdpb246OGE3YzNhMjViNzhiNDJiNWFiNzU1MjFmOWVkOTRhMjhfOTU1Mg_7c2a02d6-d7ff-4cb3-9069-106f0e2331f1">two</span> to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s intangible assets resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $2.9 million and $3.1 million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through June&#160;30, 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div>Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities (VIE)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock', window );">Equity Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its </span></div>equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038088408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of June&#160;30, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,475,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,459,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,203,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,210,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,972,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,130,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,783,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(633,448)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,752,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036639064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of June&#160;30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,459,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,459,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,210,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,210,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,752,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,669,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,082,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,661,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,578,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,082,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038028616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Summary of Intangible Assets by Major Asset Class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,608,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,693,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,593,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,879,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,593,865)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,393,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div>(b)Other intangible assets represent the estimated fair value of acquired intellectual property.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043680120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at June&#160;30, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,963,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,536,448&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,616,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038759384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of June&#160;30, 2021 and December&#160;31, 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,146,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,146,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,851,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036642584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three and six months ended June 30, 2021 and 2020: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,330,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,193,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,516,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,868,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,962,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,563,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,622,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038303448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.67%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348036599832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text">As of June&#160;30, 2021, the maturities of the Company's operating lease liabilities were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,014,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,753,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,261,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,464,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,797,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038891576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text">The following table shows the amounts related to the deconsolidation accounting: <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The remaining $4.2 million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 1, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043842424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 82,139,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,703,059<span></span>
</td>
<td class="nump">$ 136,542,089<span></span>
</td>
<td class="nump">$ 161,244,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Working capital</a></td>
<td class="nump">490,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="nump">1,042,738,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,042,738,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,196,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 443,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,105,030<span></span>
</td>
<td class="nump">$ 329,960,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348131084872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 2,879,896<span></span>
</td>
<td class="nump">$ 3,146,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044090952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 272,824<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 643,945<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember', window );">Other Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_OtherCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348127882584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 358,000<span></span>
</td>
<td class="nump">$ 585,000<span></span>
</td>
<td class="nump">$ 358,000<span></span>
</td>
<td class="nump">$ 635,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">194,000<span></span>
</td>
<td class="nump">686,000<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="nump">$ 136,493<span></span>
</td>
<td class="nump">$ 4,358,634<span></span>
</td>
<td class="num">$ (711,465)<span></span>
</td>
<td class="num">$ (691,458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | position</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043687864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 383,783,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,239,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">1,602,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,365,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(633,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(690,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">384,752,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">207,475,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,177,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">1,563,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,339,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(579,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(644,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 208,459,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity (less than)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 170,203,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">10,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(4,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 170,210,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity (less than)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 2,972,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">25,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">2,998,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">3,130,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,062,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">2,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(49,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 3,084,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,025,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348154966520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 384,752,382<span></span>
</td>
<td class="nump">$ 160,914,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">208,459,732<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">170,210,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,998,500<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,084,021<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">384,752,382<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">3,908,709<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">388,661,091<span></span>
</td>
<td class="nump">225,372,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">378,669,861<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">3,908,709<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">382,578,570<span></span>
</td>
<td class="nump">219,330,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">6,082,521<span></span>
</td>
<td class="nump">6,041,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">6,082,521<span></span>
</td>
<td class="nump">6,041,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">208,459,732<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">208,459,732<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,996,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">170,210,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,996,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">170,210,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,998,500<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,998,500<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,084,021<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">3,084,021<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348041097336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="nump">597,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043612088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(7,593,865)<span></span>
</td>
<td class="num">(7,326,991)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">2,879,896<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, net book value</a></td>
<td class="nump">13,393,267<span></span>
</td>
<td class="nump">13,660,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(1,291,226)<span></span>
</td>
<td class="num">(1,276,852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">32,535<span></span>
</td>
<td class="nump">46,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(2,608,889)<span></span>
</td>
<td class="num">(2,468,889)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">2,491,111<span></span>
</td>
<td class="nump">2,631,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(3,693,750)<span></span>
</td>
<td class="num">(3,581,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 356,250<span></span>
</td>
<td class="nump">$ 468,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043838872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense on intangible assets</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="nump">$ 266,874<span></span>
</td>
<td class="nump">$ 273,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated aggregate amortization expense for remainder of 2021</a></td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense for 2022</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense for 2023</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense for 2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense for 2025</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Estimated aggregate amortization expense for 2026</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348042334392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 466,726<span></span>
</td>
<td class="nump">$ 2,846,641<span></span>
</td>
<td class="nump">$ 979,760<span></span>
</td>
<td class="nump">$ 5,650,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(97,755,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(110,976,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,963,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,963,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,692,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,535,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of date conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">$ 930,000<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 533,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002756873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038305800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance of Convertible Bonds and Notes (Details) - Convertible senior notes<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount on the liability component</a></td>
<td class="num">(1,963,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(270,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">355,658<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 14,536,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044562616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - Convertible senior notes - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 14,536,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">16,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 19,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044740760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">210,146,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">210,146,880<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348040318968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Underwritten public offering, common stock (in shares)</a></td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes', window );">Commissions and other estimated offering expenses</a></td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under share based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,998,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,814,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,516,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Prior Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | New Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,919,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044376344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">16,563,562<span></span>
</td>
<td class="nump">32,622,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">10,330,818<span></span>
</td>
<td class="nump">9,193,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">2,516,102<span></span>
</td>
<td class="nump">2,868,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">Convertible senior notes | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,962,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348039313064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,242,305<span></span>
</td>
<td class="nump">$ 7,663,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 9.52<span></span>
</td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="nump">$ 6.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,000<span></span>
</td>
<td class="nump">$ 224,000<span></span>
</td>
<td class="nump">$ 737,000<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.99%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.81<span></span>
</td>
<td class="nump">$ 14.50<span></span>
</td>
<td class="nump">$ 10.64<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348040465688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,824<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="nump">$ 643,945<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,000<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="nump">691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">408,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348043565880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost | $</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">$ 814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Agreements To Sublease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseNumberOfAgreementsToSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348127739528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 1,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">4,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">4,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">3,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">9,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">26,014,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(6,753,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">19,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,463,878)<span></span>
</td>
<td class="num">$ (2,329,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 16,797,476<span></span>
</td>
<td class="nump">$ 18,063,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348027475608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="11">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 643,945<span></span>
</td>
<td class="nump">$ 1,594,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,859,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,859,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,474,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,538<span></span>
</td>
<td class="nump">145,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementPaymentEarned', window );">Collaboration Agreement, Payment Earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AnnualMaintenancePeriod', window );">Annual maintenance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod', window );">Territory expansion option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromCollaborativeAgreement', window );">Proceeds received in upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAdvisoryFees', window );">Advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementCorporateIncomeTax', window );">Foreign corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementForeignNonIncomeTaxes', window );">Foreign non-corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones', window );">Anticipated development and regulatory event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones', window );">Anticipated commercial event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,000<span></span>
</td>
<td class="nump">913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AnnualMaintenancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AnnualMaintenancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Territory Expansion Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementTerritoryExpansionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementForeignNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementForeignNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348040203016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 901,757<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">$ 901,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember', window );">Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 1,399,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="nump">4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348040464520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,111,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,111,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,348,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (4,121,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapitalExcludingCash', window );">Working capital (excluding cash)</a></td>
<td class="num">$ (59,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="nump">171,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="num">(16,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="nump">3,181,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedInterestFairValueDisclosure', window );">Fair value of investment in Geneos retained</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapitalExcludingCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital, Excluding Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapitalExcludingCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInterestFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInterestFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348044658312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Investment In Geneos (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,113,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,618,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348035443944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details) - Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityMethodInvestmentEnterpriseValue', window );">Geneos enterprise value</a></td>
<td class="nump">$ 4,966,531,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AlternativeInvestmentMeasurementInputTerm', window );">Equity method investment, measurement input, expected term</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.0246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AlternativeInvestmentMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AlternativeInvestmentMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentEnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Enterprise Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentEnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140348038501704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos upon deconsolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (901,757)<span></span>
</td>
<td class="num">(434,387)<span></span>
</td>
<td class="num">$ (901,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of March 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos upon deconsolidation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(434,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,584,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of March 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (819,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*1'GASO. B[U W!_(X0ZG^@?*#9;1_\!4$L#!!0    ( 'U_"5,FT(_P:@<
M (<@   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK9I];]LV$(>_BN -
MPP8T-=]?NB1 FV);!PP+EKW\K4AT+%02/8EVTF^_D^Q:LDC1#C $2"3[2/U(
MW=US)'/];)O/[=H8E[Q49=W>+-;.;=XMEVVV-E7:OK4;4\,W*]M4J8/;YFG9
M;AJ3YGVCJEP2A,2R2HMZ<7O=?W;?W%[;K2N+VMPW2;NMJK3Y\L&4]OEF@1=?
M/_BC>%J[[H/E[?4F?3(/QOVUN6_@;GGL)2\J4[>%K9/&K&X6[_&[.R:Z!KW%
MWX5Y;D?723>41VL_=S>?\IL%ZA29TF2NZR*%/SMS9\JRZPET_'OH='%\9M=P
M?/VU]Y_ZP<-@'M/6W-GRGR)WZYN%6B2Y6:7;TOUAGW\QAP'QKK_,EFW_.WG>
MVTIX8K9MG:T.C>&^*NK]W_3E,!&C!IC--""'!N32!O30@/8#W2OKA_4Q=>GM
M=6.?DZ:SAMZZBWYN^M8PFJ+N7N.#:^#; MJYVSM;Y_!23)[ 56O+(D\=W'Q(
MR[3.3/+0==PF5\E?#Q^3[[_]X7KIX*%=TV5V>,"'_0/(S -^W=9O$XK>) 01
M'&A^%V_^T630'/?-T6GS)0SU.%YR'"_I^Z-SX]TVC:E=DK8M#.Q=I$=Z[)'V
M/;*Y'M-VG:1UGF3=A?EW6^S2$A[1AN9JWY7HN^HB;'?+E2:<(G*]W(UGQ3<D
M'$FB,%9'RQ.Y["B71>4^K&WCKIQIJJ2H=Z9UU9S6?3]\)($J)CFA:BK6M\0"
M:<PTY6&Q_"B61\6^SS*[!7F0,#(#\_I8FI!2[C^?8J(H11.A 4/%N=9"AG6*
MHT[Q6IW)JK%5DJY615GT(0737+C"!*=:>+HD(9KAB7S?C",J1Z_C1+P\BI=1
M\?>-V:0%"'S9=)F@[9W9NK5I( &-HR6D7'J2%..:8*DGVGU#ABB7C(NP>G54
MK_X?]:]Z(<KW?429GKX0WPPCP>C,"]''(>GHD/ZT+BTOF'OMNP,C\",(G^CT
M+9G$6"*A45@J1@,_4%3L3\4+S.5>Y)ND-BZ("!0(/(PA1M5$:<@24Z8P8S-*
M1Z3#4:6?CND.,I_G"%^"NK'O!QHIB:;>'3!D3" J9KP;#[S"Y!6J?S:UL4%G
M.'0S5C#-?@$31AE5,\D/#P3$<01^JEU:/Q5=UCOG"-230)342HNI5M^08B:D
MG'/8@7\X#L"?K<V?B[(,R@N0#'%,J9Q&_B66IP('YN$X]'[?F"9U1?V4E 8*
MU*3I*M$KN[K:MB:2#7  ;I"'*<-LJCUD*1DF>LY;!P[B. A_[Q-O1*2/,*PH
M4L)[_[XAX1IXP6;J'SS@#L=YMT^O$8T^JKC&BA$LO+ /F%(M)6%RA@%XX!I6
M%U6JD*0>(5-UI(J5JWB@"X[CY5BL;-(O?:72$3/-LF9K!HP&)\;'"$5(<RZ]
M+.Y;$DP056CF[9&!-R3.FXO4)_G6),Y>2GL2@(Z44.U.O3)@*!B$C9X9U< F
M$F?3^\, ,OBBR, ]75/ []C;(#YR,&)88#&-]X"EUE YLIGJG(P64W$X?30K
M UZ:0]V[,_4V6)P3GSH8%@=DZC,!.R8$F7.8 4XD#J=I.OT:3T'@DP"?F !$
M>FH#AI1HJF?*%#+PB9SA4Y-"U*^V==YKCJKU(204Y"H^K?\"AI))1O$,3<D
M*Q*'U8S:5Q7;Q.<1+-_XM'P)F''%T=P0!F:1.+-.R^U1N@UJ#:S!L&1*ZRD;
M I8,2FZ V)R+# 0C<8)-PZXOMQ*[.@YB VO\PM;! ?C(DEAZ=7C(#)9U<]('
MJI'X<FTV&E\UAL"Z2T@-+NTE[("E0H)R/)?[!HR2.$:/+\&E+V>])D!.@GR\
MG#,[W: :F$GCS'Q5D+[J35 ?B%2.8_*PFW7.['1@ S9I')O[<O/,Y%,??P**
MXFE%'S#C4@@ZHW%@)(TS<I]>SFGTX:<HK(ZIG@9FP%(J0;&<BTTZVLBDT8KS
MP=GL\]J6N6G:[[Y1L'CXL=_/=%^B^Z0#V6B<;/?-UY!INR<%Y\$'E>=+,9-3
M90/%:)QB=[:J;!V1Y:.'8(2]  [8805(GED3TH%1],P&8YX770R")W6[75=%
MG63II@#/"LH-K+(X[[91&)V6!B%;*B1#0LV5M70 %8V#"LK:;;4M^^22FU61
M%<%= >K#Y@IJ60(EN$9>G :,-1)8"X5G%EUTP!.-XVDL^+"):*M-8];=P=4.
M<&7;</SZG+DB@FMOHRAHR 7F<SX\\(A>LFOXJ;:[PB;WZ[2ITLQL7;>::-_
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M8#:WP$1O0;^B1QV5SOJL!BDMZVX!9H_QEP\A5$K'GDM,1[5VX^:-KQM1Q4C
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M(W_"Z1!IH47^V-,A$J.(?F.8I*&8:CE"ONSI$.DC!*-IZ BZY0=UW),A"H$
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MU?N#F;IT@BX$ 9Z(XT'7E."BX&G. B<UU+*,GNH87R62X5A8;8>XE<^R*^M
M]4\]>$.,9L5\+WH,"U9 X1/8B_3H(6*<<?\6S]+4_K4I1)NA;)B>R@W'W4G_
MZDA\.N,33Z*K_#/RT(P44!XY#;S/$J>07X(!;;%'3_60(+.O]WFC-4=^JM6=
M:AH3U?O'*%[];G/H"'=-,,D@D@(\HA:B] 1$7X71F.Y>[9)6:;GOT[SJ75HZ
MZCW/+S/8,X%ZCEJ8TA,'J_LTN.W48UU!'-V_>%.)5[BG8>244&"ILQ5<4T+3
ME# (L\ <+$II'*6_K%:R' /]N1P?;T*]!_EG.K)4$Z],;S-\,/OA$>J&0'U
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M@[&<+X]H=V1\I&&"@L'L-QX[G*14I(L:I[.^#BB:-(6#*2=.EOKC>\,WCJO
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M&L4*!D5H->Q9L5W%<W_/W#QLMC_@" 6;!0OL=]F&&@GY71I@?;!X5XUG7Z4
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MP@5_W0?O'^*=AB@E6]POB(#U1#?A3FN<:NGJJ=Q3(GW2):+1^ZS*F.[W1<L
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MO&V= _*B:.NV<JY_++!MHX='3*[\1U3IMI!PADBHP 03<E.E?*184;XPK1Y
MBL OI?,\XLDMV0ZH_*;@-F0W;N:$'2XY.(F/0>II2I)R^NIV[N.RJ/,-7+%>
MRF()0;8:):A=TGZ^6&BQH#QCE876GI\G_<?>4+TB<8UI065+V.FE4LU"D'I
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MO0'[>3">+()9$A\].0/%;SNK3\/'(;SNL.ZZ41G-PB".PB"*%[WUGG#_?X^
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MU,Z![!NE[%%P"<;/C\5_4$L#!!0    ( 'U_"5.@"?"L,A   #4[   9
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MB'61ISRS$8*%E#N,^*P1!E1R Z7-1^>UTOP#R:+11Y49VAN"YZM$0Z<8:D@
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M[EG==0\#-46A<9LYT9^YT<:%6F.D@U]X6I1W!69*5D9;OV8%UJWK/!WO*W7
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MM<S9:I&&[86@#$%FB+[<)\1F4?M#X@4\$,[#\4YJ"N%R*S.R+D., DQ7QCG
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MO.C'%O0YMV>727H^&^#FC0W"5AL;!.:'-%F<+R+<.Z/79Y2%9R$1)IAP>1%
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M428Y)ADF=6ID"0@;=VP"8S:5[8V4=0H0\".20)W]JD%[@9& =M'E3*AYJ:?
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M:B3O2]BN93$ !)>4R8D9KBSK:6N+CW'&WD.!:L&%[7IAH(D9!!*I4%YSN/;
M#M"7DIRY7C\:?N2C$\^XL!-&^%R.)(9T H)O6T:S94.%GL9&2R ()**<QUCV
MDB1([H7=SN4X ONM@YQ.NB",E8>#(#2P[W3<Q$Q9B8%\T<E^:W90R__LOG+0
MWQ%3Q[83"JLT;$FQ=XMX:Y=?D::,_E G>JCY#(\&$SHP*#**^L1DEH=&-V(C
M[+K$9 8JT7R1+0WTK/59-O19797=TMJ$YK#(6D7.?WN/U3IE2L"CE5,9-=K
M_N_CH94J]EL(5,R.O5:25PCOXIYKO\T8-9B]?'U[XY3(-SF\8ZLS:OI]K\9F
M4F&-^\J4]7CIZ[77!S1L4V_&]E_\ [OT7VYON R<OT.S9:W/PI4";J+8YWLE
M!D5E%7YLYWZ,HX*Y2Q.FUT<)J.Y&AKB@/_6=:&^[@\CU(B0>?EK9!A\;I/-#
M^&UEMA?\=Z]W#T [4&H>^< B*C?WC=E?56X6_[^+S&)+:?EH2VWYWR7@_P,E
MX(S@@6]0M[]K/7@H[?EW/7B]'CQ4NR.KS;UWJHV ;Z.^R0S83?/]&Q'=RH"[
M%)\3#?[NU>>-$7M$C\G9UF*T+T3_X0KS!8K2?T'8E@LL+UUT\P[B)[HF-#G9
M>L<I+G+WJH;I1.Y;65QB(47R=G:B=JH0%2Q[;I']"O&.0;R_%WW:2ZXA19,0
M\1,BM]E#KQ9D>M[W[X9:L<>3R5%:]\&R;RTJUOFW+U]<'CX\>>3&M5K1S"4.
M)JW5?!8=, !,[!+$2%?B6C6=R>Z_OOK\(&M72]"E"1=[D=->#=WX XU&3[W;
M7F@31(ZA3SFW:6:8A/E1-(#6&R(&6_@1_+*M* +'^]N2V;,RQ-)?B2]RW?-N
M<1841^YSEN*3EAX<K8;<&I6"L\)[DZ, <E+\\FX@!/@;]N]M.#D)6:4;,LVQ
M,'[7A-%) AA'FJH'#J9S%ML4(R4S&>I9AZI<#MV\$<;HG*]SL4*YHQ,Y38W.
MUJP;TSJ>RJ6*J 91<_.Y-H4,61> [<]S%5#*(W?0O1S3>ZP@V0FW'L_=.$F8
MOW'.O1?(M7[.O_!33KG<8F6QEJ27MD6EN(?1R"7?9 UIB#4$-CS9%J,.3G3W
MB^_868I#A+(,,6&LA'TM#;$$10OX7!2&>VB'S;JA8\EC5K)=F_[DZA8>E-GB
M#=WX"&T$+*[R]49;:SU?J]0.Q#S)1(0:&(IP[9Q(&B!BF\_=Q9?H!Y_\\[A%
MS $WQ!Y=RG!W[/J!H,NT)98[;>:C&B3?KU1O+6!Q.]#%&XCIQX \6(_6%6M?
M+H$=%40/5PT.8<J"!IHNZQHB368!D/4"9+*,//>PUPPWD(E1SU]>78[PIHKI
M!%_QL&XEL=%@^PH3]R[6+K<:/R#\!HR%R&:PD-/IMR\_?&1%F6OAY7&WVY$(
M'1J2Z'[,1E]MK*BI^AH$P<HFEE]:G7]9HG1$\:@H5CPCYW@(*33\GZ]LD[*5
M?"?21DK!^D/^AX.+.,V,=8<O-IL;(BOE$K):HL'&MHP_R[1=05<VHL"<Y8S[
MQ\,7)W"&D8(N*@(@=:L.#.2RM%V3M80JOOP4$]C.]XX82"SB6,,&5"8?L*$P
M>G+J]8TN-5 %G+A,4^3[5)2P51&D[6THNRNE.Z'.6:05@O6QR]33Z<;5&!$?
MI!>9 L(WN<G2\[BQS?,N=YR]".$R=ZDHK[]EC&"PU^3 H:@H]/6Y^?,P-'_Z
M)B(M$P.%J-^X5K;'(,U;OX%6]89N\%TP/-P!P\GX+,7P:'S^5V$XV##ON\Y[
MQY-3:B;%G2Z^Z^[P*I4?$-[:VW*#'/P"ES7L2!0917*)T<6Y0ZN8XD;X;DRX
MPL[0 "HVK#R/O*"]X0B>*M$]T@WW(9FUCB9TW;T"IXR</#@S.'Q!-?(YNT)]
M[S2( #D;W7P)R<=ES?<GV'!_MC[F$KR*:CNP0O?W+C]?[CWP547N0K]S#X2%
M<-)KB=<[X)&?WUV^AF=VO#2+^0C8]@7O/4I@/TEI'0T;]ZB:)G6U_-KN<Q_-
MMB- 9,'E5^AV<,"#2B+\&]]-&65?:GU3H_0]?_GFS<OGGSY<9#_\;?+HX>/L
M^.KCU<B/?\5[Q761<#&1\O,(B<GX>$A@2DPC]PW>;.K%OM%N?Y8IG/1-X?'X
M9).A")9\D\E(KE,F]H/J?:ZB]M?;QY.^?3R[9=3K?QOMW8QF9-43PUFX]Y2D
M%O1;[*:OX$7V,B9 $,QG&-K](*KEX^PMZ$%=B.PG"DM? =KV74)@K][GK79)
M!Z.RRX/NK3?T0WB=BC5U2#Y$;HO5BP= T'(4UX1DO\B-!<VW%U/#:PIZ(0J-
MS%!RH6KJ\NC.^"AT2=F0'Y2+\G ,FM/14;H)"[23?+:S("0,FN)R.*#L9/T[
M]Y)?7WZV&_4-&)6XL7SA[T\'PP,*H?.2&_P V%07U->AF3PJW'#+QT,FJ+Q.
M]^%@MU+?\*4Z512E=",H_BTU['*X0,AY(K/*4E_4\7Q!8E6B2\?80_X^&LV2
M?N^88P8>X'E$TRA][=U=Z?H3 8P@2@6+TQ\PP<X">,BI6X,C'16^PV4W93]Y
M=+(6(7T'1>]A;5&]# -82'ZFQ3>HW6:'/:!Y;&8&O*UURCO[W._C):UP6;DZ
M.S\>E"L4HF^7Y&C_LY/#(+WGD^%3[BB]8#J894YRL7;1.GJ_ *G!1^Z_T"\>
M4 QL1XNWOM@,3#@UKSY%;9,+?J5&RRG]5:-;C07N_BRI->+O/UVLOTTLQ*
MC4^$(S#"BZIF6&HE@VP)X-] M$UX* P+553,S5?&9K54L)_U.EO!E=NZRO/W
MGR]?[$_.XZIG@DMOZ&F]:+,;D P9C4R'EQ7],OXX1E52+68I2[W$VGKD=GA!
M_#U.LMTL="F3P9UXJLGJ(!YLLWG:Y!6^TH7&Z+&W=Q'-G*$GCACYZL5%>!G<
MISXU:-()*[]^%F[7:/<V,B5%C'@G'-A=EL* ]W*%:N=[-M_QCD=*ZHXJHA@&
M:"/7$A,'/7P-N&^@)9."N@_6XM,U?VN3><:*FS770I7".MY8<KIA\?*C8U]5
MQ;W;>R</0YR>UL(7Y!;6&_#ICF%6GV88"M)S/OYC-VVI7WI^<K9_>G@RPM=1
M[0,I]T&_\:++2_M:N>R#+0A_X#(QD7P4>N[NM0-4FG47>N,)%9XQF6,EJ^9B
M^)RN19/1ZKU=C.A(<P)<SW?SI?"7PCEBH#E.,7A?H1JVG&K:#8Q^4#F23?&?
M>*O E:5%)5UUSK,CZK#[]VQA"]W-V^(E9!=0E?0:K$U6FGK4SC-G,_55%OO<
MSO;3J;'N7O$;$PC<YW:!M\4^ZD=;[",W]R:I-+^.2O?!*Z]I[Q&ZN-C(4=2I
M.:;\-*3OT1.A;DR&FEZ,1_:L?W&V#Y(K<-)HW[ZA(<=>[2'65H]A?]1GB%@#
MVC@Y'9]^FS8.;NQ?^T@B0&_QFV%#*,#CU0B'O>C*4#0WDROJ4N)((/9@!<T%
M1*^^)+WT9^#K5M*>7*\'37,"J[57*$0]DU#E_JZ!U^0XFL7GZN4D9''?+\!/
M+.+=\Y*&Q].^X0J01W4[0#M?<KOECELV?,EM$E</.(6:;*Z#WZEV %9DY_IO
ME##\N1G.D.JE%=4>?&!*-,Z/1>J+YA'!QEG.F;M@$!0)>V%VEK=0)HPMNY9(
M9BWK]E>+_MWT7^ U\&*'WD Z*'GIWU]"XAP%U#B97<JXQ]I[::D#9#ST(N>#
MZ(W:E838"]\;;KA$P"_7]M_Z5Y-?\!NYPW)^KSFDEG.(K+-2SN#1P_&CDSWN
MQ[L/$(#0^[FGNFUU17\N)/H87 "_S[1NW0<\P+^P_>F_ %!+ P04    " !]
M?PE3KB_47!P%  #["@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R=
M5EEO&S<0_BN$ @0)(%N'[3B';4"64R0!@@1VDCX4?:!V9[6L=\D-#\G*K^\W
MLX?EYFC1%VE)SO'-S#=#GFV=OPTE451W=67#^:B,L7DYF82LI%J'0]>0Q4GA
M?*TCEGX]"8TGG8M274WFT^FS2:V-'5V<R=Y'?W'F4JR,I8]>A537VN\NJ7+;
M\]%LU&]<FW49>6-R<=;H-=U0_-Q\]%A-!BNYJ<D&XZSR5)R/%K.7E\<L+P)?
M#&W#WK?B2%;.W?+B;7X^FC(@JBB+;$'C;T-+JBHV!!A?.YNCP24K[G_WUG^3
MV!'+2@=:NNIWD\?R?/1\I'(J=*KBM=N^H2Z>$[:7N2K(K]JVLD='(Y6E$%W=
M*0-!;6S[K^^Z/.PI/)_^1&'>*<P%=^M(4%[IJ"_.O-LJS]*PQA\2JF@#G+%<
ME)OH<6J@%R_>VLS5I#[I.PIGDPB+O#_).NW+5GO^$^UGZKVSL0SJM<TI?Z@_
M 9(!SKR'<SG_I<%WR1ZJH^E8S:?SV2_L'0WA'8F]HW\-3UV9D%4N)$_JC\4J
M1 ]"_/D+%\>#BV-Q<?P_,_C?M=6GDM32U8VV.Y4"-K15%*(!^2C'PB9=*2H*
M$BJKB*@\CL9J6YJL5"8(07,%MM-= ZE[+2-^QBI$'5-T?C=HLY=<5DT%86/7
MRC6-\S%9$PT?;[2I]*HB&%$1$#?:&Y>"^BMY$W(C[17XL(41]Z+ \! ?8Q4=
MFB62!X=A* ;U-6F/=;53C7<;(UV.(=,A94 4#M62?,1H4<&LK2E,IFU4$$HV
M!0DK4@V$J&F@1K,KV/.4.4A_0_0=XL[7 XP EV7)2_0PJU:DM HN^8R4*R1(
MO3*5B;O>RO>9#ZKPKA[,(\;N\_#QH]FSZ:NK1+S)RCIWC<PAV%[<? ;!9R\.
M9O,.CZ?:;6!.W-QEU(HF=)6']%*='D\/YM.#XY.#4S:8(>&&SW15=9@#&^YR
M![S.YRV@^Z2S;0:^(DN%B? 9,+JXWA*$5NB.+B#8QT%JN< 5Y J/OT-B'73L
MFG$T306N''ZPZKWV"&A^*CV,3F:WGT$E5.,F2L[(:J%F2Q3OK-X8#SXM3#Y6
MUP1#A53E-6"XVF3JAE H+L0BB^K)<G']^H8_GW99;ONFW^4VX+ZIR:_)9CM%
MO1GNI%3!4:.S6]PX * CYZQ*.6 %7'0YA]SWPPJWW&W@)&):D%T#K_U1.&)_
M)VH%2H9,6LD8)KF0!KTD14M,Y6J/2ERRY8<O;Z\.9B^Z6!Z&(ITAV+9$#6-C
M7%FID73I.-2P06D&EO76$"*X@Z!?@1ZU$)J/:\>=LM=*0^NU320T1%M!/.L:
MKS*UB2T!>*ZDB);XIGLF6SP;.H8 '!.(>QTI1>J"X(57X56FO=^MD'@%<>-R
MZ?7!B2AR$ 6WUXZTAQE.Z#],]1TIQ,X35]N"WQB2,O&0":@%M<4MS_^Z[DK:
M.]J+MTL)GC(;GF:8&STO^;98IM@.QG=N%;@677WP%&@;J?1$(A#,'?(JMR#Q
M+:APAU$KW%]DXP<SL00PZZ*,*9_+B-[M3;U[C),G7:L^5?G](.G,/'[T?#X[
M?154:8+,\Y]40Z$)9 ;G+:^9!9J39K5M)YT&:Y$NU#VU=<50<5LYU6N((K<\
MK]DXGCOD/;7MH6$>#\(?7:&3O0>)]"$_N\ !EVQLWR;#[O"R6[0/FGOQ]EF(
M<;(&!E51 =7IX>G)2/GVJ=4NHFOD>;-R$8\E^2SQ.B7/ C@OG(O]@AT,[]V+
MOP%02P,$%     @ ?7\)4\)/"0N!#@  WBT  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&ULS5KY;QLW%OY7"-?MVL!8UN4K%^"X20^TW2!.TQ\6^P,U
M0TE$1D.5G+&L_O7[O4?.)<TX=C9=+-#&DH9\?,?W3LZ+C;&?W%*I7-ROTLR]
M/%CF^?K9Z:F+EVHEW<"L588G<V-7,L=7NSAU:ZMDPIM6Z>EX.#P_74F=';QZ
MP;^]LZ]>F")/=:;>6>&*U4K:[6N5FLW+@]%!^<-[O5CF],/IJQ=KN5"W*O]]
M_<[BVVE%)=$KE3EM,F'5_.7!]>C9ZRFMYP4?M=JXQF=!DLR,^41??DI>'@R)
M(96J."<*$G_NU(U*4R($-OX,- ^J(VEC\W-)_2W+#EEFTJD;D_ZADWSY\N#R
M0"1J+HLT?V\V/ZH@SQG1BTWJ^%^Q\6LG9P<B+EQN5F$S.%CIS/^5]T$/C0V7
MPYX-X[!AS'S[@YC+[V4N7[VP9B,LK08U^L"B\FXPIS,RRFUN\51C7_[J!Y4I
MX\2'I;)RK8I<QRX2/V7QX,5I#O*TZ#0.I%Y[4N,>4N?B5Y/E2R?>9(E*VOM/
MP5;%V[CD[?7X08(_%]E 3(:1& _'HP?H32I9)TQOTD/O-Y/%X-":%$\6D#)7
M5KE<_.MZYG(+?/S[@4.FU2%3/F3Z-13ZA:3PC[@N%D '5#,ZCT2^5.+&K-8R
MVPIR5)6(L#DWP.@=?&\M9):(V*Q6RL9:IOHO);!"9KE>J.R$D)V(M;+.9/P0
M:V46*TNT<;Q6;E#2W$@'0O#+!/I+A!1WTFHY2Y70I4H5R.9;<?3QIS?'Q)'8
M+'6\;/%)5.C[VFH*!V(&XG,-UNR6!7RK9K:@!Q#Q*BK/A@#K5.4XEO;J3.>0
M1<2I<612,P<WM\J"6W$-RFJN++$(-XH_B;G.(!+6#4BG%2,ZNP/+6'4X&HSA
M8T 'PH7.^(3/$XN";"1/BL>S+30M$/](/X&XL0/Q%K S&^(R7VJ(;F7F)(>F
MMOV6*DW$^>A;$H9^)THY;$<[U9\%U!H)"F?XSYW #'?*LCH,&Q=//'\PJ 9<
M0"1HSIL?=LF*<GGF3*H3F8/-W 56$7!S$C[L*N#+5ES?WHC+$3SQIMI#.F([
M_2RS8*;QL,=,3N&LI&FEQZH6C.PCIS;8Y7 8#8?#AY4+N^#$7Z4%F<DH"HSN
MJ?QL_/^A<J_4(E,[&H7RR-G 0Y)HD@RX_[P*A34PX==19'.KV638-[UX0&<-
M13Q6>>28[5/Q62\6(<X@FJ 0*$./K,S;9"PS(C49=GBK2M$,^4$MT%P9J0;B
M-4<^DS6I?/?-Y7AT\1P6=$XY1P9J0+MAT)D*;($+G8M$)V @%TMY!]07<XIG
M9-R@$)D+J]TGVN@Y\2C@R@0FA24W.E]"DTT;NV)F+-0J26NU *Y8KXT%_S^:
M#0*\C?:"*S'2$V!KTT1=G/,ND+6</C14[BDU&,V7$&9E$.J=7F0:=)%)4D *
MYV.U)Q[4*,AD9J5CRB]<1T+R@;B.8Q9LD6[;S">JX2=)?VSRCLVN4KDU;(IZ
MC&R-=5(L4);2HL/I8%2&=O90[PR'X\&TBOA6I3(@D[BQ:J6D*^@/3@THMRH'
M146Z:M425>)K,$I6EMHB.Z:%\BF'V5F"[YE2&4/9)N2S:BT!9P7]M7'X#X9;
M@AI8):*E%/A:7G&&$MU[@_/'S&LGYK3LEF;CO42N$ Z@SQU9FQKWM7),ZT#A
MF?@#5361BE$$Y #>D;J/TR+Q/[GEL3@41V=7T=75^%C\9A#8UG++IXXN1M'Y
M>"C>ZGOR7GA2#KAEBEG&"<6J\$PD"N$+N.2CCU#/3*;#8W$CK=W2*:P_VM.G
M\TDTNL114QQ5Z9O6=X*FLN D.A]=@NU+\0.#)-O30AV_CJ;1:#R*AA=GQ^)[
M%:/[<93:60$-R,VM677JLZ9T*,;1Q<4TNCP;L:D28B=U);YVXP\%V(KC$$4Z
MQ4+4)"M7=8LW_(R:KHBC2@.+ )5,XZ#\+B=B$2A'X<F.*%41>+N4%ORFL*O_
M[,0[JQ'1@,7PD*WQD:UQXT/]A)(,_0\]# ?CBPG^7J*ZHU_>52EL'(U&DV@\
M/,?3T6 R/O-:N[IB:WTPA,*SQIK:D@S^%@9*;OL2)07*63,#$/N.V5][<:3F
MF@[IT"8G\-/* L8ZQH#)LM!BLIZ)" =&8)IL].2JA^OE.G$V33/HE["53$DJ
M($O9%0.'2M*6 +2YE3XAKJ:,(=;%+$6@1L+X!$<E3ER!0,ED![MAG1P06H(O
M,#?-2ACZ0=8A@!4LO2Q)RO7:&LF%"#((TCB:<BYKD#E2S2&)[!NP[J5DOY*M
ML@ F,.D=AP&$,P(^BLS"<G**F .)&!B700Y?8 C.YJ2S0-VSQM7+FJF2R>FG
ME4(:3@;B=ZY^>Q=$0I$D@1K3YZ-7)E&I]RWD4R]^3"P$*HP3B<P*)64Q043J
M50E +_^.>0?B#9WD]U?10=U3+^=*J.YAN4E*WB'.<% @HS+?A 6(LY8<O(+^
M4 V;%%)[J,7P!&@<5G+4?K+N:*N7E5(/ZD#KEGK=Q!N=W2L3'<^VWZ?ASZRA
M$SAO&K(%<R@/F<@GEV+%NME+;6UGH5]JV,)^]VOX+AUEL$NG7.I7/Y) $5?Q
M5+:=S*UJM+B4L&&6?0)M.Z">1:1 >93Z%%@OI#!0XI\1GL!"VR":MRC4CU*6
ME;0H4//2A*!TT9A3!??E;:VUV&\S(\6&QU2D,M2,<E$KI=J.OV2P #Q4()FZ
MSQO1B=2!F!"C+IX7<-1[5(_8PX\J,WB>>K2V#]2MIEH=K/P^N,56RX77MO03
MEM0R=DFDG3"T$_JT\\!"2>H]4(I?:  B)JWJW^6VH!3J&6WBIR"^0A9M@*=,
MF5P>[>5,X1.&<@2NQ.?=9S4XV!)'6R6M.Q;CP=58?*SA<C'\5KSOT13JT_-O
MRQ"_&V]1U497Y^?1V634&F@@Q*:^1E=E;/+QBLQ:5P\A>S5T1Z;%$D,)87<A
M3W2JRI_;!.YEV#O41MID+UCP2E(,6ACJ#6E40P '6%+)O87,=JH9/]3AKE1U
MVG<@;C7U35W%4F]J[:R8EHR-BC7(DVHH*U1LGH3"41&U1]JW4[V"=+&S$ZHJ
M%DAC&_0</N\B'%*=5C<#Q%96VJT*RO4<9C(>H7?JJ=HJ"/@"WG&TI0S9QTRE
MCYX102KC3Z[LH<4,K6EBE*O;1#GS((8.JFS4Z A!= ZDDL4, D[9J80P4COD
M&@5FS*F[SLDMZ'JGMZ3WZ(D'PW;DF05-13=+U009E+,VW.(KRMJ69(+RQ\-J
MK'%G\F:O417J)4C#Q,(?X+/[2E*OS?)"ZZJ.= [1@-A#6(GS,!W2%GT082HN
M72M1,!3-HW/E?WBRM,0HT@<"#\^2*!QL.Y7:QHQ'H&N(Y^&*3$WE;)&ET%-K
M[$H[%IGV!9D+#3(U0Z66.OH@[W(ZH3%$ W,Q=U2Y9[_TA'RO@:[[8E21-/^@
M&4FN0L5./2(R+ INUZB,FR1U5G=1O!8A.8-N6NN?VH*[KAZ\WMX.P<VP2CQ;
M=:?5ADH \M0L@3VYLZ#^%12T+8W =9=5+#2,B>.T21A$1&:#*)$#VPF5PJW)
M@]#SNL+'88GW1K($*PKB^G4,-JSA\']"CG "^7 >3^2O:3"CYR$H N#Y1@5?
MBLM.W4\7^GK9G1!8CR-H \<W#]/:0.UV@\SEIPC$);9"$7^Q33FML:]1:8ND
M"V-Q" SC);8(*8G^09/#L\:&-""84'XK2X8>]":52VY,@7HE4_40L.0&/<-Z
M?Y30Y6AALO68I-5RA">TJ^*1[6I_*]K9?U9C\W:7Z?'S2)'J/,SYI!H]2D%7
MRU0'EY1]SU*+3]A9EETK9T^^X@UM1W-F)U-00'B@W([S0O(DBU$( LP4CRR]
M.7K"7B0XZO&TO')'I*EU6CA"&QC$A[).WQD%&9QB[UB =CU/\R;+@&\VM2%;
M,Q2I7Z#F.Y08S:@1T.GDBES:%=2K_4%YK8D11>[@6DJ,OHRIZ'/.S+4,?( ;
M_*1C[ D3L6UYZ GWZ^6 I*^5W'1*5Q5]74[):>XW)-S5#.[PP$54YSWAR>A+
M;@JG?3>%#Y'KN"O<O2@,Z:/DM!S#[=[&[(YXFG<1.U<D"/K0X_-VW'C"18?K
MNNAH.>W_Z*:C:8H6<\3(3#WALJ/%_5>^[7"=UQV^;5[ZO&'RUDU@.>)YT@TQ
MS]'NN6<'(Y/SKW)Y^<"E3$OAH;UX?'?1[FKV2J%6>S-A71'9_OS!!-L]$MEI
MITOJ&Y;N=8P=/OOW#(:K -2(5Z-Q7W(%A3#@VLNM'1PW]1[:U;I!]>K4L-=C
MLG-2\ @H!E3H;H1 9KG@I^&1\P $? EYT$ ?13](="$'4*K>N:2DQ%'BBLX+
MF?CI-425K*MI]M^=<#YTQ-"])D0UVPH_]U1EX<ZYN#5"RI?6%(LE73!Y8)0O
M*S 6#Z>#\RKE</,<Z&&;HAL'?O5*T:M7[7<=1G[[:'!6;G\NEN6=L<E@PL/I
M9,I7,+2P+$[I*C4IXK)OK-L9/\OM- -,> @8_W/>&/KZ$C\2A^4]3W7]V9KK
M[L^JZA,B;]/9MLW23*8<6?G4KK<\0@1 -0@0TR[HL'[!AYN??F9ZATND^T=Z
M83U;X=DKTK&_E?/OB7RA4/1CWU7?,Q1"72_Q=+0DK7NSSET/"#F*)GP;=Q5N
M^D(SO=-X[T/\I /<1]/H['(*5H;'#U-[--Z/",^3RXOC;KDZE7HHV-+CYZT@
MS!&*(BG;:.^='=8YVZD<Z?FU512K(L*\L#Q4[8P,.V^P+/G=#02M5"^\J:B*
M0FIKOB#4>#MN/.JH=N5G7KIZN$KM' 66KXC4UT;JOZM9SKY2S=);%_*;"@[M
M'TY+$?<SYTUXN\UN0.2[;T87T^?( *LBXZ&'7&_9E#=O?OGES<V']]=A2==K
MH:>-=VY7RB[XS6*R **=?_VV^K5Z>?G:O[-;+_=O/@.*"YU11S#'UN'@XNS
M9]KR2V[6_ ;OS.2Y6?'');ID96D!GL^-R<LO=$#U2O>K_P!02P,$%     @
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MZEY/;N2<!.+ SB]42SO(OD'1KH.*Z:AB1.^AMTMI 1_BB&[_!2\AZ4ZOT0&
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M+W64Y-71QX&M;'?S@LXU^!L,M)$5M=J:7I$!_.KA-^?S)P41BB*!88. %V:
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MAM4!$Y>,B] 0W"D)W#%2;\V?,9^2,8SXK/N^U0$+9"QDAF-<W(?HAEZ0; \
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M_,FC$T9CX1<05OI#%@ H>[NA'[%)0CM\ +['"Y?#+SA!_-,F/_X34$L#!!0
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M'7M$M>M3>S!RXU:6I32X #EQC1LG**N [TN)K=T=K(-^AYW_ U!+ P04
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MA:B] IVWB@*_$_P%X^NZ^ ]02P,$%     @ ?7\)4XBK$N*Y @  %08  !D
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M;SLY9\W > YOQNXUTVLN#<E;46K<&?0#T,TH:PRK*C\^%LK2,/++@J8_:A=
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M<\#ZL^@I-]3=-&?W5ZA_=.NV0/]GMTT;C0=^.QY#U-O0\?Z-/QXP'32Y7"B
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M%;5\ &M9T;@N:: !&AZX8ZG<"O!;NJ*K)MY24ZKGA5[F=8V,#O_(TG. [8\
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MET;+ZTRC@2>%%QS:71?T?>Y1SINM)H ^8D??/ZDV.3C<%&2+2@$V*Q;0NEA
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M@'E_EAHL;F^*7Q3L?D$R^A]02P,$%     @ ?7\)4^[F[2X9 @  6 0  !D
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MT0XG,2Q+?/I@O .>;[5V)\./8_]GDOT%4$L#!!0    ( 'U_"5.'MF\+M@0
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M:IPH5U=&+"\>J"0L%N^4S\OS [CXX=W<DDIA<1]K6:FY.ZA! VH\\(&G<B/
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M>W>?B[&OM^;BEUP */2242;[SD*IY;7KRMD",BRO^!*8?C+G(L-*3T7JRJ4
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M'2YT2PS"&.CG<\[59F("E$WVX!]02P,$%     @ ?7\)4V>93C[!"   DC$
M !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULQ5M=;]LX%OTKA'=VT0*M
M+7Y*FDD"3.Q\.&UF@Q;=>1CL@R+3ME!9\DATT@[FQR\E*Z9D4K3DQM@^-+;#
M>WAX>7G/Y95S]IQF7_,EYP)\6\5)?CY8"K'^>33*PR5?!?DP7?-$_F:>9JM
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MS&.]5#CS>Y6"52 TDX(H6,^\Z]'5/+7VSN [@YW>&Q.;R4K*)SNY+69>8(&
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M&#BV8;*X)XM/DCT*),+C\0=1"EN)@NG<(2*/*8%P1E>,,_-B(6LI8'CGXD/
MT64270;I,%_2\R7_Q\>T;MP=R*4>)$D.2<))$ 7A,,BD!YF<!+G.<]6T]0(L
MTF#HR4'H*(Z3^,@6I'WD]&3D.^S_.57JA8G-B;.;'IS=T3B.DO'X;7A_KR79
M[OZ5*KPAFG!8HVMP,<$$5-LQVXF1M>M2*VFPY[EAB1\94-8 U]<2&THWL8VO
M_VQE?P%02P,$%     @ ?7\)4]Q#H':S @  *@@  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&ULM59M;]HP$/XK5K1)K;02YX4 %2"MH&F=UJDJZO9A
MV@=##K":V,R^0/OO9SMI1M<D7:7M"_'9]SS/W>5R9GR0ZDYO 9#<YYG0$V^+
MN#OW?;W:0LYT3^Y F).U5#E#8ZJ-KW<*6.I >>:'E"9^SKCPIF.W=ZVF8UE@
MQ@5<*Z*+/&?JX0(R>9AX@?>X<<,W6[0;_G2\8QM8 -[NKI6Q_)HEY3D(S:4@
M"M83[WUP/@L<P'E\Y7#01VMB4UE*>6>-RW3B41L19+!"2\',8P\SR#++9.+X
M69%ZM:8%'J\?V3^XY$TR2Z9A)K-O/,7MQ!MZ)(4U*S*\D8>/4"74MWPKF6GW
M2PZ5+_7(JM H\PIL(LBY*)_LOBK$$2"(6P!A!0C_%A!5@,@E6D;FTIHS9-.Q
MD@>BK+=ALPM7&X<VV7!A7^,"E3GE!H?3F11[4,B7&9 Y+)&<D85IE;0PMER3
M*X:%XLA!DY,Y(..9/C4NQR@-@DM%A$3C=$9N%W-R\N9T[*.)SFKXJRJ2BS*2
ML"623X7HD8B^(R$-@P;XK!M^Q52/T,#"@]%3N&]J4A<FK L3.KZHA<\5XU)H
M5(7I6B3?/QL'<HF0ZQ\=]%%-'SGZN(7^B_E"5TRI!RXVA.6R$-A4LI(D<23V
MB]Q/@[@?)7$\'/O[!OFXEH\[Y?]\[1T9]6O*_O\H6%+3)YT1WX =2BDHVY8M
M+7)14O2/RM6/8DII<[$&M?2@4]JHA4UJ@V=J 4T&K7+#6F[XDES4)#=\G=RH
MEAN])!<WR8V>RR6C>-BJ%]#?(X?^B]ZO6)XT_R@)DO8(CH9>T!G! AE"2KA
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M8O,'F\V#XLOT&_!'KA2/TY<+1@,FM %\/N-<;1_TE^KYG\U&_P%02P,$%
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MAR2E-K)HP,B@X*+^9\]-((X Z&@WP&\ _E# J &,A@*"!A ,!80-(!P*B!I
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M4[:JY_!Z8>2V&@.?I,&ALGK,\-L%E!7 ]VN)I[-9V,FR_1J:_PU02P,$%
M  @ ?7\)4P!:O) T P  3@P  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N
M>&ULM5=M;]HP$/XK5K0/K=21.&] !4@KT*W3-J&R=A^F?7## 5&3F-D&.FD_
M?F>3ADPD*>H+'XB=W'/WW/GA<O2V7-S+)8 B#VF2R;ZU5&IU;MLR6D+*9(NO
M(,,G<RY2IG K%K9<"6 S TH3VW6<T$Y9G%F#GKDW$8,>7ZLDSF BB%RG*1-_
M+B#AV[Y%K<<;U_%BJ?0->]!;L05,0=VL)@)W=N%E%J>0R9AG1,"\;WV@YV/:
MU@!C<1O#5I;61*=RQ_F]WES-^I:C&4$"D=(N&%XV,(0DT9Z0Q^_<J57$U,#R
M^M'[I4D>D[EC$H8\^1'/U+)O=2PR@SE;)^J:;S]!GE"@_44\D>:;;'>V8=<B
MT5HJGN9@9)#&V>[*'O)"E #4KP&X.< ]%N#E .]8@)\#_&,!00XPJ=N[W$WA
M1DRQ04_P+1':&KWIA:F^06.]XDP+9:H$/HT1IP8?(0,NR?<E"+:"M8HC>4:N
MLJA%WN-E U*A*A0N26YY,@+%XD2>HL'-=$1.WIWV;(5,M#\[RJ->[**Z-5$_
MK[,6\9PSXCHNK8 /F^%?F4 XK86/FN$CB JX4P$?'T'>J83;6/WB"-SB"%SC
MSZOQ]XUG$<^4X D^66"I%0BL._GY!0W)E8)4_FH(XQ5A/!/&KPESR6)!;EFR
MAJKSVF%#@]7-93/ U#;EFAY:^)[O==J%V7^L_(*5W\BJ5G\-&0>%[^ M"QL6
M8<+&%*9+AF[)29P1:995/XCQSD=0*E] J><Z877]VD7P]@M.M?W4J0Z?M!@?
M6G@A[72[G6KBG8)XIY'XD*<IOBBPP47WY"]YC@ZZ1:CN6^J .OM>ZKR"$G(G
M92EXCOE45Y26>CEMC#\1<01D!8(8)H;(#+-F0IJ[AE0UI_PM0<M":+EMKX;2
MOK=1]_GZ'.;@H$%^N4E9?QW:K2_6OAW2YGXXP8D$A(#9BS1(]XV.^F^JPGW7
MH\%KJ# X*+W;U)#HOAW2YG[X A6&ARJD+<\-:BCMFR1]09<<TJ>;8(6)V^YV
M#[N@71K%]*2-H\HBSB1)8(Y(I]7&@HO=\+K;*+XRT]D=5SCKF>42!WX0V@"?
MSSE7CQL]\!5_(0;_ %!+ P04    " !]?PE3'HDF4;H"   S"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970U."YX;6RU5LMNVS 0_)6%T$,"I-;#CO. ;2"/
MIDW1%D'2I(>B!T9:6T0H42%7=OSW7=**XA2V3O7%XI+<V9FAQ/5HH<V3S1$)
M7@I5VG&0$U6G86C3' MA>[K"DE>FVA2".#2ST%8&1>:3"A4F430,"R'+8#+R
M<S=F,M(U*5GBC0%;%X4PRW-4>C$.XN!UXE;.<G(3X614B1G>(=U7-X:CL$7)
M9(&EE;H$@]-Q<!:?GL>)2_ ['B0N[-H8G)1'K9]<<)V-@\@Q0H4I.0C!CSE>
MH%(.B7D\-Z!!6],EKH]?T:^\>!;S*"Q>:/5+9I2/@^, ,IR*6M&M7GS!1M"A
MPTNULOX7%LW>*("TMJ2+)ID9%+)</<5+8\1:0C+8DI T"=Z(<%7(L[P4)"8C
MHQ=@W&Y&<P,OU6<S.5FZ4[DCPZN2\VCR&4O4%G[F:$2%-<G4'L!UF?;@(UP)
M:>!!J!KAS/*Q5<Y'"WN72$(JN\];MJ:/0F)VKD:8-DS.5TR2+4R^UF4/HO@
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M<013 !HP)(KL>W#G?12NWE/A^O^;P]]02P,$%     @ ?7\)4Y>*NQS
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M)/2HQ-$$   [)P  #P   'AL+W=O<FMB;V]K+GAM;,6:36_;.!! _PKAR[9
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M?[)<O0)02P$"% ,4    " !]?PE3!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( 'U_"5/ZJT0V[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( 'U_"5.97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ?7\)4\PNNW-=!0  >!4  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( 'U_"5,FT(_P:@<  (<@   8              " @:$-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !]?PE3.G2<4><'   $
M(@  &               @(%!%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ ?7\)4V8%P6[/ P  8@P  !@              ("!7AT
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( 'U_"5-UKQ.K
M+PL  -I#   8              " @6,A  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " !]?PE3"NSKQ"<"  "2!   &
M@('(+   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ?7\)
M4Q8_L-+*"0  K"@  !@              ("!)2\  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( 'U_"5/ A/437P@  &@2   8
M      " @24Y  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" !]?PE38L(JX:,,  !0(@  &               @(&Z00  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ?7\)4^&(8F(C%@  :$,  !D
M             ("!DTX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " !]?PE3]T"N^ML#   '"0  &0              @('M9   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( 'U_"5-TP'ZFY@(
M (T&   9              " @?]H  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ ?7\)4QW'I4 -"   3A8  !D              ("!
M'&P  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !]?PE3
M]%SEQA (  #>%@  &0              @(%@=   >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( 'U_"5.*H,1[L ,  (H(   9
M      " @:=\  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ ?7\)4Z )\*PR$   -3L  !D              ("!CH   'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !]?PE3C@/PP((&  "[$0
M&0              @('WD   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( 'U_"5-4/$M2.@4  *,,   9              " @;"7  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ?7\)4Q=TKS51
M!P  Y18  !D              ("!(9T  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " !]?PE36&A+W+P&  #G$@  &0
M@(&II   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( 'U_
M"5-3#*G.=P<  (D2   9              " @9RK  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ ?7\)4Z_I=[G$&0  O%T  !D
M         ("!2K,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " !]?PE3KB_47!P%  #["@  &0              @(%%S0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( 'U_"5/"3PD+@0X  -XM
M   9              " @9C2  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ ?7\)4^24YP^>'P  YF0  !D              ("!4.$
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !]?PE3)]1[
M,,@#   C"   &0              @($E 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( 'U_"5-UA]=I"P0  ,\*   9
M  " @20% 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M?7\)4Z]L:2ZQ P  &P@  !D              ("!9@D! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " !]?PE39 #8!EP#  !I!P  &0
M            @(%.#0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( 'U_"5.(JQ+BN0(  !4&   9              " @>$0 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ?7\)4Q*9)<1D P
M!0<  !D              ("!T1,! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " !]?PE3B! R5,8"  #J!0  &0              @(%L
M%P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( 'U_"5,B
M&2ZZY (  %L&   9              " @6D: 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ ?7\)4S2<@82<!   .@H  !D
M     ("!A!T! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'U_"5-2Y[HF-P4  &07   9              "
M@34P 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ?7\)
M4_;!GU@F!P  33(  !D              ("!HS4! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " !]?PE3[N;M+AD"  !8!   &0
M        @($ /0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( 'U_"5.'MF\+M@0  #(7   9              " @5 _ 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ?7\)4W$HK; ; P  < L
M !D              ("!/40! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " !]?PE39YE./L$(  "2,0  &0              @(&/1P$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( 'U_"5.1DM,T
MM@(  ,(&   9              " @8=0 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ ?7\)4]Q#H':S @  *@@  !D
M ("!=%,! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !]
M?PE3"@Y7'O("  !C"@  &0              @(%>5@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( 'U_"5/$1W^/]@4  *(;   9
M          " @8=9 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#
M%     @ ?7\)4QU[3*/O P  N1$  !D              ("!M%\! 'AL+W=O
M<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !]?PE3QA2' 7\&  !Z
M(P  &0              @(':8P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM
M;%!+ 0(4 Q0    ( 'U_"5.8J;LI404  ,H6   9              " @9!J
M 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ?7\)4TJ$
M\3VG P  S@T  !D              ("!&' ! 'AL+W=O<FMS:&5E=',O<VAE
M970U,BYX;6Q02P$"% ,4    " !]?PE339\,WU(#  #&"@  &0
M    @('V<P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M 'U_"5-,F7;Z+@H  +@_   9              " @7]W 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ ?7\)4Q8UO2*"!0  0AL  !D
M             ("!Y($! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " !]?PE3U.*N'*<#   9#0  &0              @(&=AP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( 'U_"5, 6KR0- ,
M $X,   9              " @7N+ 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ ?7\)4QZ))E&Z @  ,P@  !D              ("!
MYHX! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " !]?PE3
M8R(\IIH#   C#@  &0              @('7D0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( 'U_"5/X?HDI3P,  .P4   -
M      "  :B5 0!X;"]S='EL97,N>&UL4$L! A0#%     @ ?7\)4Y>*NQS
M    $P(   L              ( !(ID! %]R96QS+RYR96QS4$L! A0#%
M  @ ?7\)4R3TJ,31!   .R<   \              ( !"YH! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( 'U_"5-9=@'X]0$  #@C   :
M  "  0F? 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M 'U_"5,7R,P;VP$  -$B   3              "  3:A 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !# $, 3!(  $*C 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>335</ContextCount>
  <ElementCount>406</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Impact of Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards</Role>
      <ShortName>Impact of Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108105 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110106 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118108 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2122109 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2127110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131111 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2137113 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2139114 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2143115 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2145116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2146117 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2347309 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Critical Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPoliciesDetails</Role>
      <ShortName>Critical Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognition</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Short-term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails</Role>
      <ShortName>Short-term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails</Role>
      <ShortName>Convertible Debt - Balance of Convertible Bonds and Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2436416 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438417 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441418 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442419 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444420 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448421 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2449422 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2450423 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Investment In Geneos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2451424 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2452425 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ino-20210630.htm">ino-20210630.htm</File>
    <File>ino-20210630.xsd</File>
    <File>ino-20210630_cal.xml</File>
    <File>ino-20210630_def.xml</File>
    <File>ino-20210630_lab.xml</File>
    <File>ino-20210630_pre.xml</File>
    <File>ino-63021x10qex311.htm</File>
    <File>ino-63021x10qex312.htm</File>
    <File>ino-63021x10qex321.htm</File>
    <File>ino-63021x10xqex101.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20210630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 335,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 548,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://xbrl.sec.gov/dei/2021": 6,
    "total": 11
   },
   "keyCustom": 63,
   "keyStandard": 343,
   "memberCustom": 36,
   "memberStandard": 38,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Critical Accounting Policies",
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "shortName": "Critical Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Impact of Recently Issued Accounting Standards",
     "role": "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards",
     "shortName": "Impact of Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108105 - Disclosure - Revenue Recognition",
     "role": "http://www.inovio.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110106 - Disclosure - Short-term Investments",
     "role": "http://www.inovio.com/role/ShorttermInvestments",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - Fair Value Measurements",
     "role": "http://www.inovio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118108 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122109 - Disclosure - Convertible Debt",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127110 - Disclosure - Stockholders' Equity",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131111 - Disclosure - Net Loss Per Share",
     "role": "http://www.inovio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137113 - Disclosure - Related Party Transactions",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139114 - Disclosure - Leases",
     "role": "http://www.inovio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143115 - Disclosure - Collaborative Agreements",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145116 - Disclosure - Income Taxes",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146117 - Disclosure - Geneos Therapeutics, Inc.",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Short-term Investments (Tables)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Convertible Debt (Tables)",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Leases (Tables)",
     "role": "http://www.inovio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347309 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i0ae8485bffe44645bcc2d2d69167e061_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Critical Accounting Policies (Details)",
     "role": "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
     "shortName": "Critical Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ic6c3eb7929d54a7db36dd6d7dbc2b7dd_D20210101-20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Revenue Recognition (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionDetails",
     "shortName": "Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Short-term Investments - Narrative (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails",
     "shortName": "Short-term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ibc709f4b94bc48ed922b211843a64806_I20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i9cdd7b8ef815473385e371284b1691bb_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i9cdd7b8ef815473385e371284b1691bb_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Convertible Debt - Narrative (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icaaf8fc6a6c144978817e6793fd2365a_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icc098f58f8a041b08a33357d6648fbc0_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
     "shortName": "Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icc098f58f8a041b08a33357d6648fbc0_I20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icc098f58f8a041b08a33357d6648fbc0_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "idb65bbc9382a4813ad514235377b41b5_I20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i35a378f1adfd4003a890450ab84a2bd9_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i35a378f1adfd4003a890450ab84a2bd9_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "role": "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "if20cd84b26984f8f9e8f6f29f783d43c_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i9b55a1c703da4f9193e57797f7a186a7_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436416 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.inovio.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438417 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i79aa827c9e8f4b358c9a1724e62d1c61_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441418 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.inovio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442419 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)",
     "role": "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444420 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i95c7a96f00054646b6f751e13b02c56e_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i00d9f08cb2264b0abc64d85714445c8e_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448421 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i565b71404f58429384bf7e01598dd420_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449422 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
     "shortName": "Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icb812a090bdf454a8d614a22e3087514_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:WorkingCapitalExcludingCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "iad1208ba98074d448260b48944e05ebe_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450423 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
     "shortName": "Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icb812a090bdf454a8d614a22e3087514_I20200601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icb812a090bdf454a8d614a22e3087514_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451424 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
     "shortName": "Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "icb812a090bdf454a8d614a22e3087514_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "i6ec4fd5d328e4ac9aae815b66c487a7b_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452425 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "id506e21662664607abb5ada53bef4c71_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "id506e21662664607abb5ada53bef4c71_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Operations",
     "role": "http://www.inovio.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210630.htm",
      "contextRef": "ie8bdb1d6a8524a5a90dc5354ad3260db_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AdvaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advaccine",
        "label": "Advaccine [Member]",
        "terseLabel": "Advaccine"
       }
      }
     },
     "localname": "AdvaccineMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AlternativeInvestmentMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Measurement Input, Term",
        "label": "Alternative Investment, Measurement Input, Term",
        "terseLabel": "Equity method investment, measurement input, expected term"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInputTerm",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_AnnualMaintenancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Maintenance Period",
        "label": "Annual Maintenance Period",
        "terseLabel": "Annual maintenance period"
       }
      }
     },
     "localname": "AnnualMaintenancePeriod",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_August2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2019 Convertible Bonds [Member]",
        "label": "August 2019 Convertible Bonds [Member]",
        "terseLabel": "August 2019 Bonds"
       }
      }
     },
     "localname": "August2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation [Member]",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill and Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA2000DeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 2000 Device [Member]",
        "label": "CELLECTRA 2000 Device [Member]",
        "terseLabel": "CELLECTRA 2000 Device"
       }
      }
     },
     "localname": "CELLECTRA2000DeviceMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "label": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "Gain (loss) on equity investment in affiliated entities",
        "verboseLabel": "Gain (loss) on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated commercial event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated development and regulatory event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementPaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Payment Earned",
        "label": "Collaboration Agreement, Payment Earned",
        "terseLabel": "Collaboration Agreement, Payment Earned"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentEarned",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborationAgreementTerritoryExpansionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Territory Expansion Option Period",
        "label": "Collaboration Agreement, Territory Expansion Option Period",
        "terseLabel": "Territory expansion option period"
       }
      }
     },
     "localname": "CollaborationAgreementTerritoryExpansionOptionPeriod",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAdvisoryFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Advisory Fees",
        "label": "Collaborative Agreement, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "CollaborativeAgreementAdvisoryFees",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Option Amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "terseLabel": "Awarded option amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementCorporateIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Corporate Income Tax",
        "label": "Collaborative Agreement, Corporate Income Tax",
        "terseLabel": "Foreign corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementCorporateIncomeTax",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementForeignNonIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Non-Income Taxes",
        "label": "Collaborative Agreement, Foreign Non-Income Taxes",
        "terseLabel": "Foreign non-corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementForeignNonIncomeTaxes",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received",
        "label": "Collaborative Agreement, Funding Received",
        "verboseLabel": "Funding received for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingReceived",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Bonds [Member]",
        "label": "Convertible Bonds [Member]",
        "terseLabel": "Convertible bonds"
       }
      }
     },
     "localname": "ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Accrued Interest",
        "label": "Debt Instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual maturity (less than)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "label": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "terseLabel": "Grant funding liability from affiliated entity, net of current portion"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateNoncurrent",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Of Defence [Member]",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EquityMethodInvestmentEnterpriseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Enterprise Value",
        "label": "Equity Method Investment, Enterprise Value",
        "verboseLabel": "Geneos enterprise value"
       }
      }
     },
     "localname": "EquityMethodInvestmentEnterpriseValue",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Estimated aggregate amortization expense for 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, net book value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Policy [Policy Text Block]",
        "label": "Grant Policy [Policy Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantPolicyPolicyTextBlock",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INO-4800 [Member]",
        "label": "INO-4800 [Member]",
        "terseLabel": "INO-4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "negatedLabel": "Loss from equity method investment, recorded and allocated to investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.",
        "label": "Increase Decrease in Deferred Revenue From Related Parties",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenueFromRelatedParties",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.",
        "label": "Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "negatedLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InitialConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Conversion Price [Member]",
        "label": "Initial Conversion Price [Member]",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "localname": "InitialConversionPriceMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever and MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Area leased (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_LesseeOperatingLeaseNumberOfAgreementsToSublease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "label": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfAgreementsToSublease",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License with Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements with affiliated entities"
       }
      }
     },
     "localname": "LicensewithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities and fair value measurements.",
        "label": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]",
        "verboseLabel": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAndFairValueMeasurementsTextualAbstract",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NewSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Sales Agreement [Member]",
        "label": "New Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement"
       }
      }
     },
     "localname": "NewSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Income (Expense)",
        "label": "Non-Cash Interest Income (Expense)",
        "negatedTerseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestIncomeExpense",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "terseLabel": "Number of potential shares authorized for issuance under share based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OperatingLeaseNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Non-Cash Lease Expense",
        "label": "Operating Lease, Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseNonCashLeaseExpense",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OtherCounterpartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Counterparty [Member]",
        "label": "Other Counterparty [Member]",
        "terseLabel": "Other Counterparty"
       }
      }
     },
     "localname": "OtherCounterpartyMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PriorSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Sales Agreement [Member]",
        "label": "Prior Sales Agreement [Member]",
        "verboseLabel": "Prior Sales Agreement"
       }
      }
     },
     "localname": "PriorSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ProceedsFromCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Collaborative Agreement",
        "label": "Proceeds From Collaborative Agreement",
        "terseLabel": "Proceeds received in upfront payment"
       }
      }
     },
     "localname": "ProceedsFromCollaborativeAgreement",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RelatedPartyTransactionsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transactions.",
        "label": "Related Party Transactions (Textual) [Abstract]",
        "verboseLabel": "Related-Party Transactions (Textual) [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsTextualAbstract",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "label": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "terseLabel": "SARS-CoV-2/COVID-19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SalesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreements [Member]",
        "label": "Sales Agreements [Member]",
        "terseLabel": "Sales Agreements"
       }
      }
     },
     "localname": "SalesAgreementsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego Office [Member]",
        "label": "San Diego Office [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoOfficeMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A One Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "verboseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "negatedLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)"
       }
      }
     },
     "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "terseLabel": "Maximum contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Stock sale agreement weighted average price per share"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Maximum authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TheWistarInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Wistar Institute [Member]",
        "label": "The Wistar Institute [Member]",
        "terseLabel": "The Wistar Institute"
       }
      }
     },
     "localname": "TheWistarInstituteMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_WorkingCapitalExcludingCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital, Excluding Cash",
        "label": "Working Capital, Excluding Cash",
        "negatedTerseLabel": "Working capital (excluding cash)"
       }
      }
     },
     "localname": "WorkingCapitalExcludingCash",
     "nsuri": "http://www.inovio.com/20210630",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r113",
      "r114",
      "r274",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r182",
      "r360",
      "r366",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r273",
      "r316",
      "r386",
      "r387",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r586",
      "r659",
      "r662",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r273",
      "r316",
      "r386",
      "r387",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r586",
      "r659",
      "r662",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r182",
      "r360",
      "r366",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r180",
      "r360",
      "r364",
      "r589",
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r180",
      "r360",
      "r364",
      "r589",
      "r658",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r273",
      "r316",
      "r376",
      "r386",
      "r387",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r586",
      "r659",
      "r662",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r273",
      "r316",
      "r376",
      "r386",
      "r387",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r586",
      "r659",
      "r662",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r113",
      "r114",
      "r274",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r183",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r562",
      "r564",
      "r567",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r22",
      "r638",
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r22",
      "r184",
      "r185"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r21",
      "r112",
      "r547",
      "r550",
      "r646"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r45",
      "r112",
      "r547",
      "r550"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": {
     "auth_ref": [
      "r649"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.",
        "label": "Accrued Liabilities for Commissions, Expense and Taxes",
        "terseLabel": "Commissions and other estimated offering expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r55",
      "r56",
      "r57",
      "r642",
      "r670",
      "r674"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r63",
      "r64",
      "r65",
      "r117",
      "r118",
      "r119",
      "r460",
      "r665",
      "r666",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r417",
      "r555"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r413",
      "r414",
      "r415",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r388",
      "r390",
      "r420",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r390",
      "r405",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Equity method investment, measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r96",
      "r238",
      "r245"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense on intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r168",
      "r172",
      "r178",
      "r211",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r454",
      "r465",
      "r501",
      "r553",
      "r555",
      "r612",
      "r640"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r48",
      "r110",
      "r211",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r454",
      "r465",
      "r501",
      "r553",
      "r555"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r193",
      "r226"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r191",
      "r194",
      "r226",
      "r619"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Debt securities, available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r392",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r7",
      "r116",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation, Liquidity and Risks and Uncertainties"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Banking Regulation, Total Capital, Actual",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8",
      "r31",
      "r98"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r98",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r517"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "terseLabel": "Decrease in cash resulting from the deconsolidation of Geneos"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r107",
      "r110",
      "r142",
      "r143",
      "r144",
      "r146",
      "r148",
      "r156",
      "r157",
      "r158",
      "r211",
      "r256",
      "r261",
      "r262",
      "r263",
      "r267",
      "r268",
      "r314",
      "r315",
      "r319",
      "r323",
      "r501",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "verboseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r443",
      "r444",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Product"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common stock, other shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r555"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r71",
      "r626",
      "r655"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r61",
      "r70",
      "r451",
      "r452",
      "r471",
      "r625",
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r61",
      "r69",
      "r450",
      "r471",
      "r624",
      "r653"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r182",
      "r499",
      "r500",
      "r675",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r182",
      "r499",
      "r500",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r464",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities (VIE)"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r341",
      "r342",
      "r361"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r341",
      "r342",
      "r361"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r17",
      "r614",
      "r641"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r273",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r303",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r314",
      "r315",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Cost, Maintenance",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r160",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument principal amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r287",
      "r294",
      "r295",
      "r297",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r16",
      "r17",
      "r109",
      "r115",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r303",
      "r304",
      "r305",
      "r306",
      "r529",
      "r613",
      "r614",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r272",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r39",
      "r272",
      "r331",
      "r334",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r270",
      "r303",
      "r304",
      "r527",
      "r529",
      "r530"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Original principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r285",
      "r303",
      "r304",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of date conversion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r38",
      "r301",
      "r527",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40",
      "r109",
      "r115",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r303",
      "r304",
      "r305",
      "r306",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r40",
      "r109",
      "r115",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r303",
      "r304",
      "r305",
      "r306",
      "r331",
      "r335",
      "r336",
      "r337",
      "r526",
      "r527",
      "r529",
      "r530",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r283",
      "r526",
      "r530"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt discount on the liability component",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r199",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "Gain on deconsolidation of Geneos",
        "terseLabel": "Gain on deconsolidation of Geneos",
        "verboseLabel": "Gain on deconsolidation of investment"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r33",
      "r283",
      "r528"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r249"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r360",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r34",
      "r112",
      "r259",
      "r261",
      "r262",
      "r266",
      "r267",
      "r268",
      "r547"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r112",
      "r259",
      "r261",
      "r262",
      "r266",
      "r267",
      "r268",
      "r547",
      "r621",
      "r650"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Accounts payable/accrued liabilities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r72",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r140",
      "r142",
      "r146",
      "r147",
      "r148",
      "r152",
      "r153",
      "r486",
      "r487",
      "r627",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r142",
      "r146",
      "r147",
      "r148",
      "r152",
      "r153",
      "r486",
      "r487",
      "r627",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r63",
      "r64",
      "r65",
      "r117",
      "r118",
      "r119",
      "r124",
      "r134",
      "r136",
      "r155",
      "r216",
      "r330",
      "r338",
      "r413",
      "r414",
      "r415",
      "r432",
      "r433",
      "r485",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r665",
      "r666",
      "r667",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r169",
      "r209"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "netLabel": "Fair Value",
        "periodEndLabel": "Investment in Geneos as of March 31, 2021",
        "periodStartLabel": "Investment in Geneos upon deconsolidation",
        "terseLabel": "Investment in Geneos",
        "verboseLabel": "Investment in equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "verboseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "verboseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r208",
      "r657"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale equity securities",
        "verboseLabel": "Unrealized gain (loss) on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Net unrealized loss on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.",
        "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r488",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r285",
      "r303",
      "r304",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r489",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r488",
      "r489",
      "r491",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r285",
      "r377",
      "r378",
      "r383",
      "r385",
      "r489",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r285",
      "r303",
      "r304",
      "r377",
      "r378",
      "r383",
      "r385",
      "r489",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r285",
      "r303",
      "r304",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r489",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r285",
      "r303",
      "r304",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r204",
      "r205",
      "r206",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r296",
      "r328",
      "r475",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated aggregate amortization expense for remainder of 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Estimated aggregate amortization expense for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "Estimated aggregate amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Estimated aggregate amortization expense for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r239",
      "r240",
      "r244",
      "r247",
      "r590",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r244",
      "r597"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r239",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r244",
      "r590"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net book value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r516"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction gain on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r78",
      "r96",
      "r192"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "(Gain) loss on short-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r96",
      "r307",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r232",
      "r233",
      "r555",
      "r611"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "totalLabel": "Goodwill, net book value",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r236",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r234",
      "r235"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r168",
      "r171",
      "r174",
      "r177",
      "r179"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r67",
      "r96",
      "r167",
      "r209",
      "r622",
      "r651"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Share of net loss in Geneos",
        "terseLabel": "Share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r426",
      "r428",
      "r429",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedTerseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95",
      "r587"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r237",
      "r242"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r166",
      "r525",
      "r528",
      "r628"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r79",
      "r291",
      "r302",
      "r305",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, contractual interest"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r93",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r676",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)",
        "verboseLabel": "Shares (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r203",
      "r610",
      "r631",
      "r678",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r538",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r110",
      "r173",
      "r211",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r455",
      "r465",
      "r466",
      "r501",
      "r553",
      "r554"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r110",
      "r211",
      "r501",
      "r555",
      "r616",
      "r645"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r110",
      "r211",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r455",
      "r465",
      "r466",
      "r501",
      "r553",
      "r554",
      "r555"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r284",
      "r299",
      "r303",
      "r304",
      "r614",
      "r641"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r115",
      "r253",
      "r289"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r115",
      "r253",
      "r289"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r115",
      "r253",
      "r289"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r40",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r46",
      "r110",
      "r211",
      "r256",
      "r261",
      "r262",
      "r263",
      "r267",
      "r268",
      "r501",
      "r615",
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Carrying value of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r46",
      "r76",
      "r449",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r159",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r58",
      "r60",
      "r65",
      "r68",
      "r97",
      "r110",
      "r123",
      "r129",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r145",
      "r168",
      "r171",
      "r174",
      "r177",
      "r179",
      "r211",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r487",
      "r501",
      "r623",
      "r652"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r60",
      "r65",
      "r135",
      "r136",
      "r457",
      "r470"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r121",
      "r122",
      "r125",
      "r126",
      "r137",
      "r138",
      "r139",
      "r189",
      "r190",
      "r217",
      "r218",
      "r371",
      "r372",
      "r373",
      "r374",
      "r416",
      "r434",
      "r435",
      "r436",
      "r483",
      "r508",
      "r509",
      "r510",
      "r543",
      "r594",
      "r595",
      "r596",
      "r669",
      "r670",
      "r671",
      "r672",
      "r674",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Impact of Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r120",
      "r123",
      "r124",
      "r125",
      "r127",
      "r128",
      "r131",
      "r137",
      "r152",
      "r187",
      "r188",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r255",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r430",
      "r431",
      "r432",
      "r433",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r511",
      "r512",
      "r542",
      "r591",
      "r592",
      "r593",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r339",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedLabel": "Deconsolidation of Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r339",
      "r453",
      "r459"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Acquisition of non-controlling interest in Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r338",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r17",
      "r614",
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r168",
      "r171",
      "r174",
      "r177",
      "r179"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r537",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r536",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r7",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r53",
      "r55"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r392",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r555"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r620",
      "r648"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid balance"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from Geneos issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r85",
      "r408"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r58",
      "r60",
      "r65",
      "r91",
      "r110",
      "r123",
      "r135",
      "r136",
      "r168",
      "r171",
      "r174",
      "r177",
      "r179",
      "r211",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r450",
      "r456",
      "r458",
      "r470",
      "r471",
      "r487",
      "r501",
      "r629"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net loss attributable to common stockholders",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r250",
      "r555",
      "r632",
      "r647"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "negatedTerseLabel": "Fixed assets, net of accumulated depreciation",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r384",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r384",
      "r546",
      "r550",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r544",
      "r545",
      "r547",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r423",
      "r588",
      "r692"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r338",
      "r417",
      "r555",
      "r643",
      "r669",
      "r674"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Retained earnings (accumulated deficit)",
        "netLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r117",
      "r118",
      "r119",
      "r124",
      "r134",
      "r136",
      "r216",
      "r413",
      "r414",
      "r415",
      "r432",
      "r433",
      "r485",
      "r665",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedInterestFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.",
        "label": "Retained Interest, Fair Value Disclosure",
        "terseLabel": "Fair value of investment in Geneos retained"
       }
      }
     },
     "localname": "RetainedInterestFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r164",
      "r165",
      "r170",
      "r175",
      "r176",
      "r180",
      "r181",
      "r182",
      "r359",
      "r360",
      "r589"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from related parties",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r363",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Summary of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r239",
      "r243",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Summary of Intangible Assets by Major Asset Class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r392",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r107",
      "r156",
      "r157",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r323",
      "r328",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r311",
      "r312",
      "r313",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r389",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r400",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r15",
      "r617",
      "r618",
      "r639"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Critical Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r107",
      "r110",
      "r142",
      "r143",
      "r144",
      "r146",
      "r148",
      "r156",
      "r157",
      "r158",
      "r211",
      "r256",
      "r261",
      "r262",
      "r263",
      "r267",
      "r268",
      "r314",
      "r315",
      "r319",
      "r323",
      "r330",
      "r501",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r44",
      "r63",
      "r64",
      "r65",
      "r117",
      "r118",
      "r119",
      "r124",
      "r134",
      "r136",
      "r155",
      "r216",
      "r330",
      "r338",
      "r413",
      "r414",
      "r415",
      "r432",
      "r433",
      "r485",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r665",
      "r666",
      "r667",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r155",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r288",
      "r330",
      "r331",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r330",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)",
        "verboseLabel": "Underwritten public offering, common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r330",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r330",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r44",
      "r330",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of carrying value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r330",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r338",
      "r391",
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r26",
      "r27",
      "r110",
      "r186",
      "r211",
      "r501",
      "r555"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r64",
      "r110",
      "r117",
      "r118",
      "r119",
      "r124",
      "r134",
      "r211",
      "r216",
      "r338",
      "r413",
      "r414",
      "r415",
      "r432",
      "r433",
      "r448",
      "r449",
      "r469",
      "r485",
      "r501",
      "r518",
      "r519",
      "r523",
      "r666",
      "r667",
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r204",
      "r205",
      "r206",
      "r296",
      "r328",
      "r475",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r140",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r693": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r694": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r695": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r696": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r697": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r698": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r699": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r700": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r701": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r702": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r703": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r704": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r705": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r706": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001055726-21-000055-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-21-000055-xbrl.zip
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M6=)2D%B0I!DDZ5T@">J<C7.<E_L\5834\4*%CI>@L\V0(X1SDCACO=,_29+
M*C-4A9!R '92/@B*%DB%G"/3\C342*5LY_S%@B1S(,G)14\B14D^V@YJ#C-
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M_D1>KR^TVT\(<T5"2U1U- Z[)%%0**U#RM&#TB7!'-JMS5&] 8 &C<%P;BI
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M&, :[[7U5+<D%;%$*>4=,+M;PO)F%L-TPL8D?4[*0G;%"Y8?.A=CA-9&^#L
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M_R#38W(B%(@!8@)/.2@555TZ6]<1VZ)=3+\GZ8R+I11!$8U4X#FS,5EF<"J
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MO3-%4"G9AY9U]S3&(=PC(6=CMMJ)9.JNH";+P$&-#"%I3Z+(=N7#]TG(-85
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M1ZK/^:R/X_%&V9H,T[NK59'#P^%@>J EABDY>P6C/ H,P#XS8%# ?A)!26/
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M.=AJ/@4&/.H-TLDH)+"EVL<HE6.%1V_-HS=SZL+G:.UYM-6O;-6&1XD5: #
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MAI?(:IGWX<=SA_#CJPX%PO.#\%2%P#X8D[*KP3N->) J&P(<$9,L,R(X[@A
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M\33<0I'P?G@Z;#<)/2&FEF\-GI?#X:>G4"'Z\)3_9P/=@8A>QX&%L89=V^O
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ME1OP"CFM;IE"7ME.N(.:>,MLNM&R_87!.@_=86XC-'FRA^TBU\WE(C>1_[7
M^5F7W?5)T_&W.Z'LM0_<:R_EZ'M+HPZ@7#/*1,ZS$$A;Z9$+26 &"C=5%#1L
M0VK-:4WF%@$Q/R MV'%8&+4PZLK9*X51Y\VH4^LE)C!=@I6(&Z813R8B@Y-$
M6#/*F3,I!@R,RDRM%*VY^O:X=U49M5&^_S6P\*7P;VA]VOHW_)@,?.9>/L)J
M[XUQN/5OU_O7UL73WO9C<X,OP3_"+VW*),1869^/B&WG/)>?;EIP5X,N(-D.
M0RL?(P.*0^ST1[\U\]N<+J=6QW9\"Q3W_@!>.(7'Z&_>^,#C;V5D4\# SKK]
M)NSSEUYLVT'K4_SU<RL,3B:D,O.YL>#Q]"/6P1B&@YL_LBQS2R]/QNS//-J&
M@;S%5N$4J=68JZ1<L,JR8(*+W+@0_R%F8_*AD][D"<[L^XA<+]J/R"9XP%]L
M^[,][V_\Z](\G+8ZDP%QNJGRO%^=LIO7ZA*LV&]LQ696]PX._]H[K/[X[_;K
M_>T7NV^.]UYLOSJJJ[V#%S>OOE/;>P^SD4E"7-8T%OHL+PX/=G8/CG9W*OCM
MZ/#5WL[V,?QQ= S_[.\>'!]5AR^KPS]V7V\?[\$%J_9X/[V9<,C/WPS]J;65
M9D!7MJ![3&.S#4RYJ=EZ8/!M>]:/OTQ^^77BPVEUFC$T'_IU?/<QH>4ON.I^
MR=\W>GL*U$T\ NO8^S/^YO';F\U;5[;2T7N";C+-;WP;;Y(;W_O>;<VFD3>_
M^[V[?O\](=3<QTK@ME*NR&#-)A/W$]<BQFJDN-5=?^"XO*-_\G$,'7TK0^=Z
M[?7BF<QMGFG$(HMYJAL<KR<]4 #WX;J3?K4+:EZH?A]V8L5P?8LJ63\\OUO1
M63EJ?;G%G#R;M3WC1KJ#K;7<(L[.VWD]\&U*M:W3Q.%Y4,.:SDU95'-95*M[
MX/ECTZAYXM?Q4^P,8_]^Q2CO4B3T7H4D;QM67 :YU(-<W5C3'[O89F%4P2,T
MF2Y@?\,L-1[%JA?[T?;\21-+$.#"=O<L.RDKV^O9SON1P_(A*4@+/KFZG6YW
M^Y.KZYYP06=/MWNT.YP]\>B3,C@FK0*GQAN<>'1><4Z8E$S^L].<YG-,T$./
M]<=+,O<->P%#R(/[NS4X>3'LPT3%WNX7WQ[F"=[N]R/\+RQ3!L#AT?A<ZO3=
MA_WC_7.XU^?]#_OBW8?7'P\^'.3[G!P<;^/]G7<G[W;>D[?T[9>+<ZG3@X\'
MQW^>[Q__]7'_Z]Z7=\>OVP<?/HK#XW;KX,,V?OO!L_V=/?+N>%M</9=Z2_\D
M!SM[7P[^_O/K_H>7[8/?WM##8_CLWWMT?^=UZ^"KAW'\U=[?::>+,ZDC_/D?
M2;2A' <D!/.(2TN1\Y0B*IQQE(ND!-_8TK0V=)E:@LPI3K:0U5J2E9%!F<2#
M%UQQJ97F,C+'3$C>"BQ\0U9X0E:XD-52D]77"[(*,46!N46648>XT;G],HY(
M8&F4)(PPG3:V%*\)?O#I>2&K0E9/HUG!RHV8..$UX4I;320AW&$F*6S-2HPU
M*U(TJU4@*W)!5AP+S)@V2'N>LQ4P1T8RAX),!K0N2J++%5LHK06;5Z9"8:O"
M5H_+5LHEYB2W$;/$I4\N.I:\#EY;H[S58]6*%-5J%=B*7;"5(J R:Q\1L5B#
M'6@$LC:(W!5#$A&E]DP"6W%1RZ72K=;(S_U(#KKJ,X"FLI,.[*&"%Q_<97*9
M\D+GSG'!84+!8E0J4,ZY=S$ - R0G)52<UY\72O#<0<O9GQ=(ME @J=(4ZT0
MUTDC1[R!'PGDFH*3UC3FH])JB0IZ/O-*-O.'MS0*8Z:8<80'9YV+#%[38(%)
MJ; MWJ%5@O?4.Y3M+!>50C))@CAG'@%E>V2\Y<0S1;2D&UM&S*-=1X'WTL(;
M+!(9 G,>H,P5L8Y+X7/F#27<1TN+/V65X#WUIV FL*#.HI QSHF,R+ HD8K<
M&,6C9BED?PILWZS@>WWQ+8ACH(XGE[@%:&-'=(HBR&BY5LD5#\1*X7OJ@: N
M8<YSK7VA,>(!Y&>XT(@S%4%!#U%@G2M<4ZEJ.K?LR.==D.Z6/HBF"&/5&Z%A
M78KMSYV8O$M.:8M9<IRG %3$O+!&2*]-M-(4M\'J$-/1C-O "R]XL 0Y"S]X
M!)W#R<21CX();3"5C6N4@&'Q\.[URW>04_ ].:@U@&SIX3EIX!(;^#-9IZWF
MPEJK0_$;K!*^IWX#9S73F'$DN*:@>%@,AD7P2 /P;=!@6ABUL654;=B#J]P4
M>"\MO!-EH()J&@@5G"AE @&CTC(FK8^<F^(W6"5X3_T&1A@OLTD10"<#:R(F
MY(0$(1*O/"8I" %V!3.REG.K$UOPO7SX=L&R$(F2E(*=*6#[%HDI0T20QA,G
MB]]@E? ]]1OD8%]G%$'84XZX"P)I%37"029I-/R/Y(:;FM3BX<=Z3Q>YL'PU
M5%?ERC*QI8CN_7)*1U5TQWZN!\7'K$Q1];EOLQ@'D[#VCE+)';;.2QZT4(3#
MINMU+%ZPE=EF#V>#9XC5QF)&$8,-$*QDR9%.*J&@C>")QA $WMBBBM::/M@+
M=E<4K=#9W/-E!FN(I$'Y8+SCSDB7?&34NQ"=STW3B_]LE9AAZC^C3"?+<CE3
M$33BUDODM&$H^4!"P"27_,[-X51-YA975YAAG9@A:A<<"=)J0;D5UN#@!1/<
M!D8E#JZXWE:)&::N-R6 [34S*.>U(8Z90IKAW+[:>&(839J <2$YJPT7A1D*
M,WR;;A0\D]09[SWAQ"2KO0@^*.*R8T>&XK1;)6:8.NUXM-0Y&E$^:$&<VH T
M"0EAY8#S??*:-^WLA>$UEP]VRS\5-ZQ1)-#U'I+#LYASCSKOJ_CE+)<TOV?]
MK;MTUKI7Q:?;GHJ402[U(-?(Y7A3>M_U*7PE.6\9_(LCV6QWPLY4,KLCXBM[
M_UU2C2^WDU=6,D]4#O4E ?&4*-))6F22MTI3$YEW&UL*UQKKFI,'5T<HT?Q+
M"^<G=0H6.,\1SC.=C4(@+#0>OQAS#_F8<^X,PB;:@ ,(TMB-+4IKIF0MU+PL
M_0+GY8/SDWKR"ISG!^>#Z>[,DP @P^Z<',,Y39XA2S5!5G&0HZ1"YI*0!)L:
MA%SKDFRWQGA^4O];P?,<\3S=GIF.-'F/D0^YE2L!1=M%;5%T-%FO3 P2;VQQ
M4G.M:B4?7.:U9-;=WOS_+79BS[8;Z]^&TU:GU1^,BON4-+O%.P#&T@%&VKXD
MFT)*]R&EW5D7 &PI1"81$7$NH)QB@UP.'S"@:DB=-Q1)<C9_+:6L&2^!^>L+
MZ"=T 11 SQG04RV#<,&8Y@8YF@L(YEP;JZU#3B="B"&:*9.S9&NL2"T(+H!>
M6T _H1.@ 'J^@#Z8W:&9L\8G)$W ".1HD &9(9MX4C2QB)/(87VUX*H&\19
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M.[N&\<8 +,OB$1W6&AUN:DVQ%#306VK_N,4>*O]JE/_C3/F#D4)'E8NV"TH
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M2<I:DMQRVTBQ3#HTP@&"-DIIW9R%"-JM >V9ZS%*XW34F>3,$@%60-M2Y@F
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M'AQW9U0M)B5YT))806VQB7,JYG >-YU*P=@@N5.7N(N8BYB+F'NOF M,\AA
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MNJ;C4[%I>C4*HY\[9V,5Q:#1+R"M2@%RE(6VF00N6.>28=(K%<!HI_T?SRO
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MPM#5JK,)CCHJIE,C%CJA=._5RUH<A:_[:"1WHUO*;AG4@L@TNV0CQE9GQ&<
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M:U#HAEM<B/[F<FB-A*UYB?Z7J0L9KTM:H)]?GW*3M(J)O9-Q%0>^(M?7%(E
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M? 0_%1B_#4_B-S#=<(XE!_#TS&]J/IV5YW G?'B.SVB\7?B%CY6990JK-]N
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M3"@1**S*%5(><^8K&4<QY:!")+X2IGA-4!6O<0T5NQH!%N WY?9WBJF$RP(
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M5A!U5C ?+Y\!S&IO 'CQ#+Z&H<<3MP+<$??TMV(ZLVROK.0!E!OP-F 3J"D
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M3'-_(]*M)2XW(IV,P]S/?$H"SHSU5!,119Q$40;0&S A\DWW\=\!DSF/,IJ
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M-6P79I=_B?\9M;_:SK4EXWY2BG']C)_TC$<O)V[0/&'8+U;RV37M$NZ<=_*
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M=[J8@?_=VXBXR;*-_4_WLG"7#-^R<-G3UI@XV=:Q?@]U(;:CC\<N]AN,E,7
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M*T T!)/19SGAK8P^*G@FJ3. >6!VF62U%\$'19R61LLP)@)2$\'/(@+>>GG
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MRE]%,!MIN&=.$)T;(4@@$^D\X$C4(DG!2EP.,9CA"W$Y;UNO5U#4,K&_[0Z
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MS$(L#1=6"TP\UU'P:+'5@>9NQ#0E;F@*WXNEN2B;[FECIBGGP!9HWCT= &U
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M6OI2 #D3$AV8X@8E9AC*U7V!G*5'#&B/)2VIY#$?!F]=KE#Y7RMI%_<O@X@
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M#&E+,<))>VL8X*_+X?"\*9AL<GYG1%\CL]Q)$ORK'%+/%V:8[["Q6"IA' +
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MQP7CP!(O6F\^P&>@'^T==5K;?[=W/[[BG[:_B)WM5]]:= ?OGW]J[]#7G<7
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M=HI\:F)V=_O5MURTT\/">B&0DLGGKK01&:(EBI:Q9*B/FKDL9B_77)R)V5)
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M&I?40Q/KV86V1-C>/?OWHK+ ?G 6\!U$>)T%O#J['(I6+H$ON<2"(1%#1-R
MP>Z,YL@PKZDWVG.A[Y %O(0JK\T#7D9PJR8$[UCXJT'4I''B\+IQ_)"<X#M*
M@MHB_B$M15]^V_G\Y8#IE)@'@H\N@:H"Q ZT+AV*6,M @.IT8*54.#9-+I9(
MB5LG!2^CP173@D&%5E)>F1:\S(2JWK-:<O!Z,K6H 3W0T("E2UQ)XT( $1Q%
MP!BP!>/E<%YG:MV&M,];G]\=J& D98*C%'4F;0>D[2)!RG"=&/'8IG5D65[$
MZ.P[N$VZI8==M#E[<9QL^?*J4Y'\\3)(7^20(UN%OKOLJJW2+J<J_A5<]<2S
MTI8!TBWRTD(/YG-5TL%T"Y:\##:],SPJ$;O?>T=.4!O[Y6-JC]WE&:GF_.W-
MG)&68^ES%N_,_W]%2EO^NCV%E<$X1R./OC<\:N2=_38V+8%&81V'9]EW1=1O
M0*>G$\]GE9IA!X,J<;@]_GP<(#^^83("^#:[_"\<7CC;*3LR.(()?D=ENI1H
M!U, 6NA^+^%N.NXE:7=3$Z$WZL!LSTYR_5# _*_M7C[@*(\!3AIV*N\?B(6O
M[;(QOM\NN2!P/[";A6>>G1<;^BB.![$L>:D]N.'*;C7^7^\4H*'?+,@T2:*:
M8H0%W:P,J<*")3.K0&%,DN5U#HR@P31)<3:V =@"MM_N%1E;M;Q>2)L^Z<.>
MA$G\^:(?8G+IF*;W<H9WWIKQT#JC'%8TG,;97![I)&FG#=OEAXMK?AD5J\7<
M:KRN%(MFE182QVDZH'%X.SA:QD5 \BYV@8'\ AA.+UCN:6D60I_.L2+',N+*
M4BRF'Z!_5F4*SL*"';>S66!G4453QTNY^V):WO2D;+$05UV89+$PB=G\PB3?
M+32R4)B$$YH\"'9/?>!6,ZT93\YJH[7/JLS2PB0;+(AOGOEWM5GZ1'/_-FQ7
MUY7XMW2?OY/ZMQBLL%+VWY6$M=;\O[WEV5@3[]]U,U_-,R@#XR$EP0..W&*F
M7;)<1QPEH$HT9GE=?79SO^"KR2QJUV"V)]_BUN>W!\H&$:@3R"GJ$$^,@32A
M'#GLJ#!2)$O#LQ=R20C/?VUDPM@LY^[:;#?2G&7"WS&[C#&3:RIR3;WGWG'-
MB/4X!L^<54GH$AI#)J$QEPBXSBZ['?62G>W# YVXY!$(5ZG $'<I(AT$$',P
M3!J%!:7NV0N!E^>)W""?:.F)RZTRBNZ13)YVD@F0RN[>X4&@R4D<<ZGL@',J
MM$=:Y.-KY92+VG*72<4LIY05,DGJG-^-R/GEG-JHL ?QYCE6TGH;8>.Y5E&0
M2'2=\_N#\[GV=L[RT:,%E<X)@K0FH%X$IY A/B %#!<B<9()#^K%%0"]:B*?
MQ4EZJ:*5Q'+JM67,46P!99-E4?^4]-\GONGGK<,#+(,GP&W(B@A2.9& C(@"
M*<Z(48IQ27-K KH\Z?L66;_KD]+W"!M/6TI?I"(,5.2"PLP;C#"A.<@G*>1H
MLHAPSC@8B9KE<K;DX4-'O?&SC2>M=Z"I&:T8R RL'&AJ3A)DE*<H6*-(=C)*
M@W/?Y1^; WRM5WHU3]:]:U17U);^KDMV?&![T7"N7)VSF(:;Q=W ^J\67W-'
M>ZF.K_DQMA3;.7]WX# %#E4.[&P7$9>6HNSV1SJ!P4VILA*G.\?7;#4N)1'F
MBW^FS;U*M.[[/.:*0+9'.=3XK^+J+0GF,]+:31]@N(,G&\";*6AW;_^ DF"<
M"Q$I:P7B6%CD4@19+YP4%!O*M<QA+)?3E2YF#BXO[7F50QILR=E!/B#2_$'^
M?X^/\+<N(W_C7FWYNP8J7]6:LM"=M]@JG'("&>8J*1>LLBP8X&MN8'\.I'KV
MW= 9]A/.;M3RDU*\-1$KXRZ?%P$@:D H$J35@G(KK,'!"R; *F54XN"6 L 2
MOA[32%7$M]4;QEQ@L-/+6>%[\+)_=^":>^;DUMF$DU^>Y?ZXK3<?R*<W^V>?
M/K_[UJ+_'.V^:<'S/HC]\W^./\'_6I\]6^3DG6UXSYMW^-,></+G/XY;VZ_8
MIX^O^#YM';7V.I];'_.=\-=Y2*WM'0'*FO7.&:HX\K"RB%-.D8F"(R<5%5CE
MH%AVJ4D%\1$@F;I()+<I=U4CT8/Z$8-@BH,M'0$>3_*)?'\4G[UXOR3>IMJ*
M2RU>+U#Y\H/K[[[\XF"#QI'$F+.> B<P61*=BCK1Y#0S.;_Y1Q/@.(IZ-Y5U
M^/?9[QG#GC#9\=V7!]%CL,U]3G6-.:1=,*"X:) 3/F(&=KOQ9)&,K@:P@C:;
M>3J=CU]3K]/IG68IUQZ4()SCX]R1XI+V9$?#HUZ_N$HGZ>#EP+[H5%53Q9AB
MOU\2ZDMHVU2]'\?BCW7\<O'2,'W\_*;B"-:K-&.>Q>.4SM>P;AU[,HC/)[_\
M-FGFW.Z6V9>;?KL<F[G0^+IL3_7U.*#%Z"W-BK63.T'/.G6/PUVVRE<+7;RK
M[SC=PD9<^37>(E=^=]UC"=GBBMWJL==_)YAYXH/E6X3)AS)8M@6X?J/'EA[F
M8^I=TO9\H47\?'OMW,?\RM[P:\4M_3W8*G%E%6A,H>+J5NZ/>4XXS^CZ3O9/
M<OKF)M.O(C#O9P$N&1ME 7;G?%Y%<EY8BYIW-WOW7DZ5HY_&P9NW")5_:KT+
M,%;LLMH'US9*<&AC,I,'M3H7_-PW6*0;S?Q)K>"EXENK0.3E8Q+O8TSINB58
MAIVPCO.![3_18BMK\'ME;[VO<D1/["3B^C;IE3)ZGH((C.K(K3?61DV$D])S
MK:P:UT5=6FWKHA.A&E09TU^VO]NO<N2+<WKVZ@TYU;BE2^%H__A;9_?X%=W_
M_,^7G>TOM/7Q%6E]AK&\^?MH9^^?SSOT#QCOSNG.^;\[.V]VSB?WP+M&G^@'
MN;_WJ=WZ^.YT=V^?[.>B-V]@/&]>?6M]W#F'\9WMG[\\WWGSX73_O)5VVOCT
MS[U7PYWW\.^".^/3YW^*VV)G[PO=^?@)QO_/T?[G0[[[YA7,\=VWG8]_=&!>
M\-_?:>?SX0&EWB0:'**.2\0)_#!*<81U4)89;+"W4R_3*M1C Z%8.VLT5CQP
MKJG$CFO#><0BNK@\HKJFG@=%/3$XJ5W,S1IU"9,P*!=.1IZ'A#'5P3OQ[ 7>
MPOAR89YK4H07#L,7A1?]/FK?6*KAQA)@[V=$_3FB[8:XOMKQ]1UX[\9'CG-L
M69U/SW3<FAU78\=O$W8\B-B1I)E&R@F,>#0,.24IPD[AY(G)\2<Y8A%/*C)<
M<4*YJ#^NC5WRMX5M;LXNU^F>WU.ZKM1?:PC81 BH++R:_5=C__,I^SL6J")2
M(TD%1SSE$N6:$$289Q+(&CY1SU[ MC5!3VMJ7;-_S?X;Q/YS/LH: U;# #+%
M@"!-<)@K% ,1B"LAD$DF9T=2%X(FK*@ -0;4&/ ]#+B#_Z;&@'O  #;%@*1D
M!!A0R H?$7?$(0WX#09V3#YA&0V-SUX0#?PO2).;JUK9;1P&?,<).XG&@)G$
MZV&COO+BE?7"WL_"7IE=\;".#=[#;7%0@<;OC;^FD5KK.4?0)GC"%0B?7"<0
M:RW!CLEU>XA3()!N[ F>CJMV!J]+[+3>7^T,WH$1M3Z_9/N?__Z\^[%UW-H.
M1_M[7T1KN]79V?OC<^M\!W]Z ^_Z_$=J;;\\P P'*QE8KYQ0Q#6SR-)@D-#8
MZH@#U3[=ZBA!*:*TX(P:3+ERU@:KE?="*\(L5_'&!U$U 6TT 3EAP;A) 6F:
M4W>MI,AP'! @1G146I5B^KFG"4O _'&:"K>'Z!4Z"LPS7WUF<#>FFYT9@#7'
M@3<82E+FHKPA(9=$1#9:SI,@S%-3\N',9:Y9T4Q8KMO\4&_ PBO_?_;>O+F-
M(]D7_2H(OGO>G8E@<6I?[!N*H"W95^<-*4NFQB']PZB5A 0"/%A$49_^958W
M5H([)9$6=,[(%('NKJ[*Y9=96?F[4S9@H\5?5XLW:?^[:/ \[2^1_YOS0B0O
M&ON4%.)@]8@)-"=C4F)*;31XH\%W#I4VJ;E[ZNH\/>\#SPY6B("6!O"VX&BM
M\YQD58KFL'S9 T9U&SW]6^OI5XI(-WIZ3SV=I]"MS(D+K&NT)H&>1DJ"5)8H
M"D8U">-E9(]+3S<IW*^9POU7/=JYV%]G\>3V7;AC+VMM<-O[? 5+5^]X<P[:
ME7SOPW"6"/W=CBV_[#==@] &;]^R\X^B#&XJ"B#Q(JW 8_;,%X:=B /7>=J#
M35_2BFMM_?*\_\J"E9_U^7D\'7V^]7'ZO8-(#U4V18<D2.94$"F%("[H0K3,
M@*MX4,EBI[6;4D?/F#Z6MS16#Y^O:Q%U/THVY2*$<$68*(PT2OB4J5).!<.I
M3&VSA6L$YQ;;[FMEZK&UB/KF O7AW?DA5=F)5"+1QF0BC8DD4  "-FD&@" Y
M+]W6,[4-(/ZV,K74(>HI4#O=TA$LGAYZ"J]W'17Y?_O^!)M5<+7(Z[5*0HZ:
MG?+P;-@=CW._<SH),%MSTMY;6P*AO#"V,)]*0E_BK:-241^L]!SD;]IVA2LR
M_>'NEN"2SE^-/8"9K!^-?ER+\.7CYT.C"O7>2E)8CA +"$:"];BO)*Q56:EH
M>>WI*)1:W]!S;A8634!#2[0J+S.2P[OLE;LBF,_!&&S90ZD**3/A=&!.*%TT
M;1- *R)S@=+P3S]KV5.I"_\N6YOWZ-SS6AS:++"KJL#55T0F[4A(Q1'C5,F<
M6R<BW7IF=]8U#9SM)C:D)/U%HN]EPIKM3F5$@N5)DSB><GK-3$SM]@9A2B7/
MF]+AG9QT1Z/*EXS_;JA\\FA<"3+37+3:#L2CED;Y-MT([R98MVI"N-L0-O^[
M9?X!]/7;8/CK_-W:CK.[_73@/R_8I._=AO";R^+!1WDHO0)O8#DQ,5<J34Y"
M*0&@BI%."EL,30![-5]#:;_4A7"5T.P)>NJ72*E\COT2[;*'KD?,9_"\@U9M
MU-F=,O.U)%7]V@^VFW('(O_8?.*/\.]_X+T0O''Z\Q^SSW;QL_I;]O,_:R/&
MW.LM6/B&0G'!RC>/F44&1\/!:#17?KAB<HJWN8TV:D^3B<HK&KUD@=ODD^0N
MT!BL8K[A;[94U6 !?[A+C6ZW/VC@09VWV;3M^<_=D\G)?.M]MU+Y_KCJ^.5(
M'6K !X(Q1F =$I$,(8*"\,$I! _&@)'$371*=];XAE83MULN4E"-ZA+@O]LS
MLBT0TU82_9B 7!)0Q8]Y*H=3!L\%$#$X&OJ3QFTLT&ZMB'''5R8P/^J,JFY4
MN=_I-$BPX5CK#D?C*6DZ"FN3%%FBX&JI%U?OO:)]S9TJK4=&1K8."%D_G;2$
MSWB#5?VL^K<% &0P7/ULJVI>MQ^'&4G!*N/FC%%Z2?LJ[]D)F(>0L2 YM5.R
M[GEU^C=J^#35<._@!7_U^C!D34V.,.&::R*MBL1;#VXRB!ATL<&&=)TBWM8:
M&YNS,J88;[)4QH4@X'\ %)4//F=Y3?O]C1@\K!B(_=>'PCMA,BW$:)^;4U#!
MY$!HL$8&*9@Q#$(V=9483"F_&V[O:5.8[04FVUMU\PX^Q>1]<$4&)ZUA-MH0
MLT2V><Z;'3\JKK80@) BBL?98)A&N7^-;+S))[[;!TM^J73\:&'<WL'+SWNO
M#VDP"8PT SB*F_#*&^)+*41 :*,RC2XYL?6L/UC'I=5.:2?Z4Q_1Y\[]R5I/
MM=-YU>_L0E#?ZXCMNWO//D#E]?YQ_^(G6S?!I5^G+3B[(='A]VQ*OKH@=0TP
M@F!\W0J5;B]C^]E!I>:8 %::G)XVW-> XR=#)%Z=89@UJS$C>J_HK$% \(WI
MFBPF3>M7KP\55G<:;N.L;,#6]3XF5:+45EF;18I4!.J-U2S/2()$XZP4XQMG
M]=7,T;MS[ <M<W96>U(D5N"R!+$\UY%$B.\# T1!K;C>63WY,'XAZF@H )>H
M_]9XX9F&5EQ_RP/N/%NCI7+2(VU6 / N94Y>2UXBFZG!#+-=XYAOH 8S+=B=
MJNY^91(>E+]3%>Q]=$'M'QV*8F 1-"?>*4^D](D <,HD0NS$#?[Q<>N9%-M,
MVFVG+C+[7I6)N=958VJVB81K@O0$GMPDZ1O!Q5#Y4QY"E'R_+/T]A8]?+5]_
MM6/=;8:Z2> WXG7T>6_W4%#!+%.9L*(=D=E"7""T(30SFW#ZB^!(W>+6"-8L
MA5]INB:]FIOO+KKBI:S^+?WR/67B1IGV:^S1'^W0?QL.3EZV?/+M+M /[**/
M^-[988C,Z9 DQ E&$NFX(-8S<-;*I*PI&"L5< O0KN$:W\23?V?I4*]>'[)B
MF8LI$:J#PZ23(<X*04RPEE'AI/'RP>+)2W'>]X=Q3"W#N//LARU\N]!<=PV"
M\Q#;C'WO]A43W"BDP*0>PG>9"UA/KQ)H@5)*:)_=BNV\6\N2#9B[32'5[CE8
M32JDRYY&DAA/1-+BD%\I$AVHX59$43CV(^/;CKEM)ZZLT;L"S*V)N;\9E+NG
MZ&V@W%V$Z\67_=>'5CECBG.$>5>0:=43GQDXY\0]$_"7]+R2K*TY]3;'<E\#
MRMU3)C90[JO)C=P_._0Q02 I.!$*I4530SRCE-CB4M &?JDS&"6I;P#EUGNU
MVZ.Y(B7$)8GE(K,LR"$< TVJ.$5UX<+?K-76!LW=5T#VSO9W#U71*2F;26&1
M@H"P3!P3X+62"*#-+M'D[H#FUGJI>])C?O^2WR9M_>IT/*L^>Y-'8_!3X^EQ
MD$XEC7U\+WHM<]T4FQ[[2ER'[T*"']4]&62OZ'ZJ)4,MM2^HI^Z\.NEWPV34
M>3G[PA_PA<X_\ XG#1 >#SH)#'1ST5:]:OG;6__<7MI5F!=O3 >$U0Q'0_RX
M04*#9O9K6F(Z]6V!Z9D'4[#F [1%B\6"BV_77-09H(<<#,=DG(<G(-"CXX7W
M;K\#P\LGI[W!><:BPM0=YC@>#*=5B7WTK##,T6.4\VN7?\W25+,.IA)&['N]
M\XX_!8CP":8LG*^P&2Z2\W8&37T:J]M-3&_7Z<$]G-4"&)2F"W4M_1I8H+=I
MP;#_Y+N]RDZ(NT7=UKO7L:T.:-TP;!V%F[JP=1MQWYWS_2*KX_?<+VQT]:39
MO+JX'C<X[''9FL%:-<ZAZEA[HY5^0ZN$SHO:TPY3\AV#VG,Z&'7Q.S\-<\^C
MU+;LDNT1Y84+V\T@.K_$!XC!)^/++[G W?.=='.!EZ>9H(6_CX=S#JBC3 )H
MT4=2RZE_\KTS?S[:^M>R]0'3LS*'JZ]_^6'-ZSE$O\?TK"<.OI8(>(4XN !"
MKMTC,F-29!N*E\KQ:#R$\T(A0+[$/-XR<T.IBB8$ 4&<-$;[4JQ@@E,!O]=4
M(_ %,Z"8N,<1%WSP+^C:4$5S?U3G97<('O2HPK!?SN=?^<.?UT *_5N3TGE5
M_FZ]INYQ&N;%9P#(VJ64J/>$UB.7L'S$IV"(ELZ%((M7,M;S,)>13+26LY;&
MS(M, 3B!-(]&@(\J/W#V@'MPHOO)#VLN<;LSFL#O+K7$W5&G3(85T$Q=*+K"
M]DS^HQ%,#,BFLO7'8(P:Y'NK0O;;8#@-W-]B#+%>BBM@_''%\2663S"3C8K2
M$:.1Q5UK2WRTG'##L^"!4V/07ETGC1<JAR?]'DHC"N@O S 'L,[HIE%&MS%I
MB%4]@]D90=;4[F N>W)1;A=!W9(,MU7+@-=\I^0SD-R+^ )^-QA?P(4K=\#<
M9J]7!U$?@,^M"C8;X.(9QLM5:$%O;FG+2\C>A<(R5T:*8*P6RLMB4LQ)AZ2G
M1X3H79/O^-!PA1T/Y_.O+-KQE^T[O>PO)^DW%AU4Z.WGO:-#&7E.@H/.,+#C
M,L="?!":T*PR]Q*LGRI7J1 $$^,U5.S+>SS'_M9%.E;8HH+V0BBI'?=4NLRM
M\J+8R/R#-*1[*'0P!?A@MW_'V/Q'%JDOKUX?:A:M99D1'D(DDE-+'%6&)&ET
M<3ZFS.C6,[GMG-WFZF('^DO/S"Y%4F4RG@QSFPV9Y]K6@-/;-O)XU++WHA[W
M>=D?C8>36H?Z"D'/P;'OMYFX?6SP,!KG5DI_8&%\AQN1 @*?@,)HC,></]JW
M#,+HDY>B!&$T^ "P;XKI;48O+RJK$M8[K\?Z%PBUPP2%KYGP*W-M;9IT\5IP
MZZ>383Q&M_[X)'2!GZ.*V-^NP]@])"LB^$S8HERF2+0SCDAI-;'&9J*92M;[
MK!,+6\_,MF5R6YLK.X9<LKN]QI8UN]MM#K;:OMJ'(MW9.':.<C\/:TX3I;C)
M2_V?I297*^&1B!D/&4=MI!09!$\QZYET,5KF-)OVJ&BV.%LA7-VJ2I/ARE;5
MO0UC_>L_>/1]VLF"_7!R>23W7Q\J$8W3R9.L@B62QDS 6!CB3)!:I&B4 HO7
MU%ECJ#!:[6E6Y>G88ZY_%BV@"*#@3GQOEK'\#E(R"P;N(B'M&81?YZ]R &_R
MPPG)Q_/]LT-I0I*"2I*, B'Q01*K.27* #RS012=% A)[J\7D<8,K3,G39SL
MQV#8((Q$]X>_:;<@P-DU88*K48+>69/C?EK;1>MSKM?G4''Z=MM]P>G6:>W8
MP2DUEVXFMAN'\(W5C<-F#R@!S,"N'TMSW10HP#7UO-ET>=)5R]-<PLR-@[N'
MA3<T>21N8%3Y) O8C62#2X+E: U52FW@S==M>/,2Z^6]LSD$'@D@: 517!(D
M>( W0;(H8K")%38#SG)-H=4-X,T%05X+;ZZ\XM;X!<^_.2<!+3,A5?28N/*J
MT&(+C\*I#7[Y?H*W]V7_Z#""\FL?$@D6&]L[3TD(WA,;(,J1-@*X#E\=OWPE
M*=G@EP<0$@'!EQ-"< I"(CT8)ID!R;@<.+$"T*4RO@1[)7ZY"#PN%JI<W:RW
MSCK(JC>T9.XME:8 J/+&B^12 ,@;4CXT=.MJ+"-WOL6&L5D+7AC;Z5RI!8!<
M4F!)>VS]Y95W-$4E%,XYU[3M3+JJ!<OV\(4?8EG<:%J[?  W_Z57BU&_I]R*
MO5];N07)>G7P$63W_7&]_\%K_N[#.P77P//>JKV_]L[??8E\[\MKOBJW()/J
M%3QK_^2WDWW^W[W]Y\A(]1'&ET[V#SY^?O<%F:K>?8'?XR%'B7+KK0E9@2\5
M!G"W2YIXG1F)(FBKBB].Y-4=>6NCTB:+8"27*@=K5"XR"<6M56 IMSH9H,HI
M%FH,)X M]_.X\V\\/@YSWJF3WKG0MGI)G-=BV&N?^B1/&H-1!2''$N]>/6 _
M*P;OUK*=TTF+C.'5NFEZF&7V]>EQ_M/JGZ>E5A>.%:RK$UK"0(LP.<T/S32W
MW>D\[_;J."X9IN_%2<\WS8<[/D9P,4T9&'8;JR5%N.<U&9ZW3SO)XV,8[:P7
MP<+#EZH(J]^\(H<YS*67'V716!PWF[6GTRUU6#^8PMK0!YM G0TF/0A28IP,
M.]V"7:A@TK'-(.ZP-F60H #?L]"L>O1:58D58GFEC1S6E>?/>1B[N#T[&"[T
MGX8KEGH+5P#=O#T H"Z$:'$\+2];7/G] 8;HN*R_#/IIU#QVM9RQ\P]L-SD9
M-96O]9J.^V<MBPT9?"L6>G93;5:"%1R-%$/X2V;CVVJEKQG75'1Q86!,Z7(Y
M'V);,U0=7+_M:94DV)!:,XDQ0JMK33.T^4F>6<?,)E??*N!4]H?Y=#"L1SY:
M%<Z?VT:<Q_,97K[9++2=2LJ"]$P[N)SB49*3G.:W0-W'O?C%+P\7%@9>:,U;
M+]N7[5HIFCY,1N/%4M'9=9-V6<8K,PLVHIV^*A[#?#+XU!0.0# .&!.O*;X[
M)69=,]2F&UU3@0K3/,:,\M+0=CK_[G[,9_"FEPP2[/R@)AIJS>/*>,",Q'&[
M'HTAF\U+LU[;J*4@?SN=W]K'-G"_-E#I?EYN#U$;]D]3$_4KS7&,4$T]_OL*
M.:NJ5>ME/?;<\XTD^-'J<N*RC\=-ZY<Z8[<QG$NFJ7>^^K9-42BF[B>G@WZK
MVZ-61^KY@15=;<Q9C7"J&D*8W"73F^Y<\.U?$=W]&8]SFF#'X%T8PW0(?\XD
MZ<7GV)O (N%AI%^K>ZTB^JIL8.$4%D8\>,)RBHGS1%)(E$C.&0E>18*K8T*0
M-#&Z"O.>(OQ")U &O=[@K'J+*O2@:C!8N,EHP7]? IP:;]ZXPT:RYK;J"BU?
MM(XA1S\93<U[=[BL/9U<"AJG<E>[\]--#SS "K3O/ZW+'H+70@#5\Z>C_-/T
MAY^GQ#3=?IW/>M'/%Q=\E18<%[SY>%[8O$.;XN:6*ZA]<OOQ3OUHA;>H^<RP
M'68N_YCNL$L_N^JVC.\HZ>YTVZL_4\Q^C<%R+6YZVZ_%)K]2_L]X(TAK;W,M
M'YN[^5<?^#6N&_(:XK=>+M^(]\U>ESP!)6I&EC($7]6L_-1@SBZ^Z5);-ZS7
M^805H0L'X:[@UFN, )H() ,;#7K=U)F^RA63TQS+>#S3@S7@\Y,[5[SP+03O
M;S4W] 9S\U4U[6+,'B$2NDA(=YT*PG)\)][%Z<G3Q7W&=5TN;T5#V4["C67M
M;\I1R:EP-&<FD]29^B(H\]KH$AG\SJP-#.8;L?0VS _W"QL>U['UNT8/#=?E
MAR.Q]]=;&,=;MG>RQ^ :]@HB!^2_?/?7VR][!^_.]K[\YWCOY-V,'W/*=?GJ
M>?S\_B =[Q\@K^5_(.)X*_=/_KN[_]>;X_<'>Y_W/^Q^V?_KQ3F,I>QU%QC@
MBTC.I1 (LTH3J9,A@1M'4LE"%):=P.96C&X+ +J6V?N27MY6O;XV<^V*S;L3
M<^W&9*#&1:PG*J684J1+/  $U\RR&,%D9'&AA]W&9#PMDS&GG'>\.%>")D%:
M222+@5CC,Z&6A91<BB;JK6=NFSFQ39U^VA;C&T.P]9S CQ>"_9F'G[HQM]TC
MUF= [P3#?A0V<)J*C"X'0%=4)BL]%IU0@3T=2\[!;9#64S:;YPM("Q95!B\-
MD:%0(FUQ) "@(E&"D[14QY3I5>=0OA^[^!V-UYVPU(^B]U)%%V1"Q=;2:^N"
M3BZ**%GA(E*Q@4M/6^_G<"GG'$4*G&CFL- >@BN?.">TQ&"SA;7FR""Z;;7=
MUEH]>KW?)*6N- .@-E4S^U\#%:V9C+^E=10Z\>2XD$%Y*2#"*-09+J/FUO(@
M\P85/6'KN/_K BI21I>DHR.*%3PJ+AEQ63B26*8.8! 8R;+U3&NQ+=8<%+];
M*/E$\TM_>ZU7SF?)-0O.1<!$V<)-+#><I5)HUOQVF.A+'@Z2'QUO%/X1*/P<
M#AF?8?&"(M9:1F3&A+,V@7CO:=+&:T]!X6LG/?[SHU?X37KH2OW_M:D"[6*5
MR^DPESP<3E'0)BMTA27445DAP,!IER3+W"&EA+52B& 4BQO\\Z3-X9]+62&K
MDBB4^* %D2ID K@WDFP5E=P[C4O[#- /=8\^,MQDA.ZC\\&50"'N"28PB'N$
M]])[837#J(>[6Z*?C<X_-IU?R @E(="FDZ)%!IW7H/."<F(+R\*G**)],CJ_
MR0;=& #UL8A_D_:YP@0Z0[F.C@>ON2QXY-""/0JR("\&YWX#>YZR"5PL.Z)1
M,=SZ),9S/.X B,>JJ C\2](LI8;_H@FDTFT[>['IY&.+ S>)GWMMA@4=>$HA
M)9LE%<*)E)RV.2@E+>-I WV>MM[/H8^%"*=0QR'<D1CN<&1+Y($(GH2GWH<8
MV=8S)K>55=OZ"61\-PF@*^W [N1H,AI7TI'FZ.(F[7.5':3.6N-M\=I+(;5G
MSJB@6/8TF\ST[?#/)@'^:$S@8AV0\,(EYK&9%M)0"Y.(+\(2%WS6R@0ALWBP
M!/@FY_.H%3ZQP*///G :);7)6R1Q#D%D:2+(R0;X/&VM7P ^S#-K$B<N>TZD
M%YP$&Q)Q$ @5B'IHY+&V1-=\6^B+;+B/3>\W>9\KS<",'/2>R.>'B0#! PKE
MA9&12YZ,-YDKAX?06"F&K^\6O$$^C]X&OEJL]4E2!(CI \D0[!$IG21!6Y!U
M9Y*D1E*6^-/9^M^D?.ZUVQ6UE2)C#:R2(!0NLL2BC<4K)U4(&^3SM+5^CGRB
M907WNXA7!I"/$88$P0IAP5( 1-[#ZF\]8]N4NFVI'G^J]U%D?!J3X!XS!#H8
MC'WO/NF>]L1?V^%&P$NGP00WTJ9C_[$/W-ZI>=?&@CX1"[I8(\2XD<'80D3D
MFLAB(W&"%Q(Y#4Y'67@J8$'UMM("_O=01\<>3O^>4,II8W2N;@R2HM \.#S5
M+YDKWD:58C+@S+6S>K-3]\2-SARV"<U$B3:06)(B4BA' K> XF+)V(1?UN.J
M@F]KSK>5N,AN]?<R.@^ ^OY5&_<M<KLO]>.^BNM]3?/&3>O 3>O ^[4.%'^O
MSH'WN_E3^>9F$C:3L)F$S21L)F$S"9M)V$S"9A)N%W9=VC*?/;FHRDCY-0(5
M=L?XY[M$52T'ZR:JVAB*S21L)F$S"9M)V$S"9A(VD["9A&\84-R0"5AO71N%
MB.]'!<R_/A7P\^XH]@:CR3"_*HO4UV\:$L!?!Z/QZ +S]>BQ,,/M=Z=$UU'N
M?7G+7AV\%/LGOWW<?_[Z\ZOG_]W=Y[]]W/OR2_<=?_EE_\,[NG?R_L,J,]S^
MEZ,O^P=OU=Z'R-_]]9KN/X=QGKP4\/.7O=__^\.[#WM\_\/K\_<G^P6W@%_M
M'@9O-3<B$B<S=HMPFGC<C2V.&\]"$$*:5<+@K+P*N2CGBY/"A<"-X5EA5Y$L
M@TVK3'*5J8C46>\L+LS5K,%7;U!^72%>SRZWGLCX^ME8GCU6>%+,R92HD5%$
MK':0)14M791:Z(;%;LJ0VNW'R7#4J4VMVHZ?<6$*._DS_CQGNJP$F&N9(O^Q
M]>;/MZ.M?S9L<XO\D@UYZC)EYX6;=$>=E)':'J9EQN.*^E;93A<93=NA_^_*
M>#SGUFNX49%?MJ$4W?>CY/^G\WMO$'RO\V>NI)U[#=UJ^Y4$KX1W/1KZ_K@9
MY71>8'C=$S_.#:'F"MWH$GEFO7B)0?:7GH?)_#,>#WK( 5B_5U\!OW R2+G7
M/.OZ[W7./$[+I]P;G.:& AFY_[K]Z?BFCUP>X'CHD>&O'>%VY^RX&X\;PLW^
MH/,)KX7KIDLPHP"M%*X39/B$&_1')0_15>QT7B)#:NKB%[>GP\1G-1)2!SJC
M2*VCZ?9/)PW-Z"1\@&E'8L+*23H=$$A=;S+CIT896Y"$9K$_#9#PL-<=G]>Q
MS;[3/K_7+7EYQ?P)4N-^6;MBE13US _3")?>PX.&'A6/H!)6IE7XX%.>DNS"
MFXRZ(!K3F6K)=I=NM--Y,1W2PE#A/HT2P6..N_ ^0TRA+7RC&?/L;? U\+ZK
MPG3)?9:N:VXU[(X^DH(LCUWD"8,1=X8HUHMWP%&_W?D3+I@R:Y]W<Z^2[[9\
MD;[ALP696E6(RB2>807:2U9N6WREPH7K0;*FWQTMD+N>^FY:>(5>LYP(2ZJ\
M@?49@MF%7\_>#4Q,R,UU+3LPR'T>Y5RSFV4R!@^\O/3#' ='_;KV\-62N_B5
M4<N&>]X09^^LJ5&YS!^T5EGR'8.9T%,P0I4DKQI!$.9Y A2M]L*%+0ZB\TM\
M& V0U_/22RXPO7TGY[- =]=4^"S\?3Q+$Y[ZHTP"2-%'X@L,]B??._/GHZU_
M+:-"@(0K<[CZ^LU+/OL_8?BO9^L>O-857N_:OAE?\ 6@MXM6H2*1EMCM/U,+
MN3NW? <HPC\R(MQ[?0C1A2N*PR0+ZXF,-A'K 1L*SWTQ(I>0S0VX@A\A,W#S
M!;!@4W+W!9^WQ':^[/@;3X^^O?5MU?I68L!\<MH;G.>6/3N!?XU@1QLN=B1M
MS]59!( '9S]-M6CQ[2\M5/Q6T]*Y$9TPWNPI;5])N^/H5R@*I#O*J:^Q?26^
MPF#9CF-W'= W'RS=D5^EW%+8K["+27<TO=F GB(=\?I"_O7UUE=L+7YGIEQW
M(Z;<@TJ_OM?0KK]8HEU_"'+A)SHK?W8_WV!.[B[;'R80MI7S)R3>\]=Z"BS1
M-UOE&S)HW^B%_R;TVC>>N)O0:_^H<[,1J@<1JK]]$YLWZQ-C-Y&>AV!Q_5[B
M<-^#D_T)=OY9.3AIH^4)8G9%@Y2,AY!BM,(*['UB>)XR.LA+3FO+"WF46?9D
M<;]F=PB![U'&;,HOY^L3++_Y[A 3*WDAJ8(+_1NL\\MVF=_ *F]-3TX2_C2S
M+.W1R?AE_^3MY[T/[X_W^/[']Q_>=/<.WG3?'1S1]Q]^.W[__/V'=Q_2\:N#
MW;/5HY/[7_;X^X,7Y_LG+[Z\XV].]G]_^7G_=QSOFY.]O^#Y)_OP[!=J[_DO
MRYSJ.GI.HX\D,N.)# F9/JTBV-U:.*9$,&'K&=UQ%]N[_]=]E.LV9GFCH*L*
MFD+RSBEC19;,4Z\3S4XQP5-A@OKV9+.\Y&3S1D$?O8+.SS87I-2AT9%L6"+2
MB4PL.'U2<J+"9\>D4:B@\F(WFHV"?B\%Y2DA278!/VHE#=3ZK (HIW%!.N_,
M-?U.-@KZZ!7T\]ZT6]SNH=4L*,DS*4%BURAL&9Y=(-Y&XQB+(8G&AVY4]/&H
MJ/!,)Z0P0AH'2;F/4K.D<HI:.Q/C-=U!-BKZ!%2T.U-19:E@E OB- ,5!;1$
M? "GRD $@I.@M\ZBBNJ+O4'^ZWZ!]%/K@K^FSN5.-NKZ]W[R)N2><3+_JB9D
MNH[_F2WCQHC<VH@L]<+7NMB@"O&I4")]]L0*FH@I AT&+'B26\_<11J0F_CX
M>[GR'T'5[A?Q;E3M":C:/.9UW.A"*;:==X9(&3CX[1A)B51)89RG*F\]6T.U
M=3<X?=.6?#^X#MXSJ-WHX!/0P<6P5A1-A4B>%*$"D18P<V#*$QJ3<XEZ"9X/
M'-[%%IX;A_?=P].-LCT)99L'J%E+(WF1A&L?B=1*$,^%)49E Y%JP5]O/3,/
M'IX^M7W>%TMG*;K]SGGVP\OY2N[WZH_7BJPM>;]3/+K0XQ;&%']*DR%.Z5K[
M$:ZW'^$V]N,@#T_8QE9<:ROV%YE)F(A>!B\)LX$1F9,E7CM-J' N%LEU,'3K
MF=HQEQZ(_$ZIYK^1HMTE&MTHVI-0M'D4FF+*RH9">.2 ?Y.E)!3XIP\0_BC+
MM40*(+7C-HKVM13M3B'G1M&>A*(MAIJ.<ZVXIL39R(ET7!$O/2<V4RN2*SRR
MZM/L1M6^EJK=*>#<J-H34;7N@JJ9I*34Q 1*D>)*$1M3(BH#<!1%V)3L]5[M
M;[\-^GSI(/QF!_2K[("^W/_M9F287R5[-5WBI=S5]^9>>1(699'P*5 F@S6)
M2' 41 (X(\YX0SR'Q4Z9,4;]Y429FTSQ]]X:W>C@4]7!>:1*I8A4J @^O3@B
MJ='$90GPF?'$G;!*YW@O'=SLF7Z?/=.-<CY5Y5R*;ED$@QP,"3P:(H/+Q ,$
M)Z9X;ZP+3*2\<9&/=S-UHX5/5POG@6^0.H9@.'$E8#F#!'T$W$0LY4$&QK,J
M[(9:N.DO^^UZUJYF(:[L)G95K]I'TSL*N:9GO9Z66CW=I#%GV_MNUET*#%W"
MC_""?CV^X9OFBO"?VI*V:3B8A[[I3(6=IVKSO]JLI';O['[NG#0-.O)2@XX.
M0I+:E/)_76IO)Z.T8FPU )U<N)72<LF,<0;0:6'*QL25R/&:G !1M^!=76]P
M9U92/TTK>?>>:_B]L\/,1?)"):(]HQB7&^)4XH0)1E6P626;,<5WL52Y _+>
MP_5%N;C-HGO'.4T^!&>$-,%[GT1P2D43/3PV7H-S-XM^CT7_\$*!JSS?^_(2
MGK5+40 RS*]Q&N9:60"< 4)!#?A3 ]:DMD26&+@Z)G?4I1*PC0UC3YMNKKWS
M;30B35_9VTA%S-R4$GPI24AKI"\HFCE(Y24K+#VD*=CM]0813=]Z\7C1&- ?
M5TH.WIV_VCTTTB:?,R6JN$2DTHQXXPNQ"D(4*;%_M]UZQG<NUIG=V308!>:
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M(@5H>G9""6V5%T(_2&LGU/1Z1N>/X0"3.NW&3GX\G0&^O5:_E/N[A[HH[U3
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MB]>N#.;50H.Z*717(/4.?E=(8\R >'7ZRMM(>*["N)8V+5)^9DK^:+&QL@Q
M(X!DU!^X"4C&]:@8"[[_!H@8<V 8OC/*(UV$S\^T5/5=&UF8[W=3T(SJ%,K;
M(&7,@%TT6[W9,;11%XH:6^U'B+NKLU0M7]"+.@S)[U:YE!W8TNO1^*B!0OC9
M).'1A_1P^UB2(DTMG#2G*077D)I(&I%%-H^)Q2K"W/"-EY53<P6LX4R6R@\^
MN R80-X:^A$TH>7E]?3@1SJ/[(Z\+/_Q/''@6.)W5T'W,Q/%1X2JRVRB4Y4"
M%1AI(V:!'HJ8J(AGA&-6Q#!B-EZ*>?4(IU]>#:GRW'*4-P4.62 8%V!V;-81
MOQ9N1V.%/RYN1VMT[;.$ZY#W ]+Q"*[\.O5W%<#BM_WO7XX+0[$N348R,P;C
MF"(J%-.@IZSE:2RDPN'R5^?^9D)#@<S7N J/BJO0<^N!5]" O%>0A44U)6N0
MA3F0A5Y343[3O.?\ P_%YRK&P8MRB"06[MP-3%RZVRMOX:K:?6,2GK 'U.?/
MS?E]4. (*9(TS5+*=,HQE2V8(;%2.:.,*)Y652ZL2F"O5=W#JKK=B\.=W6,M
M<\)-FD="" FJCL21Y RL;Y.!46ZL+K#__6I5=^]8$4LS4:U.%))?"1U1PT;<
M&0_BZ?'PJ@TJJ#,^F:%1\MK-A&8)"E_U-$74X;"W/3V9EA,_^)ND5TXM;X."
MS#2Z=<<7[AN]AX7>QC\NC!\L^DA,V*EWA98^0\IKG_$O&ZW?-CJ#Q5OHK>U/
M2!5R/3,%Z^6,/_O?I<-=I(0DW;IT[*Q$">BLD_W=G;V8I;S"]I[ 11H$?_;E
MZ+VF$OUT"O<!QN Y,#)<S=?^>%KV?OGSS=^_]B:7YW!IQ/<G(J_5!D,%V>KF
M2!:U:WDZ*ANF]ZO?ZFQRV3RZ5>L[A-14V"1/&6&6Q@47*4V5E07X2U(F3HV
MC>[5"/RP5B,/JT;HX<Z78YWQ(C8RB;*$LPC<UQ042I%&3.6<&QJ+G.,@,+Y@
MX$"M1F8&$X*U_MZ<3SQP E[E+#DYPSQ(;Z]WSN07,Q\4N,*=<>'TR"</ZUSB
MS#HF(Q2TH(Y\XGX56BTD2XM<4"YSP2SX]3(EB<C2W!JC"T6O\^ZSNR7JA]4X
M;;W3' &<P+OZ '9Q_[_C]CL$C4;V?NV>_<S$G<*SCA-#""4VB< ZRB,&UQ3E
M&+NFHI"Y22W7"NO\DBMHN].S4WNT329O"2$^?\I[5>]Q36O7S(.[V/_\Y=BJ
M1*L$K?#4%!$CUD02+B_B0@(-*@N^,=CCA"RGM<UZ()I"'(#;EH945D2O-&Y\
M-6C_+J[X54955U2[<(2=HB$^@S\?QJB7Y4CUW1=[8ZSZZHZ-TW49KBRNPA(-
M/T'.M?R-P$RI9LF%ZI"F> *677]?U=WG2D1N8+<IK.+"TM4P@6)&;U3PZ0W>
M?!7"FHE33^J!VKI&]<=@R5(?"2L<1^<!"*SO(1O&YARMU.&DR>@&(S($X:Z,
MP3]!-^<&R 0S<&>SS>J((]2.W T&MXG1FSPC2E!A;):PPMI"QT6>Z\)J*U0F
M:-7G2$E4_;"V.!]T<.;!Y[WCA&M0QX9$-J9@<8I"1$5*5*1XEEJ3LXPQ>YW%
M.>N*-*%=%[Q%>FGEPVJV6AP]*!VYN=CEF9G,S4/RQ<'X14\2@ N%P-ZP!_[_
M:<-5KN$-Q;RO %ZC-5R-UI ]?;2&:]$79M :1$:R+*54IBIC(M?2\EC'.26Y
M%2F+Z0IH#8].XD#-8J[1=T%69Z6@ME6&I5;I5*<LUZG(M,YT1H3)P033O@<^
MA^_W0>T[09.MT5U7TA+LX.C+,3,\2;1(HSB3<<026H!AG>A(2] /V#S'$[GQ
M<H4+9YD"-L@*\*XD4Y3F(L_CV (O);&AUKH+%S&-D\C_L+[P'WKAEAF2)RR)
M5%9(, MP="XO>&2Y36(EJ<URMGB PO4 OW-#%2H(LY9+, &;^\2Y&#@=L?E#
M7<C]F, M?CA(VP6H)GZ'W+#KA!J>C- KF<VW5T6^!AO]0FE1?XQFT6?7::CA
MS9,%*'\+:F:>8%W6BCF55R-XXZ1JL]P]!S/QK*]Z;\8X9=!H-P%K;S@<?0VF
MX;.# P-;<!N\T$$KT[8XQU+[*=[B?;7[9F^S=SX=EU-,V\,[0A*B$]F=F*$N
MVW \%09@C:M3UK-'_Y)E*7L6WNAKD?=WW[WWKO')2-8.73<049C)A0D]=,V(
M8^U6AZ&#B8.P<[[^TLQ.&6SV_O K<'TP\K'H?C)27\Y1%+3J+*2^]%/@*J8Q
M%@L7U&5 89S@(X"I0F:S"07J?HFC^7!0JC,*0WG:HF/UBNCL'$,T/?#UJ^\*
M;2@3T 5N+FA3=>*YVP,C5YP^P]:;(5/JNHKPB,^F@TG_?!#08N:JA5I5*9U3
M#F,W-_U*L0P^Q#/@J%WHY^YM;RRQEB<JD[E68'HJD=K<F)RSG(J$D&*V@(#=
M/:;9[H"'3< A8;/;V@<_VJ?[GS\<4ZFUE;J(8H6!<<$*\,&UB82,L\(0#1:6
MVGB99LL]<""!T(+KV/O*JNU;W?_=*_DGHW#?@0+@B>^"S "^:F56?CHB.$D/
MOF^#Q<5-:C(2@6?((L8LB_(<B""&7[E5&>=Y&$$=+:SJ#TTC*#U;0JVW2)Z!
MZ!MB /1&<LW7/P8Q/S\ZM!N]'HVKED#K;]E;=DZ8U;V%"Z+H[?!0'4;?ZNTT
M!2P>>LN5(E\S@&$A!%6UG!5E)=46?1M@P(PPFJ2YS*TVAJ2:&4%-%O(_[&'J
MB@.GK.7DT=N+_<_ (FE"F)$T*F11 (NDF$!,1%1H33&2G I,ZB0+\+,["<25
MQC2QF*<\+71>4!9+(A.@@#PG<9K%-(GEPQ:6KPD@$,#GW?3P:!N?10]V/B0'
M)\<DS6.=&@+R48F(J=1$A2U4)%6L"+<RE1G0 KL"-&;6P>KV<X,P='B8<U@0
M6)]3^ZT+@+678#C?1IC%]RO,E#328B\]YXQE&K0]-Y(H0EB><5UX6HXK81:O
M:?D!A=G)L94R3^'H(Z.8B5@B521BDD9*)84&@X]*GB/J47Y_PHR(Q"1,6)!;
M:%/HG*O,6)W1E-(XIT4@ +(F@!\GS%2\OWV<)TF<%S:+P,P#V\\:!<),Z"BW
M5"O#4^):VY,M\62$V;+^@_G$\4II "5!M>8</)2<":J+6&<)Y8G115;HF"P9
M+W-3T*D=8PT6,_^!9Q'(\166-P]_WMDS((Z^'8 XHEF1:SCB*.741BQFH$HE
MYZ!>"ZJD4K%  %Q*LL5P4VVX,T=JM9(:]*M*UZL!SJJ)1.6I,9-Y^G4NA"?B
M6]:2/W(8\-]R.)7CRZ#7W7;DA:P!IFI_*AP?<-?JY6HH1ZS2A,6:LS3E!4AU
M*9+,L"2E.:>S I[<+[CA.K339JOO^]]/CF-B1";R+!(T2R*6Q44$3GT><4)R
M4O!,I:G>>"FN:@MQ!>+GF%GH./;.\:Y^:<MHH!RL;F=Y'*.A.9J>G-:>OJ]4
MKZ*HBX"(7/E"%;*^*:6NU*I+BSPW<4(3+EABA30\3SB3/,EEIOB<%3H;?ES3
MZ#W2*($]'.LD-32W,A)@=Z);;2*I219IIHNDL*F46*"076%]N/S$:/REZ6[8
MP^3&L(KU_QW2$GM#(+S)=&)ZOVSL_;VW\6O=6N_!]P^J#S1O!.KZT\@!//:7
MC?][L/<G?*:5=9A-KK5I'PO?1U/XH'OVYFWIE6=$2V$-09N$IE90KC0P=<SC
M- .7:DVO/Y!>$_C]V# &VBWG4::5!FLY9E$A* -ZM1:GI5B198MGS;;I%4C2
M#!!&U<Q*SYE6H2$:$1[W,>"-@8FL#5SIH&=PTI5K"?9_@R>YAO(OP]'%$&VA
M5[M__;7[ZNC=]H/DJS,T::XU/Q:4C:&!%%'WZ:]F[  X0^D71FGQ 1N8M^?L
MQ6/FV7OTS?LWF_7$ZO;!MYNH*X[W0!VW9'/-<Y$18V/0TTPP+< 5D50F2%YQ
MHL6:S7\@F[.#SV^/K1$Z-TI$A%/NV5P42D64@E%E&5BU."V1;-$;F4X#[-Z+
MW)'.E(VW*.@)9!PR"NX^!?)*J6%<6PEF?"X-B#5*1!%B-.N,P\/38(IMW9G-
MC &%$AF*(UGQ)YE8'2D*@H)D5.9<(PW>8\9!FDQHFS*0.8K90A:I!:^.)45.
MF<S2N4'W:P+X 4$Z',\K@0=-SD6D$C0[2&:B@N5)E$IN",UE3A.V\9)>42B_
M<'"K\Z^6A>M0]=4&;2=VY[!?*G25YY6&2 5C5J0B49)E-,^!U!4<;9K&3',6
MK],0/YS CSZR_>UC3ADK<G !M21YQ&12@+"C:00BB#*5DB1'!+GT/C,2W'*5
M26$8^%-@=9D\SHE5W!*62ITSOLY(/ (MI"#L"F&I27%$2\ZRB!G0?C(6,M)Q
MKBE-\ICE^<;+_ K%]R2$W<.D*< H8TJG)E$I^)O&B)S:W*9YHK(LA_\M25/<
ME%AODJ;XZ4CTZ,.W_<_J&+PR)FQ*(Z+!%6!8("4YXY$EVFH<H9J+^.I,62=5
MH<-1S^0L5LE4U"A=K0Q%F\1KW^+9%VO_CF6Z_T>>G;_H[6.,0,O>'Z[$^#5V
M([D R-/;XW5IF4,U&54]>EXJW&";O5^P#R&)7[@_N)_)BU_K*#F*(R2E^PF8
M&RVYXDQQ80C+TSA/BH*S#/Z-);C'86(5B:O>J/@ADCIK'7GTX?OAT=MCHN+<
M6D4B8=(D8J G(VDQ6,X+(L!\R<&>N6:4&08?]5<G0F9A(A$2<'^[*/U[]-A!
M-^)86=<WTA\ZN.;1M*SKW<]=M]VDLKU:/?Y8GM_@>&$E^2E0/DHFX[^["JLY
M93IR'0#P!8.I&7[W<RC^W/L[/&@V!.I (A$:(6"\M*-QX$:,U,"/M(&%%2/M
M,'%'TX'VP#(>+K=>F70 E?W"@PP,1A?NN\_Z6@],-5=+H>9';%V?G?+ 5;X/
MT;-FX#8Y;$_462DKE<29 &5 F29@B()/EUH*0@(,7^Q'S$(_6NZ9#'Y8&Z(/
MPV1@@*IC1D@:%[&*9&K!$TEXBL"Q>61C WJ_D!(,L&O"+A5U Z'B6)'[\7N]
MW; *70DNF5%6LA0<G#CE8+ 4)E8\3D%\J^):9_=N\]26T=5/5^32<7!.+@^W
MCXU.K(BIC5(B0(YKK:.<ZR*BH&E!OYH\,>#LTB7E+JOZN2)F-DT*H?,T90GX
M"#G),Y(#67!-TE1>Y^>NR> !R.#[P<5QD::)B9,D,JE,(I=5!)4>1YH)GG'#
M2693D#1\\92]61_WYJ[I[/0HK\90]WLC\0Z9B,I/KN650[7&475 + _E$G.#
ML:-4F)QG+"Y$GG-7:IK&PB9)D:PK]QY"6:8'.U] 65(:9TR"LBPR4)8JB62<
M,RPQDE@%)JP%99GR]/K*O7MPAV?HVA/S\W,+JTGE: 1XWGP8YT[&7(@8_HD+
MQHRA0B<I36612YY9</N"8J"58KCG<<1KNS.PTL=O\/]C\.M82J6)L% ^8MSH
M2#"91G%2F *S<IJQE2I+%OAW/E2TK@JY6U5(J+2Y<6W(_63V5[?_8V*Y%)IJ
M16(FA,V+++7,TH(HKF-V;3J?KJV[%9CX\N#SQV.J0)(R641Y3K$SC()E'UL3
MZ91:8VVLC$DV7MZ#49]SGAB,!:2T@*\!^R<3!:,&[/@4/%AV7:9^;=3?V[5_
MWS]FG$BX6Q#;1B)T<H*R.\\C[1**)HGAHC9>YH+>S))'LWWUB,'MA 2W*<6H
M$P4:8EG*"XD]65RF8+UAH<DZ2/#CO<,OE]ADRF(%1*6CC((I /?#(Z$0MEB:
M++,FSHD [S!/E\Q@7[D_+\D34Q );JAE2 !$JEQ2G1?,2FK648+'H(/O0 <F
MM:G("AJ)% 6,%EAQG"21Y<3$!>>9X&3CI2 WE"VWC!+TR^"*A C!T_.J5DPH
M[B#*TZ0RC-''QSW_LC/:^?4);N[:!B]4!/-AXR[,T[!WZ(97';7& &U/)Z>C
M,7;(H37[9CR:C'!L1&LJX2_XP)!R!-)L_E*E'GTHI^Z^@!.L 8-::ZG!T\ ,
M&HW]P.% =96B6WLF=R""$%!KN2>N(+V!Y4;4I\LR0*JXZ2&V.Q#,/Z$I@O'8
M7?[55X=_[^U$1+0!M3O$T*6[!>A@ZPN^3]?3SVMS%XJW"-=9-]1MO=_"@  (
M0KC5\]$YCHEHI6C]&]JOESW9NS@=#<PF#H/Y'+".JUE\K8&"^,4!@<<]Y/5H
MY$-2.SA);EMCF!?1$GV50DMLO-[9KH2%AT;KD Z"N3D$=E0\*FB<&Y7.KVGJ
M'FFJ@]+4/O:=@VU$;2K/^O6X^"K)V=R(Z4QJM9V1XD,W/=G5%XQ*A.N?$37^
MM_ZPOG1X)Y#,$A+T%.3F:H1T _Z]"A<7!O_U<XJ^ROY AMQ^6SI-%XLP1X?X
ME=_Z9W[ XFK3.HA*!0&/+Z6,"5L(,-XESXLL-F L9\%^SM;5I _KD*O+PZ/]
M8T))D1H31U;1!!%ZLJ@H\BR*XURD"2M(DLJ-ERF[HF"^.[KAU&4HYJ>B=BFH
M/'6E)AZSK.QK9WQY<GL_+29N**-(\RB+T\V'1I%=T1X^&,%7C<81F("V/^GM
MXF .+)X) ,;P7X>SW2ZT>PR)M=E,A!U-)WC$'M%6C<Y=OVY[<K:??7V"L(1#
M/QO@Q S5I7=A:J.S'B*-!@O6&[DY',A'^!;XJ0\B =M\<<9N'?3MC[T?U2^F
M"R92.U!1'XZ9<[<6N5I7)[E*;(ZO/!78YS@ TE9HOB ;*@2^FBY;\U_#EY1N
MP&M_Z&<J/D4/;MG%DQ2'A=2U5>C&]I>Z/&Z0994NZ]G^-Z,C/^M4!?SMCFD"
MY X'XD^W NBN:RKK\EKT:>JBGBFB1I;UI-U9_Z:=#7ATXP2.[CD:)^[&O5D
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M%XK"^MJO2)W2P[?'6:Q-HKB)M) D8JI@8)KE/$JI+#A7<9)*H("$+&B8ZE#
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MP,)"WZGB"':*;#QHL1&2:]T4X??2W8J3"FYM%\;X%A=8%\X;/O& :NBBCC"
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MSPIK&<NPR Q12I=# 7=*:J^GJ<I+1]H>8.P:K>:Z!\?3V&B,3:%H@GBC#V&
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M:7"DDTW.V6:>SE>PWLY&O3]NNI,2^1]7<=/JK+H:'Z==\/7(754Q5OL<.0V
ML%?E#%QIW1JP6D>+D5Q1'$R09H)AHURN\U3$F2A89F.1+$8]7G>TW*(L^/,N
M/=@^MD)034D6J5BKB$E#(LDXC2Q512R*/+6:+>EHJ4M]0]O&PA!+OW0EF,,*
M8-"7I15F,+K8=&T<K1)@1!$;J)#(6M2TX P.[%3$,=%=^;L:ZO%CU\KQF-^F
M5BYE6X3G]U\KEVP)GMWJL5?_37#Z$(5]:9;<^V+)%B'B(4Z6BILM]AJ?X@K7
M89%I"]1^WRHAOP[]#(PWORQD35]M_YL?,>P&F0:!\/X4D0A?#60YYR*LMFW/
MO3_&<KW)WC=>NJVMLJL8][1QOP?P2#>_\=*-D,36-7_%CWP,CTD'+O/@8MB=
M0WB J,$/8OV;IH!=H^I=DBEW\_&?D2M;.E$Q"Z6&<V6*G$C*+5ABF4P56+I%
M3)A*D]0FBY,MLZ.YKG9CN]:P_MU/EW@?EO,?X<.J^-,?']G!SL?XX//KTX^?
MWYW"<_L'.[#>(W5Q>*2_P&?B@^\?R9P/B_[NYQ/XW-MD_Y_7_8,_X/O/]F+X
MW+>#[]OI0?(6[.>W].#SW]VJ.9I@7XG*HL*D%'Q86T0B8S8R/!4\26QN"H9Y
MEG@)3L"=?-B'<U%O*:AFY?G#<OW3DH&W#>O=1]3N\79]5<@.G&TG7NY/V'4E
MFGNX,S[6\FLU^?6]J?JUL1 4L4T256!571;E-K$1Y291AC+.F-AX&6\EG#Y=
MV>7)_WD+KF>9DOB9,@ZW$UNK)!J6](^OA=MJPHTTK5.YRJ7.\H@G5D>,XKQ5
M(DBDB=2Y$B;F<;'Q$EYZ3J;9 ]3'/"U#ZDT%O/:3%<"LYC(2D5F6)KF,I6 B
M+H04"<MY*EE"TI2E:Y?Q*4FE=MJSX 4EO""1Y1JD$E=Y)/)<1UD!8BK+BY@F
M$M.>A-#-),Z>4/WP+27.C8VKF_+NTY)7-S>>%NWO/\NWNX-46OMV]R-H&M\N
MERG7(%HBHED6L4*FD2 TC@3('\I,G,H"IV5OT62^NNY'"IE;N&^/(6&>B8=V
M*R'S- V?>2?L=O)E[83]<"G4.&$YL;I(C(C27)N(*<HCD1D02HQF>1SGFJ?4
M57D)<1^="$^[V/=I62Y'(X0#NH>TW4/5[CXC6;702;M=$]7:27L<J=5N\B0Z
MH1D"?\,5JHA1 ;93$:=1&DNKDB011-B-E^E].6E/IC;UGN+G3^49Z]Z#=>_!
M,VR-71NA]R+.&R,T5ED6"Z$BF0L9L3Q349&9.&(\,2HC!2$XS.&^VV$?7YPO
M:#6X$KQV:7_!-7T)3W7XBP,&[L !5,6HR\:\X&" HCWQ .L:G7&'<P*PSE'V
MW7S#R6E_K*-S.:X+X$=C-[H;#G=HO!!Q9>Y^/G?IYD)CB7QWJ-@-ABNZ.:+-
MH(AV9;R?Y;EPAYWA$;@K;29F?.;J]G$\8V<#-:!Z-2X"MMO'"0F]<R#8ONK!
M!7\Q$[>2<JI._6.W9L<88#TFG%)I_&K:4R$-#FEW]?U3MWM9/5*>GX]'THW1
MD3B(>MS_ZB?S],_.!WT'UXQ>2F@U\+MT38BR,P8#KF T^.K@9B8ESE3!&6XX
M7+Z/@\MQ!3C]6E4 T/ +7(2;7H%G%IX^K>>1C\[=4_'*\:4S)XJW>A_<I,"E
M;]CL&=Q)>)I[OOOJLY$V ]_:<"J_^NTK7$)XBJ,3V=-].*2A0A*1_;.* /W^
M9ZYWJ[>+W^0_7[?<F&\XX[:L2'6.EMN/DE]E?^#:'_!2W;J1%F [YW[,>#B_
MR][I: "[]J2F@!-PF/H8EZK\V>%'_5X1;[UJM6G3&W[WTCU9-WE=3A8\8ZNW
MVLS!IR)R&F(/9]TFO0YCPG4/IMHCNTW/W&W. 95WV1M?:1@-*.[;N7'3[8'^
MX>(&;D)8_2)>P:8;_H6#52*+P^UK/";$U0="FG] EW+\('K4,1Y_KGDC"JZ*
M8QU/:J"IR[ U3X- ,,,3SV0GTSZP 1Q8)524ZQAS$Y:[I]99?G<QLN=/'X\,
M5)\\:0ZE_CC\%TDLL,I_XXC[;Y.6/,7C "FF3%G:*8B6;_T)?L;]J;X&OZ8E
MIS;/6I=]G*8#2_FP]1X^.G8#$BXKSG8['3MNPRW-",X98=TO/2OT;=_+#-G[
M"T=9]VAG/D\Y&4_1+'SPN08U,,NV0Q_<'NJ_^K((][_O)T'HP^$[E!=C.$1X
MP\%H.*Y^_1T'%_U=*9@CHTZ'_?^=FO((C^.G'H[P]C@FRFK"260*9<$:Y2:2
MEO&(*".44B*)S?QP!)6D*;."$7 _N$D%Y7"E+#9<<:8RL6@X0ENZ3)%J0U->
M2[14'7AN%,)<"U[/&T"F1-&C?1O?;U=/25BA$V^Q]%X,KW_=[I\/ #[/MU+V
M $U]8BM)[Z7U[+XBW(_JV.]V=,DOET:.RSGLD'O:_(_L2%HMKK%0-^12B4*E
MN<H983F)I:':VEBHW*1,2+L01*$5Q( UJ=\TJ#DXTS8._/8 3F'HIITTT8O]
M9F30WO!\.CF"ZWB>0C^$,4Z_?-IYFW[:^<@.OI^>??S^KO_Q^P=V</;O+PY)
MX?MV<OC'1WKPQ]O+V3 &?L<!K.7@\PD]_./3YX,__OWYX.@D^7CV%I$4ON_#
M,S]AF&3GWUTL>!EK2U@AHD3AM/6,R4@(4D0VSQA3N2[@)G&44X,$/R>:?V )
MX:/2_=^U,7LK7K]^QT^7UV^(N& )IR+.E<K1'*0DYX4E)D],ELHT3>/%8<PY
MQ(4;,?NS1UOXL3S?P<E2VDB1@G68&1,QJW@D>8%M&ED,MKW18"INO.3S]<O_
M]1@]J(]*_^\6.VL_G;*_J0 PHI#$*"Z)9'DJ\R(IM,QBBC.$;;(DC\'6 N#A
M!4"[7I@D)"D4LU'!8A;A144Y-WFDT\+:1&>J0+SA9(O-9Z'O* *>H=H/P>_9
M2/3/8P.L,L/U8:=!+4YB[M8WXT)*M5R@:[%PO5AH5ZC(/)%%JD$L@.T/8B$V
MD:1%&IE$LU@K(2@WB)\ILFPSI?/H:?.BH<X3SF4(KPKHT*<6?*^&9,MSS!_Y
M$: A(^.S-!@:;B"K0LZN%7_%\#"\981IL-DWPG];\[W=,' WL=Q%V,V%'.NY
M%(E[)X;/RFF!$^ G?3G ('D?]B_=!'$YG('0PB7[5XQ9&"/>ZKWOXW3T1;AK
M2Q.*"V&Z3EU\N5X:[&?0A\,*H)[^$0:^:A.'H/?]T/2E&UFTG)ET1[T$/+&+
M_F#@LXT@41 <K)G[B\L:5O=6IZ(<JE!O^_VK'DW(<\P.;2\!-ZN)U@^A+5U6
M##.9RXZOOL%-_-'G6=L/&H Z<Q.2<0Q'KYAB[8$IF_'U/H!_B;=69PU;D^KA
MH1;$,]+8"-1;-48Y)$^:-,3Y:-!7+L7:Y$X[S.93'6.DE,T5OQBH#2/.TS,@
MAXM3TV8+.)SS$29O,7][AK0#7#:$\_RO*AOT=31ISQZI40HKML+T3OT%/@M[
M)B^1!'&_<.JFR>^4YZ#=8'D]"WQ=NA-0_;&:GB$7J$H8: ,754Y<>LB]L/)N
M<:'C/@8KMWI[0R? +A<>:I=F/,^4K>UY!IO ]8,+-!T.X)S"7_O(M.X3)\.^
MCZJ787PW(OQ6I[0 W-<+B;[NR_%EB^:4@PF>^.57O#OIC/=N">7_QA,?G8_&
M^%0\*%]9@3-CS*0W&/G\;X,@6#^R/_0E.#7BH/N D>,A'%#G0ZL."2]GIX1W
ME]O5'&UM@ L?FZ]]<X'93V37H89+=64@.'<"GM ?5S?ADN1CXW8.-PI?UQ]I
M1TGXF L0;A,@<(UU"YWAZ+V^;<HQX,NT9TF\#G=:L%W_/D=Q\!ZGM2+DA@CV
M!]\'U[7ESVX;:$7W;1#H0.J3"Q.X2E4S?/RL[&60GC/BNQFNC1_PB&_N*<TM
M=0M$\,[\"#-<*GP43N.[NUVGDAW783'"MW.\,2<,QVA[#R[=M>!)X3_#$?(F
M/*'9#3P0A7N=,EU"Q[IFSHO1=*!A03[-7IAF-36@Y /I!_?$WW!":E_=0&,\
M0R7WX7Q^L,$BD84W/[F9P=(1*2L4:/5N6*"UO/AJ8<55M8_3;EV59\(;;JFQ
MP9QF1L/*:6<)IR,UUE%43_95.LWVD??PF]=3Z:^>2B^>_E3Z:Z?,SR7_=<(9
M3Y0QDE&:YSR1NA"&\ )\/EIL7"$@'ND:&OO>#$(F%BLBFP!A3S811.2*8-ZC
M7$:3 Y0)O&E0"8TE9LYFSUDYR)2-Y@6S]'PP+5&GP 7"#U4UTLP\@Q%\R_BK
M8[-NU1+.:!D[M=8N-@S6N5,X6!6%19'!"6H;"$$'E?(,M7<Y->.@B/]!8[8M
MS@QJOK+#[YNW6]GF=7K;N5R@[ESUI>X:&V%Y0=4Z852@A0#Z=NDZ\"":\VYK
MX;+V4!=IX>?HO(%-?@#> 8;2@^O6U-J>#TQ%VJT"7UEK@H@LUS%=G1(\%-U;
M)927T-@2QDFFB60J,;E(#4MM;'3.%!7"I_))*/."'[HXZE&ZRGQ3>>DN^VBT
MK<#0&YMMK9UJD(-JEM?>\'WE+/1;;6C9\PSRW;K*Z^#S"3O</A997+CN,6MS
MK/*R*BHLS2);Y(E@(+ZY,MB(SY;T'0 I#WR-<Z=B_"J2:I=>#WS%]V@Z@1MI
M/.C@ZE346L&K3] M;E=6S]2.!VNY]_?>KI/(0WRH=Y[ 00&Z>-$USV9ED:NY
M+I& 6NSC55S9>3A\;7\R8QN54VLQW@""+/@8(/Y=  X%F=N\<088KOVKC]2A
MC0=[[\F:2E&M.,?">8)-,*.<GJ.#UF7'SN)P(84)%B/PQA@C!D.#:\*?:S=T
M<^'JW<=&%\;%RC0PC@I!@F:QSH)TW0*M*,' ZS1X]TS9*![_Z*ROT 9V[(O;
M=]6MI]Z]&4W:7F]=._YZ-!B,+GQHH7O;73/]%&M:78'^-U=:"PM9+<4HM%*"
MI(4DF6$\5CF).>%**\E)H7+I,PRSTFBNQF!V>.F">0Z_7[X!%V#X_!.-MQ<V
MWS]<[E\<ZY0E*><TD@57$<LISDE.;90(P47,52$-WWA)%R0+*X,%!<4$J*CQ
MY#==Y376A49PO9CN6E#*[ESRK=YVX[1WB:G#2"'.>?,P9S<@/!>.Z42&J>,!
M?.QR]\L]L!M>1O[K!IB?G86RK!MH+CFP0'<\3.=3;0RU;">2+/.EX0FA'V+.
ME5ZPXC:=A,Q$DXOPU]\'^KJ),ZZGKF-  6GC8$84=F,7*<7#+;T@!#&*$A!.
M8-D3?:=,&8)5Z/-T6< 9WQ4?X/<%EV;UD$'M]=3M6@]LKC]+5IBU/>:BS:8=
M.O:-2*8*SCK_JU,#/SD=CZ8GI[T=HSPAT^HOR#NKF.L\)2)E+,^LC9E,TCPM
MTEB!5H3_$9ME,Y6W)*%DUEQO$NU[+G"*,REQ/-F2WN%W1@XPNKD]U-M5-]+1
MJ'G#3VNC'^Y\N#C8/L[2E!"3ZR@5618QD^D(=)2(<EEDQ###=2PW7K*M>;W9
MJ\QSEQD+- 2D8K#M<S@YQ6H4E&C[<@P&>2 9LC+)@%[/-8^+/.:2$:4+:64L
M<TZSE( +D<PV\M!YDKE1V<::FNY(3<G!V^."LH1GDD4FIBQBVA91#MP<29.3
ME"1,2U:@Q[<,>"V0U(O>*;@+8&^A 0:JYT?2"U9&@0L"/ZT$1G,#XGGN, 9W
M(0X&%GH69PG)"AU1(TS$:,HB88B->)8:Q0H0-3(#44/90EAB)SBJ_,DF_*2G
MJDH2-VE+WV"[T'0 LV,5.LIB"M2<%S:F,7@629X5>991R1-*+2VJP7P+R.>G
MP+2X S%\)$ ,1<8S4L@D4IH4$<NDC7*P :)"JD)GA;"$(@#_'!EL]0YMJY7:
MIV$W5[I9PXVQ,@/AA/6^J9!IIE(F<B,D_$;9=4;(6D(\!%'0P^UCGG!;Z,1$
MQ@KPX6.21@+D=I129DQA:)%*NQRXW'E2SA/H])W/U\$UXF'3.Q'%95>>%!Y,
M;%610;76J95Y#%*-Z8P(+54"4H,J366<DK7(N"UU*#0N4LGB/,EE9%P76!K'
MD9!"1L"[B=2*JE@6BT1&J(OHVJ&^>WP^,0F2@&><:21#1L!NH9G2,269LIF1
M6LPF)E6>QT612P,+8)I3F?'"@H]3%&EF8QGZD,?F#-QK)*^53)FX$ *X(,_R
MG&5)(I@1B,(&2C0O,I;>P%NJ!=5=I-'/9\R>H&N4IH+QI%!1+KA&!,\L$B0!
M965H9JC)8ITYURA9[AJY6J7E8FEI"2NZ5#<, #7UD XE8BS#P%F,2MZO> .U
MJ1,;"P(.(P.&$YP6*M=97H@XC8NU>+LUN7VA^]O'H@#Q$1L:9;D!WRG)P!BR
M>88_"2ZH3D"QW%B\X8O+QA#_MJC2_491KF7@!-<+P1\,3D#B>"OV%2JKHA/D
M;(O0VTWQO6[<;OH@XW97PSR8*8PBB;O5>QM7>MNW_L=C#N\M<DFG"PH&[Z-K
M<U4XT)\ T',-R;F&Y)SO7WM]=OC'I[.#[Q_B U#7!T=O$_A_>GCTJ7_PS\>+
M3Y_AO]\_7!Z<[5[,]J_M__.1?3K[2-UG/N_#=WV$_W])#\[VR*?/OY_!?^%O
M>PGL!?O:+YOA7)G6"NXMTM*"FA>"1B)G-L)BF(058%?I!X#D7$_@NJV,7FZ&
MWT=S[5)]^9/-^IH7;6F6%IRPF-DT9XF@.2LL-S%)1:XU2Y; =*Q%VP\6;?V6
M:$OBU'+!BRC7A8D8&/Y1H4P:,::%D=J(G(B-EV23NI$78CWRXL<QGIN+4+6/
MS?2;S2?\H_E4_T.8I:M,W'B&PNZ7'U<8$:]3$D]"&EZVI"'-##$FH5%F<I"!
M"OXI,JNB++=YFBFJ<XKAPTU0;V#LS<=UYL#ZUC;>0PO"FQ:QK"V_!Q6&=RSA
M6 O#)R$,#UZU34-IN4RICG))><0T%9$$9S?*A>19FH@XUMS7?M"<WT$4KFW"
M.[J[BY()CQ&2O'*&R/(!(C]#*/->CN9I:XL'K].:B1-\-^.1EN7I.D3P 'J@
M'?U46$E!N(@2P8J()5Q&,C<JLG$FTX* UYF#'G )\>3%CQA'=$-^N9]!1-<#
MC/VH041+->=C():Y]A!L8W%5"KZ1L57BX)+6*U4J !W%*HT-94!F0F5%EFF:
M$Q%K;5)BJDJ%K-M^MV <]W\H_]]A?,,V/;@XMFD"_BQ/HLP2%C$PV2(9DR0"
MXUPG19[&2B\LWFS S_QMUTU =8.*G8X=_-S"1A7?\]-IG'(]/\!WOA@!FV&!
MI*M^S_\<;MD;]EZ;8CS%9ELDW04=^!+;^48(T;5XSM;57=,+L=1TW[?2-O.1
MS%;O@5&"KCR&']:_6ZA,@RV!X1OP0(L\ETE!>9[GH)ZDM5D0($F2K_MW[RY3
M]MGAVV.J"2F4()'.A0#+P-)(9JF*>)RDLI 932W9>$GG.T?NIW]W!4RAY5-=
M/D_+2=]>KC36Y1I<FYER4Y.EEA.1)5EFF96YE)F2"MZ:&9L5DCU^TV&WW]E\
M4X-IV?^*+#CH*P=OYKH^+X>OFEJ7>UURAN=][9H70$'AA49T:T&!&;8'XP/0
M,B6<O>C:H8]QX/VSL^G08=[)\TNG5E_M_O77[JNC=]O/]5!K#ISCO<<XX,7L
M>CW[>=*8X+0O6.G)9>\<#@)=S68P6T#[Z,RCJJ:HG8-^0*@.;#+<!"MHA'"S
M)V88^0[UZL(Q4JVPAC>,)ZQ82YZ,C<>6 MV'J(D^J'T^FIBA1\ <7<K!!%85
ML&QF*I&K]3A $]^+WAJKB3B>;FD>;PJ^ LSU2=F"0 WKP*%#U0',@/SX?O5@
MLWEI/,6%#QV*B(,P\4")E2WGCF<ZF:)]6*-5M@9"SM/+B@A+-Q#=-W# ?D:@
M.1HO!YK#Y?K:8!E+'EN#Y<N,6]!KDDNJA2X,$X4VQR2F&X\(3W?E6^H_/MS1
M\L4&_]'N?B\)P&3S_^YO'VS_L;N_>W 4>@?>]W;VWK_Z\/[]WN%!;_M@!_Z_
M_=?']WOO>X>O>Z_W#K8/7NUM_]5[=7BPLW=4O>?=[OL/?QVYMQR^V7VWC7]X
M?Q/>85MS;A-_2,"#%:%#'<+Q6W"6)@XG[IV#GW5VB>Q[$#L$+(\&H]$7-_"U
MAL1UL!+:6 ?X!*+PO4?U\&>>\.W&IZJ!4[:5 X$E@E+W:;#_AZY!U;=PM#]/
M=A=\?O>;AZAH/8BU'^3$)X(G-[B]?DRJ%Y!.+CII[3 N1M-Q]6(+J[H!27+X
MRB7"S2)^,>SW<C1%15(!8EQ><3@. L6A87G%YN8APT*1 I/XQ9F\W'0_DA?5
M2^CIS[[F$9IF7_6#3V=?!=4YG'T-]:%W16?_4H U 2<Q]^@P'G7NX> ']Q=\
M9Z4JJ]?A5,.?*L.V_@A>Y="<> !'N#MW(GA$_BY<(&-F FJ_I12[M^H"(-CL
M'A;F09F!*J8X!;J^88_@6#K0;@\#7(.V#"YO%_%@3G ^&>[='B!NV<EI[\+U
MJ^"=-KCBGE!D-2_8!F3-RHQ:3KP>M5JB<17:HSS@#W(,#FQUT&KMAR/_@H7S
MV50 DQ?(-$.T7DY M  =FMHP"9>"6)S@Z3CK)&";@0O:QBB#"Y3J%+?D5K75
MVQ^-S<@!'0Q-WQ',A8&?\7UH$;E7O$VXZ8>9NB\[1_2Y@+!>%2U(!=N0RCL#
M55AH:,H:CW/YX6SU_C'N@#P*U%Q,;7KN4-2"C7;=0:.V#D;MH(Y#+1+(SA$?
M.MLXS%:O'^*0LASE5_0^<N!&;130Z;AS83>B?3%#^Y0\+%+/RHH+C[:*<>E^
MJ:9E&7#HG6BO93I&^CR.O9_ $0ZIC>A>@>&YZ1)2!Z"JS]-A"ZG*4?]BH/@6
M/&#K<H-!7DWJ!FXP_E5/JNTYS3Z_YI9X?F[DV(5E!J6Y\+#NPR54X1X&RY)3
MV."-%]5=4,43.* S%/#,8Q?5(\@#,6T/ATAP81FP[-=(F22._B]2,LYBJ+"]
MW*CKE@['!=1Z'#R=L[Z[M4TDVO>[KUP4RF?4J^Z\7_ +W2HZW_KK%OP@$4K+
ML:,<E,!\XY,0M(*7['3@ ($1?3\PNL>A]+,?X)!'T](1SF"$,,.H)[1!S3VM
M!K),$![?,9_47W$L0S4JPGC0\+YI) ;P($*<^0^"KD$3!19>H,,'DF4SG"'>
M;(4V.>B?]2=!<B"FUNQ2X+#W8 7>)"+.HGH#W^I_W]M;+BV\;/*@_6&B<]#+
M./ZN]]JOM5+->#;AS_MR"+X$DLI_E[V=AJ?P+=O@:E\BHCY\[>N:MEYUF.M=
MPUR'-7-MMK]HV4877_+\3J[;2'C4'3ABZW:@PT_,,G#GTR%*Y22<DBZ$T%48
M#FK4V4>NOAFH$]X3?( ;60Q!/K@9,M)-7PC4[=CQ-W<E0*FP&*<6?;;JA7L9
MA]"X:$X5(6E-30(Y!.8BWL\)CAW'3[M,Q5<Y> &D$9#X'!OVAR@J?7F.@N-P
MH-L3-/5J\P0?#QX+6!VC\RKN<S*69QW>Q!UT5U^SMU\9F)SU\YU4J7YI6YL!
M S9,^P@F;_4&;]4XTPJIU2F#L%(0@K8VAZM/!\CN8-65$UBH1^D+'VI](=@&
M"H0-B+Z6^01[+OMCHQO3:VXCU4,[&YIYO(MJN2E/<S"[PS$H8G>D\*V%:67:
MJHYJ(/: F8=?4KDE.BRE.AD/9S[TF[RLOWEH<%,@L >77D-7IBR"JGL\7A-0
M)TU'O[MCK/ >PQX7?26F/8:8F)KYXAM>X>GTS+%\^_G-*:)3A5.&RC"S!!_E
MSAD^,Y%?$&8=C$4W<SSD6]S9M:X<=(4?>V*=7=F]('QPS0H>7T[V!VAIXQ>,
MT-)%)$C\H+L%/1U7$<B9!P$[**>IO)R67H$Y0'XWCR=HJB9<V^8KA<DD%+.>
M8' -#IS_='01 ",]#9;2FHG_J$$"0BM\,I;],&.M2WO>;91?X6'5D"27]W9Y
MJQ>SPY/@'*?(IR[\"2N?7]JBY[4COK/?U!XZX,/)-><9&2!B*_NIMC+A%D%-
MF$"2TSK6X!KW"SQ&$,EMD=/ZE@K<V4^9<D.KPBDY8P4CV:-R$AEG7_A5.=J]
MK*/=[<6%*3:FMA,[2^B=@OWK1+\7B5X<M\XSB-^VR-SLB&+O/-6A[A:^=PC!
MUY%SK\:[2W!\4,7@X6K UG7\&J[N?-PW$\SA!WA55"L&#65E'-_!1K6QR$_A
M-["BD;*]XS@8&# %$12[?G58/:F2#/X\I3?O7384Z$_VS_QHIB$HF3[<Z*4G
MF@"N#7\Y01]TZ,[WU,#=G:*Q"6KLHE8TYZ/2$6]E[S2??77X]]Y.1 2N9EK6
M]])&RW7CV(+>=C#=4S>C<'P[IZT5:UP6E+]IY#G;6/[53;W8(QA BZ/"AW!+
M:/H_.U#:$%^0O:(_:@E;%;)"=J2F(1Z#\@AIO$ *=T)]Y&=V>.4.#HL;$(0%
M_NC5'6SWSC!<AOZ(LVM03E0T.T&'Y=R,SG&,$.I$8!P7SO$^DO$A4)]'\QJB
M>A5C+2.0 )/*[?/J\!P6!][YF?S:'\,S?MGX\\W?&^"T'0*]=Y=RWC]WR4W4
M9+A+'/RJO7.#O263RW/O9LW+\]_<D[Y*Y1ZTZ7YK9WLKDP9?!]-EA![LV6@X
M N]CZ,RW2;\8.</GEPV]OUV4N,"].37DXEG.Z&G-[PLJLKL5E"8%OFT T@W5
MG4?P=W+(04</!O7X.?CFRQHN>%;HE7"/SECM>^PAY[N6$S_DQL7+,,HT'H%[
MZ:_0>[LV1"Q@Z4?NV_SX.+_/RRH<AJ=R@N']2:.JP!P['9V8$,SS]WQ;5^@Q
MN0?):P@2>M"YF;9Y@LSEO$Z?BIT]^>==;?&8=19MT]#;P"A@D'?!<S]S0_S.
M![(\Z^NR&CV"=^'&9'H#?0RWY%@=[\ZCNR.W(=-+3\[ "EX,F%[(]CM1=FH&
MYQ4N=XE)I&JH$0H#<"<N@77.JI&6W[U!I'&2YN@RT'HPKT!8N8&U7OIA  %9
M]ODAFR,;H(<UQ#W\QY2[/ I55Z+8B?3+()/+JFBD1=S3<^?.A?AS5S&@8@QR
M'REJLYH@Z^S_WA=SV0X&UJXK/*,J9FEY71@! 0<4%1Z64 *UXB,="_DE/$.Q
M_:>S&68<4I#7TCDHJ.M\T,'!M$EP+[^.?*(P^)-P)!AX7GSX-U?'377.FF?N
M@V><^8*S,NKQRQSA:'M2 ^7WG2'E$XAJC.W%S=NH>QM(L+Y+NJU+B=JE1&1Y
M*='C% 4]=>ERZ (/8Q?#,CUOOY^X CN?VI$NK%EY06 <8!H*30P7;,8P9:>D
MSXF8>2/3/>W,@/>%>:@P_]C QYQO=C(8%2#3?,C #17VN>3VJ)>PE$X8%H25
MBT3XK#)83&-Y69E(B\Q;'S5T9OUB'ZZJ1:EB$:Z"YL+Y"F4/G+2HY<\U/E[M
M%/@$>/^LO=Z)*]#H+,*[-?/AH9"(J[>,50!C(-5.# 3\%#ABU7E0'3:J"P[@
MK:%%H!-.J]S$N3K/Y^K.5!L-9]<.X55YE^USS(3_WA_U7@&9;VWVMI'(/YFA
M41)^T<%%WG3UI;]C4]'_D6?G+WK[J#*T[/WA;NTU=NWX:_K%O?+K)CP/[LZ]
MA('.W7,P>7"8W)NQ@649[8HF]H; #.%F?MEXM?MF;P,^N>.B<\9].Q")2PX:
ME]E]XTM%RMXVL(FZA,_L;+][LXT?.JI2QCOX?!_%1&(/SX)WCG;P?5C0>@B$
M_U??FMY[3$,@!_^Y]W?O[Q -Z!TY&^+ 3"Y&XR^;33*Z>M;1J8M_O,,^.K=!
MOYK:=]A'YL(,Y^_O#NH/O<)\(NC=Z1FL9?_5SBM<C&M9&<K@>(<%P*OEI#\!
MA0+OW/O;'<E!]9Y7CI6:M[3^5+_F'*$_G;A8]&?\Z_9@ -+%1V+W&E[?J7G]
MT%F,0!<XZ@G-5G\.;S!(U/IZ=[?5FMK5\IN]-X/I6>&B,^VCAN>\,W!<X#<-
M>V].Y?A,*C-UY@C^"5P[.)'H3S,XPR__:W325Z6[W/'9J/>Z7Z)QZQZ%@Z54
MN)PA&FEE"+V_,<-A>3D TNE+__=_7)P<OA=(:7M\=MD]BHJX?&P*R>@?L"]D
M:Y//SXG[QRS,'7BOV==A#5S V%$PQC+&Z&$/'7CZ7&YOH6GL+CXH A '?:W!
MB-Z5)?)%>=X?^TC_^\NA'H_.C*O2V-]]]_Y%[R_0$F"'H_1^@7SWHK=;C ;R
MQ17*!&.2/J[4%M?*4:8$E^CK%*X[!!<ETKJ^1(3CL@]/G7G4@N><8MV.EVH@
M]8#AFP?CP["V;-C'F<GMK_DJX>(QF>S]K7GMYQJ>6TIS;*H"N''K?.I8YV3D
MD,3AE-Z]>_,"='Y_5, .P-*4O3.<)HV%/OX8__A]_T45?'69]$J_/CLR!2E4
M$=>";*"L"IA<:M8K !]^:27B3T%<.</">7FN;A"%B[L%#'J/,:N$;5*A/@']
MOD&=$*U*!_R=7IB>]E-8?<D;6AG5T]S;W5TV3QRY_.C (-'[*M5ODU[IS)*!
M3\NZE<$/P^I3?AF5@6%-,)#@;''0X=#4[^MJ[/[7*\Z@;:8<+CY*UPT\-FZ>
M<GOV:WML[=+G&PL[G718!C8:\M%+BQI"]GH+5<VB)=49QLH2',UGOCO+7E#*
M$48PAEY#;RYBH\MFTP*]:-.8"?77-V=EN@M;7!81ZH.N/Z9 2NXI2 P-#;4J
M'ZH3J>[;=RNY8(3#,7B&S.P4!2(<^C(S&F^&+FJ7 ]'.!U%J>C;U)5/:#39V
M1MJ_R%;<*_PT!\\R-?^U+7Z@ORG6;128<G5I]U"'":02VMBK@B-?,1SF;GH]
M>';6#[GMT=47V13W^$?Y7E>71IJK>]E<6#+4)M5F^G*5U/7DA_E@1Q<AT]**
M:WQM#VU>C1 Z;59/)J.ZY]+892>/?3ATPNKW4.7XGX,B4)<OH@?>) "1I,?.
M!-:^-P1LA/$TU%AB)THH$:K*0NN#@KTYS\D+]YE 9ZL0N1G1"B(53 \,[_IR
M4@Q#-+)[IE8#'C?I>P6G*XO0:V2T!S& ' K,VL7@^#*<V<!9@G4M<:< 9#SM
M3P(SN/JB*B)7R5'_6+\I%ZY%;1?F^S;/=IMR%;IN9[X>PC7^N('-L"ML-\!M
M>80!=WJ^)JF"4ZCZ$D+E/PKVN@S$:WM0PP,7#NZ=C%S!U= EANH*#2L5[LRQ
MN\\^88-E*"V[;-7QU!MH=0>$L+S;8BGQ)6PX:>Y[$R>Y8SQ)?O%R;'CBZE9=
M=4Y=[M:N[_)543-'%DJPMAZF+?/),-?>L$Y%5P66H^G$!2N!)EI$T-3:()>,
M=14%"<T>4_!,5152.YF"38(VR!G0DJLMOG#%\WC<9SX15H69T0 ,# I>)_[E
M/5K@'>,HZ" WA:AJHT6*'Z'RQ[?6#MD"!0*&RJ36%?UQJUH<L4/ =KQP?0&7
MC<W;668/0Q;>R#Q%(7,^@GU>NIE(KMO!P)M'EVAVPL-\"5/W Y@T&8& <I2.
M[52NHA>#CJ%,Q+T?MEAOXK+%'_5?R].^]>7! 6W(V<?U[81RD1/I)B<A=9_X
M$BXL'1SZJL]FAX[_N]L\D^47H!3?[P!4Y8*<UM=OP1,B/,6V$NT=P(O 'Z%<
MKZJMQP)"#,;6PZ/*:7G>:BT<N0DY_C:PG'$TM%@KC/MITFI81EEZ%G4QW*_]
M,=9(8PN!]"6ZITY4A11SLR_,N T;HL.B1W02S;7FR6<7;*YW5]W5W-7T36LN
MUFA\(H<NW=C<RAAKO=M:V8&]A,Z*_R!D'U0R@SYX EB6%R"-)F&>>6@MQ-1>
MT"YUYC 4!C<:>*<I@;VJZ\5I_;%TU4B/F4W[%TO95EK-25NTDD>_F0HDV.DO
MHQ?XZ0ZUJA:B'5"9=@W4AIQ$\+'(E[%M5,,H1]B<$(+[:-4[=GI43)%A[]]R
M6&-,N89'<%Y<N,)7NUZ,^Q-PKRLE5>_ E<AUSLK!.G@'*DNV2&>Z\Y.\[<I^
MJ@#(S/#41_A''0;U.:-S]"^:C(ZSFF"OCWEY\][M$SUFQRJR/ U'"3\@/WP%
MEJHZE\K3T1@XQHS/6BB P?+Y%V-TBU=RXPX>Z-.)3H3:V!!."+:,8SP0_"!1
M^I-@Q3<EUPN]L-H/J@RIS=D0.YZMSYE4E3X8!SQR;=63$']H4.#JY[IH5?7E
MK?8_;X<T;IY[GS9HI>!:JDA'8R!T;-%@WV#GX3BTNU?V:<=^;=G&"F<]>].T
MBEC470-5I[-45;\"6C W?6 5SZG:37P9<>CKP[Q3>^5@X96A0#>T!U3Q-=\H
M"9L^A?N%VZM[6+:PF;0=TFRWQX96R:9EPV^JO/:FFS[,E1J#-X$*O-E[1=]A
M&;PW#[X)QX)=FKV]O4W7OMDCVW6G9M4F^_;N5ME=R_G%(Y?S7QEJ>H7=PNA-
M;2M'=TA*;] )0OI;%P.UBX&2YU@,]* (.-?!!HQ-*\HV''63"@$TH8HW5W0H
M&SH\K^@0! IHASFW(<@OK"^&CY_7%9W7/6ZV<[R]K,]3?=*T*U<P+64'%^W<
ME63(SO?='*X .[NP 1@V?@#"M4>K(WA5/^-5^QE-!_C[N39@O12QH%-KY(0C
MWYSO/:]+,.ZK [T2U,O[S/&C;M])M>^J@_SZ77<:I1<__Y:51_?6O$62IRSM
MM_6H9I-W!L5I1^Z/1\,16@?NM.]XCC]:W.RU;)>Q.9%C9Q6-_2;;4J"S2=\)
MU:(J)$WOL; &A?#&?+EY/6/>SAZY/_I,GS)]+I0I3X\05T6(\#GKQT6I/AKY
MZ(!/GU^ 5OA7PGWQ-XKD?V6,X2^;+E_@O1=,QW6G3SEGK?^M.X7*#>EKLM>R
M#/!B/C#XKR3CS;>0K:QRD^_X33&BTOC-G(]!23O,@JIY3WL(@5!XXGNB;UH=
M,AZC83+G&;9?]Z$EL"#Z U^_A"Z2CRRO>E[N+7X[1ZYYWR7H7"%/70(3'@D/
MBMR# KZ##ZEBWL;_A'?:'(6NJGXQ#3-7+H,U-FB?.!@(U,$S>[GLO?GK_5U%
MU5/@O&7%)PX@HE4M\"C-&]<N;W5R\O$H'F_E%9\%QHO%EEC&>G,LFVRQ[L<9
M:>+B=V?<O2$0(&Q;N1B&I^W&! ]):C-#T'(R&?>+Z<2C%K9!*!Q$#N+41]/S
M=@$)+FSOX#!B>8S 6NZ 'NC"DYM=^*,J -<Z4)]'ZYPJF^6WF_)[F$$3X=2J
MWW@R(P&B1[0"G?^1/6)+5O=L$NKC2#4_5_A7P;24ZG^G_;+QJ; )5PX&M6O9
MI7$,20=PD%!6$3C%X9_\"XB[YG!'^X['0KC.,6=0'X%%.\HD@&BL*>"!*$"/
MIR?=Z]QTHR&PL;5J&>@6A'J I(IR%E\YR;:2KJ!.^ P1W.CRNR+]<67D71WX
M']XX%"#$_+V4-S_T6?MM+88?F@G_U6:.8!8MMVO 8C"(]F)\.KG#I8$M=2.3
MVZ+=1?/6;<UWL(SIF_=OJJYFWX@II]C;4=7N847/BS6?/!2?T(8K/)_D6W0Q
MFS@N";G=NN74HVHYGP*XQ%W:B[5I\8"W%7=OJU6,L$"HS9LBO47V*0JQ=^_>
M>#O$68>WND&:S=R@6-_?S/WE@C41,MIX[HL44L5JKJ K0):T^>S.^8\?>"(D
MJ=W2QGQR 8R1M:69H(G;_,$CA8-LB9:W%'DR#C,<J_C6R5AVNKY< =A3JT-R
M9Y%OD1GS)+N[-;_9D_#7DU!<@FC<6$)VVQ;]QY.^K_#R,0 4IBP$Q&)WQ56K
MZ-Q5^W*30 VRO#$%^3 :X;/N%26-K+UKJ'PN[";FKI\UK]P]ZH;QY3JVMHB8
M5@@K-[TDQM=3TE;$, 27&T3QG=&.OYK-%F=7H6[/CZQ)# 2+(XV=4)Q[F'M0
MJ'M%! 3W]C]\4T'WB%K*K E[^0M'N[(3]6\5A_\_]MZUN8TKR1;]*XBY,]?=
M$46V2$FV-3[W1M"2[-:T96DDV9YSOQ6  EE6H0I=#U+H7W]VKLS<.W<]0(HV
M3>(:$Q-MD03JL1^Y\[%RK8GM,CI\M\K)!YM&;WYZTE]D)M>Z8RSQ60R C$CO
M[#9]X_@H=9,K@Z-I+.V%_K-K[/$ULW9BEK O+DP\Y+5S(F@Z(G_0Y7,CP_8
M+=MGUBV^G^YT])6+>TTFW^ !3<9*&.L%H#E6Z. J@)M/%Y+^RZ<_\[)-701.
M"7_1WV,ZFC;^JACKT^#U2B[LR]^M:#%2USPY&9CKKW_?(LDAH_3P???!(KBA
M_RZA,L$=R)9/N?.'',<=SMRC_MGUY"8S=YB>/R8H-C'QZ;333>U[V;F>1 'F
MI:?#[1,7AUFZP2P]_?IK"^[9-4VY,W8UVH8'X(L#OISPY8_O 5\^\I*KU=TM
M(HSUDN)QF,__1%C#18?_E3Z89YDY/VOU__S;_W4]G/*K?_M_/S YPHK H2WC
M9M.]!>P/(S^TTZ,Y.\2 1765U3%&":W4HBF9+6V4%]A N=,46#K1,^G*W/3\
M__N73QY98S)1<=BC?-9G1GWOK\WIWL>RF'HJGRO+&^W)7\ZD/XT3%)1?2(*H
M*:M[Y31G19<I,"4EI3-NG<N;0!R/;)W> 1$-\YHQ7B:;70KE%4<^QS.&MT;N
M-5-0DW+5=6_P^2@[@L\^#2O4I^LFXK_CV9N5<+>ZQ=L!6OKO@WCUJVF$'MW0
M0LNO2V!*,Z*[1R]!\^4T +=_CQUT2R$)\4>.^R,>]\=]<.)74UG2T6$_Z4,C
M=R19;SOL)_UA?SSM&MUNV)51(0KVQV"3QA2GZ "%FB_M;]IC0@D<]JO=H5[$
ME[9HPQ\R(H5YW;2S?W)[0\ R2YY/]Z<10=.MNO=V^I5HD]*05^M[QO7W'N:6
MMNS9:>3'3Y:/!TFP00[L]TR!_?]GI<C.?2!+Y;>=>T]L0\>SKQ]QV\CL.DQY
MW^P^G5YEMZMM^=Z)T:_OSI32B]F.B;P_5*&D[(F"2P"H((V1E<2K"5%;4,[2
MW7_DG^2JS%T 7UJ^VJC?ZS_,1&H[^%M4XQ-$5_1>JXJ(0=0(XTLX)_&WKK"W
M8G)OZ:#%9'Y;D090KBK0/LNM7:-EM6,8I-G_K#LG7:S31R?/Y'KA?=TYTG^&
M&[R@O^+O: #^B,+^9UJ&YZS+[5XX=HE=#$J*8W3:%[DP!([B<>^=- 5[;O$9
MKW$[=^]>^:">?16LUL.<A/NF9_KWDQ.3]GN08]2/"7ZAHX*(?-#SZ^5WAZ;,
M>^4II?_GV7+)_?UJS599"C(9IF9F= ET[_G(FV?@)AC9"$RR#!'L?-75G ,)
M3%[+;*YZ;+X0WC#E0*81<LOF%$\^QC+ 1^+(PUZ!6QT;U8?KX,99<;](C2[E
M$%IS9+XF(GMW[6(;.*3;^ 9RDHT-HS7J"9HGN<6Z]2K2X*<71HC8F 0-:E7U
M&J5:X L:H?2(7 :C(2_OCK51JW6KBC!/U\@4PZ'(3#JCVU1E?\CH 3KF=+_)
MT.U_/^;W1&7T%^*>_NL,[Z]$6O2F(_VT]]PR39DL\\21DGD;G7X^MR6JL/X@
MI/T9O^;;']XS\R9?&Q"@KYYYCSH%-3=^_?3IZ>_1DMUWQ6_XY"#W,DQG\NA
M6XDF#+^&?]['O>X*_W[/IG.YG^_J&TY)=H0U!2'.+\@DG5U@DCSL+^$VS$.H
MK*^ TX"=VHFI(FG,MHE')TII$BD:$TL0@$D&3GU<_L@_*A>88%6^_"0C_YJO
MYZX.JSM/"Y3&F@MB1.7$*9K,?Y-1G$W:P[VW)#^2^%?IAK6 =3V/#8O(RQ?9
MD5M?1V#&E#4 QM@'8EO*W_P.GV\+&*SY90C@__+5R0G]]-?K4CU/^FG7OWSY
M;/R;G[NG$[&LBN9-;V&>]G]%XVQT8TLE2=W"XE>1L:KNF:O 'X8^!> \1<J'
MDW&!$_EI(6R'PT(/$S0+RTY9E8!A5VXM@?[;FEQ^58_]7*1UO47)$/E[O?K@
M$F+8?:%HY'M\Y2\LDE#=-:A->#F.F6<E%N)XB6BC:=G_]?;^0@2#R SI&?Y0
M5EHS_7!VW8&]#1\U$RS2)H/*PPR B<'^(H)AFO7?)>/T6]F9OG[([$P_1(3#
MSX5P^)T2#C^\';%;"#EOB/)]P;(CK*E%13/2)N;T)'B  X&A.P0YTM[%'M1G
MU8@$XEBQ(/H,UB=9,Z+&3Z 9=ZFZBH$2-K=2@<3EFOK\J<*JCV?OP9)(_P..
MMR"E0E779I4+;33>2F2>V#5T[UV2;@:A/'  3Y.+#SP0@G91OD($*DT%$/_T
MJA*^+_3&)_6#4>/YI:HA-:(+GE[,;X4]6_37BD[1ZD@^BP$;?2"6_QH?OI)!
M4UIR?.K9(UOS&3B8)X.R^9/39]/U1-X#6M.0]SD9[7:BWD%E]YYX#7-<C'JK
M\7B--_:TXM1/[Y\#XM$B'I_\H8C'WWZ2WYO%VCF,8U6TZ[01>JH*MB\/I3YG
MVJ"QTNLIN\&Y-Z[P1C ]$LR] ;C%WA/0[L0T2A# )H"\<15BCTT$4JA00_-H
M>W?</"=#]5U17>V;0T4I&5A9Y4H.:H/&Y0&$X.3Q21\\]]1"U4Q[Y4VX$_L5
MGIL]R0UO$G%*FG"$#P1*IM@C"NB!CKMB2WV,^ G&X\]PP2>F,64,?DN7=0'P
M$9]H2Y*.T)-8+_$LM)3R25C>:$1"P0M$4@&P80]2L%_GR[!?@YO*KY:8@W&=
M+K-9MQ$UR$VZY2>EH;<J<8%%ARX6<U.,=(SR.ZF[/CH6[M-^KOQK30(2P\@]
M#2.7D&Q$G9%$L:[2?H-BS&=*G^CE]'BMW#"91Q>4;%P,<L[;;/T@ <Z_@SVX
MT2Y\=.TN_/+4U!CXE[]]*SX[><R3<<MM>/(H+(^)-1MV$:K+5"P?7[MMSY^]
M =X""_0DZLJY?@=\95WT ?Z'RSQQX]QUNT1'(U2'M,M\. J];G/_@7-)CEY;
M,1S6F\ZORZM*)WL,9.RS,Z(;V=Y[DC57[$((AU1U"ZL\:UN6Y6-9&+@RRF:!
M3A*F%@Z:+ $M1=>V?MZN+-UJ=<>YH+TW1CR;8\[)Z>F3/E;QV1/#T? ;G1,R
M ]JUT@LC QX"B>Y\#01UOA(11>2+1L-7Y]\[KSP% )T.%U%))\3'+421']!L
MB2(4V"X%YC+F3G[YI.]./G[RR)BINYLR"^^<C/JCZ"Q0>9Q]>*VSI8PU0E/\
MR 9DTUF%2!AO5[QW TX,R2/0(GAX@=%73PB^W#0=6KVXVPY#BN:D6[_:0UGN
M;TPT_M0DY&XH= C@0_+XZ5-4=7? :TGV9O!MCUOX]Z^/GSZB6@E?(@0.NO 2
M7T$AT6O-EOE'R^KF"U(FDS--F_Q8'-6&":JJLPP/X1T %R+@&)Q3&MY3>PS4
M&J]WALVD/QA1O5>$M:;M>O(UYA?)-QQ'3*ETQI*<@@UYR0'"&QVC]S 59VHJ
M/-!\\'MV(4K/+[PI4I8[<7;&?O&M__T9_QZ*ND6Q:PGQM<_/26*EI<8A<E*]
M97+?<,$>&D,>/;)^)YNLG 63Z;^)=XO<@XHN4:1(JDI"4[JD;$:#,&#O9697
M55<0(T!+>6*ULI0/(O;Y8?^2!0_%T^*NN?0QI?LBK\/>H%M:)Z6RD;KSB IK
M2N40>KRY()6LB]A_D7!>C-R35,_]9 RWM$S&Z5,S&3T$%4$THB.1NP$B:5X\
MXY/'R<F3KY-G3T_-^I@XV?I/"J"8?\[H, /^[='7-F'Q7:7RV]R[A]E#-3Y
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MJG#E>=&JVG9><DJ'RP09!\W(Q=,L-M1C3P$,A\<Q+'7LGM ?M]?5, $ %OW
M7.O?E,&W#S+-.,'RWII*MRDQNJ  O*Q3X?-G+@3RM!CA:U@PW8) O*N.*_3Y
MBH9'J)9GZ8:R<70AS3]]]^*,E;@0KS*$KJ+<0,0OZSY9TG7P7&7&B[1.\R9^
M.K?3169>KL=M;^X[&%K<W'U7[B R'%HW1!^'NVE9T=;*EOF".]M<" Q6!)V@
MN;L&Y471+8WN-Q<M\'2*XCU:XU(1#%;M\P-LQ\)VGAY@.[_#,!H]2J3'FEX,
MX$8+D-..\F:FD_$7@J,6>7:9A=Y5Y3^_#N3&>WQ%EDD\_W6F.[=PNR<; O<B
MI"C.L796./O52E[ZD_O'559<^BQ":&,5Y#SV6/UYZLP/)NG\9K4Z^E::L]ZC
M.>O,"('NV;E)G<\Y-6"T# P>0.0I> 2T/A-*+F>VEQ6^($NLV.*K]%<DY8[B
MSK58/14]L"N55D9UJ]/BE/.%NB*0OR%K]/+Y/J&UL#Z>"ZR9%,C?S)UQ?JB:
MQ3<-)J_+"#[4F"ZE/NJN;=J4_0C#=>+;J>%%"W&+9LT(;O,L>?)T5^'DWEL%
M:U&D*"LIH5B]5&T1%8SFPJS(*JS(4(]1P'/6+.I\[L4%7J=ERCN74N\G7WW3
MS%[DS:)#^0;?/G/'TK;),41!_9SDT8."Y:B"M^(ESLJR0\<(G06$R?BN<@?4
MR:.C?_AT&=AX>-D-LCWW+)U^>O*0FW->?7CY>O;XF .BX?_^]T]G/[SZ</;A
MU<\O9V<_OIBYGW_\H+]X\>K]\Q_>O/_IW<OWL[-OW_ST8?;Z[-T_7GZ8O7OU
M_A^W&?23D^/3!V*E8^:K=^23O,N;:VO&#\Q 2TFP=D_>[[O$[]QV0X@*CW#M
M/,=\O:':EQB$T!$>N$(T\-#NVUZ+.-4-X$ZN"(KL=5^6Q%V116WI_HIJ82KT
MB$D4AUJ4'/D4#X9 Z],&U>T0\.%- K1"7 ;J=D)^)=SRIS*G=WE/W>V&JPO7
M5V9]MDF^Q6I!06$K=Q*:1H;;+)"-+CJRF/XK(]<4"*>'UFG .GH#^QH\$^)D
M$4$N_*4!-P2/C'A;<,_(Q:(Z.;K&W!?=@BC%#UML:7[X+##8OS 7@3[&7?<G
M&'@;*&S<@ECD+)ZA]^P +#3O;:]LKB?BV\0;B3D$!4[5^ZK,%L^V"[?7FV&-
MM$E7F3038D77EQZ9%X8&(;_TIV',&U 0Y^X< SHJ6Z6$EZ*UDT0+B9U,@Y&B
MW^)YZ*OG_'[ARRPVIIBP/((:GM<I9'H#=<#L1<#]F%@K(*Z\&S'6247?<KM*
M%WQ%E:>1!4&AUEB2B\27E)#'G9Z/B(_"G<J;*O?>P,@:YH)X6%QA:66K%>6_
MJFMH3/JOLF]90^X(LXM42.QL!V.B2&,!UK2!R<\-\2K_E#$C$HUCT\U_E<3A
M;OLQ'*G=#LE($>KD\=W6GC_S0/V.%LG/6!VOF?MY'^/A#Q&'Q!BB>#N^!_L]
MZ-55Z8[%BWP3<<QXZI?2(*[)J+_]X;T0S\ 11H+$/(>[I45W[V1XB</OKM$P
M;L!*0^CAB6)%JNF90&H36 ^8*$T,\S5T-C>R""=/^DH;#VUMRTG[7$_:F_J+
M3XX?T-K^19J_I8RQ'#I6L1<%P'!%:;W:W97J F3*EOW$P$U(8BE215%JX*HM
M*>=9N_/S;$$D(N[2Q3;TJ?/9M(S]'NMB#'P@6'%K>PVDA?A(-NI/+%S$G]HN
MX,&Y?)$5R%*]KSIW 5[B\*;)5W6366$79/W/E+-?3,> U Z"#^.9IWJT4EX<
MK;GIM4N>F"+UF8N)H1UQ(@?C=I$MS]G-"5X=M781 &CO^HR>R]Q&"[<_:]'J
M[XV'T!@H74-_!I+9RZZNW$>^)=?.+9NW%=Q0)L$H4^>'E;,7.OQ<CHN>Y9P<
MZ)KJ7>0Y5V76$M)WHOEH:LV%9Q6WWWU0]O&Q.TUX^A6J'CB2FNS:.W)1P+LR
M)L[RZR53.\^NI$_Q,Z+S(AN.?57GY_+PU*Q;V%JT[$.@>E*)/I,>DZ7&I!XG
MF<))E4X Z(L3)(L*HTT4C?:7>N_12:LD2S_.J!G(#>^B%RKJUS6,NY+<&SY&
MA4U/M[&/!X()]*X+&KG8O7$A#Q<R"?M \3HO'[E05IZG'&M$H^S-B[O$!8CX
MG(_=-,RQB>'U'_>L()P ='$6G!:YUX@INB_Y+?+^;I\Y?/+@,X=/)C.'S]_\
M^.'=&^<]4MKP[;LWSU^^H$3A'A5J\)8OH[.9,ML%^Q6HX%3"4_"6 #=+HC[8
MQ_U-Z$<<A<OP>@O[>AO_>NJ \$E#Y01.Q65EXRF-\Q+9*HR9E(&5V%AN8 I[
M"" :Q='2EG=GRCJ/\.NAU=D'#F<+H&=.GCU^@GHAX/94?10QH!H_X+G=Z>7^
MV71K.LC_)7&X#US([U-^?#J5M*!)-BP'^9'\]?W+YU\T7(CD!<Y$^O7:9P4)
MSMQ!N3:\OWL<B^Z)%:P"0<;:%U&L1P$1Y(L\6[GW=F, >_J&JO!9#7SV\Y=O
M^-[\H5!;B3[TW1L>(4+".'>&#"UE9 DKCU<NH,Z<<[<-0<W@8(>9"XMB5R_Y
MGQ+1\N5!>N]A/,L?*;WWH*SWJU+,L/+:&!P:F8^;6/1@?(*.F@04-_EZ60DR
MSCEM5ZP"XCX+[!\;/$TE$#]8J:VYLZJ$RE3:5"7-1P+/4+<^62R5_<2# )2'
M6,-=UB,_KG\\'%3KK'5!@X=(B;!H&+>;O&5LI6=E1@<+1X9,C1_..6=I*5YT
MI]JOW?)<0Q<S,9R7:]JC>59FJ[QE%"[97TH%$N=)U310B+G^R53#AMX%W  N
M;F^V39NM.5^G7RJ:B@XC3BCFS!##Y/*:XZ 17PMH.9V[8);K#?G'K,@OJFK)
MQ2N( 627 M3A'$,-#"6=[VXM]":.GD>>#D!.0$7Y$=*%.[8ND4]P8P7.::+^
M(^XG/OP)FQ' E'+O$'A]([RM: OT;TI5S'D&]*8[#Y=N7NC$<[])A=/#!JK^
M6K[?:9E1EX?D.C>%]&Y3<DAK7_1)L\#H?DAWYN"0.IY]&V[%Y!LT0&X-H/84
M4OVI/K),E]N'+M@)Q-M2.<WJFBIV+L:MTVZ)NU7.H:A]-6'.LA04X^Y;9>5;
MY4-/P_:@!9G6-;-.MD+6A[P<BTT87M8%33]']DB%_S?W9+J]QTB1Q/B03>>^
M=)E[3(I/]X&BA:J$-OVVPQU[^88]+O*J>K_@Q!G9/J5>2=MD^ ;P$?D5DAO:
MZ-E?8DC<.^>%LA-Z\C@].GGZE^ROP2<]>;JTO[JQ'_U7Z3Y P@3 [0FXO,I_
M!.-M-GU!6/.;Y0(IH_]@XKSGP2H ]5$R1 D;%&8F>-?O5.ID[V(]AH3YI#GH
M:<E &Y/(A4T9@(4= )MD4ZT71A(OD#5;VJR_]D=/$F$*XH2S]6[+:IX.AI@.
M;;^ZMGP&;1D_T/M"\GD/O&-A3@45UQ1;_Y1QSU?3<<_GI+>^^K<[CY9NA.O_
MX\=UW :])9_LU:OCV1MDZE^%/,)=YS.?_1'IS,>/'GPZ\V0RG?G#R^_/?N \
MYLL7KW[\?N\2F>;T_X&!3&/KZF$[C&]4=%+[[Q,0T]22RP-.@2H';O,LBI1X
MQ1?L49(K3TG.9/9Z\8*0"<O9)3%ZN%"TFKUU7UNGBZQKB7[6A0*ORL4Q/+#_
M.I[]5]5DFXO9/_(U2RYSM_]H*?P%D=)2!]ESDM?TT.27:4.G4_@SH2JRLFRV
MQ65:YJF+?%,P=G7-V$UW)@'9+72';.JUVXKTJNE<3.D.R>Q<X_@KJ:R;\W/E
M7I7K\B[N*#*NH)CX(V0"X:.:%D**,I5M'F_Y_,W/KUX<G3Q3_T&H@DSBD/[B
MAKI(^X7U5;8$L:^ALZ07$-9#S%F^<CYSEGVDJ#!D97UU<IFN4WK/B@+0B[18
M^2BA:[D$)4NAY/Y.ZF3E\*[1;D OPAU\?>O;.L-4E]FV$7R[>V8*N]^(_@-Q
M\@39CP6F/MT 5(<>B+++BMDOU#F:KAOFQJC9N:9!#^^(*XIJF^?J>%T?A^\J
M/48$Y#%+.UY&C+N0@*;B!=/T%XR[Y?MLTTK'P\GH;7G@N'AL]AI!@'BO);.S
M<EF['?[_9:6[D7].9LJ1S/QO?- 7_M_^\NL*B\F-J%MH%#N'L?2="!./0(OE
M1^<CXK6?*O6[&XSOLGD-/JV3+Q4U&685M4@L(BHOU"Q8(*A/"B,3:;8MM]$O
MPZ/K AH\N:HNTEU4+OT&7Y,;\@]2RR!([*]N#2\R>73WPFOT9ZUSHSXFG# L
MYA13I@[%(.FQW&OE-WLJZ!M6$B$JL8:]J+?BSW2,![/;0@;8G117F=&,E-F3
MO>=LV*F_PEN=^L8]T"7GX<C&Y*NM#H,_#N2U0(A*_!]7,RE]4=2PW;<DBB?X
M.7UTW9EHBO=F-WZ;71!ZF0Y$'#C4CE<<W_EIAW?PP'(MIM%3YG7&.(U=IYM;
M\+5F#?G;<I+(@D<?>A-+[H%LB,_%92_;)IJ<UWL0O<=PH2]47TA1I9*3);P
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MK A.YQ/>DH8[<V8M4PZ264-0*)Z+!:MU^K:QQ,-P2 BBJNOJ*H/L$4.:49,
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M)HU\/'M=U1G1<R:X2+BQ=@'*U&AB"!RW$%:2-_4[(ZS9'LH2.K]9AA1,V*G
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MP;9IL[7\F:L=[FF;-;938V7)Y?%8@G55=*P3P!0!\6R9AY^>G" 5YH'CH?<
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M=TJ(DTYE2)<9'4W.C</!4/_$#[^164ZQ0-TU7Y)A<(9S._O)N1=G[)[_B]W
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MY8V@O"JZ=1:J7UH(VH6I23QT;;CIG6]1.<MV+BTN3(HH_/5 );@-6;:Q7("
M>]P+9[V$W0#.9M!WD5KBYQ*,[%<[8_#8#62+8"\T^%692?KINE70M3E0BS2R
MC9P12'R.+[L>1JP%:Y;6^^([\S$N]^("&9TVP2TQ?%V3-[.+>3<ES%A./8*T
MB+TUV?1E3HMOWGG#1@GN475=CS6<S%KPN1IA 7M#L*M-P@O$F1H0%QG:7 !%
MBW1#%F0Z"_6G1%X\W@_DQ3T-3UY>9DW+*/58.+R'M8#P(=788OXF@/YRJE.K
MR4161#*U;LV_CO9KY0:W!,Z^HS418+)Y9@')V&T13I3<$K=MX4-M^KLT?$OQ
M=>XW+GA9-QYK']U(F>+D2\+$2\^_S3-(KORS2^&:R'O8L6E:]5O$I[J6E8I^
MK1<T&58N\R:SQAD(WT. SZURCSXL,RIUND<FKRAEM'V1AQY>1NQ1%89Z"FE^
M5BP@1& ^=MB7?:^7 07[=Y2QUR-5S9X*FF1[P\H*E<BF-_NC%QA"TV_@H21]
M-Q:R1\MQQRHL$ZD:T_HNZ=XI0^<E[SMQA@VP.[4G>E7D;)%V)3GD(:;42/77
MK-H0,N1?%*+V^P,(0D2=+ #L%#F7T7_^_G]>]8]R:I'9%&FSSI<[JLL3O1*O
MRMGIH]-'"5^YK%I>Y5U(XFS#\X9,KI[NG+W5)@'_%/2$K)=.:6'R.RD]Y0D)
MM.4SMEGNG$RI^.BB]<#C@*% >IUQY4NN,%%G2D 46$VH:8_$2D$JQ (8^"/&
MP,=/8^J=Q[._*Y2GW5V9&4D.D=82I;6UN]4\]OCK@PO1KA_&-P1&36Z4<(%4
M6.!\DZ4M5XQ?/'35V:^[ 2N;55:;J8R_3A"5HXOJBNOX,:*_%_89],O0OZ=A
MMQAH^)6$=\#GZVS3L3[K?94+8<]FL]!E<!_V= ^/ $%H4!<+0V4\:3Z2>'7'
MY3N) T,EK4]YHB)C$?RH\J<&$$M(9TTV/?&-!1YBX5QCG=-*^B^?A[?1--6"
MF;%PQ%"$I-"Y$9(6WWQ8+@F>0A0Q[ M)^A9]0$O(#=.#)3XBYXR3!SA2[5]#
MGS:*)8R]X )5%C'0"(2%R>$%G%5L]]*-B/IDBJ+O"41YV49[%@<2BE:?4'TO
M4]5N+VK@>:D4811=#=&'3*FZK-$5Q6U-A%>8UV)+),ACSNG0N=34D& T GDQ
M;9,2'P$VB@AAI(U'L"629^V[[;TQZ<NL]YRE9DS%D=N[2"8;;P,D]:2/VB>E
M078 Q[-[T[;(].59:GW@SWTQ<)1;&60C=DG)1F4'=+[ +"+2Z;]/]"J,?=:V
MFA67.NBPZ:LR6C7&513=Q#J-'@KG<^6^AJ^_$77&(,Z8# 4>^]_68HDFZZLX
M@9'S5JZK=4[]3N(VP?B-CJD9H'1Y(2ZWJ145Z54C679?31.NSYV=>&,8/5RC
M-NCB8CO=1=M$O?4$;71AG%LIV@J,M]8N+AIZ 5 8'B\JW9B(0=&+;.RYET81
MBT/07V)?(>AY-XFAJ*S&_)3>QDIFM /=$KIP]@K%E*85.4Y=;$AS@^XK[#[;
MSSD]1A[?R*=GOAH)@S3XD:8^R=X))L)$W+;=<YCR!7(BY4A'0B*WU9S=PUD3
M=E_:3CJ@ $F&=1,9&WC\RVPM9B,V35@'F+2B:J):[V?JYCR89/]+Z4^.7E,K
M^B-;)^%@"CB-EH($9,@%]=)/C=LF/A,D[V&B6X<I!H.-F9:\,?6IUM0Z>;A\
MWTCPC2*16RQXF8@O&B4@1BS+V850["6_E*^F^/?H&*'%:Y//M-TI ^#^<^2?
M5H@?H/G<Q*V;X/ZC(? \JC9EQH\\(/8;T[>(6^(%R""<AZ:55E^"QBMZD5#Y
MI^'4YE%*X2T^IN><Y7)S@%991' M5=W/<;BM*SX0V1F9?<RRC:^3>TN*:B.?
M8:%U%N,DE<.<7+"U."]1AD,GV&?*5+^[47PC/P$Z7T*KL(PHRN=<RM8R;["G
MKTHSXHE)O)BCCJ\O' 18(;@\04KH$[9LH$^:TK)=%=G" 'WERJ&%1[^G@WT\
M>WNQ;5Q,GM*Q(U$!C],%@@9ZIHU;!XLZGQL$#PSH:G6$Z^ !>\UH>"(_YG8_
M$?0 _(^,"M1QI7'01_'/N[BH!/4.\>^6.I'7G#Y89OXE!U\CRP(ZS#*,_Z_=
M\IP3UK!SR\IOSW@R*P(L^_,&1?* B^*"=EX+Q /^^Y [/!H7XV#QL&FOK>YV
MSU<!$ #//]DD0D@L36XG/ 5W?0=86%X[)YQ\4BH&-1>T2-JZ:R^HN8K!DBT!
M5JC3@5G\_*+G597;1*;SD-UI3-8E8"OZRPB3.UQ*_::..!3 #$8'+@^E"7/2
M.C(<0J\65 &0*4?(FB],3!2Q&8XO.H-M6&DOAG'SM17GO*KZI8H-9>O8JZ O
MNO@DF449<9]?3@?+?.MI>6RZM"LI7U6&:@/+P0?XIT(38Z(%&D/GS93*FB^I
M1J3DW"B29650#Q-[F$M+7PWGTZ[8 S<8;497Z601;''D14QK9/]8PQKR#]_&
MU4JXX[%0/9\!]*\X#+'/Y!&78JCAT]N@*)HDF81DJ@HJ.)1X8LVZF\Y*C^;U
MQW%N<:?HQ!@>I,?O3K4:X-!?4O8H?LC:%H:'>')<S%&0I>+?':2D[VX.V$)P
M0H/,94W=Q*E);AP&_\X&7SC QX*7PZC?^:BC!C#>KKQC]/^4V)HG>X"M.>R%
M6^P%%W]2QI/3NZ!)U(J3Z0ICK3TJI4D:(&2#)>;*"U4N.-BMNSZJ^\Y\@#?'
M2EM(,5$9,':BK=/[#4WL8;[NZIS)D)FGH@^B?A])5YZD1JJV*IYD,DM<^KEQ
MV75OD]BC#>ZAC 3V9-_5YGD=ZAWECYVM$'N8[WYE&D]]^\3V\S4S=W>(*&EO
M1K#'(F\N@G:\Q-!EYP:<. _I#Z2,F\>ZY+&TR,JW"0DODB$M,@E>)0$X]LW,
M#"U==@2!AOXN5\;#=1@!78J2<X1_TK=69AW4GL*?TZ5S/@CHS;H]DJ+B])2@
MMM$J;9N#I7)IEVO_Q=;(S+,DL*9!TG;L*B$+EPJQ37LQOBMLUW'_=FE@EB94
M@\PGMSC"U-!AG,XKWG RYO;6DS1J"CZ5;!Q=L9=D'^GFNQ$!F>'ZZ)-H7=/T
M6ZU'>Q,]#6@HR_B.-(;]$E/0O#I2+HDL+#;S5.ED]U',^L:5QGY5V_E*XR)+
M&&#$U8$6+"K*3EA"HK;GKVP##9PTYTY\)65.T 0R>ZDOW5NL0>#JNL%M:7EA
M8-.@<)4)!*_LK]?^,J77'+293=VTMZZE>N^!7DW6S@G6&;T )UKU*ERTQ],R
M^&&=A12LB G>?D<<S][3W?1"NN?"9L/BV*%VH<O%LE/3CK52ID@"-]RM:[K>
MP.:.6VE%8N(^9$1XNLK>J\MTY3&"WI?)C1/"OF)BZVS,^R&BB:$TN6_>B&*)
M/)/&FWI#ZK<OJ++Q(J/2K[164CZY'#3KFHXPPA!3$5 _HBV(,YPGV?G6.RU!
M8T8Z0'?==.3TL@CK&.W2E5,D?.3G+\.EI3S=PU,H'W;M08A,>J&=]'VHXL1S
M]QM(PIIB+ ^^A-I1]LE]KB$MP>WM'*^O[K.=[H8KQ[)>*,ST\<FCK_ #@RFU
M!DJ">6._K#,M9U%1DEK!85S33>YVX-K]U.0&&-=0R;85G-]G+C>L<6&'OP;_
M&I%@N[.%K)F*3+A;_?S]_]!K/AI_H[^__?GHY,NCOYU\?616%2F!SI;;AF#]
M>4J@3*D_3R_Q)=)S374\>S?N!%##$/D($8U??XD.Z;->=LYWSKA:KALGPZI5
M#L!".<V;-1EMD;QUJWT3D(6-7>YNBGX"30;=T4["F5;9%'\2;ICR1J'281EM
M'1=",36)? )XSB4//4::ZE4@:F(^+(Z)2JWE>IH !H:")RQ;!2S<\&VP.#.O
M#W[ZZ%'R"#1?;JOFRVZ*,IK[?L>NIR3DO<N-S(<O<'K.#0,08W8'4_M6:#5C
MH#U+%5K9:*0"Q0_JN'3N@C 7]?_Q<_[5Z(M-[:.,JU,\C#4W/(0V=+?PZ .7
MP!]R5;A-/W%;'7=_H=>VH5@A<XYE2O@[ N:@EZ0K0WV3:0F">-F5<USZ[B8#
M!ZUT:7KIW!V/AQQQQ,T:-^NG45;90KCYE#]4Q[416C!9N4N_[V75NC?JX0ER
M2\R"J2.XQ-2HD@8$"N(,W4'$S\B=55Z[V8[<-;VW+OZ TLCY+D)(:\ZL7OT\
MTQ(CG8OC1]9()& WL4'U<"G!,JKXYK$@N\'NJ2^7RQO@E\$A9)8M*)5LLY2$
M5=T#91L@0M7X1NB16P+S[^]@/3,V_^:^V1T=JJ)O+#FK*WV8W4?HKIX1.HT$
M_VK=_#XN.BSKX)89ZAC#7]IJF^M8KV#8?D=F8YK5)$AOQ!&EH(\8M]-S]8PA
M[:EN&!0<E$,](4L/!..!29ZV*6Z3J/2].4IK=KO;,BC-V*@(I7?73&XBX;H#
M/%GS0'K!R<T^3:';C^,(GE#TNG',I9QM61)C%BRI/(JZX,ML[98#(H8=X2,
M^V*YH93"ZC_',V1745RS!-P^HQ3<*+450ST(A>=$3$O6;.N;6#*CFC;P^.DY
MN"/V$1/'67.-C)V?H7E=I4MU#JY=QB&8*:I NTC+JH"+,<84)H$U[FT. G?@
M-I8?RGE%0<)*>7XL&"IO3 2%QIL=>DCVD DMJQD8@QA7R'Z2@7E-.G&&IGAH
MH"96L8B%&6A7VD9_U^5L.PG<IUOE+H[07+K7,6&9Z(P@S4EOSDX!6P__RTWM
M_)]\0[VH59$!+TL!<D>#20O!V6=D=J7A-4J-^)ULAL L^. @FV-<+Q#\:[IR
MY$OH&>TO+UZBC+^<RC=[[/''M N2DI L6NA7HJQ1>/$-DM]N2F-]+E[A'^%3
MKM-?>1EX0A*T5XB#O4B).6KJ?"J%]AQ4 UG)_I-M!5!R]RAOCS0X_V6E\49)
M#JAWP3A(*;?!C55;,+Q050_2V#T+X]RJ(E-C=6W(BNAN\J"8*!7U_;]=?M*?
M$M'Q= \0'0^K#O?!17'@M%[/BNP\;PJ-!E/%[Y\^.OE*F*ZYLA.T+NFG0/GA
MHS*O>\EQ'%MO<P;V#!YW%,Q S"UG(EH9.*9?N%OG8KJ?/OH/LAJG3_]#^DGP
M6$*"0@EF%58,B>:PM4FR0+-+AG1-.HL&B<\^G#[QE,K]1(C9VO??G;4S<?P.
M"?YW0?[!_9/1YVX$/X"PX"T3%MS[>]R*4@X]<[3:ZIA.&=02[N&*=%[5K*11
M!0835;)@+H:)#VF;B% _*TU%T'7D@"37')M;RQ?Y1CP)Y5K1%=]O8XMSS>Y3
MJ]S3]"#Q0ZY95N]CN_HOGI:D1=;*16I5,IKEQ2?D[S%QV:(Z,IU6.B-N>!,U
M&MER%HGM2M:BKHE,-72K1:K&$8 HX4Q:TJ,ZU6I>O_$5*DCL'UM9DUZ_:J_$
M#$\T;5I#U1+&1!@TA0K-KT+<3/6.K"YO<EWW\4UU>]D;X>@^BD^B='/>5Y39
M"4=AU54^)H '\%I.1@<5'!:(IH<;#]+/Q#E#_!?A3OQ!5+[W<2^\6D7Z.)+'
MJ?P9%(\!>2B+"^D:41X+5@T/*\*S4C96%3$>4(",PH+-3<<SLQDG$S0TMF/,
M2 ,#;G+![/_SHEI\S)81I\8O(;\0F+NWW#TDK9N;="N/[X;9Q;.4-='?P9&O
MMFE!3,WZ.V;J'GFOL#<&%IS^[LUW: UGT5;_8L/AL#JZKQ"/.4^XR7&:,#VY
MG2;89V%MEIX\]B#RA=M:BTX;R@G6XJ:QY.>*U&:#98H^8]KJ.?[QI6_JVJJ$
MA-I:BL!/T9@X.^1/A.>#,OL=PZE815[P('7$ID4?F=B?4067YIG,62+R6CZK
M@()7(ID")4R2Q#^;B(%TCB464\)*V$[3E#S>ZFOXE+S:$[*@W(>SCQ"Y7[@P
M4?=.1U3%IW:!Z=,<YZR(&"G*[+P2B":B8%^T[UW>GJ/HQG4SXR%UDJ8 AM=Z
M/N;F#;)*:$<7]O()S63NY%91>CDS?>__!BG(O!3$PB ):,;(V 5#VD*\%,7V
MB$M",&#G:2G63EO4)8<3%- EVPR&)N#MH($A/RPX[YG3C8**&P]'[^KO$?';
MWP544EZ:Y%L/T,<\!X5D#U=UJBD<61>8V<@.-,K)5&Y-MRZE92&X*(@<$CSY
M1.57+C)0HH1B)N1KK)]A%PGI-0M>'EES<U,W=<+0Q/6XO'&VKQ$TD**3O"'M
M/2^=]]R,*G.NW=+2!MUN=Q7R<$]*FRW<F0H9.DOU4I95QY*F$YM&VS)1/-M^
MT?BO>/+0,3,K"#7Y5H]31S%+Y%=IY9C;\#N4).ESXE:!UDU\Q\#LYKET-2[=
M1W_G1=ZX]_&<8VRGP:(_S]HK:B[O FDP%$&$=6+,'P*/*&@12?%+Z(#6*3HI
MK:<::M8LD>-\$L(4=YRW(\+AK7XMT/Y;;LS@:EBS^D&8.*,W<G9B7I&NB4KB
MJ+>;$4"SZ=8:1\2KXY9TWQ9I+RQN+-#.2R?87JUAV?';/Y3;F4!4RFX]IPE9
M28@$.V+)1P.IB&>UA"U ^,'))TJ=MZE(M\>BN.(M[./^<@Z"!!$H^=3Y99;(
MJA\&F_QW=-5;;ICQT>!T6^K+7Y\S!P!X*'NE3 ?AG/C"=.RL"CJ_Z$2)%6$#
M,:!@<D/<V&W<$\D&&0LDA#BI_DC%2\IF9E[*5#U_NI?U<;R1T24CAR;5*2;>
MDIXIO*E@03R3*JK$T!5ECWZ5U: QX.P2CELQ<?XKK*/&VJUP/199(9JFYLG=
ML4"NA6"$Y*O<O> 64E"-L!-X-91Y44G$_3,%FD3J>W5FU2F=B[HW/0H/*_T!
MI)+B!G09^+AD+\W ,)UTHZ'R4"ZWL'Y\=?;J13)[<?;N[9E?["^J%S[68ZR>
MX4.1.[(?P^E/:KK<;KAJ;$-SZ\BSC^_S[7FCTMW> L#M*OURIULM=5\C6\T(
MC"8;>ZL@]R5:G_E<Z34ZQ3$V691""<Z#S^N&^RI2K3(J7MJPP_?1,#I@6<LJ
M)GCDDJ+/?)7AJHB\Q]Z" 9675:M0E]XS*WO/MD=RY7Q7)JIQID%\(/YH@$S*
MEX(,H2):QIXCY;XL\FF&&<VS3>TLU.FCTQ.O6>FIL>6:;@7-#$4VQ>O@HI$5
MI..@)6AMM6FR<ZM&_NK'']_\?/;A)0/^CF=[N$N_GYADKVK#Z_MSUVY8!XQD
M<)]8*RSI)A/<+V)GHP_%)\N-'@GDJS[)&=W1VX.><4[=YHO?I:)(SE.8 S,H
M> F#3W+?Y&]@7](U)$YN5%".?YDO.?F0Q>HCG7,"BNI*PN>FY:([.];.(I#_
M[R$UE."KSSV_J":5&'.@)4C5:$F;BYG6SH<D[6.(<+6C["N4F0M&<B7'I#\E
M;&#EJ!H=T[T\U#7VBS.J0P&=/!NFMV,(L-'5B[\F9;N8B#6M:]05?"<1^U1D
M.)>=JBP YJ0J?,X6ITMZ!UXEXP]^*XK8F]1HII.7?TJ4QY<'E,?GNXCC2_9Z
MQ_'YNS<J5 5QD'55LG"A%AE99H/R$&ZMI@%,7![U2&@B/TD]3%Q>-O8(98V_
MW&<WAK,L=&A6CCC0+<V>>3[+L/?]\[=-Q+#G=3JATC%.FZZ]D/V,36XZ:DV^
MQ^C?\L4:W':F[.NC'(/DB')3+M>^J<#D@7XLB$2YK$ICUM# :S@";S+TTS#F
M:\CH>.C@OON7IJ4A=.Z!%K1_1SD;E[0 *48C01=<45>+=BEHCZ<M6?2N)7AJ
M-K><A]O&N&O?T;"/09_4DD? )KQAU?=+C.C0M:>5+:#8F@]/L"E-TCUZGJ,Y
M?$5B!@^B3+'8PVZU5-O,=( N*-7>^F!)D_KN>2'4#H)4#H),?02E"E'##.";
MW38'4![UL'F!9'I!JEES>A=/[-N.8!M'!K@/"N$20![W%O9D7A-IYN&NRFW4
MVS2V!:4W.62H@56-4L6^HA_W6'N9&(]SIE*R=T?=NL%;WMXOLKGR76X2PX>W
MK"O+$8DDLGQ.S.,'F3N4ZS<++TT66P]<3/RI<>I_Y!C&2/XCAY& X97;"C'M
M?<R:68VJ (PI,(K)XDI:!G43GP(, =B@8'X'*@+]MNX0=0#FZ,LBJB$;]%>M
M$EW#.NP[F$A]9I%6&N:R4ZI_'SRQ7(RZ'*9$JT= *-('8 D/W/'L.=H@+TD/
MAREU*9NJA1=/SN'W:IQ#]C?GFA*48-QXW#AC\%"0F<_'JD"4.'LK,_+<S\B]
MO]GG!WZA;*'YLJ'$>!,5R[VN= 3M#+P^8]\G-2^?K:CJ7?B 0:PY)ND< #GC
M.]DO[D!W]7FB#0_(OXAK2Y5'^5#Y:# Y/GWG9T'PE*S-8\"<MY8NGEG"J-@&
M&DT80_DT[_)B*1HA\4/UX:4<O=1:,F:C7SI?@M5! 4/HK23J:AEQD0:KR"3U
MFB _C "(#E=RB&B]^&6LG@,A(2RU.]IG%7T>/"Q?G +*N;=*!6*EE_:#VU-&
M';M=S,D5T%:9IJ6!5=.6]&'U>Q97OZWDF!7P8<7'76=C=/+I?5N&Z<B,,. P
M ,&8-Z<2]R>S+ENO!Y1N.\\K#\6S8!E4W19UE[OCTPTX"3'48,R"V]GO;/46
MQZN>NL%G?P2.0>LUS,?36OT3W3>0A66M6#B53E1D95%=90;RALY#[JF++KN,
M6VX!(W4KYG(J 6RUJN"-#PL:_,;.BZYJU<.V+R9$9KY9<PAKD*]ZH@+4=8<V
M7J==%^K8N/M=$D*<3%$0=L-<=\HDDZQ8-X)2LQ\NWQ>:J2+J-AESA0:GQ?W[
M*I_??3$B+8$U/TV1J T5BXO<O3CWSGJSLR!Z@!1P-2Z>A?6-)>('3XEJO!:&
M6B6!+NSAT?LA=LH5#7G+DS.>D.FN_(CQQ\0^H_0T7,=#L3:(.(9)&[3XPXT'
M5&H4W,>//B!;H5" *D#G&N[GZSF9+7MTC;PP\G'VD-Q6,43,%%#TCZ$Z2CA"
M.D<,9)E&8^/.-7GD>%[XF%UFY% R)*VW@E6V3AYX8-NCP80Z4T#;B(Z;>?B#
M<,.=,=M.J&'+3(*UAWXA4SI"]WE@B;ZSN>%#@&M:Y(JXXR#/5"J4X_U5!)RN
MRL-LW.EL4*>(.W!U#H(&$%L[21MRVA5.P#*@HFE;"0'E89;N;);@ 85$[96"
M%LB39VZB/-8"="?_T4!.RYP]G,3V *#0M8H!>/3-'(+U\^H3?C[Y)MSR,,=W
M-,?"B\:'%FT]VV.FO%&'379W$T!*KR'/T;1Q3]MAX._T#!KM'Q3&Y;$>DB],
M5C*$0-JO>1"%NFN7H9L7^8(=@HUF@PG"WJJ2JV&/UTXH!M\5SM,XM_1#PFM.
M_>I=0PS?.0O5@P[<5U$ >JRK*_KUNB);V*T]DM>=74=ZF;4[\P33[\/$OIYF
MGU.]^>:P6OZ84$RR%A8#8 +\A4T2&&8.DRWX!G\[3-<=;F[*8K@_J"7VE'!@
M^6)4 ?V:Z ):Q?^D\R;SZ:+AA![8K6+<XU<'W./GHZ1N#1X,VM9NZ?:2U9 E
M$$-34'T"OG=(^<VW00VZ2687&7&"+\#>B82C37C&Y62?V#;&+FK*B_.J(\6S
M1:5D>&O19P*;4-$G,L; 2/6&2NGN>LS?.96@'295M4O'<^U/)V4M:J^G36_:
M8@+E';I: BW OE5$?LGZ30Z!J591>\P9M)A.<6^J(D>?"-+WJ '2%*_22[>0
M%3TTP1\H8+"<FYE9]QEI<U,A_F(TG;U_!9.W>M:,*P!1AK!H,N9C#XG^J!X;
M+VM4?V4FA&RBMJI$C';JLPUK-QA$ZMF_%8IQ6MFRI4)0?CP[6RPJ\"(40M1K
M7)YAO?&SC5A4/+=%!L.@84K4OITFE$>H2!ZJ/M8W?HW7J7G5\@_Y$D#D2S(B
M;/! :U%K\VPE? V#T3;B7&1RW36X V]R7\#B[L2H6<Z,:,0;%(3=%%U4Q5(D
MV*?NDXP]K%T_;,T0DL2B\JB>SXG@(**"#2%G@(SOXWY['W51!;.&_N9&>!IX
MGTS.H9OSMFLT6SQ>/48GV"0ZTE0'E]DB;SRCBK>1B"U#F>W"S0<3U ;J&MK8
M#*% \H8#40!$;"I-'(+"K:3E-F@1")%O1&'L7YF)!XALUC-=<BW;F(UX2.H^
M,[=Z&'I*!*1E+&//Q'=)3&\WRGQA6>\RAD,-(5J*FDR4H3HH*AWY?GNL>N_D
MKW+T5/M2V194.\<S;YD9TE'D'\GHTFG8].0-A5@\'A&JQ0X& 7:XGJ8Q4 .M
MSDBT-?<0#G#F>QSHF!CA#19TD.>,5@2$%#"7H5&3.=<OL5>8V,9[J<>S7RY
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MK</>4?B<[5ENN5O)M$I>LP$%">WN&VO<&X, ]*\'.9 7W6\X,E &L9%(H?9
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M'TD1>.],U"_"5X"P@A&@THZ+@**I-A?$%+R0DV5TB'5H*<86M*Q=7=B/TJW
M:Q0M/@@*E@EQ6K1<A&4U,#%F8(\2 @\!WW@4*N4+G$>UK&J&GP@A!RF&5')
M"U=>*^_$$BF-L%"L& @$.H;P1G_I1R>]OV,?-EFWK,KM6IPS_]>_>J5;MRB=
M'>%U)Z-!I")UG?(VCP(O5<9BGC"HA*#WEABGT]P'=/Z!5>N6JVQB.6#LIEZ+
M)+YLN(C >XDVB;R\3!LX HNJ]CQHRXQW!I,S*?4%@^IK"FA8/,S;+6\DKUD=
M@"C9?9=HXPOUXJ#O/E&X*V)"R8']*ULJ5Y8 J,P5W>.$3_&L-=.>L2'J_'M:
M+Z]2B Q6JY;_Q4<H91^%F2"SB2!-'S'YEJ4UU?Z2%"!N)A#&/VG<.8=DV.Z4
M[P2%!'AZK(+L/)RUAR73"W2E%ED+QLP!#\E[J[\NRZP%)8::*.F_<4;_R+0H
M=]*U3,WW7D,F3)6U>@MW0BZ/YB@NTKT[AO4O /AK>O@R+W]5(H+6Q+$[F;*U
M]@T)CXK_8UAE.S<E=O12FXRD=::'QV,.E"]T72106T3<3?I#*=J%W&58B5-(
M6V U/ -=:+4FPCK-O\2+W[W@JMWYK.CB4RYWSW#/*T;TH4!AUVSH[^<0?$H7
M'X&*+*Y2NSAPWAS)WZUE(K-6K>G#?]437R&59GGP2/3/.=(2U=8G<V@E2MF$
M]P4_B.#L)L=:N?D\RRU8;3RUA47.*R>3G+LC%N):60*K!(Y4F ;4RH-C)XJ[
MP_HG-;%8;=E0V@_/()<$>39)OJEM65SO&O=*M'^+FSC!GLQ)/6\A\61E QS^
MSF4T(8Z:>DZU<",#O2V<Q2N2&" 5+4BPZT/=M!<(BJ=L/,NLO,SK2G-N7B(I
MVIHRR,F %0NA&R',?1_&0F6$FEA8K!;Y"A7#$W>7) Y:=I9]/T\DAF6J1'(H
M!'(0P%N9#%>T2JHFB[\^JFL0L6(T-Q>L>TA>,5S9@!'6O)YB%;>!<\X-,_H7
M0P)1)%S@G0TEC#PJ&="M"++EK[Y_[N^'6+1QMX;YBQ_/M%TUP0^V]Y?]LN7K
ML[FM10ZSV9X]2\D[I_6EQ>,P>6TM%F(65:22$=;,%3V<<-7E>3OQE]DZ!W_J
MV)R3@\9J(\C>CS,;[FH8$W?.6= "R26;%74?]"2 \)Y46R@2C8S3#Y/W"OW2
M)N4D+X@SI T3C5AD0YX!\?V$GF?#6FO\?R)9CILAYM!$X,/=61OJ:G:?+-U9
M1'AM.7KE[$=*T#UML_;]S<,.40%#!@I2MC^,586FCWQ-II++"VZ54<VY5P#H
M20#I7$ZM"^QJMH;3^SH?L-RQ_%8A12NW.G)@-G$J=\P#M0"?]]1]8XKF W+]
M[H!J8PWLX\7L [+L#T*614YD<- .XW]GXZ^LI8S[Z5.%&G:&PQS<V1SPF:;
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M/2L,4MJNJ5\'=1C *)5EVQ$)PZV G,J%+6%]F4QJZ0.2.-"8<#XY1T[8@6*
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MYQ0)[YYGX2ZWAM \"NF_XWAL=<H^ONYNIBDDW3WADR"Z:V;V]NRMT0GJO,F
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MS47HVUTWM35D.:]EQ3H.]&!.O>876<(C*8%SKY7VK\KWF&N+L>QY%=?^XSP
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M\ 1RIBFD<<ESZ$C@"A*,*;6*Y6HB)=*Q]0S1TH9?2XT,#\%E,MR=SVX]3BL
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MF!@I+HT6?2T55TRN5FT7O>SBDP-$(S7::,:X[V,^OZ=+[/DR-%$-C5Q*Y8P
M#US&P3: D&S:@H^18M1P!%[0V*UJDRGH56AT+:N;M:CST3#^&C)L^L1X0ER$
MAY:XEMJJQ$FIP2SA_U2$JFVL>1\46B2443"?([YBD_X2Q"&&\H1Q#[EXA.U
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MPO[^V&MIWEFMKO9?__3HQ$RIAA&FA/'P7>L![IB=7HE^J4RO@9Z)LQ@&T#Q
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M-)-#1V:\Q=51[^]A7LV##;C$BRW&2G!8X^ >!7CIZ8O+)CDG,'?R([<$.+S
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M=PSI=M%HO\V6N&DI.1+">I53!L2 H'QV$+VK9S(QV\R\D*J_1749T9!NC#^
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M&@3VWN.<!(GYYS =TY)G+U(Z/SM?)#61DSA,P_D@E"*R=1%T9&3A"ZW!E9A
MD_F'FBOABFA"H_NQ/6M&]:RZ!A' :XB6K1LF9U^F^+GV/_V*RSC4Z\FL1I_>
MEH_ASX&,I7!/2 ECJ!=E%GSM(20#9\Y&J;EKP[0]@3YKVK54:H-ZRG7)#8(M
MW$JFP J)H"(MW+-$(K!(_Q\*"TP>R.5[UDSJJ)H&P<;[?%HZK>E<EI+.:*;J
M57ZV$)G+((SSD?G$<_N:C8W(3M3_[U4A&SRTSAUJ+\N:/M;79<"Y*9:X2YY
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MEXVU+P0A$"6!L^#$HEF!+."-,X"Q>-K)15:-"H"V0GKRVTD_PF[ @O<X0_K
M.M_G)7%X-%ET4UZA'&1N0])(=E8L]$IX7\ 9M,!E8-E[5TINTRW@3EB'9T-/
MZEO;-/J2?0-B_(IC6O.H-KS)9R3@NM[Y\"M>P,,8- I5:./B6(?^&(@F)*!7
MI,02:I^3-I=G]P [%7+T*?\&N49KBQZDG#*3]5*'RUB+91F$$B089;SE3,N4
M&W6OO WE5"C03<8MJ_^NKO<'7"*/6AD(6//^<\$ZZHG<<R6BE:*XR!JK_0K,
MZ9@)#Q1P@Q?]S60\N8GJ8C[/!<5E5E*0B0Q(YC*HD@D@<P6TL$9R41, VE0
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M*=VLF]8C:7G3Y43K(,QCM[R93><UR)C/T_SM] -.OPX3+OHX>*F2,_7>-K%
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M:X-IKDF_/NPB3' >1K^%>?VE;P.KDV<L,PA(T)55B62""$QJ%23S=+3['7;
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M[^H$5%>OC'@JX&/1Y-AXZ42SICSWHCL&J0ZAZYT-E0<JJD58:KM0E@<JSW5
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M6VOPL '2*Z!OPAE>=!_; 6[;[/7] !^MR7T; NQ.M-ZT=]AKG8VPDPV>YR*
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MHW8^G'U>#$M;WO,:ZX4RV4-QD;8\I02X(CVDK)&.4.W(<VO"AWNAG08S^M7
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M% 6XVFA=DF==?(G.Z%O'Q,8N.[L^[]@1I8=J9])8M#UW4GIQ_NE\-A>,^VM
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M:40EF14Y6652<-*101BLCH7^S-F@5R3]-7*XBKB)D%@)(4(QM+>K(,AD$D&
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MX.A0/ZU78>,Z_WH_'@^->IS9W%G8JP%'BX%>LU?CY>)NS2->_/ E'9>7)OS
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M !]KB)P'#X%'!G5V$'IRF*)KG"=P_-X*Q]?XSOT8]E%7@_J:NVO!A;$Z<.%
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MEPX9% ,EY>2%ZI-,^ 2R!'HQO8U,6X^^DUS859/LE=>>[),*)Y,)+2V9T)J
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M7$RHM5(^2GH=9+V1\!KI>,T^Q_EHY$').UOKQ6H\/RR55F1U&'SV$-6MXSP
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M#H85AA?F XP<C#J, 8P%C .,.XP?3 1,$DP63 E,+4P[S"#,%,PJS ',%2P
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M.$DRCZ,/.@ZV8&NL-14^)1[5WU,D/I@.?:-E^$>X#%X'_'!\;<4IH>?!5=O
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MUHLNFO^]W*PMMU^@=*Y6!XZI*+\VGA)KBJMOYCV!QNS*J[-B.-*@UF',F%N
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M&#I\*-3<W (*=7GQ_=;2RXY);CDY9]V3W'%/M+)8\,H=PF-X8/Y0E+D-@NL
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M\V8-'1+-SR*B8,ABQYG_JEA$*#)B&ODB-//2QDUJ-_=04=A*HPD\#;*,=VE
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MV86V'(V:7$D5T]UM>W3FDTFO#FEO25.E\3&Z<J>_(N6F*T880DD#1=P KCL
M+Q *ZDP#A9E["?FM<D4N^'&;6HM182O+NKFY@:E4>:<(19](:ZI\1&1F]D8A
M0V,,8RK:;-4GP1IA#)5/=0E=/_M2%;>'G]A>_;T^?_G #G_DI9[S?MV3]?G8
M%T9\PL_,!3S"8B('&*LK^>NZJ#*%F;I,"RS.#R4(N/=V#X?/FB9A<@4CSP1@
MHSS"ZF.M5U8!C=:ZR:5RRI%(#HZ/'C:BAK+-9$D+JR,W594IUM,D*^I9AY#Z
M,A#[Y7Q2NQ,933:PTAL##( MQ1<Z>-4S41"2$C?@$IRGZCQM(@#)RWM93!A&
M@2/6MU)7,)%YF"S%+F2'GBTP50N/Z!Y+B&[W\16-&1DL[&+>=/'ZP_C=<:*V
MAH(3\["1F]\'M1<16$G55LZT[];3CW)NUMBIKEY>+RZS/K]YD7*8WH-^'-8@
M$5,=I-T_Q7N,R?:GMMM0-C=.3M1]^RW&@D(EZ6DE'[>KSKHVF=-)3>.(+O"S
M*IX;W^F?J<>B\NG627"G)\8LRZ:=S,B.*"%#XW\+\,@W;\F")>S=&;&_*TR2
M],S!?FAK^8IRO@\$"DKM'$-(SVE_+# G<HRY"-%+H4RQR;0N9&MD&^*#]VDF
M_9E2$YB3;ZT)O?W9N1(@?*N5=UW&Z8GVR\"\J$ X!!X\_O 76&AKQ [/UH&V
MJ"O!1)6G?@-NU2H6YWK]G-P+_#SDQ^HT"A)26-A$/A@*Q5^<2^<@8*H#3%(C
M,R_$_%)UY'.0\A^%:]7]4EL6H0_W6%K1-K>4&_=8/PH!W_!C+/RS/W#=6=R9
MFQKF35ST_OB#'(#M(>9G4W;X80'<[S6PE0$@\/)KSZ7$+"F1F)[E=':E\ 8Q
M%U_>I" D*?" X^/Y,TL85\DT:<OZ7..8:N;5Y0[&,9"O[5KZ^WIA'-V?]IW#
MZW?(X6XOA9L2=29IFFJ]H&OAQ17M3FR.K36)S/.-L(.@RT:"&^O5 H;OO9/L
M%$LY.?[Q=K$]M#[1E%?:9$^#X-'RV]?:PK\)--2&FT(B=MVV=ZS^N+Y<H_GZ
M8_GI6?A"5@S25"R[]@AUC[7I**_-/TYW)D6P<X5P/[#I%;>VN7NUW#X/G9E>
M%KJT+S ;S_:>BJ>@HV'@ZH]0I<B+JZ'(CHP=6*;W*WHK_024."E$T]J!VV>/
MJ!0_VL-L(\+)RF']XS']&M1$AQI[ATC9"96FGA4H]U@NU=_ALHW,W]R>>=WX
M$KO7Z%,KS 0FJ]UC"6^WM7<^X4JT&4,L<L(1V/9O7-V3IB94_C+70:,><<^%
MF)83KQ+TKFLRYJW<KFS_*\P+Q7,O62$Z:5"5Q921C$.J".WCF;UC4X:ES<_%
M=A:KX/B<2V%J/ICZEC,IMO)*O2%:,[$\NNMC-5,S&BE$+D]&1A85\94=!<Y[
M1CGQ*-D@(9RMD)^7Y*/:U;2O@^&,I&[AK_G5UZ,;KAC+SB==OL^8/]WJ./YZ
MI3P!@<@R,6@1A^!D&)EE^FL"-PD6K8+?GJIS3UZDXP_9^ZNI3'E6B0QRT(*X
M_+9;"\LESP9*H"N&DH5T?*T+6TW;C0^"/(2[E=F];Y0B4'V[28:G<K7\N65E
M"NR]SM/<^6Z&+"G^(\K+AHM"%E03)^=!/"<\J]O< )U[K/1CFTL2GJI[K.'K
MH<:JVLPA1?L[<,<RXXMF8:S3@XL""5E'__<@X-_S2^CF3B@DEP*<E_S%=K8#
MEI<-P:T+-FA+EH3'F79'UE*57]RFXB]8^0 G&U^,=ZOX$N^QCHPWH]*WM/*6
MXJ$\PTZ=(:8!(%N3@,R6>ZS3<SS+-M;Q]!*U[4QN#1\ES2<JE',[ET>V.C;"
M9^B:I>H2WVZJY!_-[?=8)S:)Q@'!Y%9'&\#7SJ5>SJ+'Q\"#P^6JUF0EBZ6>
MM7T$)  X>RD"E*X\]FLQQ$MAJ#6CU"T4=537[*7FQ<N&:/ ^=^DF%\X<I$_H
M>[AD_6%DR>&*[&XK*#CO2O17_9KJE8^@.FNL(<E)=6E\09?H)SUH.O2T7]36
M8.VL/G/U!%/LQ'@4E\_>^L/>:6PSI6F_<"IH]?;SIK@3O,W%RX^7&^_=]K5/
M5+XWF#GA9C>L6\YBQ#*=*Q5<4BU-4IBZ.[>;A,X/=ZO4 WVUC0MH8_.5HI1]
MO&+C92[D.\[X4^E$/,J!/$=4!QSA[8B@Z" 9Z>2\&>*)K.V2 *KKQU91?S]W
M VF]*%Q\SOT*P1M7//1EJ]%Q(MV8U.U&,R6E3X'0/8+(]'O?!W]^94Q<]Q-O
M)%>NRONC.0*UM3%6WQ)'J;S8DKE3&E;:K=$(-1=PZB5OOA.>TW";SY 7^ZTJ
M[RY*O1I9?GB/U:UJ*HU'LS&WN2$B#Y()&IQCY[JD%F-OX4J!C=F,@)4\1/ 1
M3F:9$Q<#;UNU-58;EEC:7/'%G\:6QY117R;"B-<B\;6YU0W5OAE:NR7),C*P
M;N,O2);5@:6;,]OM@KK29CXOQ#VFX<S!29\FPWW?M[X."(38ODZ::8I/CJ;3
M0T9L/U'MY]#E%5\0-T[;V;?8CI$XX(Y=W-5S;8C$R^!KC0B/$$P#V()$=I7Y
M+-GHP,2":(/8&W$85^4OYX=&8Z7R#-6RCRGD]XI-=.@I.>SD(]GV"O;39N04
M;,G=QSCLX?6NR\3ZA79-2U KJ^A*RJ=,T 4_E?1F+M<EC9+%LOY2/L:X&@W&
MC %K#'?@!I2ZPPB5G:N%B?!*0^ZZ$4\-F%SB282BJ=_WN/1T/9?A[6.8Y$7:
MPEDOJ_<-4"<DN4Y4WTN+,X:??]?0YTCW439A(40N=F?Q94'-![H&X\MGG\V^
M+QB0GU1H[M*O%SI:\,/34X&:% ^U[ 6(&,)4O/:'2'9_T6G7:!/N!%D_3N;&
MR5DXEHR\YII8H&GKVGYV1PQ_'0K<48U1W8-+RKF)C+-:F[1WZL7)VZ>\NRW[
M,U>#,UB7: RD;%D3XTZJX[6N'!D-Z2]XN\ =XUU,5?--!8D*T=5NYI[*2A$^
M+OK6NW+P=-QPAG/&;2I7DNA$\JYBL+G]H]/Y9A+(<-F[/\F4):9IU>>##GFK
M!:$KEU>-JY$M7LHTQ7"BU1&YO1"?*!4D^;GGCFY,<9K,I>F5PI<'&QO"+W'=
M6&ROYTQ*V7X1NJ5DQ5@1(XK9)5,LT_46[9A:FR?H#)7D1(62E)H6X4RM3<L%
M*FUOMV#B3;G2-AXDL)\II)YZ%E66IP 6+5HGU!#IYLV1SX#W"(<*#2(D$J)R
MF1L1_:@Y/\4NK\@+3PA43Q&S*;]DY-_8)LJ9/0=@9X7X;A1+@M\!#E8'.<,_
MK$C(]F/]XF18ATM67VO8G/>[U-HOH@7]F67 =$5U?&U!@V+^K(PAO:1>N ,;
M(GA0V<<LF*^4ZTP)NL%S.(NQ-6.[MYIAOUO56\;31N#VA\0Y:D9%KZ688;%3
MN QQJ>2/]@R%;+F_?.[*E7W@%Q^RA^G.]&?-*3H*!$>46]E[B#<:G;QRZ8]U
M2:D\YHF.;6FVD!L:L%DW-,68C]OH%9,[*=WHK7-XHN7;A7&4AQSJ9,IZG;>$
MIOU'LZY!*LBO^_GU<*7AP.M?@!7H<]"V 0-^AU46!3Z[11:KK>53AM=I>"_S
ME(+[WG.R_/PD8_JHA*>NTW=BU8U\] 5,N,?U?.-;7"8"7/]#81<@\_(3IJJ(
MD<2!C_](5CL[V&CWJ5P:Y=FZWSDD1/O<]G/7 LPLN$N61K4DNUK@(E:6TY(4
MO>G(KY0(266#+]E?1O6?J')OSBC\]$7X5EGJ5B,EZT3&!8LP7 ^_?6:JBQF<
M2$\4 <1D4W]IWY-1Y9_Y02LO17Q$^ "O\R2D[TJH;@5(/LXA,S T+<*C,U1G
M6=6>75]'+[0>72;SC$2_8FWZ<F>@0K!R=^GC\70]6^EPF=W",C9@?4/;OCXF
M0S:3:XG[0R$QNJ=#$E3?M)SJ 0*'G' $#4W7W#SJ&=G[6\;^4<8WQ\80$$@S
M6-P_^DJ78K_O0&,0#2@HK:?J3>8P4HUQ^-/NGIB^U:+(&33:@AA-.@$_98^:
MJ?;58J\CC:HPD/[ZBS_?601%1/J:A9[%\A69[:M7S@9ABX/_^ /%?^P]3KH/
M7GKL,TV53WOLZNPVO4S9!2Y7:']+BDE76YLST+ N:MZFD'>)K5L)%.F>^S&K
MQ^&:;12N+K!PXEJ]Z/44?59PU8K^AJKG\&Q(*:1#$Y(>.EO\SQP>Q X'7'MS
M-R/-5M)QY7C=P>.*OF"-MWVKSW7<DD>98_P)NO'Z8P8$*UR?7/;K./"Z:4P;
MX-;@+&O JQO#X4(UQ>8]HTX;:7QQG\:.:;.;WH8',EA<L>V^\,U4<'.V>$;T
M,N'!R*0VYI_Y>D5,^W.* VT%4;<= ^H3:Y@>'"N*->4N8K%T$A/4DQZ->:(A
MJX<]-*HR6O!B&<CS>A6B1[0U2H6>X;(:-D<^"-4#8_;P3FW6^!SHY4RK=ECD
M4WC+SN.W%@G2\O@R=^I?YN?'HHNOQ8&2+WY-4-H:KK>0\U]DI5N'E$=NF[+-
M\Q$S@XY]/IOBD3"YGJGFNS]F&U"ZSO\_'LOQCZJI:3NX-O;W@LK'G1OH#ZO3
MNS>SR@"OE1(VJR#]2BHWI#:B_N-TS0NTDL1$'^>&ZL"S&:_ML^0+6]U5T!R=
M;45<<BR$8F M\9LH_Z78K^E/V89(F*HSBW8"SH7KA9EZ29!%'XX^/\+)+V'&
M*$2XO'X2!I>XTSHS.VH[N2S A&3_E!R9D.G[_>OA+]Y><OF'KQFXNO]Y989U
MR&UXS[FT9\,L[F>3PP9'?\FRT9Y<H>XU14XE R0LHQZ45?-6% 1R4.#GC7G$
M$[JS:#H0D)6GZG2+]$H,*>2JV7NJN4MF%:*ZKKA6,#H./2931JV!CL7N\L<;
MJ>H?.A9$OON ]0$+)Q3+,/2#7 LAH3/Y!\/,?Q1P^+'YORR(Y/S7V(XJC ')
M4O#18VC>I]4;COAWFHG_Z9\&[J_31:G0.5^%G)?0J":%+_U;\W_!<<2I@K9=
ME/VPMTFVRJ7I43Q@&*?0O;W#0PV-Z<G?.YW[$B/S[+OSJ.5MTK>J%^.-3,B7
M&13\91AN<0+Y60TNWUQ^*F6B.K?;Z[?3I7I/%LM0=9;N3PIB#*%N_*3 BLK@
M1;^./J7<S4SX+)N%JPCG;INK*V\;]$%33M]\V#Q.Q-=XC@3G9K<@;%K.!Y_7
M2IND@>WN,#BVXVCMU],>(5Q'LZ3^ ;78RE5(C/92<G Z1\()(X<0-(Z1U=ZS
M$MOE0NK+%1QQ>U.]*,I9O)O)&0N/ZQV^Q.,W;7/VP:M0JEJH=].0*%'?UU*T
M5C\X,&?^EW>1S,K)^?=.+#"96BCIYP8&5['%K3:VRKT!R^2("WIA?YH?F 3(
M0OSHVT=RJIOP8=?HHXT:DA5?=E,GJS&>]C_GS:X?T-CX1=C7 U"_4_TU=H]E
M:, /"7+%=3X(3D#2R.)2ML'<I'*GM'#VP!&<6R_V8(=24MDP_GBU)VZ)S9Q.
M#FG>T_N.!%8TD$5R+(' E/[?#?13+&;=2DFC<*_  M'CN;'>I>?M)>'LEM4$
M4C3>])$RO ]+_1X@Q6%9AQ:-+-B;TD0<T4VR^@T7T"'ADR/Z;@F%=-[U$5K?
M1JO4;&71)W3E:D+=Y^3HV4<6D.KZ2TE7?]]GRC][2P]EU#;?";+#\^C?2DL^
M<D>9%EE8D7]R<]'^$HE?L_@B<>+J#?CCI)$53NF;ZR$)*;YBLHPK7S-COJZ7
M:O9NI"M[ADF&1;?4H;L-(F::__6I[QI@GG_8^C6E!7%&1P;N5Y?D_SV\OF-=
MKBH!.1W6V^-___IXY(;:&0&1IJZ/5CO<-X6CM?C'OU8&R6Q86[&AIDX$6KI2
MY[/-5+FVLB#O9_=0+]C9I-]=N QBB[\<SGK-OMHI.02N*^IS,'*I6[C'HB%C
M&H\$AO S4_DA?C17*?(P\HM*"-1[Q8"+"W<38$)12(UBOA85B)6[-RR-BM$D
MDK4?5;;0MQ3:/Q!NE,X0[HTP7^JE\H/?C@U;?=OA0LR;4M1^IN4WV*[2^U[V
M[AU70L5C2UP6%K=RD%1T0S$9Z^NLG$B6R(LD?B)"%FPS2PXQ4,P^38\Q%5E3
MFZ921-T@M5&0MHKE&=<-]#/'IF6<8['FU@#^AJC6[?.(S>/G3X%;-C1=BU12
MM=4>HWNJ"JQAN&H93JO5R6T_!!T;]=,R,T_;0EDY033MAQ (Y$'\O\Q?"4B;
MN+CXWZ/1D#:1A$Y.&?1FSU]01HB+\T..AP#7K[RZ[4>Q=WR#S-J1MD7!?>2U
M:A:;TQ>*%*$*/QLM!D\$Z0&KY689G/U4=P!8%[$G4[C .T=Q>#MZ<C$XM+:L
M(=P^#4ABD0FS3XI2T0.1,I;ZMK5IR.])-$?K3;NJ/E\SQ7_$9%K1>'+FA^:J
M.FL3I0V2![#TP=VB:G58[(Y\?(^2.RML/BN=5'Y,2/PRL$13@01R<0B66J0X
MC<[;PA85#IY_7.,\M6MWIY;4$\"4&\\<2[X8:?*XA8 P?XS_%)4SXER-CIOP
M_>*R?\<T^+^)/9H.L,7U _? ,=V;QU'ZQ3I&!T(7UXAE2&K0@[6/Y&S_5X+=
M?\^56UBN6.M1.T76%+2(\3KTJTP@\_L?=O^ A.;4_*58\MY8THUU_QLKCNSS
M"?]W.QH0,96C9.KRF/]\3MEJ'?L]_?N/;559VB9^&]#TX XMU^E4#S,[R>FE
M[J:.4[SP45HI]_D>BA_<,Q%S)CNSQ0VFY7SW?H%GH=>./DD1$+/Z#PYJF?),
MU#*-SR6)W4K(*DYQ1/'YTXS0S)[,G)STM7\.E;2/=EYJ%@)J7Z7I*57]X9(#
MP RO<N2#'LVC\J,U/X:U@GNK'G4E?>6UZI1_"W"OT_H.^UR ;;5$(*K!JERB
M0 >@:N#1#T>*>Q91.,"K+7G3*%83:'K6D_A>/;1=A<,#='4[_J@?_3?JWC(H
M[N?;$X8(@4 @@>"6X GN#@D:/$!P"S:X#<$M"0[#X(-#<(? X)H@,P.#!->!
M #/HX.[[^]^]NWMOU;[8>NK9K;KOOEW576WGG/[V.9_^',8,IU216N.EK0D_
MZD6A7./%GK&_0&_ ]@5-7Y+[V"I05^7U5$+15GZ"=WCA:4 QJYKV#ZG_>T_^
M'["W_\=L2D\QMZ<6SS-&H?.Z!Q@]C4?_CF7Y3ZF-*J0J>WUT;WD7/,YD>2\&
M,MY]T/D_Z(V0*L#"NV(B2S0?>+6@/3!%SG? GSX;9;SNQB])]K%?ES)D,QF!
MTAW$KNC_T'(T9PZ#J _S*3UF">.'/5 "V/3@/!A1L%'\%14KV$K6+B@HV7Y0
M1KDTO##BLKL8O=*WD-!  89,,ZN]8[_,8^9#KJ!/^1^ZP_R,F/ W,UI]?2M.
MS?EC3$3F/[3WUS[/[YTWW8OD@@+%RW_7F!ED(/?-Q,Z]_F2FI"UEU30WR^P0
MUFQ74D2R-F=QKQF',!H)'T2&9,W+M*?GS#,WN):B7*Q3I^?KEZMLCH"2\N8"
MLCI]:X7,IU)*(LQ 7_OQAQX@LZOUA.)&<?KH=<$KXX?OO?A,.DC@8_*F64M+
M9^(FVX$%)/M'GFY_:E@;C=FG3=WFB9U"#\T%W-X44:Z@O4/8P0*NM$M](8;2
MY=U[P]AO-Q->929(_<,O$>D<M>OSA@,K \8\%O3A=JZ/YX<*SEP)VYO+9B#L
M@ #^9& RCW\:J5/*%I4 1*FX'".&2A0714K2YIS-";>#WM3F8J.+%E\3<)2R
MUGT2B]0?F/3"=Y (S#ZJYS[:;_?9&]C#FB(K]."9/L->859KC'Y"*HQ>E)]]
MZ[S>N$;4%K FM=)Y"P7S3*KOQI6^.E7.RV2V6]W]]8K+1"Q:M[(_WR=S2,O8
MR@=N^U,RO%C06%)7S\DW$"57_=FDN*2665)-_U0%7R._4^F/HFO1+>_*Z$N;
M50U$MV,O/@Z^$A/./X)"U,/$A&)B8N[%CQ44)!04%'1?PES5M/D:_3(,9"Y9
MV;HR/T52]^P(S+0G)F>VVDJUL[5=@CTT&[NFY(2GGA7B0R(C?-7(U'Y%Y*DS
M2US2=.G$++,-P)V<&[V6\^IC47)/A6N].68N.Z\9\^;-7-+^&&?[;Q3(L]*N
MDM [3S/\_C![TZ_DP\-4SY\^P*@M;>(^5V&C_+#]>@&WVP^5/R.6XU5JMNX?
M^=?6H\B6/G#I:5]BESRE. D7B=!G@4\Y?;<Z)WI5%T AK1?S"YV4/QM,>@N6
M]BCPY2T<#-?;2ZI:3B!*W2EI)[O1M*._$5^]=#S1G.CO'?%].H;;I3QO@=EL
M^< WKYK-53B''ZT>CIH/L6EKF=LCOX,-BQ^ W[%9$>#V94',% YV0'4MI1]R
MC-QK_%[4;LZ#!<VQEZOC3?QF%8@85TF7 :MLYC-F]H\W"BN!8*JIRM$>3[#4
M>G6%AYOO4>>BQ>[DF<YRL*]8\UFFR8,F.U\^B6MURU/OC!;*GW-MH8Y%O;TJ
MM$>'L^4 &;._K:J_U/0QP+._4*(ZRO2:T4\G>YF[_6S3COOI9AK.H7*.USU\
MHU*=PB=+Q75C1)27R7/QC"D>8(A*^!I5B7]S])55W8Q[?G!PZ6Y 5WV).8L[
M]SQ>(8"KM30.<+:R>(\#^[@T*.# NCYYB]11JYE0D4.XN8@QQI9/NW,.5A=;
MJ5*3U[:ZHKS-+MG/?ER=G)NL@YJ.HF+?B3ZDN+;UMH7MK2]M--B>XW,MUIRY
M^Y$2-_?;;1.HQ'0-HS'/#5<Y/0APM52=^ A@1T*AB@,_C;AXE#F+&Q_+%Z;W
MFD%! [J)MQ4S%:H'0T2F@E3BA"E *!_RQ:-0;#)WU#8TZ)(^_E9I6'IG8HH^
MT^B-9>.BWEJP^"9-NH:B*-UU^JL>L^32S>"G3&=*NK3TV$MXGMPP)#%1N@Y:
M.@Q"7QEDU)O&KM"ELY)8U(2KL(ZRO<\5/9"8=&=PX;^[[ 4?.764:R!#8.4R
M;NOB^]UOE4C.];V;N8L6?_9@-@X:S#MR:SBY@&0-AAV]XOUA0]=7>+PT;J&U
M:<_Z35[;( NB8E%$*GG#'7-.A4-Z1'&\+XVRTWUYI._VV3=N9;6GVB5_7-M"
M,+O7#AV8F3QC>[&*U2-;*9#^T:P=:>RS+)Y2!_:$E?!-M)TW,& JUR\G!AMD
MPMZ@A7L;YT-#+SWH.6FP\E3 XM:8*V13Q,(A\Q[G:P=PO\)84[VI*>V-];%,
MI\2"SL75 DE:QL&'-/+QH((SWA>MQNS:F]D+DMJ35 -;C0DO_ [/)?PW;=^>
M1A,:PU#X/.\G6:E5"!_ELRAYI'E!:]]66&&,%!M1GW*\)\1,3-?&/]:3ZH2E
MC0BHU&9R>4WV(#1;^U7)0/EB7>.@9%#!G89(1BVGCKUS4]QDQBU)V<J!($T
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M6E\:8,E"-8]]T:K$IGE?,7.)^$^83?BV!NW3D7S*PVQ7V#YA-!D4<2N'T_'
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M01DWOXNA2;HFV$LMN?T&4&F[*T'2/;0L[K6PJY,Q/_W1DL\CT=*(?25)=,H
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M0QNU=__0]@=#W[S72N;Q"@OUZ*VSF/[Y/0P".4[M^F@0;W/76"+>QE,U2CO
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M3*B^FJXNDQZ^F$[%C1"4;H4I/KQ&)F>:6#3:?R]Y(\<"/3$RX0/JV'0(K[O
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MKS^BX=!.0.8WP<8:BW*,4;ZRAOR=*LW\IQX+,-9W;S'MAXHW%D;K17^NF'N
M].RE3+Q-LMDT>(KZ>U<[UZD0_8O2X;6&0])N'"Z+_86"%3@BW/76,:8G&=UJ
M(@\C?GF<#DT36NR]K>:U.QN1>AT6#D6V*6?Z;2C=)%7MV;!%/\WP4*YS!;0Q
M>7'%P:U?E:C3I>XNV?7V.'OBU=YPYV*64M-"$4^E2-($/&5P>'U0:V:Z1)_
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M_\:RA3?TMU<+\/GG%6L.4OY?KD3_9QS'OK3!<Z\?_G_[U7/B02\WQDAM_V-
M3>^;$.LZ"%3[C\?=4%W6GXW_I?B_NW9]6F,M;B-A]SJ"\U-^O K.%_&-)Q#
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MA5Q]:SQ](#B-#1%^@?:">VNIBK*LSD!<OFFRQ?VW55U3Y@X/J\G(D0)3@.O
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M2TAG(18+&VL5G( !MQE][-)>\W63Q[O[L:MG]<4M1"C=RBJ\@6FIK=*75<<
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MTV_OXN]PU,U.(0-V%$)%^[UCFKI?!^?(R"@L/H4I[RW,@UJ=O6$.^U,=65S
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M3GT+\'(AMN;@_8-Q([SJ %C:(0 % K1J?&L;@ U_,*P\5)AU]:E"%%^_3@0
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M[\BZL[AE)PQ=MUT,%,$" PK7\H"?M2-)3-RG7B?5V85UC!,<#]_Z[F1[&EJ
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M+C K.H7LMC-TP8+>8>AP&Z48@,SY6RY1%\'#JXP0E"0 :KV&BML3>762=?J
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M=,+Z=C)CS+*2CB[B2-.Z@6'#TW5UTL=[%WK2M#JU=YM@4;=VI6Q;SY*]O#;
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M7+2<WX(4T[$V)<K>.>+?F[P-PH;/["#B0]-^2!%V;E5EL\(M_.K$#N,!R]4
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M:V&"C+N?T21_KT8\QN$#=VE13WT$6JG-+%2O5!KDA&LQ4MAJ?TO#I,OG\H0
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M?,%_Z- &HK<*FO@F0+\\P^/_WC(L\AT+R^,[-1IKS\X/OMO@:L.$K4^[G7L
MT49*R-WX_=7"1$L$U$/T^K&&SKZBT0@<J=JTX1A5'^_LO06>TV:A%-R80@(!
MI^\:)GQ>TW48L\#R2AT/4+C#8_R_<58((QIVM,5E"F=Q:8- '"$69H26GP(,
M+Z= $-HF11M^P%M%G;$^^UL%E<\>ASQDVJJI.<VH9_H41(,?1>I"<KJ7-C1#
M)=)18 .$EKZ+P&\<W75;U7=&UE2K\+2,G##NJ(07(UXJU)K.;X;-=CM7!^[Q
MB[JT@@=:Z+@:V,ZG([:COXAZI25/)U[N[/[&Z6[88B@^?]?FV2ZVF5^0K(.,
MU((+:0)\A\-)#NRP)\Z'J1E;$$NXTH%#B.NW"^&Q:;M/IW%\)J(OIG.G&_47
MIC-75XR?K;9&X-9,/E6+BF+//1+JVQ71<GBVRWSB=9*&K5U8*67\RH3.D!>"
M>1?UIO!-V&>5;"JS>/-=OI-,'JE]OI2[^XC%EOI5E 8Q6E@C@;?\CA#RFU&;
MXOVO?7S29KVO5#'/KG:PPU$/#"W"VL$/7U,]U%UQ2+YY,X3DD!5<UX93OPX?
M6%V0H$N7(WQ8;F#8_]V7\=1A].=J.ARFXBI2I8DR,_?.3,UA8S[=8['7OY1.
M<7= 1[ #K9;S30=S#U7[2_T,3Q6Z;JEBKQ5]V"HN%?1@F>)Y'2?D@^9CPC11
MEGFA!XMLM7[*8Q?Y27[OVIIZ6V'8H+T$C+CEO%8W:/57LF[=@PU;BC9:Y1R6
MC?TV4<+^H+.#%IU:_<+\))G>!"N2XQ"HR--W=5/D#T*JC%GT*;_/H^Y7VCU(
M8JS]>51+Q]KZ/O6'KXW)P9'[9W,FJH5>!$$:RVG4+S=JR>"* [ZRBI]=O4T$
M9*$KTF=UW18C7 IZ*H(NG43AWD@NT+#^KIFW[T2YL_L[$2'DA-]P27,FS<?1
M.6!?[@0YZ9Y,W08"&ZOJ5CT;(&QG]'0;BXCEO<"^M:)C 2ULJPP<BGK7H_&
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MCLNL6-:TG4@+9:0P\@4/Q8LK\PJ7H&>P]9Z!,Y=US25-9_*H,%;83LENW@7
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M0?7 /3,S35Y'0+'G3/7<07M%N9_6-P>BC6LF]A.&8BJ>DA5R2LZ)0H* W*S
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MK+E"475QUU/DJW\1;3ACJF+@M)ML,->A[L$Z)#OY*@^3_MU;Q1^;/<.KJSS
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M@8;67?1[5^M2"_V=33M<I&.>,3Q=R>Q#I"3.6T0*BI0D"ULEPIG9>GD\4K2
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MJCJ1D:G&*=\\ _3YDL9G8TE]L;)@&F?'%.T1(319R>"^>VL2:<9 [RH9#VD
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M5&E6I$JL839N=)$CF6HPTUM>S:*D"(/-;8,Y;DG$2/B:;WZ:A*9]MVY%GK6
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M&$BU@<M-CP;^4M&7_SK#"/2C^'DU/M&^VC[VR%,&GALG2\NE'?XC_J]1;@"
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MQ\'6-SWW]5.7UQU3?GX1]V*;KB"-X"^3Z7XO>1]C: A:ZWGN+599JT>E6GQ
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M[PSTK5C<@@8H:GB;TJ9/MYG_Y=SU4IG&I?AKX\DLN/#&;TDU38)P<$0<?4F
M+#)#N[U7#W<DV_,$TN 1QAG@:M67Y0Q'=I:N9M?=H _+FZYFU4'B#&*;I@-&
M#^X'5H]_]AKV4T7<89@,+^] K^"W97]@"+3Q>C;Z#J,@N=#OU-G#*>CH=3.Q
M.),M_KSP\-Y^LUV16.V\JV(;S)*T,B;"O.954GVWGE?F(0/GB*?8%&VSCJ:_
M>K$CVGS<\=PEV7-0?<>+Y0XC^99M7,+E//H.@^M:)]<863>[?8=!7914M2<F
M+&ZR>(<AQ27IY+6?639_HUCIZO;Z(+[+:'B#"Q^'Z*4T"H!1ZU$[RI+@MO-#
M?.G,BO5G@.@Z#\HJ8RDZ#U+BM%_?A6XIB5S:_N0PV==W3[$@#S.XY)=.S1N\
M6 H!1O<GKIHY<4^#Z'G>MV*_F%SEK^2>_-BD1;G7O)4X$1:@G[ YB$!8Y!A:
MLDZ3M)TIL'ZT$9OIW>ZZYDO-6C_:3B@+NIYI!]=/[I6(QV7!<ZB6M=I@);I4
M=DTOCLS4@I7+(@\^87^.O'"D]J1(PHN?H[8 H[&RM"EWAA5<6<S[FMA2>0"R
MN'L]CW^?ZB_L#^B7M:[[&QUS.2FBSO:)OI/#[-UDY>1V6XCV,/VIE=2UFR@N
MM'?[E[IB>Y<<[=:/9O300:?"3 &1^5\DHX;X.J@%ELXA-TC&[5O-W<!Z%8'.
M_I)9>\:")YT*0H,$4=N]"@=I#OP["OH"X<:<M[O@RKB,F0G56@6)[VUL[7GV
MZ,/?RW#Y(N+<Z3QI-VIX ;*2<4\A=:*)#V,ZC7YZ@+87^!/XW&X:.Y2AS_:I
M&F2#/45ZGU6PQ/A)Z?,+GJ'?!Z5_CH>RJF+?<!^$A#/%)/JC)T>I3>.@V%5A
M 9E, :L*)U] 7 )C?KP!D_8@@7HX*,Z[L%5B;?:<P@[PZJQP?'$@%T1^+K4>
MS! XV-/1J]3A3N+'B7G \M(@^54J.0&TRXP Y8>I&R;/&*;>WU.VUGS54J8)
M=II50VXEH,7PT[/JR#<5+@)_KI<\N#!/ZGO0'FSP?C67/BXQB9KC!TM$_1!!
M'Y-#LK=@"[F[R;8]=>V$IQ#OI;N:^<J 60W1<DQ62TMX:/2XC%E+%Y.=6_ZJ
M;4-.6DLG;[?9%%8/%R[GRG7=RC X,_:EJ%+P=,^YQ_GK.!WMYA+&/'L2475;
MM]F6[>8(IVBCQ%CC$_\CKOA;O**.MB%I&6(R[O]9#63]>:BR-WX] 4[GH1*Y
M%?!_UV2;0=B+HS' *=XR')M#@283D"(%FUL_@A?44_%^B),WLV38[8*(&]]A
ME'^:03!W#^UOC SM[5W_Q3,M,>6&M)+PF 7.+.S/3I&*U-^88"6 IM)  48Y
M]K+:-LO3IGZDNJ#9'&BT]6+T,Y$C"2HL,F*<O_;IP6*.GU=MAVUYT:.T6AFS
MNJ-V+-P01C+3!)IUH?5[//XQ@9DFKM6JUAZ"<@ZO>ZON$[<ZQFL,_^""38^L
M94_SQ@*\YQBK*18JIH;DU(<]O0RZ5XJYBZH:(74Y9OS&5@Z\?$?1TT2C/%^/
M<%/H1LT9B"':/"Q IX C7PU!10BA6;<NSAZ*5C_Q7Q;5YD5V5%<E#0;>):>9
MD,A1PFBNK]]B4M,VC.<C1;5XG,9%SS<^R1O 2?2@(:'/Q[AX4NICFUSIO#PY
MC/L-:OWV4Q5&# 0YE< .N@D#2U$*FTD*%KSN#+PN_H+:]PX1^TR[\^68,VN;
M&VT$0O6<N<]9MB]43GA[@HK8^(Y6M?H4Q5;O W_R:N$V[3BFG?V-$;4%<&/B
M@JK%_FYE10CG&)O4-]-=.L*?I^S-!>\ [9]QRN\9?>[W</;Y[*$[)D#GS!;Q
MX> #_4]]EF9 K<;^V:1YY?+GU2GR&=FI>5F>[:16 _P(#R7OJ\R@MM?FM;3M
MG()<!D 6S.A"-9TU8XPP[C#:QZL1LD)K$=+WA3I2WF \^OW3"Y#62Y%)34WU
MZ_^G^#CN0\?$:<_Y]B@E D&[8MK_:&P9>V'Q]YDVN&KL6U7O6VS[=K,=K,&8
M _E3\\\/?E!T)7F',88+.LLN:;\/UT=]N\2XPVB6V++\OEGW4(;YZ\SXI]C4
M;2IYC/LCTM*Z=N7T] A'Z8.A(83C8>=LY(.K>W<8SOYC_7C3?R4YR&BE\4>'
MN[8-;;<CR)ATIZVXY-9NS9:6:T6<SH,4[IFN_V=,(7^_54M=QC]I=L0ZNR&\
MIK.18;;E\5ZS?PQVGWUS?<S?2D+JC#"2JCP9.IS>6!*49ME8NC(4I)1@?_3J
M[Y8<$N4#ATN3U^Y[-R87RQGJ0;G'39!MG_'EVE/_-3_0._+_W^E'_K<YN:S>
MWQ(.@#:+'\1/X;?X.NWJ9N2_87+%3HKB>SI/'F7HLC*CIO<9GE>OK6"77DM!
MJN;MTR"EYC!3/+"-JZ$QA;IH(@O/6=HU*F.+GQIXGQQT5(R(\-%' 9X(0G Z
MB$(*0P0H6!</Z?<HY#SK:D>CHEJ5W3]]4?BX(=]]K[*[9TVU"$5PQ7A2Y>U7
M1D>B(G+]V5DZE\U9]WZ<=5MOSN1YM>#!*NKCGCE*=Q',NISG2!\T#4BT9+77
MKL:O?>'2P_K\>;PGP--E=/!BZV],Z*M[)(L:7#4+G>SY?OS#7(E"MCLMW)ZM
MS9(;XXA"SKV.A-Z60'Z-<U6*X7=RSZM79;X6?YKK^N:&8-%8 :4%/_#"2:+A
M4:&XV)V&E;(1%6'2,J.E^X:8(N8L@M2$"O!C'LLEE_J<:YP'$<\#@V5V%@LO
ML22LR;&UF?RQ%)!%XMDFCH7@:'R/@>!7."M4&EL#@CB"Y':?I;CE'S!:L)"%
MI) 2/B<EY'GR!!OZEUJ @#\BG'Y]NOFG=S^^V)^\Z3I<AZ47 2.^61/9P:]*
MK?^VLE6X<-63=H>^N>OV-69+->2?G>WW)?]KT M6Y]1"4A0%E3]'0CTNNR-O
M9OCY@8K1\^DB=8:LGE"%FXX7;V1-N'#71W926FN@1B8(7#MSGNG7Y*[4J/&)
MN2ZKZ.GJ(>-I&'Y[=B<9 W&MY4!*+E90GC=1>BKS8=5^E%JF\K<?!BO(Q[QI
M"_JH*V7L1N60'_U'[?&J=QC"ZW3BV)V4UK^.=&.S[G\W/KHUT3)LQV@1C^+D
MG:DI6V;AY!0"Q>VJL,$!<;Y%\9#F.XQ^A]J%;?J\"W3O1)N30E_6W 5*'0;R
MY>Q7])A9.'PJ9CX/ASMIZLT1WKK?%!EI9)TG[[;?821 ]9U&#B]'FHM$K]T
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MMFI*"QV2UP(Y0<,V>=7&W6JC#W^EP'#&AG 9-61H 1&Q V1/^FBAGT-YL*$
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MB*DMK34[=Q='\7\RHFA;?#Q].7S1%[^$O^U#._?VM7W2-?-:)7P Y]6:M<P
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MTL*C-C>V^S='L&,S2*D2[5->$FYW^ +>\%^LJ Z+-TZU4/H""O'V'1M3)U)
MO_,3MUK#6=E7@K*Y3(DZTJZY7CM&YN:8KX.S,_;)&'[0IV2JOEJ_*M HVA;M
MX"I38W;R7"X3__;]\VEJX]39V;(;$NG)W!B$*:9(G=O)$Q'X77&\YL*&,&V
M=;6IFS\-=NL&4W!K;D6X_%(;>[6U@8 -=OO=WHKDYAY7R#C5N#0BIDYV9NYR
M/^]GA'[;JM+PO?,CI^+G^ #6B'5,^N;S(EF/>3*BB1VH-BS_.'WU>N$0CPL%
M=SH"E_$HC_ [3=Z84*/\HI1338]7DL$KO73!GD'N=9,-<;8/!#&S=,0^$*/,
M$->]H/-4&&_0K=?IZO@"SZK-J Z-G<VN9'K':?3V7V?Y OU/?] :F>R:2,6;
M?4>Z1$E_\*I^>=5*LB..Z;7VD^]\#PP0X=QP2*/8J?5D#U3]_,UIS.WQUI[R
MI?+THK/L;$((:%TD.4-XXIOX,S:YM^\C%$V=Q5\KG<@:'Y.W;!N<"80\^T@<
M\E%76B9=6MH@["W!>KI>1D9&6P8XS"0_BC?7CLWX<#,<%!E.N*BQ,]@0U,#!
M7K,J1=M.NG MT[^H,X0LNSN:^104%<>;>U5Q<C/#7Y_F$E;3>W@D1=>T>'DI
MNV[1W$SD&$;008D-+GGG)IH%Y']4;[>.-<S-5R0 KM8J=O9\W@VNJ8I9_#(T
MZ[NKW3"<CIRI;!0[9 %,#I@C^_F89T@]"AD=)Z$R76TG>C6<[S3GZG%X-+#D
M:+@ $*==K9SCJ2.'N"^GUTWNCJ<;I&D1^?VYG=JNL:(>D87/5%VDIM91,^/?
MR\J49@B[W_]RG57>!5&X[K:QG\Y1^ZCA&K?KO0(3)H 9M33R%QQ3=)CSC.PC
M81 ;YC/+AZM]IYDVM:_U*%TF,[,I@^#]%I^MR4M-2([_\.UR@-!U?F#<=)TY
M]SRR4%7U2[64:48N7+Y/+3><XP]:;^A6=.[J(;2LOW?KU<OV(?<L:PR<5L\\
M!O3HWC[[*RJ^JZ^=\W012R,*(6#$#WW=UP"!K:?1FX H^2T\]-B/#%@T\5CI
M7S>Y/G#2F^,1XEE[KBOKV(Q*G13'=\TS["<R;ROJ! 5%RDI5HA[DJ*)5P'<:
MA.<V-MII&C7>?0; )KN[XLP]V' !C2I__S5C^Q?7Y/(DHZO$G?!U2'0C2N^G
M5.W*77_SO5,1K\4@\0HT.JS#UL+L;;AHG+/&2!]7=&*;>LJ-=6:;M3.-5BIF
M0OKR0IV5MG-S2;W$['3KJCTW >DO6&Q1#4^]M<KT5#?+.J^3_&V@,=_;*9\7
M^3'-Q(Z6Q0GS14#'@9;!#<S7CZ"9<RZ\Q2(;<%R3,_5%51E'7&K1MM)5'MUO
M%01_60 ')LG5=?)^%.2!5G18W#]_\98S J0,^/9?_=Q8^>@*.%/3#"UPP(S]
MJ6&7_82M#>/U]_W@%5/+:-[GTD0FA>&S!V%\6*+% JZ/(M*G\Q2.W2M8B[R-
M378>UN5?>]Q&E5U)_$U6Z;VXG62_@?PB[+SK+(LI9(8:F-(I:XIR(@0R8C5]
MZ+@3]7"V$O7(![;BATM'!F_=:+C=J(/X&;RTXQ;Z0U)2MP[XI3QD;]+!=P:,
M3):Z[9JAFJ'J#@4ZNM#^0JS-H#<"%C,E.FQMRS4#2[/-@^6FCQIUW&"CJ6I<
MB+ [QEE0T%6SD44SM&^+ =0]^.LVM/(K(:5N?JG*F=\\$KM)['?S9M4-'W1N
M!ZG;^GQ#S,SM%^RUB7:;],K.'[2-]-LDU&%N45R&PU'44:?HU$!O=4.5@OE2
M&V^M?7+,$/HLL6+_M);$4J08>M&'[Y:[F+A&\1VX52P71@*L8^]<Z=F3PCV!
MEK?,96R)"_!A$O\4+8(YWE2Q!(/"UB%5SNC"//97)T=Z+;P&'O[G23O%&0\1
MO:*H^SMQ3^%CHOHYI^DBQIY894(KHVXR F'=L1^\H=ELB=%5&B-:ORRK+9 ?
M\8A\IZ<^UPA^+K8B%M$&OGIC0$C,,DSK]B031TL^.R^5:)/*VAF[*)\**&!]
M<D.1"A38+(EC%VDV(&*:BFKCTJEYYR+QS+7[V9NO_>\X>UC?]KXS'7G;3_3B
M*QKD!8@3!.#>4YE ]C=E+@+BM'ZW\^?XD"-V!LSMANT&47>+JR%\(0L/>5P9
MT4J+A.;G6L/*5YG;6:G:R6U-?)LB_G&!O$>WG_.<_%3MA9EXK5R3EDM[19-'
M>QXQI,137:<=H]?)\[ ZRZ<;#>'L+27O&?X*W8V#C?E1+]^_,BH^<WT=6 %H
MRITSAJ,3)W2K'61Z 1*Z]<T/2 7\8]J,4OFN"4&*MG3FSNR4%3D"Y^OZ<U^@
M(#YG[K/1$OKI.^;!EC=A_!ST!B3TSL-)DV.-LMW8XN-2!E3Z;PA=7LS[$EDD
M?8%&\ />;Z@5\ 9F3I^@M^"P-B.F6@B?.W^(^@1BB<VQ"1+/58F-S%A-LK'>
M3[ZH(?-V$/7QM%1Z/U90(Q3^ I9<&0Z.33NODH]R;R/>4,8<BW1HEX,4KWA-
MK1/[> 7^;C0GF/<"7X5.Y)"I'^@UB!+=Z94=O/QDH] _",HJP_'?"I/:GA'3
M<,4#-KXVG-\2=VS_X!_J%D7NU>C,XS0Y9?DES% ?2!K&\(K/FC$O/K*%0^30
ME1"80PXJI0:Y^9$? R/LL-6=9@M>GKK/N1-_!EQX.^=SZ'4.Q\?E@4<BLD/D
M1IJ!WKV_/0($E==S..TLJ&-U5^=3F3#NE&DQU[LD G5#%B),4CVW+;G]Q=95
M[%\OGKJPJU7 U.IX+X-\QEZ[1!?>WZ.6[DJFSS3[LPP*%73BZTA,W&X$^=(Z
M+27J&Q_T.-+,M^ZU5K%_+N9MQ*KH^IHOG(SI:'^J#?_-__#$V#67",4/'N"/
M8A>\W65%%FK*.2 )\DLHI-1V:@47\?Z@2;:'#VH.3B<TV]PN9VJJ8=T*B]<Y
M;R'_H#'/97ZN]=2[62-?1:"$@S@633IR>TVZ#&Z45*UJUFONR8RZM]@LV)+0
MH1%9%]O!F@1>0=D);X3? D"UPB(.E?< ,S4?4WOB=V+[Q._GDG!WRJ0&LG1&
M;^.<Y?;:[,0FCMCDQ#$XY!@%_SI_D1=6@5#\4;<%YC#6K'(9IUV?,5LGLO&&
M +MS*0T^LTL<H^@*<+ <[@^+YB=RW+\Z?UUTID<.+[H'^O-CO5\<D\=#J)#I
M7P/)!YN)W4B4Z :2 J,D>K?O#,6T;<%,##,^!HA\(X>%/V@17%XIO)N[$LY_
MT.A;9/TX8GQ>IJX.O;:L*K@9SMM&=B2P^H@K%4S=:4'Q4%9#(,[\:)6BX^_S
M*KJG77?-%[V;>SMA-?WZ76_>PIY2OFB>[QP"&H_)^-?WCI$U/6,_XRBZ3*41
MU*M>=TM'-G!O@G27&FIT @U2G0GJ$\-% D,'<P\82[3642ABMYWUK8WV*^,
M@L^YYU8"I8/^9 9J$XGLKRM *12.CE'.)B25(5>HSP9VJ)R17Q07U<<H-=N
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MPN.W[R'7)7R<5#,S+: "*#Y9WX%WC;UO&T0[/;). S"P/CH"@QA>O,C^^T;
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MJ1(IK#V6VYHSJ%)R[#*U[WW<?<V"IE/#B!I!U?B=@Q#J30RH.;.C'5?S;-N
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M/IW1O8+K<!?'6M&9P\OA7#T:)!LV!OF4>;Y+N5B=49-1Y&!,;4>$=;N0 G=
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M!^P&K=/1@U0]?T2@@1?QZ*G.K?67UL0Z%-K[1)7_H-'4 J!! =FY?]"LOCR
M&^BL$\!1J^TQ63MI7<0\<T,="G"PR6;+JQM0S'"&"FR;JR509<YB!S5M@[OF
M"#RZF1H%S5?EE/SETD[5H%H1_P<<Z&)@Z$$T2A@"JUK(N+59?T!","P(S?U.
M%Q:R"R"$'.]C:L<U>[:6:4]'BURYT9L?0^\46FRNQ1,'E*_R^S?*![T8?'.$
MLEBWV:"S9F7Z7&9N7H)(,E=T3A"T!=\' !O8SS^ NT\#O%3@/AELA6"@1H=?
M%?085N*F-W6E>^%QK<7K<;$@*>J%PJV+8N3O[G"PY/D^9D*:55OMYG*)_7GR
M?<X#?[Q1,R$<KG52S''HY\&^9.;JRD>X+K5R<?T;6)S/5/X[^CF^M,58*4V+
M69RZS0!YA"[*#UWG_:?(;%#7*ZN",%D@J Y;7/N@>P7WX"[M7T!,->?JT<>K
MOX.8.[D%U64<&>4.@32V-_\*8N(8<70V=\C#DDL(##A$2QG-RU6"&#R+A6(\
MS6O=+M.9IK\:S>L6UYINAE%Y>5J[<]EX6>^FJ3O#R,_]Z/)7[.NYKSW@NB(2
M]B22I<N5>"!A;+U1@]14:@&4K&G:3!6B@=3-0E65.*I(.*'RLKJ]69#<N1S0
MFMF-G^R</J!F7F7#D6__Q3 L]"W'!([0.)8X&-*Z,6YJJT5P^BH@-][[;'-K
M]P]:5?)Q=\<H4</9V&<XA-IH6:!,_:_TJ/PP5[11!F5!0G?S)A5V2$B^;9P=
MW;1J)4S:&!1532K)%CA=0MF+=]F^?&=05MIFWXJ+%3Y>/Y)=,* 7):J08WM[
M94AQ01-2'415GPY%'NY@$/N45B&<G*HN+U-;JAI4W36&>B8QNVZ)D=H1X;\5
M7ZI*R4+B1'"_&;.GKLE]L[9&?6E76@!_CY[2-8QUIU:EYJE]QV9Y"$V+]]\H
MU !SB2<)@[C$<<;8AQ3Y3%KQ_2[30FWXU2A_<"7ZU&<&3WNZ]>)#\,F\#0T;
MK<)3O2BQZ6PH37&'%)%B]MHUF*$WY@UL]0]B_P]W;QW4]K?N^U,7K+A#<2CN
M$J3%G0+%K1 ('B"4X-!2BKL[+5J\(7B0%H<@Q34$"('B[G:_^[?/GCEG[F_V
MN6?NGG-F[IK)3#[_?))9:\VSWL]KGO6\5<$EP&@X6_U531:<%QW'35N_50ME
MSG"\-N[2=2]K*9UFWT^VC[/(ZI%*EG>-SC8]89K"!R@5>#"&\>Q9W6K>IED&
M:1C T]OIF367]]8.:\0$?G?KPA*;Y88'#WWK5+#QUA1L6\F?"N)2/1A=11QB
MXG?%YX9D=,PFIX\RKU[RLKQ%I[M3WA/P\MJ'B4_3Z'Z"'_=1T5;^%2.R@1&H
M674EE(M6QACI$ZJB'Y0QLF\:O<K#OYF$*,EQ\[ ,6?#[8)<S<AVRL;S2!9XT
M!Q2UJ5G*PL(+ZG";!K5YRU%[]&B5_?!&T1:5OKK?A\1=L D[O <L'Y-9!:F4
MJ2H[JP\2OK!]GH_NUEK,&=]^AP AOGGU&DD)8<NM:PE>:4FIUN&7P%+VHU*]
MJH.[\8,E%/.&:6.VW^Y?AU1M;Q>E@1 QHN7/#V:G1(]\=Y=^-!G"H3VXS\?@
MA&S";E-<"RGILPO6=8F93<_$5>_%X8T;( >"Q:-Z;E].B$4BC41D<BWPS E=
MCW?U^M"8NE+_U-7YSENB/R80L_2$OLRK"U/3.QR[6H=KE,OU%9UK_95LT0=/
M@=X-34#H>.V7=),V!CJ#CR1^-^V&X?1:YAFHH7[4->K"/#X\/ZHZ)S%Y.[LB
M._<P>Q7+*1M=Q#8?)-K/UHQY^KU#(-JZ7B=2)U)]E+5&?368Z6#@.JX)J_N@
MP6 MMA+5ZI5)9:(VE)5%8Z ,W7#T5L%T=6WO;#>ZJT1$Y(51;*X/3;;Y&;BR
MF#QQ%;$HY01&#@.(7)=ZXC^U.->%#[0)OB2&'ICOJA(E _NEWC##W89WWK@,
M#;?BB20>/-N>=34([\M9E6#'%J7THTO[K ]L(%Z!VK'^R.$A/X ]V,!NO6[#
M@HP/O*MI'F0YBRVXU [L$EOI\1+[O9]_.:#;YK2\6)9E*>,42 -)IVN4$.NW
MK:'PO[2#<W6/M'Y]LK]D=QFW]-'3'3N)O"Z3\TNJH[(&:.T4?AI9NSAJ#,;$
M\?<Y7&>#1_H)TVI&L!/7<  N@F,788K&7K>GG:4Z>)D,;;86G$("PT3I;'$^
M-"3=VO>N<GGL!GT]:$9O_D! %D_LQ0>^2-/H5X/C-(95 RGKM]M]E6C>U,E=
MVS1SH#0,ET?(;I3Z#2P,0RT,!52/_Z4BE^/#WLR$P/CV648A)!H".A%-Z/G)
MN]HKG'+$O[8:*I/'6U(>!F.$7?'A01I&/Y1&Z0\?AWMFU:?.!PBR#(N)\*J_
MU63XTPRCS'!/T48?\\YN!=]J+<!]&I OO0V_K!\0)!%.($.5[W!2=/NW#B\K
M8[RB(%*58H*6U+:6-USZ09A7P+0@ J(X;,H=SK7.,OKZ.G":*ZZ':\=N)(M
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M',LZF"MQK1](,I^F+B<)!CZ1G-@V<H"D&:>WBZ\XG<_BNO0=2_PRPY"XDPA
MP.^5:RV#BN9=@32US2I?X^9CI77*NW/E GV5?"6AA86=#/C3I!G<'_O,-82
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M1;05-5>#&W"J/Y(6I/5G1OVK&)^V8XNS1(!05K?=@<<=CGQ[>+LIHS$J([N
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M:JE.4O+:TMT\%4!EGU48/Q>@$-"[E&&8]2.0DI5E'_X\X_H=RQR@/PYYTAJ
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M:4(TB=BXBD@^0Y,%CN3NMU^:%.?A%>W#[./RHB\[M!#K5+A3%9O7JOOMGUA
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M*WEWQ'Q<D?#!VL-?8B=B,*@4S^XM>'=O;>_$+-<G*-7&?>OL;/%W9^.M2:>
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M'0/Z;$2-2=,Y=G1A,V=Q?H/&?H:,=+T$?(U;R=XSF?M3-(L87EJG3GA/*.K
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MU(?3&U3#MQS)*>A]7?:?'W7A3LT^+6VX2NI_:I1RRC/%5RFV129O1=0KQJH
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MF/#7UHHVN#KI=$+3PGT]JXCO <?G57NRU9BWNB.%W4:Q=X6=6 EFF-_AD73
M+_^+#OBK=(CR!-RL:L-5<Q,:.SC9$->I9N3'REOYRZ-".RG,ZD\Z^0ON]?DK
MQK^/1]5E?4??\J*#9TF]TFS\\)/$Q.=@.BNSYJA,Z1F6=5_ J);+J398AH#
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MVF^VK^2*'&88[]*K\!K2+4P>'I 0@ VNKB)Z>#IQ2SZN""XV;I_9-KY^(NJ
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MKYR'Z3$#:\T/<&H>_W[P[4%X$FCH'=_(_@AQ_*0N?#1K6$(3Y<56<"=U%6U
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MUB>]'X1Q^<J8D"JAPS5B])"!E3^7?-AXX!'.^ZCWX77OHX"X\)$>'A[O?]S
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M_8Y9\[NIA<\E%ZB\GXD@%>^X;L>GL5&%/?#8>6\6?G/^]C\,T!#].[-.WGO
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M*]OI:]![B8*"F/4Z&4B,%:Z/M=LZUC')#8!ZR1I,IR6).B 3S9QL>,VA7)'
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MS;6\CQ9I&NTY\+ JX<P1D=XB7GL/SZZLH3OA2 9&Y'%N*7=]EQ=2F8C4,4S
M#FT1G[3NIP2@JW0Y$$8[S-29E#@T7J)]:"6! 7 ]YA;@Z9E[L/O,3'JMN0.4
M>4[AT?EFCH*<)..!7N"*C1BIEX-X>C>[5OUZXXF""_6E9YJ7PK#&<3L]>L]
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ML71Q08%EZM; N/4R PO0[W6S2O<HOJ0IM_O7+FSI?8M#)B5R1T_"C>>D(4G
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MO:^&;61FH9!0-]<4$WZL?65TN,/J]WY(FFH)GZY'9Y;ULGNI#W.Z_BS^2UT
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M YAROF[P]5VX)"N^ 93.W@"\2TM@E^2XG6#@ MY#(?!*5Z$%OON/!P.E^C<
M:Z#B[$FITB#H-)9Y$QX$Q>/7-O?[4F\ )M2!.U.G$3,+]3**6YKE177(4R&]
M&P#P!H"MY$N%Q5TVOKZVO0$$W9$B(S-8GB4=7J@)/XJ)DK625XV=.'?H"J)F
M'4.EQ%/#L%V/JB0E-C"YGAZEWD)37R G^S> Q+*8D_XE>2ALM5Z"J>I5ZJVO
M)_2'=;3;OM(!3#MT0$D%I<SY>:PNO\H1AMT]A!C9=W(#.+@&"JP<NW=D*K4S
MHOW#E2^?E/0F:!VX7=O+'W\I2]7OA(&.]"\F)OM"T+6"%6C]M*,1Y(6K]0W
MN NI>MET4! /!VYVR'F+@N=$]U>&=PR>_ AHUN(^EE7<Z!_(CDUQ,3:4V-@
MW7]EG2.8*[GI?KO;,C65:WS.8ZZUNC2N+\G/?+X*F.\CM])!DH]JW!/@(K):
M=<H(O %8$%%>G[\)C%&*B&)3WE$(69<L-2N23%64J2?\Q94J@*QUQR*\=K!M
M6U:Q.3T#,?TK^Z)Q+Z:W3O83[W3\UM(<G^"X?])8[4EZ/378("+S7<A5@.5
MLGVV[,N;/4R05\9@MT*0P./O-0<J]/<5OY$.5A-)UO++WUEA$-O=[LE%I)8N
M[UX6T)P47(</3'#= +I53DG[ZG1S5YW23C@NLU.Z0K*6:/NNQC]+[E!,"NF!
M)4ETFA5I8SA4)&GP5\3^4)$G=A F7UOA\=$C64E.,A*A,9K*_L-,68U[.3-6
M\@U'V\\6YG24*.'UO6JT)'H;A*7VA6QQ R/W1Y@> %>V;JTADC^TC<E45+?]
M\)Z.;U+-ZG%FH(6%3,H=R@<#0LJ/:ZHIKG23*1C/K<I_H!5&94HM@XI@8;]_
MJS0V@3[85.J];PQV11>GT7Z,[?W6EA!9Q.EG'Y9MFC5(M^?9XFQ)>UA%RI+,
MW<$9S1^D.^ VBM:3X!2#;N=7%,+)CV)$+O6@GUH:,SL/?XD/530R!N8)5*:N
M3,2$U$4>_('W@#^HF\\F#S[?9OVC*,'7A_S=Q=913^/7](NMJ?%WKSZL/*7;
M<7/AO>OK-,[(=GU,O% 2.[,O?> /[9$Y_+SNR/XDA.@H=68LH_*8-X0I"TG?
M0>R9Z*/*?7 HHG:M>D23^8'9-U$FUZU;K]Q?<1&)?+WDO#/O@[-J6]#Y+GFA
M(1AS70MD'-O)9R\ )@XVA4\[NCD7"P[$]0(S+*T<&Q/IZ@OK&<V_W6=/&5JZ
MXU'QQ'. _\\@J_@R(4=R+PL/_8YO^?8($J&(P,L&60<;+;]"U8^EN[4LE"XT
MW  >73UZ/$<[(:W<CQ\4<LA!C@5?Y:KE;'F/J;?B_^81&#Q<NR5QX%Z.O&R[
M 50<*?RXM :N(/ \(:D*+D<?F7U:0MAP#X^WIB].=?0#:-D8_7(+<G/"0,4+
M1[\64%>>D"NHU41AX^J((E\4TG;$4B& R+]2B_YKJ:[MHTUP]&_M(33Y'9\/
MQ/%X&\_F4&J-IG(//Y,5?&#%M?V6DZ;(IWB#CS\PW'59]E0-3H5_U3&]/#T'
M/["8I4M%^(LR/)[/J?,\LW)\#"VQ_"<%Z=8\WG"(RJ0/H#@>&J/O^U'=\H$Z
MH2<68AG(+.8/9OCD5RLE5Q<B!2<^H@G_/9[0SY V:S 5Z?8G@?#C\\@\AD&L
M\VR7(\ZV0L7_$USJ8@)1VC9CS%D"NGV=0604*[TDQ'F<]]6JZ<J>/4!\?K_C
M7/A[>$YKKK2:8([P3&VRCI)EM\+'AW,8*@>I62Q=L_,.D ]>O6_8E(EJV968
M]2Z?"2P9,0R7>.U:,4$U:Z1VRM<Z8K33,T+9'I6AL\LEN9'#JJ1,.EC8Q]TK
MG#R!1V3G)V9].Y.VV!FWL#C6\):XQ5L*G3D6.4M#=K7Z@_+"V0PLPV)A5>:"
M+-]SI<YYUHC9'&B>#A,(F!^.#-U->V>?]&7R]1<]"^<KMM9RVR?F4V[KLY"W
M3B"GP-;Q>>4KLG!9/L::S^FGD!B\P9$?K!^Y"KM]$@1TN.H?:[;BJ>3=G*/B
MDX_+I$_\(%!4T&_,71X5*A\@XQPX\2WAMF<&$8?NG; WA$IIH=DN#!R=EOI=
M,@729=K]_=\5^7A;I4T2US ZE3XTAM+(#%D^OGG",A8F4%;_55,JE\9DM4 W
MC+-84RNCQ#([V*A$04-2+ ^&[K50J$F<K1PJ;U<CZQ]WLH72YCE GG'1$GR:
M#GO^#,(BS.EH0^U([< "@=A[C&PRS>0. Y^'\TFZ%4R9\_+Z5J@NIYV/&%>%
MZ]L<,6L].U+0E,&K![XWO<]EC=AG\'HNI&N9/*= ))_4C1&_JZ,:7@9Y5^,W
MK>P_:N]9>3G>X(-3,?=O>'S[7KVUJ=)BG:B:_/.G]@M!:1<ZEC.,G9U;Y0+O
M8;H\:H7?>[O$W/<:LAOY@80&&]C92=MH-?2=8#K9H[)FQ8_XSRBA)TV\[2Q_
MS$L5%Y+Z-J1$DBRYAI:SBC,R#,+ZPUXEV>4-.%<:SB+>55C3;:$8I,NTJ%E%
MSRGQ/M-_P!6"CG48CE9@LI"_H,"!,99F=ZBAPU^P;'06G0^;S@*Y4Q=[' NC
MS(UJGQ2>JJ4U3]63(NB_RJ'U,PF?#=!Z>/;WT,)(X4)P1_#A"MN41 @A*7AX
MBM/XXUO$16;QMBCX!L &;MZ5D\WC(C2R2;*(BOJ8:*#GD#'K/;8^"LD+I-/1
M%1#+<-9RR'T]ME#J4C,\R0A9WOX0,1]$&*(%]"VU?POM=\I"O>B3H)<$=(2*
MRGJX:TX?Z'%9$F;X@S-A8ON_V(/BBR^,<#E/&?#F-P#UUV1KN=3ZRWX@F>85
MY5$*SS] KO[M&CW@"1P2_//6D<LF*OU3\\-S+\;DD2=5R-^?,L203(^'$<VF
MS<3!ECY'4E';<HH%+J0#>5RZ72,IJE1J@^5Y=!OX$:&\DS<8Q :'D$^?C\#R
MC'!&H3%Q26T6O&;"6*FSW\R5M8!6(&.+_>34;4(^8ZM&ES\E9W"C?,168]/<
M ',@I74L["=C3/!QJ=YTCJ&K7+VGZMFA:9&==#A:XSOLU@#!:+K]U)O*:6B#
M$/">VL!,S0]1'.4CB^B(2OT',CV;:YO&('^\5,06Y,TB[E4.VL0VJ31)4:]U
MJOYZ9O=>?K>S%5F1SV-F25U"X;/H!E/AH[=(VSP'7A)!A8*R/X]:R'U#K5'3
ML1H\IK[\W=B[2E7TDJ+'_)$?BX9L#__.[]%PZ4.-@\,4Y40%WX\VP/+4LBT>
M>NL)Q@GQD0>X6XZA!LEU+>&ZO)L<QTL[7AQ2=8:?NM+I=)OP=>6EV#@BZ>1,
MA%.?V_&*_DG.\)0-Z%G&ZHR.>(<[- &"F\HN/1+PQQA?1\SH*(+<W]==#1#N
M8K<)(IB'J4#%OI[(Q)3'MV/4O?(^1:[2\*-KV"?9^V(>?1?V#ZXJLRV+#M)&
MRB<LEL^P7#'@]Q'[:W\>=7LV\K/.=<A7-="[%8OG@&,S_YR6^96O/L\NQ6S<
M8:B\_5S$-&V@EZYNT>].']SA9>FOR4?\/U<94!]J@&!.46(C\<>[.B:R"20/
MAX-8XC)4?HTEM]C=&II[&PD3Z;T4&__^ID>Z1I5E94OQ=<9D5?>Y$-&;B:A6
M[LKBD(#%L=T5*WC <$^[PYK W&Z+_H>4K<R@'UJ\=#G-+M@H(_==C=V'+(U;
M6HY(CK%WZNF5,<KR9C3R[^%U]8)[EE49@_45\HV_=8;+AZJ_6HSXJG8GB1V"
MJ^NR=9&4T; :PT+<T][)BA='X<NRM@TT O1A?4YMXC%57[IL%NF.>"8?QY.Y
MYZ48'DAOCP0B'(:ZO:;31LRBH[,7TG[WF900B#O_HG2>P#QX4T7PEIA4A:9:
M_8FP6B=9[^VAIP!^UJ&_2MN$KN]!MS;:'\L77$35,*_ SC['=[A6:\'E-NSM
MY<3>^"J:P@EQ*=XY?>[FIK+0XK+EGC!C<)56V9I<-,/3=C$P@*LA>Q+LNO3?
M%RTP&MA=VI[&3XQE%L54CO@0UHT4<6-6<NI6#-]4#=KNQ!(IU,<EQ>5HXLBH
MJ6YOUM1N6AW/\$/:1F?BU+'T!TS?>BSZDK+ 1HXIDOZI-NY"N09UOV>C<E17
M/II.A_9;/O+C;G9H':45$/W+/N>Z%:J2.^T$EO&D9WL2)4.O!A=W=R/G E]J
M(2I9[V!F+'7^,3!:T>G=NKLQU7,Q N4_1)W3+C! \0=DSV9_KM!NVG_[:M%_
MSO?RA*]&^(%5F7%P&/>GY'-//RG!R2IP^7=Y"P]5A[I]^!,ODQSA%-KGF?UA
M+X>TK=J6M[<L-IMRO9B=%#/E*^*TK:L/'!KP+Y\E^,#E:M\XTN:/P13K$7UW
MWW'UW/*..L3<+RL^SW_&,3-1O/A%H_!OX+JT?8KRFU@I#+7HU_XF,@ 5F!7J
M\-81BK=7GI]#_UA%,XZ,GQ=$+U"=D% 7_1"!OJNF&6"OB)5@]G;T-<4;OC\8
M%>^*J]0-EZRC#K@!."G_#M"'4L;5+*X==5<5O2--)9_JHZE+WPH;VM89B[7-
M(X/!^APN11H5*&!CM.F9 ZWI;<-'_Y9G&NBHZX1 1<<JDD550O!F%O6>3><U
M^U,VN(W.>E/U5 ?'!*?G_I^G[V;WSREE3Q,1G9! 7&EQS@(3_5,K3DDM%CH,
M-1UKG]G">O_RT82XUL/-IT=KZ&6].-5@+T<DV(S?6-&CJNRXW7K#Q\R%F/]F
M+*@QR?$ I30'ZSH.6 6;?9[';KB:!C=LGF&$_6IW_S]3OO__BE3_''V?]"__
M9R#_-^[^?XMK-)YXQG47Q#4&*5V,/2[44''_=\W_4'<O3GRG(" ^J!.B1&QQ
MO O$(;,M;.%!X^3\\BV(K<\A^N[G<@+7_5>#<(;ZS*XPSXRT]RK\W.^GA"K$
MC(&Z]NZ+!].SOEGM(MW)[K:[RJ_,JL3LEK>?Z_SJ#?3ID@-YF$:&O6-/H 4@
MHLI^'>_MX,?HQZ("[BXM^50JU/1]&H]7NQX3E5:/'5:E]['N9<A9@P2\MHPU
M5Y,W5)$7/^FP%5=#._-E $UL.7KM2SH,B3H^&^-LH.^J;"M$Q:#<(\-#AGVK
MR"$O D."> #CR_]-28#;]INGKSH&]?_Z7'?6)L32;/%'VH5"07@NJE2CQLN3
MO\DB8FU"X.5@7?<5E&?F:5P10?RM@,H!^;;C"U^GN*%KU>(US.?8X^3!+/$#
M(__GFF9//\=T<6A*"N9:_<!WRTG&/J,5<Q%O-E_<\X,W(>K!4K.0=W8\FJ)C
M;;I^?!9ESV#5".MN=O)NUVZ5<0+!Y1="_8DP9*IM^\5<PU/GQ490.6K.U]=H
M>6*ZB<UUXMU5VHSVB-Q#;G HZ8679?ZS%6*:Z-(5 =G6;^8\U)9N#CL;V6Z1
M'V3S#[Q%IS,9JBV_2PT^=3M\A:0_'#;^&1S;EK:<I:A.#YX[EODO@ZC/:*^4
MU"DU1]2YP)6*S+JL.>A96(]YQ3OU]?P,OTBV2/H44!XGR"IS?GOPKNQ;Z/R2
MQW5CV(SYZ"9QFO0OSK+^KJ>+O+F,')R"WY](>)&K65;KB1KW-4=I4*SPP7U"
MA3,O9@Q5<2D,!_Y(:4-*BS#G^L@,RQ3-MR#S=E%F^K:R1-E]Y$<2!NTKKX$G
MKJL39KCZ^:5RJ$#E&[$R\U%_07<Z0I8P).TE3GE%"C%?N3U>9O9YH:\;LR*5
MI5TVTQ;,Y)\GZ]WH:+#EVGUV99;1EC-D"DJ$!QN+/$A']S[\_;[/.OL5%_1A
M/4M8DRS\HPKB8"KRCLC_GH/VR<PQ/^(1Y10NBK\G( %&*?.$I]-PIM'99B/V
M 6M,5O3 Y0(B_V[DT$>"S^]/%PET65E?O-AF?2JH]D+O9V0D+)Y,%O8@2A8.
M%Q5M@:E#H-Y=MCGABSL-8B1/Y^\.R^:!NL:GQZAIWPPZT^B<ZU[($DYV:]''
MD%.EG%@5.4_((N$A+2GA\_4";DVDDX,N1<S4C%$V]%(5?)/;BV]V!!BWM^Z(
M:GCV;/UF37C(Q"(ZG^+:])S^$C'XGU;U_T0"^W]EY1&]&(3?-9R7%]IJ:EJJ
MJ!+#NHAL;,7^HK=;@NS;CZ$(6W,G*OH9_F2HL_2A)=-,W]:XVB<2/'?Y,/)F
M!R,XV[OBC%1G41X:WS6HI^^Q*6A9U=>S]ET88O^B])3E &0Q@&Z"GCF/R^_*
MHW/%G^!V<C[WP39= ]DXRWLF8BZUKWD+H/<&?S&X7@LZTA+HJW-7'RWTJG=E
M(M5:#2>\-;+39X>SFQW=O6 7V=FWL/^B!HJD%_<]5#HR.N6I)= -$-2[ ?RM
M)'[":'(CHM$1J@Q3]@16F*GUN)O=8MB[Q02H="Q7@MG+\R"R_TZ _C_$2U>3
MV'<KX::=I@6W8TWSR:16HGNZ,5\)L[2)K;H_IG?_G60CVR2D,<*K:SIEIW*&
M]R=YOZHCV_>6'V&W.:EY',<,7WKVW<IL%(K(ZKTO$F*00;5>>LRI"MNKHEY[
MAR)B>SAO=6P\)H_5V=<+MGC;L@!JK8V*7H*O)$$#ENK;[M._*AOL#[_P^12/
M,K/L,"='X0ZBYD507JK;,1#_*!W3$O%68R"SO,6SYJF.F('Q!-IE0:D$(F^<
M&B?)VJ\^,==+6?R\"W$C5RT'415'A;P4AI^BF9*V)8Z9K4.HFWUN6/\,CUFK
MWN\B]CR#;[_!"4]'N$N:PR_'EMZ+C';O&X[[3M&9#<8@614:;F/ <,4;@#,P
M=ABRDL46J^YTK[WM&SP-2J^==2+FDY&Q1HYD4240I&E3(7:]C/9Z5</VIT%;
ML'/,$#XE3)@Y6B[(>KSVX=+MS\%KVZ HW<$ 'I-XH>+,&X#DU^-PY*@55@M:
M][H!W7EVR5CJE)C<!#(3.YDO:,VP2F[:31^XW%J;;=\_+-2%S3(< _K!3;/B
MH;FAM6P8@_CV<LB/S4]G)X?QQ&%SPN\5$[9ZR\B^'A$'@^9'B61)A YU+[VZ
M BY;)S[YI(0/OA5 ?!DW#3B-^MZE%SN$V=:O'KIVQ9IO"].J!>\I)-P!/7B0
MCIJ4=*X<;E'DQ[(LAT=CD<C]\-?9Z!O B[T(\0?9E_TYCV%79#*9W!-YW+U6
M&/8L1XMY$3V87G#)I6% CJNUF ;>;HQ;PQM4/ZJ8Q3D6.]]^F-M_%D#?.,&-
M*>G1SY,*E$A>BROH]5)TULB*2 DN@F(B%E4_6@RD9^)V<U:G?MER9A9;OC?G
M_7TD^N28\/26PPE<,BM!-HC81@\O*6_+[" WPDWLW=LXB+$1NIY(S_?-+5N!
M5L@]G7=?L:YT/PHN\^XMVRZK$M+"6"!>#;U<4 :O@*1A7CL.C<;"))6=EWX>
M(]=:LPR#,Q=!07Z->J=5.#;_4W5FOM?G(.LBG:9-4(]E60.< ^Y6<E EX(X:
M%$U!!*5:IT$3^G6<_<JG)1,"R+/&7NKN8-D_KNBM[G:!=X84EICNMF9^V@#7
M:@8/9,Q)W0 2-YGE;@ J_1,AG)CA,XFEW!5L\WG9806*RR(W<[2(WJOK-)UN
MN&]J\65NG&)\]MD:8B#PBK5C*F[WQ5Q]%GN"F=0&1ZUF/WN"%;G%>2#UBJV6
MX!GJT611X5J6^WB"_Z2N-),SFJF&[(/WGC*(C5U7P77(1C_5$$9M<7@L*%GC
M4)8^V]<87KS QU@F2B\Y2<.31G& [1J4V[L.W@D0O3\-8O$,S/DA+8U)*]9_
M -R":=DX9:5?-D$^,B]@D8_;$Q E0;AK#<DKB[0*H-&8T(]!H39-*H&,JJ'5
M]3%=D0KY#"<W..HXH#)NTX5I>EK/8$_XB?MT9E[H47QL.7^(L;+MUSFS]N?W
MH7B0>D[A+YX(X1*P(9+2Q8QOLF!3:F,R!>H(760#1.I] _B2.D(<'+#H2[3>
MKN/(ZI5*J35A-=PGH\-<-X&XO9BG)BV!W &2)!^T8=)\BZ3I6P58,M@LMVQ
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ML'50IWR@Y[M/P8#][-#$%._4MJZ#C"B+;3C?&\Z^L=!F/F$[E\[]/LWN!'L
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MQ:3MV!EMU3//3=JMYU7;IWK[,N?N\R%1=DFIFHM?0@5K2ACKX77]#X"/-0^
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MYHJ>Z\,1AC&,YL&W[PZ34+55F^URS&WVUR?))]-8XQV8%]Y,UD&57.?P8]5
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M_E4X#&$%<7,0M)]RMHU/@"-H>M>7^W_MNM@)6FT6F^[A\&?A3O>K S>A\+0
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M&7NL.+A&*\<CT=/E,*B$(\@M'H?W59 _+?@F^3FAE#C^S5?G;$'WWN5M5]W
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MK%86;*2_M1_K;<C /V3/83_VZ[]QG1U]X!_S-*R/^6_4:N&N?/V?K_UWX='
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M'Y*Z\I<;*_KKFE9A>&0:_%<).7\QBPY3));K/YLWZ*^&D4^B8X;_Q;XE__2
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M)!'VVKB"+.8A*VX$*F^9XO3EV4&B"A.1]6KR#/<$FLL-)^T!QO*S^L#\,^;
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M4!%W_PWZ62A[YT)UOL*G0?S]4>G,=0D<DQ]Y$(F@3%L@;A)?P(H[B<AZYBR
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M6K0C &!=&W91,O;,/Y".)>U_\P3FO79Z0(@EKHLYJ'/II;NA,2(C^EF+\9*
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M<IQCQ*[:>QI;D0^,2D5@HK/!^S68A_ ]-VJ6&BR5/ ]J3.N#-!>A9<R<6W>
MZY2X![=VH6L-4<4E7;(0^$Y,NNGMQD$__@RIE6OJA-.]J^"G6LW$&?_1;K.K
MKX[40IG3DSU=:,VJ9*HB42+ !-I0JR <VD6-4;##Z)8F@N(]2R8I\M+3]F//
M0-31BTJJ+./0'"BP:GV+=.WE=SQZD:!"JPOL?,PQ!9Z32S30  O1PVN3NJ9T
MM??]CD#Z3<@5RU7PP$(V5IO29AK!&)CFHK57]N?"P66#%*7/Z?F73@N>UYA#
MV]Y>PK:@7:)=$+XK,DS\(S(+L\HR^1L-G=JX%*<\*TGY\&3WZP-9C_[E15NF
M85D9=5GUT='1(6:X7'7E\4ZD/:Q<.,>S=D1\6,N&'C)^DYK-34BX)R!1O1Z$
M\SK&CQVWHD&1<\.6<W2?['O[XZHIJ@GEAX=',JSKY^%+X^1(Y%A+>RW+)/)]
M8-NR>6?'2\NJ(GSA_';H%+\@5#)(*G5:=]/[H : ACGWUMDTS#^C-=)_*%,0
M)'#66X>@,2&K.%\HMZCL.<<Q%'(+_7I%+6<B[=CJ<-:F<FCU$WU1<;++4NA=
ML%A1? ]+7/(DDH R!T!PF7&0YA!CFW919K[F-?OBVW/^#"='*;R9!J-\5I1D
MKL*C*V/5!'*X/%C2;%?U;9B!>G>8UX1#Q\)([[2XDDC<=),>('5*/)H08-1K
MSVMX8,.? B0EW7N_9,R8_/E&H3!D<7\N/KU<@5-3YG+Y2/\LMVQOW]>\])##
MK5! ;T'T9#[8IY?"=Q$=-"83KBK>6TM39?@DHY5UU'G3 1&-$32A1#*^!LRF
M2\?^RO @#_E#M^=\L+??A.;\.3],YT'AG@X[]U;=YOQ3!49)V>%A8E$%<Y_H
M[H+\JV]6[>N=!VZ&J]4:D%Q'TY_R1'W;9]QWW&?R3]S;(?'N8U/AP2<56'?F
M9DJ6:P"?W1@\=UV[\WSM->\+1E;HH 9)$X6?=9\UNU9",Y-V!'0_0Z;"0A<S
M=#X!$O)VZ5,F@@>T<I6Z] OE#UFB-T3'48)L!C7;N?5R/]@H['<U*U'Z52-&
M-TQ8WL46O0=PTI/,!Q3W=:90C[1 5N+]^]NW;!9^GJU:WCG+!I,:NE\^N;/8
MEX:CW.&K:!$]8@H0?3E/J>[ M33P \_7S<YQMXP<E]R)>.KB:=@9;^,M*?!U
MC\T+F0UA)7*ZV+ERU!8SS*^^N6^"D2NM[6 ^\7;-C;JVK^W%WB$K<6W!M%(\
M:"8">4[\[P/HI41P#::,^G J$J+8MMR?[=?*HQ.)MGYM5GMKYOP+I1:J?_7T
MIN32)GLP>$3+"FQ"0>BS9\Y3?$(1K24*'^-4,WT"L.P!P,0(;(M;WA&(-)V]
M&EMDZG[2[W&-R37[?L8XK]IDF,^HRIJ8G#X;*\0VRB$?PR-)S(:>EP],3&1M
M#_(Y8C/_C>'-;L9DAKZ<P@CMSS -RHPW6+P:"UGW<%Z%CM5NQR2Q>X H/SBL
MXOCY>-E\9OF(8D%]]3.8Q3W@7F%3,<<_WNEB_K"ZC>Q6"KUH9MU>R_$R!E)4
MMFX(&@0RNHO0OB\9FB$9YN9;J991NZ&#O7MJW@A P%G,^Z8%+Q8,YCH<<7#6
MWQ>?L5FY*Z0T:FPZ(XU=;*O!,18SU; GHKGIUB]>?8&$;XI!R\%SS6:;=<+3
M.YP/_KL;,')7,<4CQ;/$V0@U@P(B/Q;1TIXG;SQ!/\FLXH3O,?G+: XO#"0Q
MD#8:3F\+@!^T]^^'IJY5'E_[[3E>>1?67SW-@LJ.$FE13=FQH@>S-I/H @;0
M8,9]S5-K2BY!TR?M>T1H_'^=53)1N'W]UOUH>\G04YI:(!HL.\FS@+8>#);:
M:TZ\VLV2L6FJA^?]0EE4@;667#0;.IOWC!S1"'"]FTWU'A'UCO#"B/GL>_7&
MR"Q!Q9JJ,'UDA!E>G9BEJEU-XD[0S8693$ZM:M#7+F>YAN8IM0]O)ZFM08,&
MZ<%JMG=A 0^WM1_NI+0&02"S>V'WX!50PB^4#X.S#B&EK)L  '=0IDC[CV;E
MX*Z-NR)[N[$IX.7]I2/^U=L*4.33W/\9&55_9+R5^IL,,XY7_A22V:Q1EN\N
M>0*J4]7*.@,@KFB?BDCI#KCV#N%SMY[8M"II!DK%X9%D'Q+IX._IV%#;I2+0
M2XI,'"^&_$^,FU&XWZS[]&9FXOQ,DQK&3^TP[>_#3VOK6AL;:'0ZNA- 8-=7
M@6AN+OP;CH_JES>_BG95[YWYZ#.$BN75V)[Z>O@7YO9 H]ZH6"W24(@9]-I1
M]H:Q?,&IP7'V6EO-#(<;X9J&#>RVZH7W['%)0XJDI+G"1G0JDGLV2HQC<K,K
MYD484ULCF6,B-7]O!%"P)YHB$8?4C1QU#^&%QX!"$\#*8OI6H*2F0G&+-?IY
MP8++X9BX-W.]'6?2KDM+J\]Q_6'.Q]CV52M@A@$\QK.<Z-'T0ZQ]('/%)P39
M4N(B9U:-*W?3B(*>UDJS&)5I0%G-9)])B:)GCH(&>TZ3CN& +/6S:C$ 6OIN
M7%U,?AZ,/B='^*?]I73_X7EJY/IS%H\@XYP;0P_0S9KL@:S&#VM2:]*?]O9N
M!G.62APM1%OW%YX=J7FM^_,_W5Q5/I_[?,0O'56HK@YK HM8-=B?G#;YFSP!
M:2H#!V;;V:Y<7'%DM)S^1M.\* ?OW2BDNX9112 .[N:@.BV]A#UI_9IC"5.9
M'CAWC6W:'$-DMG6FWY:\:W^AE(>L9SLA<18D:/#$?Z'L[CZ_W!7N6+6=YZIH
M)VD>*/6H>:[%8^$0?PW9W9^)81BBQ(;@E0W4AIAX9E6'(,H%MK;Y'#R.+1!@
MT,&%??9,R3;<;?JGR>^?2>,ZMYF/3YV?5QBGQSD_=U&W%_PY;,\Y"5&A3TQN
M?C<,5_+V88%/&T,MR[T@7!JE/KBP]HPQ(">T)4YQXIIOA._ZL78HSK,7,GQZ
M>0:BI;I5%N5\LE2$SU]="!_H-9K>5I3N4%=,U6S_A"GM&Q8EQ%42:ZT;S>'S
M%)^._(Y9U9UN$X^34,?<.IZ8Z!\8\>"&]+#;_>E<07438P !W<PA+2M#:6 @
M\-H<F3FB^>%UO%)H;?9=K$2+^&O0BKR) PNU30.]E,#LB^%..6%L=33AS\,B
M<N>U4X8]ZQJ07HE$U;&GS6 ?I3P?V'U.;I]3K(U%W/Y1"S-U>X;9EKC U+S;
MBKS;A,,AP+FOZE6I:N^Q_2FC/8 ^>01G;F>1O<OFY?/GP+]?;N20%LB?SIG,
MQ>&04B7;>'E3&"+Z_&W<)E#(XFCK94A<MNJTO[.2 J.T::T1%:528I/$3Y)8
MR)BMTPC91R$RW+'2KDS<N2J'^C:R+PLC=1/B@ Z,.  9M5ATGD](YH='_4J6
ML_D8[MP0SDR/L;3,<J@\JJ^%#HJ%Z(/ET'5P@9\\AM;1MOT(5M6>)*Y'GG=;
M9<DJ%2->7H>-%QJ)IQ>"]]G-%!0<5 1B>\I/%/2%A4?H46M9Z[/1P=O(YUR.
M6=SN#K (6K%F^#5*--XDYC&NL^J6U< J'CKW;Q<G][&11\+_&#,4-RD1M6P,
M_B&W9Y[6R08&&>=#+(]PH":2.T9B4);O(#9NF.OR*Q<2:JPY)V*JBMQM#ZN'
M9HY?ST0Y\R&*.*+@LDNEI'NF?2MY8C.MLO>.NQ8%3JQK)K/LR#@.(1?%!UTY
M"9U^_ W9H0"BR+C3[$W<N$,1V0 *F)9<R.P[7=4KZ."4_O<OI>S)IV^4DI/X
MXG#5XMZ#3Y0HLRAU>F:M2M24#XV29(30>)8+2IS'GF3\U#"9,5ZK,YCQLZT"
M5I1N\<_"#+J9B UACW.).JR)L:P2%)6'U8TR- %C@ (1TYK*@@^DE8X1EJIV
MY204AAYO9LKC,J;1.W6%L%H,4XXSPAB(DER>[8X:,\89G]1[ZEMG^.:AHOH?
MK?U"4:GWS,&%+14*>!"KZ_.9 ,#NR=V;[ V&%1\6 8^U, ?86SRF9D:%]IO;
M/^0XQ 219%]^U20*42&/2>QG\.A_W(N.OB3S6O:(Z3'W*!/WP<'!X4:M"AF?
MP$<!@F31A&2!:!@<;W1LX_??!P^:@\?+L:3!C^<6C+A',D<RDUQ\&DVIZ\07
M!+PW4S^5Q$15AH[9<H\JZMOSGYO3>\J)A SBBKL1W#T??G+[IPQ_LER%5+B$
MPT8/#EM]\])XLB:N';W'HM;0:,I[##DK(:PIR'D4B1'Q-QJ  !W#5!M:1XBR
M^/$.+A$U$7:#&DF"^F.=D<???G\GFL.^:I +D'C)T:5X]JKW4+V7^0WA^PL6
MVL$UB2X_G%IGI]Z\\D^7.#+!#2P4?]E)_C5C$GU0\_S:S4+<_V,=.MO*TOIZ
MH8<[;H>\ZJ/;H AW9W[8QZ78^'[-(U]GT?O^R9-$XO8.I*<+=TD9F<=JF'?-
MIV,X!+FL4C"F-3U,\*BE=!IW46F^I]ZK3G'&B0-TKX56[,4%G\^0?>.@1%RA
MRJG@3)P20:B BW.R6F5<S=AL6&"Q^'[8C.#P^C^V)I!8@_LONG"C#Y::*&[$
M>JFZC<AY*<QH9..,SQ6+$GB-M-]]6T_KKG+:MQ#XN%@V6R0) T:TY/.#BNUV
M(2"8HXNK5.]XW5@9M&)BNFX]>4>MLW\7^N*YC9M$?-]T*MWF4M9GS]T-F>ZG
M+_0K)Q2HY(9J7Z.,/ER^?DYC&<]M&6<>@%FC5KT"E$"<N66'SE=(2WB?9FSK
MZ'6BRSIM.N%H,#ARV?W4FR$O>U;\]2IJMD9!VP7!$50ZHSC\A'<0Q<8IF/7>
M;A0NY\8_#]#;DZ3/#IWQ\C>43)UJ]*4L^<9/YOQS_5!"WOJQSV8J1D9Y)=JZ
M01)[>).M78<VI6XK:27"O3$PQ3L;[SRA.GL^( VT0#=R3U@M^MY97"+_.2K*
MF\G4DU>F^?'=_D_$O"66R8P@SIIG\@%F:GG@WTF#J\^^' T&2#!_ZE6$,96L
MI'U>OG,#K+([B& @X9OY]#-73(QXE]TUR,!Z?N<"YW^<0']BRJ.:7 =Q';.+
M0:1]L?L\ZG9A3_W9F;>YMN(=_]NVJ@3)]X^PCGVOO\+X1 DBG'L^WJS;.[-4
M.-*DV3O+(B0_?P58*7I*2$WNFHSY\WU:)O<)JGX]N,* FI KT+=[=2R4F]A3
M^-X9HKJQUGT@HT\>I#?,]Z[?0HXL,1DN)<NY\6-S^\@]>22H3*+Y*X Q]>;'
MQ>QA3 +)5=9188G[*VR<L*Y\7O?CW@)R"08L1NR&><^UB&_)_BU(S"(0"P81
MFGWPFW@;*R3-4+-'$2>"3 @O/]?T79G:9W1C'_0J3)X$S9?W!-7I[[J_?Q<3
M_52R5MK'(9B8E'Y^W4.@R(#"@/+H&PI.)]VC)08&SN%.AI&N/V<0OQENET=U
M-/U!<V,#D U<NHR_4IHN\V'XYR$-,F#%RYUS,),KJ],A92-%J*> ^"TY6-GI
MP V#G"9NQ,K#IZ#(_8DE*_M2/$?ASR0UNW)562(Y+M]Y%D+?R$:1TILYC1V3
M.R/W^"56C*L"%=3$7R@I!P>--R[+OU#:#NE_H> GGT*A:=(:F2N72_G2JZ=U
M\W0O/EYKC@[E%([\N#V:I#V^EF9'(KW.D*V_4 +GY1YH.<QS'Q7G_-\EI:/@
MGJ!MV"BKD(?+5-_=&-F]<7)MTB%5/JF$BNPUBSCT2,>0Z57"'D$1S"52M,53
MYT=]H^%X]C?:].!LM(T1%'_42QOI/^"<:TH:*% 5N91W6_UAC:;&9">!>@S9
M[K:S=]\S3J'&SEQ<G5%DZF@NEI@:D]@#>D'><DCEVL@^)"A,'S7^$BA;Q52W
M'<-LQ1CQTAYC#OK76W,^/! Y68 %^YBWW+EV<R&+_Z>2@O^QQ.+O,J3-;*1W
MG$'N64QOW=;<L\6MK1SNU"_>M1N( (&L;'8+Z16TAE3-_L<"TN,P_$<5W9%/
M*=Q%OCA;B]JFN5TN%N5LAU-SN>=;$ZQ"EMG:"+[9,FQ$]ZL:]F&&WOX.+6>Q
M;@#W2R90\L$OE&<QV0T+M^34');S7*ZY!W$E4_2T$CXKXHD]Z9V1UXTT[OAQ
M59.C.G,I\A_A6#R=,T9%?]YPQ!+QYPU'VN2,20+VQ%B,PAZ\]& B(GM[>Q!H
M=9R"&64.$FD>J0+I#D?V(!=20?]6Y/5\^'362O<+14D:3_3MUATHH$._R[@+
M,6 O0NK*]\R60LR?#V8&+_&V>[JDO<YOM-.[%%.97?#*<;.,$MD;#I@>K#<(
M?^VBWLW=S30L*_L[H#^X_ G>AUNCRYK+#CA'1[L_GLZV9HCPD#8T42Q^(,LB
MJ0-"4JVI-&NFW$7T6X15:0KC$8R/DGHI&;N,>FPSQ-82/R<M/A>^O] \?)D/
MSW$[*]S:"1@)UG1:?"7VPE9C I@U-FQX8HQI^;XJJ7LYKA= CP8G7*C@0*5R
M(Z))#/>)EYN%?VHQJ$) L[W &\FX)0X:58*<PBP,.&X!9,>(&=_!$/<I*O)2
MXO$A7-\L>>ZU4V$*@31ZB??H'6'R,L_L[KF""]!8+Q475CHGRP1?#-V8_$)1
M1=<ZBH6WAQ?(.%U: OBN)V</_'ZA>#*?_66NXZC]3/07RA'^37F[W3\-=:!9
MDA9"3L*_6CHVW1XOI[\J-]0[FY+BK<<^%+$,HIQZ^BGR$6?= 1^2DJ/MMJ"P
M/@\CM2ALQ*D!]N5CORV'BE.T+1]%,'M6A>Z<G 11#[JBNL/ZZ'>2>#F$R3JB
M?ES2T1_?J[Y/QP&JE#5)T8X/UG**%4J"?1A=]224,#A!4GR8$F09'9Z4MYF2
M5-,1,VS6->+63S*9ZJ%'O;R@?"NDB'0VYVLPX6#Q=37..QT'OO$CL*>/&I;U
MT#"9YGR-J$92),WUV;&3QX ]$.4SB7-V>ZZ-]Y/4.R:&O^'(."(](I2TM#H;
MC\-RER6S)T=CCS=V6?'C0(0:F<OG=Y8=R_2DU:J*<59Q2P&\/456]BN@*M_4
MVH.>)M'6_DEJ<!FOL("AHS'7)Q.*+O4A7C5G8H<;NSC*!+*Z%F'Y_5&C_>^]
M#,=:0#&9Q;UHZ@ V4/&$Z<QG[Z.-PP<3SM[TZ93Y$>/PCO*I:G()D6IC\>_
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MQ!HC[.H+7_]+WA,.-N^0'U_S67#Q"^=OL@/K4?MP&!7L.0D=\W;TD>M#VZB
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M@%RM8E.\><53Z7FW<+EW5[.O234<DQJF23_EG(>DS#9WO*-@0(O!]>C<]2B
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MZ[KSO3N$X7%FM#3V7Z]P2;W9/G)WC^&)*Z ,P?]4D]BW39/O[I@%4]P[7L]
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MJ9>Z.?J]4,49!CM;.]%,"449?+D=F9L0?$[##7J;?T,FU3LJYI+ BX== X!
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M]W[!Q4FIT%L&^$C&>34=T!#2W'(K4(V+&]-7O21]*/-ZL0V4/0V.7KI%&O4
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MYP)&KX5S#\X>F[,%L,D9EO0VMXR>\@^K.K5FF.Z%.B[57-H7G+,#S-6:FL#
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MX[M46QCM711;2OO/LQ=YHP79/KP_O##4;EY9\$R7?EO^<15 ]A;,/^AW(QS
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MPNI"K*UG@56R$;"7$=Z5T05E27[I'_^)0P_Q7U%\UG]R;;W*7Z)H7*Z[TQJ
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M<!@^(PDG#+Y\>]HLTOB#- /V9TC3N1_Y1)M,'SB[ 77X$8"FY6!V\P\[/#X
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M,71'B?,9 @BI7,%N6GK @5OEOA;M\R98MM8'VI[]3&U7'0QI%?S6C%XI'%*
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MR4OCDEAA0GI?VUK!,<G#D[&1;LU(/L<.%)]N]LW*5#*K48$SSQ%M"CWA^,3
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M4C1B<_SF/9BP4IN "RTTIO_[FJ^ @:0LMEX"]\FYV?#?O,#_,Y3;H V8RH^
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MJ?\.,ME1\$&LSLJ\F"77H_:V,1I706'1A0X*,&27B9;1?7%1M2$Z&D'ZC5B
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MP^J9-=U=,P[Q ;3JY86%L!A%H(B#/NUR 'U$1*T1\_[!YCRMYB%SW>3"I\^
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M8L]7=_9"B?(I#0O3^SZY3#:.,R!--4MO+';D"K6:-7/+@//G2PO\1_DU6QY
M_ 5!T^NJ0 WG@OP (?8%6%IDVI[EU2(SR/@HXE?\QH)0WI+Y%W4E'PH>P(HC
M=NB%"TL:A1<C88-S'9;#3''!+/Y#ZN]Y+?0"0WCI\E[]3+\O93CE:D&O@I9X
MM\OH&F3E&UDL2$92NRPX9_(6(CQ#TE"*S\M%90G>.$+X 8@"[\Z2=Q?%;=?8
MI_6!U\VG3CC%<;#U,C5^Q!1^B["+V\N-^7?J-MXV,DK3$.TKI>?\ZAL6=(L]
M)]#U\K[]Z['DC<3>U!%G.2=$NYZ,KS1IA+9V 9 K8V1[;9WFECOO_<CAYHS
MQ3+,]WEOJB245'=W03RGJ>WR ZR94G"Q"#0(@*AB:[5MLR2<.'QFJ6DLK0IC
M.U]CQ=E;6N^Z?<4C6[^!("FEO1>M=H3-: >2LH@G56Z,K69KLNZZ:A"^F9)O
M%)L3N(;N;S0K.#Z;OJ(@>X'?2MZ>UUR#..]MU\M(D3+]JV89;!'$S=>I@J'K
M+@.V<;#)=5?S8/(*!MK^?5^1\0E&$_8WU;(_V5 L2>G#4[T3C3'M1F_BS=4@
MX,,O0\;^M;*5Z9>,"N3-\ YBJ&9408I?R9C%#X9V7GC>&A"WALG:9*;,6:-=
M!7,WSNIPED@B(X'"1"QV6R0_FQ)\$I__J.)%C)I+V:#=8UQ5$TE/44\N55XF
MK>11:).FE^WZP_Y*N#!3GDN)CB>"6%O+A.?TED6I=VX('L=OH!?I6 K[9I^M
MFPT^A7_XCOJE'']X+A1VY++:VDE[X9U%&5[!7L:26$GUM3?@8_&S[K>F3DG?
M>R?PC,APPVDKV15-WF,*OY(C#W@OOE  Q+O4ZSPHGS;7*YV,"3$ZU\\J_$3P
M/"TMJ;5$RRN]O),P([Q<N^<@(44:?A-B*4-UV9]AN7"$<\@-26-I[6E*6XT9
MG/HHLWLGEEV\5C,CI=)RF\6Z'54?F^PP-G2NA!GLJ3*3J!^<?%8P[N+&?KXT
M>S8G$"DD?[M^G[X7]4#Q;""DQ.S&FJ2/M,#;X5'11>HQ0HCIX]SZ^6BYT,!(
MT1/,^&?&Y- ZW\3. X=;LUG2C>UWOCN3OYSC]?_2.7+W6UD@G.ACS9@-A'J6
M/(\OA];T+Y/KO"DTEPP"X]F;+,\=L:*$@U1+<0ZC= W-2(TV>2-*H$G)#?=U
M&,91DX(-3S"T?+E/,))9ORQE['73V9QG\GX2&_3-A.J L<U\GXF%_ C@;;\R
MA%INFAH/!$ZL+3+UEP3;HG,;",BR>-D>6?>N'B^7+2J$-T=#\CDGN[XXX;#S
M>1REQ095MSAY3?!S,O<@*^%J]R,X>K+U#M-(47IM\-+P(DM,P+U'S%Y=&%T5
M8"OS!&Y785 _,-G:N'[.J129N35@H_:XC<-46C".117,81ODX1=7]IK"O^W4
ML)S>6^JTT#GZ<?@A9DYA;V$)VM>R21(_ KM5K.&X-V#AE<Z^5LO,DTLZ2L)%
MLIEBU:&OY-/**[*>BI\?Y=3V858S0L7_ZY[U\UNH+GI.M[%3@WP^?2Y$B3ID
M<#*8/*)=M9O*?E1[$_ARSM\\?#V1'J8C1"^C8_-W6XG_7@KASP2*V7JEMWP*
MCCJX*SEW>6,_-Y,L335]Y\K6XC! 4O%5K9J:CQPDPO*,Z,&"Z3M3DC+BAUB*
MZ&ZQ(I=G<O 0HN@Y?\L9\EAI:[5J C%068A\3F9MLD*JM+5&,CK!*I=QJ#+/
M<'(@U,Y&N]&;=OF(GLO,^\ 6_46(2/W=*'7Z TV9WFI9T,P)O%T):]\X_@QI
M(#79U'D3<5["&8'F-YH+4I(.G"\ZZ*V8)*?F+EP!(V"G*>Z4ZCLP%R=-$.$K
M)V8Y,=,J6AK50 UZHCPFAHPF"F56.)'PX74$Q%@>VA=-I^I:E[B'P5ES3-!Q
MG>I"!!W<\T1M( &1KA,16N9D8CO DA$^B.@$*O\NKD<WC\#H(QE'F0SJL$$7
M&;=^SGY9SI(70O/$O*_6KFZ$5UOZ-'XHP1"S;.D'*KR?#^WI?!EKO(GQ8!\E
MQX>I8Z)PAR1X].&YO^M7!Y(\P2B>G!R<0K??F3IHP1167-1Z\E':B7N@3Q&T
M]&@9UF=6H(:?9@VUL1Z - N0&6H;Z"4X .&'^GI2+<UG&Y(FBAMFY)@#Y'&-
M1+'2BIL_$7(#]/-[)'ZD>%38-\%QC!=<@VC.'Z'[?*OY,]=G1SY"&3G4'B;&
M1$E@S/W<WIN(#O%34_8IJ_5]K7!YVW7[=TQ21I:3&CM^&XBGY)5A,4"D,%Y,
MX,E7IJVCXS, -_-1798'0&_1#K+P7$[-[+1'R9X[EE^_:@H.Q/+B$:#4*D,U
MGNK8[2B)-15'&MXN*'E(T.:IP9+2W\73QVB'^N[]$<'1:5:-AKD-2W"[V(PS
M>DAF6]VB5G[$2,D:I)"Q01<SBH1H8L_ZPB,>O26([#JDFDL:=*%>8F;KQ1KP
M'K,7CL@AQ \&!0D&A34$)@R %%+-&@;X\T,F]*<?-FQNUB_,P?*YE>-PM(X[
M[YGV\!NUJ1VTV+;?>(-?:+-+SFMLN9>>8%1]$3SER^K^D"K"N_O7?$'U(Y*%
ME5<+K5<LLT\PH2FF>9Y_M2Q6%B!6'"7T33^PJ(+*SP2.0\,SFCR&#TT<4XV1
MH]M-UQ:]#>&5C#:; )HIZT%TJXBQH@ZAK.%N,+@V&OLV&+D:Y[$'K@<"=O<T
M5ASPA?]O:;K]%ZR#%$MQMQ1,DN %H@EDU.=*]\&1]^$KQ2Z:#OLRV%6F6N,@
M N\M+C&.;20@?MS'?/]0\]_!""P\EFE7EHHYS&X\DYHXE,/*=I":V+B7D9)3
M,=[;,[R\21I.2=<9]/?E?/9"&;C/C<ND-C_J6W6Q<<K M6K0_56!09;RAX!L
M$$*WD?77H?&E/NU7Z((NE$1V@V'-/;?/C%I)6X5HI.HDNU'?]^UIIU'')C2%
MN(5F)H\T9U6-#GY,;I<[#[LYNW<77#8MP1A7'6,'-1OOIGW$^X2>-.9QIPR]
MC?GPMF]WA]J7ZY;0P[^ROGV>ZVP]DROS#Q@I*BR0.V\YW%X*QKO.+4FLSZ_"
M^XU-"-<._%4O;0(/*K1N8-FV>^=^O1ZHT_K'=7A+.2DVT<,U85UGD[OA<)<?
MTX/=SG^)PI8+4.\5)&BA/26$EQAH#UG&<K->.SNM(+"!.:\#=U0_Q)1M^NE&
MB=M*!DT_&Z*R98,F4>9:$[+>)3-80B/%P Y(J6+,^![!&K=P4^TH _#C]6W2
M>0@/CHBX3S"R2PI+S64ZJF!O*/]UN_(65[7HAGB3.%_03%J?+,L$2?]9]VC'
M#?M$?]V8!Y=G[0^]N3Y07J)*[%9Z;E&-'@2/XD1'9F]HF1 786/X<.!#Q:<J
M4?X0CS[AYLK/M"+_B;73!\^[QW2?,5);-2%<5A2[B2F4E97S]4N_.\<OUQ _
M87'9%M)LA2<8Z3MI[\!Y@Y6%V*+KWT34/K/,_TS J\UA3S!2U>V&55DM9KH#
MOY ,/W-H&OZCM=$6>C/W3P4UO_G G3)OFB;*PRR#1\X-M; $9V^<BKQ9<>_J
M_2>8WI90B./?TON+EI_8U#HX]SC9A+65)?.NXJTG!R?RJ,S27FB-=@DV.TZ:
M!R4G?WC7=VW:Q)$7&T%"ST'2NN'F>OT!=03B"*'RER\NWSS<JZMFI(/?XGAL
ML=!'-F)U.I'&]FDE9MSBKK)8$KX[[.+TQ!1*EB.(8NECV&3ZV!97X7"Z_\*=
M9$)')MAHVLU#57-)@26\<&B^ D42UF&&YYH!0#0?]EP=*XKM9:= ^#)Q=DHD
MD,<!9?X:9BXEY&\O8T*A/0N)?XS#P#_,[&A-X"==*5V;S(#T1^]UFIE*[I1*
M&2<+&U][T&U4,[)V]Z$)Z 64TRSQ#F')'AO1=8P"0BQ.NQ%!_-8)=4,V(VO?
M+\"(&,4<(ZJ9=DIFI]/L<]9M@H:9B5+$'B\SRXK/HF*D&"59ND[>WP?XTU Q
MY:+I2(T7'S<]&J?<IN$UN2>OSGLKN2U(;U>!4=\O'*KX=&$IIW;GG:A-: <-
M3<1O,O08H*1$VUQ_4'SH\T.+VVD!_#BZ\5[1<_\CI51(_6H_5QZXF^<%.A":
M9ZZ]%_KXKE58(2HW[OS@@ 6JYW"/8]53]V I?.[HDY$1>,=0+N1?YE:W\D>)
MPZ1-DC [&54DN)WF?;= 5Y=4]NL!O[*S&KL<J?HY-)EY*8VQ*4U^09]P3Z&,
M:F+^9?9$]5*PF+KY7&^WRW&G$=TV_D8L6S)LGOE&-'Z3/'1OH\Q]Q_4!D-IW
MQ)9U;S<NC1;D^_^9Y/"_L Y$+?.(A/$F4/?,^7+L))_'=(BW?D\Z"2+.)XB
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M84N,KZW(G,\B^@$<G/9C*^.]'],.&G6+ @V[*IZ&;(DM&YB.;#7*^=O)_$2
MF.JJ+_#:?PT?GQW9.RFI2W/6'BE(>_Q&@A3[FI"LY9N 8Y83O3?#:-8;*93I
M+4I1R]@YW0 ?36!-4_UK?6TAS8QAR\A8SM.QF&E^)OZ(9A&D(8^1!4+#_$8
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M$_ZZ&RR+$2CZ-#0S-7,<)_8[UC*B>(UMEQ5FNR!;<'Z-7NVL7QY5[^0&I X
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M&1W0D*)2?Y7\KQ_97\"$C=-)C>(Z-ZFQ-/O7M^B)\AR2:/QA>*4=$-<FBM8
M6ZCZCI:05(\0=Q/?-YJW54LEO$\KU/@BC=+9"P?MGELOIU112=AO? K;^*)A
MG),(ALSNQ*MP_(#J-J6EB^^2:I1--.Z7)T]?"V):X69VZL6!Y0(/-HY>G8A
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M7_C[( X)N5Q^ZN@@@\EG^*PSY4H9-@3V\,K'<A\*VUF+D^QUOAH5*V5H/=H
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M"0_JGRWZ1H_D/'[^LP5@<E[+,FKW\=CC+86N8:JJ70O$PM<7=:C?E[(GFV6
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M?UZYG-2"V@0Q-SN)=LO0LOJSB]RT>F%TV32&@F.N;U\XI4=:=#(_-D#;G8!
MZ8U'*I,L0K8T._('*&%E O5EE7Q*BG]V:A5#]M"B"A ,@F"U3KO#:V3TUD6K
MXK7CU+!:)C3$BKN*MA]R5'M$;/ 46S>L=* ^<MSHW*Q&!O?/@^]1/#U FWVW
MO1BI5Q;U;\_=\8S8U#))U%F19^5@C4G/!]9G-B-I[?*/#A1)OCIW<DN^D*+$
M1?WT%*.N\6V>SG[S))*G!-*2.)=!57CD]VP%5(R=.#[+N/F )40$-;'9X-)X
MLT8U?C8W.K'ZO0D-8UN!"FX>O6,/'K8X)7W/:-\5"$2 **N[>P99F?.%4'H)
MB"@-=]PF3%.T:S3I.OQA;HM?BBVWN]TS0>$RU'*+_*HK/_7[#E&-2YWCG_M7
M0)X8N*G(Q>*/A/>3Y4+/[U'R7+1NN[GN4:*NF%"K1O^U\$,3;RP0P0=T;^19
M@SQ_EI[$8_%S3<+0E%F,J,_B[@4AW??BRI\R) (#?&T@^O[I(,EP;ZUDYD".
M8>@4P"!3@N)QP_$D!%/#&A:B\VN0" <>'2C\(BM#N)6/OL@3X<@217S^Q!\/
M %0]E.PEP:G$J'S*Q1_;2HU #@  GK]^P#>E>Q+X]'_Z#ID0V&O#;C(RLA:&
M%Y065>85%GU#061E@R33L1VKQ;US#F6T?3M1U75[,J2$575T7\="N<!NNF,:
M]IH%U$I'Y.13U- @YP&F)BY*7G$O5I\]'G<&<4W$/4K94?O-*.@LHB<;H9]Q
M"]2R)':2V6E[H6#FSN6ETK!E&$F:&X]).!CX&<\@EG6Z?S2F)BVEP-7B>Z?U
M$%UJK]6\8KXSCOD;S\$/^[I44:WZBYV939%06N@CQYGR-_(Z\]K 0GNBG1%N
MAJJ!^O@QJ9]IN\IXM=?E-A3?W*-?GQ3T\/05CXYY!SO!EDY+N>RUDYTNBU6E
MN73'"9IHB$IER)\/:^!_M?YDZ?K;M7DEU,Q:=C@(BIO=N<UT),(1,J[OBNJS
M[K76>@,.G+LQ4 4@>!<(7D1L@%DC,-]IQ(F=P@6)ZG)#K.-(7L:ZMY^?(,O-
M$>J1^,)RJ?L>;-TJ)M7TG*?NF+CR!K)&@[L1*KU20=!N)$'HNP>V"PH;_E:C
MQ.9 .GF-:4NL>Y3)Z_R24[0E&_ADY%W)Q+G<F2X=X U&$A;IRVU-[ R5[I]E
M'),]HY]2B2'93WH*KM;>O'7S>_&.DM;LY@G&%Y$)7'O]>Q2K%#]K4T 4 ((X
M2UW4X\WL516H.9=N%M*MYWV'520;7&Z51I:7DZR;/P4QWWH6H6%"9 :=&M)Z
M'J/.1(@5?!?#;N99XUV5"3=QYNY/]-/4K*QKB"82%6\S@X0&@DKPO9XDYWX/
MB,&. KJ;$!9*H@V*(O(F?9TD*7]Q?Y0';2B8';_H2@<URZ_WX"#+'TOQ7$X=
MM__32FZ_-JT(D)\.6QNSW/1[;UR'6><QWK7:8D?=PJ^+]F16\YQ0HW=-%[^7
M'Z+64[C-+8;K:-L$Z9+?8OF%8?5>ERW<J([U8GC]^)_HMX*B+S+7[%J0^OX8
M8%GRN'D],KY N=U92( J(TK.5T?BS(**3$-E198JPFY.*6\BH]D-X3:P5J&]
MW2AJSCU*C:8Q\N>ON[F$X>=U<2YB&][X*K!;#X\DF4Q>O"GR5\012/;C,F=\
MQX"92W)!).@Q$X#9+4+BF%FQXC5?/MM:.36[[QM?^Z-60M8$8O!L@$B,[&KE
MO)+O&5\DIX=@[)N%3G,CX.70S<<#+?P-3JZ@M<@MF@7#K8P]@X46374$V2Z@
M,.>!!(0\'$RJ7HN'I390!A$(=^RQX2CO(Y72XQ#XS S6)/55.K$36GK- N:K
MK/4P. ;Y]0[X6?%L&,I)6;?I]BX_;.^UBFSV-\)/8LIWZ!'FA.;@2I'69(=@
MC$D0BFLT4:+8JDSJJ+%^ZIWM!%8**.!;?&ER=R)J<H-+:Z2 Z^ITN]>,2ITK
MW9YR<?\,;(PXW#-$1?44[O5- :FBE$<OVA47.W9!:2=U34WD(HVG>R(<9*V9
MI_H%'K!;6S%:,W4,#INC"4?ZX$ "0=AC4@B7\E3^'_.S;P&41D?D(DZ5VE%X
M2Q%\/Q.!'$JL'"R99P=%0-M>.%<L%XZ M:$DVH$0UJRF_:F0AYW5O'OV<0+"
M\4 ^?"+9NY.==<#5J[F/M-Z!=[EIVE7JS3MJI]AD/&?Z1U#:1?4P?=C<+KCT
MQ8>'DW16.X")C.;Q2892+I>-O7'1P]Z1D2P6^4JGQO:2PD8A(6!)$0 CT*NL
M9(+GX@'('?7 6:RM$0R(<!Q&C/3$/?0$,I="A(\M;RAEZ8'J5H/O)(6<$V7X
M(G-& S$H5+R&DB_L0TT<BMA^!<\!6=9;Q#1^LLY4_=29EE>RCH]Q(;WQKH7I
MMA6GV=#$X*">#QZ7RPAFPRZKO>TGCC46K=XT[Q@J$YMN.!>&(RC:Q/YQLNY(
MKW9P4TH*:FV6[_7--15R@!#(URIGMO_PW5#X:-:3W::L* I-GHWR'"8+&0HF
M_I-*<[IL#(&'Z=_H'QVPSI:/LXY.F("5S7D;>0KMZV*G1FPN.Y6,:?C(T8 =
MJQ:-:754#&K-IEEXJS)C2.<7#,;3!RC4@W^L,@QV_)JP0WL6%LLI+6!/]FU4
M1I\&P+JW).AS=+>($\_:P;;-"X[,D+'WY"EC:-3FM._A/=-@DS,+PHRY/)8S
MY=>/5#I9 EPZ2;,)1!^P=%#_$0%^Q8+!A0T+!WJ+2Z+F@2L#TQ<"5"%O!("5
M+(Z: 92_?@OFM+]\M1PII[WY=3Z T00O40*$\X#!PE&0;0"&3)U,"RZLU.&3
ML$*4%4UJ]]T:$@1V:GCSV5$D:;>RX:@7/\0C*SZG+Y?.\1.$F##>Y@+FYQ:B
MR&\=R@N!I_KR)!RU4Q30"QLMX]+HTGX-4_S=MJTT\ZBF-UKH-/D)PXI1^=QV
M9/T)1Q_6@S9FM.=WYS7!9"D5,A%S0AR8 C857>3>.N8W+-&5$U)XSHM/-Z()
MUY\%TJ3'FA0\%E14Y?0ZR69@<*0:J5L=[6Y#,*W4*KM+AQ0MJ 0 "-/-S%_-
M<]6,];-)7OS8VAJPCGUH?>;VM'XJ9Y56"R>(-O5T0(WSZ+<0%95Y7M9;VB*4
M7JOL0!4XQ7E^,A]9EHK_O![]@]4XYEZ6AU106$X\G?@S)&&=1R>'J/,CY[1"
M>DFTL/ :8JWLA!183B2MA9\W1P0>U_7-7%91JQOC[4ESG"E,>-R[^(>5QC,/
M9J*>R2N#)A5N'+%\MT!\ZU*YT9CA@#+>-1BFOM8*-6&Q2CC7]E>S2.IE%+U?
M,'+6RES&HY$\JD78K[!0/L&OS_$9)VJ#/8BKGOBB?XQ; 7'$S:EM%4G4U4O#
M1M:\Z\_,Z\4D%!/H!) /J>^=/#Q(XPG(4L/^C">KHZB>$;Z!KOBYOMM)\.N/
M>/8D?ZT J*;E>PC&(6HC:I4+.+'7A'=<U+*YN4W\I[&K1E*'5:2MCS+-51D!
MF4$0D#:'VD612VQE2#!R3)DIO>KC0=]BP^^ZY5&A_#."5PVZ;J4UF[S46J4V
M>2[$SJOQ MS&\;FL1EDAR_.[<DXSY$DF.U$-^EFA]F>2:!$9GM^<9]6$,L92
MKC8U ;G'VG9\::4T&+*&[ &]6EUFW^D?4&X $NC)1</(4M+?!<,6PXM?>WVX
MC9VSNU;6F9Q@$OJ(?VADLW-A_@1NDYG7):@EI/D$#T5R2M@]N$\[6E@^O4(K
MI5^7WERG&M6/;K)G>#5.FR(DFC%X6-N,88DZC"1.@);/*/)Q1F^O5%J2^2V3
M[)XF(M9[>M;=JMJV0O!"AS@ZKW;25D7PY\W@5MJKXVD;+7PGIT .YQ: \LL,
M/>AER%?M*S)4\&+]8A4CPMUBOG .9HHS,#;^/76B>X'HY6S^!UB6*G!^+5*F
M*[I&AHGGF9E>LNG.AT^+82FI"G^%WM^%3L5NU/_@D?.>T*($'3ZR6 ^LPD^>
MNG+& H<:U( GOKIAP)/4\3,_NA>:&'=Y98OSL[267&3B*8U[Q+JZ"?H2.4T5
M7X1A#-WI:])<913=HWRM%_EL=>FF%[,#*KY37;NC*^*D?G#LEZ3>>Y=OW;K.
MIKRBX_O7MM:18?Y-B^N3SB*%L^67\O$7B5E_;9M-3<G.]]?N\O_:M*#WO_+0
MQ8'G7J"J>!]>4X=S:SU"JT*>;DPNNL 8RDO1'K<1058]Y\>JGW2,+;V:- L-
MDQ@NYQRKRTJ;A&-:Q^PJ#*U>W:/XSHLJ>%%3,L&V,SY*(RGF(T5P3N.F)6O8
MKH"&N(TRYZ;84"$SR"@E9\SO?D&E]/J_"\?^*<5Z7$XR+C9FBK9M&V(KUE!%
MC*=A:L[[G&R1*!,Z$_;DJKD<2,/L?S O2'*D=S#W7)U1B-NGTK/F'L6,IT#R
MEG_>,W4LL<3QAJ]SUGK#Y.OSNXU=5AZ0M(.GAZ^!^!:6SP"_=Q4?R89,=4B'
M-5]*<6?T_&UK]!ITK1.?C[F0T=@Y[Y9M&,$_F-"QO1D LF"3FD_$9K<.L;"U
M"X>]OK4#$EG7R(&[]^BG.(Y[G-$?4'#P)N(XT1^;6(#.*?G U#N*@?,Z7KL2
MVUA <4M@?E'U%)[((TA?] /,LK?-"]2\1Y0O4MHS6G/U:_Z;. S]N?F$:W]T
MSPL**IH+91&=[+;?B P8FF\=D3ML?S5-[\FZ=8,,B.P[T![.I(DOP'B52)SR
M1N0! %*Z$S3]EH(GC\O3AZ>0P_U-:BCJE]JPH>4C7 ^^RI2W+[[B;\,BDBSB
MF![#PIZL))/2!\A2Q0E@>+TMD,EIAX<!<C^UMC9JAM# YYG"X_3-\RO5!>5)
M@O.<1@5;P!JECIXE.XC'1LD%D52LD7LBY2\.!^Q9=+O1ZLP,B.Y1#!<0?[[V
MAJ$C&U"V82C;X!]_#L/9&1_,H6]!;VFN6:]I7.]10NPZ=;+P9T2D&;8I8 XP
MDOP;+GOB!]Y_JT'YD54YCP-6XG8C;!"ED,G,I-0M0A?=_ A4:)!M3Q,P*>^V
M@1?N=489NY+(],B_K5<V(ROX7 6UM+&5:[1FY!?/[]Y!L-%0%?)6696N@:_8
MLOBXYER(&D=8ZHK@/$T;4?Z98F&4-IXEF.28(.K6F&C;*+F81P'B4#8H[>"*
M^*_3O;-%(-<0R#V0+ASS#P5VNGY&1D8*#/:GW^X?QK]^#.;J!F<B4JOV[JG=
M$GJVR$B#<7NAE-S&N)[.*(=D(4,+S439$:J(;^H#RAMVRC3*;.YX+T=A7Y67
M217K2X1FEVP ^HV5NK]H+V^G2GMQS:X&T%4CKP0;QX+[=#770F=-'*B*L.W1
MI'G7BS(<+=U<%$PIP]RYTD44XP3J1& W7J-GI*$V7.'QY>;8O.B4X*&S8K-2
MV))A#^)U?)M904Y#\W(!^LEPBJJO[064[_!D4^1Q)2JJTT)W2S)H<[N]/&(!
M^30$+N@J3GF5)'.R;:<]-G@W"=>O1U@UE93IBP@6>#D%$<%_5#)4GXDC+K=%
M02+3B@8M$H:+<_ <)$XSF5_>L9;7)R:PQX^K\%*%D.1H?C/?&/P%D^Q^MK$>
MDL!WASO?)-&0MV!D3'7J<([[2>+&%JNLDJ9%^#")QE(53M_$X.IRALT8QRD7
M&!S#@D!V].H($)]E6]DH8X5E1=,&O$_E6Y.<"XP,,XREHE^^@08U#P]7R\EH
MO$G(?](AT'45XM$58,S&OT,DE@RM.UK_G!4\<CCWO:CPQ"NS>/+#+"=>5.&.
M[;I*9'NPO[]1*^$G#)2*6#!_1007^ D8M6GYH^!P7O=J:#E5;+8H/W"GWOY9
M=N>IXZU:+U;G"07V2):8G]R-%4J6+^3DF\I .03^)<W1F+YZ8N/1XON@JC+:
M!<5?]\9:78BR[J8#5Q3BS.NBT7'5CR^A@6UP>'"8M_37)U1AJ <3JK HJ?>I
M@09TW<'++":I9L.Z-.?#^^#11W.WZ&?506WPNIZG^IZY"3=!5&'/M;&@- \X
M\3T\%O?E6JMX8Z(]3LYR)QJ3XL+,C(JSJQ/MB1GX7<9)-MUX%)[3OUNS.+-[
MGT5E&&?ALAZ3K?'QP_?(] Y"_\4%"<+/(@,#\7QL-Y='^_O'!OT/YN>KA-B1
M&Y.E-@3@61%E.Q"Y1AS5\$;K-?M4G+028DSCQ>M4FV<.)'4XK[#$F$D>G>YK
M\![,EJ1-MKP=<.;!:M:M(\X6*(&P3K-3<!6P#\76M*F2MI3K=OFA!5/%23 6
MF*X42Z-3']A(#R,:*GV=^RG9+,0?"-M+(JB'3N=O4E"O6, (S9D(IVO1W2;[
M1;O,9[8M.FL):WUK6)F";$F=??R=P/?6S&NKKP3=WAS2$6J%G\F]RTQD:RX.
MX6"2WJL^\7#/KK8+%[@9 LQI0T)9@+P5$QXIJP.;UI5<_<1\2O#7(&<LRM,>
M<N=CL:!PC9W@HYB7DVGF?,:^;23ZL&EIS5& 8;[-"I-(L+ I*_/C#+'"*A7H
M*+ZFBGDOVK#<,@8_M'M5)UUYY\1FJHP&#_4GV;C/A!=!5?0B;^)XT&6I>JH'
MNTVI@WW3^S4W-@V.^,YH_E5[QJ5#.VY(15V[ 'FSNV>IHO7-6:DB4YPD/2W:
MGS9@"L.TM'"<QC]LP'[=W!O#R#W#'P?^H^TM6M1=-J7N$1R.+/9U4_Q'Z!8$
MZ+F%S@GII))A,OD=V]LOJ.SY@2 +M_&_5ZIB6=RG',\.0Q+,HN.C+G=)?'2W
M;GK020C6(/,I>%9< 1TBY-!@5/1_I$78\%8B/[<BD.//,B7W*,ZT:!<O_U%<
M'C5?Y<O(I[GG4.:'SQGQSO?OZ\[NH;99X5B3UVF[65V1/\8H_KX(_7"K6/?<
M[NJ]IK>@;4T$; MDTE(<(].3%NFR6:;\7/..:,+31W3O8F.<"+_L=)'EU,,F
M[B+JH3S"(^/AAR!1 X>CG7J*":3F36[?C;SR0-&:GQK$\"B)X9!5Y0L.0=I-
M0YG,*4#]'H7)V>_%^%_;?C"3?+QQC\)6_.56:=*O7R\+6OU;XTDB7%3/UK]V
M*/*7MA!I25%]3<TKJ[1/W&S\6 &C,[ND67@6/'LV7!C@N@O[4RNK=%QP1>4I
M6(_>G6J;RLCOA5"MWU@3TK/(- [37MG^A);S,^K'GJV^X9^?L.7Y]2<]D2HL
M+MBC%S\QA1?9VBB1)!I#.$0/9YDA(9OVR*TCP/?R4X,F,&8PC]%$BC>!I=K7
MGF_K/<O0'YVK.6^6GLN]9$X)K3+3:^6_Z6U&2+]>D%[_"'J;VQ0M#:MVXYC9
MJ6$WK*4"O.G12'BW 3&1<;<P"J%A<#\R0__1Z&["BZ%C'U+<9>G3/*XMI%MT
MK'KA<</[FDH@C-#?O-;>4^YU,L+.H((Y13#HM.## X),1V=4IGN4O;T3_?-C
M#[/L-+C<,2(D-#G -$UM5<['_4L!E$TL>K1*6;6;7+:GC+_$.H7C6,/)FR&X
M$?O3J]( LL7;&5T!6+Y2(K8M-\2:KZS30$BLN H5"VE<N%8VO.39M"V);U%.
M&DP+<4JX-<23W$C95OFTGC#X9'2/?P][7#^Y,M;&QY1.2*T9%NGP*;Z_:UP8
M3_H#9)PN2B1'1\LT.>KB">=5@ 6)MDG$CVINCAMU9J)_SW@@SE[:ADKX\GOF
MWT1<)S L9W^O$4;)_*%4>\O'A_MMVAZ@X!Z%Z,2K*/7W(F%;6,EA_[BJ5P3>
MICJGND?A\^'5[:S1VG./D#+)P0RA+M;\7$LB-V&1?AAWVMW#EM_>0SIN]5D'
MJFC/5+9LBQ58&1$77)@4C4-,NQ;9-BR LA)'PY\;_IX_-T0K:C61Z$>L]+N\
M<#'&]7 Q(IK8=YB27;#68/<LV>/Z)XXNZXV*=FS$,EWSE611\+'D7_AM6JJP
MBFK_G#/7R3WD:]=22%DYI@&6)\5&9!/A(A?7V*M?"<;<4-80ZA_ZLW+FSNL,
MU/J!!O=M+<3X.0JL=6E7B>4>10MU'G!2 K*Z]K==/'#+Q_?[QA%3XV[-@M^/
M-&B8%Y*E><XL9;4+"XS([9<_%]7!5'I=QX&N7]*BXZ75_V.3L#G"Z70 Q^T=
ML>ZYMYN+SK[&3I13P>9IAEB)VW-#M8W\'1?3/HMR1=_>3P35!QTN7LT@OV_E
M+\76.@:GG4Z@C1]KB9G!H&>+[&]^Y0H=!^9 _/*79\R6@Z\^&?O9>R?L6Y/@
M-GVBI9+!H)*AY0M*_?SN08O[]\D98;D3R*)E$Y*>H%_ [FPQ_=L"S>K6("\D
MVH0 M&/)9M9#%O0)UE-P4$] Q=A?'1X])U:=<NM3S#T5.@8AW\N9O&P"979H
M;,<&'1$!4'68Z \"9*5+-3AKG44C%X@=E?EDN>T'7&M-RP:U6)-GD1B064?=
MI5*\O$,/1H2@*6D]B3HSRN* #LYZLP.S)\*,%0"HC3&;\<#'%S7[5V;KD)HK
MO=L0&8E]\O0%6YX'$8\;JVF_%P!#A%^WEYTTR\5R*" 'I(!"^4(Z4!\E5LL#
M3R))\G<(6?H^NE<^)QG!/=4,0/VVGPFO)8 ?IKK[BKBIY"B[R*O&*^7]L T$
M!@)*#\!!,[(;>+C$,*8FBSCL%T0HX]WU2B'31'8<Z1T[MEA5V>GC*1\MO+%<
M25-VUAW/C7O?9\U0,1 B-3^OX5*YQ!0(V.=V/Q= "1?XGMAT2-0EY-GV([/I
M$*^'QW.%US3<@PXOW#(J>?7K$ZSD8%CK5[2=Y_OD,UI1U["HUGE;&073HHI7
M^?VCP+7#M]%IB2*JQNOVL;Y.]0VUQ5(T_EBI[8][M7=GPB*X\5L-):9K!Y.;
M%4L!;S?W:ML; DH:SD4QC])X;.?10\K*.C4?.'_N89;6\[6O=KI@PUMU>4%1
MDO'S@/<QY7^A^NP7II%E[ H%'=YFUS#H(>V2GG"FO.58YTY\%\+ HE39W@LC
M$W++U#2RI&W$,#VBWL0;^=SL"U9$CUI%2QN2SZOB5\A4?IJ<SP;@".XS[#0_
M/ 9'3G#6%;N8'G%; "U6=))L1@R4V7]$71PM.VCH3#>SW.TSGFVZ<Y# \IT6
MT)(6J"L-585T]LD$?5=-7G<X]PF@<\@ -8W]CXP[I<_VC;D2U_# M.,*CQ5^
MG>AFSOR,:>1&+%R<T81 P.+K? B_"=JQ@#D?X2K:,1<]_C%(%P0(NZ[O 0.!
MMT)Y50EM/ M%L9"\9:7!>8D"YY^B;XS;TJ65-<;KDAF-5U\< =3+YHW"]OH(
M1QU&$_<V69&+.UX]@&AO@!^804+#/!RJ2(>96<Z4?F*/)L;K@1#4L)F9T/BV
M%,)_R#T[@CL? B!1^FM13F*!\^O5AX["BV[EJ\+J;F^14;])L_QAS%O6MZPD
M4>=^$UGMF>/,=D5Q7K^+LRS_5L[R'%JS[S-P>H^RDJ=M1?X?BOSE_TRE)>KS
MRJ8%^8N2$^\#2Q-&283P!Z8GG;9Z71RC/Y[VK6!3'0SG#NXP,/3P)O?R.&A^
M;)Q8+E-<X2;GJUSQ,/X@^7\TR_C??.SVDTE.-O'%X7WUADCTK(TDAB25-\?W
M*.)W2IZ:G9T+IT4)=JXG7D,>#%N;F3'$'/'YQ2&;^<71'O8^-YRC4A2C/;<U
M[/./'13'1(Z5N! ^[ NCE +/J"FYA8W]!";O1@FN EI2+_^B9?.OND=QC<DQ
M=:BJ&<>?%JNNL#$6TLZ:Q$Z-UR9_/+?<_6,A=P<KG[,UHUGY2J3TYASJD"$S
MBI3=_#^WGE:&723$?>O \B*$ +R7D&M:<$-"I \=,%LV7DKE2\P0H@GG8RN+
MX\! P#FD&0:JHV2AHMJ-[D*LT5.ID<])V8_?_'2,3_Z\/401V[MH^3DJV:R^
M"(+O5:] K=@5/C-K,(,:)(;D$.NQBH;K=C6!/1ISZ[U:=:$]I%]6N8BL6E #
MWADHH^E<@;**EGY4XLE3!E?V>"U*1)H+/'*J6.F@%'SRA[D9%U\\%Q_FT"E1
MB]2ZG]N*0%Y(-4>?4!K:Z'2Q 5?F9 I%-$VY 95 _I=+"\N5R*%Y6$I6HL;#
MO8L3.X"40XI:_T;%L>U&:-6M<B'DC'I-H/&-WV'%[ NK0^V!RE[A>1LBV8H/
MK-TJRJKKX6/<B$?X=L/PS=,0/]Q<[DP2NH)3-E^XZYLZ%B%MMK4CC34_QF*-
MJ(9T4<]$SS7'4E74N*'"[^6D<2&];,LQ,D"*2L6(^:'5@#R@IWF)L\D;W"%=
MJORS&1: MSI#-&<,<W$_=CI\L(?EJU,VRXEC*8T@3+YJ>KX2?E@UGW3(CA_4
MSBNO 2_#L3C'?M^C<U;>7ROO,;G:]-/?^%"U?X1Y^6!9-2(IY.P!-+:+LC_@
M[[!;D)\G?]*$W)P/);C(+DZLS:TB^ >'KH>M (8;&Z3FO(B#"*ECL?N/,0*8
MR*JA=<OVM>?%:K!N\[^M8^KQ.8+.T8O?>"KR%%9R<]5ASC,=PCX**U6[<UP^
MTQ#KL#ZS&:1](6UR4\LZ\:C#:,6$%MZ'0PSUWA4B532L '$VAE:K<U[-F<^5
MK<]&*L=/IGDP,'W1[!-[:><@D,>,X?]AN/-59#"A5.![CA-\@R&#-FAPF'Z8
M; HT& :#S?VM)M0Y@!4)%G^!VD.)^:67%@V-1=1(8474Y!<O%-^#LOUACX+L
M*(SQFO[167M=;G)7,W/MT5PX#:(#>]/E9Y%+?>-1_)R\QFO-G>-_$JUDP[[2
M(O_J<8EKF7./PQ-G1;(=(QL3O6,;=V6U+3LQ"?6M9HF4,:\T?#MZ$:'\(WP.
MS[<W +RN71XESLR2)E=8MGE>KCT?H]UT)C6E[RW2>X;/_8R$CQX#Q$WN+CNP
M2LKM?#P)\#+D9=&G$L90F[!RA%$FI"L6!W_KG38EW%?)%_E $]:+805B.VET
M;Y5J5E#:VVYZCE@RB:1BZ:*Z_#JM\B:6+X*G@-Q'(!44IMA$Y$1HPZG@RPW3
M)FIBJ,H'9LDU5DF#PZMU8E1V%"O[E3@^CT]YZ7*P/MD4%H@Z14LMS>R4(N2Z
M!AWA.YTF)P?G^)F6:_13\NDAV1TR8J=C>3)(&M-<"HV=3':@-IA8O\B.?7PT
M8(3R'=LP Y%_']%GU+#81EY5DV/7<O0(N7G=+P<C*^J5K_R7X2E9930<RW#9
MM)$A:-K"<+4"&>&[6?$0SB]UH"]M>C#8)1 /M ,$'MN3U?DY;YSPH:M\( _W
MBE<9?\Z_E9\U^.&Y@/OJC^:9GA!W=XO5$'>&\\8CM!.>(^?Z*^Z'T&90+N/%
M9ME\F TZZ>'(AVZL'K:A$>%[%':OT;O;;WR/8;!S=$, P!%Q-??A;V;@'2W[
M)74A$H;6)';C+BK6S-][E*7@9P8SKL<CRE)I<3&DEX<]I)?7,-0&+E"CKZUO
M8.@43^*>W7!J1 B(I:6B_8/S9F&0*&U3MX4];3LA1DJ\JW]\(V>(_<^6A'*S
M4I)7R2=3WR;FLKX&61!N;]TRIQ3'Q$&5.R4O;U4T'X;',7E<3@Y^A!'GKMTQ
M8 ]83X='HB@98XH[C-!S!)(<W;32#DW<M*8=W=DWYSPN!UA?Z9'LE\TN,%B_
M21;*:E,8DQ;0Q)U\NV=$ST&$3N-*,W[AONTH@E9&0&7"%!H[0&J_I&X_G;HO
M4 36QI(M/!90E"IP'O>X%-RP/XW,U+F99V$!E>O%::\9H1(N1XUT!% ],7JR
M@H*Z$G$1)X:_EA%<;[&6D5+/L)PVLNX.LG#P;@1S.2-[*681/M]A2,TZXB2\
M;%?AK'[K#/6,RIVZ='SR1EBSLX$ YW(O5:D.RAE2OY;E99'48$V)%(D;4\3>
M[(GW^7&U7H+SR.<LFYHS8+C,M,XJ5FR9]K,Q@(!BKBNT)ZIOA]?RT@/Y]:*)
MI8J_BUPO#&C)R^EN=RYKNV^.>+A:C89IMR,/68UX;W.SIFZW<W,=(TNJMB;^
MY%:"8)5K (V F*>R J_2@U-N@?D3T6V7<$P>-MC':RZ^KDM9;=]"GAPW)G1)
MIPTY:<-!4+IR L_$(&L:7.::&-JAC@WH%>=QPIG(.3/OU2[\]Z]=_GMI#-GE
MZ:+*09!P=\J027E'>9U)7=Q'DXCI3,YP#X80:<;U$,NP[$2F1P&BU"^ !""#
M'4H>ZRL)LO[$1CX;"3C6XZCD,X"N68,3$N]BZ)N;4'><9W7N,*$2"^OJ4\2V
MO#0[Z?O(9*8-;QXFLBMXZ8KN><65LDNUKY_8;B2/PEWBQ,QE9<I'_3;3:.MC
MOJ]?",C4D5-? KH CG4CJA,J6OX=6M T%7=O9;>-8D1^ Z^KAMZ>!7>T'GV_
MW1XX%=R#_Z.M&HJMBJA\J!:CMFS869Z1_11;R,VYHOTQ2X)E]@/V+[BHO,*_
M5XH[+7SX#_*_/VFBI9>FH9+PM^M,N_-]VQ^S!O^PXT%MO[KWM\;A/$16O6=4
M5Z"T3!DV:[;#-@&T+YWEH>ATU85>>3FDO=N\22;J (E>?%57R;WGR]AD2_?J
MW7^7KS+_OQVZBL"YU@L9/4V,H6FC2TS.^D3'4*<O1X(,_R,$0__)R1F&P.ZZ
M626AGR8#2Y_&J46(A7$9E\?-X*%4P6=;LQ...VH^X-Z(Z2&Z)"4;85@8YI-]
MZKWC4;(\4"M[S=48=9F:7S^QC8IZ) 93+@^KY5 EK,D["XM9TNQ@C?&=!)HR
M&6LJ%PYW)[=.',#E[!5<:?@Z,'ZNM!<J*T'W(;<R=$"<Q4-?,\ SC&D'$ZLB
MSC*OT%H$"S'.9'!&/IH(8,#$7Z'RF1QXZNWA[HUTL$02L87/8PGA:Q0(@I==
M>/2L=X0XOB0R1"PK"B41#GOA-W@0_5B1<S?%#;G5?1/Q$#4WUU=-_ 5&D#\]
M=@^U"92]\P@._J-B!,#'35A_2SB&[1SDG+G@0")^MH.,-'-&JQF;\1RA"BF#
MU_%6C/.8]^I#P=@//+W,W9^H<EV<.76QO%KSW[)X^CB:$P_]'*<1IQ6[\P"Y
M=O,+>R;\&$25V8U&WHU7EW5I]BR%BBB[<*L_3S8=NPZ;=M8H&C.A&)SQT308
MU$:X0,F,5<IE4[]KQV0OP8RC";,A/18."AC@LYR :D!*/D_9C#EV)P:75&2:
MKM42'^YA7OA>>HC"^-1#!LNKDPM8K.CGW< #[-(4')*X,^46DJJ]%0D#?8:6
M-#<O74H&<N$S7TPTRT=IB3;\9)(S)9-<#DXR]D$O4#E0PY+C>=V6SR44S?PV
M;B4"6O=O-I-Z9J_PU^]1OFF)N'BV3CCPZ;S9+"<M':<UIKR5P.6].^2JNO)(
MSRCQ!I@BX3W@QL8;"OM?@3PMX&:7Q5!R0>I4M^_2@1;MC-YMW7(JNVEVJM!-
M8VIVJM[UQ$VL&$(J-;J.."97,,SO:\YRC_?T9'>>NK;I:U_),M@MS&8C6TW2
MWK%"A>NGZ[<=1;.M((;A?UP;2CX?B]-H&L)A;98R/G*:?>;IH@F+(Y-CS_6H
M-!C(3^0+['8 IS:FJ16\L/@HN.0\V\[U4IKV[C'2,/BTCU0JJJ.9T&[ >6+^
M.?2G1H!V1M,,1>BJ DA78X/S@=B7P0UG2C]I(M(6Z8NL)/*?<V N@J2D-)&D
MI'HG#R8) O:7'-+[^QZK*.ZK\P,1?((?LZZ_\7J#0DX@URQ6[Q!2V?13WKFQ
M475A;X@-Z?(/5=.<H>P)4^^-9*%/4YIT3FP[&5WH/,W)0U_7@S9/\J^E[*LU
M#[P8EDI3QD !.K=O]39[=W75<[=?G [I>_HS?NF&8O)C"K-Y$&OK+I-(_U3$
M HZB(O1K>=+P[;53;3399E+7YQ+SXKH:DUA(!BSF!]1P1ZPG/[_+S80>R7*/
MX<K2!MGOW37<F<5*I?]1:VJ^-R-9.VUA;W]M<)&Y]1[EP_@Y\!S;(=_*V\V9
M<%!R]J%]M/*0]Y<2#LWO/4,83_%:$CKEM*X;6H @RVX=C=?& >*.63POO\CB
M?"(3BO>FW47N3_/[-,[9OHK<RQY4)!$1K5L]F+E'>4E3FS$\[TO58WS8YLM3
MS)E&&LFJDP-B&WKLR0L_UW"WM"(? *A'S\WS<:Q730$%N\&3B=]"2$,*)Q+3
M-L_6"4TCC7K>?\[N6MHZD)+'TZAV&;#8GJL';KD[GNLA1<QO:8[Y:K7>7ZA1
M82FG-EO%13\]-2BO?X\5\+%;DN8!L:,\3PK'C'7F<X97NUR0UY7IQWW<D?])
M+<>_;&+HH]UYT=SFN4DW3^MDD93POA8$Y4TU@%5-5YJ+>6[X3'(S)XA((5KV
M$H8VK.UD!=_J24$/2#2HB"1G!7*?Q_M$;/E/?;E4\IVX1\D7\K\^A!M>O"LM
MW;I'<3>QIS#W*9^<978Z2N5B31RQ&7B;^?6*@2F]?S60C!?]:21AJ6+&N)?)
MH+O.\-OVE^_'*]']WZ=I>V(NAWNH_"\J7>+BH@8)53;6\<KX.;6B[;4L&)W*
M2@M^&(C5ZMK1L^)3EEWEX27W(MH1Y'_X\KT96M.2\.-DBS(@KCH!9.1[=F3%
MU!')JP:7%5M 'YT^1WW"6N]*UORR.I9:0,&EETHM9-IZ&$^(O3&,8FAR Q>U
MX+B:(;MU]MS> )H$^C%5_%T_AZ_?[DPUI*C$$=7UHE/A6:)=PX7[$VP<WG0O
M_24">F#H?.=/@5LJGT.O5M2,,6U>($.W=3JOLM+:6^TKO=1$BU)F-A:#@7CI
ME:ZU_9&XA? 6-C\ETR.(>?;7[_)T<A;;J9GB)02O^W]QM;'IBA=2-(Y[<!P
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M^1M/=VJW(%;<A(Z(FE'EOK5X2+'!@+']SX(SBR<;_,759S2>.4_,*6,*0KA
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MU,60$$] A'VI(7P/09\(+J3=$CL\7G8MQI/??+O M!Z5LR:SS2>FD03P1A2
M,P9R)0R@M30 5^+4+A"\%0AP)5'*2SWM8WF!^]75&RS:-/JM%0JT4H$T ^T2
M?N@N824::&0#5YTEW(D':OG>9 %9XVRK;(09+N0>OO$6].Z!@XRO 7V0GW+
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MO\O?5AM5I_(V+RJ@ZW61DLU:;2/N\OT<T#99<!EZ8<(9\6"(5&=1'W&8")3
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M=96QW[C\.\._XC4O/^:;K"Y"T41C1"$+N$"1W(/'JC0.CR'V8@QC0?S$#9*
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M?\(I:SQC1SM?.@A1(<(0!AZ7!CSV0QB3 $&'NQ$.N>\+:E2R]/R4LS/K:\2
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MJCZ/2B55E9JVGDV*!%7>'NB))($H0@PF/E4M?1P2AA%R?*'9AFTXB/DI<R4
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MJ-J(W?.EZ^)8!97#F#HJU%S]Q$0 79?YH2"<A8&1XTA[YKF9%UN(X&F+T=#
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M(""3*LI+J'JM-R\::Y@:57FX!5Y=9>R*/:99J@95QN:'[T\\*_G2BWP_YD)
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M!@JV2/5=X">I/']R8(.@D=7),6X&Y+V?)$G_>, &61-V*C GS>@PX!P;/6<
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MB"%-4 H%9RE&DJ9,I7YQ+)X:3"_,I64 6%D+RJ.=G0E@8;3WSMOWFA0WWW)
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M%_3E-Q&7%\V#PCLP9Y7!8.U&GCOUH=$?6@- &_W&A"$1]PN]&PSY,</QSL_
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M<II$,$\PY5&:12IR;HSH+'5JM-FH:%<31:.D>T\^=[2[B7 P# ?FNS/5L6[
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MR>H(M5'RFH3,X>?9<>MI2K,W]+:5-:0^PFQ;"UKF OX"VM?5)H/29EO.9UZ
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MN@B=VE*UT@PLC&IENZL7Q0K?;E=.8#MNC06&<.@]LE)=6.I[M,R\ 36X5NF
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M2(4A@2R&3*>9S?G)(4L-?)%4"&D=HXAROWZA9R1-C20J98'1%KQ6U[M=5S?
MW>00%+:!*:(W8CT:C5Y XXJ>H^=&'KG]Z 4#CSN17KHA1(&]G4?RN_W]Z_SA
M<?-9&V>EK+A?_NWWI@26361G,8XICW(8,VT61#SCQK5 !!(J$4<92O,L=2T'
M=*TR4Z.7O:N^*,M]%%9_N-+0+)GJAA=E,'M34ZP\5%HJQS"W(-/7S4QC3\K
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M6*'D[O^O[EUWY,:U--'_\Q0$!CA=!23WD42*(OL  Z1O!6-<ML?EVAM]ZD>
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M)H:">Z1^EN. [<?NL2$<F.9;Z-TWZ#ER_^G0"W,G].4C_#ZM+KTQBMW_\OK
M8S?%](;B3*=,_WO[T?[ORY6N^Z#^PN=+M_I_6KY?_M#K395%/>.4"J-2 I5
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MIPO-;I*)A-'0UG(P/-[4X0' &9ZP"\,_OI4__E][=TT1]B\5,U2<T/7,40C
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M]1[\=$V=P)FU;3%*4P1EU9V %P8RHW)(I>1:2:02UW?._]3F=(BIG<Y\=6,
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M*KG*"$1<NK-+NZWG2EM>S% J>):2@F2^]5V.GCTU+MR+%^C3.P=;-_7=",;
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M+W='F?;M*U"66^RY%!#GPD J4&[G(>$&TYQBYN4ON3[4U*S92EI0B5MY6IW
MH)$XP,CJAM?#AHT&VM 6:PNO^R.\KI\EAP(78(M& W LR_,F(,.L3"]LNFS*
M[@>,9T%Z*?+,7O2[HW][F$/?]M_M;)>KC:N'[+C;%>B>)8(+AE0!\\*R*::Z
M@#S5!/(LYT@F-)4BJ*GSU1&G1J]5PX[Y7N([L#W(#%0C='C/E2NH)QGAI.#.
M"-<0&Y592]RDT*1(J(0PH8V8+?4WM^Y^'1M\5H-_,OQP<_![&W(W'SO<0;D$
MF^^ZE?_F^@R42^_T*O\I\;/,H[[> R^$U9O]OO5FMV%^<^W-[M4]Q@N:Z/U?
MND<=O8.+%PCG>K#XW7AK4_".ZB5-LV\+M>2&0($RRU!4&<@1YQ!IE!:4,J&D
M5VA6^-!36QN>!?EWEN6YM5GWU4GQHZ=AH!Z8IR*B?$,3;5_ !FJ.?77X%VIZ
M[0O+Y6;6WD_H1VP1>F5_L.;V^XU^6,]$HI!(4@Q)BEW-)<X@S:V%EDA->,HS
ME>9!41DQA9L:.3YO;]^2OO)2M/_]R9IPJ[J3X?.;_G#*@4J[0.:,.NM^W/I2
M<SDP^XXUC<'4/ 3>4<D[JH"CTOL0T!XO (.,<6F):+]U]JX__\=_V_W$_N'Z
MF?V/__9_ %!+ P04    " !]?PE3W_5D^(R=  #W!0< %    &EN;RTR,#(Q
M,#8S,%]P<F4N>&UL[+U9EUM)CB;X7K\B)OMUD&'[4J>J^BBD4+3.*"2-I*CL
MGA<>6V 2.]U)%4E72/7K!T;?W>GN7*[QFK*Z*D/RA;H7!GP& V!8_N6_?SL]
M^>DK+I;3^>Q?_\+_RO[R$\[2/$]GG_[U+W]\? GN+__]W_[IG_[E_P+XG[^\
M?_W3BWDZ.\79ZJ?G"PPKS#_].5U]_NEO&9=__ZDLYJ<__6V^^/OT:P#XM_4_
M>C[_\GTQ_?1Y]9-@@M_][>*?C=.980B0BN6@K$2(3FB0&GW*F0F)\O_^],]9
M^RRDDJ!C4?2Q*"":5"#+PEFVBGE]_M"3Z>SO_US_B&&)/]'B9LOUM__ZE\^K
MU9=__OGG/__\\Z_?XN+DK_/%IY\%8_+GRT__Y>+CW^Y]_D^Y_C3WWO^\_NW5
M1Y?331^DQ_*?_^?OKS^DSW@:8#I;KL(LU1<LI_^\7/_P]3R%U9KG3]+UTX.?
MJ-_!Y<>@_@BX ,G_^FV9__)O__333^?L6,Q/\#V6G^K??[Q_=>N5T]G\ZW3^
MUS0__;G^^N?G<P+#N_"I$KO^QZOO7_!?_[*<GGXYN?K9YP66?_T+_5.H0F5&
MLOK&_W;];W^^?OF7!2X)+^O%OJ8?7#RBOFP?0O#;"F<9SY=W^8Z3>;KUH9/*
MW/GB\E^>A(@GZY].,DXGZR<_B\O5(J35)&3CE(D<I.,9%-,(SJ&$G+-6(6",
MR=U>=R5Z252O9;'$]-=/\Z\_TX-_KLRH7ZRYLN;(O=>=<V8_NB^WWD?Z["1%
MZ1FB@V"3 85.@+?) W>1?N[1N%(.(OOFVVY3?5.BSQ;II_DBXX)TQ^7KPB+=
MD^YMW%Y\XN<O84$/@O1Y>I(O_W55(D/(:C4?@'/G8B%R__(3K;K@8H'Y];E4
M'ES<>F4KTJBX_N00$O]_S\*"GGCR_3U^F2]6$V<+0ULB2%$T\2$%"(&848IB
M*O$4) N#"/_.B[?"@>@?!X?PLQ-(O,/%=)Y_G>47= I/K$Q6)>?!:N= *<;
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MA*UY\YW;H:'CF..!;.P"!$3X:4WCF*>_?_A,?%N^/5O5(H[J64\8CR5&77.
M:B M<C*!?/!@9'9.1,Q>J0% \1@-VX&DX^CDP&P>&33/3G&6:][HRY/P::)5
M-CZB@<P"F48N1? ^T[>YF"*]LB(<EGU[ZW7;0:'C2.7^S.LD_?KE=)G"R?_"
ML'A)/UE.D(?(G.603;U:LSF#BTC<P*)+T)[G W.D'GCQ=DCH.'0Y!$.[PL1Y
M9<'Y(F)&(A,3*(D"E,H: @]D-]LB:P*@BHX/B(H;K]X.%QV',X=A:A^&!2UC
M$4Y>S3)^^W_P^\1&H0P7')(R"I0QM2XMV*KN$D$[!,:'R*>\\]KM$-%_%/,
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MT3&W!5 V/WV<EB?-8#$ "SLX?J[.8G)$\!5]N9RXX(H)T@"R>AYCT>3CF1I
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MJ9D_@BTU)@(ZN-=_9/E;+3<6GX2VDGB=,BC2.U!;8-(9*55DR03G_+$!/QC
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M-_UHP#Q A#T?\>\6^"5,\XL+LBZ,[V>S\PE=%]E1,:A(?"Q@$Z\5PVC!1Z?
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M'0B]&5H29+\*[PJHS,C!4CI <+0^,FTY>I^+"\>ZP'Z0R.XZC(\2OMY7:AT
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MRI7:<DQ[,(D5P5PJ.MTI!-F8E_34>T9&RL RG3=B\,A@J6Q:/ONTP',=?K$
MP;/.@3BC8QW)(VT$5Y@#BT8(8Y-W=XMD-B)DX\-'KD5N!XO#6=G!X;3O^?YZ
M.L-7Y(4L)P&]X4H$,#9$ K\A0[*>]J9X4LK&9&R4%G(PZ6,W<![+LCJNS+L
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MP+C=RM9M%(5+R3.C &VHAT?M/A8<G2 ZAI(=>B?:)!YO3^.X@9NNP+BSR#H
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MUT!X'4#QL1(NK(:)<PFR2[2KM"<O#&T"$T(=2Z,<CVTB=/\U*N\. >%08NL
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MF#/Z"((=>^1D6/P=5Y5E-SKESO+F+H?XK99M7G=^TX765SQH+NJ\Q&S >VE
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MP%PN#@4KEO-M $E/O0%&^NXN$&^]MIO)SZW%/#^4YST Y?*2R%JM"MDR)H4
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M1QRNU>AI[K223+6AE 7TM38Q&[*2J@30+#"3!"K#3E'*U^Z=UCX8Z'*GM8_
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MC9OS<@02[NXD/8J_99NPSB,[W#)L?KTW^["+G&&L1,PL(N,)@J_-WW*TX&Q
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M8/C0@MYPPX-4W@=:IEK47B&6@0_1@O9<>I^T"KI3_\/>KJE; -F@D.AX!WV
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MDX1HM8>H0J*_Y*SN)E7LOO/H^L+Q[CKZ1\LP4AX9.F_??U".L>O[/A=(!#*
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MZD MM "HC7F_Q]+-Z&NCB'0.V49BQS$+7E*DP0M:KJT349=A0/4X88T!ZU
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MPY'6[/5L>Z+Z@_>VFR_J'S$L\?_Y/_Y_4$L#!!0    ( 'U_"5-5(1804P@
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MN)_%]>'/(&9#F(<[WY"I'N=#-JD6ELZ'(Y,:.WS5YG\G--*(9:;3V?#UC<[
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MO"#_=7?Z[V?IT&OHGVPF;G,S34&-H1[<6#E/&50D-UC(<1^I<^2KF2AS;TM
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M,#SVG\#&QUY+@(=X+I?($:*\])M+'O@^K/H-7ZOQ=W-G_P502P,$%     @
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MEZ=;!1GX^?C.W$3-ZP[#D.=,Z0/YV^B/:\ZO5L[NKJEKKJV%/%R<KL7C^A-
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MY&"M/$2,UM4%)QZ!<85LLL*H &<#P%VJ4T')LF<K>/1&I'[F!_SDKKS%#7'
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M;=DQ1+WE 9V.(>K?E3D-IJYB.,SIS3D(/$HNK891S&:DL)D4VPWL*B:1NT#
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MY[C%^H[AYL (N#GP,OP+=CPK@5R)1WS(\O7A(E^[JW58AGW].H&M6HH/,HA
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M]$T\%)UEZX2<Z'P*Z?;M=8MAX$FWU0NJMI^#\L-Y" CULR\6W? :3KU15#6
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M1+V\B0.E/..Q9F N/&R7&9(;\<O%GEAE%UEL)_V:S3,EQU@DD]7>]',<8'.
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MD])U,9]38JP-%3*JUOWG[ATU*<_;K.0?;MZJ)E4%0.P(3=,^K4V?6ZY.]])
M0NO!VV$]?@-(?QL.",Y\+3'7M_3AI]QA'2S]9OU?V")-#B]TPQ?M2UO:1_W
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M:ZE=R8;;Q *H&*PB'!+@YT8A-VYRAU=N1%A%)JCCB7V(JZ10-IBE5L'N"31
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M# 5F5B_M-#XOL*9B;'V8&5RY%L,!*W-^16U0K[$*KI"N)M*?3REG;)U9EK.
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MF6+ J&LWS^./;0?EZ7VN^R:S8JC&/E*C2QD0::4)@Z#!,4LET_(25$=(CU;
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MX,M,_,&^!8M V)&W'Q(/UR6,V;TN*YLW[L@3[Z1]H.* DS-0)ZD/;!Q122)
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M&\.X=LHW:8\@D'B3]#6[IQ@46W:*R9(Y!H;RK'+WK+7(7?=-FGA0SD",H$X
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MET22UVSLQ$)MG$PC\PL>QVVU/5.,BN],]2C5V(V(-LAHZ:E<F:@AQ#R.KDU
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MF%L.S:YE;)X-(6++F]868BH)8[/"=6KWD6DUR:Q(EJVJ##!6)D@21<:W/89
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M>%&9-!%QM$0[8CS?(J::%UUEA@KWYZ=ZCM"5WG2\1 (!JI-1$J(28]B&E=W
MEQ!"<TBE%F)!/Y[@:/VYP(AXE QJ3ZV=2:")B(5OND'LV)8QJLF>[I?CFN7
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MUC140L$!,F$Q92]=8EFD5QG$@Q=I!%<27;Q:7$L3ON6L\13^"$MRF<VR"G%
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MED,)V9J<MH2W;!5DAD_U,C-W#Q5 $M6$ )K &&IN;8&D.(*>@:6MBX[R )Y
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MLG5DP"S8S([=?=+%TM+.2JL(AP+GD!*WOR1Y'(N F>':B_AHG*QIG"SKKAX
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MKHG@VJ,20U)ZTX*'-7O#PFN8EZOS7FV%0*=E#T=;$A;:.'(>B+'&<\T*3&R
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MS_'=FK;4VG[U<3Y+PZM%K6R3V(U'V(UO!_%HH?YUDT[&W_\74$L! A0#%
M  @ ?7\)4T;55"%J[P( _^<; !               ( !     &EN;RTR,#(Q
M,#8S,"YH=&U02P$"% ,4    " !]?PE3-^V?<E$3   NT   $
M    @ &8[P( :6YO+3(P,C$P-C,P+GAS9%!+ 0(4 Q0    ( 'U_"5,APWP.
M&2$  'A+ 0 4              "  1<# P!I;F\M,C R,3 V,S!?8V%L+GAM
M;%!+ 0(4 Q0    ( 'U_"5,P[/^V0'4  .(,!0 4              "  6(D
M P!I;F\M,C R,3 V,S!?9&5F+GAM;%!+ 0(4 Q0    ( 'U_"5/!(%7Q'BD&
M (<%!P 3              "  =29 P!I;F\M,C R,3 V,S!?9S$N:G!G4$L!
M A0#%     @ ?7\)4^=4/)7>!0$ 7+ * !0              ( !(\,) &EN
M;RTR,#(Q,#8S,%]L86(N>&UL4$L! A0#%     @ ?7\)4]_U9/B,G0  ]P4'
M !0              ( !,\D* &EN;RTR,#(Q,#8S,%]P<F4N>&UL4$L! A0#
M%     @ ?7\)4U4A%A!3"   J"8  !8              ( !\68+ &EN;RTV
M,S R,7@Q,'%E>#,Q,2YH=&U02P$"% ,4    " !]?PE3ER#$S%T(  "2)P
M%@              @ %X;PL :6YO+38S,#(Q>#$P<65X,S$R+FAT;5!+ 0(4
M Q0    ( 'U_"5,"QG+D; 8  '@B   6              "  0EX"P!I;F\M
M-C,P,C%X,3!Q97@S,C$N:'1M4$L! A0#%     @ ?7\)4QEK7&:+$0$ X2@)
M !<              ( !J7X+ &EN;RTV,S R,7@Q,'AQ97@Q,#$N:'1M4$L%
3!@     +  L U@(  &F0#     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
